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ABSTRACTS
PLENARY
1 
LUX-Lung 3: A Randomized, Open-Label, Phase III Study of 
Afatinib vs Pemetrexed and Cisplatin as First-Line Treatment 
for Patients with Advanced Adenocarcinoma of the Lung 
Harboring EGFR-Activating Mutations (Subgroup Analysis)
L. Sequist1, M. Schuler2, N. Yamamoto3, K. O’Byrne4, V. Hirsh5, T. Mok6, 
D. Massey7, V. Zazulina7, M. Shahidi7, J. Yang8, 1Massachusetts General 
Hospital, Boston, MA, 2West German Cancer Center, University Duisburg-
Essen, Essen, Germany, 3Shizuoka Cancer Center, Shizuoka, Japan, 4St. 
James’ Hospital, Dublin, Ireland, 5McGill University, Montreal, QC, Canada, 
6Prince of Wales Hospital, Shatin, Hong Kong, 7Boehringer Ingelheim 
Limited, Bracknell, United Kingdom, 8National Taiwan University Hospital, 
Taipei, Taiwan
Purpose/Objective(s): Afatinib is a selective, orally bioavailable, irrevers-
ible ErbB family blocker of EGFR (ErbB1), HER2 (ErbB2) and ErbB4. This 
global study investigated the efficacy and safety of afatinib compared with 
pemetrexed/cisplatin in patients with EGFR mutation positive advanced lung 
adenocarcinoma. 
Materials/Methods: Following central testing for EGFR mutations (compan-
ion diagnostic TheraScreen EGFR RGQ PCR kit), 345 patients (stage IIIB/
IV, PS 0-1, chemo-naive) were randomized 2:1 (afatinib: 230; pemetrexed/
cisplatin: 115) to daily afatinib 40 mg or iv pemetrexed/cisplatin (500 mg/m2 
+ 75 mg/m2 q21 days up to 6 cycles). Primary endpoint was progression-free 
survival (PFS) by central independent review; secondary endpoints included 
objective response rate (ORR), time to deterioration in cancer-related symp-
toms and safety. 
Results: Baseline characteristics were balanced in both arms: median age, 61 
years; female, 65%; Asian, 72%; never-smoker, 68%; Del19, 49%; L858R, 
40%; other mutations, 11%. Treatment with afatinib led to a significantly pro-
longed PFS vs pemetrexed/cisplatin (median 11.1 vs 6.9 months; HR 0.58 
[0.43-0.78]; p=0.0004). In 308 patients with common mutations (Del19/
L858R), median PFS was 13.6 vs 6.9 months, respectively (HR=0.47 [0.34-
0.65]; p<0.0001). ORR was significantly higher with afatinib (56% vs 23%; 
p<0.0001). Significant delay in time to deterioration of cancer-related symp-
toms of cough (HR=0.60, p=0.0072) and dyspnea (HR=0.68, p=0.0145) 
was seen with afatinib vs pemetrexed/cisplatin. Most common drug-related 
adverse events (AEs) were diarrhea (95%), rash (62%) and paronychia (57%) 
with afatinib, and nausea (66%), decreased appetite (53%) and vomiting 
(42%) with pemetrexed/cisplatin. Drug-related AEs led to discontinuation in 
8% (afatinib; 1% due to diarrhea) and 12% of patients (pemetrexed/cisplatin). 
Additional data from sub-group analyses will be presented. 
Conclusions: LUX-Lung 3 is the largest prospective trial in EGFR muta-
tion positive lung cancer and the first study using pemetrexed/cisplatin as a 
comparator. Treatment with afatinib significantly prolonged PFS compared to 
pemetrexed/cisplatin, with significant improvements in secondary endpoints. 
AEs with afatinib were manageable, with a low discontinuation rate. With 4.2 
months PFS improvement in the overall population and 6.7 months in patients 
with common mutations, afatinib is a clinically relevant first-line treatment 
option.
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2 
Dacomitinib (D) Versus Erlotinib (E) in Patients (pt) with 
EGFR-mutated (mu) Advanced Non-small Cell Lung Cancer 
(NSCLC): Analyses from a Randomized, Phase 2 Trial
S. Ramalingam1, F. Blackhall2, R. Rosell3, T. Mok4, M. Boyer5, J. Liang6, J. 
O’Connell6, T. Wang6, I. Taylor6, 1Emory University, Atlanta, GA, 2Christie 
Hospital, Manchester, United Kingdom, 3Catalan Institute of Oncology, 
Barcelona, Spain, 4The Chinese University of Hong Kong, Shatin, Hong 
Kong, 5Sydney Cancer Center, Camperdown, Australia, 6Pfizer Oncology, 
Groton, CT
Purpose/Objective(s): In EGFR mu sensitive and resistant NSCLC models, 
D displays superior activity over reversible EGFR tyrosine kinase inhibitors 
(TKI). D significantly improved progression free survival (PFS) compared 
with E in a randomized global, phase 2 trial for 2nd/3rd-line for advanced 
NSCLC. We report efficacy analyses in the subgroup of pt having EGFR mu. 
Materials/Methods: Eligible pt ≥18y, ECOG PS 0-2, no prior HER-directed 
therapy, and 1-2 prior chemotherapies received D 45 mg or E 150 mg once 
daily with stratification by smoking status, race, and histology. Molecular test-
ing was required. Efficacy analyses included comparisons of PFS (1°endpoint), 
objective response rate (ORR), duration of response (DR), and overall survival 
(OS). Other study endpoints included safety and patient reported outcomes. 
Results: Of 188 enrolled pt, EGFR mu was seen in 19 on D (exon 18/19/21/
T790M: 0/8/9/2) and 11 on E (2/8/1/0). For EGFR mu pt, PFS hazard ratio 
(HR) (D vs E) was 0.46 (95% CI: 0.18-1.18) with 2-sided p = 0.098; the 
median PFS was 32 weeks (wks) for both arms with a 95% CI of 17 - 80 wks 
for D and 11 - 48 wks for E. ORR was 58% (95% CI 33.5-79.7) for D and 36% 
(95% CI 10.9-69.2) for E (p=0.26). OS data will be presented at its maturity. 
For pt with Exon 19 mu (8 vs 8), PFS HR (D vs. E) was 0.27 (95% CI: 0.076-
0.94) with 2-sided p = .03; the median PFS was 77 wks (95% CI:16.9-NA) 
and 24 wks (95% CI: 11.1-72.9), respectively. However, due to small sample 
size no definitive conclusion can be made whether Exon 19 mu is predictive of 
treatment effect. Frequently reported AEs include diarrhea, acneiform derma-
titis, stomatitis, mucosal inflammation, and paronychia; the majority of events 
were grade 1 or 2 and manageable with standard supportive care. 
Conclusions: For EGFR mu pts, D had a superior PFS over E with an accept-
able safety profile in 2nd/3rd line therapy of advanced NSCLC. To our knowl-
edge this subset analysis is the first to compare a PanHER TKI to a selective 
reversible EGFR TKI.
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3 
Results of A Global Phase II Study with Crizotinib in 
Advanced ALK-positive Non-small Cell Lung Cancer 
(NSCLC)
G. J. Riely1, T. L. Evans2, R. Salgia3, S. I. Ou4, S. N. Gettinger5, G. A. 
Otterson6, S. Lanzalone7, A. Polli8, A. T. Shaw9, 1Memorial Sloan-Kettering 
Cancer Center, New York, NY, 2University of Pennsylvania, Philadelphia, 
PA, 3University of Chicago, Chicago, IL, 4University of California at Irvine, 
Irvine, CA, 5Yale University School of Medicine, New Haven, CT, 6The Ohio 
State University, Columbus, OH, 7Pfizer Italy Srl, Milan, Italy, 8Pfizer Inc, 
Milan, Italy, 9Massachusetts General Hospital Cancer Center, Boston, MA
Purpose/Objective(s): Approximately 3-5% of NSCLC harbors ALK gene 
rearrangements. Crizotinib is a first-in-class, oral, small-molecule competi-
tive ALK inhibitor with anti-MET activity. 
Materials/Methods: PROFILE 1005 is an ongoing global, multicenter, open-
label, single-arm, phase II study evaluating the safety and efficacy of crizo-
tinib (250 mg BID in 3-week cycles) in patients with advanced ALK-positive 
NSCLC who progressed after ≥1 chemotherapy for recurrent/advanced/meta-
static disease. Tumor response was evaluated by RECIST 1.1 every 6 weeks. 
Results: As of June 2011, 439 patients were evaluable for safety and 255 
patients for tumor response. Median age was 53 years. The majority of patients 
were female (53%), never smokers (65%), and had adenocarcinoma (92%), 
ECOG PS 0-1 (83%) and ≥2 prior chemotherapy regimens (85%). Among 
patients evaluable for efficacy, median treatment duration was 25 weeks (77% 
of patients still ongoing). ORR was 53% (95% CI: 47-60), disease control rate 
at 12 weeks was 85% (95% CI: 80-89), median duration of response was 43 
weeks (96% CI 36-50) and median PFS was 8.5 months (95% CI: 6.2-9.9). The 
most frequent treatment-related AEs were visual effects (50%), nausea (46%), 
vomiting (39%), and diarrhea (35%), mostly grade 1-2. 29 patients (6.6%) had 
treatment-related SAEs, including dyspnea and pneumonitis (4 patients each; 
0.9%), and febrile neutropenia and renal cyst (2 patients each; 0.5%). 
Conclusions: Crizotinib demonstrated a high response rate and PFS, and a 
favorable tolerability profile. These results provide strong evidence for crizo-
tinib as a standard of care for advanced ALK-positive NSCLC.
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Merck, GSK, Infinity. G. Consultant; Chugai, Tragara, Ariad, Daiichi, Abbott. 
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Pfizer. G.A. Otterson: E. Research Grant; Pfizer, Genentech, Tragara, 
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Clinical Activity and Safety of Anti-PD-1 (BMS-936558, 
MDX-1106) in Patients (Pts) with Advanced Non-Small-Cell 
Lung Cancer (NSCLC)
J. R. Brahmer1, L. Horn2, S. J. Antonia3, D. Spigel4, L. Gandhi5, L. Sequist6, 
J. M. Wigginton7, G. Kollia7, A. Gupta7, S. Gettinger8, 1The Sidney Kimmel 
Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, 
2Vanderbilt-Ingram Cancer Center, Nashville, TN, 3H. Lee Moffitt Cancer 
Center & Research Institute, Tampa, FL, 4Sarah Cannon Research Institute/
Tennessee Oncology, PLLC, Nashville, TN, 5Dana-Farber Cancer Institute, 
Boston, MA, 6Massachusetts General Hospital Cancer Center, Boston, MA, 
7Bristol-Myers Squibb, Princeton, NJ, 8Yale University School of Medicine, 
New Haven, CT
Purpose/Objective(s): BMS-936558 is a fully human, monoclonal anti-
body that blocks the programmed death-1 (PD-1) co-inhibitory receptor 
expressed by activated T cells. We report here an interim analysis demon-
strating that BMS-936558 mediates antitumor activity in heavily pretreated 
pts with advanced NSCLC, a tumor historically not considered responsive to 
immunotherapy.
Materials/Methods: BMS-936558 was administered IV Q2wks to pts with 
various solid tumors, including NSCLC, at doses of 0.1, 1, 3, or 10 mg/kg 
during dose-escalation and/or cohort expansion. Pts with advanced NSCLC 
previously treated with at least one prior chemotherapy regimen were eligible. 
Pts received up to 12 cycles (4 doses/cycle) of treatment or until unacceptable 
toxicity, confirmed progressive disease, or complete response. Clinical activ-
ity was assessed by RECIST v1.0. 
Results: As of Feb 24, 2012, 122 NSCLC pts had received BMS-936558 at 
0.1 (n=1), 1 (n=30), 3 (n=33), or 10 mg/kg (n=58). ECOG performance status 
was 0 for 34 pts, 1 for 83 pts, 2 for 2 pts, and not reported for 3 pts. Tumor his-
tology was squamous (n=47), nonsquamous (n=73), or not determined (n=2). 
Number of prior therapies was 1 (n=18), 2 (n=31), 3 (n=27), ≥4 (n=40), or 
unknown (n=6); 94% of pts had received platinum-based chemotherapy and 
34% had a prior tyrosine-kinase inhibitor. Sites of metastatic disease included 
lymph node (n=50), liver (n=12), lung (n=62), and bone (n=13). Median 
duration of therapy was 12 wks (range 2−101.3 wks). Common drug-related 
adverse events (AEs) in NSCLC pts were fatigue (18%), decreased appetite 
(10%), anemia (8%), nausea (7%), pyrexia (6%), and diarrhea (6%). The inci-
dence of grade 3-5 related AEs was 8%. There were 2 drug-related deaths 
because of pulmonary toxicity (both pneumonitis). Among the 76 NSCLC 
pts evaluable for response, there were 14 partial responses (PRs) at doses of 
1 (1/18 pts), 3 (6/19 pts), and 10 mg/kg (7/39 pts) giving response rates of 
6%, 32%, and 18%, respectively. Additionally, 2 NSCLC pts who received 
10 mg/kg were awaiting a confirmatory scan and, therefore, had unconfirmed 
PRs. Responses were observed across NSCLC histologies with 6 responders 
among 18 pts with squamous histology (33%) and 7 among the 56 nonsqua-
mous pts (12.5%). All of the 14 responding pts started treatment >24 wks 
before analysis and, of these, 8 had a response duration ≥24 wks. Five pts 
(7%), all with nonsquamous histology, had stable disease lasting ≥24 wks. 
Additionally, 3 pts had a persistent decrease in overall tumor burden in the 
presence of new lesions and were not categorized as responders.
Conclusions: BMS-936558 is well tolerated and has encouraging clinical 
activity in pts with previously treated, advanced NSCLC. Further develop-
ment of BMS-936558 in pts with advanced NSCLC is warranted.
Author Disclosure Block: J.R. Brahmer: None. L. Horn: G. Consultant; 
OSI/Astellas Advisory Board December 2011. S.J. Antonia: None. D. 
Spigel: G. Consultant; Bristol-Myers Squibb. L. Gandhi: None. L. Sequist: 
G. Consultant; Clovis, Celgene, GlaxoSmithKline, Daiichi-Sankyo, 
Merrimack. J.M. Wigginton: A. Employee; Bristol-Myers Squibb. K. Stock; 
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Phase III Comparison of Prophylactic Cranial Irradiation 
Versus Observation in Patients with Locally Advanced Non-
small-cell Lung Cancer: Updated Analysis of RTOG 0214.
E. M. Gore1, R. Paulus2, S. Wong1, A. Sun3, G. Videtic4, S. Dutta5, M. 
Suntharalingam6, Y. Chen7, L. E. Gaspar8, H. Choy9, 1Medical College of 
Wisconsin, Milwaukee, WI, 2Radiation Therapy Oncology Group, Phildelphia, 
PA, 3Princess Margaret Hospital-University Health Network,, Toronto, ON, 
Canada, 4Cleveland Clinic Foundation, Cleveland, OH, 5Michigan Cancer 
Research Consortium, Ann Arbor, MI, 6University of Maryland, Baltimore, 
MD, 7University of Rochester, Rochester, NY, 8University of Colorado, Aurora, 
CO, 9UT Southwestern, Dallas, TX
Purpose/Objective(s): To determine if prophylactic cranial irradiation 
(PCI) improves survival in locally advanced non-small-cell lung cancer 
(LA-NSCLC). This is an updated 5-year analysis. 
Materials/Methods: Patients with stage III NSCLC without disease progres-
sion after treatment with surgery and/or radiation therapy (RT) with or with-
out chemotherapy were eligible. Participants were stratified by stage (IIIA v 
S205Copyright © 2012 by the International Association for the Study of Lung Cancer
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IIIB), histology (nonsquamous v squamous), and therapy (surgery v none) 
and were randomly assigned to PCI or observation. PCI was delivered to 30 
Gy in 15 fractions. The primary end point of the study was overall survival 
(OS). Secondary end points were disease-free survival (DFS), neurocognitive 
function (NCF), and quality of life. Kaplan-Meier and log-rank analyses were 
used for OS and DFS. The incidence of brain metastasis (BM) was evaluated 
with the logistic regression model. 
Results: A total 356 patients were enrolled with 340 eligible for analysis. The 
median follow-up time was 24.2 months for all patients and 58.6 months for 
living patients. The 5-year OS (P = .57; 26.1% v 24.6% for PCI v observa-
tion) and 5-year DFS (P = .13; 18.5% v 14.9% for PCI v observation) were 
not significantly different. The 5-year rates of BM were significantly different 
(P = .009; 17.3% v 26.8% for PCI v observation). Of the patients who failed, 
10% of patients on the PCI arm and 23% of patients on the observation arm 
experienced failure in the brain initially. Brain metastases were the only com-
ponent of first failure in 9.1% and 21.5% of patients with and without PCI.. On 
multivariate analysis PCI is significantly associated with decreased BM. Non-
squamous histology was associated with increased risk of BM. The overall rate 
of BM in this trial was insufficient for reliable subset analyses by histology. 
Conclusions: In patients with stage III disease without progression of disease 
after therapy, PCI decreased the 5- year rate of BM but did not improve OS or 
DFS. This study confirms the effectiveness of PCI for prevention of brain fail-
ures. Further information is needed to determine which patient subset could 
derive a survival benefit from PCI.
Author Disclosure Block: E.M. Gore: None. R. Paulus: None. S. Wong: 
None. A. Sun: None. G. Videtic: None. S. Dutta: None. M. Suntharalingam: 
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Decreased Overall Survival after Prophylactic Cranial 
Irradiation for Non-Small Cell Lung Cancer
M. N. Corradetti1, E. Xanthopoulos1, S. Cheng2, D. Horowitz2, A. Fernandes1, 
A. Lusa2, C. Chao2, R. Rengan1, 1University of Pennsylvania Affiliated 
Hospitals, Philadelphia, PA, 2Columbia University College of Physicians and 
Surgeons, New York, NY
Purpose/Objective(s): Prophylactic cranial irradiation (PCI) may delay the 
incidence of brain metastases in non-small cell lung cancer (NSCLC) patients 
after primary therapy, but its impact on survival is uncertain. Here we report 
on the largest and longest study of survival in patients treated with or without 
PCI for NSCLC. 
Materials/Methods: We reviewed 17 registries from the National Cancer 
Institute’s Surveillance, Epidemiology, and End Results database to capture 
NSCLC patients who had PCI as part of their primary treatment from 1988 - 
1997. Cases were limited to those with non-metastatic NSCLC; median follow-
up was 14 years. We matched each PCI patient with four non-PCI patients based 
on stage, histology, race and sex. Associations between treatment type, clinical 
factors, and demographics were assessed using a Chi-squared test. Survival time 
was calculated as the number of months from diagnosis to the date of death. 
Survival was censored as of the last month when patients were known to be alive. 
Overall (OS) and cancer cause-specific survival (CSS) were investigated using 
Kaplan-Meier, competing risks, Cox proportional hazards, and log-rank tests. 
Results: 472 PCI patients were matched to 1,888 non-PCI patients. 
Characteristics were balanced across groups, including race (p = 1.00), gender 
(p = 0.95), histology (p = 1.00), stage (p = 1.00), and surgery (p = 0.81). The 
PCI group was younger, with a median age of 64 vs 68 years (p < 0.01). Median 
OS was 10 vs 8 months (p < 0.01) favoring the non-PCI group. OS in the PCI 
vs non-PCI groups was 14% vs 28% at 2 years (p < 0.01) and 5% vs 12% at 5 
years (p < 0.01). In Stage III patients (n = 365) OS was 10% vs 21% at 2 years 
(p < 0.01). The decrement in OS with PCI was also observed when patients with 
bulky disease (T3 and above) and adenocarcinoma histology were examined 
separately. Median CSS was the same (9 months) in both groups. 
Conclusions: To date, four prospective trials examining PCI for NSCLC have 
been reported in full and demonstrated a significant reduction in the incidence 
of brain metastases, but the effect on overall survival is not clear. Here we 
demonstrate in the largest cohort study of PCI for NSCLC that there is a 
significant decrement in overall survival associated with PCI. While patients 
with limited stage small-cell lung cancer (SCLC) derive both an overall sur-
vival and brain metastasis-free survival benefit from PCI, there is a signifi-
cantly higher likelihood for intracranial metastatic disease in SCLC than in 
NSCLC. Our results imply that there may be a propensity threshold for intra-
cranial metastatic disease below which PCI is not warranted, and that future 
clinical trials investigating the role of PCI for NSCLC may not be justified.
Author Disclosure Block: M.N. Corradetti: None. E. Xanthopoulos: 
None. S. Cheng: None. D. Horowitz: None. A. Fernandes: None. A. Lusa: 
None. C. Chao: None. R. Rengan: None.
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Initial Cooperative Group Experience of Bevacizumab (Bev) 
Plus Concomitant Chemoradiotherapy (CRT) in Patients with 
Inoperable Locally Advanced Stage III Non-Small Cell Lung 
Cancer (LA-NSCLC): Preliminary Results of S0533
C. R. Thomas1, J. Moon2, L. E. Gaspar3, D. Raben3, T. J. Fitzgerald4, A. J. 
Wozniak1, K. Kelly5, P. C. Mack5, K. J. Pandya6, D. R. Gandara5, 1Oregon 
Health and Science University, Portland, OR, 2SWOG Statistical Center, 
Seattle, WA, 3University of Colorado, Denver, CO, 4Quality Assurance Review 
Center, Providence, RI, 5University of California @ Davis, Sacramento, CA, 
6University of Rochester James P. Wilmot Cancer Center, Rochester, NY
Background: Bev combined with chemotherapy has improved survival in the 
treatment of advanced NSCLC. Pre-clinical data suggest that Bev has radio-
sensitizing properties in solid tumor models. The specific aim of this analysis 
is to describe the results of incorporating Bev into the standard SWOG CRT 
regimen in LA-NSCLC. 
Methods/Materials: Pts with unresectable stage III NSCLC, PS 0-1, ade-
quate organ function were accrued in two strata, low and high risk (squamous 
histology, hemoptysis, tumor cavitation and/or near a major vessel). Pts were 
treated with CDDP 50mg/m2 (D1, 8), Etoposide 50mg/m2 (D1-5) for 2 cycles 
concurrent with TRT (64.8 Gy at 1.8 Gy/fx for 36 fxs) followed by consolida-
tion Docetaxel 75mg/m2 and Bev 15 mg/kg for 3 cycles (Cohort 1). If safety 
was established then accrual would continue with Bev administered on D1`5, 
37, 57 of concurrent chemoradiotherapy (Cohort 2) followed by advancing 
Bev to Day 1, 22, 43 (Cohort 3). 3D treatment planning (CT or PET-CT) and 
delivery, including tissue heterogeneity corrections, was mandated. QARC 
approved 3D benchmarks were required. IMRT was not allowed. V20 limit 
(total lung volume -GTV) < 35%. 
Results: 29 pts (17 Low, 12 High) were registered, all to Cohort 1. 26 pts 
(stage IIIB 19 pts, squamous 4 pt, adenosquamous 1 pt) were evaluable, 
including 10 high-risk, 16 low-risk cases. 22 pts reached a total dose of 64.8 
Gy (with an unscheduled RT break in a single pt). Of 9 high-risk pts with 
RT data available, median V20=30%, range: 23%-35%; of 14 low-risk pts 
with RT data available, median V20=35%, range: 21%-48%. In 12 pts V20 
was near or > 35%: 34% in 2 pts, 35% in 5 pts, 45% in 2 pts, & 48% in 2 
pts. Grade 3-4 toxicities during CRT included: neutropenia 10 pts, thrombo-
cytopenia 2, anemia 2, febrile neutropenia 3, esophagitis 2, and pneumonitis 
1. Two episodes of fatal hemoptysis in the high risk group, occurring during 
consolidation therapy, resulting in closure of this stratum. The low risk stra-
tum, in which no hemoptysis occurred, subsequently closed because of poor 
accrual. Median overall survival was 23 mos for low risk pts and 17 mos for 
the high risk stratum. 
Conclusions: Bev could not be successfully integrated into CRT for 
LA-NSCLC as designed in this trial due to unacceptable hemoptysis. Trials 
with bevacizumab in this setting should not be pursued. Supported, in part, 
by the following PHS Cooperative Agreement grant numbers awarded by the 
National Cancer Institute, DHHS: CA32102, CA38926, and CA29511
Author Disclosure Block: C.R. Thomas: None. J. Moon: None. L.E. Gaspar: 
None. D. Raben: None. T.J. Fitzgerald: None. A.J. Wozniak: None. K. Kelly: 
None. P.C. Mack: None. K.J. Pandya: None. D.R. Gandara: None.
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A Randomized Trial of Lung Stereotactic Body Radiation 
Therapy (SBRT) Delivered Over 4 or 11 Days - Acute Toxicity 
and Quality of Life
S. Jain1,2, I. Poon1,2, B. Keller1,2, H. Soliman3,2, F. Lochray1,2, A. Kim1,2, 
P. Cheung1,2, 1Sunnybrook Odette Cancer Centre, Toronto, ON, Canada, 
2Department of Radiation Oncology, University of Toronto, Toronto, ON, 
Canada, 3Carlo Fidani Peel Regional Cancer Centre, Toronto, ON, Canada
Purpose/Objective(s): There is a lack of international consensus regarding 
the duration over which lung SBRT should be delivered. In the absence of 
definitive data, some centres treat patients on consecutive days and others 
every second or third day. We conducted a randomized study comparing acute 
toxicity and quality of life (QoL) in patients treated with 4 fractions of lung 
SBRT on 4 consecutive days or over 11 days. 
Materials/Methods: Patients with a peripheral solitary lung tumour (NSCLC 
or pulmonary metastasis) ≤ 5cm were eligible. 4D-CT simulation with immo-
bilization by a thoracic vacuum device and abdominal compression plate was 
performed. Planning target volume (PTV) margin was 5 mm around the inter-
nal target volume (ITV). For NSCLC lung tumors ≤ 3 cm, a dose of 48 Gy in 4 
fractions was used, otherwise 52 Gy in 4 fractions was delivered. At least 99% 
of the ITV received the prescribed dose, and ≥ 99% of the PTV received 95% 
of the prescribed dose. Patients were randomly assigned to receive treatment 
over 4 consecutive days or over 11 days. Symptoms were recorded at baseline 
and acute toxicity assessed at last treatment, 1 month and 4 months post-
treatment using Common Terminology Criteria for Adverse Events (CTCAE) 
v4.0. Cough, dyspnea, pneumonitis, radiation dermatitis, fatigue, nausea, 
esophagitis, fracture, and chest wall pain were measured. QoL was assessed 
using the EORTC QLQ-C30 and QLQ-LC13 questionnaires. The primary 
endpoint was incidence of acute grade ≥ 2 toxicity. 
Results: From 3/2010 to 12/2011, 50 patients were enrolled, 42 are currently 
evaluable at all time points. Treatment groups were well balanced with regard 
to age, sex, tumor location, tumor type, and treatment dose. Patients in the 
11-day treatment arm had significantly more respiratory symptoms at baseline 
(p=0.011). There was no significant difference in acute grade ≥ 2 toxicity in 
patients treated over 4 days or 11 days (44% and 36% respectively, p=0.387). 
Grade 3 toxicity occurred in 6% of patients treated (4% 4-day group, 8% 
11-day group, p=0.48. No grade 4/5 toxicities were observed. Grade ≥ 2 acute 
respiratory toxicity occurred in 44% of patients treated over 4 days and 24% 
of patients treated over 11 days, (p=0.116). No patient, tumor or dosimetric 
factors significantly predicted for acute grade ≥ 2 respiratory toxicity. There 
was no difference in global QoL scores between treatment arms at any time-
point. At 4 months dyspnea scores improved in patients in the 11-day group 
(-17.4%) but were worse in those in the 4-day group (9.5%)(p=0.01). 
Conclusion: There was no significant difference in the primary endpoint of 
acute grade ≥ 2 toxicity in patients treated with lung SBRT over 4 consecutive 
days or 11 days. However, more patient reported dyspnea occurred in patients 
treated over 4 consecutive days.
Author Disclosure Block: S. Jain: None. I. Poon: None. B. Keller: None. 
H. Soliman: None. F. Lochray: None. A. Kim: None. P. Cheung: None.
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Kras Oncogene Substitutions And Clinical Outcome In Lung 
Adenocarcinoma
L. Villaruz, M. Socinski, D. Cunningham, S. Chiosea, J. Siegfried, S. Dacic, 
University of Pittsburgh, Pittsburgh, PA, PA
Purpose/Objective(s): The prognostic and therapeutic implications of the 
spectrum of KRAS oncogene substitutions in lung cancer remain poorly 
understood. The objective of this study was to determine if KRAS oncogene 
substitutions are prognostic or predictive in lung adenocarcinoma. 
Materials/Methods: All patients diagnosed with KRAS mutation (KRASmut) 
positive lung adenocarcinoma at the University of Pittsburgh Medical Center 
Cancer (UPMC) between 2005 and 2011 were included in the analysis. 
Mutant-allele specific imbalance (MASI), when the mutant allele is pre-
dominant over the wildtype allele, was defined as either M>W (KRASmut 
peak greater than wildtype peak on sequencing electropherograms) or M=W 
(KRASmut peak equal to wildtype peak), and no MASI was defined as M<W 
(KRASmut peak less than a wildtype peak). Clinical data were collected 
through the UPMC Cancer Registry and Medical Archival System. Survival 
probabilities were estimated using the Kaplan Meier Method and Cox propor-
tional hazard models were used to examine the effects of the KRASmut and 
MASI on overall survival (OS) and relapse-free survival (RFS). 
Results: 318 patients with KRASmut lung adenocarcinoma were included 
in the analysis. Baseline characteristics included: mean age of 67 (range 
39-92 yrs), 91.5% white, 59.4% female, 45.0% former smokers, 32.1% cur-
rent smokers, 5.7% never smokers (17.3% unknown), 45.0% stage I, 16.3% 
stage II, 17.3% stage III, and 20.1% stage IV. KRASmut were most com-
monly GLY→CYS (46.9%), GLY→VAL (18.9%), GLY→ASP (16.4%), 
GLY→ALA (7.5%) and others (5.1%)/unknown (5.3%). 56.6% patients had 
M<W, 5.3% M=W, and 6% M>W (32.1% unknown). Median follow-up was 
24.3 months (range 0-6.5 yrs). OS (p=0.612; log-rank) and RFS (p=0.065; 
log-rank) did not differ by KRASmut. KRASmut were not a significant predic-
tor of survival when controlling for age, clinical stage, or chemotherapy (OS, 
p=0.204; RFS, p=0.118). RFS differed significantly by MASI (p=0.007; log-
rank). No MASI was associated with significantly better RFS compared with 
presence of MASI (M=W, p=0.024; M>W, p=0.011). Controlling for clinical 
stage, MASI was associated with a greater risk of recurrence compared with 
no MASI (M>W: HR=2.79; p=0.016; M=W: HR=3.51, p=0.028). In stage I/
II/III disease, the mutation type and MASI were not associated with adjuvant 
chemotherapy benefit for OS (KRASmut, p=0.487; MASI, p=0.305) or RFS 
(KRASmut, p=0.307; MASI, p=0.324). 
Conclusions: In this large series of predominantly early stage KRASmut lung 
adenocarcinoma, the KRAS oncogene substitution was neither prognostic nor 
predictive. However, patients with KRAS MASI had a significantly worse RFS 
compared with patients with no MASI. MASI is an intriguing candidate bio-
marker for prognosis that may be useful to incorporate in prospective studies 
evaluating novel therapies in KRASmut lung adenocarcinoma.
Author Disclosure Block: L. Villaruz: None. M. Socinski: None. D. 
Cunningham: None. S. Chiosea: None. J. Siegfried: None. S. Dacic: None.
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Clinical Behavior Of Lung Cancers Harboring EGFR Exon 
20 Insertions
P. C. Lo, D. M. Jackman, M. Butaney, N. I. Lindeman, B. E. Johnson, P. A. 
Jänne, G. R. Oxnard, Dana-Farber Cancer Institute, Boston, MA
Purpose/Objective(s): EGFR exon 20 insertions (ins) are the third most 
common family of EGFR mutations in non-small cell lung cancer (NSCLC). 
These cancers are believed to be insensitive to the EGFR tyrosine kinase 
inhibitors (TKIs) erlotinib and gefitinib, but their clinical behavior is other-
wise poorly described. 
Material/Methods: An institutional database of patients (pts) with NSCLC 
was reviewed in an IRB approved fashion. Eligible pts had NSCLC and had 
undergone sequencing of the EGFR gene. Pts with cancers harboring exon 20 
ins were indentified, management was reviewed and treatment outcomes were 
assessed. Time to progression (TTP) was calculated from start of therapy to 
date of clinical progression, collectedly retrospectively from medical records. 
Survival was calculated from date of advanced disease. Characteristics of 
NSCLC pts with other EGFR mutations and wild-type for EGFR were used 
for comparison. 
Results: 951 pts with NSCLC underwent EGFR sequencing from 2004 to 
2012 (99% non-squamous, 29% never-smokers, 5.8% Asian). Of 233 pts with 
an EGFR mutation, 25 pts (11%, 2.6% of all pts) harbored an exon 20 ins. 
Both pts with exon 20 ins and the 208 pts with other EGFR mutations were 
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more often never-smokers (56%, 53%) and Asian (16%, 12%) than the 718 
pts wild-type for EGFR (21%, p<0.001, p<0.001) (3.8%, p=0.02, p<0.001). 
13 different exon 20 ins variants were identified spanning 15 amino-acid 
residues. 8 variants occurred more than once and the most common (V769_
D770insASV) constituted only 5 (25%) of the exon 20 ins cases. For pts with 
exon 20 ins and evaluable disease, median TTP on initial exposure to erlotinib 
or gefitinib was 3.1 months (1-4.1 months, 9), shorter than the median TTP 
of 6.3 months (1.5-19 months, 17) on initial exposure to platinum-based che-
motherapy (p=0.001). Median survival with advanced disease was 19 month 
for 22 pts with exon 20 ins, shorter than for 166 pts with other EGFR muta-
tions (31 months, p=0.002) but similar to the survival of 561 pts wild-type for 
EGFR (21 months). 
Conclusion: Pts with EGFR exon 20 ins have similar clinical characteris-
tics to those with other EGFR mutations, but do poorly on TKIs and have a 
shorter survival. This subset of NSCLC has a similar prevalence when com-
pared to other uncommon mutations in lung adenocarcinoma (e.g. BRAF, 
HER2, ROS1, RET) and is an attractive population for trials of new targeted 
therapies.
Author Disclosure Block: P.C. Lo: None. D.M. Jackman: None. M. 
Butaney: None. N.I. Lindeman: None. B.E. Johnson: None. P.A. Jänne: 
None. G.R. Oxnard: None.
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Single Nucleotide Polymorphisms in DNA Repair Genes May 
Be Associated with Survival in Patients with Non-small Cell 
Lung Cancer Treated with Definitive Radiotherapy
W. Wang1,2, K. Shedden3, R. Ten Haken1, J. Hayman1, D. Arenberg4, T. 
Lawrence1, F. S. Kong1,5, 1Department of Radiation Oncology, University of 
Michigan, Ann Arbor, MI, 2Department of Radiation Oncology, The Fourth 
Affiliated Hospital, China Medical University, Shenyang, China, 3The Center 
For Statistical Consultation and Research, Michigan University, Ann Arbor, 
MI, 4Division of Pulmonary and Critical Care Medicine, Michigan University, 
Ann Arbor, MI, 5Department of Radiation Oncology, Veteran Administration 
Hospital, Ann Arbor, MI
Purpose/Objective(s): DNA repair pathways may modulate cancer treatment 
response, and have significant association with cancer prognosis. This study 
aimed to examine the association between single nucleotide polymorphisms 
(SNPs) of DNA repair genes and overall survival (OS) in patients with non-
small cell lung cancer (NSCLC) treated with radiation based therapy. 
Material/Methods: Patients with stage I-III NSCLC who received defini-
tive radiotherapy with/without chemotherapy were eligible to this prospective 
study. The primary endpoint was OS which was calculated from radiation 
treatment start to the date of death or censored. DNA samples for genotyping 
were extracted from buffy-coat which was collected before commencement of 
treatment. 24 SNPs in 11 genes were selected as they are known to have corre-
lation with treatment response/toxicity or risk of lung cancer (ATM, ERCC1, 
ERCC2, ERCC5, XRCC1, XRCC2, XRCC4, XPC, MGMT, NBN, TP53). 
The MassArray System (Sequenom Company) was used for genotyping. A 
Cox proportional hazards model was used for multivariate analysis to exam-
ine the effects of genotypes on OS using three genetic models. False discovery 
rate (FDR) correction was performed for multiple testing. Kaplan-Meier log-
rank tests were used to evaluate the effect of SNPs on OS. 
Results: 119 consecutive patients, 93.9% Caucasian, were included in 
this study. All SNPs call rates were over 90.0%. Assay reproducibility was 
over 99.0% by random double-blinding duplicate or triplicate genotyping. 
Genotype association showed that 4 SNPs (ATM: rs189037 and rs664677, 
XRCC4: rs2075685, ERCC2: rs238406) were significantly associated with 
OS, adjusted for age, gender, smoking, histology, clinical stage, tumor vol-
ume, Karnofsky performance status, radiation dose, and chemotherapy. 
However, only ERCC2: rs238406 remained significant after FDR correction 
(hazard ratio, 0.46, 95% confidence interval, 0.27-0.78, p
correct
 = 0.044 for 
GG vs. GT/TT). Interaction analysis of radiation dose and genotypes demon-
strated an additive effect. ERCC2: rs238406 had significant effect on OS in 
the low dose (<70 Gy) group (9.93 vs. 20.46 months, p = 4.15×10-4 for GG vs. 
GT/TT) as compared to that of no significant effect in the high dose (≥70 Gy) 
group (33.37 vs. 28.96 months, p = 0.919 for GG vs. GT/TT). 
Conclusions: This study suggests that genetic variants in DNA repair path-
way genes, particularly ERCC2: rs238406, may determine OS of patients 
with NSCLC treated with radiotherapy. Genetic variants and their interaction 
with radiation dose may potentially guide individualized dose escalation in 
NSCLC radiotherapy. Larger sample size studies are needed to confirm our 
findings.
Author Disclosure Block: W. Wang: None. K. Shedden: None. R. Ten 
Haken: None. J. Hayman: None. D. Arenberg: None. T. Lawrence: None. 
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Significant Numbers of Irradiated Tumor Cells Enter the 
Circulation Early During a Course of Fractionated Radiation 
Therapy for Non-Small Cell Lung Cancer
M. P. MacManus, D. Jacobs, H. Do, D. Ball, A. Ivashkevich, A. Dobrovic, R. 
Martin, O. Martin, Peter MacCallum Cancer Centre, Melbourne, Australia
Purpose/Objectives: We hypothesized that changes in tumor ultrastructure 
occurring during fractionated radiation therapy (RT) could lead to the entry 
of intact tumor cells into the circulation. Circulating tumor cells (CTCs) 
have been detected in many cancers, including non-small cell lung cancer 
(NSCLC) where they have prognostic significance. Tumor cells released 
into the peripheral circulation early in a course of RT would have received 
less than the prescribed dose, could be viable and might cause metastasis. 
Phosphorylation of the histone H2AX leads to the development of γ-H2AX 
foci at sites of double-stranded breaks (DSB) in DNA. γ-H2AX is a sensitive 
biomarker for RT-induced DSBs. We designed a series of experiments in vitro 
and in vivo, investigating the use of γ-H2AX to detect CTCs entering the 
circulation from irradiated tumors. 
Materials/Methods: In preliminary experiments, using whole human blood 
spiked with irradiated tumor cells, we demonstrated that tumor cells could be 
separated from blood cells by fluorescence activated cell separation (FACS), 
based on the intensity of γ-H2AX signal, 24 hrs post-10 Gy γ-irradiation, 
using an antibody to γ-H2AX. We designed a pilot study to search for 
γ-H2AX-positive CTCs in human subjects receiving fractionated RT for 
NSCLC. CTCs were identified by FACS using a combination of antibodies to 
γ-H2AX and cytokeratin. CTCs were also identified by confocal microscopy 
of cytospins made from buffy coat by labelling with both anti-γ-H2AX and 
anti-cytokeratin antibodies. 
Results: Ten patients with NSCLC were enrolled in the pilot study. Patients 
received palliative RT with daily doses of 3-4Gy. Histologies were squamous 
carcinoma n=6, adenocarcinoma n=3, other n=1. All patients had baseline 
venous blood samples and a sample 24h after fraction1. Subsequently 1-2 fur-
ther samples were taken 24h after a range of different fractions. We identified 
marked FACS changes consistent with γ-H2AX-positive CTCs in all patients 
but one. Tumor cells positive for both γ-H2AX and cytokeratin were also 
identified on cytospins by microscopy. Methods were refined during the study. 
In the 5 cases where relative numbers of baseline and on-treatment CTC lev-
els could be compared, different patterns of CTC release were seen, including 
a rise then clearance of CTCs, but with the greatest CTC increase seen most 
commonly after fraction 1. In the 2 cases where absolute quantification was 
possible, CTCs were detected in both baseline samples and their numbers 
increased by 344% and 136% respectively after fraction 1, with a peak of 300 
CTCs per ml in one case. 
Conclusions: Early in a course of RT for NSCLC, significant numbers of 
irradiated tumor cells enter the circulation. This novel finding has potential 
clinical significance.
Author Disclosure Block: M.P. MacManus: None. D. Jacobs: None. H. 
Do: None. D. Ball: None. A. Ivashkevich: None. A. Dobrovic: None. R. 
Martin: None. O. Martin: None.
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A Randomized Phase II Study of Pazopanib or Placebo in 
Combination with Erlotinib in Patients with Advanced Non-
Small-Cell Lung Cancer
D. Spigel1, H. A. Burris1, F. A. Greco1, K. C. Shih1, A. J. Lipman2, D. B. 
Flora3, D. B. Daniel4, D. M. Waterhouse2, J. V. Haymach5, J. D. Hainsworth1, 
1SCRI, Nashville, TN, 2Florida Cancer Specialists/SCRI, Fort Meyers, FL, 
3Oncology Hematology Care, Inc/SCRI, Cincinnati, OH, 4Chattanooga 
Oncology Hematology Associates/SCRI, Chattanooga, TN, 5MD Anderson 
Cancer Center, Houston, TX
Purpose/Objective(s): Pazopanib is an oral multikinase inhibitor approved 
in advanced renal cell cancer. Preliminary activity was seen in non-small-cell 
lung cancer (NSCLC) where preoperative pazopanib reduced tumors in 86% 
of patients (pts) with stage I-II disease (Altorki JCO 2010). Pazopanib has 
been safely combined with erlotinib in a phase I study (Dy ESMO 2009). Pts 
with refractory NSCLC were treated with pazopanib and erlotinib (PE) or 
placebo and erlotinib (E) in this multicenter double-blind randomized phase II 
study. The primary endpoint was progression-free survival (PFS). Secondary 
endpoints were objective response rate, toxicity, and overall survival (OS). 
Blood and tumor samples were collected for biomarker analyses. 
Materials/Methods: Pts with IIIB/IV NSCLC, an ECOG PS 0-1, measur-
able disease, following 1-2 lines of chemotherapy were eligible. Pts were ran-
domized 2:1 to erlotinib 150mg PO daily and pazopanib 600mg PO daily or 
erlotinib and placebo until disease progression or unacceptable toxicity with 
imaging every 8 weeks.
Results: 192 pts were enrolled (PE=127, E=65) from 2/2010 to 2/2011. 
Baseline characteristics were well balanced: median age 66 yrs (35-88 yrs), 
54% male, 63% second-line. The median treatment duration per arm was 2 
months. PE resulted in a statistically significant improvement in PFS: HR 
0.59 (95% CI, 0.43-0.83); median 2.6 (PE) and 1.8 (E) months; P=.0016. The 
partial response and stable disease rates were 6% and 39% (PE) and 0 and 
35% (E). OS was similar between arms: HR 1.1 (0.77-1.55); median 6.8 (PE) 
and 6.7 months (E); P=.61. PE resulted in statistically significant improve-
ments in PFS in pts with proteomic classified VeriStrat good tumors (HR 
0.49). Additional EGFR mutation, EGFR FISH, KRAS mutation, MET FISH, 
cytokine and angiogenic factor analyses will be presented. Grade 3/4 hemato-
logic toxicity was rare (<4%) per arm. Severe nonhematologic toxicities were: 
diarrhea (PE 19%, E 9%), fatigue (PE 20%, E 14%), and proteinuria (PE 5%, 
E 0). Elevated hepatic enzymes occurred with greater frequency in the treat-
ment arm occurring in up to 3% of pts and reversed with therapy cessation. 
Conclusions: The combination of pazopanib and erlotinib improved PFS over 
erlotinib alone in this double-blind randomized phase II study. PFS advan-
tages were seen in several biomarker-defined subgroups. Additional study of 
pazopanib in NSCLC is warranted.
Author Disclosure Block: D. Spigel: G. Consultant; GSK. H.A. Burris: None. 
F.A. Greco: None. K.C. Shih: None. A.J. Lipman: J. Funding Other; Florida 
Cancer Specialists. D.B. Flora: None. D.B. Daniel: None. D.M. Waterhouse: 
F. Honoraria; Lilly, Genetech. G. Consultant; Lilly. J.V. Haymach: E. Research 
Grant; GSK. G. Consultant; GSK. J.D. Hainsworth: None.
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Randomized Phase 3 Study Of Concurrent Cisplatin with 
Pemtrexed Or Vinorelbine And Late Course Accelerated 
Hyperfractionated Radiotherapy For Unresectable Stage 3 
Non-small-cell Lung Cancer
B. Li1,2, Z. Wu2,3, Z. Wang1, Q. Wang3, 1Shandong Tumor Hospital, Jinan, 
China, 2Dezhou Tumor Hospital, Dezhou, China, 3Linzi people hospital, Zibo, 
China
Purpose/Objective(s): To evaluate pemetrexed in combination with cisplatin 
in these patients, a randomized phase III study of concurrent cisplatin with 
pemtrexed or vinorelbine and late course accelerated hyperfractionated radio-
therapy (LCAHRT) was performed. 
Materials/Methods: A total of 86 patients were randomly assigned to two 
concurrent regimens. Arm1 included cisplatin at 25 mg/m2 on days 1-3, 
22-24 and vinorelbine at 25 mg/m2 on days 1,8 and 22,29 with concurrent 
late course accelerated hyperfractionated radiotherapy. Arm 2 used cisplatin 
at 25 mg/m2 on days 1-3, 22-24 and pemtrexed at 500 mg/m2 on days 1 and 
22 with the same radiotherapy protocol. The primary endpoint was overall 
survival (OS), and secondary endpoints included progression free survival 
(PFS) and toxicities. Kaplan-Meier analyses were used to assess survival, and 
toxic effects were examined using the Pearson Chi-Square test. All statistical 
tests were two-sided. 
Results: 84 patients were analyzed for 2 patients in arm 1 were not finished 
treatment according to the protocol. The mean radiation dose in arms 1-2 was 
6.2±7.5Gy and 67.9±7.4 Gy. 76 patients used 2 cycle concomitant chemother-
apy, 4 cases 3 cycles, and 4 ones 1 cycle (3 in arm 1 and 1 in arm 2). Median 
OS were 23 and 25 months for arms 1-2, respectively (p=0.224). Median PFS 
were 15 and 22.5 months, respectively (p=0.109). Concerning toxicities of 
grade 2 or more in the arms 1 and 2, the white blood cell was 32/41 and 20/43 
(p=0.003), esophagitis 14/41 and 10/43 (p=0.269), pneumonitis 8/41 and 6/43 
(p=0.494), vomiting 13/41 and 9/43 (p=0.261), hemotoblatin 8/41 and 5/43 
(p=0.318), platelet 9/41 and 5/43 (p=0.204),respectively. 
Conclusions: Concurrent cisplatin with pemtrexed and LCAHRT was as 
effective as with vinorelbine for unresectable stage III non-small cell lung 
cancer, however, the treatment compatibility was better.
Author Disclosure Block: B. Li: None. Z. Wu: None. Z. Wang: None. Q. 
Wang: None.
15 
Clinical Activity Of Crizotinib In Advanced Non-Small 
Cell Lung Cancer (NSCLC) Harboring ROS1 Gene 
Rearrangement
A. T. Shaw1, D. Camidge2, J. W. Clark1, K. Wilner3, L. Tye3, P. Stephenson4, 
M. Varella-Garcia2, A. Iafrate1, S. I. Ou5, 1Massachusetts General Hospital 
Cancer Center, Boston, MA, 2University of Colorado Cancer Center, Aurora, 
CO, 3Pfizer Inc, La Jolla, CA, 4Rho, Inc, Chapel Hill, NC, 5University of 
California at Irvine, Irvine, CA
Purpose/Objective(s): Chromosomal rearrangements of the ROS1 receptor 
tyrosine kinase gene define a new molecular subset of NSCLC. In cell lines, 
ROS1 rearrangements lead to expression of oncogenic ROS1 fusion kinases 
and sensitivity to ROS kinase inhibition. We examined the efficacy and safety 
of crizotinib, a small molecule tyrosine kinase inhibitor of MET, ALK and 
ROS, in patients with advanced, ROS1-rearranged NSCLC. 
Materials/Methods: Patients with advanced NSCLC harboring ROS1 rear-
rangement, as determined using a break-apart FISH assay, were recruited into 
an expansion cohort of a phase 1 study of crizotinib. Patients were treated with 
crizotinib at the standard oral dose of 250 mg BID. The objective response 
rate (ORR) was determined based on RECIST 1.0. The disease control rate 
(DCR; stable disease [SD] + partial response [PR] + complete response [CR]) 
was evaluated at 8 weeks. 
Results: Thirteen patients within the ROS expansion cohort received crizo-
tinib and all were evaluable for response. The median age was 47 yrs (range 
31-72), and all but one of the patients were never-smokers. All patients had 
adenocarcinoma histology. 12/13 patients were tested for ALK rearrangement 
and all were negative. The median number of prior treatments was 1 (range 
0-3). To date, the ORR is 54% (7/13), with 6 PRs and 1 CR, with 6 responses 
achieved by the first restaging scan at 7-8 wks. There was 1 additional uncon-
firmed PR at the time of data cut-off. The DCR at 8 wks was 85% (11/13). 
Median duration of treatment was 20 wks (range 4+-59+). All responses are 
ongoing, and 12 patients continue on study. One patient had disease progres-
sion at first restaging and was discontinued from the study. The pharmacoki-
netics and safety profile of crizotinib in this group of patients were similar to 
that observed in patients with ALK-positive NSCLC. 
Conclusions: Crizotinib demonstrates marked antitumor activity in patients 
with advanced NSCLC harboring ROS1 rearrangements. Like ALK, ROS 
S209Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 7, Number 9, Supplement 4, September 2012 Abstracts
defines a distinct subpopulation of NSCLC patients for whom crizotinib ther-
apy may be highly effective. This study represents the first clinical validation 
of ROS as a therapeutic target in cancer.
Author Disclosure Block: A.T. Shaw: E. Research Grant; Novartis, 
AstraZeneca, Pfizer, Ariad. F. Honoraria; Novartis, Millenium. G. Consultant; 
Pfizer, Ariad, Chugai, Daiichi-Sankyo. D. Camidge: G. Consultant; Pfizer. 
J.W. Clark: E. Research Grant; Pfizer. K. Wilner: A. Employee; Pfizer. K. 
Stock; Pfizer. L. Tye: A. Employee; Pfizer. K. Stock; Pfizer. P. Stephenson: 
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Consultant; Pfizer. S.I. Ou: E. Research Grant; Pfizer. F. Honoraria; Pfizer. 
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The Select Study: A Multicenter Phase II Trial Of Adjuvant 
Erlotinib In Resected Epidermal Growth Factor Receptor 
(EGFR) Mutation-positive Non-small Cell Lung Cancer 
(NSCLC)
J. W. Neal1, N. A. Pennell2, R. Govindan3, R. S. Heist4, A. T. Shaw4, A. 
Muzikansky4, P. A. Janne5, T. J. Lynch6, C. G. Azzoli7, L. V. Sequist4, 1Stanford 
University, Stanford, CA, 2Cleveland Clinic, Cleveland, OH, 3Washington 
University, St. Louis, MO, 4Massachusetts General Hospital Cancer Center, 
Boston, MA, 5Dana-Farber Cancer Institute, Boston, MA, 6Yale Cancer 
Center, New Haven, CT, 7Memorial Sloan-Kettering Cancer Center, New 
York, NY
Purpose/Objective(s): Cancers with activating EGFR mutations are exqui-
sitely sensitive to EGFR tyrosine kinase inhibitors (TKIs) and retrospective 
data suggests adjuvant TKIs may improve outcomes in EGFR mutants. This 
prospective trial investigates the safety and efficacy of adjuvant erlotinib in 
EGFR mutation-positive NSCLC. 
Materials/Methods: Patients (pts) with surgically resected stage IA-IIIA 
NSCLC harboring activating EGFR mutations were treated with 150 mg/day 
of erlotinib for 2 years (y) after completion of any standard adjuvant che-
motherapy and/or radiotherapy. The trial was designed to enroll 36 patients, 
and powered to demonstrate a primary endpoint of 2 y disease free survival 
(DFS) exceeding 85%, which would suggest improvement over the histori-
cally expected 70% 2 y DFS in early stage EGFR-mutant NSCLC [J Thorac 
Oncol 6(3):569]. 
Results: Thirty-six pts were enrolled at five sites between 1/08 and 11/09; 
53% stage I; 19% stage II; 28% stage IIIA. Toxicities were typical of erlo-
tinib; no grade 4 or 5 events or pneumonitis occurred. 8 pts (22%) required 
one dose reduction to 100 mg/day and 5 (14%) two reductions to 50 mg/day 
for grade 3 or persistent grade 2 toxicities. 11 pts discontinued before 2 full 
years (<1 month (mo) [4], 1-12 mo [2] and 12-23 mo [5]) for toxicities [6], 
patient preference [3], prostate cancer [1] and recurrence [1]. After a median 
follow-up of 2.5 y, the 2 y DFS from enrollment is 94% (95% CI 80%, 99%). 
10 patients have recurred, 1 during erlotinib treatment and the others after 
stopping erlotinib (interval before recurrence 2 mo [1], 6-12 mo [4], >12 
mo [4]). Genotyping on repeat biopsies from seven of the recurrent cases is 
underway, as is assessment of response to subsequent erlotinib therapy. Two 
pts have died of recurrence: one at 1.5 y who stopped erlotinib after 1 mo for 
toxicity, and one at 2 y who progressed while on erlotinib. 
Conclusions: This is the first prospective study to report the efficacy of adju-
vant erlotinib in NSCLC pts with EGFR mutations. This approach is feasible 
and yields promising 2y DFS compared to historical genotype-matched con-
trols. This trial was subsequently expanded to 100 pts to permit subgroup 
analysis by stage.
Author Disclosure Block: J.W. Neal: E. Research Grant; Genentech IST. 
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A Veristrat® Analysis of Samples from a Randomized Phase 
2 Trial of First-line Therapy with Gemcitabine, Erlotinib, or 
Gemcitabine and Erlotinib in Elderly Patients (age≥ 70 Years) 
with Stage 3B/4 Non-Small Cell Lung Cancer
T. E. Stinchcombe1, J. Roder2, J. Grigorieva2, A. H. Peterman3, C. B. Lee1, 
D. T. Moore1, M. A. Socinski4, 1University of North Carolina at Chapel Hill, 
Chapel Hill, NC, 2Biodesix, Inc, Boulder, CO, 3University of North Carolina 
at Charlotte, Charlotte, NC, 4University of Pittsburgh Cancer Institute, 
Pittsburgh, PA
Purpose/Objective(s): In a multicenter randomized phase II trial of gem-
citabine (arm A), erlotinib (arm B), and gemcitabine and erlotinib (arm C) 
similar progression-free survival (PFS) and overall survival (OS) was observed 
in all arms. We performed an exploratory, blinded, retrospective VeriStrat (VS) 
analysis of serum or plasma samples collected as part of the trial. 
Materials/Methods: Between March 2006 and May 2010, 146 eligible 
patients received protocol therapy. Pretreatment serum or plasma samples 
were available from 124 patients and VS and clinical data was available for 98 
patients; 13 samples could not be processed due to hemolysis, 7 had equivo-
cal classification, 5 could not be matched to clinical data. Of the analyzed 
patients (n=98) the majority had stage IV disease (81%), had adenocarcinoma 
histology (63%), reported current or previous tobacco use (84%), and 26% 
had a performance status (PS) of 2. 
Results: Patients were classified as VS Good (n=63) and Poor (n=35); sig-
nificant associations were found with VS status and PS (p=0.003) and his-
tology (p=0.03). In arm A, VS Good (n=20) and VS Poor (n=8) patients had 
similar PFS and OS; PFS HR = 1.21 (p=0.67) median PFS 133 and 137 
days, respectively, and OS HR=0.82 (p=0.64) median OS of 201 and 197 
days, respectively. In arm B there was a statistically significant difference 
in PFS and OS between VS Good (n=26) and Poor (n=12) patients;PFS 
HR=0.33 (p=0.002) median PFS of 89 and 22 days, respectively, and OS 
HR=0.40 (p=0.014) median OS 255 and 51 days, respectively. In arm C, VS 
Good (n=17) compared to VS Poor (n=15) patients experienced a signifi-
cantly longer PFS and a trend for a longer in OS; PFS HR=0.42 (p=0.027) 
median PFS 122 and 89 days, respectively, and OS HR=0.48 (p=0.051) 
median OS of 302 and 106 days, respectively. There was a trend for worse 
PFS in patients with VS Poor status in arm B (n=12) compared to arm A 
(n=8) (PFS HR=2.13 (p=0.11); OS HR=1.62 (p=0.30). Among patients with 
VS Good status in arm B (n=26) compared to arm A (n=20) there was a 
trend towards improved PFS HR=0.60 (p=0.12) and OS HR=0.66 (p=0.19). 
In multivariate analysis only VS status was significant for PFS (p=0.011); 
for OS VS status (p=0.017) and PS (p=0.005) were significant. An interac-
tion analysis adjusted for confounding variables revealed a significant inter-
action of VS status and treatment (arm A vs. Arm B) for PFS (p<0.001) and 
for OS (p=0.017). Analysis of quality of life (assessed by FACT-L) by VS 
status and treatment is ongoing. 
Conclusions: A prospective phase II trial of erlotinib vs. gemcitabine among 
elderly patients with VS Good status should be considered; elderly patients 
with VS Poor status should not receive first-line erlotinib.
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What Disparities Exist In Stage I Non-small Cell Lung 
Cancer?
B. E. Lally, University of Miami, Miami, FL
Purpose/Objective(s): Multiple disparities have been shown to exist in non-
small cell lung cancer (NSCLC) outcomes. When accounting for stage, mul-
tiple groups have shown significant difference in outcomes. The proposed 
etiologies range from access to care to patient co-morbidities. Here, we 
studied the impact of race, histology, and insurance type on whether patients 
receive surgery or radiotherapy for stage I NSCLC. 
Materials/Methods: The Florida Cancer Data System (FCDS) registry was 
used to identify a cohort of patients with pathologically confirmed NSCLC. 
Cases were included if they had complete information on date of diagno-
sis, type of insurance (uninsured/private insurance/Medicare/Medicaid), and 
race (white, black, or other). Only patients who had a T-Stage less than 5 
cm, Negative N-Stage, Negative M-Stage, and AJCC 6th edition stage I dis-
ease were included. All patients were diagnosed between 2006 and 2009. Two 
groups of patients were analyzed based on the treatment received (surgery 
(N=10913) or radiotherapy (N=2069)). The chi squared test was used to sta-
tistically assess the differences between the groups examined. 
Results: Our analysis included 12049 white [W] patients, 713 black [B] 
patients, and 220 other [O] patients. No statistical difference (p=0.9136) was 
identified between the use of surgery (W=93%, B=5%, O=2%) or radiother-
apy (W=93%, B=5%, O=2%). Analysis of histology did show a significant 
difference in the frequency of the various histologies (p<0.0001) between the 
patients who received surgery and who received radiotherapy; the main dif-
ference present was a decrease in the incidence of cancer NOS (not otherwise 
specified). When we examined the relationship between type of insurance and 
treatment received, again a significant difference (p<0.0001) in frequency 
was found. Primarily, patients with private insurance were more likely to 
received surgery, while patients with Medicare and Medicaid where more 
likely to receive radiotherapy. Additional analysis found significant frequency 
differences in both histological distribution (p=0.01) and type of insurance 
(p<0.0001) with respect to race. 
Conclusion: In an analysis of a highly selected population of only Stage I 
NSCLC patients, the treatment administered did not vary by race. However, 
various other disparities were identified with respect to histological subtype 
and type of insurance. Thus the etiologies responsible for disparite outcomes 
in NSCLC are multifocal and complex. To overcome these differences, future 
clinical trials need to focus investigating approaches to personalized medicine 
that study all aspect of patient care.
Author Disclosure Block: B.E. Lally: None.
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First Survival Analysis In Elderly Patients (pts) with 
Advanced Non-small-cell Lung Cancer (nsclc) Stratified 
By A Predicted Disability Status (DS) Model: Analysis 
Of Surveillance, Epidemiology And End Results (SEER)-
medicare Claims 2001-2005
J. Feliciano1, L. Gardner2, M. Edelman1, A. Davidoff3, 1University of Maryland, 
Greenebaum Cancer Center, Baltimore, MD, 2University of Maryland School 
of Medicine, Baltimore, MD, 3University of Maryland School of Pharmacy, 
Baltimore, MD
Background: Eastern Cooperative Oncology Group (ECOG) performance 
status (PS) is prognostic of survival in advanced NSCLC. Few NSCLC 
patients with PS=2 receive chemotherapy (C), but there is some evidence that 
they may benefit. Administrative datasets commonly used to examine treat-
ment patterns and effectiveness lack PS measures. Previously we generated 
and validated a DS model to predict PS as a function of claims-based service 
indicators such as preventive care, elective surgery, mobility aids, and nursing 
home care 1 year prior to cancer diagnosis. We found DS predicts receipt of 
C. We report our first analysis of factors associated with survival in pts strati-
fied by our DS model. 
Materials/Methods: 21,019 pts with advanced NSCLC aged ≥ 66 who sur-
vived ≥ 30 days after diagnosis were identified in 2001-2005 SEER registry 
data linked to Medicare Part A and B claims. They were stratified into good/
poor DS groups based on the value of the continuous predicted probability 
of poor DS. We estimated Cox proportional hazard models to assess factors 
associated with survival when stratified by DS. 
Results: 13.7% of 1,916 pts with poor DS received C, compared with 40.8% 
of 19,103 good DS pts. Recipients of C in good and poor DS groups had 
improved survival (HR=0.43, 95%CI 0.42-0.44, P<.001 and HR=0.53, 95% 
CI 0.46-0.61, P<.001). Females had improved survival in good DS (HR=0.83, 
95% CI 0.80-0.85, P<.001) and poor DS (HR=0.90, 95% CI 0.81-0.99, 
P=0.03). Poorly differentiated cancer was associated with worse survival 
in good DS (HR=1.28, 95% CI 1.21-1.36, P<.001) and poor DS (HR=1.23, 
95% CI 1.02-1.48, P=0.03). Doublet C is associated with improved survival 
in good DS pts (HR=0.84, 95% CI 0.79-0.89, P<.001) and a non-significant 
benefit in poor DS pts (HR=0.84, 95% CI 0.61-1.16, P=0.29). Good DS pts 
who were a race other than non-Hispanic white or who were diagnosed in 
2005 vs. 2002 had better survival (HR =0.82, 95% CI 0.77-0.88, P<.001). 
Conclusions: Both groups of pts derived significant survival benefit from C 
but rates of C use are much lower in the poor DS group. The small sample size 
of poor DS pts may help to explain the non-significant benefit of doublet C in 
those pts. There is a need to identify those pts with poor DS likely to benefit 
most. Future work will attempt to distinguish pts with declines in DS over 
time, compared to those with stable poor DS. Prospective studies to further 
evaluate outcomes in advanced NSCLC pts with poor DS are needed.
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A Phase II Study of Accelerated Hypofractionated 
3-Dimensional Conformal Radiotherapy for Inoperable T1-3 
N0 M0 Non-Small Cell Lung Cancer: NCIC CTG BR.25
P. Cheung1,2, S. Faria3, S. Ahmed4, P. Chabot5, J. Greenland6, E. Kurien7, I. 
Mohamed8, J. Wright9, K. Ding10, C. O’Callaghan11, 1Sunnybrook Odette 
Cancer Centre, Toronto, ON, Canada, 2Department of Radiation Oncology, 
University of Toronto, Toronto, ON, Canada, 3McGill University, Montreal, 
QC, Canada, 4Cancer Care Manitoba, Winnipeg, MB, Canada, 5Hopital 
Maisonneuve-Rosemont, Montreal, QC, Canada, 6Memorial University of 
Newfoundland, St. John’s, NL, Canada, 7Tom Baker Cancer Centre, Calgary, 
AB, Canada, 8Cancer Centre for the Southern Interior, BC Cancer Agency, 
Kelowna, BC, Canada, 9Juravinski Cancer Centre, McMaster University, 
Hamiton, ON, Canada, 10National Cancer Institute of Canada Clinical Trials 
Group, Queen’s University, Kingston, ON, Canada, 11National Institute of 
Canada Clinical Trials Group, Queen’s University, Kingston, ON, Canada
Purpose/Objective(s): Radiotherapy is a curative treatment option for early 
stage non-small cell lung cancer (NSCLC). Based on promising retrospec-
tive data using accelerated hypofractionated schedules, a prospective multi-
institutional phase II trial was performed. This was done in an era when the 
majority of centres did not have stereotactic body radiotherapy capability. 
Materials/Methods: From 2006-2008, 80 patients with peripherally located 
T1-3 N0 M0 NSCLC were enrolled from 17 institutions across Canada. All 
patients had biopsy confirmation of NSCLC. Maximum allowable tumour 
size was 5 cm. Eligible patients received a dose of 60 Gy in 15 fractions 
using a 3-dimensional conformal technique without inhomogeneity correc-
tion. The gross tumour volume (GTV) was the primary tumour only, with 
no expansion for the clinical target volume (CTV). The planning target vol-
ume (PTV) margin was 1.5 cm in all directions. The PTV margin could be 
decreased to 1.0 cm in the transverse plane to spare critical structures. An 
assessment for breathing induced tumour motion (fluoroscopy or 4DCT) was 
required to ensure that the tumour was adequately covered by the PTV. Daily 
image guidance was not mandated during treatment. All radiotherapy plans 
S211Copyright © 2012 by the International Association for the Study of Lung Cancer
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were centrally reviewed. Patients were evaluated weekly during treatment and 
every 4 months afterwards until 2 years. From years 2 to 5, the follow-up 
decreased to every 6 months. The primary endpoint was the 2 year local con-
trol rate of the primary tumour using a modified RECIST criteria. Toxicities 
were measured using the CTCAE v3.0. 
Results: Five patients were found to be ineligible and 2 had major protocol 
violations. Median follow-up of the patients was 49 months (range 21-63 
months). Median age of the patients was 75.9 years. 80% of patients were 
ECOG 0-1 at baseline. The actuarial rate of local control at 2 years was 88%. 
Overall survival was 69% at 2 years. The actuarial rates of developing regional 
and distant relapse at 2 years were 9% and 24%, respectively. Distant relapse 
included the development of a solitary tumour anywhere in the lung separate 
from the treated primary tumour. Tumour size > 3 cm was associated with a 
statistically significant increase in distant relapse (p = 0.03). The most common 
grade >= 3 toxicities were fatigue (6.3%), cough (7.5%), dyspnea (13.8%), and 
pneumonitis (10%). One patient died of massive hemoptysis over 2 years after 
radiotherapy that was scored as possibly related to the protocol treatment. 
Conclusions: Conformal radiotherapy to a dose of 60 Gy in 15 fractions 
resulted in favourable local control and overall survival rates in patients with 
medically inoperable T1-3 N0 M0 NSCLC. Severe toxicities were uncommon 
in this prospective study of a relatively simple treatment technique.
Author Disclosure Block: P. Cheung: None. S. Faria: None. S. Ahmed: 
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21 
Ablative Local Therapy Extends The Clinical Benefit Of 
Crizotinib In Alk-positive Lung Cancer
G. N. Gan, D. R. Camidge, A. J. Weickhardt, R. C. Doebele, W. Dzingle, B. 
Scheier, B. D. Kavanagh, University of Colorado Denver, Aurora, CO
Purpose/Objective(s): Crizotinib (C) provides extended progression-free 
survival in patients (pts) with metastatic ALK-gene re-arranged (ALK+) 
non-small cell lung cancer (NSCLC). Oligoprogression (OP) is defined as the 
emergence of ≤5 C-resistant extra-CNS (eCNS) sites of disease suitable for 
ablative local therapy (ALT). Safety and efficacy of ALT in this setting was 
analyzed. We also studied the prognostic value of baseline maximum standard 
uptake value (SUV
max
) and metabolic tumor volume (MTV) to predict the risk 
of eventual C-resistance in individual tumors. 
Materials/Methods: 38 pts were enrolled on IRB-approved prospective clini-
cal trials of C for metastatic ALK+ NSCLC at the University of Colorado. 
Pts had surveillance PET and/or CT scans every 6-8 wks, and those with OP 
were treated with ALT, either hypofractionated radiotherapy (HRT, 16-54 Gy 
in 1-10 fractions) or surgery (S). C was continued if the pt was still receiving 
clinical benefit, defined as sustained control of other eCNS sites with minimal 
toxicity. CNS progression was treated with local therapy, and C was continued 
if eCNS benefit was maintained. C was discontinued for unacceptable toxic-
ity or disease progression beyond OP. The MTVs of each eCNS lesion was 
measured as tumor volume of SUV>3 using MIM Vista image processing 
software in pts with pre-C PET scans. MTV and SUV
max
 were analyzed rela-
tive to risk of lesion progression on C. 
Results: Median follow-up time was 19.6 mos (range, 2-32). 21 pts devel-
oped eCNS progression; 10 had OP occurring at a median of 6.5 mos (2-24) 
after initiation of C and were treated with ≥1 course of HRT. 23 total lesions 
were treated with HRT (22) or S (1). No grade ≥3 toxicity was observed. ALT 
for OP extended the clinical benefit from C by a median time of 9.2 mos. 
Median time on C was 17.4 mos for pts receiving ALT for OP vs 12.6 mos 
for the other 28 pts. 1-yr actuarial OS for pts who received C+ALT vs C alone 
was 100% vs 70% (p=0.002). 6 and 12-mo actuarial local control (LC) after 
ALT was 94% and 79%, respectively. 16 pts had pre-C PET scan and a total 
of 160 discrete PET-avid lesions were identified, of which 58 (36%) recurred 
on C prior to ALT. Lesion locations were abdominal (n=55); thoracic (n=59); 
and bone (n=46). 12-mo abdominal lesion LC on C alone was 91% vs 48% 
for SUV
max
 <7 or ≥7, respectively (p=0.002), and 74% vs 38% for MTV <8 or 
≥ 8cc, respectively (p=0.007). No correlation was observed between SUV
max
 
or MTV and LC on C for thoracic or bone lesions. 
Conclusions: ALK+ NSCLC pts receiving C who manifest OP and are treated 
with ALT suffer minimal toxicity and gain 9 mos additional clinical benefit 
from C and is associated with improved OS. Treatment of C-resistant OP 
disease using ALT departs from the traditional practice of changing systemic 
therapy at the first sign of progression. Pre-C PET scans more clearly discrimi-
nate lesions at greater risk for recurrence in the abdomen than in other sites.
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Investigation of Folate Receptor alpha and Thymidylate 
Synthase Proteins Expression in metastatic Non-Small 
Cell Lung Cancer Patients treated with Pemetrexed-based 
Chemotherapy
D. C. Christoph1,2, B. Reyna Asuncion1, B. Hassan1, J. Maltzman3, D. 
O’Shannessy3, T. C. Gauler2, M. W. Wynes1, M. Schuler2, W. E. E. Eberhardt2, 
F. R. Hirsch1, 1University of Colorado Denver, Aurora, CO, 2University 
Duisburg-Essen, Essen, Germany, 3Morphotek Inc., Exton, PA
Purpose/Objective(s): Novel therapeutic folate receptor alpha (FRα)-
antibodies, which do not inhibit the transport of pemetrexed (PMX) into 
Non-Small Cell Lung Cancer (NSCLC) cells or interfere with its efficacy in 
vitro, were recently introduced in clinical trials in NSCLC patients (pts). Very 
limited information about FRα-expression in metastatic NSCLC is published. 
Thus we investigated membraneous FRα expression in metastatic NSCLC as 
well as the expression of the known biomarker thymidylate synthase (TS), the 
main target of PMX. 
Materials/Methods: Formalin-fixed paraffin-embedded tumor specimens 
from 207 pre-treatment pts with metastatic NSCLC, treated with PMX-based 
chemotherapy were analyzed. FRα and TS protein expression was semiquan-
titatively assessed by immunohistochemistry using the H-scoring system 
(range: 0-300). Expression levels were correlated to patients’ clinicopatholog-
ical data, radiographic response (RECIST), progression-free survival (PFS) 
and overall survival (OS). 
Results: Median H-score for membraneous FRα-expression was 120 (range: 
0-290). Using the log-rank test and the median H-score as the cut-off, FRα-
expression was not associated with clinical outcome (PFS or OS). Using 
a H-score of 100 as the cut-off, overexpression of FRα was found in 48% 
of pts. FRα expression was significantly higher in female (mean H-score: 
108±8) vs male pts (mean H-score: 86±8) (P=0.033), in adenocarcinomas 
(mean H-score: 103±7) compared to large cell carcinomas (mean H-score: 
59±20) or squamous cell carcinomas (mean H-score: 46±24) (P=0.006), 
and in early N-stages (mean H-score for N0/N1: 114±10 vs. N2/N3: 89±7) 
(P=0.04). Median H-score for cytoplasmic and nuclear TS-expression was 
200 (range: 60-290).Using the log-rank test and the median H-score as the 
cut-off, there was found to be a significant association between low TS protein 
expression and improved PFS (median PFS of 5.8 vs. 3.7 months (ms); hazard 
ratio [HR]: 0.679, 95%CI: 0.484-0.953; P=0.025) or prolonged OS (median 
OS of 22.5 vs. 14.9 ms; HR: 0.611, 95%CI, 0.399-0.938; P=0.024). TS levels 
were associated with response to PMX-based therapy (mean H-score 188±5 
for responders vs. 202±5 for non-responders, P=0.044). 
Conclusions: To our knowledge, this is the largest cohort of PMX-treated 
Caucasian NSCLC pts investigated with FRα and TS protein expressions. 
Expression levels of TS were associated with clinical benefit from PMX-
therapy, but no association between membraneous FRα expression and clini-
cal outcome were found. Targeting of FRα by administration of therapeutic 
antibodies might not interfere with efficacy of PMX, which should be investi-
gated within a prospective clinical trial.
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Preclinical and Clinical Studies of Itraconazole as a Novel 
Antiangiogenic for Non-Small Cell Lung Cancer
C. M. Rudin, I. Dobromilskaya, R. Smith, R. Sebree, J. O. Liu, B. T. Aftab, 
Johns Hopkins University, Baltimore, MD
Purpose/Objective(s): The antifungal drug itraconazole was identified as a 
top hit in a high-throughput screen for agents with potent and selective inhibi-
tion of endothelial cell proliferation. We sought to explore the activity of this 
generically available oral agent in relevant preclinical models and in patients 
with advanced lung cancer. 
Materials/Methods: In vitro analyses assessed effects of itraconazole on 
several hallmarks of angiogenesis including endothelial cell proliferation, 
migration, tube formation, and phosphorylation status of key receptors. In 
vivo analyses included treatment of multiple human NSCLC primary xeno-
grafts, a better reflection of disease than traditional cell line-based xenografts, 
with itraconazole as a single agent and together with chemotherapy. Clinical 
analysis consisted of a 2:1 randomized phase II study of pemetrexed with or 
without itraconazole 200mg PO daily in patients with recurrent metastatic 
non-squamous NSCLC. 
Results: Itraconazole demonstrates potent, specific, and dose-dependent 
inhibition of endothelial cell proliferation, migration, and tube formation in 
response to both VEGF- and bFGF-mediated angiogenic stimulation. In vivo, 
oral itraconazole in mice has potent single-agent growth-inhibitory activity 
associated with induction of tumor HIF1α expression and marked inhibition 
of tumor vascularity. Itraconazole enhances the antitumor efficacy of che-
motherapy against multiple primary xenografts. Interim clinical results (N = 
22) demonstrate that the combination of itraconazole and pemetrexed is well 
tolerated, and suggest that it may be associated with a higher response rate 
(21%; 3 of 14 vs. 0%; 0 of 8), and longer duration of treatment (median time 
on study 4.3 vs. 2.7 months) than pemetexed alone. All 3 responding patients 
have received combination therapy for ≥ 12 months. 
Conclusions: Taken together, these several lines of evidence suggest that 
itraconazole, an inexpensive, safe, oral agent, has remarkably promising 
anti-angiogenic and anti-cancer activity. Ongoing preclinical work includes 
analysis of higher potency structural derivatives of itraconazole as second 
generation inhibitors. Based on the initial promising signal, the clinical trial 
has been amended to explore a higher dose of itraconazole, and to include 
15O-H
2
O PET scanning as a measure of intratumoral blood flow. Updated pre-
clinical and clinical data will be presented.
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Clinical and Dosimetric Predictors of Radiation Pneumonitis 
(RP) in a Large Series of Patients Treated with Stereotactic 
Radiotherapy (SBRT) to the Lung
T. J. Dilling1, R. Baker2, G. Han1, S. Sarangkasiri1, M. DeMarco1, C. Turke1, 
C. W. Stevens1, 1Moffitt Cancer Center, Tampa, FL, 2University of South 
Florida School of Medicine, Tampa, FL
Purpose/Objective(s): Few analyses have been published regarding clinical 
and dosimetric factors predictive of RP in patients receiving lung SBRT. We 
report here on predictive factors from a series of 240 patients. 
Materials/Methods: From 297 isocenters treated in 263 patients, 240 patients 
(n=263 isocenters) had evaluable information regarding RP. Age, gender, cur-
rent smoking status and pack-years, O2 use, Charlson Comorbidity Index, 
prior lung radiotherapy (yes/no), dose/fractionation, V
5
, V
13
, V
20
, V
prescription
, 
mean lung dose (MLD), PTV volume, total lung volume, and PTV/lung vol-
ume ratio were recorded. 
Results: Twenty-nine patients (11.0%) developed symptomatic pneumonitis 
(26 grade 2, 3 grade 3). The mean V
20
 was 6.5% (0.4-20.2%) and the average 
MLD was 5.03 Gy (0.547 - 12.2Gy). In univariable analysis, female gender 
(p=0.0257) and Age-Adjusted Charlson Comorbidity index (p=0.0366) were 
significantly predictive of RP. Among dosimetric parameters, V
5
 (p=0.0186), 
V
13
 (p=0.0438), and V
prescription
 (where dose = 60 Gy) (p=0.0128) were sig-
nificant. V
prescription
 was not significant in patients receiving 50 Gy. There was 
only a trend toward significance for V
20
 (p=0.0610). PTV/normal lung volume 
ratio was highly significant (p=0.0024). However, conformality index was not 
statistically predictive. In multivariable analysis, the clinical factors of female 
gender, pack years smoking, and larger GITV and PTV volumes were predic-
tive (p=0.0094, 0.0312, 0.0364, and 0.052, respectively), but no dosimetric 
factors were significant. 
Conclusions: Female patients appear to be at higher risk for RP than males. 
Some dosimetric factors were significant predictors under univariate analysis, 
but not under a multivariate model. Among other clinical factors, a higher 
Charlson Comorbidity Index score or larger GITV or PTV volumes were 
predictive under univariate or multivariate modeling. These findings suggest 
that factors other than the treatment plan itself might be predictive of RP and 
should be considered in patients receiving lung SBRT.
Author Disclosure Block: T.J. Dilling: None. R. Baker: None. G. Han: 
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A Systematic Analysis Of High-dose Radiation In The 
Treatment Of Surgically Unresectable, Locally Advanced 
Non-small Cell Lung Cancer.
M. Behera, J. J. Beitler, C. Bhimani, K. Higgins, Z. Chen, X. Deng, W. J. 
Curran, F. R. Khuri, S. S. Ramalingam, T. K. Owonikoko, Winship Cancer 
Institute of Emory University, Atlanta, GA
Purpose/Objective(s): The 5-year survival rate for locally advanced non-
small cell lung cancer (NSCLC) is < 25% with concomitant chemoradio-
therapy. High-dose radiation appears to confer additional benefit based on 
surrogate endpoints from relatively small clinical trials. However, survival 
advantage of higher-dose radiation delivered by conventional fractionation 
of 1.8-2 Gy is unclear. We conducted a systematic review of pooled outcome 
data from published results of studies that evaluated the role of high-dose 
radiation in the management of locally advanced NSCLC. 
Materials/Methods: A detailed search of published clinical trials was con-
ducted using computerized databases (MEDLINE, EMBASE, Cochrane 
library) and meeting proceedings. Single arm studies using high dose (>66Gy) 
or randomized trials of high versus standard radiation dose (60-63Gy) for 
locally advanced NSCLC were selected. A systematic analysis of extracted 
data was performed using Comprehensive Meta Analysis (Version 2.2.048) 
software under the random effect model. Clinical outcome in patients treated 
with high versus standard radiation dose was compared using point estimates 
for weighted values of median overall survival (OS), progression free survival 
(PFS), and response rate (RR). Treatment-related toxicities data between the 
two arms was compared using T-test and chi-square test. 
Results: Analytic data was retrieved from the results of 44 eligible studies 
reported between 1994 and 2012. The studies enrolled 3699 patients, 62% 
males, 2095 and 1604 treated with standard and high dose radiation respec-
tively. The weighted median age was 63 and 61 years (p=0.66) for standard 
and high dose patients respectively. The weighted median OS was 19.1 vs. 
16.4 months (p= 0.97); weighted RR of 76% vs. 70% (p=0.79) and survival 
rates after up to 3 years of follow up of 39% vs. 46% (p=0.45) for standard 
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and high dose arms respectively. There was no significant difference in the 
rate of grade ≥3 toxicities between the two treatment groups. 
Conclusions: High-dose radiation therapy does not result in improved survival 
over standard radiotherapy dose in patients with locally advanced NSCLC.
Author Disclosure Block: M. Behera: None. J.J. Beitler: None. C. Bhimani: 
None. K. Higgins: None. Z. Chen: None. X. Deng: None. W.J. Curran: 
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Comparison of 3D Conformal Radiotherapy (3DCRT) and 
Intensity Modulated Radiotherapy (IMRT) in Stage III Non-
Small Cell Lung Cancer (NSCLC)
P. M. McCloskey, S. Atallah, L. Coate, A. Albert-Green, A. J. Hope, J. Cho, 
A. M. Brade, A. Sun, F. A. Shepherd, A. Bezjak, Princess Margaret Hospital, 
Toronto, ON, Canada
Purpose/Objective(s): To compare outcomes in patients (pts) with stage III 
NSCLC treated in a single center in a 12 year period with IMRT (‘IMRT 
cohort’) compared to 3D CRT (‘3DCRT cohort’). 
Materials/Methods: Pts with stage III NSCLC treated at a large cancer cen-
ter 1997-2009 with radical radiation (RT) (50Gy or more) (+/- chemo), but 
no surgery, were retrospectively identified. Pt, tumor and treatment character-
istics were extracted from an existing database or from electronic pt records. 
Acute toxicity, ( esophagitis (RE) and pneumonitis (RP)), were graded with 
CTC AE V3. To investigate associations between cohort and time-to-event 
outcomes, including loco-regional failure (LRF) and distant failure free sur-
vival (DFFS), Gray’s test and multivariable competing risks models were 
employed. Both cohort’s were correlated with disease-free survival (DFS) 
and overall survival (OS), by the log rank test and Cox proportional hazards 
models. In the multivariable analyses, N3 disease, stage , weight loss, age 
, sex, ECOG score, comorbidity score, use of PET and chemotherapy were 
assessed. Toxicity was correlated with cohort, chemotherapy, N3, larger field 
disease and RT dose using logistic regression analysis techniques. 
Results: 324 pts were identified: 217 in the ‘3DCRT Cohort’ and 107 in the 
IMRT Cohort’. The only differences in demographic and tumor character-
istics between the two cohorts were the N-stage (p=0.002) and PET staging 
(p<0.001) variables. Median RT dose was 61 Gy in 3DCRT cohort and 66 Gy 
in IMRT cohort. Similar proportions (73.7% and 77.5%) of pts had concur-
rent chemotherapy in both 3DCRT and IMRT cohorts. With a median follow 
up time of 22.8 mths in the IMRT cohort and 20.0 mths in 3DCRT cohort, 
competing risks analysis showed that LRF was higher in the IMRT cohort 
(p =0.028); no variables examined were significant predictors of LRF rates 
in the multivariable analysis. No difference in either DFFS (p=0.749) or DFS 
(p=0.696) was detected between the two cohorts. The OS distribution was 
significantly different (p = 0.017) with patients in IMRT surviving longer. 
Predictors for worse DFS in multivariate analysis were N3 status, no chemo-
therapy and ECOG ≥1; male gender was the additional predictor for worse 
OS. There was no statistically significant difference in grade of RE between 
3DCRT and IMRT cohorts; chemo was the only significant variable predict-
ing severity of RE (OR 4.663, p = 0.001). Grade 1 RP was more common in 
the IMRT cohort but no differences were found in rates of >=G2 RP between 
the groups (23.5% 3DCRT vs 17.78% IMRT p=0.248). 
Conclusions: Although the IMRT cohort had more pts with N3 disease, their 
toxicity and distant relapse rates were comparable to the 3DCRT cohort, and 
the OS was better. Higher rate of LRF may be due to longer OS or increased 
use of cross-sectional imaging in follow-up.
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Symptomatic Radiation Pneumonitis In Elderly Patients 
Receiving Thoracic Irradiation: Comparative Analysis of 
Clinical and Dosimetric Predictors
J. R. Kharofa, E. Gore, Medical College of Wisconsin, Milwaukee, WI
Purpose/Objective(s): Elderly patients have increased pulmonary toxic-
ity following thoracic irradiation compared to younger patient cohorts. The 
impact of lung dose parameters in this group is not well defined. The purpose 
of this study was to quantify the incidence of radiation pneumonitis in elderly 
patients and to examine clinical and dosimetric predictors of pneumonitis in 
this group compared to younger patients. 
Materials/Methods: Patients with stage I-III small cell and non-small cell 
lung cancer treated with definitive 3D-conformal radiation +/- concurrent 
chemotherapy from 2004-2009 were reviewed. Patients with palliative or 
postoperative treatment were excluded. Of the 256 patients who met the cri-
teria for inclusion, treatment plans were available for review in 228 patients. 
The V5 Gy, V10 Gy, V20 Gy, V30 Gy, and Mean Lung Dose were recorded. 
Acute pulmonary toxicity was quantified within 6 months of completion of 
treatment according to the Common Terminology Criteria for Adverse Events 
(CTCAEv4). Univariate and multivariate logistic regression analysis was per-
formed to evaluate predictors of ≥ grade II pneumonitis in all patients. ROC 
curve analysis of dosimetric parameters was performed to evaluate ≥ grade 
III events in elderly patients. 
Results: A cohort of patients age ≥ 70 (n=99) were compared to patients 
age <70 (n=157). Patients age ≥ 70 had more stage I tumors (26% vs 7%, 
p =0.001) and were less likely to receive concurrent chemotherapy (54% 
and 84% respectively, p=0.001). Pneumonitis occurred in 32 patients (grade 
II= 22, grade III= 7, grade IV= 3, grade V=1). Predictors for pneumonitis ≥ 
grade II on multivariate analysis included the V5 Gy (OR 1.05 CI [1.01-1.09], 
p=0.005) and age ≥ 70 (OR 4.52 CI 1.82 -11.24, p=0.001). Decreased risk of 
pneumonitis was observed in ACE inhibitor users (OR 0.22 CI [0.06-0.79], 
p=0.02). Pneumonitis ≥ grade III was more likely to occur in patients age ≥ 70 
(10% vs 1%, p=0.001) and only one event occurred in a patient age <70. ROC 
curve analysis identified a V20 Gy >31% as the best predictor for ≥ grade III 
events in patients age ≥ 70 (AUC 0.732). In patients with a V20 Gy >31%, the 
incidence of ≥ grade III pneumonitis was 33% in elderly patients compared 
to 2% in the younger cohort (p=0.005). Pneumonitis ≥ grade III pneumonitis 
occurred in 20% of patients age ≥ 70 if the V5 Gy was >62%. 
Conclusions: Elderly patients have significantly higher rates of ≥ grade III 
pneumonitis compared to younger patients. A V20 Gy < 31% and a V5 Gy 
<62% is recommended in patients greater than 70 in order to achieve <20% 
incidence of ≥ grade III pneumonitis. ACE Inhibitor use was associated with 
a decreased risk of pneumonitis. This is consistent with preclinical data and 
may warrant further evaluation in a prospective trial.
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Comparisons of Local Control and Survival of Stereotactic 
Body Radiation Therapy versus Surgery for Stage I Non-
Small Cell Lung Cancer: a Meta-Analysis
X. Zheng1, R. Reddy2, M. Schipper2, Y. Ren1, A. Chang2, J. Lin2, M. Orringer2, 
F. Kong2, 1Huadong Hospital, Fudan University, Shanghai, China, 2the 
University of Michigan, Ann Arbor, MI
Purpose/Objective(s): This study aims to compare treatment outcomes 
between stereotactic body radiation therapy (SBRT) and surgery in early-
stage non-small-cell lung cancer (NSCLC). 
Materials/Methods: Eligible studies of SBRT and surgery were retrieved 
through extensive search of databases of Pubmed, Medline, Embase and 
Cochrane library from 2000 to 2011. Original English publications in stage I 
NSCLC with adequate sample sizes (30 minimum for SBRT, 100 minimum 
for surgery) were included. SBRT studies with BED <100 Gy, fraction dose 
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<8 Gy, or using more than 8 fractions were excluded. Data is presented as 
mean (95% confident interval). 
Results: Forty-six SBRT studies (3,322 patients) and 34 surgery studies 
(12,367 patients) published in the same era were eligible. The median age and 
follow-up duration were 74 years and 27 months for SBRT patients, and 66 
years and 42 months for surgery patients, respectively. The overall survival 
rates at 1-, 3- and 5-year with SBRT were 82.4% (79.8-85.0%), 52.6% (48.4-
56.7%) and 37.3% (28.1-46.4%), compared to 91.4% (88.8-94.1%), 77.5% 
(72.9-82.1%) and 67.5% (61.1-74.0%) with full anatomical resection, and 
90.2% (87.3-93.2%), 71.8% (64.3-79.3%) and 54.1% (42.2-66.1%) with lim-
ited resection. The cause-specific survival at 3-year was 76.9% (71.6-82.3%) 
vs. 79.6% (73.0-86.2%) and 5-year 63.7% (53.6-73.9%) vs. 67.1% (56.9-
77.4%), for SBRT and surgery. In SBRT group, overall survival was better 
with increasing operability of patients: in those studies with operability over 
60%, the overall survival in SBRT group was not significantly different from 
that of surgery. 
Conclusions: SBRT offers inferior overall survival but similar cause-specific 
survival and local failure rates compared to that of surgery in patients with 
stage I NSCLC. Randomized trial is needed to compare the efficacy of SBRT 
and surgery.
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Does EGFR Amplification Have Better Predictability than 
EGFR Mutation on Response to Erlotinib in Patients With 
Advanced Non-Small-Cell Lung Cancer? A Meta-Analysis
N. M. Tun, A. M. Soe, Z. M. Bo, L. M. L. Yoe, The Brooklyn Hospital Center, 
Brooklyn, NY
Purpose/Objective(s): Erlotinib is a small-molecule tyrosine kinase inhibitor 
that inhibits the protein kinase activity of epidermal growth factor receptor 
(EGFR). It has been shown to be effective in patients with advanced non-
small-cell lung cancer (NSCLC) with or without EGFR mutations, but appears 
to be more effective in the group of patients with EGFR mutations. The objec-
tive of this meta-analysis is to compare the response of patients with EGFR 
mutation or amplification-positive (EGFR-positive) versus EGFR mutation 
or amplification-negative (EGFR-negative) advanced NSCLC to erlotinib in 
terms of overall survival (OS) and progression-free survival (PFS). 
Materials/Methods: A Medline search using the MeSH terms “erlotinib” and 
“lung” in the title field, filtered by ‘clinical trial’, yielded 108 articles. Clinical 
trials involving erlotinib with available survival data on EGFR-positive versus 
EGFR-negative NSCLC were searched for. The intervention effect estimate 
and standard error of each study were derived from the hazard ratio (HR) and 
p value. Generic inverse variance method was applied to compute the overall 
effect size and HR with 95% confidence interval (CI). Fixed or random effects 
model was used according to the level of between-study heterogeneity. 
Results: 3 studies including 504 patients were eligible for the analysis. All 
patients received erlotinib in a single arm irrespective of EGFR status. EGFR 
gene mutation was tested in 326 patients (35 mutation-positive, 188 wild-
type, 103 indeterminate). EGFR gene amplification by fluorescent in-situ 
hybridization (FISH) was studied in 353 patients (100 positive). Patients with 
EGFR gene mutation had significantly longer PFS (HR = 0.4, CI 0.25-0.64, 
p = 0.0001) but not OS (HR = 0.59, CI 0.18-1.95, p = 0.39). In contrast, the 
presence of EGFR gene amplification was associated with better PFS as well 
as OS (HR = 0.52, CI 0.39-0.71, p < 0.00001 and HR = 0.65, CI 0.47-0.88, 
p = 0.006, respectively). 
Conclusions: EGFR gene amplification may be a better predictor of survival 
than EGFR gene mutation for advanced NSCLC patients receiving erlotinib. 
Survival analysis of EGFR mutation and amplification is warranted in the arm 
receiving erlotinib in randomized controlled trials for further verification of 
the findings.
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Weekly nab®-Paclitaxel in Combination with Carboplatin as 
First-Line Therapy in Patients (pts) with Advanced Non-Small 
Cell Lung Cancer (NSCLC): Analysis of Patient-Reported 
Neuropathy and Taxane-Associated Symptoms
V. Hirsh1, I. Okamoto2, J. K. Hon3, S. R. Dakhil4, R. D. Page5, J. Orsini6, H. 
Zhang7, M. F. Renschler7, M. A. Socinski8, 1McGill University, Montreal, 
QC, Canada, 2Kinki University Faculty of Medicine, Osaka-Sayama, Japan, 
3Clearview Cancer Institute, Huntsville, AL, 4Cancer Center of Kansas, 
Wichita, KS, 5The Center for Cancer and Blood Disorders, Fort Worth, TX, 
6Essex Oncology of New Jersey, Belleville, NJ, 7Celgene Corporation, Summit, 
NJ, 8University of Pittsburgh Medical Center, Pittsburgh, PA
Background: Neuropathy and its associated symptoms are dose-limiting tox-
icities of taxane-based regimens. Measuring disease symptoms has utility for 
maintaining a balance between the benefits and risks of treatment, particularly 
in a palliative care setting. A novel albumin-bound 130-nm formulation of 
paclitaxel (nab®-paclitaxel, nab-P) has been shown to improve the efficacy of 
taxane treatment while limiting the toxicity typically associated with solvent-
based taxanes. In a phase III trial of nab-P + carboplatin (C) vs solvent-based 
paclitaxel (sb-P) + C, nab-P + C significantly improved the primary endpoint 
of overall response rate (ORR) (33% vs 25%, P = 0.005), with a 1-month 
improvement in median overall survival (OS; P = NS), and improved safety 
in pts with advanced NSCLC. Here we report on pt- and physician-assessed 
neuropathy and taxane-associated symptoms, important factors in a palliative 
pt setting. 
Materials/Methods: Pts with untreated stage IIIB/IV NSCLC were random-
ized 1:1 to C AUC 6 day 1 and either nab-P 100 mg/m2 on days 1, 8, 15 (n = 
521) or sb-P 200 mg/m2 day 1 (n = 531) q 21 days. Treatment was continued 
until disease progression or unacceptable toxicity occurred. Neuropathy, pain, 
and hearing subscales of Functional Assessment of Cancer Therapy (FACT)-
Taxane v 4.0 were assessed at baseline, day 1 of each cycle, and upon treat-
ment completion. Physician assessment of peripheral neuropathy was done by 
using the NCI CTCAE of “Neuropathy—Sensory”. 
Results: A total of 1031 (98%) pts completed FACT-Taxane at baseline, and 
987 (94%) during follow-up or at completion of treatment. Baseline scores for 
neuropathy and pain were well balanced. Significant treatment effects favor-
ing nab-P/C were noted for pt-reported neuropathy (P < 0.001), neuropathic 
pain hands/feet (P < 0.001), and hearing loss (P = 0.002). Physician-assessed 
rates of neuropathy were significantly lower in the nab-P/C arm vs the sb-P/C 
arm: 46% vs 62%, P < 0.001, all grades; 3% vs 12%, P < 0.001, grade 3/4, 
respectively. No pts in the nab-P/C arm vs 1(<1%) pts in sb-P/C arm reported 
grade 4 peripheral sensory neuropathy. The time to improvement of grade ≥ 
3 peripheral neuropathy to grade 1 was 38 vs 104 days in the nab-P/C and sb-
P/C arms, respectively (P = 0.238). 
Conclusions: nab-P/C was associated with statistically and clinically signifi-
cant reductions in pt-reported neuropathy, neuropathic pain in the hands and 
feet, and hearing loss compared with sb-P/C. Pt-reported outcomes for neu-
ropathy were consistent with physician assessment.
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Oncology of New Jersey. H. Zhang: A. Employee; Celgene Corporation. 
M.F. Renschler: A. Employee; Celgene Corporation. K. Stock; Celgene 
Corporation. M.A. Socinski: E. Research Grant; Celgene Corporation, 
Lilly, Genentech. F. Honoraria; Lilly, Genentech. G. Consultant; Celgene 
Corporation.
S215Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 7, Number 9, Supplement 4, September 2012 Abstracts
109 
Weekly nab®-Paclitaxel In Combination With Carboplatin As 
First-line Therapy In Elderly Patients (pts) With Advanced 
Non-small Cell Lung Cancer (nsclc)
M. A. Socinski1, C. J. Langer2, I. Okamoto3, J. K. Hon4, V. Hirsh5, S. R. Dakhil6, 
R. D. Page7, J. Orsini8, H. Zhang9, M. F. Renschler9, 1University of Pittsburgh 
Medical Center, Pittsburgh, PA, 2University of Pennsylvania Cancer Center, 
Philadelphia, PA, 3Kinki University Faculty of Medicine, Osaka-Sayama, 
Japan, 4Clearview Cancer Institute, Huntsville, AL, 5McGill University, 
Montreal, QC, Canada, 6Cancer Center of Kansas, Wichita, KS, 7The Center 
for Cancer and Blood Disorders, Fort Worth, TX, 8Essex Oncology of New 
Jersey, Belleville, NJ, 9Celgene Corporation, Summit, NJ
Background: The median age of advanced NSCLC pts in the US is 71 yrs. 
However, elderly pts (≥ 70 yrs), are generally undertreated, with only ≈ 30% 
receiving systemic therapy, underscoring the need for better, more tolerable 
therapeutic options for the elderly cohort. In a phase III trial of nab-paclitaxel 
(nab-P, 130 nm albumin-bound paclitaxel particles) + carboplatin (C) vs 
solvent-based paclitaxel (sb-P) + C, nab-P+C significantly improved overall 
response rate (ORR), the primary endpoint (33% vs 25%, P = 0.005), with a 
1-month improvement in overall survival (OS; P = NS) and improved safety 
with advanced NSCLC. The current analysis evaluated efficacy and safety in 
pts ≥ 70 vs < 70 yrs old. 
Materials/Methods: Pts with untreated stage IIIB/IV NSCLC and with an 
ECOG score of 0/1 were randomized 1:1 to C AUC 6 day 1 and either nab-P 
100 mg/m2 on days 1, 8, 15 or sb-P 200 mg/m2 day 1 q 21 days. Stratifications 
included age [≥ 70 vs < 70 yrs], region, stage, gender, and histology. ORR and 
progression-free survival (PFS) were determined by blinded centralized review. 
Neuropathy, pain, and hearing subscales of Functional Assessment of Cancer 
Therapy (FACT)-Taxane v 4.0 were assessed at baseline and day 1 of each cycle. 
Results: Of the 1052 randomized NSCLC pts in the phase III study, 15% 
were elderly (74 pts in the nab-P/C and 82 in the sb-P/C arms). Similar to 
the intent-to-treat (ITT) population, most elderly pts were male (72%), White 
(71%), ECOG PS 1 (73%) stage IV (83%), with history of prior or current 
smoking (72%). In elderly pts, ORR was higher in the nab-P/C vs sb-P/C 
arm (34% vs 24%, respectively P = 0.196, response rate ratio [RR] = 1.385), 
PFS trended in favor of nab-P/C (median 8.0 vs 6.8 months, P = 0.134, HR: 
0.687), and OS was significantly improved (median 19.9 vs 10.4 months, P = 
0.009, HR: 0.583). In pts < 70 yrs old, ORR was significantly higher with nab-
P/C vs sb-P/C (32% and 25%, respectively, P = 0.013, RR = 1.300); PFS (6.0 
vs 5.8 median months, P = 0.256, HR: 0.903) and OS (11.4 vs 11.3 median 
months, P = 0.988, HR: 0.999) were similar for both treatment arms. Adverse 
events were comparable in pts > 70 yrs vs < 70 yrs in the nab-P/C vs sb-P/C 
arms, with less grade 3/4 neutropenia (54% vs 74%, P < 0.05) and neuropa-
thy (7% vs 23%, P < 0.05) and increased thrombocytopenia (23% vs 14%, 
P = NS) and anemia (23% vs 10%, P < 0.05); these rates were similar to the 
ITT population. 99% of elderly pts completed the FACT-taxane assessment at 
baseline. Significant treatment effects favoring nab-P/C vs sb-P/C were noted 
in elderly pts for neuropathy (P < 0.001), pain in hands and feet (P < 0.001), 
hearing loss (P = 0.022), and edema subscales (P = 0.004). 
Conclusions: First line nab-P/C therapy was well tolerated and led to 
improved ORR and PFS, with significantly longer OS vs sb-PC in elderly pts 
with advanced NSCLC.
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Safety and Efficacy by Histology of Weekly nab®-Paclitaxel 
in Combination with Carboplatin as First-line Therapy in 
Patients (pts) with Advanced Non-Small Cell Lung Cancer 
(NSCLC)
M. F. Renschler1, I. Okamoto2, J. K. Hon3, V. Hirsh4, S. R. Dakhil5, R. D. 
Page6, J. Orsini7, H. Zhang1, M. A. Socinski8, 1Celgene Corporation, Summit, 
NJ, 2Kinki University Faculty of Medicine, Osaka-Sayama, Japan, 3Clearview 
Cancer Institute, Huntsville, AL, 4McGill University, Montreal, QC, Canada, 
5Cancer Center of Kansas, Wichita, KS, 6The Center for Cancer and Blood 
Disorders, Fort Worth, TX, 7Essex Oncology of New Jersey, Belleville, NJ, 
8University of Pittsburgh Medical Center, Pittsburgh, PA
Background: Treatment of advanced NSCLC differs by histology, with fewer 
options and poorer outcomes in pts with squamous cell (SCC) histology. In a 
phase III trial of nab-paclitaxel (nab-P, 130 nm albumin-bound paclitaxel par-
ticles) + carboplatin (C) vs solvent-based paclitaxel (sb-P) + C, the primary 
endpoint of overall response rate (ORR) was significantly improved from 
25% to 33%, P = 0.005, with a 1 mo improvement in overall survival (OS) 
(P = NS) and improved safety in pts with advanced NSCLC. This analysis 
evaluated efficacy and safety by histology. 
Materials/Methods: Pts with untreated stage IIIB/IV NSCLC were random-
ized 1:1 (stratified by histology, age, region, stage, and gender) to C AUC 6 
day 1 and either nab-P 100 mg/m2 on day 1, 8, 15 or sb-P 200 mg/m2 day 
1 q 21 days. ORR and progression-free survival (PFS) were determined by 
blinded centralized review. 
Results: Of the 1052 randomized pts in the phase III study population, 518 
(n = 254 nab-P/C; n = 264 sb-P/C) pts had adenocarcinoma (ADCA), 450 (n 
= 229 nab-P/C; n = 221 sb-P/C) pts had SCC, and 84 (n = 38 nab-P/C; n = 46 
sb-P/C) had large cell carcinoma (LCC) or carcinoma not otherwise specified 
(NOS). In SCC pts, nab-P/C vs sb-P/C produced a significantly higher ORR 
(41% vs 24%; P < 0.001; response rate [RR] ratio = 1.680), similar PFS (5.6 
vs 5.7 mo; P = 0.245; HR = 0.865), and > 1-month prolongation of OS (10.7 
vs 9.5 mo; P = 0.284; HR: 0.890). For LCC/NOS pts, nab-P/C vs sb-P/C 
yielded a higher ORR (26% vs 15%; P = 0.208; RR ratio = 1.729), longer PFS 
(6.4 vs 4.2 mo; P = 0.061; HR = 0.565) and similar OS (10.5 vs 11.2 mo; P = 
0.702; HR = 1.100). nab-P/C was as effective as sb-P/C in ADCA pts for ORR 
(26% vs 27%; P = 0.814; RR ratio = 0.966), PFS (6.9 mo in both; P = 0.944; 
HR = 0.991), and OS (13.9 vs 13.6 mo; P = 0.639; HR = 0.949). Consistent 
with the intent-to-treat population, nab-P/C vs sb-P/C produced lower rates 
of grade 3/4 neuropathy (SCC, 3% vs 11%, P = 0.001; LCC/NOS, 3% vs 
13%, P = 0.121; ADCA, 3% vs 12%, P < 0.001), and higher but manageable 
rates of anemia (SCC, 27% vs 5%, P < 0.001; LCC/NOS, 27% vs 14%, P = 
0.170; ADCA, 29% vs 8%, P < 0.001) and thrombocytopenia (SCC, 21% vs 
7%, P < 0.001; LCC/NOS, 14% vs 4%, P = 0.240; ADCA , 16% vs 12%, P = 
0.198) across all histologic subtypes. nab-P/C vs sb-P/C produced lower rates 
of grade 3/4 neutropenia in SCC (43% vs 51%, P = 0.103) and ADCA (49% 
vs 64%, P < 0.001), but not LCC/NOS (62% vs 53%, P = 0.500) histology. 
Conclusions: In pts with advanced NSCLC, nab-P/C demonstrated a favor-
able risk-benefit profile as a first-line therapy in advanced NSCLC regardless 
of histology. Significantly improved ORR and a positive trend in OS were 
observed in pts with SCC histology.
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Intermittent Chemotherapy and Erlotinib for Advanced 
NSCLC with EGFR Activating Mutations
M. Zwitter1, V. Kovac1, M. Rajer1, K. Stanic1, M. Vrankar1, I. Kern2, 1Institute 
of Oncology, Ljubljana, Slovenia, 2University Clinic, Golnik, Slovenia
Purpose/Objective(s): Lung cancer with EGFR activating mutations is sensi-
tive to tyrosine-kinase inhibitors (TKIs) and to chemotherapy. With the aim 
of exploiting the benefits of both classes of drugs and avoiding their potential 
mutual antagonistic effect, we designed a single-arm Phase II trial of intermit-
tent chemotherapy and TKIs. The primary objectives of the trial are assess-
ment of toxicity, response to treatment, and time to progression (TTP); the 
secondary endpoint is survival (OS). Preliminary results of an on-going trial 
are presented. 
Materials/Methods: Patients eligible for the trial have primary lung adenocar-
cinoma with EGFR activating mutations; are chemonaive; have stage IV dis-
ease; PS 0-2; meet the standard criteria for platin-based chemotherapy; and give 
informed consent. Treatment schedule: 3-weekly cycles of gemcitabine (1250 
mg/m2) on days 1 and 4; cisplatin (75 mg/m2) on day 2; and erlotinib (150 
mg/day) on days 5 - 15. After 4 to 6 cycles of intermittent treatment, patients 
continue with maintenance erlotinib until clinically significant progression. 
Evaluation of response according to RECIST criteria is performed during the 
3rd cycle of intermittent therapy and every 2 months thereafter. Normalization 
of PET-CT is required for confirmation of complete remission (CR). 
Results: By March 2012, 26 patients (16 female, age 37 to 74, median age 
61 years) entered the trial. Six patients were in PS 2 and 11 patients entered 
the trial after completing whole-brain radiotherapy for multiple brain metas-
tases. In general, the treatment was tolerated very well. The toxicity profile 
was typical for platin-based chemotherapy and for erlotinib, with no grade 4 
or greater toxicity. Due to grade 2-3 hematological toxicity, 6 patients com-
pleted less than 4 cycles of chemotherapy and were switched to continuous 
erlotinib earlier. In the maintenance phase of continuous erlotinib, grade 2-3 
skin toxicity was seen in 10 patients, leading to a lower dose of the drug. 
Among 21 patients evaluable for response, CR and PR were confirmed in 
9 and 9 patients, respectively, for a response rate of 86%; a single patient 
progressed during the initial phase of the treatment. One-year PFS is 86%. 
No patient died within the first year of treatment; median PFS and OS have 
not yet been reached. 
Conclusions: For patients with advanced NSCLC with EGFR activating 
mutations, intermittent treatment with chemotherapy and erlotinib followed 
by maintenance erotinib has an acceptable toxicity profile and is remarkably 
effective. We believe that a pause with erlotinib on days 16-22 of the cycle 
restores proliferation of the tumor and hence its chemosensitivity, leading to 
synergistic effect of the intermittent schedule. The trial continues and is open 
for participation of other centers.
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How Do Social Factors Explain Outcomes In Non-small Cell 
Lung Cancer Among Hispanic/latinos In California?
M. I. Patel1, E. Chang2, S. Gomez2, H. A. Wakelee1, 1Stanford University, 
Stanford, CA, 2Cancer Prevention Institute of California, Fremont, CA
Purpose/Objective(s): Hispanics in the United States have a lower age-adjusted 
incidence and mortality rate from non-small cell lung cancer compared with non-
Hispanic whites. The better survival rates of Hispanics as compared with non-
Hispanic whites despite lower socioeconomic status is known as the “Hispanic 
paradox.” Previous studies have demonstrated the influence of birthplace (nativ-
ity) on survival among Hispanic patients but no studies to date have evaluated the 
interplay of nativity, clinical factors, social factors, and neighborhood factors on 
survival among Hispanic patients with non-small cell lung cancer.
Materials/Methods: All Hispanic patients with non-small cell lung cancer 
between the years of 1988-2008 were identified in the California Cancer 
Registry (CCR). Kaplan Meier curves depict survival by nativity status 
among Hispanics with non-small cell lung cancer. Cox proportional hazard 
models estimate the hazard of mortality by race with adjustment for individ-
ual covariates (age, gender, marital status), clinical factors (histologic grade, 
surgery, radiation, and chemotherapy), and social and neighborhood factors 
(neighborhood and ethnic enclave status). 
Results: A total of 4,062 Hispanic patients with non small cell lung can-
cer were included. Overall, there was a 7% decreased risk of disease-specific 
mortality for foreign-born patients as compared with US-born Hispanic 
patients (HR 0.93, p=0.08, 95% CI 0.87-1.00) although this result was not-
statistically significant. Adjustment for individual patient factors and clinical 
factors resulted in a statistically significant 16% decreased risk of disease-
specific mortality for foreign-born Hispanic patients compared with US-born 
Hispanic patients (HR 0.84, p<0.0001, 95% CI 0.78-0.91). Adjustment for 
socioeconomic status, neighborhood socioeconomic status and ethnic enclave 
status did not explain the differences in survival between the foreign-born and 
US-born Hispanic patients (HR 0.84, p <0.001, 95% CI 0.78-0.91).
Conclusions: Overall, foreign-born Hispanics with non-small cell lung can-
cer have a decreased risk of disease-specific mortality compared with US-born 
Hispanics with non-small cell lung cancer. Social factors do not fully explain 
this survival advantage. Further investigation is needed to understand the 
drivers of the survival advantage outcomes in foreign-born populations.
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Effect Of Smoking Status On Non-small Cell Lung Cancer 
Outcomes: A VACCR Analysis
R. Batra1, L. M. Smith1, W. Gonsalves2, P. Silberstein3, A. Ganti4, 1University 
of Nebraska Medical Center, Omaha, NE, 2Mayo Clinic, Rochester, MN, 
3Creighton University Medical Center, Omaha, NE, 4VA Nebraska Western 
Iowa Health Care System; University of Nebraska Medical Center, Omaha, NE
Purpose/Objective(s): Lung cancer (LC) is the second most common cancer 
among adult men and women and results in the most cancer-related deaths. 
Although much is known about tobacco smoke exposure as a major risk factor 
for developing non-small cell lung cancer (NSCLC) in the United States, little 
is understood of NSCLC in nonsmokers. A retrospective analysis of patients 
included in the Veterans Affairs Central Cancer Registry (VACCR) was con-
ducted to evaluate the effects of smoking on the overall survival of patients 
after diagnosis of LC. 
Materials/Methods: Patients diagnosed with NSCLC, between January 1995 
and February 2009, were identified. Data abstracted included age at diagno-
sis, gender, smoking history, disease stage, and overall survival. The Kaplan-
Meier method was used to estimate overall survival distributions, and the 
log-rank test was used to compare survival distributions between different 
groups based on smoking status. Multivariate analysis for survival was con-
ducted with Cox regression looking to see if smoking status is a significant 
predictor of survival after adjusting for confounders. P-values less than 0.05 
were considered to be statistically significant. 
Results: Data from 100,568 NSCLC cases were extracted from the VA 
database and 96,824 were included for analysis. The patients were then cat-
egorized on smoking status as Never (n=4050), Former (n=31,800), Current 
(n=47,485), and Unknown (n=13,489). Current smokers developed NSCLC 
at a younger age (65 years) compared to former (72 years) (p<0.0001) and 
never smokers (71 years) (p<0.0001). A larger proportion of current smokers 
presented with stage IV disease (41%) compared to never (38%) (p<0.0001) 
and former smokers (37%) (p<0.0001). Multivariate analysis after adjusting 
for age, gender, and stage at diagnosis showed that current smokers had signifi-
cantly worse survival compared to former smokers (HR=1.06, 95% CI=1.05-
1.08; p<0.0001). Current smokers had a marginally worse survival compared 
to never smokers (HR=1.03, 95% CI=1.00-1.07; p=0.069). There were no dif-
ferences in outcomes when non-smokers were compared to former smokers. 
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Conclusions: Current smokers presented with NSCLC at a younger age and 
an advanced stage when compared to never smokers and former smokers. 
Also, even after adjusting for these risk factors, they had the worst outcomes 
of all the groups. Hence smoking cessation counseling should be an integral 
part of lung cancer management.
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Thoracic Radiotherapy Within 6 Weeks with concurrent 
chemotherapy Improved Outcome of Patients with Limited 
Stage Small Cell Lung Cancer (LS-SCLC)
R. U. Komaki, P. Allen, X. Wei, D. Gomez, F. Fossella, J. Heymach, J. Welsh, 
M. O’Reilly, S. Lin, J. D. Cox, M.D. Anderson Cancer Center, Houston, TX
Background: Previous Intergroup Study of L-SCLC showed improvement 
of 5 year survival by twice daily thoracic radiotherapy (TRT) in 3 weeks with 
concurrent etoposide and cisplatin (EP) compared to daily TRT in 5 weeks 
with significantly more grade 3 acute esophagitis in 3 weeks regimen. We 
have compared the duration of TRT < 6 weeks vs. 6> weeks among patients 
with L-SCLC treated by TRT +concurrent EP at UTMDACC.
Materials/Methods: A total of 500 biopsy proven L-SCLC patients staged by 
chest/upper abdominal CT and MRI of the brain and were treated with TRT/
EP between 1985 and 2007.Complete responders received prophylactic cra-
nial irradiation (PCI). The data were analyzed using Kaplan-Meier survival 
function. The Log Rank test was used to assess the quality of survival function 
using a P-value of 0.05. Cox regression analysis was used for Univariate and 
multivariate analysis.
Results: The median follow-up was (20) months (ranging from 1 to 224 
months). The median age was 61 (range, 27 to 95).Median KPS was 90, wt 
loss <5% was 87.8% (439/500), 437 patients completed treatment within 6 
weeks and 63 patients took longer than 6 weeks. PCI was given to 270 patients 
with 2.5 Gy x 10 Fx or 2.0Gy x 15 Fx (226 patients in the <6 weeks group 
compared to 44 patients >6 weeks group). Comparison between <6 weeks 
and >6 weeks treatment groups in 5 yrs, the overall survival (OS) rate was 
26.4 % vs. 13.6%, p=0.1131; Disease free survival was 30.4% vs. 13.4%, 
p=0.0355; Local-regional control was 57.5% vs. 34.3%, p=0.0241; distant 
metastasis-free survival was 38.1% vs. 19.4%, p=0.0808. All grade acute dys-
phagia, pneumonitis other toxicities showed no significant difference between 
two groups. However, TRT < 6 weeks group had lower grade 3+ lung fibrosis 
(10% vs. 22%, P=0.01). Multivariate analysis showed that factors influencing 
overall survival were PCI (P<0.001), pleural effusion (P=0.02), duration of 
TRT, LR control (P=0.001) and DM failure (p<0.001).
Conclusions: The local-regional control and disease free survival in 5 years 
were improved by TRT within < 6 weeks compared to > 6 weeks with con-
current EP. Grade 3+ lung fibrosis was significantly higher in >6 weeks TRT 
group. No significant difference was seen for acute Grade 3+ esophagitis 
between two groups. The final recommendation requires the results from a 
prospective randomized trial.
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Patterns Of Practice And Outcomes For Stage I Non-small 
Cell Lung Cancer (nsclc): Analysis Of Seer-17 Data 1999-2008
N. S. Kapadia1, F. D. Vigneau2, W. O. Quarshie2, A. G. Schwartz2, F. P. Kong1, 
1University of Michigan Hospital Cancer Center, Ann Arbor, MI, 2Wayne State 
University School of Medicine, Detroit, MI
Purpose/Objective(s): Surgery has been the only curative option for early-
stage non-small cell lung cancer. As recent advances in radiotherapy (RT) 
allowed dose-escalation and more precise tumor targeting we hypothesize that 
use of RT increased and outcomes improved in 2004-2008 as compared to 
1999-2003. 
Materials/Methods: First primary stage I NSCLC cases from the SEER-17 
database were used for comparisons between the two eras. Hazard ratios (HR, 
95% CI) for death were generated for each era using Cox proportional regres-
sion methods based on treatment modality, adjusted for age, sex, race, marital 
status and year of diagnosis. Histology was added as a predictor to an entire 
timeframe hazards model and year of diagnosis was replaced by era. Logrank 
tests were used to compare overall survival differences. 
Results: A total of 53,764 patients with stage I NSCLC were included in this 
analysis (27,469 in the earlier era and 26,195 in the later era). From 1999-
2003, 17,463 (64%) patients were treated with primary surgery, 3,969 (14%) 
with RT alone, 5,514 (20%) received neither treatment, and 2% had unknown 
treatment. In the later era 18,335 (70%) patients underwent primary surgery, 
3,504 (13%) primary RT, 4218 (16%) had neither surgery nor RT and 1% 
had unknown treatment. Comparing one era to the other, the rates of sur-
gery increased although there were no significant difference in the number of 
patients who received radiotherapy either as an adjunct to surgery (HR 0.95, 
0.74-1.21) or as definitive therapy (HR 1.05, 0.94 - 1.17). For the entire time-
frame, important factors associated with higher risk of death after primary 
RT or surgery included age (HR 1.03, 1.03-1.03) African-American race (HR 
1.05, 1.00-1.09), large cell (HR 1.29, 1.21-1.37) or squamous histology (HR 
1.27, 1.23-1.31) and being unmarried (HR>1.17 for each strata). Important 
protective factors included female sex (HR 0.72, 0.71-0.74) and race listed 
as ‘other’ (HR 0.82, 95% CI 0.77-0.87). Overall survival between the eras 
significantly increased from 44 (43-46) to 56 (54-58) months. A change in 
the survival of patients treated with surgery could not be detected, as median 
survival has not yet been reached. For patients treated with RT alone, median 
survival significantly improved from 16 (16-17) to 21 (20-22) months. 
Conclusions: The rate of use of surgery has increased and the rate of use 
of radiotherapy remains stable between the two eras queried. Overall sur-
vival for stage I NSCLC has improved significantly for all patients and for 
those treated with primary RT, while survival after surgery remains excellent 
though an improvement could not be detected. Further research into whether 
improved patient selection or technical factors belies these observations will 
increase our understanding and guide future therapeutic decision making.
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Association Between Baseline Tumor Diameters and Overall 
Survival in Patients with Advanced Non-Small Cell Lung 
Cancer (NSCLC)
D. E. Gerber1, S. E. Dahlberg2, A. B. Sandler3, M. C. Perry4, J. H. Schiller1, 
J. R. Brahmer5, D. H. Johnson1, 1University of Texas Southwestern Medical 
Center, Dallas, TX, 2Dana Farber Cancer Institute, Boston, MA, 3Oregon 
Health and Science University, Portland, OR, 4Ellis Fischel Cancer Center, 
Colubmia, MO, 5Johns Hopkins University, Baltimore, MD
Purpose/Objective(s): It is not known to what extent baseline tumor dimen-
sions are associated with survival in patients with advanced NSCLC. We ana-
lyzed these factors in a recent phase 3 Eastern Cooperative Oncology Group 
(ECOG) trial. 
Materials/Methods: Patient clinical and disease data were derived from the 
ECOG 4599 trial of carboplatin-paclitaxel ± bevacizumab for advanced non-
squamous NSCLC. Associations between the baseline sum of diameters of 
target lesions (using Response Evaluation Criteria in Solid Tumors [RECIST]) 
and progression-free survival (PFS) and overall survival (OS) were evaluated 
using univariate and multivariable Cox regression models. 
Results: 850 patients were enrolled in the ECOG 4599 trial. Seventy-six per-
cent were age < 70 years, 46% were female, and 86% were white. Eighty-
eight percent had stage IV disease; 12% had “wet” IIIB disease. The median 
number of designated target lesions was 2 (interquartile range [IQR] 1-4), and 
the median baseline sum of tumor diameters was 7.5 cm (IQR 4.5-11.7 cm). 
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In univariate Cox models, baseline sum of tumor diameters predicted OS (HR 
1.41; P<0.001) but not PFS (HR 1.14; P=0.08). OS was 12.6 mos (95% CI, 
11.3-14.3 mos) for patients with baseline sum of tumor diameters < 7.5 cm, 
compared to 9.5 mos (95% CI, 8.7-11.0 mos) for ≥ 7.5 cm. In a multivariable 
model adjusted for treatment, sex, performance status, and degree of weight 
loss, this association was maintained (OS HR 1.34; P<0.001). Patients in both 
groups derived benefit from the addition of bevacizumab to chemotherapy. 
For < 7.5 cm: median OS 11.5 mos (95% CI, 10.3-13.2 mos) without bevaci-
zumab versus 14.1 mos (95% CI, 11.9-17.4 mos) with bevacizumab. For ≥ 7.5 
cm: median OS 8.5 mos (95% CI, 7.7-10.7 mos) without bevacizumab versus 
10.7 mos (95% CI, 9.2-12.4 mos) with bevacizumab. 
Conclusions: Baseline disease burden, as determined by the sum of baseline 
tumor diameters, is associated with survival in the ECOG 4599 trial. This 
finding merits evaluation in other NSCLC populations and consideration in 
the selection and stratification of patients for clinical trials.
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Single Nucleotide Polymorphisms in DNA Repair Genes 
May Be Associated with Radiation Pneumonitis in Patients 
with Non-small Cell Lung Cancer Treated with Definitive 
Radiotherapy
W. Wang1,2, M. Matuszak1, F. Kong1, 1Department of Radiation Oncology, 
Univ of Michigan, Ann Arbor, MI, 2Department of Radiation Oncology,the 
Fourth Affiliated Hospital, China Medical University, Shenyang, China
Purpose/Objective(s): Germline genetic variations can partly explain why 
normal tissue tolerance to radiotherapy varies by individual. DNA repair path-
ways may modulate radiation damage repair and have significant association 
with radiation toxicity. This study aimed to examine the association between 
single nucleotide polymorphisms (SNPs) of DNA repair genes and radia-
tion pneumonitis (RP) in patients with non-small cell lung cancer (NSCLC) 
treated with radiation based therapy. 
Materials/Methods: Patients with stage I-III NSCLC who received definitive 
radiotherapy with/without chemotherapy were eligible for this prospective 
study. RP was recorded and graded prospectively per predefined criteria. The 
primary endpoint was defined as RP grade ≥ 2. DNA samples for genotyping 
were extracted from buffy-coat which was collected before commencement of 
treatment. 24 SNPs in 11 genes were selected as they are known to have corre-
lation with treatment response/toxicity or risk of lung cancer (ATM, ERCC1, 
ERCC2, ERCC5, XRCC1, XRCC2, XRCC4, XPC, MGMT, NBN, TP53). 
The MassArray System (Sequenom Company) was used for genotyping. A 
Cox proportional hazards model was used for multivariate analysis to exam-
ine the effect of genotype on RP using three genetic models. False discovery 
rate (FDR) correction was performed for multiple testing. Kaplan-Meier log-
rank tests were used to evaluate the effect of correlation between SNPs on RP. 
Results: 119 consecutive patients, 93.9% Caucasian, were included in this 
study. All SNPs call rates were over 90.0%. Assay reproducibility was over 
99.0% by random double-blinded duplicate or triplicate checking. Among the 
clinical factors analyzed, mean lung dose (MLD) (p = 0.002) and volume 
receiving 20 Gy (V20) (p = 0.018) were significant independent factors pre-
dicting RP. Genotype association showed that 2 SNPs (XRCC4: rs1478486 
and rs2075685) were significantly associated with RP, adjusted for age, 
gender, smoking, V20, MLD and chemotherapy. However, only XRCC4: 
rs2075685 remained significant after FDR correction (adjusted hazard ratio, 
4.86, 95% confidence interval, 1.67-14.13, p
correct
 = 0.037 for TT/TG vs. GG). 
Conclusions: This study suggests that genetic variants in DNA repair path-
way genes, particularly XRCC4: rs2075685, may influence RP of patients 
with NSCLC treated with radiotherapy. Larger sample size studies and inde-
pendent validation are needed to confirm our findings.
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FGFR1 Protein Expression (P), mRNA and Gene Copy 
Number (GC) as Biomarkers to Discriminate Between FGFR1 
Inhibitor Sensitive and Resistant Lung Caner Cell Lines.
M. W. Wynes, L. E. Heasley, K. Ware, B. R. Asuncion, N. Zhou, T. Hinz, P. 
A. Bunn, D. R. Camidge, F. R. Hirsch, University of Colorado, Aurora, CO
Background: Lung cancer is the leading cause of cancer death globally and 
while some demonstrable success with targeted therapies, e.g. EGFR and 
ALK, has been made there are still numerous therapies, and associated bio-
markers, that need to be evaluated for known targets and there are undoubt-
edly still undefined targets. Signaling via FGFR1 has been implicated in 
numerous malignancies including lung cancer. FGFR1 GC has been shown 
to be amplified in lung squamous cell carcinoma but the utility of it as a 
biomarker for FGFR1 targeted therapies is still incomplete and the utility of 
FGFR1 P or mRNA expression as biomarkers is less developed. The aims of 
this study were to 1) evaluate the levels of FGFR1 mRNA and P as well as 
GC in a panel of 32 lung cancer cell lines, 2) determine the positivity cross-
over for these three markers, and 3) determine whether these markers could 
discriminate between FGFR1 inhibitor sensitive and resistant cell lines using 
2 separate inhibitors in 21 lung cancer cell lines. 
Methods: P by immunohistochemistry, mRNA expression by brightfield in 
situ hybridization, and GC by brightfield silver in situ hybridization was deter-
mined in 32 lung cancer cell lines. In 21 of the cell lines the IC50 values to 
the FGFR1 inhibitors AZD4547 (AZD) and Ponatinib (Pon) were determined. 
Results: Positivity was defined for P as a H-score >=60, mRNA as =4+ (on 
a 0-4+ scale), and GC as >=4 copies. There were 20 triple negative cell lines, 
2 triple positive, 2 mRNA, 2 P, 1 GC, 2 mRNA/P, 2 P/GC, and 1 mRNA/
GC. Receiver operating characteristic curve analyses were performed using 
<50 nM as the sensitivity cut-off for AZD and Pon. Respectively, the area 
under the curve for P was 0.83 (p=0.032) and 0.88 (p=0.006), for mRNA 0.74 
(p=0.107) and 0.91 (0.003), and for GC 0.56 (p=0.710) and 0.79 (p=0.033). 
The positive predictive values for AZD were 57%, 33% and 33% for P, mRNA 
and GC, respectively, and 71%, 83%, and 67% for Pon. The negative predic-
tive values for AZD were 93%, 80%, and 80% for P, mRNA and GC, respec-
tively, and 86%, 87%, and 80% for Pon. 
Conclusions: There was marked but incomplete cross-over between FGFR1 
P, mRNA and GC. All three biomarkers were able to differentiate between 
sensitive and resistant cell lines using the FGFR1 inhibitor Pon but GCN was 
somewhat less discriminatory than mRNA and protein. A multiplex assay of 
all three may be a better predictive assay to study in a prospective clinical trial 
with an FGFR 1 inhibitor. Further biomarker/assay validation is ongoing in 
preparation for prospective clinical trial designs.
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Identification of a Novel EML4-ALK Fusion Transcript in 
Lung Adenocarcinoma
K. To, J. H. M. Tong, P. P. Y. Law, S. L. Chau, R. W. M. Lung, S. F. Yeung, W. 
Kang, The Chinese University of Hong Kong, Shatin, Hong Kong
Purpose/Objective(s): The echinoderm microtubule-associated protein-like 
4-anaplastic lymphoma kinase (EML4-ALK) fusion gene has been identified 
as a potent driver mutation in non-small cell lung cancers (NSCLC). It defines 
a unique subgroup of lung adenocarcinoma that may be responsive to specific 
targeted therapy. We report a novel EML4-ALK fusion transcript detected by 
immunohistochemistry in lung cancers. 
Materials/Methods: A total of 378 lung adenocarcinoma samples were 
retrieved from department of Anatomical and Cellular Pathology, Prince of 
Wales Hospital. Three representative tumor paraffin block samples were taken 
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from each case for tissue microarray construction. Immunohistochemistry 
was performed in the tissue array sections using anti-ALK antibody (Abcam 
5A4) and Envision FLEX+ visualization system. Fluorescence in situ hybrid-
ization (FISH) for ALK-rearrangement was performed using Abbott break-
apart probe to confirm the presence of ALK gene rearrangement. When 
suitable material was available, fusion gene transcripts were also studied by 
RT-PCR. Full length novel EML4-ALK variant was amplified by RT-PCR 
and cloned into pcDNA3.1 expression vector. In vivo tumorigenecity assay 
was performed by injecting EML4-ALK-expressing NIH3T3 cells into nude 
mice. 
Results: Twenty-two out of 378 (5.8%) lung adenocarcinomas in this cohort 
were positive for ALK immunohistochemical (IHC) stain. The tumor cells 
demonstrated granular staining in the cytoplasm of various intensities. No 
expression was observed in normal bronchial epithelium, alveolar pneu-
mocytes and stromal cells. All the ALK IHC positive cases were confirmed 
either by FISH using ALK break-apart probe or RT-PCR. EML4-ALK vari-
ants 1,2 and 3b were the most common fusion products detected by RT-PCR. 
We identified a novel EML4-ALK fusion variant in which intron 3 of EML4 
was ligated to intron 19 of ALK. The resulting fusion transcript consisted 
of EML4 exons 1-3, ALK intron 19,(53 bp upstream of exon 20) and ALK 
exons 20-29. The transforming potential of this novel EML4-ALK variant 
was confirmed by in vivo tumorigenecity assay. The novel variant was found 
in a 73-year old, non-smoking female patient with lung adenocarcinoma. No 
concurrent EGFR, Kras, Her2, BRAF mutation and c-MET amplification was 
found in this case. 
Conclusions: A novel transforming EML4-ALK fusion variant was identi-
fied by immunohistochemistry. The finding broadens the spectrum of ALK 
fusion variants and provides further biological and clinical insights into ALK-
positive lung cancer.
Author Disclosure Block: K. To: None. J.H.M. Tong: None. P.P.Y. Law: 
None. S.L. Chau: None. R.W.M. Lung: None. S.F. Yeung: None. W. Kang: 
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Tissue Expression of Activated Phosphorylated Forms of Bcl2 
and Mcl1 as Prognostic Markers in Small Cell Lung Cancer
T. K. Owonikoko1, R. P. Chowdry1, Z. Chen1, A. Goodman2, S. Kim1, X. 
Deng1, A. Gal1, F. R. Khuri1, S. S. Ramalingam1, G. Sica1, 1Emory University, 
Atlanta, GA, 2Wahington University, St. Louis, MO
Purpose/Objective(s): Bcl-2 protein overexpression is frequently described 
in small cell lung cancer (SCLC) but the biological relevance remains unclear. 
To better elucidate the role of Bcl2 dysfunction in SCLC, we assessed the 
expression pattern of the total and the biologically relevant phosphorylated 
forms of the anti-apoptotic Bcl2 family members (Bcl2, pBcl-2, Mcl-1, pMcl-
1) in pulmonary neuroendocrine (NE) tumors. 
Materials/Methods: We analyzed archival samples of pulmonary carcinoid, 
SCLC and large-cell NE carcinoma (LCNEC) by immunohistochemistry 
(IHC) using specific antibodies. Protein expression was assessed by light 
microscopy using standard scoring of intensity (0, 1, 2 and 3) and percent 
cell staining to generate an immunoscore (product of intensity and percent 
cell staining) ranging between 0 and 300. Immunoscore was correlated with 
age, gender, smoking status, tumor type, stage and survival. Significant dif-
ferences in expression pattern and correlation with clinical variables were 
assessed by Wilcoxon two-sample test, t-test, ANOVA, Spearman and Pearson 
correlation coefficients and Cox regression model. 
Results: This analysis employed 77 cases including carcinoid (16) SCLC 
(41) and LCNEC (20); median age (61 yrs), gender (62% females). Total 
and activated Bcl2 but not Mcl1 was differentially expressed with signifi-
cantly higher immunoscore in SCLC and LCNEC compared to carcinoid 
tumor. The respective immunoscores for SCLC, LCNEC and carcinoid were: 
cytoplasmic Bcl2 immunoscore of 97/124/7, p=0.0005; cytoplasmic pBcl2: 
132/83/42 respectively, p=0.0007; cytoplasmic Mcl1: 232/253/230 respec-
tively, p=0.5327 and pMcl1: 173/165/131 respectively, p=0.2919. High Bcl2 
and pBcl2 correlated with increased risk of death: [HR: 1.01; CI: 1.0-1.12, 
p=0.0167 and 1.57, CI: 1.09-2.26, p=0.0165 for Bcl2 and pBcl2 respectively]. 
High immunoscore of Bcl2 and pBcl2 was also positively correlated with 
increased risk of disease progression: [HR: 1.01, CI: 1.00-1.02, p=0.0072 
and 1.39, CI: 1.02-1.89, p=0.0383 for Bcl2 and pBcl2 respectively]. pBcl-2 
showed stronger correlation than total Bcl2 with adverse features including 
smoking, malignant histology, higher stage at diagnosis and poor survival. 
There was no significant association between Mcl1 or pMcl-1 expression and 
clinical or pathologic parameters. 
Conclusions: High expression of Bcl2 and pBcl-2 in malignant neuroendo-
crine tumors supports a key role in SCLC biology. Our findings support ongo-
ing attempt to target this family of proteins for therapeutic gains in SCLC. 
Activated pBcl2 showed a stronger correlation with adverse prognostic fea-
tures and may be a better predictive biomarker. Supported by NIH grant P01 
CA116676-5S1 to TKO & FRK and Georgia Cancer Coalition grant to GS, 
WJC, FRK, SSR and TKO.
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Panel of Serum Biomarkers May Predict Benefit from 
Bevacizumab (BEV) in Advanced NSCLC Patients
E. Braun, M. Fidler, S. Basu, A. Gangaram, K. Kaiser Walters, R. Karmali, C. 
Fhied, J. A. Borgia, P. D. Bonomi, Rush University Medical Center, 
Chicago, IL
Purpose/Objective(s): BEV has produced modest benefits in patients (PTS) 
with advanced NSCLC. Identification of positive predictors for BEV would 
have important implications for individual PTS and health care costs. 
Materials/Methods: We performed a prospective exploratory analysis to 
identify serum biomarkers as predictors of improved outcomes with BEV. 
Pre treatment sera were collected from 93 pts prior to initiation of first line 
treatment for advanced NSCLC. Treatment drugs, including BEV, were pre-
scribed according to treating physician’s discretion. Seventy two serum bio-
markers, relevant to angiogenesis and tumor progression, were recorded using 
Luminex immunobead platform. Serum levels were correlated with progres-
sion free survival (PFS) and overall survival (OS) and compared between 
patient treated with or without BEV containing regimens, BEV + and BEV- 
groups respectively. Log-rank and interaction p value tests were used to iden-
tify markers associated with longer PFS and OS in the BEV+ group but not 
in BEV- group. 
Results: Characteristics for each group were: BEV+ (n=43, median age 65 
y/o, 72% smokers, 60% females, 100% non-squamous). BEV- (n=50, median 
age 64 y/o, 84% smokers, 50% female, 70 % non-squamous). The BEV+ 
group had longer PFS (5.8 vs. 3.0 mos, log-rank p= 0.039) and OS (13.1 
vs. 8.5 mos, log-rank p =0.11) when compared to the BEV- group. High 
serum levels of these markers resulted in a differential decreased hazard in 
the BEV+ group: PDGF-AB/BB (interaction p <0.01 for PFS, p=0.04 for 
OS), FGF (interaction p=0.15 for PFS, p<0.04 for OS), tenascin-c (interaction 
p=0.18 for PFS, p=0.04 for OS), RANTES (interaction p=0.04 for PFS, p=0.6 
for OS), epiregulin (interaction p=0.31 for PFS, p=0.04 for OS) and anti-HGF 
(interaction p=0.18 for PFS, p=0.03 for OS). In the BEV+ group higher levels 
of PDGF-AB/BB were associated with a better outcome (log-rank p=0.05 and 
p=0.01 for PFS and OS respectively). We did not find significant correlations 
between serum levels of VEGF, anti-VEGF or VEGFR and benefit from BEV. 
Conclusions: This exploratory analysis suggests that these biomarkers may 
have predictive value for BEV in NSCLC PTS and should be considered for 
further studies.
Author Disclosure Block: E. Braun: None. M. Fidler: D. Employment 
Other; Expert Testimony for Genentech. F. Honoraria; Lilly, Genentech. S. 
Basu: None. A. Gangaram: None. K. Kaiser Walters: None. R. Karmali: 
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Other; Expert Testimony for Genentech. E. Research Grant; Genentech.
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Vimentin (EMT Marker Protein) Score Predicts Resistance to 
Erlotinib and Radiotherapy for Patients with Stage III Non-
Small Cell Lung Cancer on A Prospective Phase II Trial
R. U. Komaki, Y. B. Kim, I. I. Wistuba, X. Tang, R. Meyn, P. K. Allen, X. 
Wei, J. J. Lee, M. S. O’Reilly, W. K. Hong, M.D. Anderson Cancer Center, 
Houston, TX
Purpose/Objective(s): Although erlotinib has shown radiosensitization 
effects, 20% of patients who were treated by erlotinib and radiotherapy fol-
lowing chemoradiotherapy have failed to respond in our prospective phase II 
trial for inoperable stage III NSCLC. We have examined predictive factor of 
non-response to this treatment by using Vimentin IHC which is a strong mul-
tigene signature indicative of epithelial to mesenchymal transition (EMT). 
Materials/Methods: We have conducted a prospective phase II study 
for patients with stage III NSCLC patients. Eligibility included good PS, 
weight loss ≤ 5%, adequate lung, hematologic, hepatic, and renal functions. 
ChT/RT was given every Monday followed by erlotinib/RT on Tuesday-
Friday and erlotinib alone over the weekend. RT (63 Gy in 35 fractions) 
with weekly paclitaxel (45mg/m²) / carboplatin (AUC=2) and erlotinib (150 
mg p.o. daily except on the day of chemotherapy) were given for 7 weeks 
followed by 2 cycles consolidation of paclitaxel (AUC=6) and carboplatin 
(200mg/m2). The response was measured by RECIST criteria (v3.0) by CT 
scan after completion of ChT/RT. Fisher’s exact and Kaplan-Meier’s esti-
mates were used for the statistical analysis. Primary endpoint was to deter-
mine efficacy of erlotinib/radiotherapy after ChT/RT measuring 2- year 
overall survival (OS), progression-free survival (PFS), local recurrence-free 
survival (LRFS) and distant metastasis free survival (DMFS). Second end-
point point was that their pretreatment biopsy specimens were correlated 
between biomarkers (EGFR IHC staining and Vimentin Score) and patients’ 
outcome on this trial. 
Results: 48 patients enrolled from 3/2008 through 6/2010 and 46 completed 
the entire treatment and are evaluable for response. 17 (37%) were female, 
23 adenocarcinoma, and 87% former or current smokers, with median age 
63 year-old (range: 46-81). Responses showed 14 (30%) CR, 23 (50%) PR 
and 9 (20%) stable or progressive disease. The median OS and PFS were 
34.1 months & 14.5 months, respectively. 1-year & 2-year OS were 82.5% & 
70.8 %. There were 22 specimens analyzable for Vimentin IHC. The Vimentin 
Cytoplasm Score (VCS) < 240 vs. ≥ 240 were compared regarding OS, PFS, 
LRFS and DMFS. There were significant differences in 2 years between the 
groups with VCS <240 vs. ≥ 240 regarding OS (71.8% vs, 0%, P= 0.022), 
PFS (29.5% vs. 0%, P=0.0019) and LRFS (79.8% vs. 0%, p<0.0001), but not 
DMFS (35.5 vs. 0%, p= 0.069), respectively. 
Conclusions: This prospective phase II clinical study demonstrated an excel-
lent 2-year OS 70.8 % and median OS 34.1 months. Vimentin Cytoplasmic 
Score might be used as a predictor for patients with stage III NSCLC who do 
not respond to erlotinib and radiotherapy combined by chemoradiotherapy, 
although we need validation with larger number of patients.
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A Genetic Polymorphism in miR-196a2 is Associated with 
Increased Risk of Lung Cancer: A Meta-analysis
N. Bi, K. Shedden, F. S. Kong, University of Michigan Health System, Ann 
Arbor, MI
Purpose/Objective(s): Low dose CT screening has now become a standard 
practice for high risk patient. However, the low positive predictive value of 
CT-screening (3.6%) demands a need of developing specific biomarkers 
which can complement image techniques. MicroRNAs play a key role in 
gene regulatory networks and act as tumor suppressors or oncogenes in the 
initiation and progression of malignancies. Recent studies have shown that 
a common polymorphism (rs11614913) within the hsa-miR-196a2 mature 
sequence may play an important role in lung cancer development by altering 
binding activity of target mRNA. However, the findings from different studies 
are not consistent. This study aimed to evaluate the effect of this polymor-
phism on the risk of lung cancer. 
Materials/Methods: A literature search of MEDLINE and EMBASE up to 
February 2012 was performed using key words ‘miR-196a2’ or ‘rs 11614913’, 
‘polymorphism’, and ‘lung cancer’ or ‘lung carcinoma’. Only case-control 
studies which providing detailed genotype distribution data were eligible. 
Meta-analysis was applied to evaluate the association between different geno-
types and susceptibility of lung cancer. Heterogeneity assessment and funnel 
plot were performed to account for bias in patient selection. Odds ratio (OR) 
with 95% confidence interval (CI) were estimated using the fixed model if 
studies were homogeneous. 
Results: 4 independent case-control studies consisting of 2219 lung can-
cer patients and 2232 controls were eligible. Heterogeneity assessment and 
funnel plot suggested that there was no heterogeneity among the studies 
(I2 = 28.0%, P = 0.21) and no publication bias in the current meta-analysis. 
Individuals carrying CC genotype of has-miR-196a2 polymorphism was 
associated with an increased lung cancer risk in homozygote comparison (CC 
vs. TT, OR = 1.26; 95% CI, 1.07-1.49) and dominant model (CC/CT vs. TT, 
OR = 1.19; 95% CI, 1.04-1.36). By stratifying tumors on the basis of histol-
ogy and ethnicity, significant association between miR-196a2 polymorphism 
and increased risk of NSCLC (OR = 1.28; 95% CI, 1.06-1.55) and Asian 
subjects (OR = 1.21; 95% CI, 1.05-1.33). The positive predictive and negative 
predictive values were 50.9% (95% CI, 48.8 -53.0%) and 53.0% (95% CI, 
51.0 -55.1%), and the sensitivity and specificity were 74.6% (95% CI, 72.8 
-76.4%) and 28.5% (95% CI, 26.6 -30.4%). 
Conclusions: Though suboptimal, miR-196a2 C allele is significantly asso-
ciated with increased susceptibility of lung cancers with a relatively high 
positive predictive value. Further independent validation through large pro-
spective study is warranted.
Author Disclosure Block: N. Bi: None. K. Shedden: None. F.S. Kong: 
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Genotypic Analysis of 172 Patients with Non-small Cell 
(NSCLC), Small Cell (SCLC) or Thymic Tumors
R. M. Duffy, C. Beadling, A. Warrick, L. J. Winter, A. Burt, B. Wilson, K. 
G. Schuff, C. L. Corless, A. B. Sandler, A. Lopez-Chavez, Oregon Health & 
Science University, Portland, OR
Purpose/Objective(s): Advances in genetic analysis have created a success-
ful paradigm shift in the treatment of advanced lung cancer. Targeted thera-
peutics, based on specific genetic abnormalities (eg EGFR, EML4-ALK), are 
routinely incorporated into patient care, with improved response rates and 
decreased toxicity compared to chemotherapy. Prior studies have character-
ized molecular profiles in lung cancer; however, these efforts are limited by 
emphasis on specific histologic subtypes and analysis of a restricted number 
of genes. To overcome these limitations, this study investigates a prospective 
cohort of lung cancer patients using an expanded molecular profile. This proj-
ect is part of the personalized cancer medicine registry at the Knight Cancer 
Institute, designed to integrate prospective tumor genotyping data into the 
clinical care of cancer patients. 
Materials/Methods: Lung and thymic cancer patients, irrespective of his-
tology, performance status, stage at presentation, or treatment history were 
eligible for enrollment. Formalin-fixed, paraffin-embedded tumor tissue was 
analyzed using a mass spectrometry-based panel of multiplexed assays capa-
ble of detecting 647 mutations across 53 genes. Patients enrolled from April 
1, 2011 until March 1, 2012 are included in this analysis. 
Results: Analysis of 172 enrolled patients revealed 52% women, 95% had 
ECOG performance status 0-2, 88% Caucasian, and 19% never smokers. 
NSCLC comprised 81% of the population. Successful molecular analysis 
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occurred in 108 patients (88 NSCLC, 15 SCLC, 4 thymic, and 1other); EGFR 
and KRAS testing was performed in an additional 14 and 7 patients, respec-
tively. Fifty-three patients had insufficient tissue for analysis. Fifty-two muta-
tions were detected among 45 patients (43 NSCLC and 2 SCLC). Among 
NSCLC tumors analyzed, mutations included AKT1 (1/88, 1.1%), BRAF (4/88, 
4.5%), CTNNB1 (1/88, 1.1%), EGFR (17/122, 14%), HRAS (1/88, 1.1%), 
IDH1 (1/88, 1.1%), KRAS (21/115, 18%), NRAS (1/88, 1.1%), PIK3CA (1/88, 
1.1%) and TP53 (9/88, 10%). Among SCLC tumors, mutated genes included 
1 BRAF and 1 TP53 mutation, each accounting for 7% (1/15) of SCLC ana-
lyzed. Seven patients had dual mutations (16%, 7/45). ALK translocations were 
detected in 3 patients. Zero mutations were detected in thymic cancer patients. 
Conclusions: Our analysis contributes to the growing body of data on molec-
ular abnormalities in lung cancer by expanding the knowledge of typical lung 
cancer mutations, as well as characterizing less commonly evaluated muta-
tions (eg IDH1, TP53) and observing dual mutations, notably in the RAS/
RAF pathway. This data emphasizes the diversity of mutations among all his-
tologies of lung cancer, including SCLC. Future analysis will include charac-
terization of the clinical outcomes based on the tumor genotype.
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Mutations in NSCLC and Their Link With Lung Cancer-
Associated Thrombosis: A Case-Control Study
L. Corrales-Rodriguez, D. Soulières, X. Weng, M. Tehfe, M. Florescu, N. 
Blais, Hôpital Notre-Dame, CHUM, Montreal, QC, Canada
Purpose/Objective(s): NSCLC is a high risk factor for venous thromboem-
bolism (VTE). Although preclinical data suggest a link between KRAS muta-
tions and thrombosis, no link has been reported between cancer genotype and 
VTE in NSCLC patients. This retrospective case control study evaluates the 
relationship between KRAS or EGFR mutations and VTE in NSCLC patients. 
Material/Methods: Cases were obtained from the CHUM NSCLC registry 
and matched to patients referred for duplex, lung CT-angiography or lung 
scintigraphy imaging during the period of interest. Diagnosis of VTE (venous 
thrombosis, pulmonary embolism, and migratory superficial thrombophle-
bitis) was confirmed by a review of the imaging reports. VTE occurring 6 
months previous to or after a diagnosis of NSCLC was accepted. Controls 
were patients with NSCLC without thrombosis matched for age and stage 
(I-IIIA/IIIB-IV). Exclusion criteria included insufficient tissue for KRAS/
EGFR mutation analysis or insufficient clinical information. 
Results: Between Jan 2000 and Dec 2009 a total of 57 cases and 102 con-
trols were included. Adenocarcinomas comprehended a 71.9% of cases and 
a 56.9% of controls. Former and current smokers were a 50.9% and 36.8% 
respectively of cases (total=87,7%) and a 40.2% and 48% respectively of con-
trols (total=88,2%). DVT occurred in 68.4%, PE in 24.6%, and Trousseau 
in 7%. Kras codon 12 or 13 mutation was present in 29.8% of cases and in 
13.7% of controls. EGFR ex 19 and 21 mutation occurred in 8.8% of cases 
and 8.8% of controls. The OR for thrombosis in KRAS and EGFR mutated 
NSCLC patients are respectively 2.67 (1.12-6.42; p=0.014) and 0.99 (0.27-
3.48; p=0.99). 
Conclusions: KRAS mutation is associated with an increased risk of VTE 
in this NSCLC cohort. These findings are consistent with preclinical studies. 
Prospective data on VTE from clinical trials with molecularly defined NSCLC 
are needed and may lead to better stratification for thromboprophylaxis.
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Human Papillomavirus (HPV) and Non-Small Cell Lung 
Cancer (NSCLC)
T. Hoang1, T. Weigel1, K. Oettel2, D. Yang1, C. Zhang1, K. Kim1, T. C. 
Campbell1, J. D. Maloney1, M. Larson1, A. M. Traynor1, 1University of 
Wisconsin, Madison, WI, 2Gundersen Lutheran Cancer Center, LaCross, WI
Purpose/Objective(s): HPVs are associated with carcinogenesis in oropha-
ryngeal and cervicovaginal cancer. Data, primarily from Asia, have suggested 
that HPV may also play a role in NSCLC, particularly in non-smoking patients 
(pts). Studies using PCR and/or in situ hybridization (ISH) in US pts detected 
HPV in 5.8-22.0% cases. p16INK4a protein expression has been shown in head 
and neck squamous cell carcinoma to be a sensitive and specific surrogate 
marker for HPV. We attempted to (1) Identify HPV prevalence in early stage 
NSCLC pts from US academic and community centers using both ISH and 
p16INK4a; and (2) Correlate HPV status with clinical presentation and outcome. 
Material/Methods: Clinical data and archived paraffin fixed tumor speci-
mens in tissue microarrays were obtained from 88 expired patients with stage 
I-II NSCLC who underwent curative resection at University of Wisconsin and 
Gundersen Lutheran Cancer Center in LaCrosse, WI. ISH was employed for 
low (types 6, 11) and high risk (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 66) HPV detection (Arup Laboratories, UT). We also performed immu-
nohistochemistry staining for p16INK4a (BD Pharmingen, CA). Associations 
between biologic markers and clinical characteristics (age, gender, smoking, 
histology, disease stage) and disease outcome were analyzed. 
Results: The median age of 88 patients was 73. Females accounted for 37.5%. 
Most patients had smoked cigarettes (95.4%). Squamous cell carcinoma was 
seen in 43.2% and non-squamous cell carcinoma in 56.8% (predominantly 
adenocarcinoma). 62.5% had stage I and 37.5% had stage II. Median recur-
rence free survival (RFS) and overall survival (OS) in all patients was 11 
months and 22 months, respectively. We found strong p16INK4a expression 
(intensity ≥ 2+ in >70% of tumor cells) in 15/88 samples (17.0%), while HPV 
was not identified in any sample by ISH. Overall, there was no significant 
difference in p16INK4a status with regard of age, gender, smoking history, his-
tology, or disease stage. In addition, when comparing p16INK4a expression with 
non-expression cohort, there was no difference in median RFS (18 months vs. 
11 months, p=0.131) and OS (24 months vs. 21 months, p=0.215). 
Conclusions: HPV was not demonstrated by ISH in our cohort. The high per-
centage of pts with smoking history and advanced age are possible reasons 
for the absence of HPV in our study. Strong p16INK4a protein expression was 
seen in 17.0 %, but did not correlate with outcomes or clinical characteristics. 
Furthermore, p16INK4a expression did not correlate with HPV positivity, sug-
gesting that p16INK4a may not be a specific surrogate marker for HPV in NSCLC.
Author Disclosure Block: T. Hoang: None. T. Weigel: None. K. Oettel: 
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Fgfr1 Amplification In Squamous Cell Lung Cancer
S. Gadgeel, G. Bepler, A. Schwartz, S. Land, A. Bollig-Fischer, V. Murphy, M. 
Cote, Karmanos Cancer Institute/Wayne State University, Detroit, MI
Background: There are currently no targetable genetic abnormalities for 
squamous cell lung carcinomas, the second most common type of non-small 
cell lung cancer. Amplification of the fibroblast growth factor receptor type 
1 gene (FGFR1) has been identified as a driver event in breast cancers and in 
squamous cell lung carcinomas. 
Material/Methods: DNA from 123 squamous cell lung cancer fresh fro-
zen tumors, resected from 1987-2001, was extracted for this analysis. Pre-
designed TaqMan® Copy Number Assays from Applied Biosystems were 
used to detect FGFR1 exon 12 or FGFR1 exon 16, with RNaseP as the 
reference gene. Data analysis was performed using Applied Biosystems’ 
Copy Caller Software. Chi-squared tests were used to examine clinical and 
demographic differences between patients with and without amplification 
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of FGFR1. Survival differences were examined by Kaplan Meier and Cox 
regression models. 
Results: Men comprised the majority of the population (n=91, 74%) and most 
cases were pathological stage I (n=75, 61%) or stage II (n=32, 26%). Thirty 
(24.4%) tumors showed amplification of FGFR1. There was no association 
between amplification and sex (p=0.18) or stage (p=0.37). The majority of the 
patients were white (n=144, 92.7%), but the proportion of tumors that were 
amplified was higher among non-whites (5/9, 55.5%) than whites (25/114, 
21.9%, p=0.02). Overall, median survival was 32.2 months. In univariate sur-
vival analysis, amplification was associated with an increase hazard of death 
(HR=1.55, Wilcoxon p=0.03) and stage at diagnosis was strongly associated an 
increased risk of death (HR=1.67, p=0.0009). Only stage remained a significant 
predictor of death in the multivariable survival models (HR=1.65, p=0.004) 
Conclusions: Somatic amplification of FGFR1 is a relatively common event 
in squamous cell carcinomas of the lung and may be associated with race and 
overall survival.
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Exploration of The Classification of Gross Tumor Volume 
and Pathological Staging of Esophageal Squamous Cell 
Carcinoma After Radical Resection
S. Zhu1, Q. Xu1, W. Shen1, Z. Liu1, C. Song2, Y. Li1, 1The Fourth Hospital 
of Hebei Medical University, Shijiazhuang, China, 2The Central Hospital of 
Handan, Handan, Hebei, China
Purpose/Objective(s): This study aim was to use the volume calculating 
function of treatment planning system of 3DCRT to work out the value of 
primary lesion of esophageal carcinoma patient’s GTV as the standard clas-
sifications of T stage, and to provide criteria reference for clinical staging of 
esophageal carcinoma. 
Materials/Methods: Between June 2002 to June 2006, 607 patients (male 
412, female 195, median age 59 years) with esophageal carcinoma received 
definitive resection in our Hospital were included in this retrospective study, 
and their pre-operative CT images were transmitted in digital format to the 
3DCRT planning system by the network. Primary lesion GTV targets were 
outlined, and their volumes were automatically computed by planning sys-
tem. Compared the differences of GTV volume in different pathological T 
stages, and analyzed the relationship between GTV volumes and pathological 
T stages. According to the median volume value of GTV with different patho-
logical T stages, divided values of GTV volume co-responding to different 
T stages and selected suitable classification standard value of GTV volume. 
Results: The primary lesion of esophageal carcinoma GTV length, maxi-
mum diameter and volume were related to pathological T staging and with 
a positive correlation (P<0.001). The Spearman correlation coefficient 
was 0.376, 0.466 and 0.464, respectively, P<0.001. Except that the length, 
maximum diameter and volume of GTV in pathological T3 and T4 had no 
significant difference, other indicators of the pathological T stages showed 
significant difference between the groups (P<0.001). According to the 
median volume of GTV at different pathological T stages, the GTV vol-
umes were divided into three grades: ≤5.0cm3, 5.1-13.0cm3, and>13.0cm3. 
When compared them with pathological T1, T2, and T3+T4 stage, the 
coincidence rate was 73.8%, and the consistency was good between GTV 
volume grades and pathological T stage (kappa=0.40, P<0.001). The over-
all 5-year survival of GTV grades 1, 2, 3 were 78.1%, 31.5%and 33.5%, 
respectively(P<0.0001). If the GTV volume were divided into four grades: 
≤5.0 cm3, 5.1-13.0 cm3, 13.1-39.0 cm3, and>39.0 cm3, the coincidence rate 
of GTV volume grades and pathological T staging was only 54.7%, and 
the consistency was poor(kappa =0.24,P<0.011), the overall 5-year sur-
vival rate of GTV grades l, 2, 3, 4 were 78.1%, 31.5%, 36.2% and 27.5%, 
respectively(P<0.0001). 
Conclusions: The length, maximum diameter and volume of primary lesion 
of esophageal carcinoma patient’s GTV are related to pathological T staging 
with a positive correlation. The classification that esophageal carcinoma GTV 
volume divided into three grades has a good coincidence with the pathologi-
cal T staging.
Author Disclosure Block: S. Zhu: None. Q. Xu: None. W. Shen: None. Z. 
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An Audit of the Clinical Performance of EarlyCDT®-Lung
J. R. Jett1, L. J. Peek2, L. Fredericks2, W. Jewell2, W. W. Pingleton2, J. F. R. 
Robertson3, 1National Jewish Health, Denver, CO, 2Oncimmune USA LLC, De 
Soto, KS, 3University of Nottingham, Nottingham, United Kingdom
Purpose/Objective(s): EarlyCDT®-Lung, a clinical blood test that detects 
autoantibodies to lung cancer associated antigens, has shown high specificity 
in case-control validation studies and currently serves as an aid to early detec-
tion. We investigated the performance of this test in routine use by auditing 
clinical outcomes of the initial series of patients tested by EarlyCDT-Lung 
who also signed HIPAA authorization permitting disclosure of their health 
information to Oncimmune®. 
Material/Methods: 1613 patients in the US at high risk for lung cancer (mean 
5yr risk 3.08% from the Spitz model) were included. The EarlyCDT-Lung 
panel was modified in Nov. 2010 from 6 antigen (Ag) to 7Ag to improve spec-
ificity; this report includes data on both the 6Ag (n=752) and 7Ag (n=861) 
panels. Tests were ordered by 810 physicians in 48 states. Information as to 
whether a patient was diagnosed with cancer was requested at specific inter-
vals based upon the EarlyCDT-Lung result - positives were followed-up at 6 
weeks and every 6 months (mos) thereafter while negatives were followed-up 
at 6 and 18mos post-test. Six month (mo) follow-up for the positives/nega-
tives were 100%/97% for the 6Ag panel and 98%/87% for the 7Ag panel. The 
18mo follow-up for the 6Ag panel negatives was 80% and none of the patients 
tested on the 7Ag panel have reached the 18mo time point. This report will 
therefore focus on the 6mo results. Pathology reports when available were 
reviewed for diagnostic classification. Staging was assessed on histology 
where surgery was performed, otherwise on imaging. The clinical/pathologi-
cal diagnosis was compared to the EarlyCDT-Lung result, and the perfor-
mance of EarlyCDT-Lung was evaluated. 
Results: Sixty-two patients (3.8%) were identified with lung cancer within 
6mos after EarlyCDT-Lung; 25 of whom tested positive by EarlyCDT-Lung 
giving a sensitivity of 40.3%: sensitivity for the 6Ag (44.4%) and the 7Ag 
panels (37.1%) were not statistically different (p=0.56). The PPV for the 6Ag 
panel was 1 in 11.6 and 1 in 6.4 for the 7Ag panel. For the current 7Ag 
panel, a positive result represents a 5.4-fold increase in risk of lung cancer. 
Importantly, at least 60% (12/20) non-small cell lung cancers (NSCLCs) 
detected were stage I or II - 6/10 for both the 6Ag and 7Ag panels (stage 
was not yet available for 4 NSCLCs and one cancer was an SCLC). The 7Ag 
EarlyCDT-Lung panel revealed a highly significant improvement in specific-
ity over the 6Ag panel: 91.4% for 7Ag vs 82.5% for 6Ag (p<0.0001). 
Conclusion: The performance of EarlyCDT-Lung in this clinical audit mir-
rors that of the extensive validation studies previously reported, showing 
significant improvements in specificity of the 7Ag panel while maintaining 
sensitivity. The high specificity of EarlyCDT-Lung with its high PPV con-
firmed in this audit makes it a potentially complementary tool to CT for lung 
cancer detection.
Author Disclosure Block: J.R. Jett: E. Research Grant; Oncimmune. 
L.J. Peek: A. Employee; Oncimmune USA LLC. L. Fredericks: B. 
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Specialized Specimen Handling for Molecular Testing: The 
‘Molecular Only’ Approach Results in a High Success Rate 
for Molecular Testing in NSCLC
D. L. Aisner, M. D. Rumery, R. C. Doebele, K. Kondo, D. Linderman, N. 
Thomas, M. Varella-Garcia, W. A. Franklin, D. R. Camidge, University of 
Colorado, Aurora, CO
Purpose/Objective(s): The implementation of molecular analysis in non-
small cell lung cancer (NSCLC) is often hampered by small size of diagnos-
tic specimens, which frequently are the only material available for molecular 
testing. Further impeding molecular analysis is the common utilization of 
immunohistochemistry, combined with aggressive facing of pathology 
blocks, which often leads to minimal to no tissue remaining after the diag-
nostic process. Here we present data demonstrating a high success rate for 
molecular testing when specialized processing and handling processes are 
implemented.
Materials/Methods: We designed a specialized process which maximizes 
tissue in multiple blocks, minimizes block facing, and minimizes use of 
immunohistochemistry, while still providing a histologic diagnosis. We 
retrospectively evaluated for quality control purposes the success rate of 
samples handled using our specialized process for molecular analysis. 
NSCLC specimens collected under a ‘molecular only’ process between 
September, 2010 and February, 2012 were evaluated for whether tumor 
was present in the submitted material, and whether subsequent molecu-
lar testing (comprised of mutational analysis, FISH analysis or both) was 
successful. 
Results: During the 18 month period, 57 NSCLC specimens were submitted 
for special ‘molecular only’ handling. 18 of these biopsies were performed 
for initial tumor characterization and 39 were performed for progression on 
therapy. Of these, 44 (77%) specimens were successfully utilized for molecu-
lar testing. Of the 13 (23%) specimens in which molecular testing was not 
successful, 6 had no tumor present in the specimen, 2 had molecular test-
ing attempted despite extremely limited tumor identified on histology, but 
was ultimately found to be quantitatively inadequate, and 5 were found to be 
quantitatively inadequate based on histology (very scant tumor cellularity). 
Thus of all cases showing any tumor present in the biopsy material (51 total), 
the success rate for molecular analysis was 86%. The success rate for all cases 
attempted for molecular testing was 95%. 
Conclusions: Specialized handling of specimens in which molecular testing 
is a clinical priority results in a high success rate for molecular analysis. This 
approach is especially applicable for patients in whom an initial biopsy has 
been depleted during the diagnostic work-up, or patients requiring biopsy 
at the time of progression on therapy. All cases which were not success-
ful using this specialized handling were due to paucity or complete lack of 
tumor cells in the submitted specimen, which in many cases was attributed 
to tissue reaction related to prior therapy. Details of specialized handling will 
be discussed.
Author Disclosure Block: D.L. Aisner: None. M.D. Rumery: None. R.C. 
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Comparative Survival Of Resected Node-negative Nonsmall 
Cell Lung Cancer With And Without Lymph Node Evaluation.
R. U. Osarogiagbon1, X. Yu2, 1Boston Baskin Cancer Foundation, Memphis, 
TN, 2School of Public Health, University of Memphis, Memphis, TN
Purpose/Objective(s): Despite the immense prognostic value, pathologic 
nodal staging practice is poor in the US. We previously reported that 12% of a 
city-wide NSCLC resection cohort had no lymph nodes examined, with signif-
icant survival detriment, compared to patients with no metastasis after exami-
nation of at least 1 lymph node. We examined the Surveillance, Epidemiology 
and End Results (SEER) database to determine the prevalence and survival 
impact of non-examination of lymph nodes after NSCLC resection. 
Materials/Methods: Retrospective analysis of resections for ‘node-negative’ 
first primary NSCLC in the SEER database from 1998 – 2008. We identi-
fied ‘node-negative’ patients with one or more lymph nodes examined as 
pathologic (p) N0 and those who had no lymph nodes examined as pNX. 
We compared the demographic and clinical characteristics of patients in both 
cohorts by the chi-squared test, and survival of patients in both cohorts by the 
log-rank test. 
Results: 4,517 of 26,738 ‘node-negative’ resections (17%) were pNX. 
They constituted 7% of all ‘node-negative’ lobectomy, or greater, resections 
and 55% of segmental or wedge resections. Forty percent of the total pNX 
population received a lobectomy or greater resection, compared to 90% 
of the pN0 cohort (p<.0001). The median age of the pNX patients was 70 
years, compared to 67 in the pN0 cohort (p<.0001). The prevalence of pNX 
resections across all regions of the SEER registry ranged from 10% - 31% 
(p<.0001). Patients with smaller tumors were more likely to have a pNX 
resection. The median number of lymph nodes examined in the pN0 popula-
tion was 6, and only 30% had greater than 10 lymph nodes examined. The 
median duration of survival in the pNX patients was 3 years, compared to 
6.3 years in the pN0 cohort (p<.0001). These survival differences remained 
after adjustment for age, sex, race, histology, extent of resection, tumor size, 
tumor grade, T-category, tumor location, and use of post-operative radia-
tion therapy. Conclusions: ‘Node-negative’ patients who undergo NSCLC 
resection without examination of lymph nodes have a significantly poorer 
survival than those with at least 1 examined lymph node. This difference 
occured despite the relatively poor quality of lymph node staging in the pN0 
cohort. Older patients and recipients of a sub-lobar resection were more 
likely to have no lymph nodes examined. The existence of a significant 
minority of pNX lobectomy, or greater, resections indicates problems not 
only with surgical lymph node staging, but also with pathology practice. 
Further examination of the causes of failure to examine lymph nodes after 
resection of NSCLC are much needed, as are efforts to improve pathologic 
staging.
Author Disclosure Block: R.U. Osarogiagbon: None. X. Yu: None.
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Stereotactic Radiation Near the Esophagus: When Does A 
Fistula Occur?
K. L. Stephans, C. I. Diaconu, T. Djemil, P. Xia, N. Woody, G. M. M. Videtic, 
Cleveland Clinic, Cleveland, OH
Purpose/Objective(s): To examine a large single-institution stereotactic radi-
ation (SBRT) series to identify factors associated with treatment-related late 
esophageal toxicity. 
Materials/Methods: We reviewed an IRB-approved SBRT registry started in 
2004 to identify patients with target volume within 2 cm of the esophagus. 
Patients were treated on a Novalis/BrainLAB system using Exac Trac IGRT. 
Tumor motion was controlled by Bodyfix vacuum system along with abdomi-
nal compression for most lung patients, and deep breath-hold technique for 
all liver and select lung patients. Treatment was delivered with dynamic arcs 
or step-and-shoot IMRT. SBRT schedules evolved over time and reflect treat-
ment era, tumor location, and trial-based experience. 
Results: Of 707 lung and 30 liver patients, target volume fell within 2 
cm of the esophagus for 52. Of these, 48 were lung targets (44 primary, 4 
oligometastasis), and 4 liver (3 hepatocellular, 1 metastatic lung). Median 
age was 74 (range 42-90), KPS 80 (60-90), tumor size 3.9 cm (0.8-5.7 cm 
for lung, 4.9-8 cm for liver), and 56% were female. SBRT dose was 50 
Gy in 5 fractions (fx) (n=31), 50 Gy in 10 fx (n=13), 60 Gy in 8 fx (n=3), 
37.5 Gy in 3 fx (n=3), or 52.5 Gy in 5 fx (n=2). With 11 month median 
follow-up (range 1.6-50.5) 32 patients were alive. Disease was controlled 
at last follow-up in 32/52 (6 local, 4 nodal, and 10 distant failures). 
Median esophageal mean dose was 5.5 Gy. Median point dose and 1cc 
dose were 32.3 (range 8.9-55.4) and 24.0 Gy (range 7.8-50.9) respectively. 
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Two patients suffered an esophageal fistula (both treated to 50 Gy in 10 
fx), with max esophageal point doses of 51.5 and 52 Gy, and 1cc dose 
of 48.1 and 50 Gy. These esophageal point and 1cc doses were exceeded 
by 9, and 2 other patients respectively without fistula. Risk of fistula 
for point dose exceeding 40, 45, and 50 Gy was 9.5% (n=2/21), 10.5% 
(n=2/19), and 12.5% (n=2/16). Risk of fistula for 1cc dose exceeding 40, 
45, and 50 Gy was 25% (n=2/8), 50% (n=2/4), and 50% (n=2/4). Fifteen 
patients received systemic therapy after SBRT: 10 chemotherapy, 3 VEGF 
modulating agents (Bevacizumab, Sunitinib, and PARP inhibitor), and 2 
Erlotinib. Both patients with fistulas had received adjuvant VEGF modu-
lating agents within 2 months of completing SBRT (Bevacizumab and 
Sunitinib). No patient suffered a fistula in the absence of VEGF modulat-
ing agents. 
Conclusions: Fistula is a rare complication of SBRT. In this series, fistula 
was seen with esophageal point doses exceeding 51 Gy, and 1 cc doses over 
48 Gy. Notably fistula was only seen in patients treated with VEGF modulat-
ing agents post SBRT (occuring in 2 of 3 patients receiving these agents). All 
other patients tolerated small volume, high-dose radiation. The interaction of 
dose and adjuvant therapy should be considered when delivering SBRT near 
the esophagus.
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Repeat Stereotactic Body Radiation Therapy (SBRT) for 
Patients with Pulmonary Malignancies which Previously 
Received SBRT to the Same or an Adjacent Tumor Site
S. H. Ross1, V. Valakh2, B. Micaily2, C. Miyamoto2, S. Li2, P. Chan2, T. Neicu2, 
1Temple University School of Medicine, Philadelphia, PA, 2Department of 
Radiation Oncology, Temple University Hospital, Philadelphia, PA
Purpose/Objective(s): Medically inoperable patients with a lung malig-
nancy recurring in a region of previous SBRT have limited salvage options. 
While repeat stereotactic radiosurgery has been reported for intracranial 
lesions, feasibility of lung reirradiation using repeat SBRT has not been 
described. 
Materials/Methods: Retrospective review of a single-institutional database 
containing 118 lung SBRT patients treated between 12/2006 and 11/2011 
was performed. Nine patients received a second course of SBRT for in-field 
recurrence (n=3) or a new malignant mass closely adjacent (≤ 3.5 cm) to 
the original tumor location (n=6). Eight patients had non-small cell lung car-
cinoma while one had oligometastatic colon cancer. All 9 recurrent tumors 
were located peripherally, >2 cm away from proximal bronchial tree, great 
vessels and esophagus. Median age at the initial SBRT was 74 years (range, 
59 - 84). For 1st SBRT median total dose was 60 Gy (30 - 60) administered in 
a median of 3 fractions (3 - 5) over a median of 13 days. Median biological 
equivalent dose (BED
10
) was 132 Gy (60 - 180). For 2nd SBRT a median of 
48 Gy (30 - 60) was given in a median of 3 fractions (3 - 5) over a median 
of 9 days. Median 2nd BED
10
 was 80 Gy (60 - 180). Median follow up after 
2nd SBRT was 22 months (4 - 40). Toxicity after 2nd SBRT was recorded and 
scored according to CTCAE 4.03. 
Results: At 1st SBRT, mean tumor size by diagnostic CT was 2.5 cm (1.3 - 
3.2). Median planned target volume (PTV), maximum PTV dose, volume of 
ipsilateral lung receiving 5 Gy (V5), 10 Gy (V10), 20 Gy (V20) and dose to 
1000 cm3 of ipsilateral lung (D
1000cc
) was 33 cm3 (17 - 88), 73 Gy (33 - 74), 
38% (15 - 55), 22% (11 - 32), 13% (2.5 - 29) and 2 Gy (0 - 9), respectively. 
Median interval between 1st and 2nd SBRT courses was 46 weeks (4 - 109). At 
2nd SBRT mean tumor size was 2.16 cm (0.9 - 4.2). Median PTV, maximum 
PTV dose, V5, V10, V20 and D
1000cc
 was 13 cm3 (5.8 - 137), 55 Gy (33 - 80), 
20% (2 - 45), 10% (0 - 31), 4% (0 - 17) and 1 Gy (0-9), respectively. There 
was no grade 4 or 5 toxicity. Two (22.2%) patients had grade 3 dyspnea at 7 
and 29 months, indistinguishable from COPD exacerbation, treated with ste-
roids as inpatient. Two (22.2%) had grade 2 dyspnea managed by adjustment 
of COPD medications. One patient (11.1%) had grade 3 and two (22.2%) 
had grade 2 chest wall pain. One (11.1%) had grade 2 brachial plexopathy. 
Two patients developed progression of treated tumors at 6 and 9 months and 
ultimately died of disease. Kaplan-Meier 2 year estimates of local control and 
overall survival were 75% and 68.6%, respectively. 
Conclusion: Repeat lung SBRT was feasible and life threatening toxicity was 
not observed. Additional studies are needed to evaluate efficacy and toxicity 
of lung reirradiation using a second SBRT course.
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Stereotactic Body Radiation Therapy for Primary Lung 
Cancers >3cm
J. J. Cuaron1, E. Yorke1, A. McLane1, F. Liu1, A. Jackson1, B. Mychalczak1, 
A. Wu1, K. Rosenzweig2, A. Rimner1, 1Memorial Sloan-Kettering Cancer 
Center, New York, NY, 2Mt. Sinai Hospital, New York, NY
Purpose/Objective(s): Stereotactic body radiation therapy (SBRT) has been 
widely adopted in the treatment of early-stage lung tumors, but its role in 
the treatment of larger lung tumors is less clear. Here we report our institu-
tional experience for patients with large (>3 cm) non-small cell lung cancers 
(NSCLC) treated with SBRT. 
Materials/Methods: Between 02/2007 and 11/2011, 64 patients with 
T2-T4N0 primary NSCLC were treated with SBRT (median dose: 48 Gy; 
range 40-60 Gy in 3-5 fractions). The biologically effective doses (BED) 
ranged from 72-180 Gy
10.
 The median tumor diameter was 3.9 cm (range 3.1-
8.5), and median PTV size was 112 cc (range 55-402). Toxicity was graded 
per CTCAE v4.0. Local control (LC), recurrence free (RFS), and overall sur-
vival (OS) were analyzed using the Kaplan-Meier method, and time-depen-
dent pulmonary toxicity (cough, dyspnea or radiation pneumonitis) as well as 
chest wall pain, were correlated with dosimetric parameters using the log rank 
test. Six patients were excluded from the toxicity analysis due to a history of 
previous lung radiation. 
Results: The median follow up was 17.1 months for patients alive at analy-
sis, and 12.4 months for the entire cohort. 1- and 2-year LC was 91.1% and 
72.0%, 1- and 2-year RFS was 58.4% and 36.6%, and 1- and 2-year OS was 
75.5% and 56.3%, respectively. PTV size < 90 cc was associated with signifi-
cantly better 1- and 2-year LC rates than PTV size ≥90 cc (100% vs 87.0% 
and 100% vs. 58.2%, P=.04). There was no significant association between 
PTV size and RFS or OS, nor between tumor diameter and LC, RFS or OS. 
BED was not significantly associated with LC, RFS, or OS. 
The incidence of grade ≥ 2 acute and late pulmonary toxicity was 20.6% and 
18.9%, respectively. There were four cases (7.1%) of acute, and the same 
number of late, grade 3 pulmonary toxicity. One patient developed possible 
grade 4 radiation pneumonitis in the setting of synchronous pneumonia and 
influenza infection. There were no other grade 4 or 5 pulmonary toxicities. 
There was no correlation between the development of pulmonary toxicity and 
ipsilateral lung V20, total lung V20 or the RTOG 1021 constraint of 1500cc 
total lung ≤ dose of 1050 cGy. Grade ≥2 chest wall pain was observed in 
22.4% of patients, including six cases (10.7%) of grade 3, but no grade 4 or 
5 cases. The development of chest wall pain was significantly associated with 
chest wall V30 ≥70 cc (P=.03). 
Conclusions: SBRT for large NSCLC tumors achieves high LC rates over-
all. LC was worse with PTVs ≥90 cc. However, SBRT appears to provide 
favorable LC compared to historical results of conventionally fractionated RT. 
Pulmonary toxicities were acceptable and not correlated with common dose-
volume parameters in this study. Grade ≥2 chest wall pain was associated with 
chest wall V30 ≥70 cc.
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Prognostic Importance of the Maximum Standardized 
Uptake Value (SUVmax) on [18F]-fluoro-2-deoxy-glucose-
Positron Emission Tomography (FDG-PET) Scan in Medically 
Inoperable Stage I Non-Small Cell Lung Cancer: Grounds 
for PET-guided Adapted Dose Escalation Using Stereotactic 
Ablative Radiotherapy
V. Janardanan Nair1,2, R. Macrae1,2, T. Lee1,2, A. Sirisegaram1,2, R. Hogg2, J. 
Pantarotto1,2, 1The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada, 
2University of Ottawa, Ottawa, ON, Canada
Purpose/Objective(s): Positron emission tomography (PET) using [18F]-fluoro-
2-deoxy-glucose is a standard staging investigation for patients with non-small 
cell lung cancer (NSCLC). The maximum standardized uptake value (SUV
max
) 
is a semi-quantitative measure of FDG uptake that correlates with tumor dou-
bling time and proliferation rates, which in turn are known to correlate with 
tumor aggressiveness. The aim of this retrospective study was to determine 
whether the pre-radiation SUV
max
 of the primary tumor has prognostic signifi-
cance in patients with Stage I NSCLC treated with curative radiation therapy. 
Materials/Methods: Between April 1993 and October 2011, a total of 421 
patients were diagnosed with medically inoperable histologically-proven 
stage I NSCLC and treated with radiation alone to at least 50 Gy. A subset 
of 180 tumors diagnosed in 163 patients had pre-treatment PET/CT scans. 
PET/CT data was never used to specify radiation dose or technique at our 
institution but only to establish stage. We retrospectively analysed the medical 
records and radiological images of these patients regarding stage distribu-
tion, histology, radiation technique, recurrence and survival. We stratified the 
patients above and below the median SUV
max
 value on the pre-treatment PET/
CT scan and analysed the survival data. Statistical analysis was done using 
SPSS version 15. Survival data was analysed using Kaplan-Meier method, 
and comparisons of survival were done using Mantel-Cox log-rank test. 
Results: Of the 180 tumors, 68.9 % were T1 tumors; 24.6% central tumors; 
34% right upper lobe tumors and 31% left upper lobe tumors. 64.4% of 
tumors were treated with stereotactic ablative radiotherapy (SABR). The 
overall survival at 2 years for the whole group was 76%. The median follow-
up time for the cohort was 15 months. The mean and median SUVs were 8.1 
and 7 respectively. The progression free survival (PFS) at 2 years for SUV
max
 
≤ 7 and >7 were 76% versus 43% respectively (p=0.005). There was no sta-
tistically significant difference in overall survival (OS) at 2 years between the 
groups (82% vs. 71.4%; p=0.09). 
Conclusion: Our findings suggest that tumors with high SUV
max
 > 7 on PET/
CT scan have poorer outcomes and high risk of progression despite their early 
stage, possibly due to aggressive biology. PET/CT-based radiation planning 
might offer the opportunity to select tumors to receive higher radiation doses 
based on their pre-treatment SUV
max
, even when SABR technique is used.
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No Difference in Outcome Between Biopsied vs. Non-Biopsied 
Early Stage Medically Inoperable Non-Small Cell Lung 
Cancer Patients Treated with Volumetric Image Guided 
Stereotactic Body Radiation Therapy (SBRT): Analysis of a 
Large Multiinstitutional Database
M. Werner-Wasik1, J. Belderbos2, A. Hope3, M. Guckenberger4, L. L. Kestin5, 
D. Yan5, J. Sonke2, J. Bissonette3, Y. Xiao1, I. Siiner Grills5, 1Thomas Jefferson 
University Hospital, Philadelphia, PA, 2Netherlands Cancer Institute, 
Amsterdam, Netherlands, 3Princess Margaret Hospital University of Toronto, 
Toronto, ON, Canada, 4University of Wuerzburg, Wuerzburg, Germany, 
5William Beaumont Hospital, Royal Oak, MI
Purpose/Objective(s): Tumor biopsy is not always performed in patients 
(pts) with early stage non-small cell lung cancer (NSCLC) prior to volumetric 
image guided stereotactic body radiation therapy (IG-SBRT). We analyze out-
comes of those pts with either biopsied (BP+) or non-biopsied (BP-) tumors. 
Materials/Methods: Between 1998 and 2010, 483 pts with 505 cT1-3 cN0 
cM0 NSCLC were treated with IG-SBRT at 5 international radiation oncol-
ogy centers. Median age was 74 years (yr) (range: 42-92); 64% of tumors were 
BP+ (variation between institutions: 41-95%); 87% of pts, medically inoper-
able; 84%, 18FDG PET-staged. Clinical stages were: IA, 63%; IB, 33%; IIA, 
2%, recurrent, 1%. Median maximum tumor dimension was 2.6cm (range: 
0.9-8.5). Median volumetric prescription dose was 54 Gy (range: 20-64) in 3 
fractions (range: 1-15), heterogeneity corrected. Median biological equivalent 
dose (BED10) was 132 Gy (range: 60-180). Median follow-up time was 1.42 
yr in BP- and 1.58 yr in BP+ groups. Local failures (LF) and regional failures 
(RF) were defined using either the combination of CT progression and PET 
avidity or via biopsy. Analyses of LF were calculated per tumor while analy-
ses of RF, distant metastases (DM) or survival (OS) were calculated per pt. 
Results: Pt characteristics were not significantly different between the BP+ 
(n=326) vs. the BP- groups (n=179) with regard to age, sex, actual FEV1 
(1.46 vs. 1.5 L) or carbon monoxide diffusion capacity. The BP- tumors 
were more commonly Stage IA (79.5 vs. 64%); IB (16 vs. 33%) or recurrent 
(2.8 vs. 0.3%) than the BP+ tumors (p<0.001), with a smaller maximum 
dimension of 2.34 vs. 3.03 cm (p<0.001). More pts with BP- tumors under-
went PET staging (94% vs. 85%, p=0.005). More pts with BP+ received 
adjuvant chemotherapy (5% vs. 1%, p=0.018). Grade >2 toxicity rates 
were as follows in pts with BP+ vs. BP- tumors: pneumonitis, 6.9 vs. 5.4%, 
p=0.6; rib fractures, 0.6 vs. 0%; myositis, 0.9 vs.0.6% and skin toxicity, 1.2 
vs. 2.4%. There were 26 LFs, 7 in the BP- and 19 in the BP+ tumors. The 
3 yr rates of LF, RF, DM, OS and cancer-specific survival (CSS) were not 
significantly different between the BP- and BP+ groups (9 vs. 10%, p=0.6; 
22 vs. 13%, p=0.43; 17 vs. 22%, p=0.3; 40 vs.50%, p=0.19; 79 vs. 75%, 
p=0.2, respectively). Staging PET prior to IG-SBRT was associated with 
improved OS (but not CSS) in BP+ pts, but not with BP- pts (p= 0.0047 and 
0.5, respectively). 
Conclusion: The outcomes of pts with BP+ vs. BP- early stage NSCLC 
treated with IG-SBRT are not significantly different with regard to LF, RF, 
DM, OS or CSS. This suggests that pts may be appropriately treated with 
IG-SBRT without biopsy, when biopsy is not medically feasible.
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Belderbos: E. Research Grant; Elekta. A. Hope: E. Research Grant; Elekta. 
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Visceral Pleural Invasion Does Not Impact On Recurrence-
free Or Overall Survival In Lung Adenocarcinoma ≤2cm
J. Nitadori, C. Colovos, K. Kadota, C. S. Sima, V. W. Rusch, W. D. Travis, P. S. 
Adusumilli, Memorial Sloan-Kettering Cancer Center, New York, NY
Purpose/Objective(s): Visceral pleural invasion (VPI) is considered an 
independent negative prognostic factor in non-small cell lung cancer 
(NSCLC). In fact, in the 7th Edition TNM classification, T1 (≤3 cm) tumors 
with VPI are upstaged to T2a (stage Ib) based on an observed decreased 
overall survival (OS). Adenocarcinoma (ADC) is the most common NSCLC 
and its incidence is increasing. We investigated the influence of VPI on 
recurrence-free probability (RFP) specifically on early-stage T1a and T1b 
tumors. We further investigated whether VPI is an independent prognos-
tic factor when adjusted for histologic subtype per 2011 IASLC/ATS/ERS 
classification. 
Materials/Methods: Two pathologists reviewed all available tumor slides 
(median 4, range 2-10 slides/patient) from 777 lung ADC patients who 
underwent surgical resection for tumors ≤ 3cm between January 2000 to 
December 2008. Multicentric disease and tumors with lymph node metastasis 
were excluded. RFP and OS in tumors with or without VPI (tumor extension 
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beyond the elastic layer of the visceral pleura) were examined by size (≤2 cm 
and >2-3 cm) and further adjusted for predominant histologic subtype. 
Results: Among all stage I lung ADC patients with tumors ≤3 cm, although 
VPI correlated with a worse OS (p=0.001), it did not significantly influ-
ence RFP (p=0.077). In tumors ≤2 cm, VPI was neither associated with an 
increased risk of recurrence [5-yrs RFP - VPI+: 82% (n=66) vs. VPI-: 80% 
(n=526), p=0.88] nor decreased OS [5-yrs OS - VPI+: 71% vs. VPI-: 77%, 
p=0.11]. In >2-3 cm tumors, the presence of VPI decreased both RFP [5-yrs 
RFP - VPI+: 56% vs. VPI-: 77%, p=0.005] and OS [5-yrs OS - VPI+: 51% 
vs. VPI-: 73%, p≤0.001]. Based on the above observations, stage I lung ADC 
tumors ≤ 3 cm were then re-grouped as new-stage Ia (≤2 cm with or without 
VPI; >2- 3 cm without VPI) or new-stage Ib (>2-3 cm with VPI). With this 
regrouping, there is a statistically significant difference in 5-year RFP and OS 
between new-stage Ia (n=751) and new-stage Ib (n=26) [RFP: 80% vs. 56%, 
p<0.0001] [OS: 76% vs. 51%, p<0.0001]. As well, presence of high-grade 
histologic subtypes (micropapillary or solid) did not affect RFP (p=0.73) or 
OS (p=0.26) in tumors (>2-3cm) with VPI. 
Conclusions: VPI stratifies patient prognosis in >2-3cm lung ADC but not 
in tumors ≤ 2 cm. Among > 2-3cm tumors, VPI remains a prognostic fac-
tor even when adjusted for high-grade morphology. Our proposed regroup-
ing of new-stage Ib better stratifies patients with poor prognosis, similar 
to published outcomes in stage II patients, who may benefit from adjuvant 
chemotherapy.
Author Disclosure Block: J. Nitadori: None. C. Colovos: None. K. 
Kadota: None. C.S. Sima: None. V.W. Rusch: None. W.D. Travis: None. 
P.S. Adusumilli: None.
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Thromboxane A2 Receptor-α Facilitates Lung Tumor Growth 
Through An Auto-activation Mechanism
G. G. Chen, R. Huang, M. Li, I. Y. Wan, C. S. Ng, M. J. Underwood, The 
Chinese University of Hong Kong, Hong Kong, Hong Kong
Purpose/Objective(s): It is well known that the development of most lung 
cancers is associated with tobacco smoking. We have previously demon-
strated that smoke carcinogen 4-methylnitrosamino-1-3-pyridyl-1-butanone 
(NNK) can induce thromboxane synthase (TxAS) in lung cancer, suggesting 
that TxAS may be a key molecule in the development of this malignancy. To 
further explore the role of TxAS in lung cancer, we examined the signaling 
pathway of this molecule. 
Materials/Methods: In this study, we collected thirty-seven pairs of tumor 
and non-tumor lung tissues from patients with non small cell lung cancer, 
who underwent surgery for lung cancer at our hospital. Five lung cancer cell 
lines and 1 an immortalized lung fibroblast were also employed for the study. 
TxAS and its related molecules thromboxane A2 receptor (TP), nuclear fac-
tor (NF)-κB, specificity protein(SP)-1, cAMP response element binding pro-
tein (CREB) and peroxisome proliferator-activated receptor-gamma (PPARγ) 
were examined. Finally we used a mouse model of lung tumor to confirm the 
results obtained in human lung tissues and cell lines. 
Results: TP was aberrant in lung cancer tissues obtained from smokers and 
that both TxAS and TP were increased in lung tissues from NNK-treated mice. 
In cell culture experiments, TPα rather than TPβ promoted tumor growth, and 
NNK increased TPα rather than TPβ at protein but not mRNA level. NNK-
stimulated TxAS expression was dependent on NF-κB signaling. Other key 
transcriptional factors, such as SP-1, CREB and PPARγ, were not involved 
in NNK-induced TxAS and TPα expression. Further experiments supported 
that post-transcriptional mechanisms were responsible for NNK-induced TPα 
expression. Importantly, TPα rather than TPβ was identified to have a positive 
role in NNK-induced NF-κB activation, TxAS expression and thromboxane 
A2(TxA2) synthesis, indicating a TPα auto-activation mechanism to form a 
positive feedback loop to stimulate TxAS. 
Conclusions: This study demonstrates that smoking carcinogen NNK can 
promote lung tumor growth via inducing TxAS as well as TPα. TxAS and TPα 
may constitute an auto-positive feedback loop to accelerate tumor growth. 
This study suggests that the alteration of both TxAS and TPα may occur in 
the early stage of lung cancer development, and that patients may benefit by 
targeting both molecules. (This study was supported by the Research Grants 
Council of the Hong Kong Special Administrative Regions: CUHK475211)
Author Disclosure Block: G.G. Chen: None. R. Huang: None. M. Li: 
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Radiologic Tumor Regression and Correlation with Pathologic 
Findings after Neoadjuvant Therapy for Non-small Cell Lung 
Cancer
M. C. Stauder, A. C. Roden, D. Wigle, K. A. Price, Y. I. Garces, K. R. Olivier, 
Mayo Clinic, Rochester, MN
Purpose/Objective(s): We aim to determine the amount of microscopic 
extension and the viability of malignant cells within and surrounding the 
regressed tumor volume in patients with advanced NSCLC treated with neo-
adjuvant chemoRT. 
Materials/Methods: A retrospective analysis of patients with Stage IIIA/IIIB 
NSCLC treated with neoadjuvant chemoRT from June 2004 to August 2010 
was performed. Eligible patients received their neoadjuvant therapy and sur-
gery at our institution and had surgical specimens of their primary tumor avail-
able for pathology review. The degree of radiographic tumor regression was 
determined from pre- and post-treatment tumor size on diagnostic CT. A pul-
monary pathologist reviewed all cases to determine the percent viable tumor, 
distribution of viable tumor cells within the lesion and the relationship of 
viable tumor cells to the interface between tumor and benign lung parenchyma. 
Results: A total of 20 patients were analyzed. The median age was 64 
years (range 44-78). The majority (80%) had adenocarcinoma (ACA). 
All patients received concomitant chemotherapy. The median number of 
days between diagnostic CT scans was 87 days (range 36-156) with a 
median time from post- treatment CT to surgery of 13 days (range 2-43). 
The median RT dose delivered was 46 Gy (range 45-62.7) in 25 fractions 
(range 23-34). The median gross tumor size on pre-treatment CT was 4.5 
x 3.5 cm (range, 0.8-8.6) and 3.0 x 2.4 cm (range 0-8.0) at the time of 
surgical resection. The median radiologic tumor regression measured in 
maximum axial dimensions was 19.4% (range 0-69%), 24.3% and 15.3% 
in all patients, ACA and non-ACA, respectively. The median percentage 
of viable tumor in surgical specimens based on slide review was 20% 
(range 1-80%). There was good correlation between post-treatment CT 
tumor size and gross pathologic tumor size (ρ=0.916, p<.001). A total of 
4 patients (19%), all ACA, had a pathologic complete response (pCR). 
Of the 16 patients without pCR, 11 (69%) had viable tumor present at 
the interface between tumor and benign lung parenchyma and 8 of these 
patients (73%) showed histologic features of viable tumor cell invasion 
into surrounding normal lung parenchyma. No independent patient or 
treatment variable predicted for the presence of tumor at the interface or 
invasion into lung parenchyma. 
Conclusions: Despite evidence of radiologic tumor regression, most patients 
treated with chemoRT for advanced NSCLC have viable tumor cells pres-
ent at the interface between treatment effect and benign lung. Most of these 
patients also had evidence of microscopic tumor invasion into surrounding 
lung parenchyma. Our results should promote an increased awareness of PTV 
margins especially when adaptive radiotherapy techniques using field size 
reduction are utilized.
Author Disclosure Block: M.C. Stauder: None. A.C. Roden: None. D. 
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Synchronous Non-Small Cell Lung Cancer Nodules Treated 
with Stereotactic Body Radiation Therapy (SBRT)
M. S. Kumar, G. M. M. Videtic, N. Woody, T. Djemil, K. L. Stephans, 
Cleveland Clinic, Cleveland, OH
Purpose/Objective(s): Medically inoperable patients diagnosed with pre-
sumed synchronous non-small cell lung cancer (NSCLC) primaries (SPs) 
present a diagnostic quandry as to whether they have two isolated NSCLCs 
or early metastatic disease. After appropriate work up and the decision to 
treat as presumptive early stage disease, we evaluate our experience of SPs 
treated with definitive SBRT as there are limited published outcomes for this 
presentation. 
Materials/Methods: From our IRB approved prospective registry of over 400 
patients treated with SBRT for NSCLC between 8/2005 and 4/2011, 20 (5%) 
patients had SPs identified by biopsy or PET scan, and received SBRT using 
Novalis/Brainlab to both lesions concurrently. All patients were followed for 
at least 1 year or until patient death. The outcomes of SP patients were com-
pared to our institutional single primary Stage I SBRT experience (non-SP). 
Results: There was no significant difference comparing patient characteristics 
between SP vs non-SP groups (p=ns for all comparisons): median age (yrs) at 
treatment 75 vs 74, median KPS of 80 vs 80, median smoking pack years of 30 
vs 50, female 50% vs 53.4%, smoking at SBRT 10% vs 18%, and median PET 
SUV of 6.1 (range 1.0-20.8) vs 6.8. Seven patients did not have a diagnostic 
biopsy, 11 had biopsy of one nodule, and 2 had biopsy of both lesions prior 
to treatment. Three patients (15%) had nodules in the same lobe, 5 (25%) had 
nodules in the same lung, and 12 (60%) had a nodules bilaterally. All patients 
were treated with definitive SBRT: 30 Gy / 1 fx, 60 Gy / 3 fx, 50 Gy / 5 fx, 
or 60 Gy / 8 fx. The median follow up was 12 months (range 1.5-54.4) with 
one patient developing grade 3 chest wall pain, two with grade 2 chest wall 
pain, and two with grade 2 pneumonitis. There was progression of disease in 7 
patients (35%). Local failure in SP vs non-SP groups was 5% (1 patient) vs 6% 
(p=ns), and nodal/distant failure was 30% (6 patients) vs 31% (p=ns). Median 
survival for SP vs non-SP groups was 3.76 years vs 3.2 years (p=0.3). 
Conclusions: Patients treated with definitive SBRT for presumed synchro-
nous primary, clinically node negative NSCLC had statistically similar out-
comes (local failure, nodal/distant failure, overall survival) compared to our 
institutional single primary stage I experience. SBRT offers an effective treat-
ment approach with acceptable toxicity for this population.
Author Disclosure Block: A.M.S. Kumar: None. G.M.M. Videtic: None. 
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Anthracotic Myeloid Clusters In Uninvolved Lymph Nodes 
Predict Prognosis In Early Stage Non-small Cell Lung Cancer
W. Zhang1, S. K. Pal1, X. Liu1, C. Yang1, S. Allahabadi2, S. Bhanji3, R. A. 
Figlin4, H. Yu1, K. L. Reckamp1, 1City of Hope National Medical Center, 
Duarte, CA, 2Rice University, Houston, TX, 3Harvard University, Boston, 
MA, 4Cedars Sinai Medical Center, Samuel Oschin Comprehensive Cancer 
Institute, Los Angeles, CA
Purpose/Objective(s): Patients with early stage non-small lung cancer 
(NSCLC) have a high risk for recurrence and death from metastatic disease 
after surgical resection. We hypothesized that the microenvironment in unin-
volved lymph nodes could provide a primed environment for developing 
metastases, and predict survival. 
Materials/Methods: Tumor regional uninvolved LN sections from 49 
patients with stage I-III resected NSCLC and a prior or current history 
of smoking were stained for CD68, pY705-Stat3, CD163, IL-6, IL-10, 
VEGF-A, MMP-9, SDF-1/CXCL12, Bcl-xL and pan-cytokeratin (CK) by 
immunohistochemistry. Anthracosis intensity, anthracotic myeloid cluster 
(AMC) infiltration and pStat3 level were scored by two independent observ-
ers in a blinded fashion. Occult metastatic NSCLC tumor cells (OM) were 
detected by pan-CK staining. The LN specimens were also double stained for 
CD68/pan-CK or CD68/cellular fibronectin (cFn) by immunofluorescence. 
Primary macrophages derived from PBMCs from healthy donors and THP-
1-derived macrophages were used for in vitro nicotine treatment and western 
blotting. 
Results: Significant numbers of CD68+ anthracotic myeloid cells forming 
clusters were observed in uninvolved LNs, as well as dramatically activated 
Stat3 in the overall LNs. AMCs exhibited tumor/metastasis-promoting phe-
notype by expression of CD163, IL-6, IL-10, VEGF-A, MMP-9, SDF-1 and 
Bcl-xL. Significant correlations between AMC score and both anthracosis 
intensity and overall pStat3 level were seen (P < 0.001 and P < 0.01, respec-
tively). Anthracosis intensity also correlated with Stat3 activity in the AMCs 
(P < 0.01). Nicotine activated Stat3 in macrophages derived from both pri-
mary PBMC monocytes and THP-1 cell line in long term culture. The pres-
ence of OM was positively correlated with AMC score (P = 0.012). Double 
staining showed the co-localization between AMCs and OM. AMCs were 
also co-localized with cFn, which has been demonstrated to be important for 
pre-metastatic niche formation. AMC score was shown to be an independent 
prognostic factor by multivariate Cox regression analysis (P = 0.049, HR = 
2.34). With Kaplan-Meier estimate, AMC score showed a near-significant 
effect to predict patient survival (P = 0.055, 5-yr survival 78.5% vs 38.0%). 
The combination of AMC score with either LN stage or pStat3 level defined 
two populations of patients with significant difference in survival (P = 0.024, 
5-yr survival 83.1% vs 15.0% and P = 0.0041, 5-yr survival 83.7% vs 42.9%, 
respectively). 
Conclusions: AMCs provide immunosuppressive and tumor-promoting 
microenvironment in uninvolved regional LNs and associate with OM in 
NSCLC. AMC score predicts NSCLC patient survival as an independent 
prognostic factor.
Author Disclosure Block: W. Zhang: None. S.K. Pal: None. X. Liu: None. 
C. Yang: None. S. Allahabadi: None. S. Bhanji: None. R.A. Figlin: None. 
H. Yu: None. K.L. Reckamp: None.
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Sublobar Resection with Intraoperative 125I Brachytherapy 
vs Stereotactic Body Radiation Therapy for Treatment of 
Clinical Early Stage Non-Small Cell Lung Cancer in Patients 
not Eligible for Lobectomy
S. Platta1, T. J. Kruser1, T. L. Weigel1, W. A. Tome1, R. K. Das1, H. M. Geye1, 
D. Khuntia2, M. P. Mehta3, G. M. Cannon1, 1University of Wisconsin Hospital 
& Clinics Madison, Madison, WI, 2Western Radiation Oncology, San Mateo, 
CA, 3Northwestern University, Chicago, IL
Purpose/Objective(s): The standard of care for early stage non-small cell 
lung cancer (NSCLC) is lobectomy with lymph node dissection. In this analy-
sis, two alternative therapies for early stage NSCLC in patients not candi-
dates for anatomic lobectomy are compared: thoracoscopic sublobar resection 
(SLR) with intraoperative 125I brachytherapy implant along the staple line vs 
stereotactic body radiotherapy (SBRT). 
Materials/Methods: A total of 95 patients with early stage NSCLC treated 
with either SLR resection and 125I brachytherapy (n=45) or SBRT (n=50) 
between January 2004 and June 2011 were retrospectively identified. 
Prescription dose for SLR with brachytherapy was either 100 Gy at 0.5 cm 
(n=32) or 120 Gy at 0.5 cm (n=13). SBRT median dose and fractionation 
scheme was 60 Gy in 5 fractions, corresponding to a median BED of 132 Gy. 
Charlson Comorbidity Index (CCI) scores were calculated for all patients. 
Local control (LC), regional control (RC), disease free survival (DFS), overall 
survival (OS) and toxicity between the two cohorts were compared. 
Results: The median age was 68 years (range 49-87) in the SLR group, and 
76.5 years (range 52-89) in the SBRT group. Median followup was 15.8 
months. The median CCI score for the brachytherapy group was 4 (range 2-8), 
and 6 (range 3-12) (p<0.01) for the SBRT group. The median hospital stay 
was 3 days (range 1-18 days) in the SLR cohort, with 1 perioperative death 
(2.2% perioperative mortality). There were no treatment related deaths in the 
SBRT group. Five patients (11.1%) experienced grade 3 or higher toxicities 
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in the brachytherapy group vs 9 (18.0%) in the SBRT cohort. At 24 months, 
there was no significant difference in actuarial LC (95.8 vs 97.1%, p=0.51), 
RC (88.2 vs 92.7%, p=0.64), and DFS (78.7 vs 87.7%, p=0.82) between 
brachytherapy and SBRT. There was a trend towards improved 1 and 2 year 
actuarial OS for the brachytherapy over the SBRT group, 97.8 vs 76.0% and 
77.2 vs 51.2% (p=0.09), respectively. 
Conclusions: No randomized trials have compared these two modalities. In 
this analysis, both SLR with 125I brachytherapy and SBRT showed equivalent 
outcomes in terms of LC, RC, DFS and OS. There is a trend towards improved 
OS in the brachytherapy group, likely reflective of the worse CCI score within 
the SBRT group and an anticipated increased risk of death from intercurrent 
disease. The higher CCI score within the SBRT group is consistent with our 
institutional practice of preferentially pursuing SLR with brachytherapy in 
surgical candidates. Both SLR with 125I brachytherapy and SBRT are viable 
alternatives for clinical early stage NSCLC patients who cannot tolerate 
lobectomy.
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Comparison of Accelerated Hypofractionation and 
Stereotactic Body Radiotherapy for Stage 1 & 2 Non-small 
Cell Lung Cancer (NSCLC)
J. T. Lucas, J. G. Kuremsky, M. Soike, W. Hinson, W. T. Kearns, C. J. Hampton, 
A. W. Blackstock, J. J. Urbanic, Wake Forest Baptist Medical Center, Winston-
Salem, NC
Purpose/Objective(s):Both stereotactic body radiation therapy (SBRT) 
& accelerated hypofractionated radiotherapy (AHRT) have been shown 
to have excellent LC (LC) based on cooperative group trials in the treat-
ment (tx) of Stage I NSCLC. There has been concern about the tx of large 
(>4cm) or central tumors with SBRT. We have developed a program for 
the tx of early stage NSCLC in which patients not felt to be appropriate 
for SBRT (size or location) were treated with AHRT. We report the results 
of our program. 
Materials/Methods: 81 patients (pts) with Stage 1 NSCLC received SBRT 
& 79 pts with Stage I-IIA NSCLC received AHRT (2003-2011). The groups 
were balanced with respect to age, gender, & histologic subtype. Median 
follow-up (fu) was 28.5 & 24.6 months (mo) respectively. The median tumor 
size was 2.3 cm (SBRT) & 3.2 cm (AHRT). Median dose in each arm was 
54Gy in 3 fx (65% >50Gy) for SBRT & 70.2Gy in 26 fx (81% >270cGy/
fx) in the AHRT arm. Acute & late toxicities (tox) were graded (G) accord-
ing to CTCAE v4. Time to local (LF), regional (RF) & distant (DF) failure 
were compared using the log rank test. A cox proportional hazard univariate 
analysis was completed to examine the impact of patient & tumor factors on 
LF, RD, DF, and overall survival (OS). 
Results: 3 year LC was 87.7% & 71.7% in the SBRT & AHRT groups 
respectively. DF was the dominant pattern of failure with 3 yr freedom 
from DF of 73.3% and 68.1%. Distant lung failures (DLF) comprised the 
majority of DF (28 & 24%) with a median time from DLF to death of 
20.3 & 7.2 mo. 75% of DLF which were salvaged with radiotherapy, were 
alive at 24 mo compared to 7.8% who received assorted local & systemic 
therapies. OS was 38.4 (29.7-51.6) & 35 (22-48.3) mo SBRT and AHRT 
respectively. 34.2 & 52% of pts who died experienced a lung cancer death. 
G1 tox was seen in 5.2 & 11.3% of pts undergoing SBRT & AHRT respec-
tively. G2 tox were seen in 16.1% of the AHRT group while no G3 or 4 tox 
was seen. 30 & 50% of the complications resolved within 1 year. Chest 
wall pain was the most common (5-6%) long term tox noted. Univariate 
analysis identified covariates that significantly impacted time to LF, RF, DF, 
& OS: DLCO (OS:HR 0.98 (0.97-0.99), renal disease (OS: HR 2.2 (1.3-
3.7)), peripheral location (OS:HR 0.65 (0.43-0.98), LF: 0.44 (0.2-0.97)), 
& T stage (LF:HR 1.48 (1.1-2.1), RF: HR 1.76 (1.1-3.0)). Dose HR 0.99 
(.99-1) was the only tx factor which impacted LC. The impact of location 
on LF was less prominent (p>.05) in the AHRT group compared to the 
SBRT group. 
Conclusions: Our results compare favorably with other reported SBRT expe-
riences. OS was similar between groups with comorbidities comprising 48 
& 66% of pt deaths. AHRT patients experienced comparable LC despite 
increased size & central disease. Our strategy of AHRT for patients not eli-
gible for SBRT seems reasonable & worth further study.
Author Disclosure Block: J.T. Lucas: None. J.G. Kuremsky: None. M. 
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Definitive Radiation For Stage I Non-small Cell Lung Cancer: 
A Population-based Study Of Survival
M. T. Milano, H. Zhang, K. Y. Usuki, D. P. Singh, Y. Chen, University of 
Rochester, Rochester, NY
Purpose/Objective(s): This study characterizes the overall survival (OS) and 
cause-specific survival (CSS) of patients with Stage I non-small cell lung can-
cer (NSCLC) treated with radiation alone, and analyzes the variables poten-
tially affecting survival outcomes. 
Methods/Materials: A total of 8,524 Stage I NSCLC (6th edition of AJCC) 
patients, diagnosed from 1988-2008, were retrospectively analyzed using the 
population-based Surveillance, Epidemiology, and End Results database. 
Patients were grouped into four eras: 1988-1995, 1996-2000, 2001-2004 and 
2005-2008. Cox regression was used to calculate hazard ratios (HR) from 
multivariate analyses. 
Results: The median age at the time of NSCLC diagnosis was 74 years. 
While age at diagnosis significantly increased with more recent calen-
dar year of NSCLC diagnosis, this change was modest. Other significant 
changes observed with more recent year of diagnosis include relatively 
more females (38% prior to 1996, and 48% from 1996-2008, p<0.0001) , 
fewer squamous cell carcinomas relative to adenocarcinomas (ratio of 2.0, 
1.6, 1.5 and 1.3 in the 4 respective eras), more T1 (versus T2) tumors (ratio 
of 0.5, 0.6, 0.8 and 1.0 in the 4 respective eras) and smaller tumor size 
(average of 4.0, 3.9, 3.7 and 3.5 cm in the 4 respective eras). The 1-year, 
2-year and 5-year OS were 62%, 37% and 11% respectively; lung cancer 
CSS survivals were 68%, 45% and 20% respectively. Seventy-seven per-
cent of deaths were from lung cancer (5,292 of 6,891 total deaths). Cardiac 
(n=477) and pulmonary (other than lung cancer deaths, n=475) deaths 
accounted for 14% of deaths. From Cox proportional hazards analyses, 
male gender (HR=1.2) and squamous cell carcinoma histology (HR>1.1) 
were significantly (p<0.0001) adverse prognostic factors for both OS and 
lung cancer CSS. A more recent calendar year of diagnosis was associ-
ated with significantly (p<0.0001) improved OS and lung cancer CSS (HR 
0.84 and 0.82 per decade respectively). This trend was also significant 
(p<0.0001) when restricting analyses to those patients with tumor size 
≤5 cm (n=5,402 patients, representing Stage I NSCLC in the AJCC 7th 
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edition). T1 stage (versus T2 or T unknown) and smaller tumor size were 
also significantly (p<0.0001) favorable factors. 
Conclusions: From a hypothesis generating, retrospective, population-based 
registry analysis of patients Stage I NSCLC, more recent calendar year of 
diagnosis, female gender, non-squamous cell carcinoma histology, earlier 
T stage, and smaller size were associated with more favorable OS and lung 
cancer CSS outcomes. Improvements in survival in more recent years, even 
when correcting for other prognostic factors in Cox regression analyses, 
likely reflects technologic improvements in lung cancer diagnosis, staging 
and radiotherapy delivery.
Author Disclosure Block: M.T. Milano: None. H. Zhang: None. K.Y. 
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Three-dimensional Non-coplanar Conformal Radiotherapy 
with Middle Fraction Dose for the Treatment of Stage I Non-
small Cell Lung Cancer
K. Karasawa, N. Okano, Y. Machitori, T. Shimizuguchi, M. Onozawa, H. 
Murata, H. Izawa, T. Chang, N. Hanyu, K. Nihei, Tokyo Metro Komagome 
Hosp, Tokyo, Japan
Purpose/Objective(s): Three–dimensional non-coplanar conformal radio-
therapy (3-DNCCRT) has recently been considered promising for the treat-
ment of stage I non-small cell lung cancer (NSCLC). Usually, it is performed 
in the form of SBRT using 10 – 20Gy fraction dose. However, this method is 
considered to be contraindicated for so-called central tumors because of the 
toxicity of serial organs, such as bronchus, large vessels, etc. We have been 
treating these tumors with relatively small fraction dose (usually 3Gy) keep-
ing BED10 at the similar level to that of SBRT. In this study, we analyzed our 
10-year results. 
Materials/Methods: Eligibility criteria were as follows: maximum tumor 
diameter not greater than 5cm, PS between 0 and 2, and no limitation regard-
ing age and pulmonary function. Radiotherapy was given with 6MV photon 
beam by fixed 10 non-coplanar conformal beams to a total dose of 75Gy in 25 
fractions in 5 weeks. Irradiation was aiming at the ITV with proper margins. 
No ENI was given. Between Jan. 2002 and Dec. 2010, 111 eligible cases were 
treated. Age ranged from 53 to 93 (median 78). The male/female ratio was 
80/31. There were 64 T1 tumors and 47 T2. Twenty-four tumors were sqcca, 
71 adenoca, and 16 others. There were 92 inoperable cases (83%), among 
them poor pulmonary function was in 66 (59%), and 19 operable cases, who 
refused operation. The average tumor size was 3.0 cm (range; 1.2 to 5.0 cm). 
There were 102 PS 1 and 9 PS 2 cases. Among the entire cases, 46 cases were 
central tumors and the other 65 were peripheral tumors. Median follow-up 
period was 35 months. 
Results: Three- and 5-year local control rate (LC), overall survival rate (OS), 
cause-specific survival rate, and relapse-free survival rate for overall cases 
were, 85% and 85%, 68% and 53%, 79% and 69%, and 56% and 41%, respec-
tively. Three-year LC and OS for T1 and T2 cases were 83%, 67%, and 86%, 
70%, respectively (n.s.). Three-year LC and OS for central and peripheral 
tumors were 84%, 73%, and 85%, 66%, respectively (n.s.). Three- and 5-year 
OS for operable and inoperable cases were 87%, 87%, and 65%, 47%, respec-
tively (p=0.02). Patterns of initial relapse were, local in 10 cases, pleural in 4, 
nodal in 8, and distant in 13. There were 7 Grade 3 pulmonary toxicities (6%), 
but there were no severe adverse effects concerning serial organs. 
Conclusions: Although the follow-up period is still short, 3-DNCCRT with 
middle fraction dose for stage I non-small cell lung cancer has been safe and 
effective for not only inoperable but also operable cases, and equally effective 
for peripheral and central tumors, and T1 and T2 tumors.
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Stereotactic Body Radiotherapy (SBRT) Using Tomotherapy 
for Early Stage NSCLC: The Utility of Mid-fraction CT Scans 
to Assess Intra-fraction Tumor Motion
H. Boggs1, S. Feigenberg1, R. Walter2, D. Wissing3, B. Patel4, T. Wu4, L. 
Rosen4, 1University of Maryland Medical Center, Baltimore, MD, 2Louisiana 
State University Health Sciences Center School of Medicine, Shreveport, LA, 
3Louisiana State University Health Sciences Center School of Allied Health, 
Shreveport, LA, 4Willis Knighton Cancer Center, Shreveport, LA
Purpose/Objective(s): Intra-fraction translational tumor motion was ana-
lyzed by comparing mid-fraction MV-CT scans to pre-fraction MV-CT scans 
in order to assess the adequacy of an isotropic 7 millimeter margin to account 
for tumor motion during SBRT with Tomotherapy. 
Materials/Methods: Thirty patients with medically inoperable stage I-II 
NSCLC who received SBRT in 4-5 fractions with Tomotherapy were ana-
lyzed. Patients were initially imaged using a PET/CT scan to develop an inter-
nal target volume (ITV) to account for respiratory induced tumor motion. 
The patients were immobilized using a double-vacuum cushion device with 
chest compression prior to CT simulation. A GTV was delineated on the 
kilovoltage-CT (kv-CT) simulation scan. An ITV was generated by fusing the 
tumor visualized on PET-CT with the GTV on the kv-CT. An isotropic 7mm 
margin was placed around the ITV to form the PTV. Prior to each treatment, 
a megavoltage-CT (MV-CT) scan was performed and aligned to the kv-CT 
with priority placed on tumor-to-tumor matching. To ensure appropriate set 
up margins and concerns of intrafraction uncertainties, a second MV-CT scan 
was obtained mid treatment which on average was 20 minutes following the 
first scan. Total treatment time was typically 40 minutes. Patients were ana-
lyzed to assess tumor positional changes in mm along the X, Y, and Z axes 
from the mid-fraction MV-CT with respect to the pre-fraction MV-CT. Mean 
movements + 1 standard deviation were recorded as well as mean vectors 
using the formula v= √ (x2 + y2 + z2). 
Results: One hundred forty-one total treatment days were analyzed and 
translational change in position of the tumor with respect to the 95% isodose 
volume was recorded in millimeters. Mean movement for all treatment days 
along the X axis was 0.5 + 2.3 (SD) mm, Y axis was -0.3 + 3.0 mm, and Z 
axis was 0.9 + 3.0 mm. Mean movement for each patient with respect to their 
treatments was 0.5 + 1.5 mm along the X axis, -0.2 + 2.0 mm along the Y 
axis, and 0.9 + 1.9 mm along the Z axes. Mean vector displacement was 4.3 + 
2.4 mm for all treatment days and 4.2 + 1.7 mm for each patient with respect 
to their treatment. One hundred thirty-seven of 141 CT scans fell within 7.0 
mm in all axes (97.2%). The four images with a measured value above 7.0 
mm were found in three different patients, so 27/30 (90.0%) of patients had 
tumors that were encompassed within the 95% isodose line in all axes for all 
treatment days. 
Conclusions: The addition of a 7mm margin to the ITV for patients receiving 
Tomotherapy based SBRT for NSCLC is adequate to account for tumor move-
ment during treatment. As treatment times over 30 minutes are associated 
with increased tumor movement, the utilization of midtreatment CT scans 
proved to be a valuable tool in assessing intrafraction tumor motion.
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The United States Department of Veteran Affairs Healthcare 
System (VAHS) Provides a Suitable Multi-Institutional Setting 
for Phase III Randomized Trials of Stereotactic ABlative 
Radiotherapy (SABR) versus Lobectomy in Patients with 
Medically Operable Stage I Non-Small Cell Lung Cancer 
(NSCLC)
B. R. Adams1, D. Moghanaki1,2, W. Wan1, A. D. Cassano1,2, S. Szentpetery1,2, 
1Virginia Commonwealth University Medical Center, Richmond, VA, 2Hunter 
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Purpose/Objective(s): Local-regional control (LRC) rates for medically 
inoperable patients with stage I NSCLC treated with SABR exceed 85% 
in prospective clinical trials. However, lobectomy remains the standard of 
care for those medically fit for surgery. To date, two phase III trials have 
attempted to compare lobectomy to SABR in medically operable patients 
with stage I NSCLC, however, both closed prematurely due to poor accrual 
(Dutch European and MD Anderson/Accuray). As the VAHS has historically 
provided opportunities to explore the utility of non-surgical management of 
malignancies during eras when surgery was standard of care (VA Larynx 
Trial, 1991), we investigated the opportunity for a phase III trial randomizing 
medically fit patients to SABR vs lobectomy within the VAHS. This report 
summarizes the surgical outcomes of Veterans with stage I NSCLC treated at 
a large tertiary care VAHS. 
Materials/Methods: A retrospective electronic medical chart review was 
performed for all patients diagnosed with stage I NSCLC from 1993 to 2008. 
Associations of clinicopathological variables with LRC and overall survival 
(OS) are analyzed with the Cox regression model. 
Results: 329 patients were diagnosed with stage I NSCLC during the study 
period. Of these, 196 (59.6%) who underwent either lobectomy (n=140), 
wedge (n=48), or pneumonectomy (n=8), are evaluated. Median age was 
66 (44-85 years), and 95.4% were male. Postoperative 30-day mortality was 
4.1% (2.6%, 1.5%, and 0.0% for wedge, lobectomy, and pneumonectomy 
patients, respectively). Mediastinal sampling was performed in 71%, whereas 
29% were stage cN0 pNx. PET staging, first available in 2006, was performed 
in 17 of the 47 patients diagnosed since that time. Median follow-up from 
surgery was 3.8 yrs. The 5 year OS was 47% with a median survival time 
of 4.5 years. OS and LRC at 5 years was similar between wedge and lobec-
tomy/pneumonectomy [OS = 42% vs 48% (p=0.171); LRC = 65% vs 73% 
(p=0.147), respectively]. Positive margins predicted for increased locore-
gional failure [adjusted HR 3.7 (1.5-9.3), p=0.006], but not OS. In the mul-
tivariate model, only patients with unknown pathological nodal stage (cN0 
pNx) had an increased risk of death [adjusted HR 1.77 (0.3-1.0), p=0.053]. 
Conclusions: Surgical outcomes over a 15 year period within a single class 
1A VAHS facility appear similar to many reports from non-VAHS institu-
tions. These data support utilization of the VAHS for conducting a phase III 
randomized control trial of SABR vs lobectomy.
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Hypofractionated Radiotherapy for Stage I and II Non-Small 
Cell Lung Cancer
J. G. Kuremsky, W. J. Petty, A. Miller, W. H. Hinson, C. J. Hampton, A. W. 
Blackstock, J. J. Urbanic, Wake Forest University School of Medicine, Winston 
Salem, NC
Purpose/Objective(s): At our institution starting in 2004, patients with medi-
cally inoperable early stage lung cancer not candidates for SBRT based on 
tumor size or location were treated with accelerated hypofractionated radio-
therapy (AHRT). 
Materials/Methods: All pts evaluated by multi-disciplinary thoracic team. 
3D conformal RT, min dose/fx 225 cGy and 6000 cGy total. Dose prescribed 
included 95% PTV in Rx dose. Photon beam energy 10MV or less. 4D CT 
used to define ITV beginning January 2007 (59 patients). PTV expansion 5 
mm used in ITV defined patients. PTV otherwise 10mm. 10 patients prior to 
2006 treated using homogeneous tissue density for dose calculation. V20 goal 
< 20%. IRB approval obtained. Patient failures were scored regarding local 
(at the site treated), regional (nodal disease in the hilum /mediastinum), or 
distant. Central (CT) versus peripheral (PT) based on RTOG 0813 criteria. 
Staging per AJCC 7th ed. Toxicity per NCI CTCAE v4.0. Kaplan Meir esti-
mate of local control (LC), regional or distant failure (RF, DF) and overall 
survival (OS). 
Results: 83 patients were identified who were treated with AHRT for stage I/II 
NSCLC 2004-2012. 67 Stage I, 16 Stage II (4 N1). Median follow-up available 
for entire cohort 21 months (1-85 months). For living patients, median follow-
up 27 months (1-85 months). Average patient age 71.1 years (50-92). Median 
ECOG PS of 1. 80 of 83 patients were pathologically diagnosed. 35 patients 
squamous cell, 34 adenocarcinoma and 14 poorly differentiated/NOS. 50 of 
83 pts: tumors classified as central per RTOG definition. Average tumor size 
3.2cm (1.0-7.0). 39 tumors were T1, 44 tumors were T2. 5 patients were treated 
for bilateral stage I lung (MSKCC criteria). Pre-treatment pulmonary function 
testing: 52 pts FEV1 with median 64% predicted, 34 pts DLCO with median 
65% predicted. 64 of the 83 treated 7020 cGy, 26 fxs, 270cGy per fraction. 15 
patients < 270 cGy/fx but at least 60 Gy. 44 deaths occurred. Median OS: 35 
months (95%CI 23-47 months); 5 year OS: 24.7% (95%CI 12-37%). Local 
failure 15 patients. LC: 3 years 78.7% (95%CI 68-89%). LC more likely at dose 
≥ 270 cGy/fx (p0.05); 3 year LC 83% vs 62% based on 270 cGy/fx dose thresh-
old. No difference LC based on size. RF in 8 patients (3 isolated); 3 year free-
dom from RF 87.7% (95%CI 79-96%). DF: 21 of 83 patients at median of 13 
months. 3 year freedom from DF 67.3% (95%CI 55-79%). 3 year OS CT 39.4% 
vs 60.8 % PT (p 0.1); 3 year DF CT 60.7 % vs 75.9 PT (p<0.05). Toxicity: 
Grade 2 pneumonitis 7 pts, 1 pt grade 3; 1 esoph stricture, 6 chest wall pain. 
Conclusions: AHRT provided good local control for patients not felt to be 
candidates for SBRT based on size or location. Distant failure predominated 
and toxicity modest. Our results suggest minimum dose of 270 cGy per frac-
tion needed and provides additional supporting data for the current CALGB 
31102 and RTOG 1106 trials.
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Comparison of Robotic versus Video-Assisted Thoracoscopic 
Surgery (VATS) Lobectomy for Non-Small Cell Lung Cancer 
(NSCLC)
F. Y. Bhora1,2, D. Y. Lee1, S. S. Belsley1,2, M. Wassef1, S. S. Rehmani1, C. 
P. Connery1,2, 1St. Luke’s Roosevelt Hospital, New York, NY, 2Columbia 
University College of Physicians and Surgeons, New York, NY
Purpose/Objective(s): Minimally invasive surgical approaches to manage-
ment of early stage NSCLC may improve patient outcomes by minimizing 
surgical trauma in selected patients. At our institution, these patients are 
offered a lobectomy via robotic assistance or by VATS. We present our early 
experience with both approaches. 
Materials/Methods: Retrospective review of 41 lobectomies performed by 
either VATS (n=24) or by robotic assistance (n=17) at our institution from 
2010 to 2012 was performed. Preoperative characteristics and postoperative 
outcomes were noted. The decision for either approach was made by the sur-
geon in discussion with the patient. 
Results: Preoperative characteristics of the patients including age, BMI, pul-
monary function status, ASA class, and co-morbidities including pulmonary 
and cardiovascular disease were similar for the robotic and the VATs group. 
The average tumor size (2.5 ± 1.4 cm vs 2.3 ± 1.4 cm, p=0.788), margins (1.5 ± 
1.8 cm vs 1.6 ± 1.8 cm, p=0.887), and the number of lymph node stations sam-
pled (4.1 ± 1.4 vs 3.4 ± 1.2, p=0.511) were similar for the robotic and the VATS 
group respectively. Robotic approach was associated with increased operative 
time (296.7 ± 76.5 min vs 249.9 ± 75.7, p=0.059) and increased number of 
lymph nodes harvested (11.1 ± 5.3 vs 9.9 ± 6.3, p=0.533) however, this did 
not reach significance. We compared our first 5 robotic cases compared to our 
second 12 cases to account for learning curve. The mean operative time for the 
first 5 cases was 340.6 ± 81.4 min vs 278.4 ± 69.8 min for the second 10 cases 
but this was not significant (p=0.131). Chest tube duration (2.1 ± 0.9 days vs 
2.3 ± 1.4 days, p=0.549) and the length of stay (3.9 ± 2.7 days vs 3.4 ± 1.9 days, 
p=0.766) were similar for the robotic and the VATs group respectively. There 
were 2 patients in the VATS group who had persistent air-leak greater than 5 
days, and 2 patients who required post operative transfusion in less than 72 
hours. One patient in the robotic group developed a deep venous thrombosis of 
the lower extremity while another required transfusion after 72 hours. 
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Conclusion: There is now evidence to suggest that VATS lobectomy may 
understage N1 disease compared to open thoracotomy. The rigidity of the chest 
wall limits the access of thoracoscopic instruments in the VATS approach and 
may preclude adequate lymphadnectomy and dissection of surrounding struc-
tures. Robotic assisted lobectomy offers greater surgical access and facilitates 
extended lymphadnectomy with precise dissection and resection compared to 
VATS. Although not statistically significant, the robotic approach harvested 
more lymph nodes and this warrants further studies. Although there was 
increased operative time with the robotic approach, our second 12 cases were 
comparable to the VATS approach in this series.
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Monitoring The Response Of Stereotactic Body Radiotherapy 
(SBRT) In Patients With Early-stage Lung Cancer Using 
Serial Positron Emission Tomography (PET)
L. R. Rosen1, B. W. Fischer-Valuck1, S. Katz1, M. Durci1, T. Wu1, A. Takalkar2, 
M. Mirfakhraee1, D. Lilien2, 1Willis Knighton Cancer Center, Shreveport, LA, 
2Biomedical Research Foundation, Shreveport, LA
Purpose/Objective(s): To report on the utility and predictive value of serial 
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) scan 
surveillance following stereotactic body radiotherapy for stage I non-small 
cell lung cancer (NSCLC). 
Materials/Methods: Between March 2005 and May 2011, 81 patients with 
stage I NSCLC were treated with SBRT delivered at 48 Gy in 4 fractions or 
60 Gy in 5 fractions. PET scans were obtained at 3-4 months following treat-
ment and serially every 6 months thereafter on all surviving patients. All PET 
imaging was performed at a single facility with either a team of experienced 
nuclear medicine physicians or diagnostic radiologists. Radiation oncologists 
also reviewed the PET imaging. A negative PET scan was interpreted as a 
complete response to radiotherapy and was indicated by the complete disap-
pearance of metabolic activity compared to a pretreatment scan. For the pur-
poses of this study, PET scans were classified as positive in all other readings. 
Kaplan Meier survival curves and the Cox proportional hazards regression 
were performed to analyze whether response as noted on serial PET scans 
correlated with patient outcomes. 
Results: Median follow-up was 24 months (range, 6 - 82 months). Fifty-nine 
patients had T1N0M0 disease and 22 had T2N0M0 disease. Overall local con-
trol rate was 91.4% (95% Confidence Interval (CI), 83.2-95.8%) and 3-year 
overall survival was 56.2% (95% CI, 45.2-68.2%). The 3-year overall survival 
for those patients with a negative PET scan at 9 months and 15 months was 
60.4% versus a 3-year overall survival of 21.1% for patients with a positive 
PET scan at that same follow-up date (P = 0.0039; Hazard ratio (HR) = 2.64, 
95% CI, 1.96 - 3.32). No correlation between the PET scan result obtained at 
3-4 months post-treatment and overall survival was observed (P = 0.965; HR 
= 0.98, 95% CI, 0.31 - 1.65). The median time to conversion from initially 
positive metabolic post-SBRT scan to a negative scan was 9 months (range, 
9 - 15 months). The incidence of locoregional recurrence was 7.5% and was 
detected most commonly on the 3-4 month post-SBRT PET scan (range, 3 - 
15 months). Seven patients developed distant metastasis that was detected at 
median PET scan follow-up of 9 months (range, 3 - 33 months). One patient 
developed a new primary lung cancer detected on the 15-month post-SBRT 
PET scan. Neither disease stage nor maximal tumor diameter had an impact 
on PET scan predictability of overall survival. Rare toxicity, which occurred 
in 10 patients, was not predicted or correlated by metabolic PET response. 
Conclusions: Our experience and data support FDG-PET follow-up at 3-4 
months, which helped identify local failure, and follow-up PET scans at 9 
and 15 months, which was predictive of survival in the presence of complete 
metabolic response.
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Comparison of VATS resection and da Vinci Robot vs. 
Thoracotomy for Sublobar Resection plus Interstitial 
Brachytherapy for Early Stage Non Small Cell Lung Cancer
D. Y. Lee1, A. K. Jain1, F. Y. Bhora1, S. Rehmani1, W. H. Choi2,3, S. S. Belsley1,4, 
C. P. Connery1,4, A. J. Evans1,3, 1St. Luke’s Roosevelt Hospital, New York, 
NY, 2Beth Israel Medical Center, New York, NY, 3Albert Einstein College of 
Medicine of Yeshiva University, New York, NY, 4Columbia Univeristy College 
of Physicians and Surgeons, New York, NY
Purpose/Objective(s): Sublobar resection plus brachytherapy is a viable 
option for patients with early stage non-small cell lung cancer (NSCLC) who 
are unable to tolerate a formal lobectomy. Robotic surgery offers a minimally 
invasive approach for brachytherapy seed placement while maintaining pre-
cision and dexterity of movement and maximal surgical access. Currently 
there is a concern that utilization of robot in conjunction with Video-Assisted 
Thoracoscopic (VATS) resection may increase operative time compared to 
thoracotomy. We examined our experience with the minimally invasive 
approach. 
Materials/Methods: We performed a retrospective review of 37 patients 
with early stage NSCLC who underwent sublobar resection and brachyther-
apy seed implantation via minimally invasive approach (VATS + da Vinci 
Robotic surgery) or by open thoracotomy. Iodine-125 brachytherapy seeds 
were sutured into the operative bed to deliver 120-144 Gy to 1 cm from the 
staple line. Operative time, estimated blood loss (EBL), length of stay (LOS), 
number of seeds placed, and patient characteristics were studied. 
Results: Characteristics of patients who underwent minimally invasive resec-
tion and seed placement (n=22) versus open thoracotomy (n=15) were similar 
in terms of age (73.7 years vs 72.8 years, p=0.745), tumor size (1.5 cm vs 
1.9 cm, p=0.08), predicted FEV1 (70.8% vs 68.4%, p= 0.753), and predicted 
DLCO (62.9 % vs 55.9%, p=0.369). The operative time for the minimally 
invasive approach was similar to open thoracotomy (174.1 ± 50.1min vs 174.7 
± 44.7 min, p=0.974). We compared our first 11 minimally invasive cases with 
second 11 cases to account for learning curve with the da Vinci Robot but 
this was not significant (181.2 ± min vs 167.1 ± 33.8 min, p=0.53). In addi-
tion, a similar number of brachytherapy seeds were placed by the minimally 
invasive approach compared to open thoracotomy (33.8 ± 15.9 vs 29.5 ± 7.1, 
p=0.274). The minimally invasive approach achieved lower EBL (192.1 ± 
57.8ml vs 92.5 ± 66.7ml, p<0.05) compared to open thoracotomy. In addi-
tion, the median LOS stay was shorter for the minimally invasive group vs the 
open group (4 days vs 6 days) but this did not reach significance (p=0.324). 
Conclusion: The minimally invasive approach resulted in less blood loss 
and a trend towards shorter LOS- although statistical significance was not 
achieved for the LOS. Use of Robot, and the time associated with its setup did 
not result in increased operative time compared to open thoraoctomy. More 
studies are needed to validate the effectiveness and outcome of this approach.
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Phase II Study of Pemetrexed (P) plus Carboplatin (Cb) or 
Cisplatin (C) with Concurrent Radiation Therapy Followed 
by Pemetrexed Consolidation in Patients (pts) with Favorable-
Prognosis Inoperable Stage IIIA/B Non-Small Cell Lung 
Cancer (NSCLC)
H. Choy1, L. Schwartzberg2, S. R. Dakhil3, E. Garon4, J. Choksi5, R. Govindan6, 
D. Gerber7, G. Peng8, J. Treat8, C. Obasaju8, 1Univ. of Texas Southwestern, 
Dallas, TX, 2ACORN and West Clinic, Memphis, TN, 3Cancer Center of 
Kansas, Wellington, KS, 4University of California at Los Angeles, Los Angeles, 
CA, 5Alamance Regional Medical Center, Burlington, NC, 6Washington 
University, St. Louis, MO, 7Harold C. Simmons Cancer Center, Univ. of Texas 
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Purpose/Objective(s): There is no consensus chemotherapy regimen with 
concurrent radiation therapy (RT) for inoperable Stage IIIA/B NSCLC. In 
preclinical models, ionizing radiation synergizes with P, as well as with Cb 
and C. These doublets have shown efficacy and favorable toxicity profiles in 
Phase 2/3 trials. 
Materials/Methods: In this open-label randomized Phase 2 trial, 98 pts with 
inoperable Stage IIIA/B NSCLC (all histologies) were randomized (1:1) to P 
500 mg/m2 plus Cb AUC 5 (PCb) or P 500 mg/m2 plus C 75 mg/m2 (PC) intra-
venously (IV) every 21 days for 3 cycles. All pts received protocol-specified 
concurrent RT in the range of 64-68 Gy (2 Gy/day, 5 days/week, Days 1-45). 
Consolidation P 500 mg/m2 IV every 21 days for 3 cycles began 3 weeks 
after completion of concurrent RT. The primary endpoint was 2-year overall 
survival (OS); secondary endpoints included median OS, time to progression 
(TTP), overall response rate (ORR), and toxicity. 
Results: Since June 2007, 98 pts were enrolled (PCb: 46; PC: 52). Pts were 
followed until October 2011 (study follow-up complete). Mean dose compli-
ance was 97.1% in the PCb arm and 89.7% in the PC arm. Most pts received 
at least 3 cycles of therapy (PCb: 91.3%; PC: 80.8%). Mean dose compli-
ance for concurrent RT was 96.7% in the PCb arm and 90.5% in the PC 
arm. Concurrent RT dose interruptions occurred in 39.1% of the PCb arm 
and 46.2% of the PC arm. The mean (standard deviation [SD]) concurrent RT 
doses were 63.8 Gy (9.60) in the PCb arm and 59.7 Gy (19.68) in the PC arm. 
Both arms had median concurrent RT doses of 66.0 Gy. Two-year survival rate 
was 45.4% (95% confidence interval [CI], 29.5%-60.0%) for the PCb arm and 
58.4% (95% CI, 42.6%-71.3%) for the PC arm (P=0.242). Median OS was 
18.7 months (95% CI, 12.9-not assessable [N/A]) for PCb and 27.0 months 
(95% CI, 23.2-N/A) for PC. Pts receiving PC had a better 2-year survival rate, 
regardless of concurrent RT dose (<66 Gy: PCb, 25.5%, PC, 51.0%; ≥66 Gy: 
PCb, 58.9%, PC, 64.9%). Median TTP was 8.8 months (95% CI, 6.0-12.6) for 
PCb and 13.1 months (95% CI, 8.3-N/A) for PC; P=0.092. The ORR rates were 
52.2% for PCb (complete response [CR], 6.5%; partial response [PR], 45.7%) 
and 46.2% for PC (CR, 3.8%; PR, 42.3%). Grade 4 treatment-related toxicities 
(% PCb/% PC) were: anemia, 0/1.9; neutropenia, 6.5/3.8; thrombocytopenia, 
4.3/1.9; and esophagitis, 0/1.9. No drug-related deaths were reported. 
Conclusions: While conclusions are limited by the size of the trial, this study 
suggests OS and TTP advantages for the C-containing arm. Both combina-
tions with concurrent RT appear well tolerated.
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A Phase II Study Of Induction Chemotherapy Followed By 
Thoracic Radiotherapy (TRT) And Erlotinib In Poor-risk 
Stage III Non-small Cell Lung Cancer (NSCLC): Initial 
Results Of CALGB 30605 And RTOG 0972
R. Lilenbaum1, M. Samuels2, F. Kong3, X. Wang4, P. Janne5, G. Masters6, 
J. Bogart7, J. Bradley8, E. Vokes9, 1Cleveland Clinic Florida, Weston, FL, 
2Univeristy of Miami Miller School of Medicine, Miami, FL, 3University of 
Michigan, Ann Arbor, MI, 4Duke University, Durham, NC, 5Dana Farber 
Cancer Institute, Boston, MA, 6Christiana Care Health System, Newark, DE, 
7SUNY Upstate, Syracuse, NY, 8Washington University, Saint Louis, MO, 
9University of Chicago, Chicago, IL
Purpose/Objective(s): Patients with stage III NSCLC and poor-risk features, 
including a low performance status (PS) and significant weight loss (WL), 
account for a substantial percentage of patients seen in clinical practice, for 
which few studies have been performed and no consensus therapy has been 
defined. We report the first CALGB and RTOG collaboration in this patient 
subset. 
Materials/Methods: Eligibility criteria included stage IIIA/B NSCLC of any 
histological subtype, with PS 2 or PS 0-1 and ≥ 10% WL and no prior therapy. 
Treatment consisted of induction carboplatin AUC=5 d1 and albumin-bound 
paclitaxel 100mg/m2 d1,8 every 21 days for 2 cycles. TRT was administered 
at a dose of 66Gy over 33 fractions. Elective nodal radiation was not permit-
ted. Erlotinib 150 mg po was given daily during TRT with no maintenance. 
Treatment success was defined as ≥ 65% patients alive at 1 year against the 
alternative hypothesis of ≤ 50% with one sided α=0.10 and 1-β=0.90. Tissue 
for molecular analysis (EGFR and KRAS mutations and EGFR FISH) was 
encouraged but not mandated. 
Results: A total of 78 patients were enrolled between 3/2008 and 10/2011. 
Three withdrew prior to receiving therapy. Median age was 68 (39, 88); 32% 
were ≥ 75 years old; stage IIIA/B 49%/51%; 61% had PS 2 and 39% PS 0-1 
with WL. Based on 75 evaluable patients, 3% had CR, 55% PR, 31% SD, 7% 
PD, 5% NA. As of March 2012, with a median F/U of 16.6 months and 16 
patients still without reaching the primary endpoint, median PFS and OS were 
11 (9, 16) and 16 (12, 19) months respectively, with 57% of patients (46%, 
71%) alive at 1 year. Stage was prognostic for outcome with median PFS and 
OS in IIIA patients 15.9 and 19.3 months, compared to 9.17 and 11.2 in IIIB 
patients (p = 0.004 for PFS and p= 0.08 for OS). Risk factor (PS 2 vs. PS 
0-1+ WL) was not prognostic. Toxicity was mild with 19% Gr3-4 neutrope-
nia, 7% Gr 3 diarrhea and no Gr5 events. Gr3 esophagitis and pneumonitis 
were recorded in 5% and 1% of patients respectively. 
Conclusions: Induction chemotherapy with carboplatin and albumin-bound 
paclitaxel followed by TRT with erlotinib radio-sensitization is well tolerated 
in this high-risk population. Survival data is provocative but still premature 
and will be updated at the time of the meeting, along with the molecular 
correlation. This study proves the feasibility of collaboration between two 
cooperative groups in a difficult to accrue population and provides benchmark 
data for future trials.
Author Disclosure Block: R. Lilenbaum: None. M. Samuels: None. F. 
Kong: None. X. Wang: None. P. Janne: None. G. Masters: None. J. Bogart: 
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Predictive Factors for Mediastinal Nodal Failure in Locally 
Advanced Non-small Cell Lung Cancer (NSCLC) Patients 
Receiving Definitive Chemoradiation (CRT)
A. Fernandes, E. Xanthopoulos, T. Evans, J. Stevenson, E. Alley, C. Aggarwal, 
C. Langer, C. Simone, R. Rengan, University of Pennsylvania, Philadelphia, 
PA
Purpose/Objective(s): The extent of mediastinal lymph node involve-
ment has proven to be an independent predictor of poor survival in stage III 
NSCLC. This study identified predictive factors for nodal failures in initially 
uninvolved lymph node stations in stage III NSCLC patients treated with 
definitive CRT. 
Materials/Methods: We analyzed consecutive patients with biopsy-proven 
stage III NSCLC treated with definitive chemoradiation between January, 
2003 and January, 2010. Uninvolved nodal failures (UNFs) were defined by 
radiographic progression in initially uninvolved mediastinal lymph nodes 
(independent of local or distant failure). 
Results: Of the 132 patients analyzed, 98 patients had disease controlled 
in the mediastinal nodes (UNC), while 34 patients experienced uninvolved 
nodal failures (UNF). Patients with UNC had improved median survival 
compared with patients who experienced UNF (23.0 vs. 15.6 months, 
p=0.004). The median follow-up was 20 months for all patients and 40 
months for survivors. All baseline patient and disease characteristics 
were similar for those with UNC vs.UNF, including median age (61 vs. 
62 yrs), KPS (90 vs. 90), median prescription RT dose (6660 vs. 6660 
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cGy), T-stage, N-stage, and histology (adenocarcinoma: 49% vs. 47%). 
Analyzing these two patient groups for potential predictors of nodal fail-
ure revealed higher UNF rates in patient treated with sequential chemo-
therapy (43% vs. 22% concurrent, p=0.03) or elective nodal irradiation 
(ENI, n=47) (36% vs. 20% involved field radiotherapy [IFRT, n=85], 
p=0.04), and in patients with local (i.e. primary tumor) failures (LF) (43% 
vs. 16% in locally controlled patients, p=0.001). Among patients with 
both LF and UNF, 80% of the LFs occurred prior to or within 2 months 
of the UNFs. Patients receiving ENI had a slightly lower median RT dose 
(6300 cGy vs. 6660 cGy) and were somewhat less likely to receive concur-
rent chemotherapy (79% vs. 85%, p=0.39) compared with IFRT patients. 
Additionally, more patients treated with ENI also experienced a LF (47% 
ENI vs. 28% IFRT, p=0.03). Among patients treated with ENI, 50% of 
patients with LF experienced an UNF while 24% of locally controlled 
patients experienced UNF (p=0.06). 
Conclusions: Our data demonstrate that local failure, ENI and sequential 
chemotherapy are associated with subsequent mediastinal nodal failure. The 
high rates of primary tumor failure in patients treated with ENI and the timing 
between local and nodal failures suggest that primary tumor failure and medi-
astinal nodal failure may be causally connected. Given the high rate of local 
failure in locally advanced NSCLC, ongoing strategies aimed at improving 
clinical outcomes should continue to emphasize the importance of primary 
tumor control.
Author Disclosure Block: A. Fernandes: None. E. Xanthopoulos: None. T. 
Evans: None. J. Stevenson: None. E. Alley: None. C. Aggarwal: None. C. 
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A Differential Treatment Planning Strategy for Locally 
Advanced Non-Small Cell Lung Cancer to Facilitate Dual 
Patient Setup Procedure for Improved Target Coverage and 
Normal Tissue Sparing
D. Ionascu1,2, K. Yang2, J. B. Wilkinson2,1, D. Yan1,2, I. S. Grills1,2, S. Martin2, 
1Oakland University William Beaumont School of Medicine, Royal Oak, MI, 
2William Beaumont Health System, Royal Oak, MI
Purpose/Objective(s): Due to the dual nature of advanced NSCLC, respira-
tory induced motion discrepancies between primary and involved nodal tar-
gets have been observed. Current practice consists of using a bony anatomy 
setup registration (B-R), an appropriate approach for nodal targets, but result-
ing in increased primary tumor setup margins. To mitigate the differential 
motion, we have developed a planning strategy where prior knowledge of 
optimal primary & nodal registration setup procedures (soft tissue-ST-R and 
B-R, respectively) is used. 
Materials/Methods: 20 patients with advanced NSCLC were treated on 
an in-house, IRB approved IGRT protocol. Patient selection was based on 
imaging sets including both a 10 phase helical 4DCT simulation and patient 
setup 4D CBCTs. 5 patients were identified with the primary excursion con-
sistently > 6 mm during the entire treatment course. Dual registration was 
retrospectively performed: 1st B-R for nodal treatment delivery and 2nd ST-R 
for primary treatment delivery. The B-R to ST-R 3D translation shifts Δ were 
recorded. Our planning strategy is determined based on setup procedure, 
where the primary & nodal targets are initially planned separately using 
either IMRT or VMAT technique. To minimize treatment delivery time, only 
dual VMAT and IMRTnodal-VMATprimary plans were considered. Using com-
mercially available systems, hybrid optimization plans are notoriously dif-
ficult to obtain due to different optimization algorithms. However, using our 
technique the plans are subsequently merged, optimized together for target 
coverage and critical structure sparing, while allowing dose/segment to reach 
minimal values. Segments with < 5 MU are removed and the plan is then 
re-optimized. 
Results: During the entire treatment, the primary excursion (LAT; SI; AP) 
range was (1-3; 6-17.5; 1-5) mm. 3 patients showed SI excursion > 12 mm 
with B-R to ST-R translation shifts Δ in the (7-8.2) mm range. The D
95
(Δ) 
primary dosimetric coverage of 99% (using ST-R), decreased by a mean of 
8.2% ( w/ dual VMAT) to 10.6% (w/ IMRT-VMAT) when B-R setup was 
used. 2 patients with SI < 1cm showed < 2.4 % D
95
 primary discrepancy. 
In general, IMRTnodal-VMATprimary plans achieved the same target coverage as 
dual VMAT but with better Lungs-GTV sparing (ΔV20= - 3- 6%). 
Conclusion: We have developed a strategy that enables delivery of hybrid 
plans to complex targets while improving the overall target coverage and 
normal tissue sparing. For advanced NSCLC patients with large differential 
motion, our planning and setup strategy, using sequential nodal B-R and pri-
mary ST-R based on daily volumetric imaging, has shown drastic reduction 
of the dosimetric primary target miss. A selective primary margin reduction 
study is the subject of a future investigation.
Author Disclosure Block: D. Ionascu: None. K. Yang: None. J.B. 
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Analysis of Prognostic Factors Affecting Local and Distant 
Recurrence Following Surgery for Non-Small Cell Lung 
Cancer: A Recursive Partitioning Analysis
C. R. Kelsey1, K. Higgins2, B. Peterson1, L. B. Marks3, D. Tandberg1, J. Chino1, 
M. DeCamp4, J. Varlotto5, 1Duke University, Durham, NC, 2Emory University, 
Atlanta, GA, 3University of North Carolina, Chapel Hill, NC, 4Northwestern 
University, Chicago, IL, 5Pennsylvania State University, Hershey, PA
Purpose/Objective(s): The risk of local/regional recurrence (LRR) and 
distant recurrence (DR) after surgery for early-stage NSCLC depends 
largely on surgical and pathological prognostic factors. While multiple 
risk factors for both LRR and DR have been identified using multivari-
ate modeling, estimating the aggregate risk in an individual patient, or 
population, based on the presence or absence of multiple factors is a chal-
lenge. We sought to define subgroups at high risk of LRR and DR using a 
recursive partitioning analysis (RPA), within both a primary and valida-
tion dataset. 
Materials/Methods: This IRB-approved study included patients who under-
went upfront surgery for I-IIIA NSCLC between 1995-2008 at Duke Cancer 
Institute (primary set) or at multiple other institutions (validation set). Patients 
were excluded if they had positive surgical margins, received postoperative 
radiation therapy or died in the postoperative period. Disease recurrence at 
the surgical margin, ipsilateral hilum, and/or mediastinum was considered a 
LRR. Other sites of recurrence were scored as DR. Recursive partitioning was 
used to build regression trees for the prediction of time to LRR and time to 
DR for both datasets separately using standard clinical and pathological fac-
tors. Recursive partitioning was done with the rcart function of R’s statistical 
software. LRR and DR were scored as independent events with patients cen-
sored at the time of death with actuarial 5-year rates of recurrence estimated 
using the Kaplan-Meier method. 
Results: 1411 patients comprised the primary set with 5-year actuarial rates 
of LRR and DR of 23% and 30%, respectively. 887 patients comprised the 
validation set with 5-year actuarial rates of LRR and DR of 24% and 32%, 
respectively. For LRR, the primary RPA identified three groups based on 
stage and histology to best segregate patients into risk groups with the fol-
lowing 5-year recurrence risks: stage I/adenocarcinoma 13%; Stage I/squa-
mous or large cell 28%; Stage II-IIIA 38%. For LRR, the validation RPA 
identified three groups based on lymphovascular invasion (LVI) and stage: 
no LVI/stage IA 19%; no LVI/stage IB-IIIA 27%; LVI 42%. For DR, the 
primary RPA identified three groups based on stage and LVI with the fol-
lowing 5-year recurrence risks: stage I/no LVI 19%; stage I/LVI 39%; stage 
II-IIIA 54%. For DR, the validation RPA identified three groups, also based 
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on stage and LVI: stage I-IIA/no LVI 28%; stage I-IIA/LVI 52%; stage IIB-
IIIA 57%. 
Conclusions: For LRR, there is discordance between the two data sets 
with regard to the parameters that best segregate patients into risk groups. 
Nevertheless, both data sets implicated stage as being a major predictive fac-
tor. Pathological stage and LVI were the key determinant of DR in both datas-
ets. RPA is able to define subgroups at variable risk of LRR and DR.
Author Disclosure Block: C.R. Kelsey: E. Research Grant; Varian Medical 
Systems. K. Higgins: None. B. Peterson: None. L.B. Marks: None. D. 
Tandberg: None. J. Chino: None. M. DeCamp: None. J. Varlotto: None.
158 
Long-term Survival Of Patients(pts) Treated With High-
dose Radiotherapy(rt) & Concurrent Chemotherapy For 
Unresectable Non-small Cell Lung Cancer(nsclc)
S. E. Schild1, S. Hillman2, D. Graham3, S. Vora1, Y. Garces2, K. Olivier2, J. 
Kugler4, H. Ross1, J. Molina2, A. Adjei5, 1Mayo Clinic, Scottsdale, AZ, 2Mayo 
Clinic, Rochester, MN, 3Carle Foundation - Carle Cancer Center, Urbana, 
IL, 4Illinois Oncology Research Association CCOP, Peoria, IL, 5Roswell Park, 
Buffallo, NY
Purpose/Objective(s): NCCTG N0028 was a trial performed for pts 
with unresectable NSCLC. This trial determined the maximally tolerated 
dose(MTD) of radiotherapy that could be given with concurrent carbopla-
tin and paclitaxel was 74 Gy in 34 fractions. This secondary analysis was 
performed to determine the long-term survival of the patients treated on 
this trial. 
Materials/Methods: Eligible patients had medically or surgically unresect-
able NSCLC, PS=0-1, weight loss <10% in the prior 3 months, no prior 
therapy, adequate laboratory & pulmonary functions. Included were 25 
patients with clinical stages I (4 patients), II (1 patient), IIIa (12 patients), 
& IIIb (8 patients) tumors. Treatment included weekly I.V. paclitaxel(50mg/
m2) and carboplatin(AUC=2) during radiotherapy. The radiotherapy 
included 2 Gy daily to an initial dose of 70 Gy. The total dose was increased 
in 4 Gy increments until the MTD was determined. Radiotherapy was deliv-
ered with 3-D treatment planning without elective nodal irradiation. Three 
patients received 70 Gy, 18 patients received 74 Gy, and 4 patients received 
78 Gy. All plans were reviewed for quality by a single reviewer (SES) prior 
to treatment. 
Results: Patients were followed until death or from 50 to 89 months(median 
63 mo) in those alive at last evaluation. The median survival of the entire 
cohort was 42 months (95% CI: 29-52 mo). The 5 stages I-II patients had 
a median survival of 53 months and the 20 stage III patients had a median 
survival of 40 months (95%CI: 13-52 mo). The 5-year survival rate was 
17%. 
Conclusions: While the addition of chemotherapy has significantly 
improved survival of these patients, the median survival is generally 
reported between 15 and 24 months. These long term results from N0028 
suggest that the therapy administered in this trial resulted in favorable sur-
vival (median survival=40 mo in stage III patients). However, RTOG 0617 
found that the same chemotherapy & either 60 Gy or 74 Gy resulted in 
similar more modest survival (median OS 21.7 & 20.7 mo, respectively). 
One difference in the design of these two trials was that in N0028, each plan 
was reviewed by a central reviewer and altered if necessary prior to treat-
ment to insure protocol compliance. This may have had a favorable influ-
ence on survival. It is quite possible that pre-treatment reviews of RT plans 
would be helpful in future trials by insuring protocol compliance which can 
improve outcome.
Author Disclosure Block: S.E. Schild: None. S. Hillman: None. D. 
Graham: None. S. Vora: None. Y. Garces: None. K. Olivier: None. J. 
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Two Cycles Induction with Docetaxel and Carboplatin 
followed by Concomitant weekly low dose Docetaxel with 
Thoracic Radiotherapy: A phase II Study for Treating Elderly 
Patients with Inoperable or Unresectable Stage III Non Small 
Cell Lung Cancer
S. Abdelwahab, A. Azmy, H. Abdelaziz, H. Abdullah, Ain Shams University, 
cairo, Egypt
Purpose/Objective(s): This study was conducted to determine the efficacy 
and toxicity of low dose weekly docetaxel and carboplatin given concomi-
tantly with radiotherapy after two cycles of induction chemotherapy using 
same regimen in elderly patients with locally advanced stages of (NSCLC) 
non-small cell lung cancer. 
Materials/Methods: Forty one patients with previously untreated, unresect-
able and stage IIIA or IIIB NSCLC with ECOG PS of ≤2, ≥65years old, and 
had adequate liver and kidney functions were enrolled into the study between 
May 2008 and october 2010. Two cycles of induction chemotherapy were 
given in the form of docetaxel (75 mg/m2) and carboplatin (area under the 
curve: 5); for patients who attained responses or stable disease after induction 
chemotherapy, weekly docetaxel (20mg/m2) and carboplatin (area under the 
curve: 2) were administered concomitantly with thoracic radiotherapy 60-66 
Gy over 6-6.5 weeks. Treatment response, toxicity, progression free survival 
and overall survival were evaluated. 
Results: The median age was 68 (range 65-76). Twenty eight patients (68%) 
were men. Twenty eight patients (698%) had Stage IIIB and 13 patients (32%) 
had stage IIIA. Performance status was measured by ECOG and it was 0 in 25 
patients (61%), 1-2 in 16 patients (39%). After induction chemotherapy only 
one patient (2%) had attained complete response (CR), 14 patients (34%) 
showed partial response (PR); and 24 patients (59%) showed stationary dis-
ease (SD). Nine patients (22%) from those with SD improved to a PR follow-
ing concomitant chemoradiotherapy. after a median follow-up of 32 months; 
the median survival time was 12 months and progression free survival time 
was 7 months. 1- and 2-year survival times were 65.1 and 23.3% respec-
tively; and 1-and 2-year PFS were 31.2 and 21.5%. Grade 3-4 esophagitis 
was a prominent toxicity for the concurrent RT-CT phase which occurred in 
9 patients (22%), while 4 patients (10 %) developed grade 3-4 pneumonitis. 
No treatment related deaths (neither due to sepsis nor bleeding) were reported 
in the study. 
Conclusion: Concomitant chemoradiotherapy using low dose weekly 
docetaxel and carboplatin following induction chemotherapy for treatment of 
elderly patients with locally advanced NSCLC is a safe and effective regimen 
and it needs enrolling more patients to confirm the current results.
Author Disclosure Block: S. abdelwahab: None. A. Azmy: None. H. 
Abdelaziz: None. H. Abdullah: None.
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Meta Analysis Of Toxicities In Phase I Or II Trials Studying 
The Use Of Target Therapy (TT) Combined To Radiotherapy 
In Patients With Locally Advanced Non-small Cell Lung 
Cancer (NSCLC)
M. Santos, D. Lefeuvre, G. Le Teuff, C. Bourgier, C. Le Pechoux, J. Soria, J. 
Pignon, E. Deutsch, Institut Gustave Roussy, Paris, Paris, France
Purpose/Objective(s): Concurrent chemo-radiation (CRT) is the current 
standard treatment for locally advanced NSCLC, but prognosis remains poor. 
An alternative approach could be the association of TT, although the poten-
tially high level of toxicities may be an important limitation. The objective 
of this study was to evaluate the drug related adverse events (AEs) rate in 
patients included in phase I or II trials on TT combined to curative CRT. 
Materials/Methods: Phase I, I/II and II trials published between 2000 
and 2011 on locally advanced NSCLC patients treated by TT with CRT 
(+/- induction chemotherapy[CT]) were eligible for this summary data 
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meta-analysis. Pooled incidence rates (InR) of all and specific AEs (grade 
≥ 3) were estimated, using a linear mixed model with fixed and random trial 
effects. Heterogeneity was explored through subset analyses according to trial 
design, type of TT, CT regimen. Results were compared to pooled results 
of CRT arms of the randomized trials included in the Auperin et al meta-
analysis. Pooled medians of progression-free (PFS) and overall survivals (OS) 
were also studied. 
Results: Eight trials (4 phase I, 4 phase II) including 242 patients, testing 
4 different drugs (Bevacizumab, Cetuximab, Erlotinib and Gefitinib), have 
been selected. The median follow-up varied from 11 to 32 months. The CRT 
group included six randomized trials (1697 patients). For CRT/TT trials, the 
estimated pooled InR of all grade 3+ AEs was 118.5 [95% CI: 67.1-477.4] per 
1000 person-months of follow-up, with a significant heterogeneity (p<0.001; 
I²=94%), not explained by the subset analyses. This pooled InR was statisti-
cally higher than that estimated in CRT group (27.0 [16.8-40.2] (p<0.001)). 
The pooled InRs of hematological, pulmonary and gastrointestinal AEs as 
well as treatment-related deaths were 43.6 [19.7-96.4], 9.7 [4.1-34.4], 24.0 
[10.6-54.5] and 3.5 [1.9-6.5], compared to 12.2 [4.7-31.6], 0.6 [0.2-2.6], 7.2 
[4.8-14.0] and 0.5 [0.2-1.4] in CRT group, respectively (all p-values <0.001). 
Heterogeneity was observed for the first three AEs (p<0.001, I²: 72 to 95%) 
and explained by a significant (p<0.001) variation of the AE rates according 
to the type of TT, e.g. pulmonary toxicity was higher with gefitinib than with 
other drugs. Median survival times were 10.0 [7.1-14.3] and 18.4 [12.9-26.3] 
months in on CRT/TT trials, and 9.9 [3.1-31.8] and 16.2 [14.9-17.7] months 
in CRT group, for PFS and OS respectively (p=0.98 and 0.37). 
Conclusion: Despite the important observed heterogeneity, the use of TT 
combined to CRT seemed to increase significantly the rate of severe adverse 
events in NSCLC patients, as compared to CRT alone, whereas no significant 
difference was observed in survival endpoints. Grants from French Cancer 
League
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The Role of EGFR and KRAS Mutations in Locally-Advanced 
Lung Adenocarcinoma Treated With Definitive Radiation 
Therapy
A. Rimner1, H. Wang1, M. Tsang1, A. D. Drilon1, P. K. Paik1, M. Hsu1, Z. 
Zhang1, K. Rosenzweig2, A. J. Wu1, M. Zakowski1, 1MSKCC, New York, NY, 
2Mount Sinai Medical Center, New York, NY
Purpose/Objective(s): To investigate the prognostic impact of sensitiz-
ing EGFR mutations in inoperable stage II-III lung adenocarcinoma (AC) 
patients treated with definitive radiation therapy (RT) with or without 
chemotherapy. 
Materials/Methods: From 11/1991 to 9/2011, 304 patients with inoper-
able stage II-III lung AC treated with definitive RT at our institution were 
identified. One hundred and nineteen tissue blocks and 24 cytology speci-
men were available for analysis; the remaining 161 patients had insuffi-
cient tissue. EGFR exon 19 deletions and exon21 L858R mutations were 
detected by immunohistochemistry using mutation-specific antibodies, PCR 
or Sequenom in 63, 64 and 16 patients, respectively. KRAS exon 2 muta-
tion status was determined through direct sequencing in 68 patients. Local 
failure-free (LFFS), progression-free (PFS), and overall survival (OS) were 
estimated with the Kaplan-Meier method. Univariate analysis (UVA) was 
performed using EGFR status, KRAS status, gender, race, smoking status, 
stage, histologic grade, concurrent versus sequential chemotherapy and RT 
dose (median: 6120cGy; range 4000 to 8400cGy) as variables. Multivariate 
analysis based on a Cox regression model of all factors with p≤0.2 on UVA 
was performed. 
Results: Ten out of 143 patients (7%) were found to have an EGFR muta-
tion, and 10 out of 68 patients (15%) had a KRAS mutation. No patients 
had well-differentiated histology, with 34 patients having moderately and 
80 patients having poorly differentiated AC; histologic grade was unknown 
for 29 patients. The median follow-up among survivors was 27.6 months, 
and the two-year rates of LFFS, PFS and OS were 45%, 21% and 49%, 
respectively. On univariate analysis, RT dose was the only significant factor 
associated with all three endpoints. Concurrent chemotherapy was signifi-
cantly associated with improved OS. On multivariate analysis, higher RT 
dose and concurrent chemotherapy were associated with improved LFFS 
and OS, while RT dose was the only factor associated with PFS. EGFR or 
KRAS mutations were not significantly associated with any of the measured 
outcomes. 
Conclusions: Neither EGFR nor KRAS mutations were significantly associ-
ated with LFFS, PFS or OS in stage II or III lung adenocarcinoma patients 
treated with definitive RT, suggesting that mutation status does not affect 
prognosis or radiosensitivity. However, the lack of an observed association 
could also be related to the low rate of EGFR mutations identified in this 
population with predominantly high-grade tumors and a low IHC positiv-
ity rate due to suboptimal tissue preservation. Radiation dose and the use of 
concurrent chemotherapy remain important prognostic factors regardless of 
mutation status.
Author Disclosure Block: A. Rimner: None. H. Wang: None. M. Tsang: 
None. A.D. Drilon: None. P.K. Paik: None. M. Hsu: None. Z. Zhang: None. 
K. Rosenzweig: None. A.J. Wu: None. M. Zakowski: None.
162 
Analyzing Locoregional Tumor Failure in Association with 
Pre-treatment FDG PET Parameters and Radiation Dose 
among Patients with Locally Advanced Non-Small Cell Lung 
Cancer (NSCLC)
R. S. Rajpara, E. Schreibmann, T. Fox, L. J. Stapleford, J. J. Beitler, 
W. J. Curran, K. A. Higgins, Department of Radiation Oncology and Winship 
Cancer Institute, Emory University, Atlanta, GA
Purpose/Objective(s): Locoregional tumor failure after definitive chemo-
radiation for stage IIIA and IIIB NSCLC remains high. We sought to fur-
ther define where locoregional (LR) failures occur relative to radiation dose 
received and pre-treatment maximum SUV (SUVmax). 
Materials/Methods: This was an IRB-approved retrospective study ana-
lyzing patients with stage IIIA and IIIB NSCLC treated with definitive 
chemoradiation between the years of 2006 and 2011 at Emory University 
Hospital. Clinical characteristics of patients were collected from chart 
review. Locoregional failure was defined as failure within the ipsilateral 
lung, hilum or mediastinum. Using Velocity® software, the CT simulation 
scan with radiation dose distribution was registered to either the CT or PET 
CT documenting LR failure. The region of LR failure was contoured, and a 
dose volume histogram was used to extract the dose to 95% of the volume 
of LR failure. The pre-treatment PET CT was also fused to the CT simula-
tion scan, and the pre-treatment SUVmax was extracted for the anatomic 
region of LF. 
Results: Sixty patients were identified. Median follow-up was 16.5 months. 
Eleven patients were treated with Intensity Modulated Radiotherapy (IMRT), 
6 patients were treated with 3D and IMRT techniques, and the remaining 
patients were treated with 3D conformal technique. Median total RT dose 
for all patients was 66 Gy. Concurrent chemotherapy was delivered to 90% 
of patients. Twenty-two patients developed a LR failure, with a total of 39 
anatomic regions of LR failure identified. Median time to LR failure was 11.4 
months. Failures were distributed as follows: 8 patients developed isolated 
in-field failures, 6 patients developed isolated out-of-field failures, 4 patients 
developed in-field and out-of-field failures, and 4 patients developed in-field 
and marginal (recurrences within the field edge) failures. In total, 73% of 
patients developed a LR failure with an in-field component. The median pre-
treatment SUVmax for the anatomic region of LR failure for patients with an 
in-field failure was 13. The median dose to 95% of the volume of in-field LR 
recurrence was 62 Gy. Isolated out-of-field LR failures accounted for 21% of 
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all anatomical LR failures; 5 occurred in untreated mediastinal lymph node 
stations while 3 LR failures occurred within the untreated lung parenchyma. 
Conclusions: LR failures after definitive chemoradiation are comprised pri-
marily of in-field failures, though out-of field failures are not insignificant. 
Marginal failures are rare, indicating field margins are appropriate. Although 
RT dose escalation to standard radiation fields has not yielded success, using 
pre-treatment PET SUVmax to define high-risk regions remains worthy of 
further investigation.
Author Disclosure Block: R.S. Rajpara: None. E. Schreibmann: None. T. 
Fox: None. L.J. Stapleford: None. J.J. Beitler: None. W.J. Curran: None. 
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Assessment of Local Control following PET/CT Guided 
Adaptive Radiotherapy for Locally Advanced Non-Small Cell 
Lung Cancer
T. Altoos, M. Surucu, A. Sethi, J. Erstad, J. Magliari, B. Emami, Loyola 
University Medical Center, Maywood, IL, IL
Purpose/Objective(s): To evaluate whether adequate long term local con-
trol can be achieved using a novel adaptive radiotherapy for lung cancer that 
monitors and takes advantage of tumor regression during the course of radia-
tion therapy using PET/CT imaging. 
Materials/Methods: Thirteen patients with locally advanced or inoperable 
non-small cell lung cancer were selected for this study. CT and PET were 
used to delineate the initial target volumes and organs at risk. It was not fea-
sible to deliver doses greater than 50 Gy to the PTV due to excessive toxicity 
either to the lung or adjacent organs at risk using 3DCRT for all patients. 
Therefore, after delivering 40 to 50 Gy, patients were re-scanned to evaluate 
their response to radiation (and concurrent chemotherapy). The tumor vol-
umes were re-contoured on the new CT/PET images as detailed in Emami et 
al1. A new treatment plan using the updated target volumes was developed for 
each patient. As a result, the initial volume received an average dose of 46.5 
Gy and the new PTV was given an additional average dose of 19.5Gy. The 
changes in GTV and PTV volumes were calculated. Long term local control 
was also evaluated by reviewing the follow-up CT scans. 
Results: There was significant reduction in treatment volumes when compar-
ing the initial and re-scan volumes: 69 % and 61% reduction for GTV and 
PTV, respectively. If the initial volumes were given an average dose of 65.9 
Gy, the mean lung dose would have been 16.4 Gy. But with re-planning, the 
mean lung dose was reduced to 14.4 Gy. The mean doses for other organs at 
risk (esophagus, heart and spinal cord) were also reduced. Moreover, one year 
after completion of radiation treatment, radiographic local control was 62% 
. Nine of the 13 patients developed distant metastases at an average of 6.7 
months after treatment and two patients remained disease free 5 years after 
completion of their radiation treatment. 
Conclusions: For patients with advanced lung cancer, it is often not possible to 
treat the pre-treatment target volume with doses considered to be curative due to 
intolerable doses to surrounding normal lung tissue and organs at risk. Adapting 
the treatment delivery, by taking advantage of reduction in tumor size during 
treatment, allows the delivery of prescription dose to the tumor while maintain-
ing OAR doses below tolerance. In this study, favorable local control outcomes 
were achieved with this image guided adaptive radiotherapy technique. Future 
goals are to assess the location of the local recurrence and evaluate whether the 
reduction in target volume may have compromised local control in some patients. 
1- Emami B., Dombrowski J., Hong R., Sethi A. Value of Interim CT-PET 
Imaging and Re-Planning in Improving Therapeutic Ratio Treatment of 
Advanced Non-Small Cell Lung Cancer: A Novel Adoptive IGRT. IJROBP 
69 (3) S482-S483 (2007)
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Late Esophageal Stricture Correlates With Decreased Overall 
Survival For Locally Advanced Non-small Cell Lung Cancer 
Treated With Radiotherapy: A Potential Confounder Of Dose 
Escalation?
A. Molotievschi, T. DeWees, L. Eschen, D. Mullen, J. Clohisy, J. Brandon, J. 
D. Bradley, C. G. Robinson, Washington University, Saint Louis, MO
Purpose/Objective(s): Dose escalation for Stage II/III NSCLC (LA-NSCLC) 
as a means to improve overall survival (OS) of patients treated with definitive 
radiotherapy has been met with mixed results. While the impact of increasing 
dose on early and late esophageal toxicity is well described, the correlation 
between these events and OS is less clear. We explored a modern database of 
patients treated at a single institution in an attempt to identify factors correlat-
ing with OS, with a particular focus on esophageal toxicity. 
Materials/Methods: A total of 315 patients with stage II (12.7%) and III 
(87.3%) NSCLC (LA-NSCLC) were treated at the Mallinckrodt Institute of 
Radiology from 3/01 to 12/09 with definitive radiotherapy (+/- chemother-
apy). Median radiation dose was 68 Gy (range, 46-76 Gy). 69.2% of patients 
received concurrent chemotherapy. Acute esophageal toxicity was defined 
according to CTCAE v3, while late esophageal toxicity was defined as stric-
ture (yes/no). Kaplan-Meier and Cox proportional hazards regression were 
used to estimate survival curves and hazard ratios for variable(s) associated 
with OS. Logistic regression and Fisher’s exact test were used to determine 
which variables were associated with esophageal stricture. 
Results: Improved OS was correlated with younger age, female sex, per-
formance status, non-smoker, adenocarcinoma, use of concurrent chemo-
therapy, smaller GTV, and lack of esophageal stricture on univariate analysis 
(p < 0.05). Female sex (HR=1.4, p=0.0105), adenocarcinoma (HR=1.32, 
p=0.0438), and lack of stricture (HR=1.49, p=0.0279) remained significant on 
multivariate analysis. Three-year OS was doubled (41% vs. 21%) in patients 
who did not develop stricture. Eighty-six percent of patients developed acute 
esophageal toxicity (26 g1, 201 g2, 38 g3, and 5 g4), while 15% developed 
stricture. Esophageal stricture was only seen at doses ≥ 60 Gy, and 65.9% of 
cases occurred at a dose > 66 Gy. Higher dose (p=0.0200), esophagitis during 
radiation (p=0.0474), and esophagitis immediately after radiation (p<0.0001) 
were associated with developing esophageal stricture. 
Conclusion: Esophageal stricture is a predictor of poor OS after definitive 
radiotherapy for LA-NSCLC, and increasing dose and acute esophagitis are 
associated with stricture. Attempts to escalate dose for LA-NSCLC may be 
in part confounded by this effect. This deserves further exploration in pro-
spective datasets, and may warrant stricter guidelines on esophageal dose in 
future trials.
Author Disclosure Block: A. Molotievschi: None. T. DeWees: None. L. 
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Bradley: None. C.G. Robinson: None.
165 
Neoadjuvant Treatment Followed by Surgery in Patients with 
N2 NSCLC: Is Complete response a better sign of long term 
survival?
H. Melek, M. Erol, A. Bayram, T. Evrensel, S. Saruhan, E. Akyildiz, C. 
Gebitekin, Uludag University, School of Medicine, BURSA, Turkey
Purpose/Objective(s): The prognosis in patients with NSCLC who had sur-
gery after neoadjuvant therapy and had complete pathological response are 
expected to have a better survival. In this study, we aimed to investigate the 
prognostic factors in the patients who had induction therapy and pathological 
complete response. 
Materials/Methods: 233 patients with NSCLC underwent neoadjuvant 
treatment and lung resections between 1996 and 2011 were prospectively 
recorded into database and retrospectively reviewed. The patients who had 
either a complete pathological response or T1-2 N0 tumors were included 
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into study. There were 30 complete responder (T0N0) and 54 patients with 
T1-2N0 tumors. The survival rates and prognostic factors were analyzed by 
using Kaplan-Meier method, log-rank test or Cox relative risk models. 
Results: All but three patients were male with a mean age of 58y (38-76). 
There were 57 squamous cell carcinoma, 21 adenocarcinoma and three large 
cell carcinoma. Three patients did not have subtype evaluation. Neoadjuvant 
treatment was chemotherapy in 43 patients and chemoradiation in 41 patients. 
The lung resections were lobectomy in 69 patients and pneumonectomy in 15 
patients. Extended resections were applied in 12 patients. The mean hospital 
stay was 6,5 days. The pathological stage was T0N0 in 30 patients, T1N0 in 22 
patients, T2N0 in 32 patients. The complete response rate after neoadjuvant 
therapy was 13%. The 5-year survival rate in patients with complete response 
was significantly better when compared to T1-2N0 tumors, 74% and 40%, 
respectively. Type of neoadjuvant treatment, surgical therapy, age, gender, 
tumor cell type did not effect on prognosis.
Conclusion: Our results revealed that complete pathological response to neo-
adjuvant treatment is a better prognostic sign and almost equal to the long 
term survival rates in patients undergoing surgery for T1N0 NSCLC without 
induction treatment.
Author Disclosure Block: H. Melek: None. M. Erol: None. A. Bayram: 
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Interfraction Displacement of Primary Tumors Relative to 
Involved Lymph Nodes and Anatomical Landmarks in Image-
Guided Radiotherapy of Locally Advanced Lung Cancer
E. Weiss, N. Jan, S. Balik, G. Hugo, VCU, Richmond, VA
Purpose/Objective(s): Image-guided radiotherapy for patients with 
locally advanced lung cancer usually relies on bony landmarks or -if vis-
ible- the primary tumor for patient alignment, neglecting variations in the 
relative position of primary tumor (PT) and involved lymph nodes (LN). 
This study analyzes PT and LN position changes relative to each other 
and relative to anatomical landmarks during conventionally fractionated 
radiotherapy. 
Materials/Methods: Carina (C), a thoracic vertebra (V), PT and LN were 
manually contoured on the 10 respiratory phases of weekly free breathing 4D 
fan beam CT scans in nine patients with locally advanced non small cell lung 
cancer (total 44 4D CT scans). The centroid position of T, LN, C and V were 
identified in lateral (x), anteroposterior (y) and superior-inferior (z) direction, 
and averaged over all phases. Variations in the relative average centroid posi-
tion between the contoured structures on subsequent scans were calculated 
relative to the initial planning scan for every patient and averaged over all 
patients. Volume changes were analyzed as well. 
Results: Systematic / random interfraction displacements for the three direc-
tions between PT and LN were 2.1 - 2.8 mm / 2.7 - 3.2 mm, between PT and 
V 2.3 - 4.2 / 2.7 - 3.1 mm, between LN and V 2.3 - 2.8 / 2.0 - 3.2 mm, between 
PT and C 2.6 - 3.1 mm / 2.1 - 3.6 mm, and between LN and C 1.4 - 3.4 / 1.4 
- 3.1 mm. The resulting margins were 9 - 11 mm for soft tissue PT-based set 
up to cover LN displacement, 9 - 14 mm for bony anatomy-based set up to 
cover PT, 8 - 11 mm for bony anatomy-based set up to cover LN, 9 - 11 mm 
for C-based set up to cover PT, and 6 - 12 mm for C-based set up to cover LN. 
The mean remaining volume at the end of therapy as a percentage of the initial 
volume was 69% ± 17% for PT and 60% ± 19% for LN. 
Conclusions: Lymph node displacement relative to the primary tumor is a 
relevant source of potential geometrical miss during soft tissue-based patient 
set up requiring considerable safety margins. Using carina instead of bony 
anatomy results in a more reproducible primary tumor and lymph node align-
ment. For lymph node alignment in particular, carina-based set up is prefer-
able over primary tumor-based set up.
Author Disclosure Block: E. Weiss: A. Employee; VCU. E. Research Grant; 
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Combined Photon SBRT and Proton Mediastinal Radiation 
for Stage III Lung Cancer: The Best of Both Worlds?
A. Caringi, B. Goldsmith, M. Kirk, S. Both, R. Rengan, C. Simone, J. 
Christodouleas, The Hospital of the University of Pennsylvania, Philadelphia, 
PA
Background: Stereotactic body radiation therapy (SBRT) has shown promis-
ing cancer control and toxicity outcomes for peripheral lung tumors, but is 
associated with increased toxicity for mediastinal targets. In contrast, proton 
therapy may be particularly advantageous when treating the mediastinum. A 
combined approach for patients with locally advanced non-small cell lung 
cancer (NSCLC) may improve outcomes. This study compared the virtual 
normal tissue dosimetry in these patients when planned with SBRT/ intensity 
modulated photon radiation (IMRT) versus SBRT/ pencil beam scanning pro-
ton therapy (PBS). 
Materials/Methods: An internal target volume including the ipsilateral medi-
astinum and hilum was contoured on the 4D simulation scans of 5 patients 
who had previously received SBRT for stage I NSCLC. IMRT and PBS plans 
were generated and prescribed to 66.6 Gy (radiobiologically equivalent doses) 
in 2.0 Gy fractions. PBS plans were developed using two beam angles, bolus 
and beam specific planning target volumes to maximize conformality. While 
the planning target volumes were larger for PBS plans to account for range 
uncertainty, standard coverage criteria were met for all plans. The IMRT and 
PBS plans were fused with a patient’s prior SBRT plan to create plan summa-
tions. Paired t-tests were used to compare standard endpoints for lung, heart, 
esophagus and spinal cord in the plan summations. 
Results: Compared to SBRT/IMRT, SBRT/PBS was associated with signifi-
cantly lower mean lung doses (mean: 19.6Gy vs 12.3 Gy, p < 0.01), lung 
volume receiving 5Gy (V5Gy) (mean: 55% vs 31%, p < 0.01) and lung 
V20Gy (mean: 31% vs 21%, p < 0.01). There was a trend toward lower heart 
V40Gy in favor of SBRT/PBS (mean: 16% vs 5%, p = 0.054). There were 
no significant differences between SBRT/IMRT and SBRT/PBS with respect 
to esophagus V55Gy (mean: 51% vs 52%) and maximum spinal cord dose 
(mean: 45Gy vs 26 Gy). 
Conclusions: SBRT/PBS with our approach resulted in significantly reduced 
doses to the lung compared to SBRT/IMRT. These findings support further 
evaluating a combined SBRT/PBS approach in locally advanced NSCLC and 
may inform clinical trial design.
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Survival Outcomes of Stereotactic Body Radiation Therapy in 
Locally Advanced NSCLC
Z. D. Horne1, S. D. Karam2, R. L. Hong3, D. Duhamel3, D. McRae3, G. 
Gagnon4, N. M. Nasr3, 1The George Washington University, Washington, 
DC, 2Georgetown University, Washington, DC, 3Virginia Hospital Center, 
Arlington, VA, 4Frederick Memorial Hospital, Frederick, MD
Purpose/Objective(s): This retrospective study aims to assess outcomes and 
toxicity patterns in locally advanced non-small cell lung cancer (NSCLC) 
patients treated with stereotactic body radiotherapy (SBRT). 
Materials/Methods: A total of 43 tumors in 37 patients with median age 
77.6 years (range 54-100 years) with locally advanced (Stages IIa-IV) and 
unresectable NSCLC received a median dose of 48Gy (range 25-60Gy) over 
5 fractions (range 2-5 fractions) via SBRT for a median biologically effective 
dose (BED10) of 100Gy (range 37.5-132Gy) between 2008 and 2011. Of 
these treatments, 46.5% were salvage therapy for recurrence after surgical 
resection, failed chemotherapy or radiotherapy. No patients had prior radia-
tion therapy to the same treatment area except for four patients (9.3%) who 
underwent a planned SBRT boost after initial treatment with intensity modu-
lated radiation therapy (IMRT) to a dose of 50.4Gy over 28 fractions. Overall 
S238 Copyright © 2012 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 7, Number 9, Supplement 4, September 2012
survival (OS), local control (LC), regional control (RC) and progression free 
survival (PFS) were estimated by Kaplan-Meier curves. Univariate analysis 
was conducted using Log rank test and Cox proportional hazards model. 
Results: In this patient cohort, the stage distribution was: IIa 9.5%, IIb 
11.9%, IIIa 45.2%, IIIb 7.1%, and IV 26.2%. The median tumor size was 
3.6cm and the median gross tumor volume (GTV) was 53,813mm3. With a 
median follow-up of 9 months, the median OS was 12 months with an actu-
arial 15-month OS rate of 36%. Actuarial 15-month LC and RC rates values 
were 73% and 57%, respectively. The median PFS was 12 months with a 
15-month PFS of 39.5%. On univariate analysis, GTV size was a positive 
predictor of LC rates (p=0.03) while nodal status was a negative predic-
tor of OS (p=0.024). A trend toward statistical significance for improved 
regional control was observed with the addition of chemotherapy (p=0.065). 
Treatment was generally well tolerated, with the following subacute toxicities 
reported following treatment: mild fatigue was reported in 21 patients (49%), 
11 patients (26%) reported slight dyspnea and chest pain, 9 (21%) reported 
cough, and 4 patients (9.3%) reported acute Grade 1 hemoptysis. No patients 
required hospitalization for management of SBRT-related side effects. There 
were no grade 3-5 toxicities. 
Conclusions: SBRT appears to be a safe and feasible treatment option for 
patients with locally advanced and metastatic NSCLC. At early follow-up, 
survival outcomes with SBRT appear similar to that of surgical resection. 
Further studies are warranted.
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Differential Uptake of F18-fluoro-deoxy-glucose (FDG) and 
F18-fluoro-deoxy-l-thymidine (FLT) Detected by Serial PET/
CT Imaging During Radical Chemoradiation for Non-small 
Cell Lung Cancer (NSCLC).
D. Ball, S. Everitt, R. Hicks, J. Callahan, N. Plumridge, M. Collins, A. 
Herschtal, D. Binns, T. Kron, M. Mac Manus, Peter MacCallum Cancer 
Centre, Melbourne, Australia
Purpose/Objective(s): This To compare changes in tumor metabolism 
detected by FDG with tumor proliferation detected by FLT using serial PET/
CT imaging in patients having radical chemoradiation for NSCLC. 
Materials/Methods: Patient eligibility criteria included pathologic diagnosis 
of NSCLC; stage I-III; performance status ECOG 0-1; planned for concomi-
tant radiotherapy (60 Gy in 30 fractions over 6 weeks) and chemotherapy 
either cisplatin/etoposide or carboplatin/paclitaxel. The scanning schedule 
included baseline pretreatment FDG and FLT PET/CT, with repeat scans at 
week 2 (12-16 Gy) and week 4 (36-40 Gy). Changes in uptake were measured 
semi-quantitatively using SUVmax, SUVmean and volume of PET avid dis-
ease. Metabolic and proliferative responses were measured visually and clas-
sified as complete, partial, stable or progressive. 
Results: 20 patients were enrolled between 3/09 and 4/10. Patient characteris-
tics: median age 65 (range 47-84); 55% male; histology squamous cell ca 40%, 
adenoca 30%, large cell/unclassified 30%; FDG based tumor stage I 15%, II 
20%, IIIA 40%, IIIB 25%. One patient was upstaged to stage IV following the 
detection of a cerebral metastasis by FLT. At baseline, the volume of PET avid 
disease at the primary site using paired comparisons was similar for both trac-
ers: median difference (FDG - FLT) was 2.3cc (range -8 to 57) (P-value = 
0.08). At week 2 the median difference (FDG - FLT) was 9.0cc (range 0.5 
to 76) (P-value < 0.001). At week 4 the median difference (FDG - FLT) was 
8.7cc (range -7 to 99) (P-value = 0.005). Visual assessment of response within 
the irradiated volume in 19 patients scanned at week 2 revealed partial meta-
bolic response in 52% and stable disease in 42% using FDG; in contrast partial 
response was seen in 76% and stable disease in 6% using FLT. Three patients 
had progressive disease detected by FDG during treatment: 1 infield and 2 out 
of field; 2 of which were detected by FLT as well. 
Conclusion: FLT PET/CT appears to detect treatment-related changes earlier 
than FDG. The implications of this observation for tumor control and survival 
require further investigation. Acknowledgment: This work was supported by 
a grant from the Victorian Cancer Agency.
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Preoperative Survivin, Ercc1 And Pten Expression In Stage 
III Non-small Cell Lung Cancer (nsclc) Patients(pts) Treated 
With Neoadjuvant And Definitive Chemoradiation And 
Association With Overall Survival (os).
M. Batus, M. Fidler, K. Kaiser Walters, M. Pool, B. Mahon, S. Basu, J. A. 
Borgia, D. Sher, P. D. Bonomi, Rush University Medical Center, Chicago, IL
Purpose/Objective(s): Thoracic radiation and concurrent chemotherapy 
consisting of platinum based doublets has produced modest improvement 
in long term survival for patient with locally advanced (LA) NSCLC. There 
is relatively little information regarding molecular profiles and outcome in 
LA-NSCLC patients (pts) treated with chemoradiation. The objective of this 
retrospective study is to evaluate potential relationships between expression 
of DNA repair enzyme ERCC1 and enzymes involved in cell survival - sur-
vivin and PTEN. 
Materials/Methods: Stage III NSCLC pts who were treated with chest radia-
tion (40-60Gy) and concurrently with platinum doublet and who had suffi-
cient pretreatment tissue were included in this study. Immunohistochemistry 
was used to detect nuclear and cytoplasmic expression (frequency 0-4 and 
intensity 0-4) of survivin, and PTEN, and for nuclear expression of ERCC1. 
Product of intensity and frequency was calculated for all markers and cor-
related with overall survival (OS). 
Results: 97 pts had adequate tumor samples for analysis. 53 women, median 
age 67. 48 pts with ERCC1 prod <=6 had longer OS than 41 pts with ERCC1 
prod >6 (19.6 vs 1.0 months, p=0.034). 16 pts with ERCC1 prod >6, PETN 
prod <=6 and survivin prod >4 had significantly lower OS than 68 pts with 
ERCC1<=6, PETN >6 and survivin <=4 (17.2 vs 40.2 months, p<0.001). 
Conclusions: The association of inferior survival in LA-NSCLC pts whose 
tumors express high survivin, low PTEN, and high ERCC1, suggests that 
combining inhibitors of survivin and or of PI3KCA with chemoradiation and 
developing strategies to inhibit DNA repair might improve outcomes in this 
group of pts.
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Utility of FDG PET-CT Scan in Determining Pathological 
Response to Neo-adjuvant Chemo-radiation Therapy in Non-
small Cell Lung Cancer (NSCLC)
E. L. Friedman, M. F. Szwerc, R. Kruklitis, M. J. Weiss, R. Rienzo, W. Young, 
Lehigh Valley Health Network, Allentown, PA
The optimal treatment of stage IIIA (N2+) NSCLC remains controversial. We 
previously reported an analysis of patients with stage IIIA NSCLC treated 
with concomitant neo-adjuvant chemotherapy and radiation therapy followed 
by definitive thoracic surgery. (WCLC: Amsterdam 2011 Abstract #661). 
Overall survival (OS) and progression free survival (PFS) was predicted by 
the pathological response of the primary tumor following neo-adjuvant bimo-
dality therapy. Patients with fewer than 10% cancer cells admixed with fibro-
sis had improved OS and PFS when compared to patients with measurable, 
viable tumor. In this study, we assess the ability of FDG PET-CT to predict 
viable cancer or fibrosis. 
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Thirteen patients with Stage IIIA and IIIB NSCLC were treated with bimodal-
ity chemo-radiation therapy followed by definitive resection. Chemotherapy 
involved weekly paclitaxel 50mg/m2 and carboplatin AUC 2. Radiation ther-
apy involved standard treatment with IMRT and respiratory gating - total dose 
5040 cGY. Each patient had a pre-treatment PET-CT and a post-treatment 
PET-CT performed within two weeks of completing neo-adjuvant therapy. 
The SUV
max
 post treatment was compared to SUV
max
 pre treatment. Ten 
patients had fibrosis at the time of resection. The mean SUV
max
 pre- treat-
ment was 14.9 (range 2.4 - 34.7). The mean SUV
max
 post-treatment was 6.9 
(range 1.2 - 14.9). Three patients had viable tumor at the time of resection. 
The SUV
max
 pre-treatment was 13.5 (range 12.3 - 15.8). The mean SUV
max
 
post- treatment (SUV
max
 post) was 5.2 (range 2.5 - 8.8). The SUV
max
 post / 
SUV
max
 pre was 47.8% in patients with fibrosis and 40.7% in patients with 
viable tumor (P = NS). 
This study demonstrates that there is a marked decrease in the SUV
max
 of 
NSCLC after neo-adjuvant radiation and chemotherapy. The decrease in post 
treatment SUV
max
 was evident despite the proximity of the PET-CT scan to the 
completion of radiation therapy. The % change in SUV
max
 after chemo-radia-
tion therapy was independent of pathological response of the primary tumor. 
We therefore conclude that the percent change of SUV
max
 does not predict 
pathological response of NSCLC to bimodality chemotherapy and radiation 
therapy in the neo-adjuvant setting.
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Patterns of Regional Failure in Stage III Non-small Cell Lung 
Cancer Managed with Neoadjuvant Chemoradiotherapy and 
Resection
S. Garg, B. T. Gielda, J. Turian, M. Liptay, W. H. Warren, P. Bonomi, D. J. 
Sher, Rush University Medical Center, Chicago, IL
Purpose/Objective(s): Treatment of locally advanced non-small cell lung 
cancer (LA-NSCLC) can involve definitive chemoradiotherapy (CRT) or 
neoadjuvant CRT and resection, but the standard radiation treatment vol-
ume remains in question. In the definitive setting, involved-field radiother-
apy (IFRT) has largely replaced elective nodal irradiation (ENI), reducing 
toxicity and allowing for dose escalation. However, prior reports of IFRT 
describe failures only after radical CRT, and given the improved local control 
after resection, IFRT may lead to an unacceptably high regional recurrence 
(RR) risk after surgery. Thus we examined pattern-of-failure in patients with 
LA-NSCLC treated at our institution with neoadjuvant split-course chemo-
therapy and IFRT followed by surgery. 
Materials/Methods: Patients treated between December 2004-2010 were 
included in this study. Imaging scans from the date of failure were fused 
into the patient’s radiotherapy planning CT scan, and recurrent nodes were 
contoured to determine the pattern-of-failure (involved nodal failure, INF; 
elective nodal failure, ENF). Overall survival (OS), progression-free survival 
(PFS), locoregional progression-free survival (LRPFS) and distant metasta-
sis-free survival (DMFS) were calculated using the method of Kaplan and 
Meier. The cumulative incidence of regional recurrence (CIRR) was deter-
mined with death as a competing risk. 
Results: Forty-five patients met inclusion criteria, and the only significant 
difference between patients who did and did not recur regionally was a lower 
rate of pN0 at resection (20% of pN0 developed RR vs 60% of pN+, Fisher 
p=.02), although over 50% of the patients with a regional recurrence were 
pN0. With a median follow-up of 2.9 years for surviving patients, the median 
survival was not reached, and 3-year OS, PFS, LRPFS, and DMFS were 68%, 
35%, 53%, and 35%, respectively. The 2- and 3-year CIRR were 25% and 
33%, respectively. There were no local failures. There were a total of 11 first 
failures in the regional nodal basins, 10 of which developed simultaneously 
with DM; the remaining RR was a marginal miss of an involved node. In 
total, 13 of 45 (29%) patients had some component of a RR. Of these 13 
patients, 8 (62%) had INF only and 5 patients had INF plus ENF or ENF 
alone, accounting for a total of 27 recurrences. 21 (78%) recurrences were 
INF, and 2 of these were marginal failures. There were only 2 (4%) ENF with-
out any INF, both concurrent with DM, and no ENF as the only site of failure. 
Conclusions: Our data suggest that IFRT does not compromise regional con-
trol in the neoadjuvant management of LA-NSCLC. Tailoring nodal volumes 
may improve treatment-related morbidity and allow for dose intensification of 
involved nodes. Further research is necessary to improve regional and distant 
control.
Author Disclosure Block: S. Garg: None. B.T. Gielda: None. J. Turian: 
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Is The Measurement Of Total Cell Death, Not Solely 
Apoptosis, Better Indicator Of Response To Taxane-based 
Chemotherapy In Lung Cancer Patients?
T. Evrensel1, E. Ulukaya2, B. Coskun1, S. Korkmaz2, O. Olmez1, E. 
Cubukcu1, A. Bayram3, C. Gebitekin3, M. Erol3, E. Kurt1, 1Department of 
Medical Oncology, Medical School of Uludag University, BURSA, Turkey, 
2Department of Clinical Biochemistry, Medical School of Uludag University, 
BURSA, Turkey, 3Department of Thoracic Surgery, Medical School of Uludag 
University, BURSA, Turkey
Because the cancer drugs induce cell death by apoptosis and/or necrosis, 
measurement of cell death in serum may provide an information of response 
to chemotherapy. In this study, 43 lung cancer patients were studied in terms 
of their M30 (marker of apoptosis) and M65 (marker of necrosis) levels 
prior to and 48 h after taxane-based chemotherapy. We found that the can-
cer patients had statistically higher baseline (before chemotherapy) levels 
of both M30 and M65, compared to healthy control group (p<0,001 and 
p<0,05, respectively). After the chemotherapy, the levels of both markers 
increased. The increase in M65 (higher than 1.5-fold) was higher than that 
in M30 (less than 1.5-fold). 40 patients’ data were available to classify them 
into responders and non-responders. In responders (n=28), the increase in 
M65 levels was 2-fold higher than that in M30 levels (%68 vs %34, respec-
tively). In non-responders (n=12), the increase in M65 levels was less than 
that in M30 levels (%54 vs %78, respectively). In conclusion, lung cancer 
patients have significantly elevetad levels of both M30 and M65 and mea-
surement of total cell death, not solely apoptosis, may provide better infor-
mation of response to taxane-based chemotherapy although it did not reach 
statistical significance. However, larger sample size is required to confirm 
this result.
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EPHB4 Plays an Oncogenic Role in Esophageal Cancers
R. Hasina1, I. Kawada1, K. S. Cohen1, I. Waxman1, M. Posner1, M. K. 
Ferguson1, V. M. Villaflor1, E. E. Vokes1, P. Gill2, R. Salgia1, et al., 1The 
University of Chicago, Chicago, IL, 2University of Southern California, Los 
Angeles, CA
Purpose/Objective(s): Despite improvements in diagnosis, and treatment, 
the survival at 5 years for all esophageal cancer patients ranges from 5-20% 
(Cancer Facts and Figures. Atlanta, GA; ACS 2012), underscoring the need 
for identification of new targets in its treatment. The EPHB4 receptor tyrosine 
kinase, classically associated with embryologic vascular patterning and neu-
ral development, has become increasingly associated with the pathobiology 
of adult cancers by affecting cell growth, motility, and migration as well as 
angiogenesis. Therefore, we sought to determine if EPHB4 is produced by 
esophageal cancer and plays a role in tumor growth and migration. 
S240 Copyright © 2012 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 7, Number 9, Supplement 4, September 2012
Materials/Methods: We began by assaying both tumor specimens and cell 
lines for EPHB4 production. In total, 94 squamous cell carcinoma (SCC), 
82 adenocarcinoma, 25 dysplasia, 13 Barrett’s esophagus and 25 adjacent or 
unrelated normal esophageal tissues were evaluated by IHC. 13 esophageal 
cancer cell line (9 SCC and 4 adenocarcinoma) were also evaluated. Other in 
vitro and in vivo studies are described below. 
Results: In all histologies, EPHB4 expression was statistically significantly 
higher in tumor samples compared to normal or adjacent normal tissues 
(p <0.01for all). In addition, all 13 cell lines had detectable protein; three of 
nine SCC cell lines and one of four adenocarcinomas expressed very high 
EPHB4. EPHB4 was also upregulated in a novel 4-NQO induced carcino-
genic murine model of esophageal cancer. The observation of EPHB4 over-
expression in human esophageal cancer led us to assay patient samples and 
cell lines for gene copy amplification. There was increased gene copy number 
identified in both SCC and adenocarcinoma patient samples with 60% cases 
having a gene copy number of 4 to 20 (n=22). Similarly, increased EPHB4 
copies were also present in 33% of SCC and 25% of adenocarcinoma cell 
lines. To demonstrate a functional role for EphB4 signaling in esophageal 
cancer growth, we performed in vitro and in vivo functional inhibition assays. 
An EPHB4 kinase inhibitor decreased viability of in vitro tumor cell lines 
in a dose-dependent manner in three of four lines tested. Cell migration was 
blocked by either knock down of EPHB4 or kinase inhibitor treatment that 
also led to decreased tyrosine phosphorylation of EPHB4 and the downstream 
target p125FAK. Finally, in a xenograft model, an EPHB4 inhibitor abrogated 
tumor growth by approximately 60% compared to untreated controls. 
Conclusion: Our data indicate that EphB4 plays a crucial role in the esopha-
geal cancer biology and should be further evaluated as a therapeutic target in 
this disease.
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Role of Paxillin in Mesothelioma: Expression, Mutation and 
Functional Analysis
V. Nallasura, I. Kawada, M. Tretiakova, H. Kindler, R. Salgia, R. Hasina, 
University of Chicago, Chicago, IL
Purpose/Objective(s): In an effort to understand the molecular abnor-
malities underlying the growth and metastasis of mesothelioma within the 
pleura and lymph nodes, we investigated factors involved in motility and 
migration of mesothelial cells. Paxillin is a focal adhesion phosphoprotein 
localized to the cytoskeleton that plays a role in signal transduction, regu-
lation of cell morphology, and the recruitment of structural and signaling 
molecules to focal adhesions. It has been shown that the modulation of 
tyrosine phosphorylation of paxillin regulates both the assembly and turn-
over of adhesion sites and phosphorylated paxillin enhances lamellipodial 
protrusions whereas non-phosphorylated paxillin is essential for fibrillar 
adhesion formation. FAK, a focal adhesion kinase, preferentially inter-
acts with paxillin and controls important biological events, including cell 
migration, proliferation, and survival. We hypothesized that paxillin and 
FAK play important roles in mesothelial cell migration and thus studied 
the genetic aberrations, expression, and functionality of these molecules 
in mesothelioma. 
Materials/Methods: We analyzed the expression of paxillin and FAK by 
IHC on 50 epithelioid, 16 sarcomatoid mesothelioma, and 1 mixed tumor tis-
sues and compared them to 40 normal adjacent lung parenchyma. Mutational 
analysis of paxillin was performed on tumor DNA. In vitro functional analysis 
was performed using live-cell confocal imaging. 
Results: We found an increase in paxillin and FAK expression in mesothe-
lioma compared to normal adjacent lung (p<0.01). Using automated cellular 
imaging system (ACIS) the immunostained slides were quantified and the 
analysis of the intensity showed that normal lung had IODs of 118, 13, 45 for 
paxillin, pFAK and FAK respectively, whereas epithelioid mesothelioma had 
IODs of 268, 14 and 273 and sarcomatoid had IODs of 331, 12 and 218. We 
also detected paxillin A127T mutation in mesothelioma patients. Live-cell 
imaging studies revealed that in comparison to wild-type, mutant A127T con-
fers a) increased lamellipodia and filopodia formation b) enhanced mobility 
c) increased focal adhesion formation and d) increased cell displacement in 
transiently transfected HEK-293 cells. 
Conclusion: Paxillin and FAK are highly upregulated in sarcomatoid and epi-
thelioid mesothelioma. Unique mutations were also found. Paxillin mutations 
lead to differential processing of lamellipodia and filopodia. We believe that 
paxillin is an important molecule in malignant mesothelioma and its thera-
peutic potential needs to be explored further.
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Metformin Use is Associated With Improved Response to 
Neoadjuvant Chemoradiation in Esophageal Adenocarcinoma.
H. D. Skinner1, M. McCurdy2, A. Echeverria1, S. Lin1, J. Welsh1, M. O’Reilly1, 
W. Hofstetter1, J. Ajani1, R. Komaki1, T. Guerrero1, 1The University of Texas 
MD Anderson Cancer Center, Houston, TX, 2Baylor College of Medicine, 
Houston, TX
Purpose/Objective(s): The vast majority of patients with esophageal car-
cinoma succumb to their disease, and there has been little improvement in 
outcomes in the past decade. The anti-diabetic agent metformin has been 
investigated both as a chemopreventative agent, as well as possible addition 
to current chemotherapeutics. However, little work has been done examining 
the role of metformin in radiosensitization. In the current study, the PET and 
pathologic response rate of esophageal cancer patients treated with neoad-
juvant chemoradiation (CRT) were examined in patients taking metformin 
during therapy. 
Materials/Methods: Two hundred eighty-five patients treated with con-
current chemoradiation (CRT) followed by esophagectomy for esophageal 
adenocarcinoma from 1997 - 2012 were included in the study, including 29 
diabetics taking metformin at the time of radiation, 21 diabetics not taking 
metformin and 235 non-diabetics. Pre- and post- treatment PET scans were 
available for 204 patients. Maximum SUV values of the tumor were recorded 
for both scans. Pathologic response was graded at the time of surgery. PET 
and pathologic CR rates were compared using both the χ2 statistic as well as 
ANOVA with post-hoc LSD analysis. Multivariate logistic regression analysis 
was performed to control for predictors of pathologic complete response (CR) 
after CRT. 
Results: The overall rate of pathologic CR for the study population was 20%. 
The pathologic CR rate was higher in patients taking metformin (34.5%), 
compared to diabetic patients not taking metformin (4.8%, p=0.01) and non-
diabetic patients (19.6%, p=0.05). Analysis of only patients taking metformin 
showed that daily doses ≥1500 mg trended toward improved pathologic CR 
rates (p=0.07). No significant difference was seen in pre-CRT tumor max-
imum SUV (p= 0.88), however post-CRT tumor maximum SUV was sig-
nificantly decreased in patients taking metformin (p=0.02). On multivariate 
logistic regression, metformin use was independently associated with patho-
logic CR (p=0.04). Metformin use was also associated with decreased in-field 
loco-regional failure following radiation (p=0.05). 
Conclusions: The use of metformin is associated with increased response to 
CRT in esophageal cancer in a dose-dependent manner and may be a sensi-
tizer to this therapy.
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Clinical Profile and Molecular Detection of ALK 2p23 Fusion 
Driven Lung Cancer at Cleveland Clinic
Y. Feng1, L. Yin1, J. Samsa1, C. Lanigan2, E. Borden1, A. Arrossi2, C. Farver2, 
N. Pennell1, R. Tubbs2, P. C. Ma1, 1TaussigCancer Institute, Cleveland Clinic 
Foundation, Cleveland, OH, 2Pathology and Laboratory Medicine Institute, 
Cleveland Clinic Foundation, Cleveland, OH
Purpose/Objective(s): The ALK 2p23 translocation, ALK(+), is an impor-
tant druggable target in 5-7% of non-small cell lung cancer (NSCLC). ALK-
fusions identified in NSCLC include EML4-ALK, KIF5B-ALK and TFG-ALK. 
However, the break-part FISH assay for the fusion oncogene detection is 
labor-intensive. Our objectives of the study is to better understand the clinical 
features of ALK(+) NSCLC and to develop alternative detection methods to 
enable cost-effective patient selection for molecular therapy. 
Materials/Methods: NSCLC patients (N=120) seen at the Cleveland Clinic 
(CC) who had clinical screening ALK 2p23 FISH (Abbott Molecular) per-
formed were included in this retrospective analysis. Biopsy specimens were 
also tested using immunohistochemistry (IHC) for ALK overexpression via 
clone D5F3 (Cell Signaling Tech.) with OptiView ultrasensitive detection 
(Ventana Medical Sys.). Circulating tumor cells (CTCs) detection and enrich-
ment was performed using the CellSearch®/Veridex platform. Quantitative 
PCR (QPCR) was performed using standard techniques. Clinical data were 
extracted from electronic medical records. Comparison was performed using 
Fisher’s exact test, Wilcoxon rank sum test or log-rank test. 
Results: Of the 120 tumors tested, 34 (28.3%) were ALK(+) by FISH, predomi-
nantly adenocarcinomas (33/34). 97% of the samples were also tested by ALK-
IHC, with a concordance rate of 99%. Comparing to ALK (-) group, ALK(+) 
patients were younger (median age 53 vs 65, p<0.01) and mostly never/light 
smokers (91% vs 43%, p<0.01). ALK(+) tumors tended to have more meta-
static sites at diagnosis, especially liver metastasis (26.5% vs 10.5%, p=0.04). 
Interestingly, venous thrombosis (DVT/PE) was also significantly more com-
mon in ALK(+) patients (35.3% vs 16.3%, p=0.03). 17 (50%) patients were 
treated with crizotinib. Two cases with positive ALK-IHC screening helped to 
identify FISH(+) tumor areas. Of those with known EGFR status (n=103), 6 
were EGFR mutation-positive, all being ALK(-). No significant OS difference 
was seen in ALK(+)/EGFR(-) patients (n=28) compared to ALK(-)/EGFR(-) 
patients (n=69). Preliminary data from CTC molecular detection by QPCR 
in Veridex CTC enrichment showed detectable fusion-ALK expression from a 
patient with known ALK(+) NSCLC prior to crizotinib therapy. 
Conclusions: ALK (+) NSCLC at CC was more commonly seen in younger 
patients and never/light smokers. They tended to have more metastases and 
significantly higher risk of venous thrombosis. ALK-ultrasensitive IHC using 
the D5F4 clone helped to identify FISH(+) tumor areas and may be consid-
ered a cost-effective screening test demonstrating high concordance with ALK 
FISH. Molecular detection of ALK(+) CTCs warrants further evaluation to 
facilitate targeted therapy and monitoring of therapeutic response/resistance.
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Characteristics, Treatment Patterns, and Costs of First-line 
Treatment Regimens for Advanced Nonsquamous Non-
small Cell Lung Cancer (nsq NSCLC) Treated by Medical 
Oncologists in Outpatient Settings
M. Shah1, K. B. Winfree2, P. Peterson2, S. K. Gruschkus1, M. T. Eaddy1, 
M. Green1, 1Xcenda, LLC, Palm Harbor, FL, 2Eli Lilly and Company, 
Indianapolis, IN
Purpose/Objective(s): Real-world studies on treatment patterns and costs of 
therapy in advanced nsq NSCLC patients are lacking. The objective of this 
study was to describe patient characteristics, treatments selected by outpatient 
medical oncologists, and costs of first-line treatment regimens in this patient 
population. 
Materials/Methods: Advanced nsq NSCLC patients initiating first-line ther-
apy from 2006 to 2010 were identified through electronic medical records of 
20 large US community oncology practices. Patient characteristics, Eastern 
Cooperative Oncology Group performance status (PS), resource utilization, 
and costs for first-line chemotherapy, supportive care, and medical services 
were described and evaluated. 
Results: 1,140 patients with a mean age of 65 years, 54% male, and 79% with 
a PS of 0/1 were identified. The majority of patients (82%) received combina-
tion treatments in the first-line setting, of which: 26% received a platinum/
taxane (PT), 24% received a pemetrexed combination therapy or monother-
apy, 19% received a platinum/taxane/bevacizumab (PTBev), 26% received 
other combination therapy, and 5% received other monotherapy. The most 
notable trend over time was a substantial increase in first-line pemetrexed 
utilization from 4% in 2006 to 40% in 2010. PTBev use was inconsistent over 
the 4-year time period; however, use was 34% in 2008 and 15% in 2010. PT 
use declined almost 50% over the 4-year study time period, from 42% in 2006 
to 22% in 2010. PTBev patients received approximately 5.4 cycles of treat-
ment vs 5.0 cycles for those on PT and 3.9 cycles for those on pemetrexed/
platinum (PemP). Treatment duration was longest and costs were highest for 
those on PTBev (105.7 days/$65,900) vs those on PT (63.4 days/$23,016) vs 
those on PemP (66.3 days/$35,461). 
Conclusions: This study demonstrates a substantial increase in pemetrexed 
use as a first-line treatment for nsq NSCLC patients. Duration of first-line 
therapy varied, with patients on PTBev experiencing the longest treatment 
duration and highest costs. Future studies should evaluate the impact of shifts 
in treatment and utilization in this population.
Author Disclosure Block: M. Shah: A. Employee; Xcenda, LLC. K.B. 
Winfree: A. Employee; Eli Lilly and Company. P. Peterson: A. Employee; 
Eli Lilly and Company. S.K. Gruschkus: A. Employee; Xcenda, LLC. M.T. 
Eaddy: A. Employee; Xcenda, LLC. M. Green: A. Employee; Xcenda, LLC.
180 
A Randomized, Open-Label, Phase 2 Trial of Paclitaxel/
Carboplatin with or without Bavituximab in Patients with 
Previously Untreated Locally Advanced or Metastatic Non-
Squamous Non-Small-Cell Lung Cancer
K. H. Dragnev1, S. V. Attili2, R. Gagua3, M. M. Jain4, I. Bondarenko5, J. Shan6, 
1Dartmouth-Hitchcock Medical Center, Lebanon, NH, 2BiBi General Hospital 
and Cancer Center, Hyderabad, India, 3National Cancer Centre, Tbilisi, 
Georgia, 4Ruby Hall Clinic, Pune, India, 5Dnipropetrovsk State Medical 
Academy, Dnipropetrovsk, Ukraine, 6Peregrine Pharmaceuticals, Inc., 
Tustin, CA
Purpose/Objective(s): Targeting a tumor’s vascular support is an impor-
tant cancer management strategy. Bavituximab (B), a monoclonal antibody 
directed against phosphatidylserine (PS), causes selective shutdown of pre-
existing tumor blood vessels. Studies demonstrate that PS becomes exposed 
on the surface of vascular endothelial cells in tumors but not in normal tis-
sues. This PS externalization results from the hypoxic stress conditions in 
the tumor microenvironment. PS is a highly immunosuppressive marker and 
by binding the exposed PS, B is able to reactivate both innate and adaptive 
immunity. Standard chemotherapy regimens including carboplatin/paclitaxel 
(CP) further increases PS exposure in tumors and the addition of bavitux-
imab potentiates antitumor activity. An earlier nonrandomized study of B+ 
CP showed encouraging results with improved tumor response, progression 
free and overall survival compared to literature controls of CP alone in front-
line non-small-cell lung cancer (NSCLC). We conducted a randomized phase 
2 study of CP with or without B. The primary endpoint was overall response 
rate (ORR), and secondary endpoints were PFS, DR, OS, and safety. 
Materials/Methods: Eighty-six patients with Stage IIIB or IV non-squamous 
NSCLC were randomized 1:1 to receive up to six 21-day cycles of C (AUC = 
6)/P (200 mg/m2) alone or in combination with weekly bavituximab (3 mg/
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kg) until progression or toxicity. RECIST 1.1 was used. Safety was evaluated 
by adverse events (AE), laboratory measurements (CBC, biochemistry, uri-
nalysis and coagulation), ECG and samples were collected for future immu-
nogenicity characterization. 
Results: The median age of patients randomized to the bavituximab-con-
taining arm (n=44) was 59.5 years and 56.5 in the chemo-only arm (n=42). 
ORR was 32% vs. 31% and median PFS is 5.8 months versus 4.6 months, 
respectively. Median OS has not yet been reached. The overall safety profile 
was similar between the two groups, despite more patients in the B+CP arm 
(84.1% vs. 76.2%) reporting AEs, regardless of attribution or severity. The 
most common grade 3/4 treatment-related AEs were anemia (6.8% vs. 7.1%), 
neutropenia (6.8% vs. 9.5%) and thrombocytopenia (6.8% vs. 2.4%) in B+CP 
vs. CP groups, respectively. Three treatment-related deaths were reported; 
sepsis in 2 patients (1 CP and 1 B+CP) and 1 acute respiratory distress syn-
drome (B+CP). 
Conclusions: These results suggest that bavituximab is well tolerated and 
may increase PFS when combined with conventional chemotherapy in front-
line NSCLC. OS data, when available, should inform the future development 
of bavituximab in this indication.
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Statins (asis) May Improve The Outcome Of Erlotinib As 
Second Line Treatment (tx) In Patients (pts) With Metastatic 
Non Small Cell Lung Cancer (mnsclc)
N. Maimon, D. Keizman, M. Gottfried, Oncology department, Lung Cancer 
Unit, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, 
Kfar Saba, Israel
Purpose/Objective(s): The EGFR inhibitor erlotinib is a standard second line 
tx for mNSCLC. Statins are used in the tx of hyperlipidemia. Pre-clinical and 
clinical studies in several cancer types have shown that they may inhibit tumor 
growth. Their effect on the outcome of erlotinib as second line tx in mNSCLC 
is poorly defined. We aimed to study the effect of statins on the outcome of 
erlotinib as second line tx for mNSCLC. 
Materials/Methods: We performed a retrospective study of an unselected 
cohort of pts with mNSCLC, who were treated continuously with 150mg of 
oral erlotinib. Pts were divided into 2 groups: (1) statins users and (2) statins 
naive. The effect of statins use on objective response, progression free sur-
vival (PFS) and overall survival (OS), was tested with adjustment of other 
known confounding risk factors using a chisquare test and partial likelihood 
test from cox model. 
Results: Between 2005-2011, 107 pts with mNSCLC were treated with 
second line erlotinib. There were 51 statins users (group 1) and 56 nonusers 
(group 2). All users started statins before erlotinib tx initiation. The groups 
were balanced regarding the following known clinical prognostic factors: 
female gender, ECOG performance status, active smoking, anemia, adeno-
carcinoma histology type, EGFR mutation (positive vs negative + unknown). 
Objective response in group 1 vs 2 was partial response (PR) 41% vs 29% 
(p=0.15), stable disease (SD) 41% vs 25% (p=0. 11), and progressive disease 
(PD) 18% vs 46% (OR=2.5, p=0.07). Median PFS was 12 vs 3 ms (HR 0.44 in 
statins users, p=0.02). Median OS was 35 vs 19 ms (HR 0.63, p=0.1). 
Conclusions: Statins may improve the outcome of pts with mNSCLC that are 
treated with erlotinib as second line tx. This should be investigated prospec-
tively, and if validated, applied in clinical practice and clinical trials.
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Safety and Efficacy of Pemetrexed in Lung Cancer Patients 
With Renal Insufficiency
K. Tipton Patel, M. B. Pace, M. J. Rivera, A. Siddiqui, E. S. Kim, University 
of Texas MD Anderson Cancer Center, Houston, TX
Purpose/Objective(s): Pemetrexed (PEM) is approved for treatment in 
patients (pts) with non-small cell lung cancer (NSCLC) and mesothelioma, 
however, it is contraindicated in those with renal insufficiency (RI) [creatinine 
clearance (CrCl) < 45 mL/min]. Pts with RI have received PEM in clinical 
practice often using empiric dose adjustments. No guidelines or data have 
been published to support dose adjustments or its use in this setting. This ret-
rospective study sought to describe PEM prescribing patterns, toxicities and 
efficacy observed in NSCLC and mesothelioma pts with RI.
Materials/Methods: This IRB approved protocol reviewed pts treated 
between May 2008 and November 2010 from the Thoracic Medical Oncology 
Clinic at MD Anderson Cancer Center. Pts were identified from a pharmacy 
database by cross-referencing dispensing of PEM and prescriber. Electronic 
medical records were evaluated through the duration of PEM treatment. Pts 
had a diagnosis of NSCLC or mesothelioma, were > 18 years old, had a CrCl 
of < 45 mL/min (Cockcroft-Gault) at initiation of PEM and received at least 
one dose of PEM.
Results: Of 700 pts treated with PEM, 22 pts were included for review. 
Patient characteristics were: median age 78 years (range 52-89), NSCLC 
(91%), mesothelioma (9%), stage IV (100%), female (73%), Caucasian 
(73%), former smokers (50%), ECOG PS of 1 (59%) and median CrCl of 40 
ml/min (range 29-44). Fifty-five percent of pts received doublet therapy and 
45% received PEM monotherapy. PEM as a doublet or alone was first line 
therapy for 64% of pts. The median dose was 400 mg/m2 (range 300-500) 
with 59% of pts receiving an empiric dose reduction at cycle 1. Pts received 
a median of 3.5 cycles (range 1-7): 50% had dose delays, 36% required dose 
reduction and 27% required hospital admission due to treatment related toxic-
ities. Cytopenias observed were neutropenia in 50% (grade 3/4: 5 pts), anemia 
in 82% (grade 3/4: 6 pts), and thrombocytopenia in 32% (grade 3/4: 2 pts). 
Grade 3/4 anemia and thrombocytopenia were observed exclusively in pts 
receiving doublet therapy. Observed toxicities (all grades) included fatigue 
(59%), nausea and vomiting (27%), edema (18%), diarrhea (9%), mucositis 
(9%) and rash (5%). Median time to progression was 2.4 months (range 0.6-7 
months). One year survival rate was 41% for all pts and 50% for those receiv-
ing PEM monotherapy.
Conclusion: In pts with RI, survival was similar to rates reported in phase III 
trials of PEM-containing doublets and monotherapy. However, incidence of 
toxicities was higher than previously reported in pts without RI and many pts 
required dose modifications despite empiric dose reductions. Close monitor-
ing of pts with RI receiving PEM is warranted and further study is needed to 
determine appropriate dosing for pts with RI. A comparison of this cohort to 
pts without RI is underway.
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nab®-Paclitaxel in Combination with Carboplatin as First-line 
Therapy in Patients (pts) with Advanced Non-small Cell Lung 
Cancer (NSCLC): Analysis of Pt Characteristics and Clinical 
Treatment Patterns by Region
M. Socinski1, I. Okamoto2, J. K. Hon3, V. Hirsh4, S. R. Dakhil5, R. D. Page6, 
J. Orsini7, H. Zhang8, M. F. Renschler8, 1University of Pittsburgh Medical 
Center, Pittsburgh, PA, 2Kinki University Faculty of Medicine, Osaka-Sayama, 
Japan, 3Clearview Cancer Institute, Huntsville, AL, 4McGill University, 
Montreal, QC, Canada, 5Cancer Center of Kansas, Wichita, KS, 6The Center 
for Cancer and Blood Disorders, Fort Worth, TX, 7Essex Oncology of New 
Jersey, Belleville, NJ, 8Celgene Corporation, Summit, NJ
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Background: In large, international trials of advanced NSCLC, pt baseline 
characteristics and clinical treatment preferences may differ by geographic 
region. In a phase III trial of nab®-paclitaxel (nab-P, 130 nm albumin-bound 
paclitaxel particles) + carboplatin (C) vs solvent-based paclitaxel (sb-P) + 
C, the primary endpoint of overall response rate (ORR) was significantly 
improved from 25% to 33%, P = 0.005, with a 1 month improvement in OS 
(P = NS) and improved safety in pts with advanced NSCLC. This analysis 
examined variations in pt characteristics, treatment patterns, and outcomes 
by geographic region. 
Materials/Methods: Pts with untreated stage IIIB/IV NSCLC were random-
ized 1:1 (stratified by region, age, histology, stage, and gender) to C AUC 6 
day 1 and either nab-P 100 mg/m2 on day 1, 8, 15 or sb-P 200 mg/m2 day 1 q 
21 days. Treatment of at least 6 cycles was encouraged, but could continue in 
the absence of progressive disease and unacceptable toxicity per the investiga-
tors’ discretion. ORR was determined by blinded centralized review. 
Results: A total of 1038 pts were included in this analysis: 724 (69%) from 
Russia/Ukraine (R/U), 165 (16%) from North America (NA), and 149 (14%) 
from Japan (J). Although treatment arms were well balanced by baseline char-
acteristics, minor differences in baseline pt demographics were noted between 
regions. In general, NA and J cohorts as compared with the R/U region cohort 
were older (median age 65 yrs NA; 65 yrs J; 58 yrs R/U), had primarily non-
squamous histology (56% NA; 77% J; 44% R/U), and a history of smoking 
(91% NA; 76% J; 68% R/U). A higher proportion of elderly pts (>70 years) 
were also noted in the NA (33%) and J (21%) vs R/U (9%) cohorts. ORRs 
trended in favor of nab-P/C vs sb-P/C in all regions (25% vs 22%, response rate 
[RR] ratio = 1.125, P = 0.675 NA; 35% vs 27%, RR ratio = 1.318, P =0.263; J 
34% vs 26%, RR ratio = 1.327, P =0.014 R/U). Multivariate analysis found no 
effect of region on response rates. In contrast, there was a significant interaction 
between region and OS. Median OS for nab-P/C vs sb-P/C, respectively, was 
12.7 mos vs 9.8 mos, P = 0.008 in NA, 11.0 mos vs 11.1 mos, P = 0.834 in R/U 
and 16.7 mos vs 17.2 mos, P = 0.814 in J. The median number of treatment 
cycles (5 NA; 4 J; 6 R/U) and the proportion of pts receiving ≤ 6 cycles of nab-
P/C (86% NA; 89% J; 60% R/U) varied between regions. The use of second-
line therapy was highest in J (85%), followed by NA (69%), and R/U (44%). 
Conclusions: Geographic variations in pt characteristics and treatment pat-
terns were noted in this large, phase III trial of nab-P/C vs sb-P/C. These 
variations may influence the design of future international phase III trials in 
NSCLC.
Author Disclosure Block: M. Socinski: E. Research Grant; Celgene 
Corporation, Lilly, Genentech. F. Honoraria; Lilly, Genentech. G. Consultant; 
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Prolonged Survival in Non-Small Cell Lung Cancer (NSCLC) 
Patients with Leptomeningeal Metastases (LM) in the Modern 
Treatment Era
J. W. Riess1, S. Nagpal1, M. Iv1, M. Zeineh1, M. A. Gubens2, J. W. Neal1, H. A. 
Wakelee1, 1Stanford University School of Medicine, Stanford, CA, 2University 
of California San Francisco, San Francisco, CA
Purpose/Objective(s): LM is a severe complication of NSCLC historically 
associated with poor prognosis. New chemotherapeutic agents and targeted 
treatments could potentially impact the natural history of LM. This retrospec-
tive case series analyzed LM outcomes in the modern treatment era. 
Materials/Methods: Patients with a pathologic diagnosis of NSCLC with 
LM treated at Stanford between 2003 and 2011 were identified via institu-
tional databases and medical records. LM was defined by positive CSF for 
malignant cells or LM enhancement by MRI with contrast. Retrospective, 
landmark analyses were performed to estimate survival using Kaplan-Meier. 
Statistical analyses performed using SAS Enterprise Guide v4.3. 
Results: LM was identified in 25 patients. All cases were adenocarcinoma, 
4 had known EGFR activating mutations, 7 had suspected EGFR mutations 
defined as a radiologic response to an EGFR-TKI, 2 had K-ras mutations and 
1 had an ALK translocation. Mean age was 58, 68% were women, 62% were 
non-smokers. 68% had stage IV disease at diagnosis, 28% initially presented 
with LM. 64% had CNS symptoms at the time of LM diagnosis, 76% had 
coexisting brain parenchymal disease, and 84% received WBRT as part of 
their treatment for LM. 84% received systemic treatment at or after develop-
ment of LM and 86% of these patients received therapy containing pemetrexed, 
bevacizumab and/or a tyrosine kinase inhibitor. 1 patient received intrathecal 
therapy. Mean OS after LM diagnosis was 9 months and mean OS from time of 
diagnosis of metastatic disease was 23.8 months. Patients who were diagnosed 
with LM at the time of metastatic presentation had a mean survival with LM of 
15.6 months compared with 5.8 months in patients who were diagnosed with 
LM after they initially presented with non-LM metastases (p<0.001, log-rank). 
OS was greater in patients who developed LM after other metastases, 24.9 
mo vs. 15.6 months (p=0.42, log rank), but the difference was not statistically 
significant. Among patients not initially diagnosed with LM, the mean time to 
LM from initial non-LM metastases was 19.2 months. 
Conclusion: In a retrospective, single institution analysis in the modern treat-
ment era, mean survival with LM in a US population enriched for activat-
ing mutations and treatment of LM including modern systemic therapy was 
higher compared with historical experience. Patients diagnosed with LM at 
the time of their NSCLC diagnosis had longer survival with LM. However, 
OS favored those who developed LM after other metastases, though the dif-
ference was not statistically significant. In patients who developed LM dis-
ease while on treatment, mean time to LM disease was prolonged. Our data 
provides evidence for improving survival outcomes in the modern treatment 
era for this difficult to treat complication.
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IMPACT Trial: MK-0646(MK), Insulin Growth Factor 1 
Receptor (IGF-1R) Antibody combined with Pemetrexed(P) 
and Cisplatin(C) in Stage IIIB or IV Metastatic Non-
Squamous Lung Cancer (NSQL).
C. H. Huang1,2, S. K. Williamson1, P. Neupane1, S. A. Taylor1, P. J. Van 
Veldhuizen1, J. Wick1, A. Allen2, A. M. Uypeckcuat2, N. Smart1, K. Kelly3, 
1Un of Kansas, Kansas City, KS, 2VA Medical Center, Kansas City, MO, 
3University of California Davis, Sacramento, CA
Background: IGF-1R regulates cell growth, proliferation and apoptosis. 
Adenocarcinoma and never smokers have higher expression of IGF-1R and it 
is associated with worse survival. MK is a humanized monoclonal antibody 
that targets IGF-1R. P has higher activity in NSQL. We initiated a randomized 
phase II trial to evaluate the combination of P and C +/- MK in NSQL. 
Materials/Methods:Eligibility criteria: untreated NSQL stage IIIB or IV, 
ECOG 0 or 1, measurable disease, adequate organ function and no other 
intercurrent illness. Standard B12 and folic acid were given. P at 500mg/m2 
and C at 75mg/m2 IV were given every 3 weeks. MK was given at the dose of 
10mg/kg IV weekly on days 1, 8 and 15 of every 3 week cycle in the experi-
mental group. The patients had radiographic assessment after every 2 cycles 
and treated for a maximum of 6 cycles if there was either response or stable 
disease. The primary objective of the study was to estimate the individual 
response rate of standard and experimental arm. IRB reviewed and approved 
the study at participating institutions. 
Results: From 1/2009 to 2/2011, the study accrued 26 patients, 16 male, 10 
female, median age 59 yo. 14 patients were treated with PC and 12 patients were 
treated with PC +MK. In the PC arm we observed 2 partial responses (PR), 7 
stable disease (SD), 3 had progression (PD) and 2 were not evaluable (NE). In 
the MK arm there were 3 PRs, 4 SD, 4 PD and 1 NE. In both arms, hemato-
logic adverse events(AE) observed were: grade 3 neutropenia(5), hemoglobin 
S244 Copyright © 2012 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 7, Number 9, Supplement 4, September 2012
(3), febrile neutropenia(2), platelet(2) leukopenia (1), lymphopenia (1); grade 
4 platelet(2), hemoglobin(1); Grade 3 non-hematological AE were: hyperglyce-
mia(4) and 1 occurrence each of hearing deficit, pain in extremity, hyponatremia, 
urinary tract infection, fatigue, dyspnea, laboratory, hypokalemia, esophageal 
stenosis, hypoxia, dysphagia and muscle weakness; Grade 4 hypoxia and hyper-
glycemia. The study was closed due to termination of funding. 
Conclusion: PC with MK had a similar response rate to PC. There was a 
higher rate of hyperglycemia in the MK group. Identification of a response 
predictive marker would be critical in order to continue the study of this agent.
Author Disclosure Block: C.H. Huang: J. Funding Other; Merck, Lilly. 
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The Impact Of Renal Function On Therapeutic Options For 
Advanced Non-small Cell Lung Cancer (NSCLC)
B. K. Cenik1, H. Sun1, D. W. Rasco2, D. E. Gerber1, 1University of Texas 
Southwestern Medical Center, Dallas, TX, 2South Texas Accelerated Research 
Therapeutics, San Antonio, TX
Purpose/Objective(s): Certain commonly used chemotherapeutic agents for 
advanced NSCLC require minimum threshold renal function for administra-
tion. To determine how such requirements affect treatment options, we evalu-
ated renal function patterns in a real-world cohort of patients. 
Materials/Methods: Retrospective analysis of consecutive patients treated 
for stage IV NSCLC from 2000 to 2007 at the UT Southwestern Medical 
Center. Clinical data obtained from tumor registries and medical records. 
Creatinine clearance (CrCl) was determined using the Cockcroft-Gault 
formula. Mixed model analysis was used to evaluate associations between 
patient clinical factors and longitudinal renal function. 
Results: 296 patients (3,930 Cr measurements) were included in the analysis. 
Mean age was 63 years, 43% were women, and 47% were white. Patients had 
a median of 5 (IQR 4-18) Cr measurements. The median overall CrCl was 92 
(IQR 68-124) mL/min; the median pre-treatment CrCl was 96 (IQR 74-123) 
mL/min; and the median nadir CrCl was 78 (IQR 56-100) mL/min, occurring 
a median of 35 (IQR 1-235) d after diagnosis. Renal function was signifi-
cantly associated with age (P<0.001), race (P=0.009), and gender (P=0.001). 
22% of patients had a recorded CrCl < 60 mL/min (a commonly used thresh-
old for cisplatin administration), with median onset of 89 d after diagnosis 
and median time to recover to ≥ 60 mL of 20 (IQR 3-85) d. The incidence and 
median duration of CrCl < 60 mL/min varied by age (<65 y: 15%, 17 d; ≥65 
y: 38%, 43 d), gender (male: 17%, 15 d; female: 26%, 36 d), and race (white: 
20%, 42 d; non-white: 22%, 21 d). 10% of patients had a recorded CrCl < 45 
mL/min (threshold for pemetrexed), with median onset 228 d after diagnosis 
and median time to recover to ≥ 45 mL/min of 33 (IQR 3-73) d. The incidence 
and median duration of CrCl < 45 mL/min also varied by age (<65 y: 8%, 6 
d; ≥65 y: 15%, 72 d), gender (male: 7%, 5 d; females: 15%, 68 d), and race 
(white: 8%, 68 d; non-white 13%, 8 d). 
Conclusions: In a real-world cohort of patients treated for stage IV NSCLC, 
renal function falls below commonly used thresholds for cisplatin and for 
pemetrexed in fewer than a quarter of patients. When such declines in renal 
function do occur, their duration may preclude administration of these drugs 
for prolonged periods.
Author Disclosure Block: B.K. Cenik: None. H. Sun: None. D.W. Rasco: 
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Outcome Predictors For Pemetrexed Therapy In Advanced 
Nsclc
N. Hashemi Sadraei1, C. Jones1, L. Du1, A. Tan1, P. Elson1, T. Mekhail2, N. 
Pennell1, 1Clevelan Clinic Foundation, Cleveland, OH, 2florida general 
hospital, Cleveland, FL
Purpose/Objective(s): Pemetrexed is the first drug in treatment of NSCLC 
to show different efficacy based on histology. It is also preferred over some 
other therapies due to better toxicity profile, thus increasingly being used in 
treatment of NSCLC. The goal of this study was to evaluate predictors of in 
pemetrexed-treated population. 
Materials/Methods: In a retrospective study, advanced NSCLC patients 
were selected based on treatment with pemetrexed. Variables included 
demographics, performance status, area of disease, pre- and post-peme-
trexed therapies, toxicity, tumor response, and survival data. Clinical ben-
efit was defined as partial response (PR), stable disease > 6 months (SD), 
prolonged pregression-free survival (PFS) and overall survival (OS) Chi-
square, Fisher’s exact tests, and logistic regression models were used for 
analysis. 
Results: 170 patients were evaluated. 59% male, 60% age ≤65, never 
smoker17%, ECOG 1 64% and 50% were stage IV at the time of initial 
cancer diagnosis. Pmetrexed was delivered in different lines of therapy 
(1-5), as single agent or in combination with other drugs, with majority 
given at 2nd line (58%) and single agent (86%). Pemetrexed was given 
for a median of 3 cycles ( 1-73). PR/SD, PFS and OS were comparable 
across lines of therapy (p=0.89, p=0.18, p=0.15) However, patients who 
received pemetrexed as first line were older (median age 74, p=0.04). 
Grade 3-4 hematologic and non-hematologic toxicity did not differ among 
lines of treatment (p=0.47, p=0.39). Chemotherapy regimen used imme-
diately as prior line of treatment did not impact PR/SD, PFS , or OS ( 
p=0.55,p=0.53,p=0.81). Age > 65 and number of metastic sites>2 other 
than lung were independent predictors of poor PR/SD. Those with no poor 
features had 56% response rate compared to 35% with 1 poor feature, and 
20% with both poor features (p=0.005) Liver metastasis, lymph node dis-
ease, ECOG>1, shorter interval between diagnosis and start of pemetrexed 
predicted poor PFS ( p=0.0005,p=0.05, p=0.0006,p=0.006) Those with no 
poor risk features had median PFS 18.8 m, compared to median PFS (2.1-
3.6) m with 1-4 features, and PFS 1.2 m if >4 poor features. ( p<0.0001). 
ECOG>1, never smoker, shorter interval to treatment predicted poor OS( 
p<0.0001, p=0.008,p=0.03) Those with 0-1 poor risk features had median 
OS 14.9 m , compared to median OS 8.4 m ( 2 poor features) , and median 
OS 4.7 m ( 3-4 poor features) ( p<0.0001) 
Conclusions: Older age and higher number of metastatic sites predict poor 
response to pemetrexed. Certain sites of metastasis predicted shorter PFS but 
did not independently predict OS. Better performance and longer interval 
from diagnosis of cancer to start of treatment with pemetexed predict better 
PFS and OS. Line of therapy where pemetrexed was given did not impact 
clinical benefit. An analysis of biomarkers is ongoing.
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Egfr Gene Mutation And Epithelial To Mensenchymal 
Transition (emt) Markers In Advanced Nsclc Patients Treated 
With Erlotinib
M. Fidler1, S. Basu1, T. Hensing2, M. Pool1, B. Mahon1, K. Walters1, J. A. 
Borgia1, D. Escarzaga1, M. Batus1, P. Bonomi1, 1Rush University Medical 
Center, Chicago, IL, 2Northshore University Heath System, Evanston, IL
Purpose/Objective(s): TTF-1 is a transcription factor involved in regulat-
ing epithelial to mesenchymal transition (EMT). Previous work in a clini-
cally enriched non-small cell lung cancer (NSCLC) population suggested 
low probability of the presence of an EGFR activating gene mutation in the 
absence of TTF-1 positivity (Somaiah ASCO 2011). The goal of this study 
was to validate the relationship of TTF-1 and other immunohistochemical 
(IHC) markers of EMT to the presence of an EGFR activating gene mutation 
in a diverse group of NSCLC patients treated with erlotinib. 
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Materials/Methods: Patients receiving erlotinib at two institutions were 
retrospectively analyzed by IHC for TTF-1 (Greater than 5% of tumor cells 
with moderate (2+) or strong (3+) nuclear staining considered positive) and 
for PTEN, Ecadherin,vimentin, beta catinin, and snail (frequency(0-4) times 
intensity(0-4)). Exon 19 and L858R EGFR gene mutations were detected 
using single-strand conformation polymorphism and sequence-specific poly-
merase chain reaction (PCR)). Fisher’s exact test and logistic regression were 
used to correlate TTF-1(positive or negative) and the remaining EMT markers 
with the presence of EGFR mutation. 
Results: 216 patients were analyzed for EGFR activating gene mutation: 
15% squamous, 80% smokers. EGFR mutation was found in 11.6% of cases. 
TTF-1 was present in 8% of squamous cell patients and 71% of adenocar-
cinoma patients. TTF-1 correlated with prolonged progression free survival 
(log rank p=.004). TTF-1 positivity was strongly correlated with the pres-
ence of mutation (p=.0006, negative predictive value=97.7%). Increasing 
Ecadherin and increasing PTEN expression by IHC correlated with the pres-
ence of EGFR gene mutation when measured on continuum (intensity times 
frequency) (p=.006 and p=.04, respectively). 
Conclusions: Though a retrospective analysis, our work confirms the nega-
tive predictive value of TTF-1 for an EGFR activating gene mutation in a 
NSCLC cohort more representative of a North American population. Though 
high PTEN and Ecadherin expression also correlated with the presence of 
EGFR mutation, TTF-1 positivity may be a more straight-forward marker that 
can select patients who should be screened for the EGFR gene mutation prior 
to initiation of first line therapy.
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Weekly nab®-Paclitaxel in Combination with Carboplatin as 
First-line Therapy in Pts (pts) with Advanced Non-small Cell 
Lung Cancer (NSCLC): Analysis of Safety and Efficacy in Pts 
with Renal Impairment
J. K. Hon1, I. Okamoto2, V. Hirsh3, S. R. Dakhil4, R. D. Page5, J. Orsini6, 
H. Zhang7, M. F. Renschler7, M. A. Socinski8, 1Clearview Cancer Institute, 
Huntsville, AL, 2Kinki University Faculty of Medicine, Osaka-Sayama, Japan, 
3McGill University, Montreal, QC, Canada, 4Cancer Center of Kansas, 
Wichita, KS, 5The Center for Cancer and Blood Disorders, Fort Worth, TX, 
6Essex Oncology of New Jersey, Belleville, NJ, 7Celgene Corporation, Summit, 
NJ, 8University of Pittsburgh Medical Center, Pittsburgh, PA
Background: Cancer patients with renal impairment pose a significant clini-
cal challenge. Chemotherapeutic agents can be nephrotoxic, further increas-
ing the risk of toxicity. Therefore, safe and effective treatment options are 
needed in pts with renal impairment. In a phase III trial nab-paclitaxel (nab-
P) + carboplatin (C) vs solvent-based paclitaxel (sb-P) + C significantly 
improved the primary endpoint of overall response rate (ORR) (33% vs 25%, 
P = 0.005), with a 1-month improvement in median overall survival (OS; P 
= NS), and an improved tolerability profile in pts with advanced NSCLC. 
Here we report on safety and efficacy in pts with impaired renal function 
(CrCl ≤ 50 ml/min). 
Materials/Methods: Pts with untreated stage IIIB/IV NSCLC were random-
ized 1:1 to C AUC 6 day 1 and either nab-P 100 mg/m2 on days 1, 8, 15 (n = 
521) or sb-P 200 mg/m2 day 1 (n = 531) q 21 days. Treatment was continued 
until disease progression. Renal function was assessed in a central lab using 
NCI CTCAE (v 3.0). 
Results: 53 pts had a CrCl of ≤ 50 ml/min at baseline (n = 26 nab-P/C and 
n = 27 sb-P/C); median age was 70 years in both treatment arms. Among 
the pts receiving nab-P/C, lower rates of grade 1 creatinine elevation were 
observed compared with those receiving sb-P/C (0% vs 7%, P = 0.161). Pts 
in the nab-P/C arm experienced fewer ≥ grade 3 adverse events than pts in 
the sb-P/C arm (62% vs 81%). No ≥ grade 3 sensory neuropathy occurred 
with nab-P/C compared with 19% of pts in the sb-P/C arm (P = 0.051). 
Rate of ≥ grade 3 neutropenia was lower for nab-P/C arm (44%) compared 
with the sb-P/C arm ( 77%, P = 0.023), but more pts in the nab-P/C arm 
experienced ≥ grade 3 anemia and thrombocytopenia (32% and 28%) than 
in the sb-P/C arm (15% and 4%), P = 0.193 and P = 0.022, respectively. 
Fewer pts experienced ≥ grade 3 fatigue with nab-P/C vs sb-P/C (8% vs 
22%, P = 0.250). The median paclitaxel dose intensity was 83.33 mg/m2/
week in the nab-P/C arm vs 60.43 mg/m2/week in the sb-P/C arm, and the 
median number of cycles was 4 and 5, respectively. A higher ORR was 
observed in the nab-P/C arm compared with the sb-P/C arm (31% vs 19%; 
response rate ratio = 1.662; P = 0.300). The median PFS was longer in 
the nab-P/C arm compared with the sb-P/C arm (6.0 mo vs 4.7 mo; HR = 
0.607; P = 0.238) as was the median OS (9.7 mo vs 9.3 mo; HR = 0.824; 
P = 0.576). 
Conclusions: nab-P/C was not associated with an increased risk of renal tox-
icity in pts with impaired renal function. nab-P/C treatment results in fewer 
overall grade 3/4 adverse events, and a trend towards higher ORR and longer 
median PFS and OS compared with sb-P/C in pts with advanced NSCLC and 
renal impairment.
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An Interim Report Of CALGB 150607: Expression And 
Mutational Status Of c-MET, HGF, EGFR, KRAS, p53, 
c-CBL, And E-cadherin In Resected Lung Adenocarcinoma 
Specimens.
R. Salgia1, V. Nallasura1, H. Pang2, C. E. Rolle1, W. Richards3, L. Hodgson2, Q. 
Arif1, A. Husain1, R. Kratzke4, E. E. Vokes1, 1University of Chicago, Chicago, 
IL, 2Duke University School of Medicine, Durham, NC, 3Brigham and 
Women’s Hospital, Boston, MA, 4University of Minnesota, Minneapolis, MN
Purpose/Objective(s): c-Met is a tyrosine kinase receptor for hepatocyte 
growth factor/scatter factor plays a critical role in cancer growth, invasion, 
and metastasis. The main objective of this study is to evaluate the correla-
tion between c-MET mutation and expression with stage and overall survival 
in a large group of adenocarcinoma (AC) patients. The secondary aims are 
to determine the correlation between overall survival and the analysis of: 1) 
EGFR mutation & expression, 2) TP53 mutation & expression, 3)epithelial-
to-mesenchymal transition, 4) KRAS mutation, and 5) CBL mutation, and to 
evaluate gene amplification of c-MET in AC patients and the sera levels of 
circulating c-Met and HGF. 
Materials/Methods: We evaluated 80 adenocarcinoma patients. Standard 
PCR and sequencing techniques for mutational analysis of MET, EGFR 
exons 18-21, TP53 exons 4-10, KRAS exon 2, and CBL exons 2-16. ELISA 
was used to quantify soluble c-Met and HGF in pre- and post-operative 
sera. c-MET, phosphorylated (pMET Y1003 and Y1230/34/35), p53, HGF, 
EGFR, and E-cadherin expression were evaluated by IHC. Staining inten-
sity was scored on four-point scale: 0, negative; 1+, weak; 2+, moderate; 3+, 
strong. The extent of staining was scored similarly: 0, negative; 1+, 1-10%; 
2+, 11-50%; 3+, > 50%. The product of the intensity and extent of staining 
yielded final scores between 0 and 9. 
Results: In 9 patients, six non-synonymous (NS) mutations were detected 
in MET (SEMA domain: E168D, M362T, N375S, and Q318K; JM domain: 
T992I and R970C). In EGFR, the NS mutation L858R was detected in 
two patients. We detected 11 NS mutations in TP53 (exon 4: E68*; exon 
5: V157F, R175H, I162F, H193Y, Y163D; exon 8: R273L, R273C, V274L, 
A276F, and G266*). Five NS mutations were detected in exon 2 of KRAS 
(G12C, G12V, G12D, G12S and G13V). For both c-MET and HGF, there are 
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65 pairs pre- and post-operative sera with no missing values. There was a 
significant (p=0.008) increase of soluble c-MET in post- (1750 ng/ml ± 60.2) 
compared to pre-operative (1584 ng/ml ± 59.2) serum samples. HGF levels 
were significantly increased (p=0.028) in post- (1006 pg/ml ± 70.6) com-
pared to pre-operative samples (847 pg/ml ± 56.0). The mean expressions 
as determined by IHC: c-MET 3.9 (±0.3); pY1230/34/35 MET 2.3 (±0.3); 
pY1003MET 4.8 (±0.3); HGF 4.4 (±0.3); EGFR 4.3 (±0.4); TP53 3.8 (±0.3); 
and E-cadherin 5.4 (±0.4) 
Conclusion: Unique MET mutations were detected in key functional 
domains; the SEMA domain and the JM domain. Post-operative patient sera 
levels were increased dramatically both in HGF and soluble MET. MET, 
pMET (Y1003), EGFR, E-Cadherin, HGF and P53 were highly expressed. 
The expression and mutation data will be correlated with clinical outcomes to 
identify the prognostic role of c-Met.
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The Role Of Chemotherapy After Erlotinib Treatment In 
Patients With Advanced Nsclc: Post-progression  
Survival Analysis.
M. P. Trojniak, A. C. Palozzo, M. Mazurek, A. Jirillo, Istituto Oncologico 
Veneto, IRCCS, Padova, Italy
Background: Erlotinib is a potent inhibitor of epidermal growth factor recep-
tor tyrosin-kinase activity and its efficacy has been demonstrated for the treat-
ment of advanced non small-cell lung cancer (NSCLC) in large randomized 
trials. 
Materials/Methods: A prospective observational study was run, using insti-
tutional data collected through web-based National Oncology registry, from 
December 2006 to May 2011. The patients with non-small cell lung can-
cer, unselected for EGFR mutation/amplification and after at least one line 
chemotherapy, were treated with erlotinib (150 mg/day orally) until disease 
progression. Every patient was checked prospectively for toxicity, clinical 
outcomes, previous line treatments, length of treatment and for treatments 
following erlotinb using hospital databases. 
Results: In overall study population (130 patients), the median Time to 
Progression (TTP) and Overall Survival (OS) were 2.4 and 4.4 months, 
respectively and 1-year survival rate was 25%. 4 patients achieved par-
tial response and 23 patients achieved stable disease, making the disease 
control rate 21%. Grade 1-2 rash and diarrhoea were the most frequent 
adverse events. The subgroups analysis showed significantly improved OS 
for patients with chemotherapy post-erlotinib (pemetrexed, docetaxel) com-
pared to those with no chemotherapy post-erlotinib, 12.7 months and 3.0 
months (p<0.0001), respectively. The main prognostic factors, such as age, 
sex, histology, ECOG performance status, smoking status, treatment line and 
the median time to relapse of previous line treatments were equally distrib-
uted between these two subgroups. The data of EGFR mutation and EGFR 
FISH positive status were available for 21% of the patients, however we did 
not find a significant association between EGRF expression and treatment 
response in both groups. 
Conclusions: This evaluation has revealed significantly better survival with 
chemotherapy post-erlotinib regardless of the EGFR expression, giving evi-
dence of other existing mechanisms. The post-marketing studies in real life 
practice are needed in order to verify both effectiveness and safety in general 
population, testing for external validity of the randomized trials. Moreover, 
the post-progression survival assessment may be crucial to determine real 
clinical impact of investigational drug in combination with other treatments 
as it usually lacks in the approval RCTs.
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Epigenetic Analysis of E-cadherin and Epithelial to 
Mesenchymal Transition in Primary And Metastatic Lung 
Cancer Cells
L. Buckingham, W. Barbanera, D. Escarzaga, M. Fidler, P. Bonomi, Rush 
University Medical Center, Chicago, IL
Purpose/Objective(s): Epithelial-mesenchymal transition (EMT) and the 
reverse process (MET) are factors in primary tumor cell metastasis and 
formation of metastatic tumor, respectively. The CDH1 gene product, ecad-
herin is a cell adhesion molecule important in epithelial cell phenotype. The 
purpose of this study is to compare the expression and epigenetic control of 
CDH1 promoter gene methylation in primary and metastatic (lymph node) 
sites. 
Materials/Methods: DNA was extracted from microdissected primary 
tumor and lymph nodes from patients treated for non-small cell lung can-
cer. Bisulfite converted DNA was sequenced by pyrosequencing to quantify 
methylation of cytosines in CpG sites along the CDH1 promoter (122-160 
basepairs from the translation start site). Protein expression was assessed by 
immunohistochemistry. Methylation levels were compared by independent T 
test and paired sample statistics using SPSS. 
Results: Of the original 115 tissue samples, 61 primary tumors only, 3 lymph 
nodes and primary tumors and lymph nodes were available from 51 cases. 
Percent CDH1 promoter methylation was higher in node positive than in node 
negative primary tumors (28.2 vs 18.7; p=0.000) as well as in primary tumors 
compared to lymph nodes from the same patient (23.5 vs 18.5; p=0.030). 
Methylation levels were higher in tumors with acinar compared with papillary 
growth patterns (22.5 vs 15.2, p=0.031). Ecadherin protein stained positive in 
72% of node negative tumors compared to 50% of node positive tumors and 
60% of lymph nodes in this patient group. 
Conclusions: CDH1 promoter hypermethylation (and lower ecadherin 
expression) in node positive primary tumors. Decreased CDH1 promoter 
methylation (and higher ecadherin expression) in lymph nodes is consistent 
with MET at these sites. Higher expression of ecadherin in node negative 
tumors than in node positive tumors is consistent with the role of this mol-
ecule in EMT and metastasis.
Author Disclosure Block: L. Buckingham: None. W. Barbanera: None. D. 
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The impact of Palliative Radiotherapy to the Primary Tumor 
on Overall Survival in Patients with Non-Small Cell Lung 
Cancer and Oligometastasis at Diagnosis
Y. Xu, Q. Lin, Y. Zheng, X. Sun, X. Sun, W. Mao, Zhejiang Cancer Hospital, 
Hangzhou, Zhejiang, China
Purpose/Objective(s): The prognosis of patients with non-small cell lung 
cancer (NSCLC) and distant metastasis is poor. The aim of this study was to 
investigate whether palliative radiotherapy to the primary tumor is a signifi-
cant factor for overall survival for patients with NSCLC and oligometastasis 
at diagnosis, stratified by histology and treatment methods. 
Materials/Methods: This is an IRB approved retrospective study. Patients 
with NSCLC and distant metastasis treated with radiotherapy to primary 
tumor from January 2004 to December 2010 were eligible. Independent vari-
ables included general patient characteristics, tumor factors, and treatment. 
Overall survival was calculated from initial treatment start, estimated using 
the Kaplan-Meier method. Prognostic factors were analyzed by the log-rank 
test and Cox regression model. 
Results: A total of 62 patients were included in this study. The median sur-
vival of the entire group of patients was 9.5 (95% CI: CI: 2.4-16.7) months, 
and the 1, 3-year overall survival rates were 47.6% and 8.2%, respectively. 
Gender and chemotherapy were both significantly correlated with overall sur-
vival under multivariate analysis. Female and combination radiochemotherapy 
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were associated with better survival. Although patients underwent higher dose 
radiotherapy (> 60 Gy) had better Karnofsky performance status (KPS) score 
(p=0.022), higher dose radiotherapy was not a significant factor for overall sur-
vival for neither oligometastasis (the number of metastasis <4) (p=0.403), nor 
non-oligometastasis (the number of metastasis >4) (p=0.776). In squamous 
cell carcinoma group, however, higher dose radiotherapy was marginally sig-
nificant associated with better survival for oligometastatic NSCLC (p=0.069). 
Conclusions: Chemotherapy was significantly associated with better survival 
in the entire group of patients. Although palliative radiotherapy to primary 
tumor is not a significant factor for overall survival, squamous cell carcinoma 
patients with oligometastasis at diagnosis benefit from higher dose radio-
therapy. Our results suggest that the selected NSCLC patients with distant 
metastasis may benefit from aggressive local therapy.
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Comparison Of Bevacizumab Versus Pemetrexed In 
Combination With Platinum-based Doublets In First-line 
Treatment Of Advanced Non-small-cell Lung Cancer
A. A. R. Pereira1, R. C. Lessa1, S. J. Martins2, F. A. I. Pinto1, M. R. S. Cruz1, J. 
R. Pereira3, D. M. Gagliato1, N. A. F. Rodrigues1, E. S. Santos1, V. C. C. Lima1, 
1Hospital A. C. Camargo, Sao Paulo, Brazil, 2University of Brasilia, Brasilia, 
Brazil, 3Brazilian Institute of Thoracic Oncology, Sao Paulo, Brazil
Purpose/Objective(s): First-line treatment of advanced nonsquamous non-
small cell lung cancer (NSCLC) with platinum-based doublets, including 
pemetrexed (Ptx) or bevacizumab (Bv), has achieved more than 12 months 
of survival. At the moment, there are no head-to-head comparisons of these 
combinations in phase III studies. 
Materials/Methods: We retrospectively analyzed, from May 2007 to February 
2011, in a single institution, all patients with stage IIIB or IV nonsquamous 
NSCLC treated with Bv or Ptx in combination with platinum compounds in 
first-line treatment to determine differences in overall survival (OS), progres-
sion free survival (PFS), objective response rate (ORR) and toxicity profile. 
We performed multivariate analysis to identify prognostic factors for survival. 
Results: Of the 82 patients included, 40 patients (48,8%) received carboplatin 
plus paclitaxel or cisplatin plus gemcitabine combined with Bv (BEV group), 
while 42 patients (51,2%) were treated with cisplatin or carboplatin combined 
with Ptx (PEM group). BEV had significantly fewer patients with more than 
70 years (p=0,01) and CNS metastases (p=0,001) than PEM. Maintenance 
therapy was administered in 65,0% and 52,4% of patients in BEV and PEM 
groups, respectively (p=0,17). Significantly more patients in BEV received 
second-line treatment (72,5% vs. 52,4%; p=0,04) than in PEM, prevailing Ptx 
as the drug of choice (79,3%). ORR (60,0% vs. 35,7%; p=0,04) and median 
survival (26,4 vs. 16,4 months; p=0,009) were significantly superior for BEV. 
Median PFS was not different between BEV and PEM (10,5 vs. 7,7 months; 
p=0,06). In multivariate analysis, ECOG 2 (p=0,005), bone metastates 
(p=0,01) and adrenal metastases (p=0,005) were independent prognostic fac-
tors for worst survival, while treatment with BEV did not reach statistical 
significance (p=0,07). Grade 3-4 neutropenia (27,5% vs. 9,5%; p=0,03) and 
neuropathy (17,5% vs. 0%;p=0,005) were more frequent in BEV. 
Conclusions: First-line treatment of advanced nonsquamous NSCLC with 
platinum-based doublets combined with Bv showed better ORR and higher 
rate of toxic effects compared to platinum-based doublets including Ptx. 
ECOG 2, bone and adrenal metastases were independent prognostic factors 
for worse survival. Although there was an improvement in survival for bevaci-
zumab combination, this was not an independent prognostic fator.
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Final Report of an Open-Label Phase II Trial of Bevacizumab 
Plus Docetaxel and Gemcitabine in Metastatic, Previously 
Untreated Non-squamous Non-small Cell Lung Cancer 
(NSCLC)
N. A. Pennell1, S. R. Kalmadi2, M. Shapiro1, H. Daw1, C. Rodriguez1, A. 
Haddad1, J. Samsa1, P. Elson1, P. Ma1, A. Dowlati3, 1Cleveland Clinic Taussig 
Cancer Institute, Cleveland, OH, 2Ironwood Cancer and Research Center, 
Phoenix, AZ, 3University Hospitals Seidman Cancer Center, Cleveland, OH
Purpose/Objective(s): Platinum and non-platinum doublet chemotherapy 
has similar efficacy in advanced NSCLC patients (pts). Bevacizumab (B) 
improves outcomes when added to platinum doublets, but its safety and effi-
cacy in combination with non-platinum doublets is unknown. This study was 
designed to test the combination of B, docetaxel (D), and gemcitabine (G) in 
first-line treatment of advanced NSCLC. 
Materials/Methods: Pts with metastatic, non-squamous NSCLC, PS 0-1, 
and measurable disease by RECIST were enrolled in this open-label, single 
arm phase II trial. Pts received D (75 mg/m2) on d1, G (900 mg/m2) on d1 
& 8, and B (15 mg/kg) on d1 every 21d for up to 6 cycles, followed by B 
maintenance until progression or 12 mos total. Pts received growth factor 
d9. CT scans were performed every 6 wks. The primary endpoint was 1-yr 
progression-free survival (PFS), with secondary endpoints of safety, objec-
tive response rate (ORR), overall PFS, and overall survival (OS). Pts with 
tumor cavitation, untreated brain metastases, and hemoptysis were excluded. 
Planned enrollment was 46. 
Results: 13 pts were enrolled from 12/2009 to 4/2011. Pt characteristics: 
Median age 63 (35-69), 85% male, PS 0 (38%), PS 1 (62%). The median # 
of cycles of chemotherapy was 6 (1-6), median # cycles of B was 4 (1-15), 
with 2 pts coming off study prior to the first evaluation (1 grade 5 encepha-
lopathy, 1 grade 4 febrile neutropenia). 5 pts (38%) had chemo dose reduction 
and 4 (31%) discontinued treatment for toxicity. 3 pts (23%) discontinued B 
prior to progression, 2 for tumor cavitation and 1 for grade 1 hemoptysis. The 
grade 3-5 non-hematologic toxicity rate was 69%, with 6 pts (46%) hospital-
ized with pneumonitis/pneumonia felt possibly related to study drugs. At this 
point enrollment was halted for safety concerns. The 1-yr PFS was 8%, and 
the median PFS was 6.9 mos (95% CI 2.0-NYR). 11 pts were evaluable for 
response, and 6 pts had partial responses for an ORR of 55%. The median OS 
was NYR with median follow up of 10.9 mos. 
Conclusions: The combination of B, D, and G was not tolerable at the doses 
and schedule used in this study. A formal phase I trial is needed if this combi-
nation is to be investigated further.
Author Disclosure Block: N.A. Pennell: G. Consultant; Oncogenex, Teva. 
S.R. Kalmadi: F. Honoraria; Genentech. M. Shapiro: None. H. Daw: None. 
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Stereotactic Body Radiotherapy for Primary or Metastatic 
Lung Tumors: Analysis of Long-term Single Center 
Experience
D. Lee1, Y. Kim2, Y. Kang2, J. Kang2, Y. Wang2, S. Kim2, Y. Kim2, I. Yoo2, 
D. Han2, 1Department of Radiation Oncology, Severance Hospital, Yonsei 
Cancer Center, Yonsei University Health System, Seoul, Korea, Republic of, 
2Seoul St. Mary’s Hospital, College of Medicine, the Catholic University of 
Korea, Seoul, Korea, Republic of
Purpose/Objective(s): Stereotactic body radiotherapy (SBRT) is widely used 
as a safe and effective treatment option for pulmonary tumors in patients with 
multiple comorbid diseases. In this retrospective study, we report our long-
term clinical experience with SBRT for primary or metastatic lung tumors. 
Materials/Methods: A total of 92 SBRT cases between April 2004 and 
December 2011 were reviewed for the present study. Forty-four were primary 
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lung cancer cases from candidates with medically inoperable or refusal of 
operation and 23 cases were previously treated locally recurrent tumors. 
Another 25 cases were metastatic lung tumors from other primary origins (11 
colorectal carcinoma, 2 hepatoma, 2 breast cancer and the others). Median 
five fractions with 24-60 Gy of total doses were prescribed to the planning 
target volume (PTV). In the early period, 36-40 Gy/3-4 fractions were deliv-
ered in 16 patients, and then we escalated prescription dose to 45-60 Gy/3-5 
fractions. For 25 centrally located tumors, 50-56 Gy/5-8 fractions were usu-
ally delivered. Respiratory gating or four-dimensional computed tomography 
(CT) scans were used for determining accurate target volumes in almost all 
patients except for the poorly cooperative elderly patients. PTV was defined 
as around 0.5 cm margin plus gross tumor volume (GTV) or internal target 
volume (ITV). 
Results: Median age of the entire cohorts was 70 (range, 34-90) years. Tumor 
volume ranged from 0.5 to 136 (mean, 18.6) cc with median tumor diam-
eter of 2.2 cm. After median follow-up of 41 (range, 2-85) months, 91.3% 
(84/92) of cases showed clinical responses (CR-SD). Overall 3-year survival 
rate (3YSR) for medically inoperable or locally recurrent tumors was 52.2% 
with median survival of 42.1 months, and 20% of 3YSR with 21.5 months of 
median survival in metastatic lung tumors. Three-year local control rate was 
64.5 %. Major patterns of failure in medically inoperable or locally recurrent 
tumors were regional (12.1%) and distant (29.3%). Initial SUVmax value in 
FDG-positron emission tomography (PET) was significantly correlated with 
overall survival and disease free survival in non-metastatic patients. Although 
SBRT induced patchy or diffuse consolidation, fibro-atelectatic change, or 
focal of diffuse ground glass opacities (GGOs) were observed in almost all 
patients, symptomatic radiation pneumonitis was minimal with 11 cases of 
grade 2. Four cases of fibro-stenotic change of bronchus and 6 cases of sus-
tained chest wall pain developed. One patient died from massive hemoptysis 
13 months after SBRT. 
Conclusions: SBRT is an effective and safe local treatment modality in pul-
monary tumors even in patients with previous irradiation and multiple comor-
bidities. Optimal dose fractionation schedule and active use of FDG-PET is 
warranted for better outcomes.
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Kras Mutations And Outcomes For Patients With Stage IV 
NSCLC Treated With Frontline Platinum/Pemetrexed Based 
Chemotherapy
B. Levy1, N. Seetharamu, MD2, S. Richardson1, D. Becker3, A. Chachoua2, 
1Beth Israel Hospital, Continuum Cancer Centers of New York, New York, NY, 
2New York University Langone Medical Center, New York, NY, 3St. Luke’s-
Roosevelt and Beth Israel Medical Center, Continuum Cancer Centers of New 
York, New York, NY
Purpose/Objective(s): KRAS mutations are the most common driver muta-
tion indentified in NSCLC, occurring in 20 - 30% of adenocarcinomas. While 
several studies suggest KRAS predicts for lack of response to TKI therapy, 
few data exist regarding its association with outcomes for patients treated 
with cytotoxic chemotherapy. Currently, only thymidilate synthase (TS) lev-
els are thought to predict response to pemetrexed. This study explores the 
association between KRAS mutations and outcomes (RR, PFS) in a cohort 
of patients treated with frontline platinum/pemetrexed (PPm) based therapy. 
Materials/Methods: In this retrospective chart review, we evaluated RR 
and PFS for 16 KRAS + EGFR - pts treated with carboplatin (AUC 5-6) or 
Cisplatin 75mg/m2 and (Pm)pemetrexed (500 mg/m2) +/- (B)bevacizumab 
15mg/kg. For comparators, we identified 19 KRAS - EGFR - patients treated 
with the same regimen. Maintenance therapy with Pm or Pm+B was given at 
the discretion of the treating physician. KRAS and EGFR mutational status 
were assessed by RT-PCR on tumor tissue collected at first diagnosis. RR 
was assessed using RECIST criteria. Kaplan-Meier estimates for PFS were 
evaluating using log rank test. Fisher exact test was used to assess the associa-
tion between KRAS mutation status and response rate 
Results: The groups were similar in age (KRAS + mean 61 vs. 60; p=0.87), 
gender (62% vs. 57% F; p= 0.9), ECOG 2 (0 vs. 10%,p=0.47), smoking hx 
(93% vs. 94% current/former smokers , p=0.7), brain mets (0% vs. 18% 
p=0.22), mean number induction cycles (4 in each, p=0.6), cisplatin and 
bevacizumab use (12% vs 10%, p > 0.1;10% vs. 40%, p=0.10). Pm mainte-
nance was used in 31% KRAS+ (5/16) and 26% KRAS-(5/19) (p=0.79). P+B 
maintenance was used in 12% (2/16) and 5% (1/19) (p=0.70). RR was 56% in 
the KRAS + (9/16) vs. 36% KRAS- (7/19) respectively (p=0.3). There was a 
statistically significant improvement in PFS in the KRAS + group (10.3 mos 
vs. 5.7 mos, p =0.03) 
Conclusions: In this small retrospective review, KRAS mutations appeared 
to be associated with a non-significant improvement in RR and significant 
improvement in PFS for patients treated with frontline PPm based therapy. 
Future prospective studies should investigate and validate the predictive value 
of KRAS for this cytotoxic regimen as well as evaluate the potential correla-
tion between KRAS status and TS levels.
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Evaluating the Metastatic Cure Probability (MCP) of 
Targeted Radionuclide Therapy (TRT) for Bronchogenic 
Carcinoma (BC)
T. W. Speer1, P. Bernhardt2, 1U. of Wisconsin School of Medicine and Public 
Health, Madison, WI, 2The Sahlgrenska University Hospital, Gothenburg, 
Sweden
Purpose/Objective(s): TRT is systemic radiotherapy that uses radionu-
clides to target malignant tissue. Clinical data has been generated using 90Y 
(cT84.66; mCC49) and 131I (chTNT) for the treatment of BC with TRT. 
Cumulative administered mCi ranges, using either single or multiple instilla-
tions, are as follows: 90Y (14-112) and 131I (96-112). This study simulated 
the mean equivalent dose (Deq) required to cure metastatic carcinoma using 
90Y and 131I and assesses the theoretical feasibility of delivering this dose in 
terms current administered activities. 
Materials/Methods: A model for tumor growth (Gompertzian) and meta-
static formation was developed using human data. Monte Carlo simulations 
were performed to determine the 90% metastatic cure probability (MCP) for 
the metastatic formation rate constants (c=%[day/g]) of 0.01, 0.1, 1.0, 10 and 
corresponding total metastatic mass (g) groups of 1.4, 16, 160, 1600, for 90Y 
and 131I. Calculations were performed to estimate the required administered 
activity (mCi) that would result in the simulated Deq that accomplishes the 
MCP for each metastatic mass group. The following were assumed: a uniform 
dose distribution, the radionuclides completely decay, all decay energy was 
absorbed by the mass group. 
Results: Simulated metastatic mass distributions for “c” of 0.01, 0.1, 1.0, 10 
resulted in detectable metastasis (lesions > 1.0 g) of 0.17, 1.7, 17, 180 and a 
total number of metastases of 0.92, 9.7, 170, 9000, respectively. The Deq (Gy) 
required for MCP for 90Y and 131I against the total metastatic mass (g) of 
1.4,16, 160, 1600 were: 90Y (5,200, 11,000, 17,000, 28,000) and 131I (550, 
1100, 1700, 2800). The required administered activities (mCi) to exercise the 
MCP are: 90Y (3.97, 96, 1483, 24,429) and 131I (0.73, 16, 254, 4177). 
Conclusion: If a large amount of administered activity of TRT is focused in 
malignant tissue, current data indicates a potential to cure systemic disease 
with a mass range of 1.4 to 16 grams. If the current administered activity 
ranges can be doubled, 131I has the potential to cure a metastatic burden 
of 160 grams; 90Y will not cure a metastatic burden in this range due to a 
lack of absorbed dose because of its long beta particle path length. A meta-
static burden of 1600 g is beyond the current capability of TRT to exercise 
a potential cure. Of course a tumor burden greater than 1 kg is considered 
lethal and may not represent a realistic clinical environment. Because current 
S249Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 7, Number 9, Supplement 4, September 2012 Abstracts
administered TRT activities have the potential to theoretically cure a reason-
able range of metastatic disease (mass), the future research direction of TRT 
should use biologic and physical techniques to better harness the energy from 
radionuclides and employ them earlier in the therapeutic process, when sys-
temic tumor burdens are lower.
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Stereotactic Body Radiation Therapy for Patients with 
Clinically vs. Pathologically Diagnosed Non-Small Cell Lung 
Cancer: A Comparative Analysis
B. R. Mancini, B. P. Rowe, B. W. Chang, R. H. Decker, Yale University School 
of Medicine, New Haven, CT
Purpose/Objective(s): To compare outcomes of patients with clinically 
versus pathologically diagnosed non-small cell lung cancer (NSCLC) who 
underwent treatment with stereotactic body radiation therapy (SBRT) in 
the U.S. 
Materials/Methods: A retrospective review of patients treated with SBRT 
at a single institution for early-stage NSCLC was undertaken, in order to 
compare outcomes between those with a pathologic diagnosis (PD) and those 
treated with a clinical diagnosis (without biopsy-confirmation, CD). The pro-
grammatic criteria for treating patients without pathology were: a character-
istic appearing solitary pulmonary mass between 1 and 5 cm in size that was 
enlarging on serial CT scans, avid on PET-CT, in a patient with risk factors 
for lung cancer (smoking history, prior lung malignancy). All patients were 
discussed, and serial imaging reviewed, at a multidisciplinary conference. A 
cohort of patients treated after clinical diagnosis was identified, and a cohort 
of contemporaneous, consecutively treated patients with PD was identified, 
matched by tumor size and biologically effective dose (BED). Overall sur-
vival (OS), progression-free survival (PFS), and local control (LC) were com-
pared using the Kaplan-Meier method. 
Results: Between January 2008 and December 2011, 170 patients were iden-
tified as meeting criteria for analysis. 39 patients were treated with SBRT 
for CD NSCLC. Of these, 9 (23%) had non-diagnostic biopsies, 4 (10%) 
refused biopsy, and the remainder (67%) were not referred for EBUS or 
CT-guided biopsy due to poor baseline pulmonary status. 92 patients treated 
with SBRT during the same time period for PD NSCLC were identified as 
matched controls. Median follow-up duration was 13 months for CD, and 
10 months for PD. The median tumor size was 2.1 cm in both groups, and 
both groups received a median BED of 130 Gy (range 80-151 Gy) in 3 to 5 
fractions. There was no significant difference in LC (97% CD, 100% PD at 2 
years, p=0.5), PFS (median 37 months in both arms, p=0.9), or OS (median 
32 months in both arms, p=0.7). 
Conclusion: Following strict criteria for the clinical diagnosis of NSCLC 
does not identify a cohort of patients with improved outcomes after SBRT 
in a U.S. population, suggesting that there are not a substantial number of 
benign nodules among this group. Further investigation should be undertaken 
to establish clinical parameters that reliably identify malignancy in high-risk 
patients, but those who can safely undergo EBUS or CT-guided biopsies 
should continue to do so.
Author Disclosure Block: B.R. Mancini: None. B.P. Rowe: None. B.W. 
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Sequence Dependent Radiosensitization of EGFR Mutant 
NSCLC by Gefitinib is Mediated by Senescence
K. E. Huber, V. Iyer, W. E. Huber, D. E. Wazer, Tufts Medical Center, 
Boston, MA
Purpose/Objective(s): Non-small cell lung cancer (NSCLC) harboring an 
activating mutation in EGFR are highly sensitive to tyrosine kinase inhibi-
tors (TKI) and to radiation (RT). However, the antiproliferative effect of TKIs 
causing G1 cell cycle arrest can be paradoxically radioprotective, which 
is seen when EGFR mutant NSCLC cells are exposed to TKI 24h prior to 
RT. In contrast, inhibition of the EGFR pathway by TKIs in EGFR mutant 
NSCLC cells immediately following RT is radiosensitizing. In this study, we 
investigated the mechanism of cell death and DNA repair when TKIs and 
RT are given synchronously and whether agents that inhibit the pro-survival 
PI3K-Akt pathway would be uniformly radiosensitizing independent of the 
sequence of delivery. 
Materials/Methods: Apoptotic cell death was measured by western blot, 
probing for PARP1 cleavage and by flow cytometry AnnexinV assays. 
Senescence associated beta-galactosidase (SA-β gal) and trimethylated 
Histone3K9 (H3K9Me3) assays were used to measure irreversible growth 
arrest. Estimation of DNA repair kinetics was measured with γ-H2AX immu-
nofluorescence. Cell survival was measured by colony formation assays that 
were performed on untreated cells (vehicle control) or cells treated with 
the TKI gefitinib, the PI3K inhibitor LY294002, or the Akt1/Akt2 inhibitor 
AktVIII with or without RT. These assays were all completed in vitro using 
the EGFR mutant NSCLC cell line HCC4006. 
Results: As seen in prior work, gefitinib treatment for 24 h post-RT leads to 
30% reduction in survival fraction after 2 Gy (SF2) compared to vehicle only 
(SF2 vehicle: 0.75+/-0.05; gefitinib: 0.54+/-0.03) and 24 h pre-RT treatment 
led to increased survival (SF2 pre-RT gefitinib: 0.89+/-0.01). PARP1 cleavage 
and AnnexinV surface expression was induced by gefitinib but not further by 
2 Gy RT compared to vehicle, pre-treated or post-treated controls. However, 
senescence was induced by RT and there was up to 50% more senescence 
in cells treated with gefitinib immediately following RT and a reduction in 
senescence in cells pre-treated with gefitinib. The kinetics of γ-H2AX foci 
resolution at 2, 6 and 24 h following radiation was independent of sequence of 
gefitinib exposure and RT. Pre-treatment with LY294002 or AktVIII was not 
radiosensitizing in the CFU assay (SF 6Gy vehicle: 0.11+/-0.01; LY294002: 
0.16+/-0.06; AktVIII: 0.12 +/- 0.01). 
Conclusions: Radiosensitization of EGFR mutant NSCLC by gefitinib 
appears to be mediated through senescence, but this effect is sequence 
specific. Selective inhibition of the PI3K-Akt pathway did not negate the 
sequence dependent radiosensitization.
Author Disclosure Block: K.E. Huber: None. V. Iyer: None. W.E. Huber: 
None. D.E. Wazer: None.
201 
Radiation Activation Of Immunotherapy In Lung Cancer
D. E. Hallahan, H. Yan, Washington University School of Medicine, 
St Louis, MO
Purpose/Objective(s): Radiation-inducible neoantigens are defined as 
proteins that are overexpressed and specific to irradiated cancer. These 
neoantigens can be exploited to activate antibody dependent cell mediated 
cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis 
(ADCP) in cancer. 
Materials/Methods: We developed anti-TIP1 mAbs and anti-GRP78 mAbs 
(both IgG2b isotype). We screened over 100 subclones to identify mAbs that 
bind with high affinity to a single band on western immunoblot and with 
cancer specificity in mouse models. We used cultured cancer cells to study 
the radiation-induced translocation of TIP1 and GRP78 onto the surface of 
NSCLC cells. We separated the cell membrane from cytosol of cancer cells 
and quantified TIP1 and GRP78 expression on the cell surface at 24 hours 
after irradiation. Mouse tumors were treated with 3 Gy on the right-sided 
tumor whereas the left tumor in the same mouse was used as an untreated con-
trol tumor. Biodistribution of the labeled antibodies within the tumor-bearing 
mice was monitored by NIR imaging. To assess ADCC and ADCP, cancer 
cells were labeled with DiI to fluorescently stain the cell membrane. Cells 
were subsequently irradiated and treated with mAbs. Mouse NK and DCs 
were then added to antibody-opsonized cancer cells, and the percentage of 
DCs phagocytosing the fluorescent cell membranes was quantified. Cancer 
cells were irradiate with 3 Gy X-ray radiation and continue to culture for 4 
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hrs. We added 10 ug/ml mAbs for 2 hours. Murine NK cells purified from 
BALB/c spleens were added at 1:3 ratio of target cells to effector cells, and 
Incubated for 16 hours. Cancer cell cytotoxicity was measured by the release 
of LDH into media. Tumor growth delay was used to measure efficacy of 
mAbs in mouse models of cancer. 
Results: Western blots showed a 14 to 25 fold increase in cell membrane 
localized protein in irradiated cells compared to controls. This observation 
was supported by immunofluorescence microscopic analysis of the surface-
located TIP1 and GRP78 on irradiated cancer cells. The translocation of the 
TIP1 and GRP78 onto the cell plasma membrane surface was sustained for 7 
to 9 days after the irradiation. The cancer specific binding of mAbs to irradi-
ated cancer in hind limbs of nude mice. The mAbs were cleared from circula-
tion through enterohepatic excretion over the course of 48 hours. Antibody 
binding to irradiated tumors was observed within 24 hours and persisted for 
7 days. Cells treated with radiation and mAbs had a significantly increased 
level of ADCC (7-fold cytolysis, p<0.01) and ADCP (32 to 11%, P <0.05 **). 
mAbs significantly enhanced tumor growth delay. 
Conclusions: These data suggest that radiation-induced translocation of the 
intracellular TIP1 onto the plasma membrane is limited to cancer cells. The 
mAbs activate NK cells and dendritic cells to destroy cancer cells.
Author Disclosure Block: D.E. Hallahan: K. Stock; RadTargX, Inc, 
Cumberland Pharmaceuticals, Genvec, Inc. H. Yan: None.
202 
Co-targeting C-Met And Cox-2 Leads To Enhanced Inhibition 
Of Lung Tumorigenesis In A Murine Model With Heightened 
C-Met Signaling
J. M. Siegfried, M. Rothstein, C. T. Gubish, D. E. Cunningham, L. P. Stabile, 
University of Pittsburgh, Pittsburgh, PA
Purpose/Objective(s): The hepatocyte growth factor (HGF)/c-Met signaling 
pathway is often dysregulated in lung cancer. We previously showed that HGF 
activation of c-Met in NSCLC cells led to significant induction of cyclooxy-
genase-2 (COX-2) followed by secretion of PGE
2
. PGE
2
 caused secretion of 
TGFα by NSCLC cells, followed by both phosphorylation of EGFR and later, 
delayed phosphorylation of c-Met that does not require HGF. Secretion of PGE
2
 
appears to boost c-Met pathway signaling downstream via cross-activation by 
EGFR, in a reinforcing loop that is independent of HGF. We hypothesized that 
targeting of both c-Met and COX-2 might lead to enhanced anti-tumor effects 
by blocking both upstream and downstream pro-tumor events. 
Materials/Methods: We tested whether targeting c-Met with the tyrosine 
kinase inhibitor crizotinib combined with celecoxib to target COX-2 would 
result in enhanced anti-tumor effects, in an animal model with heightened 
HGF/c-Met pathway signaling in the airways. Mice transgenic for airway 
expression of human HGF were treated with the inhibitors alone or in combi-
nation after exposure to a tobacco carcinogen, NNK, from wk 1-4. Crizotinib 
(40mg/kg; n=16), celecoxib (50mg/kg; n=13), combined crizotinib and cele-
coxib (n=21) or placebo control (n=10) was administered by oral gavage daily 
from wk 3 until wk 15, at which time lung tumors were evaluated. 
Results: A highly significant decrease in the number of lung tumors per ani-
mal was observed with crizotinib treatment (mean 3.6, range 2-6), celecoxib 
treatment (mean 4.3, range 3-6) and combination treatment (mean 1.5, range 
0-3) compared to placebo control (mean 9.9, range 6-13; P<0.001, Poisson 
regression). The number of tumors in the combination treatment group were 
also significantly lower than either single agent treatment (P<0.001). There 
was also a significant decrease in mean tumor size with crizotinib (mean 
0.20mm2), celecoxib (mean 0.22mm2) and combination (mean 0.15mm2) 
compared to placebo (mean 0.38mm2, P<0.001, mixed effects modeling). 
Three biomarkers (COX-2, PGE
2
, and P-MAPK) were together optimally 
down-modulated by combination treatment, compared to single treatment. 
Conclusions: In a pulmonary environment with heightened HGF/c-Met path-
way activity, dual inhibition of the c-Met and COX-2 pathways may enhance 
anti-tumor effects by targeting reinforcing up- and downstream signaling. 
Such a combination has potential clinical benefit for lung cancer patients with 
dysregulated c-Met/COX-2 pathways. Supported by R01 CA79882 and P50 
CA090440.
Author Disclosure Block: J.M. Siegfried: None. M. Rothstein: None. C.T. 
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Hedgehog Pathway Inhibition Radiosensitizes Non-small Cell 
Lung Cancers Through Tumor-microenvironment Interaction
R. K. Hales, K. Aziz, B. Aftab, S. Chettiar, R. Gajula, N. Gandhi, T. Salih, C. 
Rudin, P. Tran, J. Zeng, The Johns Hopkins University School of Medicine, 
Baltimore, MD
Purpose/Objective(s): Despite radiation concurrent with cytotoxic che-
motherapy, local control remains a problem in non small cell lung cancer 
(NSCLC). Local recurrence not only results in clinical morbidity, but may 
also be an important contributor to metastatic spread in locally advanced 
NSCLC. The hedgehog signaling (Hh) pathway is aberrantly activated in 
adult malignancies, including NSCLC, but the contribution of hedgehog sig-
naling to NSCLC radiation (RT) response has not been characterized. We 
investigated the effect of Hh pathway inhibition on RT response in preclinical 
models of NSCLC. Additionally, we explored Hh signaling in tumor cells and 
surrounding tumor microenvironment that are responsible for RT response. 
Materials/Methods: We studied hedgehog inhibitor (HhAntag) cytotoxic-
ity and radiosensitization in NSCLC. We examined the effect of HhAntag 
and radiation on in vitro clonogenic survival. Using a hind-flank A549 xeno-
graft model, we examined tumor growth delay, proliferation, cell death and 
hedgehog pathway gene expression changes following HhAntag treatment 
and radiation. In a transgenic mouse model of KrasG12D/Twist1-induced lung 
adenocarcinoma, tumor response to lung RT and HhAntag were assessed with 
micro-CT scans. 
Results: High dose HhAntag sensitized A549 cells to RT at supratherapeutic 
doses, but not at lower doses or with other NSCLC cell lines. Hind-flank 
xenograft experiments demonstrate HhAntag and RT induced delayed tumor 
growth in vivo, p<0.001. In mice with spontaneous autochthonous lung ade-
nocarcinomas, micro-CT scans revealed improved tumor shrinkage with the 
addition of HhAntag to lung RT. Tumor cells show no change in expression 
of Hh pathway genes with HhAntag treatment. However, mouse stromal cells 
showed significant Hh pathway gene expression down regulation. 
Conclusions: Despite minimal evidence of any direct effect on radiosensitiv-
ity of NSCLC cell lines when tested in vitro, both in vivo models demon-
strate robust and statistically significant enhancement of radiosensitivity in 
vivo using pharmacologically achievable doses of a small molecule Hedgehog 
inhibitor. Our observations suggest that the mechanism of radiosensitization 
in vivo may involve paracrine stromal signaling. Analysis of Hedgehog path-
way activity in tumor-associated murine stroma in the human tumor xenograft 
model supports this proposed mechanism. These data both offer further evi-
dence of a paracrine Hedgehog signaling mechanism, and, more importantly, 
demonstrate clear therapeutic implications of this paracrine mechanism for 
the treatment of NSCLC. Taken together, these data provide a framework for 
clinical translation of hedgehog pathway inhibition with concurrent chemora-
diotherapy for treatment of locally advanced NSCLC.
Author Disclosure Block: R.K. Hales: None. K. Aziz: None. B. Aftab: 
None. S. Chettiar: None. R. Gajula: None. N. Gandhi: None. T. Salih: 
None. C. Rudin: None. P. Tran: None. J. Zeng: None.
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Role of Pax8 in the Regulation of MET and RON Receptor 
Tyrosine Kinases in Non-small Cell Lung Cancer
R. Kanteti1, E. El-Hashani1, I. Dhanasingh1, E. Vokes1, R. Salgia1, S. Sharma2, 
J. Sharma3, 1University of Chicago, Chicago, IL, 2University of California, 
Los-angeles, Los-angeles, CA, 3Celprogen, Los-angeles, CA
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Section of Hematology/Oncology, Department of Medicine, University of 
Chicago, Chicago, IL 60637 Lung cancer is a devastating disease which affects 
thousands every year. Lung cancer is usually divided into two subtypes Non-
small cell lung cancer (NSCLC) and Small cell lung cancer (SCLC). About 
75% of all lung cancers are NSCLC. It is a heterogeneous group of disorders 
with a number of alterations in the genome as well as the proteome. Even 
with the most current therapy, the response is poor in most of the patients. 
We have previously shown that several of the receptor tyrosine kinases (RTK) 
such as c-MET are mutated in lung cancer and that they contribute signifi-
cantly to lung tumor development. Recently, the PAX nuclear transcription 
factors were also reported to play key role in various cancers. There are nine 
PAX gene family members known to date and they play an important role 
in development, embryogenesis and tissue repair. We previously showed that 
PAX5 is preferentially expressed in SCLC, whereas PAX8 is expressed in 
NSCLC cell lines (Lab Invest., 2009). In order to understand the role of PAX8 
in the biology of lung cancer, we carried out IHC analysis of PAX8 expres-
sion in archival NSCLC tumor tissues (n=254). PAX8 was found to be over 
expressed (≥+2 on a scale of 0-3) in adenocarcinoma (58/94), large cell car-
cinoma (50/85), squamous cell carcinoma (28/47) and in metastatic NSCLC 
(17/28; lymph node). We and others have previously shown that expression 
of PAX3 and 5 in cancer cells positively correlated to the expression levels 
of c-MET. Utilizing early progenitors isolated from NSCLC cell line and also 
from fresh tumor tissues, we show robust overexpression of PAX8, MET, and 
RON. Using NSCLC cell line A549 and specific siRNA against PAX8, we 
showed that abrogation of PAX8 expression significantly down-regulated the 
expression of c-MET and its relative RON. In addition, NSCLC cells when 
stimulated with HGF, the natural ligand for c-MET revealed strong colocal-
ization of active c-MET (phospho-MET) with PAX8. Most importantly, we 
also showed that knockdown of PAX8 in A549 cells resulted in significantly 
increased apoptosis (~ 6 fold). Finally abrogation of PAX8 expression in 
NSCLC cells also resulted in a 45% decrease in cell motility thereby suggest-
ing that PAX8 is a potential therapeutic target in NSCLC.
Author Disclosure Block: R. Kanteti: None. E. El-Hashani: None. I. 
Dhanasingh: None. E. Vokes: None. R. Salgia: None. S. Sharma: None. 
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Feasibility of Proton Therapy For Elective Nodal Irradiation in 
Patients with Locally Advanced Non-small Cell Lung Cancer
A. H. Kesarwala1, C. Ko2, W. P. O’Meara3, H. Ning1, K. E. Haglund1, E. 
Xanthopoulos4, R. Rengan4, 1National Cancer Institute, Bethesda, MD, 
2Walter Reed National Military Medical Center, Bethesda, MD, 3Lahey Clinic, 
Burlington, MA, 4University of Pennsylvania, Philadelphia, PA
Purpose/Objective(s): As dose escalation has been emphasized, photon 
involved field radiation therapy (IFRT) with chemotherapy has become the 
standard treatment for locally advanced non-small cell lung cancer (NSCLC). 
When compared to photon elective nodal irradiation (ENI), photon IFRT has a 
favorable therapeutic ratio likely secondary to decreased acute toxicity. Given 
the highly conformal dose distribution achievable with proton radiation therapy, 
proton ENI could allow for treatment of at-risk nodal regions without increased 
dose to normal tissues. This study investigates the feasibility of using proton 
therapy to treat elective nodal stations in patients with locally advanced NSCLC. 
Materials/Methods: The plans from 20 patients with locally advanced NSCLC 
previously treated with photon IFRT to 66.6-72 Gy were evaluated. All of these 
plans had existing involved field PTVs and normal structure contours. Utilizing 
an intensity-modulated proton therapy technique, proton IFRT plans were gen-
erated to deliver the same total dose as the previously treated photon IFRT plan. 
For each patient, additional elective nodal CTVs were contoured and expanded 
to create elective nodal PTVs. Proton ENI plans were generated to deliver 46 
Gy to elective nodal PTVs followed by a conedown to original involved field 
PTVs for a total dose of 66.6-72 Gy. Target coverage and dose to the lung, 
esophagus, and heart were compared between each of the proton plans and the 
previously treated photon IFRT plan. Wilcoxon’s rank-sum test was used to 
determine significance between the median values for each dosimetric param-
eter (p≤0.05). 
Results: Both proton IFRT and proton ENI plans provided significantly 
improved target volume coverage and decreased doses to the lung, esophagus, 
and heart compared to the previously treated photon IFRT plans. The median 
values for dosimetric parameters are as follows:
Table 1: Dosimetric Parameters for Proton IFRT and Proton ENI 
Compared to Photon IFRT
Photon 
IFRT Proton IFRT Proton ENI
D95 of involved 
field PTV8
95.6% 98.7%
p=0.001
98.7%
p=0.002
Lung V20 29.3% 23.6%
p=0.002
25.0%
p=0.03
Lung V5 41.9% 31.5%
p<0.0001
38.1%
p=0.02
Mean lung dose 18.2 Gy 11.1 Gy
p=0.001
12.2 Gy
p=0.001
Esophagus V60 39.0% 30.5%
p=0.003
31.4%
p=0.001
Esophagus V55 43.2% 34.9%
p=0.006
34.7%
p=0.002
Mean esophageal 
dose
38.2 Gy 29.7 Gy
p=0.0001
31.4 Gy
p=0.005
Heart V25 33.1% 9.2%
p=0.002
10.2%
p=0.002
 Conclusions: This study demonstrates the feasibility of using proton therapy 
to treat elective nodal stations in patients with locally advanced NSCLC. Both 
proton IFRT and proton ENI plans showed superior coverage and normal tis-
sue sparing relative to photon IFRT. Assuming that decreased dose translates 
to decreased acute toxicity, this study indicates that proton therapy would 
allow for treatment of at-risk nodal regions while maintaining a favorable 
therapeutic ratio in comparison to the current standard of photon IFRT.
Author Disclosure Block: A.H. Kesarwala: None. C. Ko: None. W.P. 
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Novel Findings On 18F-FDG PET Uptake Distributions 
Within NSCLC Tumors
K. Wijesooriya1, P. Peng1, P. W. Read1, T. Pan2, A. Goode1, P. Judy1, S. 
Benedict1, J. M. Larner1, 1University of Virginia, Charlottesville, VA, 2MDACC, 
Houston, TX
Purpose/Objective(s): Lung cancer is one of the most frequent lethal cancers, 
giving a 5 year survival rate of 20%. Local tumor failure following radiation is 
common. However, higher radiation doses (120 Gy) yield a higher local con-
trol rate (90%). Molecular imaging studies reveal tumor heterogeneity which 
may explain therapeutic resistance. Hence the use of 18F-FDG to dose paint 
lung tumors is a viable strategy . We hypothesize that a functional fit to the 
SUV uptake distribution represents the intrinsic heterogeneity of the tumor 
and this function could be used for dose painting. Alternatively, variations 
observed in the SUV uptake may not be due to the intrinsic heterogeneity of 
the tumor, but due to effects of PET position resolution (volume dependence) 
or tumor motion . The objective of this study is to derive a functional form of 
SUV uptake by eliminating resolution and motion effects. 
Materials/Methods: We conducted a patient and a phantom study: I. Patient 
study: 25 peripheral NSCLC tumors with motion amplitudes less than 5mm, 
and tumor volumes of 5cc to 550cc. PET SUV uptake values for each tumor 
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were fit with a Woods-Saxon model with 2 parameters: radius and skin depth. 
When the ratio of radius to skin depth becomes small, this simplifies to a 
Gaussian. II. Phantom study: spheres of homogeneous18F-FDG activity of 
motion amplitudes (0, 5, 10, 15, 20, 25, 30 mm) and volumes (internal diam-
eter 10, 13, 17, 22, 28, 37 mm). Any variation observed in SUV uptake distri-
bution with homogeneous activity spheres must be due to motion and volume 
effects. Therefore, we used this data to quantify uptake variations as a func-
tion of motion and volume. 
Results: The patient study shows that for small tumors up to about 45cc, 
SUV uptakes can be described by a Gaussian distribution in all three dimen-
sions, peaking at center and dropping as distance from center increases. For 
Intermediate tumor volumes ( 50 cc to 200 cc) SUV uptakes show a flat central 
region surrounded by a skin region over which activity drops. For large tumors, 
(> 200 cc) SUV uptakes are low in the center of the tumor, and higher in the sur-
rounding shell before dropping at the edge. Phantom study for stationary spheres 
shows that for volumes larger than 5 cc, uptake distribution is flat across much 
of the sphere, with only a thin skin. This flat uptake behavior does not change 
with motion up to amplitudes of 10 mm . We have also developed a matrix of 
correction factors to the flat behavior for motion amplitudes and tumor volumes 
beyond these limits. 
Conclusion: Our data demonstrate for the first time, that true heterogeneity of 
NSCLC tumors can be modeled by SUV uptake which takes a Gaussian, Woods-
Saxon or double-peaked functional form depending on tumor volume. The model 
we developed defines the “true” SUV distribution within tumor free of artifacts 
due to motion, and tumor volume and will therefore allow PET and potentially 
other metabolic studies to be optimally integrated into treatment plans.
Author Disclosure Block: K. Wijesooriya: None. P. Peng: None. P.W. 
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What is the Impact of External Beam Radiotherapy (EBRT) 
following Limited Resection of T1 or T2 Non-Small Cell Lung 
Cancer (NSCLC)? A SEER Analysis
O. K. Macdonald1, S. Patel2, D. A. Schomas3, 1Providence Medical Center, 
Kansas City, KS, 2University of Washington, Seattle, WA, 3St. Luke’s Hospital, 
Kansas City, MO
Background: Historical series and one randomized trial have guided sur-
geons in selecting the appropriate surgical procedure for patients presenting 
with localized NSCLC. Data to this point indicate that anatomical lobectomy 
remains the standard of care. However, many patients are still offered limited 
resections. The impact of post-operative EBRT in patients undergoing limited 
resection is unknown. 
Materials/Methods: The Surveillance Epidemiology and End Results 
(SEER) database was queried to identify patients with T1 or T2 NSCLC of 
squamous cell or adenocarcinoma histology who underwent primary surgical 
resection (wedge, segmental or lobectomy with lymph node evaluation) for 
the years 1998 – 2004. Demographic, clinical and pathologic data were culled 
and analyzed to determine the impact of radiotherapy following resection. 
Survival rates were estimated using the Kaplan-Meier method and signifi-
cance was determined using the log-rank test (p <.05). Cox proportional haz-
ards model was performed to determine factors significant for overall (OS) 
and cause-specific survival (CSS). 
Results: 14,149 patients meeting inclusion criteria were included. The major-
ity of patients underwent lobectomy (n = 9,526). 1,147 patients received 
EBRT following surgery. The median follow-up for the entire group was 1.8 
years (range 1 month - 6.9 years). Lobectomy was statistically superior to 
wedge or segmental resection for both OS and CSS. The addition of EBRT 
following wedge or segmental resection did not enhance OS or CSS relative 
to lobectomy or compared to wedge or segmental resection without EBRT 
(Table). The effect of EBRT following limited resection was not influenced 
by the size of the tumor. Advancing age and grade, male sex, larger tumor 
size, limited resection, and the addition of EBRT were statistically significant 
negative predictors for OS.
No EBRT Lobectomy Segmental Wedge p-value
5-yr OS, % 57.8 43.7 37 <.0001
5-yr CSS, % 70.9 59.2 52.3 <.0001
With EBRT
5-yr OS, % 33.2 12.5 16
5-yr CSS,% 42.9 15.8 25.6
Conclusion: Lobectomy remains the standard of care for management of 
localized NSCLC. Generally, patients receiving post-operative EBRT in this 
population experienced poorer OS and CSS compared to surgery alone regard-
less of the surgical extent. These data suggest that planned limited resection 
followed by EBRT is an inferior approach to lobectomy. When lobectomy is 
not feasible, noninvasive alternatives to surgery, including stereotactic radio-
therapy, should be considered.
Author Disclosure Block: O.K. Macdonald: None. S. Patel: None. D.A. 
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Comparative Analysis of Stereotactic Body Radiation Therapy 
for Multiple Primary Non-Small Cell Lung Cancer
B. R. Mancini, B. P. Rowe, B. W. Chang, R. H. Decker, Yale University School 
of Medicine, New Haven, CT
Purpose/Objective(s): To investigate the outcomes of patients treated 
with stereotactic body radiation therapy (SBRT) for single primary (SP) 
non-small cell lung cancer (NSCLC) v. those with multiple primary 
(MP)-NSCLC. 
Materials/Methods: A retrospective review identified 171 patients with 
192 early-stage NSCLC treated with SBRT at a single institution between 
December 2007 and December 2011: 120 patients with SP NSCLC and 51 
patients with MP NSCLC, defined as either a previously or synchronously 
diagnosed early-stage NSCLC. All patients were reviewed at a multidis-
ciplinary tumor board; staging included PET/CT scan and brain imaging 
for all patients except those with peripheral cT1N0 lesions. Patients with 
a clinical diagnosis of synchronous primary NSCLC underwent invasive 
mediastinal staging regardless of PET/CT findings, as did those with SP 
tumors which were either centrally located or larger than 3cm. SBRT was 
to a total dose of 40-60 Gy in 3-5 fractions. Overall survival (OS) and inci-
dence of/time to local failure (LF), nodal failure (NF), distant failure (DF), 
and development of a new primary (NP) were compared using the Kaplan-
Meier method. 
Results: Median follow-up was 10.7 and 10.8 months, respectively, for 
SP and MP patients. There was no difference in the distribution of T-stage 
(83% T1 in SP v. 76% in MP, p=0.39) or in median tumor size (2.2 SP v. 
2.0cm MPLC, p=0.12). In the MP group, 34 of 51 patients had prior early-
stage NSCLC treated with curative intent with surgery, SBRT, or fraction-
ated radiation, while 17 presented with synchronous primary NSCLC (a 
total of 38 primary tumors). In those with prior history, the median time 
since previous treatment was 57 months (range 2-429 mo). SP patients 
had a higher median 2-year PFS compared to MP patients (37.5 v. 23.5 
mo, p=0.028). With regards to patterns of failure at 2 years, comparing 
SP to MP patients, there was no significant difference in the proportion 
of patients with distant metastatic failure (6% in both groups), or local 
failure (3% in both groups). In the MP group, the rate of nodal failure 
was significantly lower (0% v. 3%), and the rate of new primary NSCLC 
was significantly higher (27% v. 3%). There was no difference in median 
OS between the SP and MP groups (28 v. 32 mo, p=0.42). Among the MP 
patients, OS was significantly worse with decreasing interval since prior 
lung cancer treatment (p=0.05). 
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Conclusion: Patients with MP NSCLC had the same LC and OS when com-
pared to patients presenting with SP lesions. This population did have signifi-
cantly different patterns of failure, with a lower risk of NF, and a higher risk of 
developing a subsequent early-stage NP. This suggests that MP NSCLC may 
be a distinct clinical entity, with different biologic behavior than SP tumors. 
Local therapy directed at multiple synchronous or metachronous tumors may 
therefore provide a significant clinical benefit.
Author Disclosure Block: B.R. Mancini: None. B.P. Rowe: None. B.W. 
Chang: None. R.H. Decker: None.
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Lung Lesions treated with SBRT: Does Size Matter?
G. Marwaha, C. Reddy, K. L. Stephans, G. M. Videtic, Cleveland Clinic, 
Cleveland, OH
Purpose/Objective(s): To examine nodal failure patterns with respect 
to lesion size in patients treated with definitive lung Stereotactic Body 
Radiotherapy (SBRT). 
Materials/Methods: We reviewed an IRB approved registry of 350 medically 
inoperable stage I lung cancers treated with definitive SBRT between 2004 
and 2010. All patients were staged with a PET scan. Clinically suspicious 
PET findings were further evaluated by EBUS. Treatment was delivered on 
a Novalis/BrainLAB platform using an abdominal compression system for 
immobilization (rarely a deep breath hold technique). Treatment was deliv-
ered either with dynamic arcs or step and shoot IMRT with daily Exactrac 
IGRT. SBRT schedules evolved over time and potentially reflected treatment 
era, tumor location, and trial based experience. In order to examine the influ-
ence of lesion size (stratified as ≤ 2cm, 2.1-3cm, 3.1-5cm and >5cm) on nodal 
(hilar and mediastinal) failure patterns, actuarial analysis was performed, with 
log-rank tests to compare the groups. Cox proportional hazard regression 
analysis was performed to identify additional factors associated with nodal 
failure. 
Results: Median values for patient characteristics were: Age 74 years; KPS 
80; Smoking 50 pack years. Median follow up was 17.6 months. Median 
tumor size on CT was 2.2 cm (range 0.8-7.2) and median PET SUVmax was 
6.65. Median dose delivered was 50Gy. Dose/fraction schedules were: 50 
Gy/5 (47.1%); 60 Gy/3 (30%); 30 or 34 Gy/1 (10%); other (12.9%). 26.9% 
of treated lesions had no tissue diagnosis. Of the 350 lesions evaluated, there 
were 50 (14%) total nodal failures.
Rates of Nodal Failure by Size Stratification
Size
Total Number of Nodal 
Failures
Percentage of Patients 
Failed
≤2cm 26 17%
2.1-3cm 11 10%
3.1-5cm 10 14%
>5cm 3 20%
The rates of nodal failure were not significantly different between the four 
different size groups (p = 0.1488). On univariate analysis, 2.1-3cm lesions 
versus ≤ 2cm exhibited significantly less nodal failure following SBRT 
(HR = 0.406, 95% CI, 0.189 - 0.87; p = 0.0205). No other factors includ-
ing: age, KPS, gender, race, smoking history, PET SUVmax, central versus 
peripheral location, degree of differentiation, and radiation fractionation were 
found to significantly impact nodal failure patterns. 
Conclusion: Our analysis of SBRT treated primary lung lesions revealed no 
significant differences in nodal failure based on size. This finding is sugges-
tive that even for large lung lesions SBRT is a viable, definitive treatment 
approach. Additionally, aside from less nodal failure seen in 2.1-3cm lesions 
compared to those ≤ 2cm (to be further investigated), we found no other 
patient, tumor or treatment factor included in this analysis to be significantly 
predictive of nodal failure.
Author Disclosure Block: G. Marwaha: None. C. Reddy: None. K.L. 
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HDACi Sensitizes A Non-Small-Cell Lung Cancer (NSCLC) 
Stem Cell Subpopulation to Radiation
Z. He1, D. J. Leong1, R. J. Majeska2, H. Chao1, H. B. Sun1, 1Albert Einstein 
College of Medicine, Bronx, NY, NY, 2The City College of New York, 
NY, NY, NY
Purpose/Objective(s): Lung cancer is the leading cause of cancer death. 
Recent evidence suggests that expression of drug-resistant genes by can-
cer stem cells (CSCs) may be largely responsible for tumor recurrence and 
metastasis after radiation therapy. Treatment of lung cancer cells with histone 
deacetylase inhibitors (HDACi) was shown to sensitize some cancer cells 
to radiation, but this has not been established for the CSC subpopulation in 
non-small-cell lung cancer (NSCLC). This study sought to determine whether 
HDACi by butyrate alters the sensitivity of NSCLC stem cells to radiation, 
and to identify potential mechanisms for its effects. 
Materials/Methods: Human NSCLC cell lines H1650 or A569 (ATCC) were 
exposed to Cs γ-rays (0-8Gy) alone or after 24 hr treatment with 5 mM butyr-
ate, then either assayed for colony forming ability after 14 days or harvested 
after 3 hrs for RNA isolation and RT-PCR. The CSC subpopulation of A549 
cells (Hoechst 33342 double negative) was identified by FACS analysis. 
Results: i) Pre-treatment of H1650 cells with the HDACi butyrate potentiated 
the dose-dependent suppression of colony formation by radiation (0-8 Gy), 
suggesting that butyrate sensitizes lung cancer cells to radiation. ii) Butyrate 
also significantly downregulated the expression in H1650 cells of ABCG2, 
a marker of CSC and a transporter of ATP-binding cassette family member 
involved in tumor cell chemo-resistance; however, expression of several other 
CSC marker genes (CD133, ALDH1, Oct4 and CD24) in H1650 cells were 
unaffected, indicating that radiosensitization by butyrate is mediated at least 
partly by selective downregulation of ABCG2 in the CSC subpopulation of 
NSCLC cells. iii) Finally, butyrate combined with radiation significantly 
reduced the number of CSCs when compared to radiation treatment alone, 
indicating that HDACi sensitizes the CSC subpopulation within NSCLCs to 
radiation. 
Conclusions: Butyrate, a HDAC inhibitor, sensitizes lung CSCs to radiation, 
suggesting that HDACi may improve the efficacy of radiation treatment and 
potentially allow use of lower radiation doses for treatment.
Author Disclosure Block: Z. He: None. D.J. Leong: None. R.J. Majeska: 
None. H. Chao: None. H.B. Sun: None.
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Thoracic Re-irradiation In Patients With Stereotactic Body 
Radiotherapy (sbrt) As First Or Second Course Of Treatment
J. M. Kilburn, J. G. Kuremsky, A. W. Blackstock, W. T. Kearns, C. J. Hampton, 
W. H. Hinson, A. A. Miller, W. J. Petty, J. J. Urbanic, Wake Forest University 
School of Medicine, WINSTON SALEM, NC
Purpose/Objective(s): Limited modern data exists on management of in-
field failures after thoracic radiation. The need to offer patients loco-regional 
control and prevent distant progression must be balanced against the potential 
risk of increased toxicity. Specifically, the role of re-irradiation with SBRT 
as an initial or second course of treatment is poorly defined. We review our 
experience treating patients with thoracic radiotherapy to previously treated 
high dose regions. 
Materials/Methods: Patients (pts) were treated as part of a thoracic oncology 
program with 3D conformal RT; SBRT dose 20-60 Gy (5-22.5 Gy/fraction 
(fx)), and external beam radiotherapy (XRT) dose 45-80.5 Gy (1.5-5 Gy/fx). 
4D CT was used to define the ITV with 5 mm PTV expansions beginning in 
2007. Otherwise a 10 mm PTV was applied. 8 patients prior to 2006 were 
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treated using homogeneous tissue density for dose calculation. Pt failures were 
scored regarding local (at the site treated), regional (nodal disease in the hilum 
/mediastinum), or distant. Central versus peripheral was defined per RTOG 
0813 criteria, and toxicity per NCI CTCAE v4.0. Kaplan Meier estimates were 
performed for local control (LC), regional (RF), distant failure (DF), and over-
all survival (OS). All event times were based on date of retreatment. 
Results: Twenty-eight pts were treated with repeat thoracic radiotherapy 
(2001-2011) and SBRT as a component of care. Median follow-up was 13 
months (m) (1-52 m). Pts were included if re-irradiation was in the prior 30 
Gy isodose line (Kelly IJROBP 2010) and intent was definitive control. 20 
pts had XRT followed by SBRT, 6 pts SBRT then SBRT, 2 pts SBRT then 
XRT. The median re-irradiation dose and fraction was 50 Gy and 5 fx (Range 
20-70.2 Gy, 1-35 fx). The median interval between courses was 18 m. Average 
patient age was 63 years (45-80) with a median ECOG PS of 1. Thoracic only 
disease was treated in 22 pts while 6 pts had metastatic disease at retreatment; 
25 pts with lung cancer (4 SCLC), and 3 pts metastatic carcinoma. Average 
tumor size was 2.4 cm (0.9-5.4). Median OS was 22 m, with 2 year LC at 
62% (95% CI 38.1-87.3). 4 pts had RF (1 isolated). Of 22 pts with chest only 
disease, 2 year distant metatastic free survival was 50.9%. 10 pts suffered 
chronic grade 2-3 toxicity (6 chest wall pain, 3 dyspnea, 1 esophagitis), and 1 
pt suffered grade 5 toxicity with an aorta-esophageal fistula 6 m after 54Gy in 
3 fx for a central tumor after 74 Gy XRT 1 year prior. Median time to toxicity 
was 6 m (2-20 m). 
Conclusions: In field failures after thoracic radiation present a unique chal-
lenge. This analysis suggests reasonable loco-regional control and freedom 
from distant metastases can be established with re-irradiation using SBRT or 
delivering fractionated XRT in the high dose region of prior SBRT. Chronic 
and high grade toxicity occurred in nearly 1/3 of patients.
Author Disclosure Block: J.M. Kilburn: None. J.G. Kuremsky: None. 
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The HSP90 Inhibitor, AT13387, Is Effective In Mutant EGFR 
And ALK-positive NSCLC Models.
N. G. Wallis, T. Smyth, A. Rodriguez-Lopez, R. McMenamin, V. Lock, 
J. Curry, B. Graham, J. Lyons, N. Thompson, Astex Pharmaceuticals, 
Cambridge, United Kingdom
Purpose/Objectives: Tyrosine kinase inhibitors (TKI) such as gefitinib, 
erlotinib and crizotinib have been successfully used to treat subsets of Non-
Small Cell Lung Cancer (NSCLC) driven by tyrosine kinase oncogenes such 
as mutant EGFR (10-40% NSCLC) and the echinoderm microtubule-associ-
ated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion (3-7% 
NSCLC). However, responses to these targeted agents tend to be limited due 
to the development of resistance. A number of resistance mechanisms to 
these TKIs have been elucidated, including mutation in the target kinase (e.g. 
T790M in EGFR; L1196M in ALK), and activation of alternative parallel 
signalling pathways such as Met amplification for the EGFR TKIs or EGFR 
activation for crizotinib. Both EGFR and the EML4-ALK fusion are client 
proteins for HSP90 and HSP90 inhibition is a promising potential therapy for 
NSCLC driven by these oncogenes. In addition many of the proteins involved 
in EGFR, ALK and other signalling pathways are also dependent on HSP90 
activity. HSP90 treatment may therefore be a method of overcoming the 
diverse mechanisms of resistance to EGFR and ALK inhibitors. 
Materials/Methods: AT13387 is a potent HSP90 inhibitor currently in 
clinical trials. Its activity was investigated in NSCLC models, including the 
EML4/ALK H2228 cell line and the mutant EGFR NCI-H1975 line with a 
T790M resistance mutation. 
Results: AT13387 potently inhibited the proliferation of several NSCLC 
cell lines with potencies sub-100 nM. It was further characterized against 
the ALK-positive H2228 line which is sensitive to crizotinib and the mutant 
EGFR NCI-H1975 line. As expected for HSP90 client proteins, the ALK 
fusion and EGFR proteins were depleted respectively in these two cell lines 
when treated with AT13387. The depletion of ALK was accompanied by a 
reduction in phospho-ALK, phospho-ERK and phospho-AKT at concentra-
tions of 100 nM AT13387, indicating that signalling through these pathways 
was also inhibited. A similar inhibition of signalling was seen in the NCI-
H1975 cell line as shown by similar decreases in phospho-ERK and phospho-
S6. In vivo, significant tumor growth inhibition along with inhibition of these 
signalling pathways was observed on treatment of mice, bearing NSCLC 
tumor xenografts, with AT13387. 
Conclusions: These data confirm that AT13387 is effective in both TKI-
sensitive and -resistant NSCLC models. The inhibition of downstream signal-
ling brought about by treatment with AT13387 suggests this compound may 
also be effective in crizotinib-resistant models and merits further investigation.
Author Disclosure Block: N.G. Wallis: A. Employee; Astex Pharmaceuticals. 
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A. Employee; Astex Pharmaceuticals. R. McMenamin: A. Employee; 
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Curry: A. Employee; Astex Pharmaceuticals. B. Graham: A. Employee; 
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The Effect of c-CBL Mutations or Functional Loss on The 
Efficacy of c-MET Inhibitors in NSCLC
Y. C. Tan1, C. Rolle1, L. Zhu2, M. K. Srivastava2, S. Sharma2, R. Salgia1, 1the 
University of Chicago, Chicago, IL, 2University of California Los Angeles, 
Los Angeles, CA
Purpose/Objective(s): Casitas B-lineage lymphoma (Cbl) is an E3 ubiquitin 
ligase and adaptor molecule that is important in cancer. Our previous studies 
detected c-CBL mutations, loss of heterozygosity, and low protein expression 
in non small cell lung cancer (NSCLC). We also determined the genetic varia-
tions of c-CBL, their relationship to receptor tyrosine kinases (RTK) such as 
EGFR and MET, and their functionality in NSCLC. However, ubiquitination 
of EGFR showed no difference between c-CBL wild type (WT) and mutants 
(Mts). Therefore, we undertook to investigate whether c-MET is a potential 
target of c-CBL. 
Materials/Methods: Immunoprecipitation (IP) was performed to detect the 
ubiquitination of c-MET by c-CBL WT and Mts. c-MET inhibitor SU11274 
was utilized to compare cell viability of c-CBL WT cells with viability of 
c-CBL mutant and shRNA knockdown (sh-CBL) cells. Cell motility after 
SU11274 treatment was examined by wound healing assay. Soft agar assay 
was performed to investigate colony formation of sh-CBL cells. PamGene 
Chip and GeneGO Metacore were used to detect and predict the RTK phos-
phorylation difference between c-CBL WT and Mt/sh-CBL cells. In vivo 
mouse study was performed to examine tumor growth and metastasis of sh-
CBL cells. 
Results: When c-CBL and c-MET protein expression levels were analyzed 
by Western blot with/without HGF stimulation, c-CBL WT cells had lower 
c-MET protein expression than c-CBL Mt cells. sh-CBL cells were tran-
siently transfected with c-CBL Mts and whole cell lysates were immunopre-
cipitated with anti-c-MET antibody and immunoblotted with anti-Ubiquitin 
antibody. The ubiquitination of c-MET was decreased in cells that transiently 
expressed c-CBL Mt relative to c-CBL WT cells. In addition, c-CBL Mt and 
sh-CBL cells were more sensitive to c-MET inhibitor SU11274 than c-CBL 
WT cells. Wound healing assay demonstrated sh-CBL cells had an increase in 
cell motility. Furthermore, soft agar assay showed a 9% increase in colonies 
and a 161% increase in colony size of sh-CBL cells compared to control cells. 
In vivo study showed sh-CBL cells had lower tumor growth but more metasta-
sis than control cells. GeneGo analysis of PamGene results predicted an effec-
tive cell signaling pathway involving c-MET, paxillin, EPHA2, and VEGFR. . 
Conclusions: The cell viability and motility results demonstrate that c-CBL 
mutants and sh-CBL cells are more sensitive than c-CBL WT cells to c-MET 
inhibitor SU11274, suggesting they have higher c-MET protein expression. 
Moreover, the PamGene results indicate that c-MET is involved in c-CBL cell 
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signaling pathway. Thus, c-CBL gene status could be a potential indication for 
lung cancer therapy utilizing c-MET inhibitors.
Author Disclosure Block: Y.C. Tan: None. C. Rolle: None. L. Zhu: None. 
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Hyperthermic Intrapleural Chemotherapy By VATS For Lung 
AdenocarcinomaWith Pleural Dissemination
L. Yu, S. Ma, F. Li, Y. Zhang, Y. Zhen, J. Ke, Beijing Tongren Hospital, Capital 
Medical University, Beijing City, China
Purpose/Objective(s): Patients with lung adenocarcinoma and malignant 
pleural effusions have limited life expectancy. The treatment of lung adeno-
carcinoma with malignant pleural effusions remains controversial. The pur-
pose of our study is to evaluate the use of video-assisted thoracoscopy to 
perform hyperthermic intrapleural chemotherapy combined with Endostar 
(recombinant human endostatin) for disseminated pleural adenocarcinoma.
Materials/Methods: From 2007 to 2010, there were 46 patients with lung 
adenocarcinoma and pleural dissemination undergoing thoracoscopic surgery 
and intrathoracic hyperthermic perfusion with chemotherapy in combination 
of Endostar. After thoracoscopic surgery, the hyperthermic perfusion system 
was set up for hyperthermic intrapleural chemotherapy. The thoracic cavity 
was perfused at a speed of approximately 1.8-2.3 L/min with 0.9% Normal 
Saline (4-5L), containing cisplatinum (100 mg). The intrathoracic tempera-
ture remained between 42°C to 43°C. This process of perfusion lasted for 1 
hours. Following this, 2L of 0.45% saline with Endostar (30 mg) at a tempera-
ture of 30 °C was put into the pleural cavity and kept for 30 min. 
Results: There were no peri-operative deaths. During the hyperthermic per-
fusion, patient’s core temperature varied from 36.3ºC and 39.3ºC and pulse 
from 59 beats/m and 126 beats/m. Intraoperative sinus tachycardia occurred 
in 2 elderly cases. No hematologic toxicity and nephrotoxicity was observed 
within one week after surgery. Postoperative pneumonia occurred in 1 elderly 
case. The median survival time was 21 months. During the follow-up period, 
only one patient suffered from continuing pleural effusion due to atelecta-
sis, one elderly patient died of heart failure one year after surgery and the 
remaining patients were completely free from pleural effusion during the last 
follow-up. 
Conclusions: Hyperthermic intrapleural chemotherapy combined with 
Endostar by thoracoscopic surgery offers a safe and effective treatment for 
lung adenocarcinoma with pleural dissemination. It may be time-consuming, 
but beneficial and may have an encouraging impact on its long-term survival.
Author Disclosure Block: L. Yu: None. S. Ma: None. F. Li: None. Y. 
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Pre-Treatment FDG PET Tumour Heterogeneity in Non-
Small Cell Lung Cancer is Associated with Poor Response and 
Survival Following Chemoradiotherapy.
C. Yip1, D. B. Landau1,2, S. Ahmad1, V. Goh2,3, M. Siddique2, S. Chicklore4, 
A. Roy5, G. J. Cook5, 1Department of Oncology, Guys and St Thomas NHS 
Foundation Trust, London, United Kingdom, 2Division of Imaging Sciences & 
Biomedical Engineering, Kings College London, London, United Kingdom, 
3Department of Radiology, Guys & St Thomas NHS Foundation Trust, London, 
United Kingdom, 4Nuclear Medicine Department, Guys & St Thomas NHS 
Foundation Trust, London, United Kingdom, 5Clinical PET Centre, Division 
of Imaging Sciences and Biomedical Engineering, Kings College London, 
London, United Kingdom
Purpose/Objective(s): There is early evidence in some solid tumours that 
heterogeneity of tumoral uptake in FDG PET images is associated with poor 
response to chemoradiotherapy and survival. We have investigated whether a 
similar relationship exists in non-small cell lung cancer (NSCLC). 
Materials/Methods: 53 patients (mean age 65.8y, 31 male) with non-small 
cell lung cancer (21 adenocarcinoma, 24 squamous cell carcinoma and 8 
unspecified), stage 1B (n=3), 2B (n=5), 3A (n=24), 3B (n=21), treated with 
64Gy radiotherapy and concurrent cisplatin/carboplatin and vinorelbine che-
motherapy had pre-treatment FDG PET/CT scans performed to the same pro-
tocol in the same institution between 2007 and 2009. Patients had response 
assessed by RECIST criteria at 12 weeks. Overall (OS), progression-free 
(PFS) and local progression-free survival (LPFS) and/or time to last censor-
ing were recorded from the date of the PET scan. Primary tumour heteroge-
neity was measured by “coarseness” derived from 3D matrices describing 
differences between each PET image voxel and its neighbour. Primary tumour 
SUVmean, SUVmax and SUVpeak parameters were also derived from the 
PET data. 
Results: Median OS was 767 days (94-1534), PFS 497 days (84-1346) and 
LPFS not reached (129-1380). By RECIST there were 2 CR, 34 PR, 9 SD, 
2 PD and 6 not recorded. Primary tumour coarseness varied from 0.0006 to 
0.096 (mean 0.016). RECIST responders (PR/CR) showed lower coarseness 
than non-responders (SD/PD) (mean 0.012 vs 0.027, p=0.003). By Kaplan-
Meier analysis, OS, PFS and LPFS were lower in patients with high primary 
tumour coarseness (median 633 days vs not reached, p=0.003, 377 vs 774 
days, p=0.002 and 388 vs 616 days, p=0.016, respectively). None of the SUV 
parameters predicted RECIST response or showed an association with any of 
the survival parameters. 
Conclusion: Increased heterogeneity of baseline FDG PET scan uptake in 
NSCLC, as measured by the textural parameter, coarseness, is associated with 
non-response by RECIST and with poorer OS, PFS and LPFS. Measurement 
of tumour metabolic heterogeneity may be an index that can be used to stratify 
patients in clinical trials for lung cancer chemoradiotherapy.
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Evaluation of Dose Differences and Clinical Outcomes 
Between Ray Tracing and Monte Carlo Algorithms for SABR 
Treated Lung Tumors
S. E. Braunstein, M. W. Lometti, D. Pinnaduwage, C. F. Chuang, S. S. Yom, 
A. R. Gottschalk, M. Descovich, University of California San Francisco, San 
Francisco, CA
Purpose/Objective(s): Dose calculation in treatment planning must account 
for tissue heterogeneity, especially for tumors within low density lung tis-
sues. While Monte Carlo (MC) calculation methods are the most accurate, 
Ray Tracing (RT) methods are also commonly employed. We evaluated dose 
calculation differences between the RT and MC algorithms in SABR treated 
peripheral lung tumors to determine which planning components may predict 
dose differences. We also examined clinical outcomes of local control (LC) 
and long-term treatment-related toxicity as a function of calculation method. 
Materials/Methods: A retrospective series of 51 patient plans with lung pri-
mary (n=26) and metastatic (n=25) tumors treated with Cyberknife SABR were 
analyzed. Thirty-four treatment plans were developed with the RT method, and 
17 plans used MC. Groups were recalculated with the reciprocal method for 
dose comparison. Parameters examined to quantify dose differences between 
the two algorithms included: dose delivered to 95% (D95) of the planning 
target volume (PTV), dose heterogeneity, and dose to organs at risk (OAR). 
Dose differences were analyzed as a function of target volume, distance to 
soft tissue, and fraction of target overlap with soft tissue. LC was assessed 
radiographically for a median of 14 mo (range 9 to 35 mo). Late toxicities were 
graded at a minimum of 6 mo follow-up by RTOG morbidity scoring schema. 
Results: Compared to MC, the RT algorithm overestimated the dose deliv-
ered to the PTV by 15.6%. For small targets (PTV <=10cc, n=18), the dose 
difference ranged from 4.1% to 37.5% (mean 23.4%); for medium targets 
(10cc < PTV <= 30cc, n=14) from 2.8% to 25.6% (mean 14.2%); and for 
large targets (PTV >30cc, n=19) from 1.2% to 25.6% (mean 9.2%). The dose 
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difference between RT and MC plans correlated to the distance to soft tissue 
and to the fraction of target overlap with soft tissue. The reduction of D95 in 
MC plans was 15% for targets adjacent to soft tissue, and 30% for targets sur-
rounded by lung tissue. For OARs (spinal cord and esophagus), no significant 
dose differences were observed between algorithms. MC plans resulted in 8% 
less dose delivered to 10% of the ipsilateral lung. Evidence of local progres-
sion was noted in 5 of 44 patients for which radiographic follow-up was avail-
able (RT vs MC, OR 2.9 , p=0.31, ns). There was no evidence of greater than 
grade 1 long-term toxicity with either method. 
Conclusion: There exists a significant range of discordance between MC 
and RT dose calculations for SABR treated peripheral lung tumors. While 
variation is correlated to target size and proximity to soft tissue, no single 
parameter can reliably predict dose differences. Ultimately, local control and 
long-term toxicity are independent of dose-calculation method.
Author Disclosure Block: S.E. Braunstein: None. M.W. Lometti: None. 
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Complications From CT-guided Needle Biopsy For Patients 
Receiving Stereotactic Body Radiation Therapy
V. Chowdhry1, A. K. Chowdhry2, N. Goldman3, E. M. Scalzetti1, R. A. Grage1, 
J. A. Bogart1, 1SUNY Upstate Medical University, Syracuse, NY, 2University of 
Rochester, Rochester, NY, 3Albany Medical College, Albany, NY
Background: Obtaining a tissue diagnosis has traditionally been standard of 
care prior to initiating therapy for early stage NSCLC. In several recent stud-
ies from Europe and Asia, a substantial proportion of patients have received 
stereotactic body radiation therapy (SBRT) based only on the imaging char-
acteristics of the suspicious lesion. The underlying assumption is that the 
risk of percutaneous needle biopsy may outweigh the benefits in a popula-
tion that generally has underlying pulmonary dysfunction and other medi-
cal co-morbidity. Nevertheless, there is limited information regarding biopsy 
related complication rates in high-risk patients with early stage NSCLC who 
are treated with SBRT. 
Materials/Methods: Retrospective review of outcomes following biopsy in 
patients treated with stereotactic body radiation therapy. Complications of 
percutaneous biopsy (i.e. pneumothorax, chest tube placement) were ana-
lyzed in relation to patient and tumor characteristics. Each biopsy event was 
analyzed independently for patients with multiple biopsies. Statistical cal-
culations and multivariate regression using a logistic model were performed 
using R software. 
Results: A total of 112 percutaneous biopsies were performed in 103 patients. 
Pneumothorax of any degree was observed in 40 (35%) patients (95% CI 
27%-45%), while 12 patients (10.7%) had a clinically significant pneumo-
thorax requiring chest tube placement, 95% CI (6%-18%). Eighteen patients 
(16%) required overnight hospitalization, 95% CI (10%-24%). Reasons for 
hospitalization other than chest tube placement included: pain control (1 
patient), systemic disease workup (2 patients), close observation due to prior 
pneumonectomy (1 patient), history of previous pneumothorax from previ-
ous biopsy (1 patient), observation for pneumothorax not requiring chest 
tube (1 patient). Grade 2 bleeding was not observed and no patient developed 
post-biopsy infection. Eight out of 61 (13%) patients with a history of COPD 
required chest tube placement, compared with 4 out of 50 who did not have a 
diagnosis of COPD (8%). On multivariate analysis, age, performance status, 
smoking history, pack years of smoking, or COPD history were not statisti-
cally significantly associated with chest tube placement. 
Conclusions: CT guided-needle biopsy in a primarily medically inoperable 
patient population is safe with an acceptable degree of complications.
Author Disclosure Block: V. Chowdhry: None. A.K. Chowdhry: None. N. 
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A Prospective Study Measuring Interobserver Variability of 
GTV with FDG-PET-CT in Stage III Non-Small Cell Lung 
Cancer Using 3D Analysis
D. Peterson, B. Bashir, A. Chowdhury, B. McCurdy, R. Rivest, Z. Nugent, S. 
Demetor, S. Ahmed, A. Leylek, N. Ahmed, Cancer Care Manitoba, Winnipeg, 
MB, Canada
Purpose/Objective(s): A prospective study to determine interobserver vari-
ability of GTV with FDG-PET-CT compared to CT alone in Stage III Non-
Small Cell Lung Cancer using 3D analysis. 
Materials/Methods: 29 patients with stage III NSCLC underwent 3DCRT 
planning by three different radiation oncologists. Simultaneous co-registered 
FDG-PET and CT images were obtained in the same treatment planning posi-
tion. Each physician contoured the GTV of the lung tumor and mediastinal 
lymphadenopathy initially with CT alone and then with FDG-PET-CT for all 
patients. Interobserver variability was determined by comparing the FDG-
PET-CT derived GTV for differences in volume and position using three-
dimensional analysis with vector displacement. Similarly the interobserver 
variability for CT alone was also calculated and then compared with FDG-
PET-CT. Concordance among three physicians for the number of lymph nodes 
contoured at similar nodal stations on FDG-PET-CT versus CT alone was also 
analysed. 
Results: The mean GTV volume for the lung tumor with FDG-PET-CT and 
CT alone was 62.01 cm3 and 74.64 cm3, respectively (p=0.0005). This resulted 
in a 17% reduction in lung tumor GTV for FDG-PET-CT compared to CT 
alone. The mean GTV volume for the mediastinal lymphadenopathy was 
14.31 cm3 with FDG-PET-CT and 18.81 cm3 with CT alone (p=0.048). This 
resulted in a 24% reduction in the mediastinal nodal GTV for FDG-PET-CT 
compared to CT. The mean vector displacement of the lung tumor was 2.0 mm 
with FDG-PET-CT and 7.1 mm with CT alone (p = 0.0016). This resulted in a 
3.6 fold reduction in interobserver variability of position using FDG-PET-CT 
compared to CT. The mean vector displacement of the mediastinal lymph-
adenopathy was 1.53 mm with FDG-PET-CT and 10.2 mm for CT alone (p= 
0.0005). This resulted in a 6.7 fold reduction in interobserver variability of 
position using FDG-PET-CT compared to CT. Mean number of nodes con-
toured per patient on FDG-PET-CT was 1.64 and 1.53 on CT alone (P=0.55). 
FDG-PET-CT resulted in 7% more mediastinal lymph nodes contoured than 
CT. All three physicians agreed on the number of lymph nodes contoured for 
15/29 patients on CT and 27/29 patients for FDG-PET-CT (P=0.0018). 
Conclusion: FDG-PET-CT significantly reduced the mean lung tumor and 
mediastinal nodal GTV volume compared to CT alone. FDG-PET-CT sig-
nificantly reduced interobserver variability of the lung tumor and mediastinal 
nodal GTV for both volume and position. There were more nodes contoured 
on FDG-PET-CT compared to CT alone and there was a higher degree of 
agreement among physicians for the number of nodes contoured. FDG-
PET-CT is significantly more precise for both size and position compared to 
CT alone in defining target volumes for patients with stage III NSCLC using 
3D analysis.
Author Disclosure Block: D. Peterson: None. B. Bashir: None. A. 
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Influence of Volumetric Change and Tumor Motion on 
Inter- and Intrafractional Positional Variations in Frameless 
Stereotactic Body Radiotherapy (SBRT) of Lung Tumors
J. M. Schuster, M. Myers, M. Rosu, N. D. Mukhopadhyay, E. Weiss, VCU 
Medical Center, Richmond, VA
Purpose/Objective(s): To use repeated cone-beam computed tomogra-
phy (CBCT) during frameless stereotactic body radiotherapy (SBRT) of 
lung tumors to analyze the relationship between inter- and intrafractional 
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variations of tumor position and volume changes, respiratory motion and 
tumor location. 
Materials/Methods: Tumor volumes and bony landmarks were contoured 
manually by a single physician on 174 pre- and under treatment CBCTs of 
17 patients with lung tumors treated with SBRT. By comparing the centroid 
position of the tumor relative to bony anatomy on pretreatment CBCT scans 
of each fraction, interfraction variation of the tumor position was measured. 
The intrafraction positional variation was measured by comparing the pre-
treatment tumor position to during treatment CBCTs. Respiratory motion was 
analyzed on planning 4D fan beam CTs for all patients. Change in tumor 
volume was determined by comparing manually contoured tumor volume on 
sequential pretreatment CBCTs. 
Results: The average interfraction/intrafraction tumor displacement rela-
tive to bony landmark in mm was 0.6 (SD 2.3)/-0.3 (SD 0.7) in lateral, -0.7 
(SD 3.8)/0.0 (SD 2.1) in anteroposterior, and -0.6 (SD 5.9)/-0.2 (SD 2.3) in 
craniocaudal direction. On initial CBCT, average tumor volume was 9 cm3 
(range 1-37 cm3) with a mean volume reduction over the treatment course 
of 12% (range, +14% to -54%). Patients with an initial motion amplitude 
> 9 mm (p=0.002), peripheral tumor location (p=0.04), and larger volume 
change (p=0.009) had larger interfraction displacement in lateral direction. 
Interfraction positional variations showed significant time trends (p=0.006). 
Conclusions: Positional variations using frameless set up are comparable to 
more rigid patient positioning techniques. Inter- and intrafraction tumor posi-
tion changes relative to bony anatomy are an important source of geometric 
uncertainty for SBRT providing a rationale for repeated soft tissue-based 
image guidance, particularly in patients identified in this study to be at higher 
risk for variations.
Author Disclosure Block: J.M. Schuster: None. M. Myers: None. M. 
Rosu: None. N.D. Mukhopadhyay: None. E. Weiss: E. Research Grant; NIH 
grant P01CA116602, NIH grant P30CA016059.
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Treatment Of Nasopharyngeal Carcinoma With Helical 
Tomotherapy: A Retrospective Study Of 121 Cases
L. Ma, L. Du, L. Feng, X. Zhang, F. Li, G. Zhou, B. Qu, S. Xu, C. Xie, PLA 
General Hospital, Beijing, China
Purpose/Objective(s): To systematically evaluate the clinical treatment out-
come of 121 nasopharyngeal carcinoma (NPC) patients treated with helical 
TomoTherapy (HT, TomoTherapy Hi-Art) IMRT/IGRT technique. 
Materials/Methods: In between September 2007 and August 2009, total 121 
diagnosed NPC patients were treated with HT. Distributions of the clinical 
stages according to the UICC 2002 Staging System were: 8, 49, 40, and 24 
for Stage I, IIA-B, III, and IVA-B, respectively. IMRT dose painting technique 
with RTOG guidelines was adopted, as well as utilizing IGRT patient MVCT 
image registration methodology. The prescription dose was 70-74Gy/33Fx to 
clinical target volume containing the primary tumor and positive lymph nodes, 
with 60-62.7Gy/33Fx to high risk planning target volume (PTV), while deliv-
ering 52-56Gy/33F to low risk PTV. 31 patients were treated with radiation 
therapy as a single modality, while 54 patients with concurrent cisplatin-based 
chemotherapy with or without anti-EGFR monoclonal antibody therapy, and 
36 patients with concurrent anti-EGFR monoclonal antibody therapy. Side-
effects were evaluated with the established RTOG/EORTC criteria. 
Results: MVCT imaging was performed to minimize tumor registration 
errors to less than 3mm. Average delivery beam-on-time was 457.6 (358.0-
696.1) Sec/Fx. The grade 0, 1, 2 and 3 acute skin toxicity was 4.95%, 74.4%, 
15.7% and 4.95%; the grade 0, 1, 2 and 3 acute mucositis was 0.8%, 37.2%, 
57.9% and 4.1%; and the grade 0, 1, 2 and 3 acute xerostomia was 3.3%, 
53.7%, 43% and 0%, respectively. Only 8 patients suffered from grade 3 or 4 
leucopenia. Saliva function restored with elapsed time and no grade 2 or more 
xerostomia was observed one year after radiation therapy. Concurrent che-
motherapy significantly increased incidence of severe acute toxicities. One 
month after radiation therapy the remission rates of primary tumor and posi-
tive lymph nodes were 95.0% and 99.0%, respectively. The median follow-up 
was 27.4 months. The local relapse-free survival, nodal relapse-free survival, 
distant metastasis-free survival and overall survival were 97.5%, 100%, 98.4 
and 96.7% for one year; 95.6%, 100%, 95.7% and 93.1 for two year; 95.6%, 
100%, 95.7% and 90.4% for three year follow up, respectively. 
Conclusions: Incidence of severe acute toxicities and late xerostomia are rel-
atively minor for NPC patients treated with TomoTherapy compared to con-
formal technique. HT presents clinical advantages from planning and delivery 
aspects. Long-term clinical outcome of these patients are being summarized.
Author Disclosure Block: L. Ma: None. L. Du: None. L. Feng: None. X. 
Zhang: None. F. Li: None. G. Zhou: None. B. Qu: None. S. Xu: None. C. 
Xie: None.
222 
Stereotactic Ablative Radiotherapy for Lung Tumors using 
Helical Tomotherapy: A Cost-Effective Treatment Regimen
C. A. Peters1,2, T. M. Churilla2, C. B. Saw1,2, M. Baikadi1,2, H. D. Brereton1,2, 
1Northeast Radiation Oncology Centers (NROC), Scranton, PA, 2The 
Commonwealth Medical College, Scranton, PA
Purpose/Objective(s): Stereotactic ablative radiation therapy ( SABR) has 
been shown to be a highly efficacious approach in medically inoperable early-
stage lung cancer as well as oligometastatic disease. There is limited data 
regarding the costs of such approaches in comparison to standard fraction-
ated radiation therapy treatments or surgery. We sought to evaluate our SABR 
program looking at efficacy of treatment , treatment related toxicity, and costs 
of SABR versus alternative approaches including standard fractionated radio-
therapy and surgery. 
Materials/Methods: We prospectively collected all patients at our center 
undergoing SABR for lung tumors from September 2009 through September 
2011. All patients were treated with helical based Tomotherapy IGRT. 
Contours were generated via an ITV method. Treatment efficacy was evalu-
ated using post SABR scans and data on toxicity was gathered through a ret-
rospective review of medical records. Treatment related toxicity was scored 
via the CTC version 4.0. Cost data for radiation therapy was analyzed for all 
relevant billing codes including consultation, simulation, planning, treatment 
delivery and physician management. Cost stated for lobectomy was taken 
from a recent publication in the Annals of Thoracic Surgery and included both 
physician and hospital fees. 
Results: Twenty-four cases of lung SABR were evaluated during this time 
period. The median prescription dose was 60 Gy (range 48 to 60) adminis-
tered in five treatment fractions of 12 Gy each. The median follow up was 9.5 
months (range 1.9 through 31.2 months). Crude local control rate was 96%. 
One patient failed at 16 months, yielding an actuarial control rate of 86% at 
15 months. One patient experienced grade 3 pneumonitis requiring a hospital-
ization and steroids. There was no other grade 3 or higher toxicity. Total com-
prehensive cost for SBRT, five fraction regimen was $8,986. Additional costs 
were calculated for theoretical treatments using 3D conformal plans versus 
an IMRT plan. Estimated 3D conformal plans cost $12,233 for thirty-three 
fractions of 2 Gy each, and a similar IMRT plan costs $23,062 for thirty-three 
fractions of 2 Gy each. The mean cost of an uncomplicated lobectomy was 
$18,449 which increased to $39,250 when there were significant complica-
tions or death. 
Conclusions: Stereotactic ablative radiotherapy using helical Tomotherapy 
is a highly efficacious and well tolerated treatment regimen. SABR had the 
lowest cost when compared among 3D conformal fractionated treatments, 
IMRT treatments, and lobectomy. Due to the similar local control rates when 
compared to lobectomy, SABR is a cost-effective treatment strategy in this 
group of patients.
Author Disclosure Block: C.A. Peters: None. T.M. Churilla: None. C.B. 
Saw: None. M. Baikadi: None. H.D. Brereton: None.
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Comparison Of Internal Gross Tumor Volume For Peripheral 
Lung Cancer Based On Four Dimensional CT And Three 
Dimensional CT Assisted With Active Breathing Control
H. Qi, J. B. Li, Y. J. Zhang, Shandong Cancer Hospital, Jinan, China
Purpose/Objective(s): To compare differences of the centroid position, vol-
ume and matching index(MI) between internal gross tumor volume (IGTV) 
determined by four methods based on four dimensional CT and three dimen-
sional CT (4DCT and 3DCT) scans during free breathing and IGTV deter-
mined by one method based on 3DCT assisted with active breathing control.
Materials/Methods: After respiratory training sufficiently, eighteen patients 
(upper lobe group thirteen and middle-lower lobe group five) with peripheral 
lung cancer underwent 3DCT and 4DCT simulation scans during free breath-
ing and then underwent 3DCT simulation scans in end inspiration hold (CT
EIH
) 
and end expiration hold (CT
EEH
). IGTVs were acquired using five methods: 
The gross tumor volme (GTV) contours from ten respiratory phases were com-
bined into IGTV
10
; IGTV
MIP
 was the GTV contour delineated from maximum 
intensity projection (MIP); IGTV
AIP 
was the GTV contour delineated from 
the average intensity projection (AIP); IGTV
3D
 was acquired from the 3DCT-
based GTV enlarged the three spatial direction motion amplitude measured 
from 4DCT; IGTV
ABC 
was acquired by combining GTV from CT
EIH 
and CT
EEH
.
Results: In upper lobe group, there were significant or near significant differ-
ences in centroid position between IGTV
ABC 
and IGTV
10
, IGTV
MIP
, IGTV
AIP
 in 
lateral(LR)and anterio-posterior (AP) directions (p=0.035, 0.05; 0.052, 0.048; 
0.055, 0.064), but there were no significant differences in superio-inferior (SI) 
direction (p=0.09~0.210), the mean MIs were 0.59, 0.56, 0.56 respectively; 
there were no significant differences in centroid position between IGTV
ABC
 
and IGTV
3D
 in LR, AP and SI directions(p=0.161~0.612), the mean MI was 
0.50. In middle-lower lobe group, there were significant differences in cen-
troid position between IGTV
ABC 
and IGTV
10
, IGTV
MIP
, IGTV
3D 
in LR direction 
(p=0.017, 0.010, 0.014) , but there were no significant differences in AP and SI 
directions (p=0.233~0.898), the mean MIs were 0.31, 0.25, 0.27 respectively; 
there were no significant differences in centroid position between IGTV
ABC
 
and IGTV
AIP
 in LR, AP and SI directions (p=0.105~0.825), the mean MI was 
0.26. In both groups, the volumes of IGTV
10
, IGTV
MIP 
and IGTV
3D 
were
 
all 
larger than that of IGTV
ABC 
(p=0.001, 0.754, 0.001 and 0.08, 0.783, 0.097)and 
the volume of IGTV
ABC 
was larger than IGTV
AIP 
(p=0.075 and 0.319).
Conclusions: IGTV can be reduced by contouring GTVs based on 3DCT 
assisted with ABC for peripheral lung cancer, but IGTV
ABC
 can not contain 
all the informations of tumor motion. IGTV
ABC 
can contain the informations 
of tumor motion well in SI direction but can lead to geographic misses in AP 
and LR directions.
Author Disclosure Block: H. Qi: None. J.B. Li: None. Y.J. Zhang: None.
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Novel Hybrid Volumetric Modulated Arc Therapy (VMAT) for 
Stereotactic Body Radiation Therapy
(SBRT) of Lung Tumors in Proximity to the Chest Wall
L. Ku, N. Reyes-Molyneux, S. J. Wang, M. Y. Kang, T. L. McDonald, Salem 
Cancer Institute, Salem, OR
Purpose/Objective(s): It can be challenging to optimize SBRT treatment 
plans of peripheral lung lesions because of the large variation in tissue hetero-
geneity and close proximity to the chest wall. It has been shown that coplanar 
volumetric modulated arc therapy (VMAT) is capable of achieving high dose 
conformity comparable to coplanar static-angle IMRT but with slower dose 
fall-off than noncoplanar IMRT. To reduce dose to the chest wall and lung, 
we developed a hybrid VMAT planning strategy to achieve both high dose 
conformity and steep fall-off beyond the target volume. 
Materials/Methods: Seventeen lung lesions in sixteen patients with medi-
cally inoperable early stage non-small cell lung cancer or lung oligometas-
tases treated with hybrid VMAT were reviewed. All cases had overlap of the 
planning target volume (PTV) with the chest wall. Our hybrid VMAT planning 
approach utilized noncoplanar conformal beams and coplanar intensity modu-
lated arcs. Three to four noncoplanar beams were manually optimized to form 
the base dose plans, which contribute 25% to 30% of the prescribed dose. The 
VMAT portion, developed by base plan optimization, consisted of two full 
rotations. To demonstrate the benefit of the hybrid technique, we compared 
the hybrid plans with pure VMAT plans. Plan quality was evaluated using: 
conformity index (CI), ratio of 50% isodose volume to PTV volume (R
50%
), 
dose homogeneity, and lung volume receiving 10 and 20 Gy (V10 and V20). 
Results: All plans in this study were normalized by scaling the 100% isodose 
line to cover 95% of the PTV with the dose maximum ranging from 124% to 
134%. In all cases, the hybrid plans yielded better dose conformity (averaged 
CI = 1.09; range 1.03 - 1.24) than that of the pure VMAT plans (averaged CI = 
1.14; range 1.06 - 1.28). Moreover, the dose gradient was steeper in the hybrid 
plans: averaged hybrid R
50%
= 4.90, (range 4.02 - 6.97) vs. pure VMAT 5.36 
(range 4.24 - 7.45). Thus the hybrid technique was able to reduce dose to the 
chest wall and ribs. We noted that R
50%
 is correlated to the size of PTV. No sig-
nificant difference between the two approaches was found in pulmonary V20 
and V10. Treatment delivery time of the hybrid plans ranged from 11 minutes 
to 14 minutes. At a median follow-up of 6.7 months (range, 1 to 14 months), 
local control is 95.2% (1 in-field failure in patient with a 4.5 cm mass). One 
patient experienced grade 2 chest wall pain and 1 patient experienced grade 1 
dermatitis, which have resolved. 
Conclusions: Using the hybrid VMAT technique, we have achieved higher 
dose conformity with lower dose to the chest wall and ribs compared to a stan-
dard coplanar VMAT approach. Longer-term follow up is required to quantify 
the clinical significance of the hybrid VMAT strategy.
Author Disclosure Block: L. Ku: None. N. Reyes-Molyneux: None. S.J. 
Wang: None. M.Y. Kang: None. T.L. McDonald: None.
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Comparison Of Treatment Planning Dosimetric Parameters 
For Non-small Cell Lung Cancer Before And After 
Implementation Of The Collapsed Cone Dose Algorithm.
A. Macdonald, H. McCallum, S. Ramamurthy, F. McDonald, G. Lawrence, 
Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, 
United Kingdom
Purpose/Objective(s): The treatment planning system Oncentra Masterplan 
(Elekta) has both the collapsed cone (CC) algorithm and the pencil beam 
(PB) algorithm available for dose calculations. The CC algorithm takes into 
account beam scatter from surrounding tissue and is considered to give a 
more realistic and complex map of dose deposition than the PB algorithm, 
particularly in heterogeneous tissue such as the lungs. The aim of this work 
was to investigate how changing from the PB algorithm to the CC algorithm 
in practice affected the dose volume measures, in particular tumour coverage 
and the volume of healthy lung irradiated by 20Gy or more (V20). 
Materials/Methods: Data from two cohorts of non-small cell lung cancer 
patients prescribed 55Gy to the isocentre in 20 fractions were analysed. 41 
patients had plans prepared using the PB algorithm and 51 patients had plans 
developed using the CC algorithm. All the PB plans were re-computed using 
the CC algorithm, without modifying the plan parameters, to obtain compa-
rable dose statistics for the two patient groups. The significance of any differ-
ences was asessed using the two-tailed, unpaired t-test. 
Results: See table (all values mean +/- standard deviation): * Homogenity 
Index = (D2%-D98%)/D50%, the difference in dose between the hottest 2% 
and the coldest 2% of the PTV volume divided by the 50% isodose, hence a 
measure of the uniformity of dose coverage independent of the absolute dose 
delivered. Ideally zero for completely uniform dose coverage. 
Conclusions: The mean isocentre dose for the PB patient cohort was only 
1% less than that for the CC cohort; however, the relative dose coverage for 
the PB cohort was demonstrably less than that for the CC cohort when the 
CTV95% and PTV90% were compared and the homogenity index computed. 
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A smaller homogeneity index was achieved with fewer complex fields when 
the CC algorithm was used. The V20 was not significantly increased.
PB era plans (n=41)
CC era plans 
(n=51)
CTV95% (p<0.001) 87.56 +/- 18.99% (relative 
to prescribed dose)
98.91 +/- 1.73%
PTV90% (p<0.001) 91.24 +/- 10.83% (relative 
to prescribed dose)
98.74 +/- 1.58%
V20 (p=0.132) 19.55 +/- 8.23% 21.92 +/- 6.73%
Homogeneity index* 
(p=0.004)
0.166 +/- 0.065 0.132 +/- 0.040
Dose delivered to  
isocentre (p<0.001)
53.94 +/- 0.66Gy 55.03 +/- 0.24Gy
Author Disclosure Block: A. Macdonald: None. H. McCallum: None. S. 
Ramamurthy: None. F. McDonald: None. G. Lawrence: None.
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Using Mid-ventilation Phase for Calculation of Treatment 
Plan for Lung Cancer Patients might not be Optimal
C. Brink1,2, M. Nielsen2, O. Hansen1,3, T. B. Nielsen1,2, 1Institute of Clinical 
Research, University of Southern Denmark, DK-5000 Odense, Denmark, 
2Laboratory of Radiation Physics, Odense University Hospital, DK-5000 
Odense, Denmark, 3Department of Oncology, Odense University Hospital, 
DK-5000 Odense, Denmark
Purpose/Objective(s): Treatment planning and irradiation of lung cancer 
patients is often based on the mid-ventilation phase in order to minimize plan-
ning margins. Imaging artefacts are most pronounced in the mid-ventilation 
phase due to the rapid tumour motion in this phase. Thus, tumour delineation 
and dose calculation on a different phase might be optimal if the treatment is still 
performed at the mid-ventilation phase. The only hindrance is the potential dif-
ference in dose between different respiration phases as investigated in this study. 
Materials/Methods: 20 stereotactic lung cancer treatment plans based on the 
mid-ventilation phase were copied to the remaining phases, keeping the num-
ber of monitor units constant. The isocenter was fixed relative to the tumour 
position for all respiration phases. Prescription was 66 Gy/3 fractions with 
a minimum dose to PTV of 45 Gy. PTV, GTV, lung, spinal cord, and heart 
contours were propagated to the remaining respiration phases to create DVH’s 
for the individual phases. Differences of the DVH values were measured as 
differences of maximum and minimum values over all respiration phases or 
as differences between the expiration, inspiration and mid-ventilation phases. 
Correlations between DVH variations and tumour motion were evaluated. 
Results: For each patient the maximum differences of DVH values for all 
respiration phases were measured. The mean (and maximum) PTV difference 
for minimum dose (D
98
), median dose (D
50
) and maximum dose (D
02
) were 2.0 
Gy (3.6 Gy), 1.2 Gy (2.9 Gy) and 0.8 Gy (1.8 Gy), respectively. Differences 
between specific phases were evaluated by Wilcoxon test. The median dose 
showed a difference of: 0.6 Gy (p=0.002) between expiration and inspira-
tion, 0.4 Gy (p=0.003) between inspiration and mid-ventilation, and 0.2 Gy 
(p=0.23) between expiration and mid-ventilation. No statistically signifi-
cant differences for the minimum and the maximum doses were observed 
between the extreme phases: inspiration and expiration. None of the DVH 
variations for the PTV could be correlated to the size of the tumour motion 
(Spearman test >0.05). Very limited changes in doses to lung, cord, and heart 
were observed. However, for the heart and lung it was possible to establish 
a correlation between the dose variations and the amount of tumour motion. 
Conclusions: Variation between calculations in different respiration phases is 
observed. But only a minor part of this variation can be related to systematic 
differences between the extreme phases. The systematic difference (0.2 Gy) 
between mid-ventilation and expiration phase is small and not statistically 
significant. Due to the reduced image artefacts and the small systematic dose 
difference it is beneficial to perform the delineation and dose calculation in 
the expiration phase and perform the treatment at the mid-ventilation phase.
Author Disclosure Block: C. Brink: None. M. Nielsen: None. O. Hansen: 
None. T.B. Nielsen: None.
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Stereotactic Body Radiotherapy Beam (SBRT) Configuration 
On Target And Normal-structure Dose-volume Metrics
M. Rosenberg1, K. Carson2, C. M. Kato3, L. Z. Meng2, W. Laub2, J. A. 
Tanyi2, M. Fuss2, 1Brandeis University, Waltham, MA, 2OHSU, Portland, OR, 
3Macalester College, St. Paul, MN
Purpose/Objective(s): Beam arrangements for SBRT of lung tumors follows 
personal or institutional preferences. While beam entry over the contralateral 
lung is avoided by some groups, others favor a more evenly spaced circum-
ferential beam arrangement. We compared two beam arrangements; sectored 
(beam entry over ipsilateral hemithorax) and circumferential (beam entry 
over ipsi- and contralateral lung), for static-gantry IMRT delivery techniques 
with respect to dose gradient and exposure of normal organs at risk. 
Materials/Methods: Data from 132 patients treated by SBRT for primary 
NSCLC formed the basis of this study. Structures analyzed for dose exposure 
were the 4DCT-derived internal target volume (ITV), planning target volume 
(PTV, 5 mm expansion of ITV), spinal cord and the esophagus (delineated 
extending 5 slices above and below the PTV), ipsilateral (excluding PTV) and 
contralateral lung, respectively. Two treatment plans were generated per dataset: 
(1) IMRT plans using sectored beam arrangement (IMRT-s), and (2) IMRT plans 
using circumferential beam configuration (IMRT-c). Prescription dose (PD) was 
60 Gy (12 Gy/5 fx) to 95% of the PTV, and maximum PTV dose of 150%. 
Standardized optimization techniques were used on all plans. For lungs, mean 
doses (MLD), V5, V10, and V20 were recorded. Plan conformity indices, a mea-
sure of dose gradient, were computed; CI80, CI60 and CI40 (ratio of volume of 
80%, 60%, and 40% isodose, and PTV volume. Maximum dose (Dmax), D5 
and D50 for spinal cord and esophagus were computed. Dose parameters were 
analyzed with respect to tumor location (upper, middle, and lower lobes). 
Results: ITVs for the current study ranged from 0.9-162.9 cm3 (mean=20.9). 
IMRT-s planning resulted in significant decrease in contralateral MLD, V5, 
V10 and V20 when compared with IMRT-c (all p< 0.001). This finding applied 
to all tumor sites analyzed (all p<0.001). Ipsilateral lung dose exposure did 
not show statistical differences between IMRT-s and IMRT-c. While nominal 
reductions of Dmax, D5 and D50 for the spinal cord in IMRT-s plans did not 
reach statistical significance (p = 0.57, 0.18, and 0.19), the respective measures 
for esophagus were significantly lower than in IMRT-c plans (20.9%, 15.0%, 
and 22.6%; all p<0.001). Dose gradient improved with IMRT-s technique. 
Reductions in CI80, CI60, and CI40 were 1.4%, 3.5% and 8.1%, respectively. 
Conclusions: Sectored IMRT beam arrangements showed dosimetric advan-
tages over circumferential beam arrangements in terms of dose gradient and 
contralateral lung sparing. Further studies are needed to evaluate the clinical 
relevance of the current findings.
Author Disclosure Block: M. Rosenberg: E. Research Grant; 2011 AAPM 
Summer Undergraduate Fellowhip. K. Carson: None. C.M. Kato: None. 
L.Z. Meng: None. W. Laub: E. Research Grant; Varian Medical Systems. F. 
Honoraria; BrainLab, Inc.. G. Consultant; CMS, Inc. J.A. Tanyi: F. Honoraria; 
BrainLab, Inc. M. Fuss: E. Research Grant; Varian Medical Systems, Philips 
Medical Systems. F. Honoraria; BrainLab, Inc.. G. Consultant; BrainLab, 
Inc., Varian Medical Systems.
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A New Reliable SUV Index For Evaluating Local Control 
Using F-18 FDG PET Following Lung SBRT
C. Y. Shang1,2, M. Kasper1, T. R. Williams1, R. Benda1, J. C. Shope1, V. 
Kathriarachchi2, A. Schramm1, J. Cole1, 1Lynn Cancer Institute, Boca Raton, 
FL, 2Florida Atlantic University, Boca Raton, FL
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Purpose/Objective(s): To investigate the reliability of a novel method using 
a regional background-corrected maximum standardized uptake value (cSU-
V
max
) of 18F-FDG Positron Emission Tomography (PET) to assess the local 
control following stereotactic body radiosurgery (SBRT) for lung cancer. 
Materials/Methods: 31 qualified cases from 73 patients treated with lung 
SBRT for a single malignant lesion between May, 2009 and March, 2010 
were enrolled in this cohort study. Qualifications included a pre- and one or 
more post-treatment PET images available at the time of study. Each course of 
lung SBRT delivered 50 Gy in 5 fractions over 5-7 days using 6 MV intensity 
modulated photon beams. The median PET follow-up (FU) time after the first 
treatment was 38.4 weeks ranging from 14.6 to 115.0 weeks. cSUV
max
 was 
defined as the ratio of SUV
max
 of the treatment volume to the mean SUV of 
sampled descending aorta (SUV
mean-nom
)*. The absolute SUV
max
 and cSUV
max
 
were then compared for predicting the local control of lung SBRT. 
Results: The measured SUV
mean-nom
 was 1.828 ± 0.378, ranging from 1.173 
to 2.592. Using a threshold of 2.5 for SUV
max
 and 1.6 for cSUV
max
, their 
findings are tabulized into three chronological groups as seen in Table-1. 
Correspondingly 74% and 71% pre-SBRT PET were identified as positive by 
SUV
max
 and cSUV
max
; while only 35% and 48% of early (≤30 weeks) post-
SBRT PET were found below the thresholds. In the group with PET FU > 
30 weeks, 4 out of 31 cases exceeded the threshold of SUV
max
, although 3 
of which showed reduced cSUV
max
 from the previous FU PET. The 2 cases 
exceeded cSUV
max
 threshold in the last group also displayed further elevated 
values from their earlier FU PET. Only one case which exhibited high values 
and strong trend of increase in both cSUV
max
 and SUV
max
 was clinically identi-
fied as local recurrence. 
Conclusions: We formulized an objective method to evaluate local control fol-
lowing lung SBRT using cSUV
max
 of PET, a more reliable index with effective 
correction for SUV inherent uncertainties. The results of this study have sug-
gested a stronger correlation between low (<1.6) cSUV
max
 and the local control 
using PET after 30 weeks post lung SBRT than that with conventional SUV
max 
(p<0.01). Assessments for PET taken ≤ 30 week post lung SBRT yielded poor 
specificities with both methods, reflecting early treatment reactions. 
* Note: SUV of Aorta was sampled with 2.46 cm diameter ring over consecu-
tive 4 axial slides.
Table 1: Comparison of Two SUV Methods in Analyzing PET of 
Pre- and Post-Lung SBRT
Pre-SBRT PET ≤30 Weeks FU PET >30 Weeks FU PET
SUVmax cSUVmax SUVmax cSUVmax SUVmax cSUVmax
Median 3.89 1.94 3.14 1.72 2.03 1.25
SD 0.86 0.63 0.37 0.34 0.21 0.20
<Threshold 8 (26%) 9 (29%) 8 (35%) 11 (48%) 27 (87%) 29 (94%)
>Threshold 23 (74%) 22 (71%) 15 (65%) 12 (52%) 4 (13%) 2 (6%)
p (F-test) 0.3119 0.0599 0.0013
Author Disclosure Block: C.Y. Shang: None. M. Kasper: None. T.R. 
Williams: None. R. Benda: None. J.C. Shope: None. V. Kathriarachchi: 
None. A. Schramm: None. J. Cole: None.
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Safety and Efficacy of Stereotactic Body Radiation Therapy 
for Pulmonary Metastases from High-Grade Sarcomas
N. M. Mehta1, M. Selch1, N. Federman2, B. Chmielowski3, J. M. Lee4, F. 
C. Eilber5, P. Wang1, J. Wu1, N. Agazaryan1, P. Lee1, 1UCLA Department 
of Radiation Oncology, Los Angeles, CA, 2UCLA Department of Pediatric 
Hematology-Oncology, Los Angeles, CA, 3UCLA Department of Hematology-
Oncology, Los Angeles, CA, 4UCLA Department of Thoracic Surgery, Los 
Angeles, CA, 5UCLA Department of Surgical Oncology, Los Angeles, CA
Purpose/Objective(s): Patients with high-grade sarcomas (HGS) fre-
quently develop metastatic disease, thus limiting their long-term survival. 
Lung metastases (LM) have historically been treated with surgical resection 
(metastasectomy) along with systemic therapy in order to prolong survival. 
A potentially less morbid and as efficacious option for controlling LM could 
be stereotactic body radiation therapy (SBRT). We evaluated the local tumor 
control (LC), overall survival as well as pulmonary and esophageal toxicities 
from our institutional experience utilizing SBRT. 
Materials/Methods: The cohort consists of 16 consecutive patients with 
LM from HGS that were treated with linear accelerator-based SBRT between 
2009 and 2011 at our institution. 4D CT simulations were performed for all 
patients to assess tumor motion and generate an internal target volume (ITV). 
Stereoscopic and volumetric-based image-guidance was employed prior to 
each fraction. Respiratory gating was not employed. Routine radiographic 
(CT and/or PET-CT) and clinical follow-up was performed. Local failure 
for a treated lesion was defined as CT progression on 2 consecutive scans. 
Radiation pneumonitis (RP) and radiation esophagitis (RE) were scored on 
basis of Grade 0-1 (asymptomatic or no treatment) vs. Grades 2-5 using 
Common Toxicity Criteria (CTC) version 3.0. 
Results: All 16 patients received chemotherapy and a subset (38%) also 
underwent prior pulmonary metastatectomy. The median age of this cohort 
was 55 (12-85) and median follow-up time was 8.1 months (range: 0.8-28.1). 
A total of 25 lesions (76% soft tissue sarcoma, 24% bone sarcoma) were 
treated and evaluable for this analysis (up to 3 lesions were treated in a given 
session). Most common histologies were leiomyosarcoma (28%), synovial 
sarcoma (20%) and osteosarcoma (16%). Six of the 25 lesions were centrally 
located (within or touching a 2 cm zone around major airways). Median SBRT 
prescription dose was 54 Gy (36-54) in 3-4 fractions (majority received 54 Gy 
in 3 fractions), prescribed to the 95% isodose line. Median PTV volume was 
9.2 cm3 (1.8-84.9). At one year, there was one local failure (LC = 96%) in this 
cohort. All patients were alive at the time of this analysis. No patients experi-
enced G2-4 RP, and no patients experienced RE. 
Conclusions: Our single institutional experience suggests that stereotactic 
body radiation therapy for pulmonary metastases from high-grade sarcoma 
provides excellent local control with negligible toxicity. SBRT is less invasive 
than surgery and is an attractive alternative for patients with high operative 
risk. Longer follow-up time is needed. A phase II feasibility study is planned 
to prospectively validate these findings.
Author Disclosure Block: N.M. Mehta: None. M. Selch: None. N. 
Federman: None. B. Chmielowski: None. J.M. Lee: None. F.C. Eilber: 
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Comparison Of The Different 3DCT Scanning Modes On The 
Gtv Delineation Of The Solitary Pulmonary Lesion
D. Shang, J. Li, Shangdong Tumor Hospital, Jinan, China
Purpose/Objective(s): To explore the influence of the 3D CT scanning mode 
on the GTV delineation of solitary pulmonary lesion (SPL), and to evaluate 
the feasibility of the spiral CT scan in CT simulation. 
Materials/Methods: Sixteen patients with SPL underwent axial CT scan, 
spiral CT scan and four-dimensional CT (4DCT) simulation scan during free 
breathing. The same radiation oncologist delineated the gross tumor volume 
(GTV), using the same CT window setting. Compare the target position, vol-
ume between GTVS and GTVA . The matching index (MI) between GTVS 
and GTVA and correlations between MI and the tumor volume were calcu-
lated. Compare the volume size ratio of GTV4Dmip to GTVS and GTVA 
Results: GTVS and GTVA volume were 8.95±8.50cm3,9.38±9.47cm3, 
respectively, and there was no significant difference(t=0.425,P=0.667).
The centroid position for GTVS and GTVA in x axis were 
6.80±2.47,6.81±2.52, in y axis were 36.19±27.11,36.05±27.45, in z axis 
were 4.99±3.39,4.96±3.35,respectively, and there were no statistically sig-
nificant difference in the three axis (tx=0.266,P=0.794; ty=0.370,P=0.717; 
tz=0.650,P=0.526). There were also no statistically significant difference 
in the distance between the centroidal position and origin of coordinates 
for GTVS and GTVA(t=0.469,P=0.646). MI between GTVS and GTVA 
were 0.36±0.23(range 1~0.77), and was correlated with the tumor volume 
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(r =0.587).The volume of GTV4Dmip was bigger than GTVA and GTVS(t=
3.37,3.49,P=0.004,0.003),the volume size ratio of GTV4Dmip to GTVA and 
GTVS were 1.73±0.64, 1.64±0.55. 
Conclusions: There was no significant difference between the axial CT scan 
and spiral CT scan in the GTV volume and position for solitary pulmonary 
lesion (SPL),but MI between GTVS and GTVA were small. A correlation was 
found for the MI between GTVS and GTVA with the tumor volume. Spiral 
CT scan was more timesaving, and it was feasible in CT simulation scan
Author Disclosure Block: D. Shang: None. J. Li: None.
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Survey of Institutional Practices for Internal Target Motion 
Management in Lung Stereotactic Body Radiation Therapy 
(SBRT)
E. F. Crandley, P. W. Read, J. M. Larner, S. H. Benedict, University of Virginia, 
Charlottesville, VA
Purpose/Objective(s): Lung tumors can demonstrate substantial motion dur-
ing the respiratory cycle that must be accounted for in treatment with lung 
SBRT to ensure target coverage and minimize dose to normal tissue. There 
are a variety of strategies used to minimize internal target motion, and we 
conducted a survey to characterize the approaches used at academic centers 
experienced in lung SBRT in order to assess the variability of current practice.
Materials/Methods: A geographically balanced sample of 27 academic radi-
ation oncology centers was invited to participate in an electronic survey. 18 
surveys were completed from this group. With inclusion of our own practices, 
19 centers are represented in this analysis. The mean experience with lung 
SBRT was 8 years (range 4 - 20) and the mean number of patients treated with 
lung SBRT in the past year was 108 (25 - 450). 
Results: Of the 19 respondents, 18 use conventional/accessorized LINACs, 
5 use Cyberknife, and 2 use Tomotherapy for lung SBRT. 6/19 centers use 
fiducial markers “sometimes” (3 of which use Cyberknife). All 19 centers 
perform 4D CT. Additionally,2 use fluoroscopy, 1 uses MRI, and 1 uses PET 
routinely to assess tumor motion. 15 centers use respiratory motion control 
(RMC) techniques which include abdominal compression devices (5), active 
breathing control (5), deep inspiration breath hold (3), respiratory gating (5), 
and stereoscopic tumor tracking (4). Of centers using RMC, 2 use RMC for 
all patients, and 13 make a decision depending on the magnitude of tumor 
motion. Among the centers using RMC, 10 did not alter PTV margins based 
on the use of RMC, and 5 used smaller PTV margins when using RMC. All 
19 centers use daily image guidance (IGRT) for target localization, and 1 
also uses a stereotactic coordinate frame. All 18 centers using conventional 
LINCACs use cone beam CT (CBCT) for IGRT. Other IGRT techniques used 
include MVCT (2), kV orthogonal imaging (9), kV fluoroscopic imaging 
(3), and CT on rails (1). 11 centers use imaging to monitor for intra-fraction 
motion, including CBCT, MVCT, kV orthogonal imaging, and real time ste-
reoscopic imaging. 
Conclusions: Our data define current practices and provide instructive insight 
into the approaches utilized at the teaching and academic centers of North 
America. The current standard of care for lung SBRT at academic centers is 
4D CT at time of simulation and the use of daily image guidance. The vast 
majority of centers (79%) utilize RMC techniques to reduce target motion 
during treatment delivery, and intra-fraction motion is monitored at 58% of 
centers. It is emphasized that there is no single standard of care for IGRT or 
RMC technique. For centers wishing to start a new lung SBRT program, there 
are variety of IGRT and RMC techniques to choose from, and institutional 
specific quality assurance of any implemented technique is critical for patient 
safety.
Author Disclosure Block: E.F. Crandley: None. P.W. Read: None. J.M. 
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Incidental Nodal Irradiation in Stage III Lung Cancer 
Treated with Involved Field Radiation: Comparison Between 
3dcrt And IMRT
S. Sharma, J. T. Whaley, W. Zou, A. T. Fernandes, E. Xanthopoulos, C. B. 
Simone, J. P. Christodouleas, S. Both, R. Rengan, S. Apisarnthanarax, 
University of Pennsylvania, Philadelphia, PA
Purpose/Objective(s): Studies primarily using 3D-conformal radiation 
therapy (3DCRT) have shown that elective nodal (EN) areas may receive 
substantial incidental radiation doses in non-small cell lung cancer (NSCLC) 
patients. Due to the increasing use of intensity-modulated radiation therapy 
(IMRT) for NSCLC, we performed a dosimetric analysis of 3DCRT versus 
IMRT treatment plans to compare incidental radiation to thoracic nodal sta-
tions in NSCLC patients. 
Materials/Methods: Thirty consecutive stage IIIA and IIIB NSCLC 
patients treated with curative intent IMRT (median dose 72 Gy, range 
50-80 Gy) from 2009 to 2011 at the University of Pennsylvania were stud-
ied. Stage IIIB patients with contralateral N3 nodal disease were excluded. 
All patients received IFRT such that the entire nodal station volume was 
included in the CTV if the station had gross nodal involvement. Stations 
1-2, 3A, 3P, 4, 5, 6, and 7 were contoured using the University of Michigan 
CT-based atlas of thoracic node regions. EN station volumes were defined 
as the nodal volumes not included in the PTV. 3DCRT plans were generated 
using Eclipse planning software and optimized to have comparable PTV 
coverage while meeting dose constraints for lung, heart, esophagus, and 
spinal cord. Seven patients were excluded from dosimetric analysis due to 
cord dose constraints causing suboptimal PTV coverage in 3DCRT plans. 
Dosimetric parameters were calculated for each EN station for both IMRT 
and 3DCRT plans (n=46 plans). All data are represented as mean values 
unless otherwise specified. 
Results: PTV V95 coverage was similar between 3DCRT (92.3%) and IMRT 
(92.4%) plans (p=0.20). The mean dose at each EN station ranged from 27.2 
to 71.3 Gy for 3DCRT and 27.5 to 66 Gy for IMRT. No significant differences 
in V40, V50, or V60 of most EN stations were found between 3DCRT and 
IMRT plans, except for contralateral station 6 nodes: V50 and V60 were less 
with IMRT (39.3%, 13.5%, respectively) than with 3DCRT plans (66.6%, 
57.7%; p=0.0154, p=0.002, respectively). The mean dose of ipsilateral sta-
tion 5 and contralateral station 6 nodes were also lower with IMRT (66 Gy, 
43.4 Gy, respectively) compared to 3DCRT plans (71.3 Gy, 54.9 Gy; p=0.038, 
p=0.013, respectively). 
Conclusions: IMRT delivers a similar microscopic incidental radiation dose 
as 3DCRT to EN stations and can be safely delivered without concern for 
increased EN failures. However, caution must be noted when delivering IFRT 
with IMRT if there is high risk for subclinical disease in the AP window nodal 
regions.
Author Disclosure Block: S. Sharma: None. J.T. Whaley: None. W. Zou: 
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None. J.P. Christodouleas: None. S. Both: None. R. Rengan: None. S. 
Apisarnthanarax: None.
233 
Establishing a Relationship between Radiosensitivity of Lung 
Tissue and Ventilation
J. Bayouth1, K. Du2, G. Christensen3, B. Smith4, J. Reinhardt2, 1University of 
Iowa Hospitals and Clinics, Radiation Oncology, Iowa City, IA, 2University of 
Iowa, Biomedical Engineering, Iowa City, IA, 3University of Iowa, Electrical 
and Computer Engineering, Iowa City, IA, 4University of Iowa, Biostatistics, 
Iowa City, IA
Purpose/Objective(s): Radiation therapy (RT) induced symptomatic pneu-
monitis is a significant problem for patients with tumors of the thorax; pre-
dicting RT-induced pulmonary toxicity remains elusive. The purpose of this 
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study was to determine if the radiosensitivity of lung tissue is greater in 
regions with increased ventilation. 
Materials/Methods: Eight subjects from a prospective IRB approved clini-
cal trial were analyzed. 6-10 MV x-ray treatments were prescribed for doses 
between 61.2 to 70 Gy in 2 Gy fractions. Pulmonary function was derived for 
each voxel of the lung from 4DCT scans using deformable image registra-
tion techniques. The Jacobian determinant of the deformation map yielded 
the spatial distribution of ventilation for each subject. Patient specific changes 
in ventilation maps from 4DCT scans acquired prior to and 3 months post-
RT were defined as pulmonary function change (PFC) by (i) deformation of 
post-RT ventilation maps into the pre-RT map coordinate system, and (ii) 
computing the ratio of ventilation measured post-RT to pre-RT. PFC was 
correlated with radiation dose at the voxel level to establish a dose-response 
curve (DRC); average PFC in all voxels grouped in 5 Gy dose bins was evalu-
ated using linear regression. PFC was correlated with initial pulmonary func-
tion grouped in 5% expansion bins. DRC’s were determined for regions of 
lung with minimal lung function (≤ 5% tissue expansion) compared to those 
with higher function (≥ 10% expansion). Our measure of PFC at the voxel 
level was compared to clinically observed pulmonary toxicity determined by 
diffusion lung capacity for carbon monoxide (DLCO). 
Results: Subjects showed a clear relationship between regions irradiated and 
a decline in pulmonary function. In univariate analysis a strong correlation 
was found (r2=0.92) between calculated radiation dose to a voxel and the PFC 
observed 3 months post-RT. PFC correlated strongly with the initial pulmo-
nary function of the lung tissue (r2=0.97); dose differences in those tissues 
were negligible (< 1 Gy mean dose). The DRC for regions of lung with mini-
mal lung function had a linear regression line with far less slope (-0.0003, 
r2=0.57) than regions with higher lung function (slope=-0.0011, r2=0.95). The 
increased radiosensitivity of high functioning lung was significantly different 
from regions with minimal lung function (p=0.039). The measured percent 
reduction in DLCO had a modest correlation with the amount of lung demon-
strating a > 5% reduction in PFC at 3 months post-RT (r2 = 0.52). 
Conclusions: Regions of increasing pre-RT lung function show greater frac-
tional reduction in function post-RT. Our data reveals the increased sensitivity of 
high functioning lung, providing direct support for the hypothesis that improved 
oxygenation via ventilation increases the radiosensitivity of lung tissue.
Author Disclosure Block: J. Bayouth: None. K. Du: None. G. Christensen: 
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Intensity-Modulated versus 3D Conformal Radiation Therapy 
for Limited-Stage Small Cell Lung Cancer
C. A. Perez1, A. Rimner1, A. McLane1, D. Y. Gelblum1, R. M. Gewanter1, L. M. 
Krug1, M. C. Pietanza1, K. E. Rosenzweig2, A. J. Wu1, 1Memorial Sloan-Kettering 
Cancer Center, New York, NY, 2Mount SInai School of Medicine, New York, NY
Purpose/Objective(s): 3D-conformal radiation therapy (3DCRT) is the 
standard for definitive treatment of limited-stage small cell lung cancer 
(LS-SCLC). Intensity modulated radiotherapy (IMRT) may decrease toxic-
ity and facilitate dose escalation. We reviewed our experience using IMRT 
and 3DCRT for LS-SCLC to compare their disease outcomes, toxicity, and 
dosimetric parameters. 
Materials/Methods: Between 2003 and 2009, 150 patients were treated at 
our institution with thoracic IMRT (n=78) or 3DCRT (n=72) for LS-SCLC. 
Treating physicians generally preferred IMRT for patients with bulkier 
tumors. Patients received twice-daily RT to 45 Gy (n=80) or once-daily RT 
(n=70, 40-63 Gy; median 54 Gy). All patients received concurrent (n=119) 
or sequential (n=31) platinum-based chemotherapy. Dosimetric data was 
available for 77 and 49 IMRT and 3DCRT patients (99% and 68%, respec-
tively). CTCAE v.3.0 criteria were used to grade treatment-related toxicities. 
Kaplan-Meier methods and the logrank test were used to assess the associa-
tion between RT modality and survival outcomes. 
Results: The groups were comparable with respect to age, KPS, weight loss, use 
of twice-daily RT, median RT dose, and chemotherapy timing (sequential vs. 
concurrent and early vs. late). PTV volumes were significantly larger in IMRT 
vs. 3DCRT patients, with a median of 774cc (172-1122cc) and 481cc (284-
692cc), respectively (p=0.04). Fewer IMRT patients received prophylactic cranial 
RT (42% vs. 60%; p=0.03). At a median follow-up of 20 months, 2-year overall 
survival was 47% for IMRT vs. 64% for 3DCRT (p=0.02). Freedom from local 
failure at 2 years was 64% for IMRT and 80% for 3DCRT, while freedom from dis-
tant recurrence was 37% vs. 55%; neither difference was significant. Percentage 
Dmax was significantly lower with IMRT (mean 110.1% vs 114.9%, p<0.01). 
3DCRT was associated with significantly higher heart V30 (median 30.4cc vs. 
16.2cc, p=0.01). Other dosimetric parameters were comparable between the two 
groups, including mean lung V20 (30%), mean lung dose (15Gy), and esopha-
geal mean dose (32Gy). The rate of grade 2+ pneumonitis was lower for IMRT 
vs. 3D-CRT (3.8% vs. 6.9%), but this was not statistically significant. Grade 2+ 
esophagitis was the same (39% for 3DCRT vs. 40% for IMRT). 
Conclusions: Despite larger treatment volumes, IMRT was associated with 
lower overall Dmax and heart V30 compared to 3DCRT, while maintain-
ing similar lung V20 and mean lung dose. Overall survival was worse in the 
IMRT group, presumably due to bulkier disease, but local control was not sig-
nificantly different. IMRT may be beneficial in situations where meeting dose 
constraints would be challenging with 3DCRT, and may facilitate dose esca-
lation, which is currently being investigated in an RTOG randomized trial.
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Validation and reliability of Free Breathing Cone Beam 
Computed Tomography (FB-CBCT) imaging guidance in 
Stereotactic Ablative Radiotherapy (SABR) of lung tumors
F. Wang1, S. Das2, J. Park1, R. Badkul1, S. Hus1, P. Kumar1, 1University of 
Kansas Medical Center, kansas City, KS, 2Christian Medical College Vellore, 
Vellore, India
Purpose/Objective(s): FB-CBCT has been widely adapted as effective image 
guidance for SABR. The aim of this work was to assess interfractional varia-
tion of tumor volume on FB-CBCT in comparison of planning internal target 
volume (ITV) on 4-D planning CT scan and to determine the reliability, con-
sistency and reproducibility of FB-CBCT. 
Materials/Methods: 182 FB-CBCT images from 35 patients with 39 lung 
tumors treated with SABR in 3-5 fractions were evaluated. The gross tumor 
volume (GTV) on FB-CBCT was contoured using a referenced CT window. 
The variations of GTV volume and its geometric deformation on FB-CBCT 
were calculated. The correlation between GTV on FB-CBCT and ITV was 
analyzed. Interfractional variability was assessed by variation coefficient, reli-
ability coefficient and conformity index (CI). 
Results: The mean GTV volume on FB-CBCT from all tumors was 12.1cc, 
which was 12.9% smaller than ITV volume of 13.91 cc. The mean GTV volume 
was highly correlated (R2=0.96) to the ITV volume. The mean GTV volume 
in fraction 1 to 5 was 11.73, 13.20, 12.17, 12.01, and 11.22 cc, respectively. 
This GTV volume variation during each treatment session was not statistically 
significant. The variation coefficient for the population was 0.17 ±0.08 with 
normal distribution. The values of the interfrational reliability coefficient (0.99 
for 5 fractions and 0.97 for 3 fractions) indicated high reproducibility of results. 
The Jaccard index of conformity was 0.32 ± 0.13. The CI. of the central tumors 
was better than that of the peripheral tumors but the difference of the means was 
not statistically significant (p=0.58). A certain degree of deformation in the vol-
ume of GTV on FB-CBCT was observed. Mean volume deformation of GTV 
was 24.9% (±14.21). For centrally located tumors it was 23.2% (±9.91) and for 
peripherally located tumors it was 25.1% (± 14.83). However, this difference 
was not statistically significant (p=0.678). The regression analysis indicated that 
the distance of GTV from vertebrae and their locations was significantly cor-
related to the deformation of GTV (p= 0.013 and 0.004, respectively). 
Conclusions: FB-CBCT is a valid tool for image guidance in SABR with high 
correlation of GTV volume to ITV, lower interfractional variation coefficient 
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and high reliability coefficient. The relative large degree of GTV deformation 
on FB-CBCT may warrant the consideration of geometric volume missing 
when non volumatric image guidance is used for SABR.
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Dose Escalation Using PET Imaging For NSCLC While 
Maintaining RTOG 0915/0813 Criteria
K. P. Orcutt1, J. M. Larner1, J. Buatti2, P. W. Read1, K. Wijesooriya1, 1University 
of Virginia, Charlottesville, VA, 2University of Iowa, Iowa City, IA
Purpose/Objective(s): Despite the dramatic improvements with the advent of 
SBRT for the treatment of lung cancer, local tumor failure is still observed in 
approximately 10% of patients. Molecular imaging studies such as 18F-FDG 
PET reveal significant tumor heterogeneity. Although the underlying basis of 
the heterogeneity (perfusion, cell density, hypoxia and proliferation) is not 
fully understood, it is likely that heterogeneity seen in PET may predict thera-
peutic resistance. We therefore determined how much dose escalation could 
be achieved in Planning Target Volume (PTVs) sub-volumes with high stan-
dard uptake values (SUV) without violating the RTOG 0915/0813 dosimetric 
constraints. 
Materials/Methods: PET CT and CT simulation scans for 10 tumors ranging 
between 2cc to 20cc were used for this dosimetric study. SUVmax uptake 
values for each tumor were obtained from pretreatment PET CT using 
the Velocity system and %SUV max dose rings corresponding to values 
(40%SUVmax to 90%SUVmax) were defined. Pinnacle treatment planning 
system was used to guide the dose gradient within the PTV dose rings such 
that the highest uptake areas receive the highest dose using standard inverse 
planning constraints and non-coplanar beam angle arrangements. Dose esca-
lation to each of the SUV uptake rings were attempted until a minor deviation 
in RTOG 0915/0813 criteria occurred. These SUV based dose painted plans 
were then compared to optimized non-dose painted plans. 
Results: The average mean dose for the 60-100% SUV volume can be 
increased up to 107.4 (12.3 STD) (range 89.4 - 124.8) Gy for a prescription 
dose of 60Gy while meeting the RTOG 0915/0813 dosimetric criteria. The 
V50% dose was increased up to 66.91 (6.40 STD) Gy where the V50% dose 
is defined as the dose to 50% of the PTV volume. The limiting dosimetric 
criteria was R50 and in some cases D105% volume as well. 
Conclusions: By employing 18F-FDG %SUVmax uptake rings as a guide we 
have dose painted the PTV volume. Our data demonstrates the feasibility of 
significant PTV sub-volume dose escalation for SBRT cases without violating 
the RTOG 0915/0813 dosimetric criteria.
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C.elegans, an In Vivo Model For Lung Cancer: Effect of 
Chronic Exposure of Nicotine on Specific Mutants Relevant 
To Lung Cancer
I. Dhanasingh, R. Kanteti, E. El-Hashani, T. Stricker, S. Nagy, D. Biron, 
K. Vokes, R. Salgia, University of Chicago, Chicago, IL
Lung Cancer is a devastating disease that accounts for more than 28% of all 
cancer deaths. Our lab has previously identified gain-of-function mutations 
in some of the receptor tyrosine kinases such as c-MET in lung cancer. We 
have previously shown that the simple soil nematode C. elegans engineered 
to over express the c-MET mutant revealed an abnormal vulval phenotype 
with hyperplasia. Interestingly, we also observed that exposure to Nicotine 
significantly aggravated the above phenotype thereby further strengthening 
our contention that C. elegans can be used as an in vivo model for rapid 
screening of c-MET mutants as well as drugs. We therefore systematically 
carried out studies to evaluate the effect of chronic exposure to nicotine on 
survival, fertility, egg laying capacity, locomotion and phenotypic changes. 
In addition, we also carried out gene expression profiling. The C. elegans 
mutants used were Vab-1 (EphB4), SD551 (k-Ras), RB2088 ( MET) and 
three sli-1 mutants namely PS2728, PS1258 , MT13032 (c-Cbl). Although, 
pair wise comparison with wild type N2 worms did not reach significance, 
in general, the mutants suffered loss in survival, especially in Vab-1 and 
SD551. Further, nicotine treatment adversely effected egg laying capac-
ity in mutants compared to their wild type N2 worms. Also, the fertility 
(the number of eggs laid/worm) was significantly reduced in SD551 and 
PS2728 (c-Cbl mutant) compared to wild type N2 worms. Our locomotion 
studies revealed that Vab-1 showed increased circular motion with increas-
ing nicotine concentration that was not observed in other mutant strains. 
Overall locomotion velocity did not change with increasing concentration 
of nicotine in most of the strains except for MT13032, which is one of the 
Cbl mutants. Heat map analysis of gene expression profiling data clearly 
revealed that the various kinases and phosphatases in C. elegans that are 
usually marginally expressed in the wild type N2 worms were significantly 
enhanced in response to chronic exposure to nicotine. The expression of 
these genes was already high in SD551 mutant and was further increased by 
exposure to nicotine. Taken together, chronic nicotine exposure adversely 
affects various biological functions of C. elegans and these effects are exag-
gerated in the mutants. Interestingly, nicotine treatment also up regulates 
the expression of various kinases and phosphatases thereby strengthening 
our contention that the initial screening studies for the oncogenic mutants 
detected in humans can be rapidly carried out in the soil nematode C. 
elegans.
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MET/RON Dual Inhibition by LY2801653 Small Molecule 
Inhibitor with Dramatic Effects on Non-Small Cell Lung 
Cancer
I. Kawada1, R. Hasina1, Q. Arif2, J. Mueller2, E. Smithberger1, A. N. Husain2, 
E. E. Vokes1, R. Salgia1, 1Dept. of Medicine, the University of Chicago, 
Chicago, IL, 2Dept. of Pathology, the University of Chicago, Chicago, IL
Purpose/Objective(s): Lung cancer is a heterogeneous group of disorders 
with a number of genetic abnormalities. We have identified the MET recep-
tor tyrosine kinase (RTK) to be overexpressed, mutated, or amplified in lung 
cancer, especially in non-small cell lung cancer (NSCLC). A number of clini-
cal trials are ongoing for MET inhibition and resistance is being seen. We 
have previously identified that RON RTK can be overexpressed in NSCLC 
and synergizes with MET. The MET/RON small molecular inhibitor (SMI) 
LY2801653 was identified and developed as a novel, potent, and orally active 
SMI of human MET and RON. 
Materials/Methods: We used 10 NSCLC cell lines. LY2801653 was pro-
vided by Eli Lilly and Company (Indianapolis, IN). Immunoblotting was 
performed to look at the expression of MET/RON. The sensitivities of the 
cell lines to LY2801653 were determined by performing cell proliferation 
assay using MTT. Cells treated with drug were immunoblotted to evaluate 
the biochemical effects of inhibition of MET and RON. The PamGene® plat-
form was used to demonstrate effect of treating H1993 cells with LY2801653 
on 144 phosphorylation related peptides. To investigate the effect of MET/
RON inhibition on tumor proliferation, the mouse flank xenograft model with 
A549 and H1993 cells was used. Further, an orthotopic lung tumor model 
was established in SCID mice using luciferase tagged A549 cells and tumor 
progression was monitored by bioluminescence using Xenogen IVIS®. 
Results: There was expression of total MET in many cell lines, with the high-
est, medium and low level expression found in H1993, A549 and H1703, 
respectively. LY2801653 specifically inhibited proliferation of NSCLC cell 
lines at IC50 = 627.6 nM, 72.9 nM and 6.08 nM in A549, H1703 and H1993, 
respectively, and inhibited phosphorylation in downstream signaling of 
MET/RON. The PamGene® platform also showed a network of downstream 
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signaling molecules affected by MET/RON inhibition, such as CBL, PI3K 
and STAT3, and this was validated by immunoblots. In vivo mouse modeling 
revealed decreased tumor growth and dramatic effects on mitotic events and 
angiogenesis events in both A549 and H1993 studies. In the orthotopic tumor 
model, oral gavage with LY2801653 reduced A549-luc tumor growth signifi-
cantly relative to vehicle control. 
Conclusions: Specific inhibition of MET/RON by LY2801653 was able to 
abrogate cell proliferation, tumor growth, as well as affect downstream signal 
transduction in MET/RON. These results demonstrate the promising thera-
peutic potential of LY2801653 in treating NSCLC.
Author Disclosure Block: I. Kawada: None. R. Hasina: None. Q. Arif: 
None. J. Mueller: None. E. Smithberger: None. A.N. Husain: None. E.E. 
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Volumetric Modulated Arc Therapy (VMAT) Reduces 
Treatment Time Compared to Conventional Intensity 
Modulated Radiation Treatment (IMRT) of Thoracic Tumors
B. E. Amendola, M. Amendola, N. Perez, A. Iglesias, E. Axenfeld, Innovative 
Cancer Institute, South Miami, FL
Purpose/Objective(s): To evaluate the advantages of VMAT in reference to 
delivery time and acute toxicity in the management of thoracic tumors. Two 
modalities of VMAT are reviewed: stereotactic body radiotherapy (SBRT) 
and conventional fractionation. Our results are compared to published data 
for both SBRT and conventional fractionation IMRT using other available 
techniques. 
Materials/Methods: From October 2008 to March 2012 a total of 81 treat-
ment courses were delivered in 62 patients with thoracic tumors: 53 using 
conventional fractionation, 25 using SBRT, and 3 using Lattice Radiation 
Therapy. The selection criteria for either modality were tumor size, location, 
and performance status of the patient. There were 45 patients with primary 
lung cancer, 3 patients with thymoma, and 14 patients with metastatic cancer 
to the lung from various primary sites. Ages ranged from 39 to 90 years with 
a mean of 70. Patients were treated during normal day schedules independent 
of being SBRT or conventional VMAT. Fifteen patients were treated more 
than once. Other parameters analyzed were monitor units, number of arcs, 
and dose fractionation. 
Results: In conventional fractionation planning we used between 1 and 4 
arcs, mostly 2 arcs. The dose per fraction ranged from 1.8 Gy to 3 Gy. The 
average number of monitor units (MU) per Gy was 2.6. Treatment times 
ranged from 1.1 minutes to 2.9 minutes depending on the total arc length. 
For SBRT, 4 non-coplanar partial arcs were typically used. The number of 
arcs ranged from 1 to 6. An average of 3.3 MU/Gy was used and the “ beam 
on” time ranged from 2.2 to 10.3 minutes depending on the number of MUs 
used. Dose per fraction ranged from 5 to 20 Gy given in 1 to 5 fractions. 
Acute toxicity was minimal for all the patients. Patients who had a high 
Karnofsky had no interruptions during the course of treatment and tolerated 
the treatment well. Reproducibility of the patient setup was achieved using 
IGRT/CBCT. 
Conclusions: Volumetric modulated arc therapy (VMAT) in thoracic tumors 
is a novel radiation technique, which can achieve highly conformal dose dis-
tributions with improved target volume coverage and sparing of normal tis-
sues compared with conventional radiotherapy techniques. VMAT also has 
the potential to offer additional advantages, such as reduced treatment deliv-
ery time compared with conventional static field intensity modulated radio-
therapy (IMRT). This study demonstrates the feasibility and practicality of 
these techniques.
Author Disclosure Block: B.E. Amendola: None. M. Amendola: None. N. 
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Assessing Radiographic Response And Failure Patterns 
Following Stereotactic Body Radiation (sbrt) For High Risk/
medically Inoperable Stage I Non Small Cell Lung Carcinoma 
(nsclc)
K. A. Kotinsley, B. M. Kotinsley, J. Mueller, O. Gayou, E. Werts, A. Colonias, 
Allegheny General Hospital, Pittsburgh, PA
Purpose/Objective(s): To assess radiographic response and factors associ-
ated with failure in patients (pts) treated with lung SBRT. 
Materials/Methods: Follow up computed tomography (CT) and positron 
emission tomography (PET) images of 55 pts with high risk/medically 
inoperable stage I NSCLC treated with SBRT (mean dose 47.4 Gy in 4-5 
fractions) were reviewed by two radiologists. Primary tumor failure (PTF) 
was defined as both an increase in tumor dimension of 20% on CT and with 
PET uptake of at least a similar intensity as the pretreatment staging PET. 
Involved lobe failure (ILF) refered to a lung cancer located separate from 
the originally treated tumor but within the same lobe and with an SUV > 
3-5 on PET. Local failure (LF) was defined as PTF + ILF. Regional failure 
(RF) was defined as tumor within lymph nodes along primary lymphatic 
drainage patterns with dimension of at least 1.0 cm on imaging within the 
lung, hilum or mediastinum. Distant failure (DF) was defined as failure 
outside of the originally involved lobe, involvement of distant organs, or 
both. Response definitions were as follows: Complete response (CR): the 
disappearance of the target lesion; Partial response (PR): at least a 30% 
decrease in the longest diameter (LD) of the target lesion based on CT; 
Local expansion (LE): at least a 20% increase in the LD of target lesion; 
Stable disease (SD): as neither sufficient shrinkage to qualify for CR/PR 
nor enlargement for LE. Multivariate analysis was performed using logisti-
cal regression analysis. 
Results: The median age was 75 years (range 55-91 years) with 27 females 
and 28 males. 41 pts had stage IA and 14 had stage IB. With a median follow 
up of 10.9 months (mo) (range 1-34 mo), there have been 5 (9%) PTFs, 1 
(2%) marginal failure, 2 (3.6%) ILFs, and 2 (3.6%) with both. There were 6 
(11%) RFs, and 6 (11%) DFs. 11% (n=6) had a CR at a median of 3.125 mo 
(range 1-10 mo), 31% (n= 17) had a PR at a median of 9.42 mo (range 3-22 
mo), 27% (n=15) had SD, and 5% (n=3) had LE at a median of 4 mo (range 
1-9 mo). 38% (n=21) of pts were noted to have consolidation. On multivari-
ate analysis, male gender trends toward better PTF, LF, RF, and DF. Increased 
number of pack /years appears associated with increased ILF and LF while 
younger age correlated with increased LF and RF. However, these correlations 
cannot be definitive with this relatively small population and low failure rates. 
There was no correlation found with Charlson Comorbidity Index, total dose, 
dose/fraction, stage, or pathology. 
Conclusions: With a median follow up of 10.9 mo (range 1-34 mo), SBRT 
achieved a ~ 90% primary tumor control with 42% achieving a CR/PR and 
27% having SD. In order to better correlate outcomes with clinical factors, 
longer follow up with a larger series of patients is needed.
Author Disclosure Block: K.A. Kotinsley: None. B.M. Kotinsley: None. 
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Stereotactic Ablative Radiotherapy to the Lung: Does 
CyberKnife Provide any Dosimetric Advantage over a 
Standard Linear Accelerator?
L. M. Keller, S. Hayes, F. Zhu, J. Fan, L. Jin, J. Meyer, T. Tam, A. Turaka, Fox 
Chase Cancer Center, Philadelphia, PA
Purpose/Objective(s): To determine dosimetric differences between lung 
stereotactic ablative radiotherapy (SABR) treatment plans delivered by the 
CyberKnife (CK; Accuray Incorporated) versus a standard linear accelerator 
(LA). 
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Materials/Methods: All approved lung SABR plans used to treat patients 
from July 2009- December 2011 at Fox Chase Cancer Center were reviewed. 
Plans utilizing a pencil beam algorithm or plans treating two targets concur-
rently were excluded. Dosimetric parameters extracted included volume (vol) 
of the GTV and PTV, maximum (max) PTV dose, prescription (Rx) isodose 
line, conformality index (CI), ratio of 50% Rx isodose vol to PTV vol (R50), 
and max dose 2 cm from PTV (D2cm). Normal dosimetric tissue parameters 
extracted included the volume of lung receiving 5Gy (V5) and 20 Gy (V20), 
volume of chest wall receiving 30 Gy (V30), max chest wall dose, max spi-
nal cord dose, and max esophageal dose. Wilcoxon rank-sum test was used 
to compare dosimetric parameters between LA and CK plans for the entire 
cohort and as a function of both PTV and GTV volume (as a binary compari-
son using the median volume as the cut point). 
Results: One hundred and twelve treatment plans (80 LA and 32 CK) were 
eligible for analysis. The median dose delivered was uniform between LA 
and CK treatment plans (48 Gy in 4 fractions). The median GTV vol for the 
LA vs CK plans was 4.3 cc vs 2.0 cc (p = 0.01) and the median PTV vol for 
the LA vs CK plans was 22.5 cc vs 16.6 cc (p = 0.6). The PTV/GTV ratio 
was significantly larger for the LA plans (5.5 vs 1.7, p <0.0001). The median 
Rx isodose for LA plans was 84% vs 60% for CK plans (p <0.0001). The 
median max PTV dose was 58.4 Gy for LA plans vs 82.1 Gy for CK plans 
(p <0.0001). Analysis of the entire cohort revealed the following parameters 
were statistically significantly different (all p <0.0001) between LA and CK 
plans, respectively: median CI (1.7 vs 1.3), R50 (7.9 vs 4.8), and D2cm (70% 
vs 50%). LA plans had a significantly larger V20 compared with CK plans 
(128.5 cc vs 59.9 cc; p = 0.0003). Analysis as a function of GTV vol showed 
that median CI, R50, D2cm, and V20 remained improved for CK plans (all p 
≤ 0.001). Analysis as a function of PTV vol showed that for PTV vol ≤ 21.9 cc 
the median CI, R50, D2cm, and V20 remained improved for CK plans (all p ≤ 
0.001). For PTV vol >21.9 cc only the median CI, R50, and D2cm remained 
improved for CK plans (all p ≤ 0.05). 
Conclusions: CyberKnife afforded improved conformality as assessed by 
high dose fall off (CI) and intermediate dose fall off (R50 and D2cm) as 
compared to treatment plans delivered on a standard linear accelerator. This 
generally resulted in a lower V20 observed in CK plans, with the predominant 
benefit observed with smaller PTV volumes. Whether these dosimetric dif-
ferences translate into clinical benefits in terms of improved tumor control or 
decreased toxicity needs to be studied further.
Author Disclosure Block: L.M. Keller: None. S. Hayes: None. F. Zhu: 
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S-frame versus BodyFIX: A Comparison of Immobilization 
Techniques for Upper Lung Tumors with Stereotactic Body 
Radiotherapy
T. T. Sio, A. R. Jensen, L. E. Fong de los Santos, S. S. Park, C. L. Hallemeier, 
D. J. Ma, H. J. Bauer, K. R. Olivier, Mayo Clinic, Rochester, MN
Purpose/Objective(s): To compare the impact of SBRT immobilization strat-
egies (S-frame/BodyFIX) on setup and reproducibility for upper lung tumors. 
Materials/Methods: Our institutional prospective SBRT database was 
searched for patients with upper lung tumors, defined as an internal tumor 
volume superior to T5 vertebra. Initially the full-length BodyFIX was used 
for all lung SBRT patients. For upper lung tumors, an extended, thermoplastic 
S-frame was recently added as an option. At simulation, a free-breathing 4-D 
computed tomography was performed without respiratory gating or breath-
ing control. For each treatment, patients were first set up to isocenter with 
in-room lasers and skin tattoos. Subsequent shifts from initial couch position 
were made using cone-beam CT (CBCT) to correct for tumor position. If 
shifts greater than 4 mm were required, they were applied and a new CBCT 
would be obtained. Couch shifts were analyzed as square root of sum of 
squares in x, y, and z-directions. Kaplan-Meier, Fisher’s exact and equal vari-
ance t-tests were used. 
Results: Median follow-up was 8.7 months (quartiles, 4.4-19.1). Between 
April 2008 and Jan 2012, 88 patients with 93 upper lung tumors (21 cen-
tral, 72 peripheral) were identified. Median age was 71.8 years. 64 tumors 
were non-small cell lung cancer (54 primary, 10 recurrent), 29 metastatic 
from other sites. Lesion sizes were: < 1cm (15%), 1.1-2cm (50%), 2.1-3 
cm (25%), and > 3cm (11%). 17 tumors were immobilized with S-frame; 
76 with BodyFIX. Dose schemes were: 48Gy/4 fractions (28%), 50Gy/5 
fractions (24%), and 54Gy/3 fractions (46%). A total of 347 fractions (65 
S-frame, 282 BodyFIX) were delivered. First couch shifts were statistically 
better with S-frame than BodyFIX (see Table). The first couch shift by CBCT 
exceeded the 4-mm tolerance in 33 (51%) fractions in S-frame, vs. 217 (77%) 
in BodyFIX (Fisher’s p < 0.0001). Correction by 1st couch shifts was usually 
successful, as 2nd couch shifts were similarly small regardless of immobiliz-
ing device; 3rd shifts were rarely needed. For all patients, 2 and 3-year local 
control rates were 94% and 81%, respectively; median has not been reached 
yet. There is no difference in local control for patients immobilized by the 
S-frame vs. BodyFIX (Log-rank p > 0.704). 
Conclusions: For upper lung tumors treated with SBRT, initial setup was 
more consistent with S-frame immobilization compared to BodyFIX, result-
ing in less CBCTs in our clinical practice.
Table. Summary of Couch Shift Differences by S-frame and 
BodyFIX (Unit: Millimeters)
S-frame 
(no.)
BodyFIX 
(no.)
P
Fraction 1, 1st shift (mm) 4.2 (17) 12.3 (76) < 0.00001*
Fraction 1-3, 1st shift 5.2 (51) 10.6 (225) < 0.000001*
Fraction 1-5, 1st shift 5.6 (65) 10.1 (282) < 0.000001*
Fraction 1, 2nd shift 3.0 (7) 1.9 (68) 0.44
Fraction 1-3, 2nd shift 3.2 (23) 2.7 (110) 0.51
Fraction 1-5, 2nd shift 3.1 (28) 2.6 (130) 0.44
Fraction 1-5, 3rd shift 2.3 (5) 1.9 (4) 0.64
Mean couch shift difference (mm) = sqrt (delta_x2+ delta_y2+ delta_z2) 
* Statistically significant (two-sided alpha = 0.05)
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Validation of High-Resolution Multi-Modality Imaging of 
Pre-Treatment Lung Function in Pulmonary Neoplasms
T. Diwanji1, S. Pokharel2, S. Feigenberg1, W. D’Souza1, N. Mistry1, 1University 
of Maryland School of Medicine, Baltimore, MD, 2Morgan State University, 
Baltimore, MD
Purpose/Objective(s): There is a growing interest in using functional infor-
mation for treatment planning. However, existing clinical techniques are lim-
ited in value due to their low spatial resolution. Here, we propose the use of 
multi-modality imaging of lung ventilation and lung perfusion at high spatial 
resolution using 4D-CT and 4D-Dynamic Contrast Enhanced MRI (DCE-
MRI), respectively. Furthermore, we validate these techniques against the 
current clinical standards for evaluation of lung function, i.e. Scintigraphy 
Ventilation and Perfusion (VQ scans) and Pulmonary Function Tests (PFTs). 
Materials/Methods: VQ scans, 4D-CT, and DCE-MRIs, were acquired in 4 
patients prior to radiotherapy. PFTs were acquired in 3 out of the 4 patients. 
4D-CT images were used to create 3D fractional regional ventilation (FRV) 
maps by applying a “mass correction” and subtracting the spatially matched 
end-exhale and end-inhale images. DCE-MRI images were acquired using a 
fast-volumetric scan that tracks a bolus of a gadolinium based contrast agent 
to extract voxel-by-voxel estimates pulmonary blood flow (PBF). Standard 
clinical protocols were utilized for the acquisition and analysis of scintig-
raphy VQ data. Manual contouring of the lung was performed to eliminate 
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the heart and large blood vessels from the analysis. FRV and PBF maps were 
collapsed in the anterior-posterior dimension to create coronal 2D projection 
images consistent with the scintigraphy VQ scan images. The projections 
were divided into 6 sections of equal height analogous to the analysis per-
formed on VQ scans and statistically compared using the Kendall’s tau rank 
correlation. 
Results: Kendall’s tau estimate for correlation between the FRV/PBF and V/Q 
measurements are reported in Table 1. Mean functional residual capacities 
(FRC) from the PFTs (N=3) versus calculated FRCs from FRV maps were 
2.7 +/- 0.6 L and 2.4 +/- 0.7 L, respectively, and the null hypothesis could not 
be rejected (p = 0.61), implying statistical similarity between multi-modality 
techniques and “gold-standard”. 
Conclusion: There was a strong correlation between scintigraphy VQ and 
multimodality measurements of ventilation and perfusion. The similarity 
between the calculated and measured FRCs further validates the utility of 
4D-CT to evaluate ventilation. Furthermore, the significant increase in spatial 
resolution compared to the clinical “gold-standard” highlights the utility of 
high-resolution multi-modality functional lung imaging.
Correlation between FRV/PBF and scintigraphy VQ
Patient #
Ventilation (FRV) 
Corr. Coef.
p-value 
(FRV)
Perfusion (PBF) 
Corr. Coef.
p-value 
(PBF)
P1 0.87 0.005 0.93 0.0009
P2 0.93 0.0009 0.96 0.0002
P3 0.94 0.0006 0.93 0.0008
P4 0.95 0.0002 0.95 0.0002
Author Disclosure Block: T. Diwanji: None. S. Pokharel: None. S. 
Feigenberg: None. W. D’Souza: None. N. Mistry: None.
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Relationship between Pulmonary Artery Invasion and High 
Dose Radiation and Overall Survival in Patients with Non-
Small Cell Lung Cancer
C. Han1,2, W. Wang1,3, L. Quint1, J. Hayman1, P. Stanton1, J. Xue1,4, M. 
Matusak1, R. Ten Haken1, F. Kong1, 1Department of Radiation Oncology, 
University of Michigan, Ann Arbor, MI, 2Department of Oncology, Shengjing 
Hospital of China Medical University, Shenyang, China, 3Department of 
Radiation Oncology, the Fourth Hospital of China Medical University, 
Shenyang, China, 4Department of Thoracic Oncology, West China Hospital of 
Sichuan University, Chengdu, China
Purpose/Objective(s): RTOG 617 reported an inferior 1 year survival and 
2.3% absolute increase in deaths from adverse events including massive hem-
orrhage in patients treated with 74 Gy arm. Using patients treated in prospec-
tive studies in 2 Institutions, this study aimed to investigate whether high dose 
radiation to pulmonary artery (PA) is associated with overall survival 1 year 
survival rate in patients with non-small cell lung cancer (NSCLC). 
Materials/Methods: Eligible patients were those with medically inoperable, 
histologically confirmed NSCLC treated with definitive fractionated radio-
therapy with or without concurrent chemotherapy and enrolled into prospec-
tive studies at our institution. Tumor involvement to pulmonary artery was 
scored on pretreatment CT and PET_CT as 0, 1, 2, 3, 4 or 5 for none, adja-
cent, abutting, encasement, invasion, and massive invasion, respectively. PA 
was contoured per RTOG 1106 atlas and dose volume histogram was gener-
ated. Overall survival (OS) was estimated using Kaplan-Meier method and 
compared with log-rank test. Both univariate and multivariate analysis were 
performed for statistical significance. 
Results: A total of 100 consecutive patients enrolled, among them 80 (80%) 
cases were stage III and 82 (82%) underwent concurrent chemoradiotherapy. 
Radiation dose ranged from 60-90 Gy in 30-37 fractions. There were 53, 19, 
5, 9, 10, 4 patients with scores of 0, 1, 2, 3, 4, and 5 for PA involvement, 
respectively. The 1-year survival rate /median survival are 67% /25.4 months 
(95% CI, 15.7-35.1), 62%/22.2 months (95% CI, 5.8-38.6), 90%/35.8 months 
(95% CI, 28.4-43.2), and 50%/7.0 months for patients PA invasion of grade 
<= 2, 3, 4, and 5, respectively (P=0.601 for trend). Two of the 4 patients with 
grade-5 PA invasion died suddenly from massive lung hemorrhage at 3 and 
4.5 months after completion of RT. Higher prescription dose was associated 
with better survival (HR: 0.939, P<0.01). Age, gender, KPS, chemotherapy, 
and higher maximum PA dose were not associated the risk of death. PA V45, 
V50, V55, and V60 were significantly correlated with worse OS (P all <0.05). 
There was no significant correlation between the PA V45-65 and planning 
target volume, or degree of PA tumor involvement (P>0.05). PA V45 ~70% 
and PA V60 ~37% were significant cutoff values to predict OS. Patients with 
V45>70%, or V60>37% experienced significantly worse survival (13.3 vs. 
37.9 months P<0.001, and 13.8 vs. 37.9 months, P=0.04, respectively). 
Conclusions: Degree of PA invasion was not associated with 1 year survival, 
though massive invasion may be associated with high risk of early death. 
Instead PA volume receiving greater than 45-60 Gy is among the most signifi-
cant factors for worse survival for NSCLC treated with definitive RT. Future 
study with larger number patients is needed to validate such findings.
Author Disclosure Block: C. Han: None. W. Wang: None. L. Quint: None. 
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Correlation Of FDG Avid Volumes Of Initial And Recurrent 
Lung Cancers After Radiotherapy Or Chemoradiotherapy
N. Shusharina, N. C. Choi, G. C. Sharp, Massachusetts General Hospital, 
Boston, MA
Purpose/Objective(s): Increased glucose metabolism may reflect enhanced 
biological function of tumors. Therefore, subvolume of lung cancer with 
increased 2-fluoro-2-deoxy-D-glucose (FDG) uptake may be the culprit for 
local recurrence after radiotherapy. The purpose of this study was to measure 
the magnitude of overlap of FDG avid volumes of recurrent and initial lung 
cancers after therapy. 
Materials/Methods: We enrolled 106 patients into a prospective study in which 
serial 18F-FDG PET was obtained within 3 weeks before, 10-12 days, 3 months, 
6 months and 12 months after radiotherapy or chemoradiotherapy for correla-
tion between residual FDG uptake and tumor control probability. We identified 
24 patients with local failure among these patients and their serial FDG uptake 
images were analyzed. All patients received fractionated RT to a median dose of 
63 Gy. Pre- and 12 days post-RT scans were rigidly aligned to project the posi-
tion of re-grown tumor onto the position of the initial one. Five patients were 
excluded for low quality PET scan data or low quality rigid registration, yielding 
a final patient set of 18 patients (19 tumors). SUV threshold-based delineation on 
pre- and post-RT scans was used to calculate overlap fractions between the areas 
of high metabolic activity. In addition, 18F-FLT PET was also available in five 
patients for image correlation with initial FDG PET. 
Results: Analysis of overlap fraction (OF) of 50% of SUV
max
 in pre-treatment 
scan with 70%, 80% and 90% of SUV
max
 in post-treatment scan showed that the 
location of tumor recurrence was highly correlated with location of initial tumor; 
average OF was 0.66 for 70% (0.71 median), 0.69 for 80% (0.79 median) and 
0.75 for 90% (0.93 median) of SUV
max
. Overlap of pre-treatment FDG uptake 
and post-treatment FLT uptake demonstrated several qualitative features. In two 
patients the highest FLT uptake was observed in the center of tumor mass where 
FDG uptake was lowest or absent presumably indicating hypoxic region in the 
tumor. Two cases demonstrated a high spatial overlap of the initial and recurred 
tumor, whereas in the other cases FLT-based OF (0.9 for 70%, 1 for 80% and 
90% of SUV
max
) was much higher than FDG-based OF (0.31 for 70%, 0.27 for 
808% and 0.04 for 90% of SUV
max
) which reflected higher specificity of FLT to 
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the tumor cell compared to FDG. Comparison of post-treatment FDG uptake 
with post-treatment FLT uptake also indicated high spatial overlap (OF average 
is 0.62 for 70% , 0.68 for 80% and 0.78 for 90% of FLT SUV
max
). 
Conclusions: FDG PET images of initial and recurrent lung cancers showed 
a robust correlation suggesting that subvolume of lung cancer with high FDG 
uptake may be a target for supplemental dose of radiotherapy.
Author Disclosure Block: N. Shusharina: None. N.C. Choi: None. G.C. 
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Predicting Symptomatic Radiation Pneumonitis after 
Concurrent Chemoradiotherapy for Non-Small Cell Lung 
Cancer: Results of an International Individual Patient Data 
Meta-analysis
D. A. Palma1, S. Senan2, K. Tsujino3, R. B. Barriger4, R. Rengan5, M. 
Moreno6, J. D. Bradley7, T. Hyun Kim8, L. B. Marks9, G. Rodrigues1, 1London 
Regional Cancer Program, London, ON, Canada, 2VU University Medical 
Center, Amsterdam, Netherlands, 3Hyogo Cancer Center, Hyogo, Japan, 
4Indiana University School of Medicine, Indianapolis, IN, 5University of 
Pennsylvania, Philadelphia, PA, 6Clínica Universidad de Navarra, Pamplona, 
Spain, 7Washington University School of Medicine, St. Louis, MO, 8National 
Cancer Center, Goyang, Korea, Democratic People’s Republic of, 9University 
of North Carolina, Chapel Hill, NC
Purpose/Objective(s): Radiation pneumonitis is a dose-limiting toxic-
ity for patients undergoing concurrent chemoradiation therapy (CCRT) for 
non-small cell lung cancer (NSCLC). We performed an individual patient 
data meta-analysis to determine factors predictive of clinically significant 
pneumonitis. 
Materials/Methods: After a systematic review of the literature, data was 
obtained on 836 patients who underwent CCRT in Europe, North America 
and Asia. Patients were randomly divided into training and validation sets 
(2/3 vs. 1/3 of patients). Factors predictive of symptomatic or fatal pneumo-
nitis were evaluated using logistic regression. Recursive partitioning analysis 
(RPA) was used to define risk groups. 
Results: The median radiotherapy dose was 60 Gy, and median follow-up was 
2.3 years. Most patients received concurrent cisplatin/etoposide (38%) or car-
boplatin/paclitaxel (26%). The overall rate of symptomatic pneumonitis was 
29.8% (n=249), with fatal pneumonitis in 1.9% (n=16). In the training set, 
factors predictive of symptomatic pneumonitis were lung volume receiving 
≥20 Gy (V20) [OR:1.03 per 1% increase, p=0.008], and carboplatin/pacli-
taxel chemotherapy [OR:3.33, p0.65). On RPA, the highest risk of pneumoni-
tis (>50%) was in patients >65 years of age receiving carboplatin/paclitaxel. 
Predictors of fatal pneumonitis were daily dose >2 Gy, V20, and lower-lobe 
tumor location. 
Conclusions: Several modifiable risk factors predict the development of 
symptomatic pneumonitis, and elderly patients who undergo CCRT with 
carboplatin-paclitaxel chemotherapy are at highest risk. Fatal pneumonitis, 
although uncommon, is related to dosimetric factors and tumor location. 
Funding: Ontario Institute for Cancer Research (DP) and in part by National 
Institutes of Health Grant CA69579 (LBM)
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Sanofi Aventis. K. Tsujino: None. R.B. Barriger: None. R. Rengan: None. 
M. Moreno: None. J.D. Bradley: None. T. Hyun Kim: None. L.B. Marks: 
None. G. Rodrigues: None.
248  
The Impact of the Lung Oncology Multidisciplinary Team 
(MDT) Meetings on the Management of Patients with Cancer
K. Ung, B. Campbell, D. Duplan, D. Ball, S. David, Peter MacCallum Cancer 
Centre, Melbourne, Australia
Purpose/Objective(s): Multidisciplinary team (MDT) meetings are increas-
ingly regarded as a component of multidisciplinary cancer care. We aim to 
prospectively measure the impact of MDT meetings on clinicians’ manage-
ment plans for lung oncology patients, and the implementation rate of the 
meeting recommendations. 
Material/Methods: Consecutive patient cases presented at the weekly lung 
oncology MDT meetings were prospectively enrolled. Investigators compared 
the clinicians’ management plans pre-meeting with the consensus plans post-
meeting. The meeting was considered to have an impact on management plans 
if one or more of the following changes were detected: tumor stage, histology, 
treatment intent or treatment modality, or if additional investigations were 
recommended. Investigators reviewed hospital patient records at four months, 
to determine if the meeting recommendations were implemented. Reasons for 
non-implementation were also recorded. 
Results: Of the 55 eligible cases, the MDT meeting changed management 
plans in 58% (CI 45-71%; p <0.005). These changes included: additional 
investigations (59%), or changes in treatment modality (19%), treatment 
intent (9%), histology (6%), or tumor stage (6%). The meeting recommenda-
tions were implemented in 72% of cases. Reasons for non-implementation 
included deteriorating patient performance status, clinician’s preference, the 
influence of new clinical information obtained after the meeting or patient 
refusal. 
Conclusion: MDT meetings significantly impact on the management plans 
for lung oncology patients. The majority of MDT recommendations (72%) 
were implemented into patient care. These findings provide further evidence 
to support the role of MDT meetings as an essential part of the decision-
making process for the optimal multidisciplinary management of patients 
with cancer.
Author Disclosure Block: K. Ung: None. B. Campbell: None. D. Duplan: 
None. D. Ball: None. S. David: None.
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Geographical Variation In Non-small Cell Lung Cancer 
Survival In The United States
R. Mandal1, B. Shah2, 1University of Wisconsin, Madison, WI, 2St. Joseph 
Regional Medical Center, Lewiston, ID
Abstract:
Purpose/Objectives: It is unknown if there is any geographical variation in 
survival among patients with non-small cell lung cancer (NSCLC). This study 
was conducted to evaluate the survival rates in the northern (latitude ≥40o) 
and southern regions (latitude < 40o) in the United States for the period of 
2004-2008. 
Materials/Methods: We used Z-test in the Surveillance, Epidemiology, and 
End Results (SEER*Stat) program to analyze 1y and 3y relative survival rates 
of NSCLC included in SEER database. Several cohorts categorized by race 
(Caucasian (CC), African American (AA), and other races (Oth)-American 
Indian/AK Native, Asian/Pacific Islander), gender, and AJCC stages were exam-
ined to compare the survival rates in the northern and southern regions of the 
U.S. Based on the counties’ centroid, northern (latitude ≥40o) and southern (lati-
tude < 40o) regions were determined. The data from 2004 to 2008 were used as 
6th edition AJCC staging was recorded in SEER database from 2004 onwards. 
Results: The dataset comprised of 21,316, 3,132, and 1,768 patients with 
NSCLC among CC, AA, and Oth races, respectively. The 1y and 3y relative 
survivals for several CC cohorts pooled across men and women were lower in 
the South compared to the North for all AJCC stages except for stage II. The 
Z-values for 1y survival for pooled data across men and women for NSCLC 
stages I, II, III, and IV were -2.17*, -1.09, -2.47*, and -2.71*, respectively and 
for 3y survival they were -2.00*, -0.44, -2.52*, and -2.01*, respectively. The 
Z-values are negative when the survival in the South is lower compared to the 
North (asterisk signs indicate statistical significance at p<0.05). When catego-
rized by sex, 1y relative survival for stage IV disease among CC women was 
lower in the southern region compared to the northern region (relative surviv-
als: 23±0.8%, n=3,517 vs. 24.9±1.1 %, n=1,853; Z-value = -2.10*, p =0.036). 
There was no significant geographical difference in the survival rates among 
any cohorts among AA or Other races. 
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Conclusions: This study shows that the 1y and 3y relative survival rates 
among Caucasian cohorts pooled across men and women were lower in the 
South compared to the North for NSCLC stages I, III, and IV. When catego-
rized by sex, CC women had lower 1y relative survival for NSCLC stage IV 
in the South. Further studies are required to explore the potential causes of 
differences in survival by geography.
Author Disclosure Block: R. Mandal: None. B. Shah: None.
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Evaluation of Esophageal Cancer Outcomes in Native 
American Patients: An analysis of the Survival, Epidemiology, 
and End Rersult (SEER) Database
S. S. Szeja, A. B. Desai, T. Sroka, N. P. Nguyen, University of Arizona, 
Tucson, AZ
Purpose/Objective(s): The incidence and outcomes of patients with esopha-
geal carcinoma demonstrate disparities based on race. The vast majority of 
reports analyzing this have focused on African American patients. We sought 
to determine whether differences exist in treatment and outcomes in Native 
American patients with esophageal carcinoma, particularly since little has 
been reported on this specific minority group. 
Materials/Methods: We identified all Native American and White patients 
diagnosed with esophageal cancer between 1973 and 2008 from the SEER 
database. The cohort consisted of 267 Native American (NA) patients and 
45,718 White (W) patients. Chi-Square (χ2) tests were used to compare 
univariate differences and Cochran-Mantel-Haenszel (χ2
MH
) tests were used 
for multivariate comparisons. Survival comparisons were performed with 
Kaplan-Meier methods to determine the impact of race on esophageal-
specific survival (ESS). Multivariate hazard ratios were computed with Cox 
methods to test for racial differences in ESS after adjusting for confounding 
variables. 
Results: The age at diagnosis was similar between NA patients and W 
patients (median 69 years). NA patients were more likely to be diagnosed with 
adenocarcinoma (p<0.001) and less likely to be diagnosed with squamous cell 
carcinoma (p<0.001). NA patients were more likely to have lesions located in 
the upper 2/3rd of the esophagus (p<0.001). With regards to stage at diagno-
sis, NA patients were less likely to be diagnosed with local disease (p=.016) 
and more likely to be diagnosed with distant disease (p=.02). Both groups 
were equally likely to undergo neoadjuvant or adjuvant radiation (χ2
MH
 = 0.44, 
p=0.50) and equally likely to be recommended surgery (χ2
MH
= 1.03, p=0.31). 
However, NA patients were less likely to receive surgery (χ2
MH
= 8.23, p= 
0.004). On Kaplan-Meier analysis, the 5-year ESS was worse for NA patients 
at 14% compared to W patients at 20% (p= 0.001). In multivariate regres-
sion controlling for age, socioeconomic status, histology, tumor location, and 
grade, NA status was associated with worse 5-year ESS (HR value 1.24; 95% 
Confidence Interval (CI) 1.08-1.44). When stage, surgery, and radiation were 
included in the regression model, NA status was still associated with worse 
5-year ESS (HR= 1.15; 95% CI 1.002-1.332). 
Conclusions: Our study suggests that NA patients are at greater risk of death 
from esophageal cancer when compared to W patients. Even when accounting 
for socioeconomic status, stage, surgery, and radiation, the difference is sig-
nificant. It is possible that environmental and epigenetic factors have a role, 
and further studies are warranted to determine the role of NA race as related 
to esophageal carcinoma.
Author Disclosure Block: S.S. Szeja: None. A.B. Desai: None. T. Sroka: 
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Improving Treatment Outcome of Radiation Therapy in Non-
small Cell Lung Cancer (NSCLC): Results of 288670 Patients 
from SEER-17 Database
F. P. Kong1, W. O. Quarshie2, N. Kapadia1, F. Vigneau2, 1University of 
Michigan, Ann Arbor, MI, 2Wayne State University, Detroit, MI
Purpose/Objective(s): There have been remarkable advances in radiation 
technology in treatment of non-small cell lung cancer (NSCLC) recently. It is 
well known that radiation provides local tumor control and technology mat-
ters. This study aimed to examine whether 1) radiation can improve survival 
over other nonsurgical treatment and 2) the survival during the recent years 
with advancement of technology. 
Materials/Methods: The study population includes all 1st primary NSCLC 
from the SEER-17 database 1999-2008. The data were stratified by AJCC 
stage and treatment type (surgery only, surgery + radiation, radiation only, 
neither surgery nor radiation and unknown treatment). Chemotherapy data 
were not available in the SEER-17 data. Frequency distributions and percent-
ages by strata were analyzed. Median Survival times with associated 95% 
confidence intervals (95%CIs) were estimated by the Kaplan-Meier method. 
Data are presented as median survival time (in month) (95%CI). The “na” 
refers to an interval that was too narrow to be computable. 
Results: A total of 288670 patients included in this analysis. The stage distri-
bution was as following: 19% stage I, 4% stage II, 26% stage III, 46% stage IV 
and 11% unknown. The median survival was 49 (48-50), 27 (26-29), 9 (9-10), 
4 (na) and 7 (6-8) months, for stage I, II, III, IV and unknown, respectively. 
Overall, 78% were treated with non-surgical modality; only 32% received 
radiation treatment. In patients who did not have surgery, treatment of radia-
tion generated a significant better survival in each stage: stage I 18 (18-19) 
vs 12 (11-12) months (P<0.05), 15 (14-15) vs 7 (7-9) months P<0.05), 11 
(na) vs 5 (na) months (P<0.05), and 12 (na) months vs 4 (na) months, and 
5 (na) vs 3 (na) months, for stage I, II, III, IV and unknown, respectively. In 
those treated with radiation, the median survival improved significantly dur-
ing recent years (2004-2008) compared to that of earlier years (1999-2003) 
in stage I (6 months’ extension) and III (3 months’ extension), but not stage 
II and IV (no changes). 
Conclusion: In patients with unresectable inoperable disease, radiation 
therapy extended median survival in all stages of NSCLC in these 288670 
patients of SEER data base. Superior survival in patients of stage I and III 
treated during the recent years suggests a potential benefit from the advanced 
technology.
Author Disclosure Block: F.P. Kong: None. W.O. Quarshie: None. N. 
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Primary Care Physicians (PCPs) And Referral To Oncology
A. Abdolmohammadi1, S. Rai1, J. Pan1, J. Alexander2, G. H. Kloecker1, 1James 
Graham Brown Cancer Center, Louisville, KY, 2Kentucky Clinical Trials 
Network, Lexington, KY
Background: PCPs refer patients to oncologists for various reasons. Previous 
studies have shown that a significant number of cancer patients are never seen 
by medical oncologists. PCPs are major contributors to multispecialty groups 
(MSG) and will be to accountable care organizations (ACO). The referral pro-
cess by PCPs is often not guideline-based, but determined by what and whom 
they know. This study examines the relative importance of reasons, why aca-
demic and non-academic PCPs decide to refer or not to refer to oncology.
Materials/Methods: 3444 surveys were sent out, (printed 2,497, electronic 
947) to 1,993 Family Medicine (57%) and 1,451 Internal Medicine MDs 
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(43%), in academic (13%) and non-academic centers (87%). The survey 
asked physicians to rate on an ordinal scale from one to five the importance 
for each reason, whether to refer or not to refer to oncology. The eight reasons 
were: type of cancer, stage, symptoms, patient’s preference, age, comorbidi-
ties, availability of oncology, logistics. Answers were categorized into very 
important, somewhat-important and not- important. Chi-Square testing was 
used for each reason in the “very important” and “not-important” category to 
test for statistical significance.
Results: 316 physicians (9.1%) responded, 89 academic MDs (28%), 227 
non-academic MDs (72%).The rate of returned surveys was equal by spe-
cialty. Type of cancer, stage of cancer and the patient’s desire or reluctance 
to be referred were rated by PCPs as the most important reasons (p<.0001). 
Patients’ age and logistics were not important (n.s). Academic and community 
PCPs responded in the same pattern for all factors (p>.05).
Conclusions: PCPs use type and stage of cancer as major discriminators to 
refer to oncology. Also, patients’ preference significantly influences the PCPs’ 
decision to refer to oncology. These reasons are a measure of the patients’ and 
PCPs’ perception of prognosis and therapeutic benefit. This decision making 
process leaves room for error and may miss opportunities for intervention 
by medical oncology. Guidelines are needed to assist PCPs and MSG/ACO’s 
in their referral algorithm. The decision to refer to oncology requires further 
research and standardization.
Author Disclosure Block: A. Abdolmohammadi: None. S. Rai: None. J. 
Pan: None. J. Alexander: None. G.H. Kloecker: None.
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Video-Assisted Thoracoscopic Lobectomy in Primary Lung 
Cancer: Predictors of Recurrence
V. L. Sales1, T. L. Weigel1, A. M. Traynor2, T. Hoang2, T. C. Campbell2, G. 
M. Cannon3, 1Department of Surgery, Section of Thoracic Surgery, Division 
of Cardiothoracic Surgery, University of Wisconsin Carbone Cancer Center, 
University of Wisconsin- Madison and School of Medicine and Public Health, 
Madison, WI, 2Division of Hematology/Oncology,University of Wisconsin 
Carbone Cancer Center, University of Wisconsin- Madison School of 
Medicine and Public Health, Madison, WI, 3Department of Human Oncology, 
University of Wisconsin Carbone Cancer Center, University of Wisconsin- 
Madison School of Medicine and Public Health, Madison, WI
Purpose/Objective(s): Video-assisted thoracoscopic surgery (VATS) 
approach is becoming increasingly patient-driven and adopted for resection 
of primary lung cancers in some centers. Open thoracotomy has been the gold 
standard for lobectomy, thus long-term outcomes following VATS lobectomy 
should be studied. We sought to determine the time- and pathologic-related 
prevalence of recurrence and its risk factors following VATS lobectomy for 
non-small cell lung cancer (NSCLC).
Materials/Methods: Between January 2006 and December 2011, 174 
patients (mean 66 years, range 32 to 95) who underwent VATS lobectomy 
with NSCLC resection were identified from a retrospective review of pro-
spectively-collected database. One hundred fifty-three patients (88%) had 
follow-up information (clinical exams, computer tomography scans and chest 
X-ray) to document recurrence rate.
Results: Thirty-day mortality was 0%. Resection was complete in 98% 
(171/174) of patients. Postoperative therapy (chemotherapy and or additional 
radiotherapy) was administered in 18% (31/174) patients. After a median 
follow-up of 11 months (range, 3 days-65 months), recurrence rate was 18% 
(32/174). Recurrence-free survival (RFS) difference within stage groups 
was significant (Stage I 80%, Stage II 72%, Stage III 68% and Stage IV 
60%, p<0.01) at a median follow-up of 4-, 2-,2- and -1 year, respectively 
with an overall RFS of 76% after 3 years. In contrast, overall survival (OS) 
was similar within stage groups (Stage I 89%, Stage II 88%, Stage III 79% 
and Stage IV 80%, p=0.28) at a median follow-up of 5-,3-,2- and 2-years, 
respectively with an OS rate of 87% after 5 years. RFS and OS rates were 
81%, 70%, 54% and 44% and 95%, 85%, 79% and 72% after 1-, 2,-3, and 
5-years, respectively. Multivariate Cox modeling demonstrated that Charlson 
Comorbidity Index scores (CCI) (p <0.001), CCI greater than 2 (moderate 
to severe risk) (p<0.05), preoperative American Society of Anesthesiologist 
(ASA) score (p1) (p<0.05), pathologic tumor size (p<0.05), involvement of 
N1 and N2 nodes (p<0.05) and number of nodes positive (p <0.001) were 
independent predictor of recurrence. Risk factors for higher postoperative 
recurrence prevalence varied with staging groups and included higher CCI 
scores in patients with stage I (odds ratio 1.55; p< 0.001) and stage III (odds 
ratio 1.99; p< 0.05) tumors only, and worse ASA scores and larger tumor 
size in patients with stage II tumors only (odds ratio 13.71; p<0.05 and odds 
ratio 1.75; p<0.05).
Conclusion: Stage-specific survival in patients undergoing VATS lobectomy 
is excellent. Higher CCI score, worse ASA score and larger tumors are inde-
pendent risk factors for lower stage-specific recurrence-free survival.
Author Disclosure Block: V.L. Sales: None. T.L. Weigel: None. A.M. 
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Patterns of Care for Patients (Pts) with Stage I Non-Small 
Cell Lung Cancer (NSCLC): Analysis of the National 
Comprehensive Cancer Network (NCCN) Oncology Outcomes 
Database, 2007-2011
N. S. Kapadia1, S. Bobiak2, C. Zornosa2, T. D’Amico3, K. Pisters4, B. Dexter5, 
J. Niland6, J. Hayman1, 1University of Michigan Hospital Cancer Center, Ann 
Arbor, MI, 2National Comprehensive Cancer Network, Fort Washington, PA, 
3Duke Cancer Institute, Durham, NC, 4The University of Texas MD Anderson 
Cancer Center, Houston, TX, 5Roswell Park Cancer Institute, Buffalo, NY, 
6City of Hope, Los Angeles, CA
Purpose/Objective(s): For medically fit pts with stage I NSCLC, surgery is 
the mainstay of curative therapy. Recent advances in radiotherapy (RT) have 
made it a viable option for medically inoperable pts. We sought to further 
describe disease characteristics and treatment details. 
Materials/Methods: The NCCN database identified biopsy-proven clinical 
stage I NSCLC pts (per AJCC 6th ed.) at 8 member institutions, presenting 
from 1/2007 - 6/2011. Pt, disease, and treatment characteristics were analyzed 
among pts receiving surgery and RT. 
Results: Of 1,506 pts with stage I NSCLC, 1183 (79%) underwent surgery, 
248 (16%) received RT, 43 (3%) were not treated, 24 (2%) received only che-
motherapy, and 8 (<1%) received other local therapy. Of the RT pts, 184 (74%) 
received stereotactic body RT (SBRT) and the other 64 (26%) received non-
stereotactic RT (NSRT). The rates of surgery remained unchanged between 
2007 and later years, although there were non-significant trends of increasing 
SBRT and decreasing NSRT (p=0.09). Across institutions, frequency of sur-
gery varied from 61 to 97% (p<0.01) and SBRT accounted for 0 to 93% of 
RT courses (p=0.01). No gender, race, or body-mass index differences were 
observed between surgery and RT pts. Pts < 60 years old compared to 60+ 
(OR 3.2; CI 2.0-5.3) or with a Charlson comorbidity score of 0 compared 
to >2 (OR 5.22; CI 3.29-8.27) were more likely to undergo surgery. History 
of COPD, MI, smoking, non-zero ECOG performance status, or impaired 
pulmonary function were associated with receiving RT (all p<0.01). Stage 
(IA vs IB) was not associated with receipt of surgery vs RT, although stage 
IB was significantly more likely to be treated with NSRT than SBRT (OR 
5.85; CI 3.14-10.93). RT pts were more likely to have undergone brain (OR 
3.1; CI 2.3-4.0) or other CT imaging (OR 1.6; CI 1.2-2.1). Of the surgical 
pts, 89% underwent mediastinoscopy and/or endobronchial ultrasound, ver-
sus 20% of RT pts (p<0.01). Median days from diagnosis to treatment was 
significantly longer for NSRT pts (49.5) and SBRT pts (46) compared to sur-
gery pts (11, p<0.01). Among the SBRT pts, 2 (1%) received chemotherapy 
versus 17 (27%) of NSRT pts. The median number (and range) of fractions, 
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fraction size, and total dose for SBRT pts were 4 (1-10), 12.5 (6-34Gy), and 
50 (18-70Gy) and 33 (1-37), 2 (1.8-8.5Gy), and 69 (4-87.5Gy) for NSRT pts, 
respectively. 
Conclusions: Patterns of treatment with NSRT, SBRT, and surgery vary 
among the institutions. RT pts present with more comorbidity and are more 
frequently staged for distant though less frequently for regional disease. 
Although univariate analyses did not show an increase in SBRT over time, 
future multivariable analyses may reveal covariates that influence its use.
Author Disclosure Block: N.S. Kapadia: None. S. Bobiak: None. C. 
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Outcomes For Stage III Unresectable Non-Small Cell Lung 
Cancer (NSCLC) Treated With Concurrent Chemotherapy 
And Radiation Therapy To 70 Gy
J. Freilich, R. Baker, C. W. Stevens, W. J. Fulp, M. DeMarco, C. Turke, T. J. 
Dilling, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Purpose/Objective(s): Concurrent chemotherapy and radiation therapy 
to 60 Gy is the standard of care in treating unresectable stage IIIA/IIIB 
NSCLC, though with standard treatment there are still many local and dis-
tant failures leading to poor overall survival. Single institutional studies 
show the benefits of dose escalation in improving outcomes but a recent 
interim analysis of RTOG 0617 showed no benefit when comparing 60 Gy 
to 74 Gy. The purpose of this study is to evaluate our institution’s experi-
ence in patients treated with concurrent chemotherapy and radiation ther-
apy to 70 Gy. 
Materials/Methods: We performed a retrospective review of all patients 
with unresectable stage III NSCLC treated at our institution from 2005-2011 
with concurrent chemotherapy and radiation therapy to 70 Gy. Treatment 
planning employed 4D technique and involved field treatment only, as deter-
mined by PET/CT. 129 patients were identified and local regional control 
(LRC), disease free survival (DFS), overall survival (OS), and side effects 
were analyzed. 
Results: Median and mean follow-up was 16 and 21 months, respectively 
(range 1.5-73). Mean age at diagnosis was 62 years (range 36-84). 94% of the 
patients were performance status (PS) 0-1 and 6% were PS 2. 48% of patients 
had IIIA disease and 52% had IIIB disease. One and three year OS were 
73% and 42% respectively with median overall survival of 24 months (95% 
CI: 17 to 41 months). One and three year DFS were 62% and 27% respec-
tively with median time to disease recurrence of 17 months (95% CI: 12 to 21 
months). One and three year LRC were 90% and 72% respectively with only 
4 isolated regional failures in the cohort. On univariate analysis, PS 2 versus 
0/1 was statistically significant on OS (p=0.001), whereas age, smoking sta-
tus, Charleson co-morbidity index, weekly (versus systemic) chemotherapy, 
esophagitis and pneumonitis were not. Rate of grade > 2 pneumonitis was 
15% and grade > 3 esophagitis was 6%. 
Conclusions: Concurrent chemotherapy and radiation therapy with modern 
4D technique and involved nodal field radiation therapy to 70 Gy may have 
some benefit in OS, DFS, and LRC with acceptable toxicities. With current 
standards of chemotherapy and radiation therapy to 60 Gy, OS is estimated at 
16-17 months (Furuse et al, J Clin Oncol 1999; Komaki et al, RTOG 9410), 
which is outside the 95% CI for median OS in this study. In carefully selected 
patients treated to 74 Gy in institutional trials, OS is estimated at 23 months 
(Bepler, Dilling et al, J Thorac Oncol). Escalating the dose of radiation ther-
apy appears to improve LRC and positively impact OS.
Author Disclosure Block: J. Freilich: None. R. Baker: None. C.W. Stevens: 
None. W.J. Fulp: None. M. DeMarco: None. C. Turke: None. T.J. Dilling: 
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Pretreatment Poor Pulmonary Function Is Prognostic Of Poor 
Overall Survival In Patients With Stage III Non-Small Cell 
Lung Cancer Treated With External Beam Radiotherapy
X. Wei, D. Gomez, Y. Zhuang, R. Komaki, M. S. O’Reilly, R. Mohan, Z. X. 
Liao, The University of Texas MD Anderson Cancer Center, Houston, TX
Purpose/Objective(s): To investigate if pretreatment pulmonary function is 
associated with overall survival (OS) in patients with stage III Non-small cell 
lung cancer (NSCLC) treated at a single institution with external beam radio-
therapy (XRT). 
Materials/Methods: This retrospective study includes 419 patients with 
newly pathologically diagnosed stage III NSCLC who received XRT at our 
institution from 10/8/1998 to 1/26/2010. Inclusion criteria were: no surgery, 
no prior thoracic radiotherapy, performance status (KPS) ≥ 70, and radio-
therapy dose ≥ 60 Gy. All of patients had pulmonary functional tests (PFT) 
within 6 months prior to XRT. Pre-treatment PFT values analyzed included 
forced expiratory volume in 1 second (FEV1) [in liters (L) and as % of pre-
dicted], forced vital capacity (FVC), FEV1/FVC ratio, and diffusing capacity 
of the lung for carbon monoxide (DLCO) (as % of predicted). The associa-
tion between overall survival (OS) and recognized PFT cut-offs (FEV1 <2 
L, ≥2 L; FEV1 <60%, ≥60% of predicted; FEV1/FVC ratio <60%, ≥60% of 
predicted; DLCO <60%, ≥60% of predicted) was investigated. Univariate and 
multivariate analyses were performed using Cox proportional hazards models 
to determine the association between PFT and OS, defined as the time from 
diagnosis to the date of death or the date of last follow-up. 
Results: The median follow-up was 19.1 (range, 2.9-127) months. The 
median survival was 23.1 months. Univariate analysis demonstrated that 
the following factors were associated with OS: concurrent chemoradiation 
(HR=0.66; P=0.021); IMRT (HR=0.73; P=0.018); gross tumor volume (GTV) 
greater than the median (119 cc) (HR=1.71; P=0.000); pre-bronchodilator 
(BD) FEV1<2L (HR=1.46; P=0.003); FEV1<60% of predicted (HR=1.39; 
p=0.011); Post-BD FEV1<2L (HR=1.47; P=0.008); pre-BD FEV1/FVC 
ratio <60% (HR=1.43; P= 0.020); the single-breath DLCO (DLCOsb) <60% 
(HR=1.64; P=0.000). On multivariate analysis, when adjusting for GTV size, 
concurrent chemoradiation, and IMRT, the following factors were found to be 
significantly associated with OS: pre-BD FEV1<2L (HR=1.34; P=0.028, 95% 
CI: 1.03-1.75); pre-BD FEV1/FVC ratio <60% (HR=1.45; P= 0.020, 95% CI: 
1.06-1.99); and DLCOsb <60% (HR=1.64; P=0.000, 95% CI: 1.25-2.16). 
Conclusions: Our study showed that pre-radiation treatment pre-BD 
FEV1<2L, pre-BD FEV1/FVC ratio <60% and DLCOsb <60% were associ-
ated with poor OS in patients with stage III NSCLC treated with XRT. This 
information is important for clinicians to include in their decision making 
with regards to selecting patients for high dose radiation therapy.
Author Disclosure Block: X. Wei: None. D. Gomez: None. Y. Zhuang: 
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Impact Of Dose-volume Parameters And Tumor Location 
On Severe Acute Radiation Pneumonitis For Lung Cancer 
Patients Treated With Concurrent Chemo-radiotherapy
J. Wang1, Y. Bao1, T. Zhuang2, Z. He1, L. Zhang1, A. Tai3, P. Prior3, M. Chen1, 
X. Li3, 1Department of Radiation Oncology, Cancer Center, Sun Yat-Sen 
University, Guangzhou, China, 2Cancer Hospital of Shantou University 
Medical College, Shantou, China, 3Department of Radiation Oncology, 
Medical College of Wisconsin, Milwaukee, WI
Purpose/Objective(s): The purpose of this study is to investigate the impact 
of radiation dose volume parameters and tumor location on the incidence of 
severe acute radiation pneumonitis (SARP) for non-small cell lung cancer 
(NSCLC) patients treated with concurrent chemoradiotherapy. 
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Materials/Methods: Dosimetric and outcome data collected for 147 patients 
with NSCLC of stage IIIa-IV treated between 2006 and 2010 were analyzed. 
Three-dimensional conformal radiation therapy (3DCRT) with prescribed 
doses in the range of 50 - 70 Gy was delivered. SARP was defined as ≥ grade 
3 radiation pneumonitis based on acute radiation morbidity scoring criteria 
from RTOG. Correlations of SARP with a series of dose-volume parameters 
and tumor location were investigated with various statistical tools and were 
modeled with the Lyman-Kutcher-Burman (LKB) model. 
Results: The total incidence of SARP was 9.5% (14/147). In the whole 
patient group, univariate logistic regression analysis showed that MLD (mean 
lung dose), V20 (percentage volume receiving at least 20 Gy), V30, V40, and 
V50 were determining factors for SARP with P = 0.017, 0.025, 0.010, 0.009, 
and 0.027, respectively. The SARP incidence rates were 15.7% for the patient 
group with tumor in the middle or either of the lower lobes, and 6.3% for 
the group with tumor in either of the upper lobes (P = 0.064). ROC analysis 
indicated that areas for predictive parameters MLD, V20, V30, V40, and V50 
varied significantly between the two patient groups as shown in Table 1. The 
parameters in the LKB model were found to be n = 0.87 ± 0.40, m = 0.27 ± 
0.10, and TD50 (1) = 29.5 ± 8.0 Gy. 
Conclusions: The incidence of SARP depends on the dose-volume parameters 
MLD, V20, V30, V40, and V50, and on the tumor location. The SARP rate 
for the patient group with tumor in the middle or lower lobes was higher than 
that for the group with tumor in the upper lobes. The predictive powers of the 
dose-volume parameters for SARP differed between the two patient groups.
ROC analysis (AUC = Area under ROC curves; P value corre-
sponds to testing that AUC ≠ 0.5)
Radiation 
dose-volume 
parameters
Whole group 
(N=147)
Patients with a 
tumor in either 
of the upper 
lobes (N=96)
Patients with a 
tumor in middle 
or either of the 
lower lobes (N=51)
AUC P AUC P AUC P
MLD 0.678 0.029 0.859 0.003 0.365 0.331
V5 0.598 0.227 0.709 0.087 0.372 0.254
V10 0.607 0.187 0.743 0.047 0.323 0.114
V20 0.661 0.048 0.850 0.004 0.337 0.147
V30 0.667 0.040 0.865 0.003 0.419 0.468
V40 0.677 0.030 0.854 0.004 0.512 0.917
V50 0.651 0.064 0.849 0.004 0.538 0.736
Author Disclosure Block: J. Wang: None. Y. Bao: None. T. Zhuang: None. 
Z. He: None. L. Zhang: None. A. Tai: None. P. Prior: None. M. Chen: 
None. X. Li: None.
260 
Development and Utilization of an Online Tool to Guide 
Choice of First-line and Maintenance Therapy (Tx) for 
Patients (Pts) With Advanced Non-Small-Cell Lung Cancer 
(NSCLC)
D. R. Gandara1, M. J. Edelman2, G. Giaccone3, S. S. Ramalingam4, W. M. 
Guerra5, A. D. Bowser5, J. Mortimer1, H. L. West6, 1University of California 
Davis Cancer Center, Sacramento, CA, 2Univeristy of Maryland, Baltimore, 
MD, 3National Cancer Institute, Bethesda, MD, 4Emory Univeristy, 
Atlanta, GA, 5Clinical Care Options, Reston, VA, 6Swedish Cancer Institute, 
Seattle, WA
Background: Treatment guidelines in NSCLC list many possible Tx choices 
but often lack guidance on the single best option for an individual pt. To pro-
vide community oncologists with expert guidance on choice of Tx for specific 
pt scenarios, interactive decision support tools have been developed. These 
online tools prompt users to input specific pt characteristics and then display 
what Tx several experts would choose for that same scenario. Results have 
shown that tools influence clinicians’ Tx decisions for pts with early breast 
cancer (ASCO #6063, 2011). Subsequently, we investigated if a tool would 
influence decisions of clinicians treating pts with advanced NSCLC. 
Materials/Methods: In a survey, experts were asked what Tx they would 
choose for 96 pt case variations based on patient- and tumor-specific features 
integral in determining first-line and maintenance Tx in advanced NSCLC, 
including histology (nonsquamous vs squamous), EGFR mutational status 
(positive [+] vs negative [-]), ALK rearrangement status (+ vs -), age (< 70 vs ≥ 
70 years), Zubrod performance score (PS; 0, 1 vs 2), smoking history (never/
former light vs former heavy/current), and pt’s primary Tx goal (response and 
survival vs quality of life and low risk for adverse events). A tool developed 
based on the expert survey responses was published online March 12, 2012. 
Users input specific pt characteristics and are asked to describe their current 
Tx plan. Then, they are shown a list of expert Tx choices for that pt scenario. 
To determine the impact of viewing the expert choices, users are then asked if 
the expert feedback has confirmed or changed their original Tx plan. 
Results: Five experts completed the survey. The experts were largely in 
agreement for cases with mutations. There was greater variability in regi-
men selected in pts without mutations with factors such as PS, age, and pt 
desire changing the choice of Tx. Preliminary data of 596 cases entered by 
participants within 1 month of online posting of the tool show that expert 
insight affected Tx choice in 43% of clinicians (confirmed in 35%; no impact 
in 22%), suggesting that the experts’ choices have influenced clinicians’ Tx 
decisions. An analysis of expert vs user treatment selections will be presented. 
Conclusions: Our data show that online tools that provide expert treatment 
choices to oncologists in the community can elucidate important insights 
into selection of first-line and maintenance Tx for advanced NSCLC and can 
influence clinicians’ Tx choices, thereby providing opportunities for improve-
ment in pt care and outcomes. Research supported by educational grants from 
Genentech and Pfizer.
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Squbibb, ImClone, Genentech, Lilly, Merck, Novartis. G. Consultant; Amgen, 
AstraZeneca, Biodesix, Boehringer-Ingelheim, Bristol-Myers Squibb, ImClone, 
Genentech, Merck,Novartis, sanofi-aventis, Array BioPharma, Response 
Genetics, Inc. M.J. Edelman: E. Research Grant; Genentech, Tragara. G. 
Consultant; Genentech, Tragara Pharmaceuticals. G. Giaccone: None. S.S. 
Ramalingam: G. Consultant; Abbott, Boehringer Ingelheim, Genentech. W.M. 
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Retrospective Analysis Of The Impact Of Age On Overall 
Survival In Patients With Non-small Cell Lung Cancer
D. C. Luu1, T. A. D’Amico2, G. Kalemkerian3, M. Koczywas4, M. S. Rabin5, R. 
Mamet4, C. Zornosa6, K. Pisters7, J. Niland4, G. A. Otterson1, 1The Ohio State 
University Comprehensive Cancer Center, Columbus, OH, 2Duke Cancer 
Institute, Raleigh-Durham, NC, 3University of Michigan Cancer Center, Ann 
Arbor, MI, 4City of Hope Comprehensive Cancer Center, Duarte, CA, 5Dana 
Farber Cancer Institute, Boston, MA, 6National Comprehensive Cancer 
Network, Philadelphia, PA, 7MD Anderson Cancer Center, Houston, TX
Purpose/Objective(s): Clinical trials have failed to demonstrate that age is 
a significant prognostic indicator among patients treated for non-small cell 
lung cancer (NSCLC). Clinical trials do not necessarily represent real-world 
experience, however. We sought to analyze the impact of age on survival in 
patients in the National Comprehensive Cancer Network (NCCN) NSCLC 
Outcomes Database. 
Materials/Methods: We performed a retrospective analysis of 6,834 NSCLC 
patients from the NCCN NSCLC Database representing 8 NCCN institutions. 
Of this population, 4,943 patients were eligible for our analysis. Exclusion 
criteria included the following: alive patients with < 180 days of follow-up, 
patients with incomplete staging, and patients with a prior cancer diagno-
sis. The study population was separated into five age quintiles with equal 
number of patients in each group. Variables included institution, smoking 
status, gender, race, Charlson comorbidity score, ECOG performance status 
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(PS), histology, stage, and receipt of resection, drug and radiation therapy. 
Multivariable Cox model was performed for the effect of age on survival 
after adjusting for the above variables. Model assumptions were evaluated via 
graphs and residual tests. 
Results: Across the five quintiles (< 54, 54-60, 61-66, 67-72 and ≥ 73) there 
was a trend towards lower stage and higher Charlson score with increasing 
quintile. In addition, there was an increased proportion of patients with squa-
mous cancer in the older age group. In the adjusted Cox model, there was a 
statistically significant longer survival in each of four younger quintiles com-
pared to the reference group of ≥ 73 years of age (p=0.01). The adjusted haz-
ard ratio of death for patients < 54 was .82 (95% CI = .72 to .94), for patients 
54-60 was .86 (95% CI = .76 to .97), for patients 61-66 was .84 (95% CI = 
.74 to .95), and for patients 67-72 was .84 (95% CI = .74 to .95). There were 
no statistically significant pairwise interactions among age, smoking status 
and stage. 
Conclusions: Even after adjusting for institution, comorbidity scores, smok-
ing status, race, gender, ECOG PS, histology, stage and treatment, NSCLC 
patients who were ≥ 73 years of age had a worse survival when compared to 
younger age groups.
Author Disclosure Block: D.C. Luu: None. T.A. D’Amico: None. G. 
Kalemkerian: None. M. Koczywas: None. M.S. Rabin: G. Consultant; 
Genentech. R. Mamet: None. C. Zornosa: A. Employee; NCCN. K. Pisters: 
None. J. Niland: None. G.A. Otterson: None.
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A Study Investigating Clinical Risk Factors for Radiation 
Pneumonitis in Patients Undergoing Radical Thoracic 
Radiotherapy
S. Ramamurthy, F. McDonald, H. McCallum, A. Macdonald, G. Lawrence, 
Northern Centre for Cancer Care, Newcastle-Upon- Tyne, United Kingdom
Materials/Methods: Ninety three patients who received 3D-CRT for stage 
IA to lV NSCLC were evaluated prospectively (December 2007- to date) 
for symptomatic RP. All patients were prescribed 55 Gy in 20 fractions. 
Symptomatic RP was diagnosed based on clinical dyspnoea limiting exercise 
tolerance of the patient and computer tomography evidence of post radia-
tion inflammatory changes, fibrosis and lung volume loss during follow- up 
period. Factors evaluated included patient’s age at the time of treatment, sex, 
history of cigarette smoking, presence of chronic airway disease (COAD), 
pre-treatment FEV1 and chemotherapy for NSCLC. Multivariate analysis was 
performed using linear regression. 
Results: The study cohort consisted of 51 male and 40 female patients. The 
median age was 66 years. 35 out of 91 patients (38%) suffered from symp-
tomatic RP. Two patients were not analysed as they as they died before their 
first follow- up post treatment. Median survival of patients in our study was 
20 months. The significant factors predicting symptomatic RP were smoking 
(p < 0.04) and Chemotherapy administration (p < 0.04). Other factors includ-
ing age, sex, COAD, tumour stage or pre-treatment FEV1 did not correlate 
with development of symptomatic RP. 
Conclusion: History of smoking and treatment with chemotherapy in patients 
with NSCLC receiving radical TRT are significant predictors of symp-
tomatic RP.
Author Disclosure Block: S. Ramamurthy: None. F. McDonald: None. H. 
McCallum: None. A. Macdonald: None. G. Lawrence: None.
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Impact Of Chemotherapy Response And Radiation Dose On 
Overall Survival In Patients With Inoperable Non-small Cell 
Lung Cancer Treated With Induction Chemotherapy Followed 
By Concurrent Chemoradiotherapy
J. Grant, D. Gomez, Y. Zhuang, J. Chang, R. Komaki, F. Fossella, K. Gold, Z. 
Liao, J. Cox, MD Anderson Cancer Center, Houston, TX
Purpose/Objective(s): To investigate the prognostic influence of radiation 
dose and chemotherapy response in patients with inoperable non-small cell 
lung cancer (NSCLC) treated with induction chemotherapy followed by 
aggressive concurrent chemoradiotherapy (CRT). 
Materials/Methods: We retrospectively reviewed the medical records 
and treatment details of 127 patients treated between November 2003 
and January 2011 for inoperable American Joint Committee on Cancer 
(AJCC) 7th Edition stage II-III NSCLC (stage II, n=7 [5.5%]; stage III, 
n=120 [94.5%]). All patients were treated with induction chemotherapy 
followed by CRT to a dose of ≥ 60 Gy. The median radiation dose in the 
entire group of patients was 66 Gy (range 60-74 Gy), and the median 
GTV size was 91 cc (range 6-1084 cc). Variables including age, race, 
histology, stage performance status, GTV size, response to induction 
chemotherapy, and radiation technique (3D conformal, IMRT, or proton 
beam) were collected. Disease response to chemotherapy was evaluated 
according to the RECIST (Response Evaluation Criteria In Solid Tumors) 
criteria. Cox regression analysis, Breslow method, and t-test were per-
formed to assess the prognostic influence of the above factors on overall 
survival (OS). 
Results: The median follow-up time was 24 months (range 5-79 months). 
Response to induction chemotherapy was as follows: 77 patients had stable 
disease (60.6%), 45 (35.4%) exhibited a partial response, and 5 patients 
(4%) had progressive disease. No complete responses were observed. 
Response to induction chemotherapy prior to aggressive radiation therapy 
did not influence OS (p=0.483). The mean radiation dose for the subset of 
patients with stable disease was 67.1 Gy, and those with a partial response 
was 65.7 Gy, which were not significantly different (p=0.095). Among 
patients with stable disease, those receiving ≥70 Gy showed improved OS 
(HR=0.5, p=0.035, 95% CI 0.35 - 0.95). Radiation dose ≥70 Gy did not 
significantly influence OS for patients with a partial response to induction 
chemotherapy (p=0.8). No other factors were significant for OS on univari-
ate analysis. 
Conclusions: We found that in patients with inoperable NSCLC treated with 
induction chemotherapy followed by aggressive concurrent CRT, response to 
induction chemotherapy was not prognostic of OS. Our data found that higher 
radiation dose improved OS among patients with stable disease after induc-
tion chemotherapy. This dose response was not seen in patients with a par-
tial response to induction chemotherapy. Further investigation is warranted 
to validate whether CRT dose should be tailored to the patient’s response to 
induction chemotherapy.
Author Disclosure Block: J. Grant: None. D. Gomez: None. Y. Zhuang: 
None. J. Chang: None. R. Komaki: None. F. Fossella: None. K. Gold: 
None. Z. Liao: None. J. Cox: None.
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Cancer Care Ontario’s Lung Cancer Disease Pathway 
Management Initiative: A Novel Approach to Provincial 
Quality Improvement
Y. C. Ung1, W. K. Evans2, N. Assouad3, C. Sawka3, 1Odette Cancer Centre, 
Toronto, ON, Canada, 2Juravinski Cancer Centre, Hamilton, ON, Canada, 
3Cancer Care Ontario, Toronto, ON, Canada
Purpose/Objective(s): To Delivering oncology care to a population over 13 
million is complex. Cancer Care Ontario (CCO) undertook provincial cancer 
control quality improvement initiatives on a programmatic basis and added 
a lung cancer-specific disease pathway management (DPM) initiative to 
its quality improvement agenda. Significant variation exists in lung cancer 
management. Standardization of care with disease pathway maps will lead to 
improved outcomes. Region specific programs can be developed for quality 
improvement through DPM. The four objectives of DPM are to align provin-
cial quality improvement initiatives by disease site; to systematically map the 
full continuum of the patient journey and to identify gaps in evidence, clini-
cal practice and measurement that impact the quality of care and the patient 
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experience; set and manage regional performance indicators across the path-
way; and leverage specific tools to model the impact of policy decisions. 
Materials/Methods: Lung Cancer DPM began with a draft lung cancer (LC) 
disease pathway map and the establishment of five multidisciplinary work-
ing groups each focussed on a phase of the LC patient journey: prevention, 
screening and early diagnosis; diagnosis; treatment; palliative care; the patient 
experience. Eight of 17 quality improvement projects developed by working 
groups were selected for detailed discussion at a provincial consensus confer-
ence. Subsequently a Priorities for Action Report was prepared and circu-
lated. Regional “roadshows” were held in all 14 Regional Cancer Programs 
(RCPs) in Ontario. Region-specific data on incidence, stage, treatment com-
pliance and wait times amongst other issues relevant to LC were shared with 
the regional care providers. Funding was provided by CCO to address oppor-
tunities for regional improvement based on the data and the identified priori-
ties. Each RCP could then use the funding for regional improvement. 
Results: Substantial multidisciplinary discussion led to the development of 
a diagnostic and treatment pathway map. Lung diagnostic assessment units/
programs have been initiated in 14 RCPs and educational materials on dys-
pnea management, including a patient video, are available on CCO’s web-
site. The percent of LC patients whose symptoms are assessed at least once 
a month using a standardized symptom assessment instrument (ESAS) has 
improved through the DPM. Each RCP decided on what aspect of quality 
improvement to focus on based on specific regional needs. 
Conclusions: Through CCO’s LC DPM, regional LC programs have become 
aware of their performance on a range of LC specific quality metrics and have 
been given the opportunity to fund quality improvement initiatives based on 
regional needs. Standardized diagnostic and treatment pathway maps have 
been developed and will hopefully imporve outcomes.
Author Disclosure Block: Y.C. Ung: None. W.K. Evans: None. N. Assouad: 
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Pemetrexed/cisplatin (pem/cis) Vs. Pemetrexed/carboplatin 
(pem/carbo) In Non-squamous, Non-small Cell Lung Cancer 
(nsclc): A Retrospective Comparison Using A Large Electronic 
Database.
J. R. Hoverman, S. Sheth, M. Clayton, M. Neubauer, B. Brooks, J. Garey, 
R. Beveridge, The US Oncology Network/McKesson Specialty Health, The 
Woodlands, TX
Purpose/Objective(s): The only published randomized controlled trial (RCT) 
comparing pem in a chemo doublet to another chemo doublet used cis as the 
second drug. There is no evidence that carbo is effective in this setting, but 
NCCN and current clinical trials (clinicaltrials.gov) treat carbo as equivalent 
and pem/carbo as the backbone doublet for the introduction of new drugs. 
We mined our EHR database (iKnowMed™) as an exercise in comparative 
effectiveness to measure the use of these 2 doublets and the associated overall 
survival. 
Materials/Methods: Data from The US Oncology Network were 
reviewed. Advanced NSCLC patients with non-squamous histology and 
documented 1st-line treatment with pem/carbo or pem/cis were identified 
between July 1, 2006 to June 30, 2011. The pem regimen and estimated 
overall survival (OS) were evaluated. Patients were excluded if they had 
participated in a clinical trial, had received 1st-line therapy other than 
above, squamous histology, presence of secondary cancer diagnosis, and/
or insufficient data. 
Results: 346 patients were identified (mean age 64; 43% female); 206 
patients in pem/carbo cohort and 140 patients in pem/cis cohort. Median OS 
was 16.6 months (pem/ carbo) vs. 13.1 months (pem/cis); p=0.228. Further 
analysis illustrates 190 patients (pem/ carbo) and 124 patients (pem/cis) had 
adenocarcinoma histology. Median OS for this sub-group was 16.6 months 
(pem/ carbo) vs. 14.3 months (pem/cis); p=0.269. We analyzed costs between 
both regimens using medicare allowable costs (1Q2012). Estimated costs 
associated with pem/cis $4978 per cycle ($19,912 per course) compared to 
pem/carbo $4997 per cycle ($19,988 per course). 
Conclusions: The determination of relative value for chemo regimens is not 
a trivial exercise and is best done with RCTs. As the subject of the current 
study involves two generic drugs, this is unlikely to occur. The use of a large 
data base for comparisons may be the best strategy. Since there is no apparent 
difference in survival or cost between carbo or cis in combination with pem, 
toxicity concerns should dictate the choice of regimen.
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Role Of MUC4 Mucin In Lung Cancer
A. Ganti1,2, P. Dhangada Majhi2, I. Lakshmanan2, S. Kaur2, M. P. Ponnusamy2, 
L. M. Smith2, C. Rolle3, W. West2, R. Salgia3, S. K. Batra2, et al., 1VA Nebraska 
Western Iowa Health Care System, Omaha, NE, 2University of Nebraska 
Medical Center, Omaha, NE, 3University of Chicago, Chicago, IL
Purpose/Objective(s): MUC4 is a high molecular weight type-I transmem-
brane protein believed to alter the proliferation, differentiation, or cell-adhe-
sion status of epithelial cells. In organs normally lacking MUC4 expression, 
over-expression of MUC4 has been observed with tumor progression. This 
study evaluates the role of MUC4 in non-small cell lung cancer (NSCLC). 
Materials/Methods: Human NSCLC cell lines NCI-H292 and A549 were 
used. Stable clones of NCI-H292 in which MUC4 was down regulated using 
shRNA and scramble transfected control sublines (H292-scr) were estab-
lished. Stable clones of min-MUC4 transfected A549 (A549-MUC4) over-
expressing MUC4 protein and empty vector control (A549-PsecTagC) were 
established. These cells were analyzed for proliferation, migration, motility, 
cell invasion and apoptosis. Samples from 54 patients with non-metastatic 
NSCLC were stained for MUC4 expression and a composite score based on 
intensity and extent of staining was assigned to each sample. Cell line data 
were analyzed with Student’s t-test or Mann-Whitney test. Poisson mixed 
effects models were used to compare the MUC4 staining in patient samples. 
Kaplan-Meier method was used to estimate survival distributions. Wilcoxon 
sign rank test was used to compare the difference in scores between lung 
tissue and corresponding lymph node. P-value <0.05 was considered to be 
significant. 
Results: MUC4 attenuated in vitro proliferation of NSCLC cells. H292-
shMUC4 grew and A549-PsecTag C cells grew faster than H292 and 
A549-MUC4. Cell cycle analyses showed higher percent cells in S-phase 
in H292-shMUC4 and A549-vector cells. H292-shMUC4 and A549-vector 
cells exhibited higher apoptotic cell death. In H292shMUC4, with MUC4 
down-regulation, significant increase in Akt phosphorylation (Ser473) 
was seen with slight increase in total Akt level. Elevated levels of inac-
tive pSer9-GSK3β and Cyclin D and A, and decrease in p21Cip1 and 
p27Kip1 in H292-shMUC4 and A549-PsecTagC were seen, compared to 
their MUC4 expressing sublines. H292-shMUC4 and A549-PsecTagC cells 
showed increased motility (4x and 3x, respectively) compared to H292-scr 
and A549-MUC4. Of the 54 non-metastatic NSCLC patients, 13 (25%) 
patients had stage I, 33 (63%) had stage II and 6 (12%) patients had stage 
III disease. Distribution of the composite score differed significantly by 
stage (p=0.0043). A higher proportion of patients with stage I NSCLC 
had the maximum possible score of 12 (77%) compared to stage II (18%) 
and stage III (57%) (p=0.0001). In patients who had data for both the pri-
mary tumor and corresponding metastatic lymph node, MUC4 expression 
was higher in the primary tumor compared to the lymph node (p=0.05). 
Patients with a score <12 had worse survival than those with a score of 12 
(p<0.045).
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Conclusions: MUC4 appears to have a novel tumor suppressor function in 
NSCLC.
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Marital Status Is An Independent Predictor Of Survival For 
Patients Undergoing Definitive Chemoradiation For Stage Iii 
Non-small Cell Lung Cancer (nsclc)
E. M. Nichols1, M. Liriano1, C. G. Morris2, W. Burrows1, R. Battafarano1, M. 
Garofalo1, M. Turner1, M. Suntharalingam1, M. J. Edelman1, S. J. Feigenberg1, 
1University of Maryland Hospital, Baltimore, MD, 2University of Florida, 
Gainesville, MD
Purpose/Objective(s): Decreased survival in single men has been reported in 
several cancer sites. We evaluated whether marital status was an independent 
predictor of outcomes for patients treated with definitive chemotherapy and 
radiation at the University of Maryland for stage III NSCLC. 
Materials/Methods: Between January 2000 and December 2010, 168 patients 
with stage III NSCLC were treated at the University of Maryland with cura-
tive intent using chemotherapy and radiation. All patients were evaluated by 
a multi-disciplinary team prior to treatment and underwent standard work up. 
All patients received definitive doses of radiation therapy with a median dose 
of 66.6Gy (range 59.4 to 70Gy). Chemotherapy was administered concurrently 
with radiation in the majority (89%) of patients with weekly carboplatin/pacli-
taxel being the most common regimen (90%). After concurrent therapy, patients 
typically received 2 cycles of systemic or consolidative doses of chemotherapy, 
if carboplatin/paclitaxel was utilized. The Kaplan-Meier product limit method 
provided estimates of overall and disease-free survival; the log rank test statistic 
indicated whether stratifications of these estimates by selected prognostic fac-
tors were significant. Proportional hazards regression was utilized for multivari-
ate analysis. Fisher’s exact test was used to test contingency tables. 
Results: With a median follow up of 1.3 years, the median survival was 13 
months with a 3- and 5-year Kaplan Meier estimate of overall survival (OS) of 
21 and 12%, respectively. On multivariate analysis, age (p< 0.032), marital status 
(p< 0.003), and gender (p< 0.012), were independent predictors of OS, indepen-
dent of disease and treatment related variables. Married patients had improved 
survival compared to single patients with 3 yr rates of 33 vs 10% (p<0.001), and 
men had inferior survival compared to women 35 vs 13% (p=0.004). Single men 
had the worst overall survival 3-yr rates of 3%, while married women had the 
best survival with 3-yr rates of 46%, p=0.029. Single females and married men 
had intermediate 3-yr survivals of 25%. When stratified by race, married whites 
had the best survival followed by married blacks and then single patients with 3 
yr survival rates of 40%, 26% and 11% respectively, p=0.005. 
Conclusions: In locally advanced NSCLC patients, marital status appears to 
be an important independent predictor of survival. The exact etiology of this 
inferior outcome is unclear and needs further clarification however marital 
status may be a surrogate for better supportive care and compliance. This pro-
vides evidence that social interventions have the potential to improve survival.
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An Analysis of Patient Characteristics and Clinical Outcomes 
in Primary Pulmonary Sarcoma.
M. Spraker1, E. Bair2, R. Bair3, P. Connell3, U. Mahmood4, M. Koshy3,1, 
1University of Illinois at Chicago, Chicago, IL, 2University of North Carolina, 
Chapel Hill, NC, 3University of Chicago, Chicago, IL, 4MD Anderson Cancer 
Center, Houston, TX
Purpose/Objective(s): Primary pulmonary sarcomas (PS) are rare tumors, 
and past literature has been limited to small case series. The purpose of this 
study was to elucidate the clinical characteristics and therapeutic strategies of 
PS and their impact on overall survival (OS). 
Materials/Methods: This was a study from the Surveillance, Epidemiology, 
and End Results database that included data from 1988-2008. Eligible 
patients had confirmed primary PS, and underwent local therapy, exclud-
ing those with distant metastasis. Survival estimates were obtained using 
the Kaplan-Meier method and the Cox regression model. Furthermore, OS 
of PS patients were compared to a cohort of 10,909 patients with extremity 
soft tissue sarcomas. 
Results: A total of 365 PS patients were selected and the median follow-up 
was 21 months (range: 1 month to 20 years). 55% had a tumor size greater 
than 5 cm, and 76% were high grade. Node positive disease was present in 
16% of the cohort, and was not associated with histologic type. Regarding 
therapy, 75% of the cohort underwent surgery alone (S), 14% underwent sur-
gery and radiation therapy (S+RT), and 11% presented with unresectable dis-
ease and underwent RT without surgery. The 5 year OS for the cohort of PS 
vs. sarcomas of the extremities was 35% vs 71% (p < 0.0001). Among those 
with PS, the 5-year OS for node negative patients vs. node positive patients 
was 39% vs 14% (p<0.0001). The 5-year OS was 41% for those who under-
went surgery alone, 25% for those who underwent S+RT, and 7% for those 
with unresectable disease (p<0.0001). On subset analysis those who received 
adjuvant RT were more likely high grade (94% vs. 70%), had a larger tumor 
size (>5cm) ( 65% vs. 51%), and were node positive (27% vs 10%) (p < 
0.001). Multivariate analysis showed reduced OS for patients greater than 75 
years old (HR 3.2, 95% CI 2.03-5.34), tumors > 5cm (HR 1.6, 95% CI 1.25-
2.19), and high tumor grade (HR 3.1, 95% CI 1.26-3.62). Regarding therapy, 
the estimated HR was 2.6 (95% CI 1.76-3.88) for those with unresectable 
disease, 1.3 (95% CI .93-1.9) for the S+RT group, and 1.0 (reference) for 
the S group. 
Conclusions: This large study examining PS patients reveals they have 
a markedly worse OS than patients with extremity soft tissue sarcomas. 
Although, significantly worse clinical characteristics made up the subgroup 
of patients who underwent surgery and RT, their OS was not statistically dif-
ferent than those who received surgery alone, which was encouraging because 
they likely derived a benefit from improved local control. Moreover, PS are 
associated with a 16% incidence of nodal metastasis while node positive dis-
ease is only seen in 2-3% of soft tissue extremity sarcomas. Thus, it is recom-
mended that PS patients undergo a thorough mediastinal nodal evaluation 
to rule out loco-regional metastasis and be treated aggressively given their 
overall poor prognosis.
Author Disclosure Block: M. Spraker: None. E. Bair: None. R. Bair: 
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Clinical Outcomes of CyberKnife Radiosurgery for Early 
Stage Lung Cancer: Low Chest Wall Toxicity Rates Associated 
with Tracking
G. H. Goldin1, T. M. Zagar1, M. Fayda2, L. B. Marks1, D. Fried1, S. M. Miller1, 
R. C. Chen1, E. C. Schreiber1, T. M. Egan1, D. E. Morris1, 1University of North 
Carolina Hospitals, Chapel Hill, NC, 2Istanbul University, Istanbul, Turkey
Purpose/Objective(s): To report the efficacy and toxicity of CyberKnife ste-
reotactic body radiotherapy (SBRT) for early stage non-small cell lung cancer 
(NSCLC) in patients treated at the University of North Carolina. 
Materials/Methods: The records of patients with medically inoperable early 
stage NSCLC treated using the CyberKnife system with Synchrony fiducial 
tracking were retrospectively reviewed. The actuarial local control, distant 
metastasis-free survival, overall survival, and toxicity rates were calculated. 
Results: 52 consecutive patients treated between 9/2007 and 8/2011 for pri-
mary (n = 43) or recurrent (n = 9) early stage NSCLC were included. The 
median follow up was 19.2 months (range 3.6 - 44.6), and all living patients 
had at least 6 months of follow up. Mean age of the cohort was 71 years 
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(range 42 - 87). Twenty patients were male and 32 were female. Mean maxi-
mum tumor dimension was 2.5 cm (range 0.8 - 4.8 cm) and 67% received 
48 Gy in 4 fractions (mean prescription dose was 4950 cGy in 3.8 fractions 
[range 24 - 60 Gy]). Mean distance from GTV to the chest wall was 1.5 cm 
(14 lesions were 0-0.5 cm, 10 were 0.6-1.0 cm, 12 were 1.1 - 2.0 cm, and 
16 were > 2.0 cm away). Fiducial placement resulted in pneumothorax in 
17 patients (32.7%), and 11 of those (64.7%) required a chest tube and/or 
hospitalization. The actuarial local control, distant metastasis-free survival, 
and overall survival were 93%, 70%, and 82% at 1 year and 89%, 61%, and 
61% at 2 years, respectively. One patient (2% of all patients and 3% of those 
with tumors within 2 cm of the chest wall) developed a rib fracture 8 months 
following treatment (her tumor was located 0.7 cm from the chest wall), and 
3 patients (5.8%) experienced chest wall pain. Five patients (9.6%) developed 
grade 2 radiation pneumonitis. No patient had grade ≥ 3 toxicity as a result 
of radiation treatment. 
Conclusion: CyberKnife SBRT resulted in a high rate of local control and 
low rate of toxicity, offering patients with early NSCLC an important, non-
surgical curative option. However, morbidity from fiducial marker placement 
is an important consideration in a patient population with limited respiratory 
reserve, and newer fiducial-less technologies need to be developed and further 
studied as a potential solution. The low rate of rib fracture in this experi-
ence (2%) compared to the published literature using linac-based stereotactic 
systems (8%; Andolino, et al. 2011) may be attributable to the CyberKnife’s 
ability to track the tumor throughout the respiratory cycle, thereby decreasing 
the delivered dose to the adjacent ribs. Whether different delivery systems of 
SBRT result in different disease control or morbidity outcomes needs to be 
prospectively studied.
Author Disclosure Block: G.H. Goldin: None. T.M. Zagar: None. M. 
Fayda: None. L.B. Marks: None. D. Fried: None. S.M. Miller: None. R.C. 
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Non-Small Cell Lung Cancer with Chest Wall Invasion is 
associated with High Rates of Positive Margins and Local 
Failure after Surgery.
A. Wright, J. Chino, C. Kelsey, Duke University, Durham, NC
Purpose/Objective(s): Non-small cell lung cancer (NSCLC) is the most com-
mon cause of cancer death worldwide. Patients with localized disease invad-
ing the chest wall (CW) represent a distinct and rare subset. Most patients 
undergo upfront surgical resection. Patterns of failure after surgery are not 
well documented and the role of adjuvant radiation therapy (RT) is unclear, 
which prompted the present analysis. 
Materials/Methods: This IRB-approved study included all patients who 
underwent surgery at our institution between 1995 and 2008 for localized 
NSCLC invading the CW. Superior sulcus tumors were excluded. Clinical 
outcomes were estimated using the Kaplan Meier method and compared 
using a log-rank test. A multivariate analysis was performed to evaluate prog-
nostic factors. Patterns of failure were scored. 
Results: 62 patients were identified who met the inclusion criteria. Two 
patients died from postoperative complications and were not considered fur-
ther. Pathological stage was T3N0 in 48, T3N1 in 9, and T3N2 in 3. Squamous 
histology was most common (52%) and most (83%) underwent lobectomy/
pneumonectomy. Surgical margins were positive in 9 (15%), and most com-
monly involved the chest wall (7/9). Adjuvant treatment included RT in 15 
(25%) and chemotherapy in 19 (32%). No significant differences were noted 
between RT and no RT groups, including margin status. Local control (LC), 
disease-free survival (DFS), and overall survival (OS) at 3 years for the entire 
population were 71%, 30%, and 45%, respectively. LC (3) was 92% with adju-
vant RT versus 62% without RT (p=0.26). There were 12 local recurrences 
(chest wall only in 6, chest wall and mediastinum in 3, mediastinum only in 
2, and surgical stump in 1. DFS (3) was 37% with RT versus 28% without RT 
(p=0.55). OS (3) was 53% with RT versus 42% without RT (p=0.15). 
Conclusions: Localized NSCLC with chest wall invasion is relatively rare. 
Positive surgical margins are common and most often involve the chest wall. 
Local failure is common and principally occurs at the chest wall. In our series, 
RT appeared to decrease the risk of local failure, but perhaps due to small 
numbers, this was not statistically significant.
Author Disclosure Block: A. Wright: None. J. Chino: None. C. Kelsey: 
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Analysis of Radiation Pneumonitis Risk using RTOG 
Radiation Morbidity Scoring and Modified Kimura’s 
Classification in Lung Tumor Patients Treated with 
Tomotherapy
M. Kim, Y. Chung, C. Lee, I. Lee, Yonsei university health system Department 
of radiation oncology, Seoul, Korea, Republic of
Purpose/Objective(s): To evaluate the relationship between the radiological 
images, clinical and dose-volum-histogram (DVH) parameters for radiation 
pneumonitis (RP) in primary and metastatic lung cancer patients treated with 
tomotherapy(TOMO). 
Materials/Methods: A retrospective review of primary or metastatic lung 
cancer patients treated with TOMO at Yonsei University Health System 
between Jul 2007 and Mar 2011 was performed. The symptoms of RP were 
evaluated with CTCAE 4.0(Common Toxicity Criteria version 4 criteria) and 
RTOG(Radiation Therapy Oncology Group) radiation morbidity scoring cri-
teria. The radiologic images for RP was evaluated with Modified Kimura’s 
classification(MKC) and RTOG radiation morbidity scoring criteria 
Results: There were total 32 patients with 34 lesions; 14 patients were 
treated TOMO alone and 18 received TOMO with sequential or concurrent 
chemotherapy(CTx). Total dose(TD) to gross tumor volume(GTV) were 
24-70 Gy(median 60 Gy) in 10 to 20 fractions. The GTV were 1.1-1098.3 
cc(median 18.6 cc), number of tumor were 1-9(median 2). Acute and chronic 
RP were as follows: greater than CTCAE grade 2, 59.4% and 47.6%; greater 
than RTOG grade 2, 43.8% and 28.6%; MKC category 1-3, 34.4% and 81%. 
In an univariate analysis, the risk factors of RP greater than CTCAE grade 2 
were gender(p=0.050), tumor volume ≥ 12cc(p=0.020) and the risk factors of 
MKC category 1-3 RP were V5total(p=0.039), fractional biological equivalent 
dose(BED)(p=0.008), TD(p=0.044), concurrent chemoradiotherapy(CCRT)
(p=0.019), and tumor volume ≥ 12cc(p=0.050). In a multivariate analysis, 
the risk factors of RP greater than CTCAE grade 2 were gender(p=0.050), 
V30total(p=0.050), and the risk factors of radiologic RP greater than RTOG 
grade 2 was tumor volume ≥ 12cc(p=0.047). The risk factors of MKC cate-
gory 1-3 RP were age(p=0.042), V5total(p=0.047), fractional BED(p=0.010), 
CCRT(p=0.019), and tumor volume ≥ 12cc(p=0.046). 
Conclusions: Treatment of primary or metastatic lung cancer with TOMO is 
safe and effective. RP evaluated with MKC was correlated with dosimetric 
parameters. Physicians should pay closer attention to the patients irradiated 
large lung volume with low dose(5-20 Gy) or got combined CTx.
Author Disclosure Block: M. Kim: None. Y. Chung: None. C. Lee: None. 
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Clinical Outcome Of Stereotactic Body Radiotherapy Using 
Cyberknife For Primary And Secondary Lung Tumors
T. Biswas1, J. Efird1, S. James1, P. Walker1, D. Fried1, J. Moran1, S. Ben-Or1, 
B. Holland1, J. Rosenman2, T. Podder1, 1Brody School of medicine at East 
Carolina University, Greenville, NC, 2University of Carolina University at 
Chapel Hill, Chapel Hill, NC
Purpose/Objective(s): Stereotactic body radiotherapy (SBRT) has the 
potential to achieve high local control with low risk of severe long term pul-
monary toxicity, especially in patients with chronic obstructive pulmonary 
disease (COPD). Cyberknife (CK) can deliver hypofractionated high dose 
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radiotherapy by using multiple angles converging on the target with real time 
tracking through a combined orthogonal radiographic imaging and optical 
motion tracking system. We investigated the local control, patterns of failure 
and overall survival (OS) of patients who were treated with SBRT using CK 
between 9/2009 and 10/2011 in our clinic. 
Materials/Methods: Total 73 (evaluable 71) patients with primary (group 1, 
n=54), recurrent (group 2, n=11) lung cancer, and metastatic (group 3, n=8) 
lung tumors were treated for 81 lesions with SBRT. Median age was 74 years 
(range: 33 - 90 years) and 47% (n=34) were males. All patients, except 7 
(10%), had biopsy proven cancer. Patients treated for primary lung cancer had 
severe COPD and were not surgical candidates. Of 54 primary lung cancers, 
44 were T1 and 10 were T2 lesions. The treatment was delivered in 3-5 frac-
tions (2 patients had 11 fractions), 2-3 fractions/week. The median dose was 
50 Gy (range: 25-55 Gy). All patients in group 1 had PET scan for initial stag-
ing. The response rate was based on either CT or PET scan or both. Statistical 
analyses were performed using SAS (ver 9.3). 
Results: Median follow-up was 11 months (range: 0.3-31.9 months). Overall 
response rate was 97% (CR (n= 50) & PR (n=20)). For group 1, the freedom 
from local failure (FFLF) at 1 year was 87% and at 2 was years 73%. The 
freedom from distal failure (FFDF) at 1 year was 76% and at 2 years was 70%. 
For group 1, median time to failure (locally or distally) was not reached at the 
time of analysis. For group 2, the FFLF and FFDF at 1 year were 67% and 
40%, with median time of 16 and 7.2 months, respectively. For group 3, the 
FFLF and FFDF at 1 year were 100% and 30% with median time of 18 and 5.6 
months, respectively. In group 1, 1 and 2-year OS were 80% and 75%. In group 
2 and 3, the 1 year OS were 61% and 75%. For group 1 and 3, the median sur-
vival was not reached and in group 2, it was 14.5 months. In group 1, 8 patients 
(15%) failed regionally in hilum/mediastinum alone or in combination with 
distal failure, 2 failed in liver, 1 each failed in brain, bone and supraclavicular 
region. One patient had solitary brain metastasis at presentation and she failed 
in brain again. The toxicity was low; in 4 patients with radiographic pneumo-
nitis only, one requiring steroid for grade 4 pneumonitis and she received prior 
radiation of 66 Gy. Only 3 patients had grade 1-2 chest wall pain. 
Conclusions: SBRT using CK for treatment of primary or secondary lung 
cancer is feasible with acceptable local control and toxicities. Further analysis 
of factors correlating local/regional failure is underway.
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A Unique Geographical Analysis of Lung Cancer Patients in 
the State of Utah—Huntsman Cancer Hospital Experience
R. Herde1, W. Akerley2, K. Kokeny2, J. Ying1, N. Hu1, Y. J. Hitchcock2, 
1University of Utah School of Medicine, Salt Lake City, UT, 2University of 
Utah, Huntsman Cancer Hospital, Salt Lake City, UT
Purpose/Objective(s): Lung cancer is the No.1 cause of cancer death in men 
and women, and the overall survival of lung cancer patients is strongly asso-
ciated with tumor staging. The state of Utah represents a unique geographic 
situation that may have an impact in cancer patients’ care. A significant por-
tion of the population lives >50 miles from a major cancer center, especially 
considering that 20% of the state’s 2.8 million people live outside of the 
Wasatch Front and Salt Lake City, where a major cancer center is located. In 
addition, the Huntsman Cancer Hospital (HCH) at the University of Utah is 
the only National Comprehensive Cancer Network member institution in the 
intermountain west. Thus, HCH provides services to many patients outside 
of Utah living in the intermountain region. Due to this large area of service, 
logistical problems related to early diagnosis and the delivery of care arise. 
Clinical data show that any delay in initiating lung cancer staging and treat-
ment adversely impacts disease progression and increases the risk of distant 
metastasis. We hypothesized that lung cancer patients living without prox-
imity to a major cancer center may present with more advanced disease at 
diagnosis and their overall survival may be reduced. 
Materials/Methods: We performed a retrospective analysis of clinical data 
acquired from the charts of 1,131 patients diagnosed with lung cancer at HCH 
and the University of Utah Medical Center from 1989 to 2009. We determined 
patient travel distance to HCH from the home address using Google Maps. 
Kaplan-Meier survival curves for different categories of distance were drawn 
and the log-rank test was used to test for differences in the survival functions. 
Cox regression was performed to test the effect of distance on survival times. 
Ordered logistic regression with proportional odds assumption was used to 
assess the effect of distance, which was treated as linear, on tumor grade. 
Results: We found that 22% of the patients lived within 50 miles and 44% 
lived within 100 miles of HCH. The overall absolute 1, 3 and 5-year survival 
rates of the entire study population were 40%, 14%, and 7% respectively. The 
mean overall survival and median survival were 18.2 and 8.4 months respec-
tively. There was no impact on overall survival in subgroups of patients who 
lived ≤50, 50-100, 100-150, 150-200 or >200 miles from HCH (HR: 1.00, 
95% CI (0.94, 1.07), p=0.91). Travel distance to HCH was not a significant 
factor affecting initial tumor stage at diagnosis (OR 1.10, 95% CI (0.96, 1.26), 
p=0.16). 
Conclusions: The study showed patient travel distance to a major cancer 
center did not impact overall cancer staging or survival. These results may 
indicate that primary care in the rural intermountain west is comparable to a 
large metropolitan area for detection of lung cancers and timely referral to a 
tertiary cancer care center.
Author Disclosure Block: R. Herde: None. W. Akerley: None. K. Kokeny: 
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Impact Of HIV Infection On Survival In Lung Cancer 
Patients In The Era Of HAART: A SEER-Medicare Analysis
R. Rengan, N. Mitra, K. Liao, K. Armstrong, A. Vachani, University of 
Pennsylvania, Philadelphia, PA
Purpose/Objective(s): It has been previously reported that lung cancer 
patients with HIV have a poorer prognosis than those that are non-HIV 
infected. The purpose of this project was to examine the SEER-Medicare 
Lung Cancer registry to determine the impact of HIV infection on overall 
survival in patients with lung cancer. 
Materials/Methods: Patients with a diagnosis of lung cancer with or with-
out HIV infection were analyzed for overall survival by querying the SEER-
Medicare lung cancer database from 2000-2005. HIV infected individuals were 
identified by having either of the two ICD 9 codes V08 or 042 (HIV group). 
The control group was identified as any individual in the database without 
either of the HIV codes. A stage by stage and overall Kaplan-Meier survival 
analysis was performed comparing the HIV infected group with the control 
group. Cox models with propensity score adjustment were used to account for 
any imbalances between groups in measured covariates such as stage, race, 
median income, sex, and comorbidities. Patients with stage I and II disease 
with or without HIV infection who underwent definitive surgical resection 
were examined for impact of HIV infection in patients receiving treatment. 
Results: A total of 372 patients were identified in the HIV group and 85259 
patients were identified for the control group; stage I/II: 110 patients in the 
HIV group and 20862 patients in the control group; stage IIIA/IIIB: 118 
patients in the HIV group and 26960 patients in the control group; stage IV 
144 patients in the HIV group and 37437 in the control group. The median 
survival of the overall population was 6 months for the control group and 7 
months for HIV group (p=0.17). For stage I/II patients, the median survival 
for the control group was 36 months for the control group and 42 months 
for the HIV group (p=0.37). For stage IIIA/IIIB, the median survival was 7 
months for the control group and 4.5 months for the HIV group (p=0.03). 
For stage IV patients, the median survival was 3 months for both the control 
group and the HIV group (p=0.98). After using propensity scores to adjust for 
potential confounders, there was no difference in survival between the two 
groups (hazard ratio 1.035, 95% CI 0.92-1.16). The median survival for HIV 
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infected patients with stage I or I lung cancer undergoing surgical resection 
was 42 months vs 45 months for the control group (p=0.99) 
Conclusions: In contrast to previous reports, we found no significant sur-
vival difference between HIV infected individuals and the control group with 
lung cancer. Furthermore, survival after curative surgical resection for HIV 
infected patients was similar to control patients. These data suggest that HIV 
status should not impact treatment decisions in lung cancer patients.
Author Disclosure Block: R. Rengan: None. N. Mitra: None. K. Liao: 
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Rescue Lung, Rescue Life: A Campaign to Save Lives through 
Increasing CT Lung Screening Access and Awareness
A. B. McKee, B. J. McKee, P. J. Hesketh, R. J. French, C. Wald, A. N. Tambini, 
S. Flacke, Lahey Clinic, Burlington, MA
Purpose/Objective(s): To save lives through raising awareness of the ability 
of low-dose CT (LDCT) to screen for lung cancer and by providing equal 
access to screening via establishment of an NCCN guideline-based free 
LDCT lung screening program. 
Materials/Methods: Following release of the NCCN category 1 recommen-
dation to screen individuals at high-risk for lung cancer annually with LDCT, 
our institution convened a multidisciplinary committee (radiology, radiation/
medical oncology, pulmonary/internal medicine, finance, marketing, philan-
thropy, administration) to develop a comprehensive LDCT lung screening 
program for this patient population. Given the absence of established reim-
bursement for LDCT lung screening the committee undertook to offer screen-
ing free of charge to enable equal access regardless of patient socioeconomic 
status. A standardized radiology reporting system was needed to ensure rec-
ommendations adhered to the NCCN guidelines across multiple reading radi-
ologists. A systematic method to communicate results to referring physicians 
and patients and to monitor timing and completion of recommended followup 
exams was required. Physician and patient education and program marketing 
material was also needed. 
Results: We developed a free LDCT lung screening business plan applica-
ble to comprehensive lung cancer treatment centers revolving around use of 
installed CT scanners for screening during scanner downtime. A standardized 
reporting system (LUNG-RADS) modeled on the Bi-RADS mammography 
reporting system was designed to highlight significant pulmonary and extra-
pulmonary findings. A relational database was built to categorize findings, 
confirm completion of followup exams, and generate patient result letters. 
A comprehensive CME program was initiated with nine educational events 
held to date. To contain costs, marketing was limited to social media, inter-
nal communications/email, and outreach to selected community groups. 
Program materials included brochures introducing the multidisciplinary 
care team, posters describing the program and entry criteria, and FAQ pam-
phlets addressing the benefits and harms of screening. A toll free number was 
licensed for exam scheduling. The “Rescue Lung, Rescue Life “ movement 
was established to encourage other lung cancer treatment centers of excel-
lence to implement similar programs in lieu of established reimbursement. 
Over an 8-week trial period starting 1/9/2012 we screened over 100 high-risk 
patients and received inquiries from five outside facilities to assist in their 
development of similar lung screening programs. 
Conclusion: A coordinated, multidisciplinary effort can successfully launch an 
NCCN guideline-based free LDCT lung screening program and raise patient 
and physician awareness of the power of LDCT lung screening to save lives.
Author Disclosure Block: A.B. McKee: None. B.J. McKee: None. P.J. 
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Initial Results of a NCCN Guideline-based Free Low-dose CT 
Lung Cancer Screening Program
A. B. McKee, B. J. McKee, P. J. Hesketh, C. Wald, R. J. French, S. Flacke, 
Lahey Clinic, Burlington, MA
Purpose/Objective(s): To report initial results of our National Comprehensive 
Cancer Network (NCCN) guideline-based free low-dose CT (LDCT) lung 
cancer screening program and compare these results to the National Lung 
Screening Trial (NLST) findings. 
Materials/Methods: All 100 patients (58 female, 42 male, mean age 61y, 
mean pack-years 41) who underwent free LDCT lung cancer screening from 
program initiation on 1/9/2012 until time of abstract submission on 3/13/2012 
were included. An order from a health care provider for LDCT lung screening 
was required. Patients had to meet criteria of either high lung cancer risk group 
defined by the NCCN to qualify for free screening (Group 1: NLST study popu-
lation, Group 2: all current and former smokers aged at least 50 with at least 
a 20 pack-year smoking history and one additional lung cancer risk factor). 
Patients with known metastatic cancer or a diagnosis of lung cancer within the 
past 5 years were excluded. All screenings were performed on 64-slice mul-
tidetector CT scanners (GE, Siemens) using standard departmental low-dose 
protocols and were interpreted by board-certified radiologists using standard-
ized language and diagnostic categories. Exams were categorized as positive or 
negative per the NCCN lung cancer screening guidelines. Radiation dose, extra-
pulmonary findings of potential clinical significance, NCCN high-risk group 
status of the patient, and availability of prior chest CT imaging were recorded. 
Results: 30/100 (30%) were positive (18 nodules 4-8mm, 1 nodule > 8mm, 
10 nodules suspicious for infection/inflammation, 1 enlarged mediastinal 
lymph node). 2/100 (2%) had potentially significant extrapulmonary find-
ings requiring further evaluation (2cm thyroid nodule: benign cyst via FNA, 
1 hyperdense liver lesion: hemangioma via liver MRI). No patient had been 
diagnosed with lung cancer at time of abstract submission. 26/100 (26%) had 
prior CT thoracic imaging. Mean effective dose was 1.27 mSv (range: 0.56 - 
1.83 mSv). 41/100 (41%) qualified under NCCN Group 2 high-risk criteria. 
Conclusion: The rate of positive exams and extrapulmonary findings of 
potential clinical significance in our NCCN guideline-based free LDCT lung 
cancer screening program was similar to that reported in the NLST even 
though we included NCCN Group 2 high-risk patients and this program 
represents a new service line in our radiology department. Rigorous inter-
disciplinary program implementation, image interpretation by dedicated radi-
ologists, and use of standardized diagnostic categories and recommendations 
were key drivers of these preliminary results.
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“LUNG-RADS” A Proposed Standardized Reporting and 
Data System for CT Lung Cancer Screening
B. J. McKee, A. B. McKee, R. French, P. Hesketh, C. Wald, S. Flacke, Lahey 
Clinic, Burlington, MA
Purpose/Objective(s): Experience with imaging based population screening 
has shown that standardized reporting and follow-up recommendations facili-
tate communication between providers and outcomes monitoring. We recently 
implemented a free low-dose CT (LDCT) lung screening program based on 
the National Comprehensive Cancer Network (NCCN) guidelines. Our pro-
gam utilizes a new standardized reporting system “LUNG-RADS”, modeled 
after the ACR Breast Imaging Reporting and Data System (BI-RADS), which 
accounts for both significant pulmonary and extra-pulmonary findings. 
Materials/Methods: The “LUNG-RADS” system assigns an single alpha-
numeric diagnosis label for each LDCT lung screening exam consisting of a 
numeral (1-5) encoding the lung cancer specific findings and a letter (P=positive, 
N=negative) encoding potentially significant extra-pulmonary findings. Category 
1: Negative - no findings or findings not suspicious for lung cancer such as solid 
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non-calcified pulmonary nodules </= 4mm or ground glass nodules </= 5mm. 
Category 2: Benign - findings such as pulmonary nodules stable for more than 
two years or biopsy proven benign lesions. Category 3: Positive, Likely Benign 
- most often non-calcified solid pulmonary nodules 4-8 mm for which short 
interval LDCT follow-up is recommended. Category 4: Positive, Suspicious - 
findings such as a growing nodule for which pulmonary consultation, PET-CT 
and/or biopsy is indicated. Category 5: Positive, Known Malignancy. The suf-
fix “P” or “N” indicates the presence or absence of extra-pulmonary findings 
such as large aneurysms or indeterminate thyroid, liver, breast, adrenal, or renal 
masses which may require urgent additional evaluation. By combining diag-
nostic categories, “LUNG-RADS” results in 10 possible overall assessments 
(1N, 1P, 2N, 2P, 3N, 3P, 4N, 4P, 5N, 5P). We also integrate a standard lexicon 
to describe the shape, margin, location, and consistency of pulmonary nodules. 
Results: The use of “LUNG-RADS” in our LDCT screening program con-
tributes to unequivocal communication of pulmonary and extra-pulmonary 
findings as well as nature and timing of required follow-up. 
Conclusions: The “LUNG-RADS” system is an effective standardized diag-
nosis and reporting tool for LDCT lung screening exams.
Author Disclosure Block: B.J. McKee: None. A.B. McKee: None. R. French: 
None. P. Hesketh: None. C. Wald: G. Consultant; Phillips. S. Flacke: None.
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Parp Enzyme Inhibitor, Veliparib (ABT-888), Potentiates the 
Efficacy Of Chemotherapy And Radiation In Small Cell Lung 
Cancer (SCLC)
T. K. Owonikoko1, G. Zhang1, X. Deng1, C. Li1, J. H. Beumer2, M. R. Rossi1, 
S. S. Ramalingam1, W. J. Curran1, S. Sun1, F. R. Khuri1, 1Emory University, 
Atlanta, GA, 2University of Pittsburgh, Pittsburgh, PA
Purpose/Objective(s): The induction of DNA damage underlies the clini-
cal efficacy of therapeutic agents for SCLC. The ability of cancer cells to 
repair this damage may abrogate the expected therapeutic benefit. Since 
PARP enzyme plays a key role in DNA damage repair, we assessed whether 
veliparib, an inhibitor of PARP enzyme (PARPi) will enhance the efficacy of 
DNA-damaging agents in SCLC. 
Materials/Methods: We employed nine SCLC cell lines (H69, H128, H146, 
H187, H209, H526, DMS53, DMS114, DMS153) to evaluate the effect of 
veliparib on the activity of chemotherapyand ionizing radiation (IR) in 
vitro. Exponentially growing cells were treated by single time exposure (IR- 
2Gy/4Gy) or continuous exposure for 48-72 h to vehicle, veliparib and cyto-
toxic agents (cisplatin, carboplatin, etoposide) ± Veliparib. Surviving cell 
fraction was determined using MTS assay. We also assessed the effects of 
veliparib in vivo using subcutaneous xenograft of cell lines representative of 
in vitro sensitivity (H146) and insensitivity (H128) to PARPi. Mechanistic 
basis of PARPi efficacy was explored by animal pharmacokinetic assay 
(serum and tumor platinum content), Western blot assay [PARP inhibition 
(PARylation); apoptosis induction (cleaved PARP and caspase); DNA dam-
age (gamma-H2AX) and DNA damage repair pathway proteins (ERCC1, 
DNA-PK, Ku80, ATM, ATR and BRCA1)] and gene expression profile on 
the Illumina platform under different treatment conditions. 
Results: Veliparib showed negligible single agent activity but enhanced 
the cytotoxicity of chemotherapy in a cell-specific (5 of 9 cell lines were 
sensitive) and dose-dependent manner (approximately, 7-fold versus 2-fold 
reduction in IC
50
 concentrations of cytotoxic agents by 50µM versus 5µM 
concentration of veliparib). Veliparib (5µM) also enhanced IR effect at 2 
different dose levels (surviving fractions were 67.4% vs. 44.7% - 2Gy and 
46% vs. 32.7% - 4Gy). Replicating the in vitro results, veliparib enhanced 
chemotherapy-induced tumor growth inhibition in vivo in H146 but not in 
H128 cell line with a dose-dependent increase in intratumoral platinum 
content in veliparib-treated animals. High DNA-PK expression correlated 
with reduced sensitivity to PARPi in vitro and its modulation correlated 
with onset of apoptosis in a time dependent manner. Gene expression pro-
file identified 23 differentially expressed genes based on cell sensitivity to 
PARPi therapy. 
Conclusion: Veliparib potentiates standard therapeutic agents in SCLC in a 
dose and cell-context dependent manner. Expression of DNA-PK correlates 
with SCLC cell line sensitivity to PAPRi. Clinical translation of these findings 
is ongoing in an ECOG study, E2511, a randomized phase II trial in newly 
diagnosed patients with extensive stage SCLC.
Author Disclosure Block: T.K. Owonikoko: None. G. Zhang: None. X. 
Deng: None. C. Li: None. J.H. Beumer: None. M.R. Rossi: None. S.S. 
Ramalingam: G. Consultant; Abbott Laboratory. W.J. Curran: None. S. 
Sun: None. F.R. Khuri: None.
279 
A Phase 1/2 Study of the CD56-targeting Antibody-Drug 
Conjugate, Lorvotuzumab Mertansine (LM, IMGN901), in 
Combination with Carboplatin/Etoposide in Patients with 
Solid Tumors including Small Cell Lung Cancer (SCLC)
D. R. Spigel1, J. C. Bendell1, A. C. Mita2, A. Argiris2, C. Kurkjian3, C. L. 
Hann4, E. Segota5, D. S. Johnson6, J. Schindler6, M. E. Gutierrez5, 1Sarah 
Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, 
2Cancer Therapy and Research Center, San Antonio, TX, 3University of 
Oklahoma, Oklahoma City, OK, 4Johns Hopkins University, Baltimore, MD, 
5Holy Cross Hospital, Fort Lauderdale, FL, 6ImmunoGen, Inc., Waltham, MA
Purpose/Objective(s): LM is designed to specifically kill CD56-expressing 
cancer cells. It comprises the potent cytotoxic maytansinoid, DM1, linked to a 
CD56-targeting antibody. Over 90% of SCLC express CD56. Based on LM’s 
single-agent activity in Phase 1 trials and combination activity in preclinical 
SCLC models, a Phase 1/2 study was initiated. This abstract summarizes its 
Phase 1 data. 
Materials/Methods: Phase 1 accrued patients with advanced solid tumors 
that had progressed despite standard therapy or for which no effective stan-
dard therapy exists. Chemo-naive SCLC patients were also eligible. New 
cohorts received escalating doses of LM IV on days 1 and 8 in combination 
with carboplatin IV on day 1 and etoposide IV on days 1-3 every 21 days. 
Treatment continued for 4 to 6 cycles. Patients with objective response or 
stable disease (SD) could continue single agent LM until progressive disease 
or unacceptable toxicity. The maximum tolerated dose (MTD) was defined 
using a standard 3+3 design; the recommended phase 2 dose (RP2D) was to 
be confirmed following treatment of 12 patients at the MTD or highest LM 
dose achieved up to a cap of 112 mg/m2. 
Results: A total of 33 patients (13M, median age = 57.3) were treated in 5 
cohorts (2 cohorts using carboplatin AUC6 and 3 using AUC5) at LM doses 
ranging from 60-112 mg/m2. Most patients had received prior chemotherapy; 
45% had received at least 2 prior regimens. The predominant tumor types 
were SCLC (39%) and neuroendocrine (12%). The RP2D was defined as LM 
112 mg/m2 with carboplatin AUC5 and etoposide 100 mg/m2. Dose-limiting 
toxicities included hematologic toxicities and related events (febrile neu-
tropenia, thrombocytopenia, neutropenia and pneumonia). Most treatment-
related adverse events (AEs) were also hematologic while the most common 
treatment-related non-hematologic AEs were nausea, peripheral neuropathy, 
fatigue, vomiting, constipation, arthralgia, and diarrhea. The majority of 
related grade 3/4 AEs were cytopenias; which typically have not been associ-
ated with LM in single-agent testing. Only one patient discontinued due to a 
drug-related AE (neuropathy). Eleven of the 13 patients enrolled with SCLC 
have completed at least one response assessment; 4 (36%) of these patients 
have achieved a partial response (1 chemo-naïve) and 1 additional patient 
has reported SD for > 4 cycles. 
Conclusions: LM in combination with carboplatin and etoposide has shown 
promising activity and has been well tolerated in this predominantly pre-
treated population. The randomized Phase 2 portion of the study in chemo-
naïve patients with SCLC has opened to accrual.
Author Disclosure Block: D.R. Spigel: None. J.C. Bendell: None. A.C. 
Mita: None. A. Argiris: None. C. Kurkjian: None. C.L. Hann: None. E. 
Segota: None. D.S. Johnson: A. Employee; ImmunoGen, Inc. J. Schindler: 
A. Employee; ImmunoGen, Inc.. M.E. Gutierrez: None.
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Circulating Tumor Cells (ctc) In Patients (pts) With Small 
Cell Lung Cancer (sclc): A Marker Of Disease Burden, 
Therapeutic Response, And Predictor Of Disease Relapse
C. Aggarwal1, A. Ranganathan1, D. Schwed-Lustgarten2, L. Werner1, D. 
Torigian1, A. Troxel1, C. Rao3, M. Connelly3, S. Albelda1, C. Langer1, 
1University of Pennsylvania, Philadelphia, PA, 2Pulmonology Associates, 
Allentown, PA, 3Veridex LLC, Philadelphia, PA
Background: Currently there are no validated biomarkers for assessment or 
prediction of disease burden or activity in SCLC. Enumeration of CTCs by 
CellSearch® is FDA approved, highly reproducible and validated in other malig-
nancies; however application as a prognostic and predictive marker in SCLC is 
limited due to a lack of studies documenting serial monitoring in pts on therapy. 
Materials/Methods: We are conducting a prospective study serially enu-
merating CTCs in pts with newly diagnosed SCLC. CTC number (per 7.5 
ml peripheral blood (PB)) and percentage of CTCs demonstrating DNA 
damage and apoptosis based on γH2AX and M30 staining respectively, are 
being assessed prior to initiation of chemotherapy, during each cycle and at 
relapse. We are correlating CTC number with PS, disease stage, number of 
metastatic sites (mets), response to therapy, and time to progression (TTP). 
Results: 21 SCLC pts are evaluable. 9 pts with limited disease (LD) had 
median baseline CTC value of 1 (0-8); only 2 of 9 pts had >5 CTCs. 12 pts with 
extensive disease (ED) had median baseline CTC value of 80.5 (0-37780); 8 
of 12 pts had >5 detectable CTCs (p-value 0.02). Amongst the 12 pts with ED, 
median baseline CTC count was higher in pts with ≥3 (n=3) compared to 1-2 
sites of mets (n=9) (2668 vs 71; p-value 0.52). Median percentage of CTCs 
positive for γH2AX and M30 was also higher for pts with ≥3 mets compared 
to 1-2 sites of mets (83, 164.5 vs. 2, 7.5) (p-value 0.40, 0.69). Serial CTC data 
are available on 3 pts with ED; all had responsive disease and reduction in 
CTC number to 0-1 after 2 cycles. As this protocol is ongoing, correlation of 
CTCs with updated response status and TTP will be presented at the meeting. 
Conclusions: CTCs can be isolated and serially enumerated in pts with 
SCLC. Baseline CTCs correlate directly with disease stage. In pts with ≥ 3 
mets, baseline CTCs tend to be greater and show higher levels of DNA dam-
age and apoptosis compared to 1-2 sites of mets; the absence of statistical sig-
nificance is likely related to a limited number of values evaluable. Reduction 
in CTCs is associated with radiographic response to therapy. Correlation 
between absolute number at baseline and TTP is not yet known.
Author Disclosure Block: C. Aggarwal: None. A. Ranganathan: None. 
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The Phase II Trial of Erotinib and Radiotherapy Folling 
Chemoradiotherapy for Patients with Stage III Non-Small 
Cell Lung Cancer Has Shown a Favorable Response Profile
R. U. Komaki, P. K. Allen, X. Wei, G. R. Blumenschein, I. I. Wistuba, J. Lee, 
J. Welsh, M. S. O’Reilly, X. M. Tang, W. K. Hong, MD Anderson Cancer 
Center, Houston, TX
Purpose/Objective(s): Standard treatment became chemoradiotherapy (ChT/
RT) for inoperable locally advanced Non-Small Cell Lung Cancer (NSCLC) 
and good PS patients. Our prospective phase II trial investigated EGFR-TKI 
(erlotinib) as a radiosensitizer for inoperable stage III NSCLC patients who 
also received standard ChT/RT. 
Materials/Methods: 48 stage III NSCLC patients were prospectively 
enrolled from 3/2008 through 6/2010. Eligibility included Zubrod perfor-
mance status (PS) ≤ 1, weight loss ≤ 5% over past 3 months, FEV1 ≥ 1.0 L, 
adequate hematologic, hepatic, and renal functions. ChT/RT was given every 
Monday followed by erlotinib/RT on Tuesday-Friday and erlotinib alone over 
the weekend. RT (63 Gy in 35 fractions) with weekly paclitaxel (45mg/m²) / 
carboplatin (AUC=2) and erlotinib (150 mg p.o. daily except on the day 
of chemotherapy) were given for 7 weeks. After one month break, patients 
received two cycles consolidation of paclitaxel (AUC=6) and carboplatin 
(200mg/m2). EGFR mutation analysis was performed for 41 patients. Clinical 
response was measured by RECIST criteria (v3.0) by CT scan after comple-
tion of ChT/RT. Fisher’s exact test and Kaplan-Meier’s estimates were used 
for the statistical analysis. Primary endpoint was the efficacy of erlotinib/
radiotherapy after ChT/RT measured by MST.OS, PFS, LRFS and DMFS. 
Results: 46 patients completed the entire treatment are evaluable for response. 
All had PS KPS ≥80, 17 (37%) were female, 50% adenocarcinoma, and 
87% former or current smokers, with median age 63 year-old (range: 46-81). 
Responses showed 14 (30%) CR, 23 (50%) PR and 9 (20%) stable or progressive 
disease. Five in 41 patients (12%) had EGFR mutation (EGFR-M), all adeno-
carcinoma with 2 females, compared to none of squamous histology (p=0.05). 
CR were observed in 3 of 5 (60%) patients in the EGFR-M group compared to 
11 of 25 (44%) in the EGFR-wild group (p=0.32), respectively. The MST and 
PFS were 34.1 months & 14.5 months, respectively.1-year and 2-year OS were 
82.5% and 70.8 % (EGFR-M 80.0% & 80.0%; EGFR wild type: 59.9% and 
35.5, p=0.52) and PFS 55.7% & 31.8% (EGFR-M 20.0% & 20.0%; EGFR wild 
type: 59.9% and 35.5, p=0.34), respectively. Toxicity showed 2 grade 3 acne, 1 
Grade 3 esophagitis, 3 Grade 3 pneumonitis and no Grade 4-5. One year OS was 
70.0% in grade 0-1 acne group and 92.3% in grade 2-3 acne group, respectively. 
Conclusions: This prospective phase II clinical study demonstrated an excel-
lent 2-year OS 70.8 % and MST 34.1 months. All EGFR-M were seen in 
adenocarcinomas. Erlotinib showed a radiosensitization effect in combination 
with chemoradiotherapy, while these results are encouraging they should be 
validated in a randomized prospective manner.
Author Disclosure Block: R.U. Komaki: None. P.K. Allen: None. X. Wei: 
None. G.R. Blumenschein: None. I.I. Wistuba: None. J. Lee: None. J. 
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Patterns of Failure for Limited-Stage Small Cell Lung Cancer 
following Definitive Radiotherapy in the Modern Era.
S. M. Shirvani, A. Juloori, D. Gomez, P. K. Allen, R. Komaki, M. O’Reilly, Z. 
Liao, J. Welsh, V. Papadimitrakopoulou, J. Y. Chang, M.D. Anderson Cancer 
Center, Houston, TX
Purpose/Objective(s): Limited-stage small cell lung cancer (LS-SCLC) 
diagnosis and treatment has been transformed in the modern period by a 
series of technological innovations including positron emission tomography 
(PET) staging, intensity-modulated radiotherapy (IMRT), and dose escala-
tion using image guided radiotherapy. To determine whether these technolo-
gies have had an impact on the ability to achieve loco-regional control, we 
reviewed patterns of failure for a large cohort of LS-SCLC patients treated at 
our institution during the last decade. 
Materials/Methods: Between 2000 and 2009, 224 patients with LS-SCLC 
were treated with definitive radiation at our institution. In 93% of cases, dual 
chemotherapy consisting of a platinum-based agent and topoisomerase inhibitor 
was concurrently administered. All subsequent relapses following radiotherapy 
were identified. In-field and out-of-field failure were defined as failure inside 
and outside the planning treatment volume (PTV), respectively. Elective nodal 
failure was defined as recurrence in initially uninvolved hilar, mediastinal, or 
supraclavicular nodes. Multivariable analysis using Cox regression was utilized 
to determine the influence of patient, tumor, diagnostic, and treatment charac-
teristics on a composite outcome of all intrathoracic failures. These variables 
included age, gender, race, performance status, AJCC stage, utilization of PET 
staging, utilization of brain MR staging, interval between PET and radiotherapy 
start time, thoracic radiotherapy dose, use of intensity modulated radiotherapy 
(IMRT), use of induction chemotherapy, choice of platinum agent (carboplatin 
versus cisplatin), and receipt of prophylactic cranial irradiation. 
Results: The median age of the study patients at diagnosis was 62 (range 
39 - 82). Median follow-up was 33 months (range 2-145). One hundred sixty 
seven recurrences were identified following definitive chemoradiation: 99 
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(58%) distant metastases, 56 (35%) in-field failures, 17 (10%) elective-nodal 
failures and 11 (7%) out-of-field failures. In multivariable analysis, predictors 
for intrathoracic failure were AJCC IIIB disease at presentation (Hazard ratio 
[HR], 3.13, 95% confidence interval [CI], 1.20-8.13, p = 0.019) and lower 
radiation dose (HR, 0.95, 95% CI, 0.92-0.996, p = 0.031). 
Conclusions: This institutional experience, to our knowledge, represents the 
largest contemporary series of LS-SCLC patients treated with definitive radi-
ation. Distant metastatic disease remained the most common pattern of fail-
ure, while in-field failures accounted for the majority of relapses in the chest. 
Improved intrathoracic control was associated with higher radiation doses. 
The transition from 3D conformal radiation to IMRT did not compromise 
disease control in the chest.
Author Disclosure Block: S.M. Shirvani: None. A. Juloori: None. 
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Role of Radiation Therapy in Small Cell Lung Cancer 
(SCLC): Analysis of SEER-17 Data
F. P. Kong1, W. O. Quarshie2, N. Bi1, N. Kapadia1, F. Vigneau2, 1University of 
Michigan, Ann Arbor, MI, 2Wayne State University, Detroit, MI
Purpose/Objective(s):The overall survival benefit of radiotherapy is not well 
defined in small cell lung cancer (SCLC). Current data on SCLC is largely 
stratified by limited vs extensive stages. This study aimed to examine 1) AJCC 
stage distribution, 2) the use of local treatment modality such as radiotherapy 
(RT), and 3) survival benefit of RT in patients with SCLC. 
Materials/Methods: The study population includes primary SCLC from the 
SEER-17 database 1999-2008. The data were stratified by AJCC stage and treat-
ment type. Chemotherapy data were not available in the SEER-17 data. Median 
survival (MS) was estimated by Kaplan-Meier analysis for the entire time period 
and two periods, 1999-2003 and 2004-2008. Hazard ratios (HR) for death were 
generated using Cox proportional regression methods based on treatment modal-
ity and time frame, adjusted for age, sex, race, stage and marital status. Data are 
presented as median (95% confidence interval, “na”~signifies that the interval 
was too narrow for a reasonable estimation by the computing program). 
Results: 44022 patients were included in this analysis. 5% were stage I, 2% 
stage II, 29% stage III, 57% stage IV and 7% unknown stage. The median sur-
vival was 16 (16-17), 16(15-18), 11 (na), 5 (na) and 9 (na) months, respectively. 
Overall, 1% of patients (10% of stage I) underwent surgery, 1% had surgery + 
radiation, 43% had radiation, the remaining 55% received neither surgery nor 
radiation. Treatment with RT was associated with significantly better survival 
for all stages, with median survival extension of 10 months, 12 months , 10 
months, and 4 months for stage I, II, III, and IV diseases, (all P<0.001) com-
pared to those who received neither surgery nor RT. Median survival for SCLC 
was 7 (7-8) months. Factors associated with higher risk of death included age 
(HR 1.02, 1.02-1.02), stage non-I (II HR 1.16, 1.06-1.28; III HR 1.50, 1.43-
1.59; IV HR 2.578, 2.45-2.71) and being unmarried (HR>1.14 for each strata). 
Favorable factors included female sex (HR 0.84, 0.82-0.85) and ‘other’ race 
(HR 0.88, 0.84-0.93) and later period (2004-2008) (HR 0.95, 0.94-0.97). MS of 
2004-2008 dataset was 19 (18, 22), 16 (14, 18), 11 (11, 12) and 5 (5, 6) months 
for stage I, II, III, and IV diseases. MS for 1999-2003 period was 15 (14, 16), 
16 (14, 19), 10 (10, 11) and 5 (na) months for stage I, II, III, and IV diseases. 
The only significantly difference from earlier years was for stage I (P<0.001) 
(p>0.05 for other stages). There were significantly more stage I patients treated 
with surgery during recent years (19% recently vs. 12% previously). 
Conclusion: Radiation therapy improved survival in all AJCC stages of 
SCLC, compared to patients receiving neither surgery nor radiation, suggest-
ing the benefit of local therapy. There was an improvement of overall survival 
for stage I SCLC during the recent period, compared to an earlier period, 
though no changes for stages II-IV.
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The Role of Advanced Imaging in Assessing Response to 
Definitive Chemoradiation Prior to Prophylactic Cranial 
Irradiation in Limited-Stage Small Cell Lung Cancer
A. H. Kesarwala1, D. J. Lu2, E. Xanthopoulos2, S. Apisarnthanarax2, T. Evans2, 
C. Aggarwal2, R. B. Cohen2, C. J. Langer2, R. Rengan2, C. B. Simone2, 
1National Cancer Institute, Bethesda, MD, 2University of Pennsylvania, 
Philadelphia, PA
Purpose/Objective(s): Prophylactic cranial irradiation (PCI) improves 
overall survival (OS) in patients (pts) with small cell lung cancer (SCLC). 
Evidence for PCI efficacy in limited-stage (LS) SCLC is derived from 
studies requiring only a chest x-ray (CXR) to determine remission status 
(Auperin et. al., NEJM 1999). We analyzed post-thoracic chemoradiation 
(TCRT) outcomes by imaging modality to determine which pts benefit most 
from PCI. 
Materials/Methods: All LS-SCLC pts who received TCRT and PCI at 
University of Pennsylvania from 1998-2010 were reviewed in this IRB-
approved study. PCI (24-36 Gy) began a median of 12 wks after TCRT. 
Survival was calculated from PCI start and living pts were censored on 
3/1/12. Each imaging study between TCRT end and PCI start was character-
ized as a complete (CR), partial (PR), or other response on diagnostic radi-
ology report. Two-way unpaired t-tests were used to determine significance 
between groups (p≤0.05). 
Results: 38 consecutive pts with negative neuroimaging assessed for TCRT 
response with CXR (n=22), chest CT (n=28), and/or PET/CT (n=11) prior 
to PCI were included. Median survival (MS) was 22.6 mo for the entire 
cohort and 39.2 mo for living pts (n=17). CR was identified on 68% of CXR, 
39% of CT, and 18% of PET prior to PCI. A censored delayed CR on PET 
occurred after PCI in another 27% of pts. Concordance in classifying treat-
ment response in pts with >1 imaging modality was 67%. All discordances 
were CRs on CXR found to be PRs on CT (n=6/15) or PET (n=1/5). MS 
did not differ for pts who had CXR alone vs CT or PET (24.0 mo vs 31.5 
mo, p=0.78). Pts with CT CR had a trend toward greater 1-yr OS (p=0.13) 
and significantly improved 2-yr OS (p=0.03, * in table) compared to CT PR. 
CXR and PET response did not correlate with survival. CR on CXR vs CT 
also did not predict survival. CR on all modalities significantly improved OS 
compared to PR on any modality at 2 yrs (p=0.05, ^ in table) but not OS at 1 
or 3 yrs or MS.
Table 1: Survival According to Imaging Modality and Thoracic 
Chemoradiation Response
Number
Median 
Survival 
(months)
1-year 
Overall 
Survival
2-year 
Overall 
Survival
3-year 
Overall 
Survival
Entire cohort 38 22.6 68% 52% 40%
CXR CR 15/22 24.7 80% 64% 45%
CXR PR 7/22 16.8 57% 40% 40%
CT CR 11/28 33.8 91% 82%* 56%
CT PR 17/28 22.4 65% 38%* 36%
PET CR 2/11 22.5 50% 50% 50%
PET PR 9/11 19.7 67% 38% 38%
CR on all 
modalities
14/38 32.9 79% 71%^ 43%
PR on any 
modality
24/38 22.6 63% 37%^ 33%
Conclusions: CXR remains an appropriate modality to assess response to 
TCRT prior to PCI in LS-SCLC. Advanced imaging (CT or PET) did not 
add information to assist in the decision to offer PCI. PET restaging prior 
to PCI may be of limited utility as response did not predict for survival and 
FDG uptake may persist >12 weeks from TCRT, even in pts with CT CR. 
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Given similar excellent survival profiles independent of imaging modality 
and TCRT response, pts with a PR on any modality should not be denied PCI, 
akin to standards for extensive-stage SCLC.
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Higher Dose Thoracic Radiotherapy is Associated with 
Improved Overall Survival in Limited-stage Small Cell 
Lung Cancer: Analysis of the 15 Year Experience from a 
Retrospective Cohort of 296 Patients at the Ottawa Hospital 
Cancer Centre (TOHCC)
V. Janardanan Nair1,2, A. Sirisegaram1,2, G. Nicholas1,2, R. Mallick1,2, S. 
Laurie1,2, R. MacRae1,2, 1The Ottawa Hospital Cancer Centre, Ottawa, ON, 
Canada, 2University of Ottawa, Ottawa, ON, Canada
Purpose/Objective(s): The addition of thoracic radiotherapy (TRT) to che-
motherapy in limited stage-small cell lung cancer (LS-SCLC) has led to 
improved survival. However the optimum dose of TRT remains unclear. Over 
time the practice at TOHCC has been to deliver higher doses of TRT. In this 
study we retrospectively evaluated prognostic factors for survival in patients 
with LS-SCLC treated with curative intent chemoradiation to determine 
whether higher doses of thoracic radiotherapy influence treatment outcomes. 
Materials/Methods: Between 1996 and 2011, a total of 410 patients with 
LS-SCLC were referred to TOHCC of which 296 patients were treated with 
curative intent chemoradiation. A research ethics board approved retrospec-
tive review of charts was performed for patient, tumour and treatment-related 
characteristics. Prognostic factors associated with overall survival (OS) and 
progression free survival (PFS) were retrospectively analysed. OS was esti-
mated by the Kaplan-Meier method comparing various radiotherapy dose 
groups. Statistical analysis was performed using SAS Enterprise guide 4.2. 
Results: The median follow-up was 18.8 months and 29% were alive at the 
time of analysis. The median TRT dose was 50 Gy (20-66 Gy). By univari-
ate analysis, the prognostic factors influencing OS were: age, gender, ECOG 
performance status (PS), pleural effusion, number of chemotherapy cycles, 
total radiation dose, timing of RT with chemotherapy (concurrent better than 
sequential), use of PCI and TRT dose ≥60 Gy. Multivariate analysis by Cox 
Proportional Hazards model demonstrated that female gender (HR 0.72, CI 
0.55-0.97, p <0.03), use of PCI (HR 0.38, 0.27-0.53, P<0.0001), and TRT 
dose ≥ 60 Gy (HR 0.62, CI 0.43-0.90, p <0.01) were independent predic-
tors of improved OS. Independent predictors for better PFS included female 
gender, having pre-treatment PET scans and PCI. Worse ECOG PS was inde-
pendently associated with worse OS and PFS. The median OS, and the OS at 
2 years, 5 years and 8 years for the group treated with curative intent chemo-
radiation were 21.2 months, 45%, 23% and 18% respectively. The 5 year OS 
and 8 year OS for the TRT dose groups 40-49 Gy, 50-59 Gy and ≥60Gy were 
19%, 18%, 35% and 13%, 14%, 30% respectively (p=0.0013). 
Conclusion: Outcomes with CCRT in an unselected patient population at 
TOHCC with LS-SCLC are consistent with those in the published literature. 
Despite the limitations of its retrospective nature, this analysis suggests that 
TRT doses of 60 Gy or more are associated with improved overall survival in 
LS-SCLC. The ongoing CONVERT and RTOG-0538/ CALGB-30610 stud-
ies should clarify this issue.
Author Disclosure Block: V. Janardanan Nair: None. A. Sirisegaram: 
None. G. Nicholas: None. R. Mallick: None. S. Laurie: None. R. MacRae: 
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Small Molecule Inhibitors of MET and Topoisomerase I 
Synergize to Decrease the Viability of Small Cell Lung Cancer
C. E. Rolle1, M. Surati1, R. Hseu1, R. Kanteti1, Q. Arif1, M. Tretiakova1, A. 
N. Husain1, E. E. Vokes1, A. Bharti2, R. Salgia1, 1The University of Chicago, 
Chicago, IL, 2Boston University, Boston, MA
Purpose/Objective(s): Small cell lung cancer (SCLC) is a devastating disease 
and current therapies have not greatly improved the overall 5-year survival 
rates. Topoisomerase I (Top1) inhibition is a potential treatment modality for 
SCLC; however, the response is short lived. Our previous research has identi-
fied MET as overexpressed and functional in SCLC. Therefore, we investigated 
the therapeutic potential of combinatorial targeting of MET and Top1 in SCLC. 
Materials/Methods: The expression and gene copy number of MET and 
Top1 were determined in 29 SCLC patient tumors specimens, 11 with limited 
disease and 18 with extensive disease. MET and TOP1 gene copy numbers 
were determined by qPCR. Protein expression in SCLC tumor specimens was 
evaluated by immunohistochemistry (IHC). The protein expression and gene 
copy number for MET and Top1 in a panel of SCLC cell lines were evaluated 
by immunoblotting and qPCR, respectively. Using immunofluorescence we 
observed the localization of MET and Top1 in response to stimulation of the 
HGF/MET axis. A standard MTT assay was utilized to measure the effect 
of the small molecule inhibitors of MET (SU11274) and Top1 (SN38) on 
cell viability. The enzymatic activity of Top1 was assayed by relaxation of a 
supercoiled DNA plasmid. The dose-effect analysisfor SU11274 and SN38 
treatment was calculated using Compusyn based on the Chou-Talalay method, 
in which a combination index (CI) <1 indicates synergy. 
Results: MET gene copy number was significantly increased in extensive dis-
ease compared to limited disease (p=0.015). Similar TOP1 gene copy num-
bers were detected in limited and extensive disease specimens. IHC staining 
revealed significantly higher Top1 nuclear expression in extensive versus lim-
ited disease (p=0.04). Interestingly, there was a significant positive correla-
tion between MET gene copy number and Top1 nuclear expression (r=0.553, 
p=0.026). In vitro, HGF stimulation induced nuclear co-localization of 
phospho-MET and Top1. Activation of the HGF/MET axis enhanced Top1 
activity, which was abrogated by SU11274. Furthermore, drug combination 
dose-effect analysis revealed synergy between SU11274 and SN-38 in H69 
and H345 cells (CI <1). 
Conclusions: Collectively, these findings suggest that combinatorial inhibi-
tion of MET (SU11274) and Top1 (SN-38) is a potentially efficacious treat-
ment strategy for SCLC.
Author Disclosure Block: C.E. Rolle: None. M. Surati: None. R. Hseu: 
None. R. Kanteti: None. Q. Arif: None. M. Tretiakova: None. A.N. Husain: 
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Small-cell Lung Cancer Specific Oncogenic Signature 
Identified By Gene Co-expression Network Analysis
A. Udyavar1, J. Clark1, Y. Zou1, C. Callison1, X. Chen1, D. Liebler1, Y. Shyr1, L. 
Estrada1, V. Quaranta1, P. Massion1,2, 1Vanderbilt University, NASHVILLE, TN, 
2Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN
Purpose/Objective(s): Small-cell lung cancers (SCLC) represent 15% 
of lung cancers with a dismal 5% 5-year survival rate. Highly sensitive to 
chemotherapy and radiation, they invariably recur with fatal metastases. In 
non-SCLC, gene expression and mutation profiling have led to patient stratifi-
cation and identification of subsets susceptible to targeted therapy. In contrast, 
in SCLC gene expression profiling studies based on differential expression 
have been disappointing, resulting in signatures with minimal overlap and 
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little insight in oncogenic mechanism. Since a critical need remains to iden-
tify SCLC driver pathways and novel therapeutic targets, we tested whether 
a different bioinformatics approach, based on gene co-expression analyses, 
could extract useful information from SCLC datasets and potentially discover 
oncogenic driver networks in SCLC. 
Materials/Methods: We applied weighted gene co-expression network anal-
ysis (WGCNA) to 4 independent lung cancer patient gene expression datas-
ets on various array platforms encompassing: normal lung (NL); squamous 
cell carcinoma (SCC); adenocarcinoma (ADC); large-cell carcinoma (LCC); 
low grade neuroendocrine tumors (NET) (typical and atypical carcinoids); 
high-grade NET such as Large-cell neuroendocrine carcinoma (LCNC) and 
SCLC. We identified reproducible hierarchical gene networks highly specific 
to SCLC, and filtered our networks to contain highly connected genes (hubs) 
that would serve as potential therapeutic targets. We also validated the net-
work signature using a shotgun proteomic dataset generated on independent 
patient pools of NL, SCC, SCLC and ADC. 
Results and Conclusions: The hubs of SCLC-specific hierarchical networks 
formed a SCLC “hub network signature” (SHNS) that: 1) classified SCLC 
from other lung tumor subtypes including low and intermediate grade lung 
NET such as typical and atypical carcinoids on 4 independent patient datasets 
and 1 cell line dataset; 2) identified 2 SCLC subgroups with high and low 
SNS expression, consistent in cell lines as well; 3) was validated in cell line 
mRNA and shotgun proteomic dataset from independent SCLC patients; 4) 
was enriched for unsuspected oncogenes with potential driver function. We 
are currently testing the functional significance of the hubs of these onco-
genic driver networks in SCLC cell lines and xenograft mouse models using 
a combination of math modeling and high-throughput phospho-flow cytom-
etry analysis. If successful, our combinatorial approaches will yield novel 
potential oncogenic hubs as therapeutic targets for SCLC, and unveil power-
ful clues for the pathogenesis of the disease. This work was supported by 
1I01CX000242, a Merit Review grant from the Veterans Administration to 
PPM, and a NCI U54-CA113007 to VQ.
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Patterns of Care in Small Cell Lung Cancer and its Impact on 
Treatment Choice and Mortality
K. Lee, G. H. Kloecker, J. Pan, S. N. Rai, N. E. Dunlap, University of 
Louisville, James Graham Brown Cancer Center, LOUISVILLE, KY
Purpose/Objectives: There are many factors and disparities that contribute 
to the multidisciplinary management of small cell lung cancer (SCLC). Our 
objective was to conduct a cancer registry analysis of patients with SCLC in 
Kentucky to identify factors affecting treatment choice and mortality. 
Materials/Methods: Database collection was done through the Kentucky 
Cancer Registry (KCR), which is part of the Surveillance, Epidemiology, 
and End Results (SEER) program. Inclusion criteria included patients diag-
nosed between 1995 and 2008. Patients were diagnosed with SCLC and were 
American Joint Committee on Cancer stage I-IV. Statistical analyses were 
carried out to identify variables affecting initial treatment choice and survival. 
Results: Analysis evaluated 4,888 patients from the KCR. Out of these 
patients, 2358 (48.2%) received chemoRT, 1584 (32.4%) chemotherapy only, 
633 (13.0%) no treatment, 239 (4.9%) RT alone, and 74 (1.5%) surgery alone 
as initial treatments. For the entire cohort, age (p<.001), urban vs rural county 
(p=.03), and limited vs extensive stage (p<.001) were significantly associated 
with the type of treatment received. ChemoRT had significantly increased 
OS rates compared to all other treatment groups at 1,2,3,4, and 5 years. 
Chemotherapy alone significantly increased OS rates compared to that of RT 
alone (27.5 vs 13.8% p<.0001) and no treatment (27.5 vs 12.2% p<.0001) 
groups at 1 year. At 2 years, the OS difference was only seen between the 
chemotherapy and no treatment group (7.2% vs 4.9% p=0.03). The survival 
benefit for chemotherapy alone was lost at 3 years. For the subset of patients 
with limited stage disease, chemoRT had significantly increased OS rates 
compared to all other treatment groups at 1,2,3,4, and 5 years. Chemo alone 
had significantly increased OS rates compared to that of RT alone (27.3 vs 
16.1% p=.03) and no treatment (27.3 vs 16.7% p=.003) groups at 1 year. After 
1 year, however, the survival benefit of chemotherapy alone was lost. 
Conclusions: Initial treatment with chemoRT resulted in improved survival 
in patients with both extensive and limited stage SCLC. The survival benefit 
of chemotherapy alone compared to no treatment is lost with longer follow 
up. In an effort to improve treatment outcome, non-patient factors must be 
considered including access to radiotherapy.
Author Disclosure Block: K. Lee: None. G.H. Kloecker: None. J. Pan: 
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A Strategy To Reduce Acute Toxicity From Chemoradiation 
Therapy For Limited-stage Small Cell Lung Cancer
E. Xanthopoulos, M. Corradetti, S. Grover, A. Fernandes, M. Kim, C. 
Simone, S. Apisarnthanarax, L. Lin, R. Rengan, University of Pennyslvania, 
Philadelphia, PA
Background: The standard of care for limited stage SCLC as outlined in the 
Intergroup 0096 trial involves twice daily radiation therapy, delivered to two 
out of four fields at a time, which results in high rates of clinically significant 
acute toxicity. This study examines acute esophagitis and treatment breaks in 
patients treated with radiation therapy as outlined by Intergroup 0096 vs those 
treated with a slight modification to this technique. 
Materials/Methods: We identified SCLC patients who received 45 Gy in 1.5 
Gy bid fractions from an institutional database. Associations were assessed 
via Chi-squared test. A break was defined as an interruption of 3+ days. 
Results: 74 SCLC patients were treated with 3D-conformal radiation therapy 
from 2004 - 2010. 16 patients did not satisfy criteria described in the Methods 
and were excluded. 28 patients were treated per Intergroup 0096 with AP/PA 
fields bid for 1 week followed by AP/PA treatment in the AM and 2 oblique fields 
in the PM for 2 weeks. 28 patients were treated with the same approach except all 
four fields were treated with each fraction. Patient characteristics were well dis-
tributed as outlined below. 54% of patients had CTCAE grade 3 esophagitis with 
the Intergroup 0096 approach vs 23% in patients treated with a 4-field approach 
(p = 0.01). 29% vs 7% patients had a treatment break (p = 0.03). 32% of grade 3 
esophagitis patients had breaks vs 8% with esophagitis grades 0 – 2 (p = 0.02). 
There was no difference in survival or distant/local failure. 
Conclusions: Grade 3 esophagitis and treatment breaks were reduced in 
patients receiving continuous 4-field treatment. Future investigation is 
required to determine whether the observed reduction in breaks could trans-
late to a local control or survival benefit if applied to a larger patient sample.
Intergroup 0096 
technique  
(n = 28)
4-field 
technique 
(n = 28)
p
Median age 64 61 0.28
White 62% 81% 0.18
Female, % 72% 77% 0.65
Limited stage, % 93% 93% 0.94
Median treatment, year 2005 2008 <0.01
Concurrent chemotherapy, % 93% 89% 0.55
PET staged, % 60% 80% 0.09
Median treatment, days 21 18 <0.01
Median survival, months 31 16 0.37
Distant failure, % Local 
failure, % 
50% 30% 65% 15% 0.31 0.23
Grade 3 esophagitis, % 54% 23% 0.01
No. patients with break, % 29% 7% 0.03
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In A Phase IIb Trial In Cancer Patients With Muscle Wasting, 
Enobosarm Improves Physical Function In Both Hypogonadal 
And Eugonadal Subjects
S. T. Dodson1, A. Dobs2, M. A. Johnston1, M. L. Hancock1, R. A. Morton1, M. 
S. Steiner1, 1GTx, Inc., Memphis, TN, 2Johns Hopskins University, Baltimore, 
MD
Purpose/Objective(s): Hypogonadism has been associated with weight loss 
and poor outcomes in cancer patients. Up to 50% of males with advanced can-
cer are hypogonadal at presentation or during the course of treatment. Wasting 
in cancer patients has also been associated with a decline in physical function 
and performance status and has major public health significance. We con-
ducted a Phase IIb, randomized, double blind, placebo controlled, multi-center 
study to evaluate the effect of enobosarm on muscle wasting and physical 
function in cancer patients. 
Materials/Methods: Patients (n=159) were randomized to oral enobosarm 
(1 or 3 mg) or placebo daily for 16 wks. Patients were males >45 y and 
postmenopausal females, had ≥2% weight loss in the 6 mths prior to ran-
domization, BMI <35 and either NSCLC, colorectal cancer, non-Hodgkin’s 
lymphoma, chronic lymphocytic leukemia or breast cancer. We report on the 
incidence and impact of hypogonadism (T<300 ng/dL) in this population. 
Results: Baseline testosterone levels were available for 93 of 103 men. 60% 
of male patients were hypogonadal at randomization. Distribution of hypogo-
nadism was similar across cancers; however hypogonadal men were less likely 
to complete the study. Baseline T levels were positively correlated with weight 
loss (r=0.32, P=0.002,) with hypogonadal men demonstrating greater weight 
loss in the previous six months (median, -9.5%). Baseline physical function 
as measured by stair climb power was higher among eugonadal males com-
pared to hypogonadal males (84.5 watts vs 70.6 watts; P=0.016). Enobosarm 
significantly improved physical function in this population regardless of 
baseline gonadal status (hypogonadal: 18.7%, P=0.0061; eugonadal: 13.2%, 
P=0.0032). The magnitude of improvement was greater in hypogonadal men. 
Conclusions: Hypogonadism is common in male cancer patients and is cor-
related with weight loss and diminished physical function. In this random-
ized, placebo controlled trial, enobosarm improved physical function in both 
hypogonadal and eugonadal men despite poorer baseline physical function in 
hypogonadal patients. These data provide evidence that enobosarm may play 
an important role in the management of cancer related muscle wasting.
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Enobosarm Improves Physical Function In Cancer Patients 
With < Or ≥ 5% Weight Loss In A Phase IIb Trial
S. T. Dodson1, A. Dobs2, M. A. Johnston1, M. L. Hancock1, M. S. Steiner1, 
1GTx, Inc., Memphis, TN, 2Johns Hopskins University, Baltimore, MD
Purpose/Objective(s): Although cachexia has been defined as >5% weight 
loss, limited data exists on the prevention and treatment of muscle wasting 
prior to a patient becoming cachectic. Cancer induced muscle wasting can 
begin early in the course of a patient’s malignancy resulting in decline in 
physical function and other detrimental clinical consequences including less 
tolerability to chemotherapy, worse outcomes, and shorter survival - under-
scoring the importance of diagnosing and treating this condition at an early 
stage. 
Materials/Methods: We conducted a randomized, double blind, placebo 
controlled, multi-center study to evaluate the effect of enobosarm on physi-
cal function and muscle wasting in cancer patients. Subjects (n=159) were 
randomized to oral enobosarm or placebo for 16 weeks. Subjects were males 
>45y and postmenopausal females, with ≥2% weight loss in the 6 months 
prior to randomization and diagnosed with NSCLC, colorectal cancer, non-
Hodgkin’s lymphoma, chronic lymphocytic leukemia or breast cancer. We 
report on changes in physical function based on weight loss of < or ≥5% in 
the 6 months prior to randomization. 
Results: 103 subjects (MITT) had physical function assessed by stair climb at 
baseline and week 16 with 24% losing <5% weight in the previous 6 months. 
Distribution of weight loss was similar across genders, however subjects with 
<5% weight loss were more likely to be ECOG=0 (<5% loss: 46.2%; ≥5% 
loss: 35.8%). Subjects with ≥5% weight loss had worse physical function at 
baseline compared to those with <5% loss (P=0.048). A significant improve-
ment in physical function was observed in subjects that received enobosarm 
regardless of baseline weight loss (<5% loss, P=0.041, ≥5% loss, P<0.001) 
while subjects that received placebo failed to improve. 
Conclusions: Enobosarm was generally well tolerated and showed a statisti-
cally significant improvement in physical function in cancer subjects regard-
less of baseline weight loss. These data provide evidence that enobosarm may 
play an important role in the management of cancer patients by not only treat-
ing, but also preventing further decline in physical function and muscle wast-
ing before a patient becomes cachectic.
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C. Lathan1, J. Lynch2, 1Dana Farber Cancer Institute, Boston, MA, 2Veterans 
Health Administration, Bedford, MA
Background: This study examined institutional and regional factors associ-
ated with use of ALK rearrangement FISH diagnostic test compared to the 
EGFR assay. Previous research presented at AACR Cancer Disparities con-
ference illustrated substantial underutilization of the EGFR assay. Disparities 
existed in access by institutional and regional factors.
Materials/Methods: We linked proprietary industry data for clinical diagnostic 
assays (EGFR mutation and ALK rearrangement) provided by Genzyme Genetics 
and Abbott Molecular to public datasets which provided institutional and regional 
characteristics of US hospitals. Individual orders were aggregated and summa-
rized to the hospital. Each hospital’s Medicare provider number (known as the 
OSCAR number) was obtained and recorded. OSCAR number and zip code were 
used to link the proprietary and public datasets. Public datasets included Census 
files, CMS/NCI Provider of Service (POS) files, among others, all current as of 
2011. Logistic and multiple regression analysis were conducted.
Results: Initial analysis of data suggests higher utilization of the ALK rear-
rangement FISH analysis when compared to EGFR Assay. However, even 
with incorporation of both assays into clinical practice guidelines, significant 
institutional and regional differences existed in access to tumor tissue analy-
sis. 7800 EGFR assay tests were sold in 2010. First 5 months post approval; 
approximately 12,000 Vysis tests were sold. A reasonable approximation of 
the testable population of NSCLC patients, given histology and tissue avail-
ability is approximately 114,000 patients. This suggests approximately a 7% 
penetration rate for the EGFR mutation analysis and a 10% penetration rate 
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for ALK rearrangement, though EGFR mutations have a 15% incidence rate 
compared to 5% incidence rate of EML-ALK4 rearrangement.
Conclusions: The uptake of the ALK rearrangement is likely higher due to 
the linkage of crozintinib to the FISH diagnostic test. Utilization patterns 
show regional underutilization that could contribute to disparities.
Author Disclosure Block: C. Lathan: None. J. Lynch: None.
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Antibody-Independent ApoStream™ Technology Isolates 
Folate Receptor Alpha Positive Circulating Tumor Cells from 
Blood of Non-Small Cell Lung Cancer Patients
D. Davis1, C. Neal1, J. Woo1, V. Melnikova1, K. Anderes1, E. Somers2, D. 
O’Shannessy2, 1ApoCell, Houston, TX, 2Morphotek, Exton, PA
Purpose/Objective(s): Folate receptor alpha (FRA) is a cell surface receptor 
whose expression in certain malignant tissues and highly restricted expres-
sion in normal adult tissues has resulted in its pursuit as a therapeutic tar-
get and marker for diagnosis of cancer. The detection of FRA in patient 
tumor tissue by various methods has been difficult and has given equivocal 
expression results across independent studies. The aim of this study was to 
explore detection of FRA on circulating tumor cells (CTCs) using a mono-
clonal murine anti-FRA antibody 26B3 (IgG1) as a precursor to evaluating 
a panel of monoclonal antibodies that may serve as diagnostic reagents to 
robustly detect FRA-positive disease. CTCs coupled with molecular analysis 
are fast becoming an accepted supplement or alternative to biopsy samples. 
The field of CTC enrichment has been underserved by the current EpCAM-
based immunomagnetic approaches which detect only CTCs that express 
EpCAM, leaving CTCs with no or low EpCAM expression undetected and 
unstudied underscoring the need for improved CTC isolation and recovery. 
ApoStreamTM is a novel, antibody-independent device which relies on con-
tinuous field-flow assisted dielectrophoresis (DEP) technology to isolate and 
recover CTCs from the blood of cancer patients.
Materials/Methods: An immunofluorescent multiplexed, single cell laser 
scanning cytometry (LSC) method was developed to detect and quanti-
tate cytokeratin+/CD45-/DAPI+ cells and FRA expression. Blood samples 
were collected from metastatic NSCLC, ovarian and squamous lung cancer 
patients. CTCs were isolated by ApoStream™ and evaluated for the expres-
sion of FRA. Blood samples from healthy donors were used as controls. 
Results: ApoStreamTM recovered CTCs from all cancer patients (enumera-
tion range 2-216 CTCs per 7.5 mL of blood). The percentage of FRA positive 
CTCs ranged from 8-33% in NSCLC, 100 % in ovarian and 0 % in squamous 
lung cancer patients. These results are in good agreement with FRA expres-
sion in tumor biopsies. Zero CTCs were recovered from normal donor blood 
samples. Leukocytes from cancer patients and healthy donors were negative 
for FRA expression. 
Conclusions: ApoStream™ recovery of CTCs coupled with LSC detection 
of FRA is a sensitive method for detecting FRA expression in CTCs and 
represents a promising innovative approach to support FRA-based therapies 
or pursue FRA diagnostics for staging, differentiating and/ or evaluating the 
FRA antigen in cancer patients.
Author Disclosure Block: D. Davis: A. Employee; ApoCell. C. Neal: 
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Expression of eIF4E Biomarkers Detected in Circulating 
Tumor Cells Isolated from Metastatic NSCLC Patients Using 
Antibody-Independent ApoStream™ Technology
K. Anderes1, W. Wu1, J. Woo1, V. Melnikova1, E. Jouravleva1, M. Pace1, 
E. Ackermann2, J. Kwoh2, D. Davis1, 1ApoCell, Houston, TX, 2Isis 
Pharmaceuticals, Carlsbad, CA
Purpose/Objective(s): Overexpression of eIF4E has been demonstrated in 
biopsies from non-small cell lung cancer (NSCLC) patients and is associated 
with tumor progression and metastasis. Several targeted eIF4E agents are cur-
rently in clinical development. Successful development requires a biomarker 
plan to identify pharmacodynamic markers which reflect pathway activity or 
lack thereof, and predictive biomarkers to allow selection of patients with 
cancers most likely to respond to the investigational agent. Circulating tumor 
cells (CTCs) coupled with molecular analysis are fast becoming an accepted 
supplement or alternative to biopsy samples to inform drug development 
decisions. The field of CTC enrichment has been underserved by the current 
EpCAM-based immunomagnetic approaches which detect only CTCs that 
express EpCAM, leaving CTCs with no or low EpCAM expression like those 
involved in metastatic dissemination undetected and unstudied underscoring 
the need for improved CTC isolation and recovery. ApoStreamTM is a novel, 
antibody-independent device which relies on continuous field-flow assisted 
dielectrophoresis (DEP) technology to isolate and recover CTCs from the 
blood of cancer patients. In this study, we determined the expression of eIF4E 
and ten pathway-associated biomarkers in CTCs recovered from the blood of 
NSCLC patients.
Materials/Methods: An immunofluorescent multiplexed, laser scanning 
cytometry (LSC) method was developed to detect and quantitate cytokeratin+/
CD45-/DAPI+ cells and a panel of eIF4e markers. A side-by-side comparison 
of ApoStream™ and CellSearch® was performed for CTC enumeration in 
NSCLC patients. CTCs recovered by ApoStream™ were evaluated for the 
expression of multiple eIF4E pathway biomarkers.
Results: ApoStream™ recovered a significantly greater number of CTCs 
compared to CellSearch® (enumeration range 9-1037, mean=407 by 
ApoStream™ versus a range of 30-340, mean=118 by CellSearch®, p<0.05). 
The eIF4E protein expression in CTCs was positively correlated with the 
CTC count. A trend toward correlation between the eIF4E protein expression 
level and the expression levels of cyclin D1 and c-Myc was observed.
Conclusions: We developed a panel of sensitive eIF4E biomarker assays 
applicable to circulating tumor cells. CTCs recovered by ApoStream™ were 
suitable for molecular analyses of the eIF4E pathway. ApoStream™ recovery 
of CTCs coupled with LSC detection of eIF4E pathway associated markers 
represents a promising innovative approach to support clinical development 
of eIF4E targeted agents.
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A. Employee; ApoCell. J. Woo: A. Employee; ApoCell. V. Melnikova: A. 
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Paxillin Mutations and Their Potential Functions in Thoracic 
Cancer
R. Hasina, I. Kawada, F. E. Lennon, E. Smithberger, Q. Arif, A. N. Husain, 
E. E. Vokes, R. Salgia, P. Singleton, V. Bindokas, The University of Chicago, 
Chicago, IL
Purpose/Objective(s): Paxillin is a 68 kDa focal adhesion protein that pro-
vides multiple docking sites at the plasma membrane for an array of signaling 
molecules and helps form a structural link between the extracellular matrix 
and the actin cytoskeleton. It is essential in actin filament assembly and focal 
adhesion formation. Focal adhesion complexes are the drivers of cell spread-
ing, migration, adhesion to the extracellular matrix and matrix remodeling. 
Modulation of tyrosine phosphorylation of paxillin regulates both the assem-
bly and turnover of adhesion sites and phosphorylated paxillin enhances 
lamellipodial protrusions whereas non-phosphorylated paxillin is essential 
for fibrillar adhesion formation. We have previously reported that in lung 
cancer, paxillin was over expressed, amplified and mutated in a significant 
number of patient samples and the protein was overexpressed in higher stages 
of lung cancer compared with expression in lower stages. We also showed 
paxillin gene to be amplified in some pre-neoplastic lung lesions. Here we 
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further study the patient derived paxillin mutations in vitro to determine their 
effects on cell function. 
Materials/Methods: 18 of the most commonly occurring paxillin mutations 
were cloned in a GFP tagged vector and transiently transfected HEK-293 
cells. Cells were imaged utilizing live-cell confocal microscopy and their 
characteristics evaluated in a semi-quatitative method. 
Results: Initially, the differential biological and functional characteristics of 
the 18 mutants were determined. Out of those, the most significant 6 mutants: 
P52L, A127T, P233L, T255I, D399N, and P487L were selected for further 
analysis. Utilizing live-cell confocal microscopy imaging, we compared wild-
type paxillin versus mutants, and found that some mutant clones confer: a) 
enhanced focal adhesion formation; b) increased filopodia and lamellipodia 
formation; c) increased mobility and d) increased cell displacement in tran-
siently transfected HEK-293 cells. 
Conclusion: Based on the data obtained, we believe that paxillin is an impor-
tant molecule in thoracic cancer and its therapeutic potential needs to be 
explored further.
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Blood Based Mirna Analysis From A Phase 2 Trial Of Nab-
paclitaxel Plus Carboplatin For Advanced NSCLC In Patients 
Ineligible For Bevacizumab
G. A. Otterson, P. Nana-Sinkam, M. Crawford, E. Bertino, M. A. Villalona-
Calero, M. Rahmani, C. Symmes, G. S. Phillips, X. Wu, L. Yu, The Ohio State 
University Comprehensive Cancer Center, Columbus, OH
Purpose/Objective(s): The addition of bevacizumab (Bev) to platinum based 
chemotherapy results in higher response rate (RR), progression-free survival 
(PFS), and overall survival (OS) in patients with advanced non-small cell lung 
cancer (NSCLC). However, Bev is not indicated in patients with squamous 
histology or with hemoptysis due to bleeding risk. We performed a single insti-
tution phase 2 trial of nab-paclitaxel and carboplatin in patients with advanced 
NSCLC who were ineligible to received bevacizumab because of squamous 
histology, hemoptysis or requirement for anticoagulation. MicroRNA profiles 
were generated from blood at baseline in all patients. Herein we report the 
initial results of these profiles correlated with clinical characteristics. 
Materials/Methods: We conducted a single-arm, single-institution phase 2 
trial (NCT00729612) to evaluate RR (primary endpoint), safety/toxicity, and 
survival (OS, PFS - secondary endpoints) in chemo-naïve patients treated 
with nab-paclitaxel and carboplatin (Cb). The preliminary clinical results 
were recently reported at AACR (LBA 225, AACR 2012). Prior to initiation 
of treatment, 10 ml of blood was obtained in Paxgene tubes for RNA iso-
lation. Samples were processed within 24 hours, and following RNA isola-
tion, miRNA profiles were obtained using the OSUCCC MicroArray Shared 
Resource (MASR) using a custom miRNA chip. 
Results: 63 patients (21 female, 42 male) with median age 63 yrs (range 
36-82) were enrolled. The most common histology was squamous cell carci-
noma (48 pts/76%), followed by adenocarcinoma (9 pts/14%), NSCLC NOS 
(4 pts/6%) and adenosquamous (2 pts/3%). RR was 35% (22/63), with 21 
stable disease as best response, PFS was 5.0 mos (CI: 4.3-6.4), and OS was 9.7 
mos (CI: 8.4-13.2). Grade 3 neuropathy was noted in 27% of patients. Using 
an unsupervised cluster analysis, three distinct groups were identified on the 
basis of miRNA profiles with 5, 14, and 15 patients respectively (from the first 
34 patients enrolled). There was no statistical correlation between clinical data 
(histology, RR, PFS, OS) and the three miRNA clusters, though there was a 
trend towards improved survival with group 2. Similarly, there was no statisti-
cally significant correlation between miRNA clusters and grade 3 neuropathy. 
Conclusions: The combination of Cb and nab-paclitaxel demonstrates rea-
sonable efficacy with tolerable toxicity in NSCLC pts ineligible for Bev 
therapy (LBA 225, AACR 2012). Preliminary results of microRNA profil-
ing from blood from the first 34 patients showed no statistical correlation 
with histology, response, PFS or OS. This study was approved and funded by 
the National Comprehensive Cancer Network (NCCN) from general research 
support provided by Abraxis BioScience, LLC.
Author Disclosure Block: G.A. Otterson: E. Research Grant; Abraxis/
Celgene, Genentech, Pfizer, Tragara. G. Consultant; Genentech. P. Nana-
Sinkam: None. M. Crawford: None. E. Bertino: None. M.A. Villalona-
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Role Of FDG-PET As An Early Imaging Biomarker Of 
Esophagitis And Pneumonitis During The Course Of 
Radiation Therapy For Lung Cancer
V. A. Ford, P. McCloskey, N. Becker, J. Bissonnette, K. Clarke, J. Higgins, 
C. Leavens, A. Hope, A. Bezjak, A. Sun, Princess Margaret Hospital, 
TORONTO, ON, Canada
Purpose/Objective(s): To determine if FDG PET-CT during a course of radi-
cal chemoradiotherapy (CRT) correlates with development of esophagitis or 
pneumonitis. 
Materials/Methods: Patients were imaged serially with 4DCT and 4D FDG 
PET-CT at weeks 0, 2, 4, 7 during CRT and 3 months (3m) following RT. 
Patients were Stage II-III NSCLC and undergoing CRT receiving a dose of at 
least 60Gy. Fourteen patients were analyzed and chart review identified those 
who developed clinical radiation esophagits (RE) or radiation pneumonitis 
(RP) and grade (CTCAE V4). Each serial 4DCT and 4D FDG PET-CT images 
were registered onto the clinical planning datasets (Pinnacle 9.0). Esophagus 
and non GTV lung (GTV from original clinical plan), were contoured on all 
serial exhale 4DCT datasets. The matching exhale PET dataset was examined 
for early indication of RE and RP. Contours were delineated using thresh-
olding to match, in 10% increments, the 20 to 80% of the maximum SUV 
value on the 4DPET for lung and esophagus. The subsequent volumes were 
recorded for each patient for each week. Intensity Volume Histograms (IVH) 
were plotted using the volumes for % max SUV Contours (20-80) for each 
week, against the absolute SUV values. Changes in the SUV IVH from week 
to week were observed for each patient. 
Results: 4 of 14 patients had ≥ grade 2 RP. The SUV uptake at 12 weeks 
increased for all these individuals. There was no significant uptake from week 
0-7 for any patient. 10 of 13 patients had grade 2 RE, 2 of 13 had grade 
3 RE. Of these, increases in SUV uptake were seen in the esophagus. The 
SUV peaked at variable times (week 7 in 5 patients, week 4 in 4 patients, 
week 2 in 3 patients). There was no correlation with grade or timing of peak 
esophagitis. Increased PET uptake was seen prior to RE in some individuals. 
Increase in SUV uptake from baseline was also seen in the patients who did 
not develop RE. 
Conclusion: In this series of patients, although PET uptake was seen to 
increase in normal lung tissue in those developing RP, there was no early 
increase to allow us to predict which individuals would be affected. For the 
esophagus, increases in PET uptake were seen through treatment but these did 
not correlate with the onset or severity of RE symptoms.
Author Disclosure Block: V.A. Ford: None. P. McCloskey: None. N. 
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Binding Of Paxillin To BCL-2 In Lung Cancer--systems 
Biology Informatics Approaches To Biological Validation.
E. Smithberger1, N. Maltsev1, R. Hasina1, Y. Tan1, D. Sulakhe1,2, 
S. Balasubramanian1, C. Rolle1, F. Lennon1, P. Singleton1, R. Salgia1, 1University 
of Chicago, Chicago, IL, 2Argonne National Laboratory, Argonne, IL
Purpose/Objective(s): Paxillin is a key focal adhesion protein that plays a 
role in many types of cancer, including non-small cell lung cancer (NSCLC). 
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Paxillin is a 68 kDa protein that is linked to oncogenes such as BCR/ABL, 
c-MET, EGFR, v-Crk, v-Src. We have previously shown that paxillin is 
expressed more highly in lung cancers than non-cancerous lung tissue and 
its expression is higher in metastatic lung cancer than in primary NSCLC. In 
a general systems biology approach, we have been ‘mining’ the genetics and 
protein characteristics of paxillin in various tumors. 
Materials/Methods: The GEDI (Gene Discovery/Genetic Disease) platform 
is an online meta-database, linking researchers with network-based disease 
models and genetic information curated from a multitude of other internet 
resources. Utilizing the newly developed GEDI system, we have been able to 
discern that paxillin integrates many signaling pathways such as those down-
stream of Ret tyrosine kinase, LPA receptor, EphB, IGF1, α4β1 integrins, 
angiopoietin receptor Tie2, VEGFR, Arf6, and Fc-ε receptor 1 in mast cells. 
We are systematically studying if paxillin can bind to BCL-2 in the context of 
various mutations of paxillin and/or in relationship to stimulation with agents 
such as hepatocyte growth factor. 
Results: The paxillin gene can be translated into four different isoforms, each 
containing four identical C-terminal LIM domains and N-terminal LD motifs 
with alternate splicing or an alternate start site, allowing for a multitude of 
binding partners. In addition to its role in focal adhesions, paxillin has been 
preliminarily shown to bind to BCL-2, potentially linking cell survival and 
cell adhesive pathways. BCL2 is an anti-apoptotic member of the BCL-2 
family. 
Conclusions: Our systems biology analysis showed that paxillin co-localizes 
with mitochondrial BCL-2 and apparently regulates cell death by controlling 
the mitochondrial membrane permeability. This mechanism will have con-
siderable implications on the metabolomics of lung cancers as related to the 
focal adhesion protein paxillin.
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Measuring Interleukin-22 (IL-22) in Bronchioloalveolar 
Lavage (BAL) and Endobronchial Washings of Patients With 
and Without Lung Cancer
A. Tufman, R. M. Huber, S. Volk, M. Edelmann, F. Gamarra, R. Kiefl, N. 
Küpper, F. Tian, S. Endres, S. Kobold, University of Munich, Munich, 
Germany
Background: Biomarkers are of increasing interest for diagnosis and treat-
ment of chronic diseases and cancer. Interleukin-22 (IL-22) is a newly discov-
ered cytokine (Aujla 2009), which is protective in acute lung injuries (Hoegl 
2011), but could increase the growth of tumours by antiapoptotic effects 
(Zhang 2008). Therefore IL-22 measured in BAL or endobronchial washings 
could be a prognostic marker and be measured during the course of the dis-
ease. Measuring IL-22 is not yet established in routine samples. 
Materials/Methods: BAL and bronchial washings were performed accord-
ing to clinical indications. The fluid was filtrated through gaze and analysed 
according to clinical indications (cell number, cytology, microbiology, CD4/
CD8 ratio). The remaining fluid was frozen in 0.5 – 1.0 ml aliquots at -20 °C. 
Analysis of IL-22 by ELISA was performed within 3 months. Mean values 
were calculated from 3 independent experiments. 
Results: Of 8 women and 18 men, mean age 58 (26 – 84) years we ana-
lysed 22 BALs and 4 endobronchial washings. In 23 samples we found 
measurable amounts of IL-22. Mean concentrations were as follows: all 
samples 41.0 pg/ml (0 – 83.2 pg/ml), BAL (n=22) 44.5 pg/ml, endobron-
chial washings (n=4) 31.3 pg/ml, men 42.8 pg/ml, women 36.7 pg/ml. 
Regarding diseases mean expression of IL-22 ( pg/ml) was 53.3 in pneu-
monia (n=7), 28.0 in TBC (n=2), 70.2 in M. Wegener (n=1), 40.9 in fibro-
sis (n=1), 63.7 in chronic rejection after lung transplantation(n=1), 26,6 in 
sarcoidosis (n=3) , and 22.3 with no evidence of lung disease (n=6). In non-
small cell lung cancer (n=5, 3 squamous cell carcinoma, 1 adenocarcinoma, 1 
large cell carcinoma) the mean value was 52.2. Concentrations according 
to cell counts (n=13) were: >100 000 cells/ml (n=5) 50.0pg/ml; < 100 000 
cells/ml (n=8) 39.1pg/ml. Concentrations according the CD4/CD8 ratio 
(n=12): < 1.3 (n=3) 32.9 pg/ml; > 5.0 (n=1) 0; 1.3-5.0 (n=6) 56.2 pg/ml. 
Means (pg/ml) according to cytology (n=14): macrophages > 80% (n=4) 
47.8; macrophages < 80% (n= 10) 40.4l; neutrophils < 5% (n=8) 49.8; 
neutrophils >5% (n=6) 20.4; lymphocytes >10% (n=5) 48.2; lymphocytes 
< 10% (n=9) 34.8. 
Conclusions: Measuring IL-22 by ELISA in routine samples of BAL and 
bronchial washings is feasible. Although cell numbers did not correlate sig-
nificantly with the IL-22 concentration, cell differentiation seems to be rel-
evant. Patients with increased neutrophil counts or decreased lymphocyte 
counts respectively had lower IL-22 concentrations. This result supports the 
assumption, that IL-22 is produced among others by lymphocytes. Although 
the numbers are still small expression seems to differ between different 
diseases. Patients with pneumonia or NSCLC had higher concentrations, 
whereas patients with sarcoidosis or without evident lung disease had lower 
values.
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Strain as a Novel Index of Regional Function from Treatment 
Planning Thoracic 4-D CT
M. Negahdar, A. A. Amini, A. Zacarias, B. L. Lynch, R. A. Milam, S. Y. Woo, 
N. Dunlap, University of Louisville, Louisville, KY
Purpose/Objective(s): Radiotherapy for thoracic malignancies can cause 
biomechanical (strain and elasticity) changes which alter the physiological 
function of the lung (uptake of O2 and release of CO2).The extant and sever-
ity of these alterations depend on the dose and fractionation. Hypofractionated 
treatment, in particular SBRT, reduces the level of normal tissue tolerance to 
radiation and therefore presents a higher risk to a patient care. Assessing lung 
function for these high risk cases with an objective method which relates bio-
mechanical change with physiological function is essential in evaluating risk 
for treatment and retreatment cases. 4-D CT measured lung strain is a quan-
titative method which provides regional volume changes during deformation 
as provided by Jacobian of deformation but in addition, it provides direc-
tional changes for the local compressions and expansions during respiration. 
Herein, we propose and validate the use of strain as a measure of regional lung 
function from 4-D thoracic CT using the current accepted standard of SPECT 
imaging for ventilation and perfusion. 
Materials/Methods: We proposed a novel approach to quantification of 
motion and mechanical strain in the lung from treatment planning 4-D CT 
images using a multi-scale optical flow deformable image registration method 
(MOFID) which permits incorporation of physical constraints in the derived 
volumetric deformation maps. Principal strains of deformation computed 
from clinical treatment planning 4-D CT data were then correlated with ven-
tilation SPECT following multimodality registration for ten primary lung 
cancer patient. 
Results: The 4-D CT derived ventilation images are spatially varying and 
have a different degree of correlation with ventilation SPECT. Our measure 
of Jacobian ventilation yields a more significant correlation with ventilation 
SPECT in comparison to previously reported studies. Additionally, our results 
point to the fact that the principal strains of deformation behave similarly to 
the Jacobian ventilation map and yield significant correlations with ventila-
tion SPECT suggesting that there is a need to further investigate strain as a 
metric for ventilation. 
Conclusions: 4-D CT lung strain measurements yields a more significant 
correlation with ventilation SPECT than previously reported studies. We 
have also demonstrated that in addition to Jacobian, measures of mechanical 
strain are indicative of pulmonary function from 4-D CT studies. The results 
indicate that for healthy patients, this method may be used to measure lung 
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function and evaluate early pulmonary toxicity associated with thoracic radia-
tion. Further research is required in order to validate this method for patients 
with poor lung function.
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Prognostic Factors in Patients With Surgical Treatment for 
Primary Lung Cancer Associated with Interstitial Pneumonia
T. Hirata, N. Yoshino, T. Ibi, Y. Ijima, S. Takeuchi, H. Kubokura, I. Mikami, 
K. Hirai, S. Haraguchi, K. Shimizu, Nippon Medical School, Tokyo, Japan
Background: Interstitial Pneumonia(IP) is well known to be a concomitant 
respiratory disease associated with lung cancer. Acute exacerbation after sur-
gery is one of the cause of death in these patients.
Materials/Methods: We have encountered consecutive 1630 lung cancer 
patients with surgical treatment from 1978 to 2010. 169 patients (10.3%) 
associated with Interstitial Pneumonia (IP group), and 1014 patients (62.2%) 
associated with concomitant Non-Respiratory Disease (NRD group). The 
oncological factors and prognosis were compared between two groups 
statistically.
Results: Compared with patients’ characteristic of NRD group, IP group 
included older (p<0.001) patients, more males (P<0.001) heavier smokers 
(p<0.001), more squamous cell carcinomas (p<0.001), more tumors located 
in the lower lobe, especially right lower lobe (p=0.004), more stage II cases 
pT2 and pN1 positive cases. Compared IP markers in serum, IP group is 
higher in mean values of those which are well known to be IP makers as 
KL-6 (p<0.001), Sp-D (p<0.001) and Sp-A (p=0.003). Histo-pathological 
diagnosis of resected specimens revealed more severe visceral pleural inva-
sion (p<0.001), more aggressive lymph vessel invasion (p<0.001) and vas-
cular vessel invasion in IP group. Univariate analysis using Cox regression 
model revealed that female (p=0.009), no Diabetes Mellitus (p=0.003), no 
postoperative respiratory complications including postoperative acute exacer-
bation (p<0.001), pathological stage I (p<0.001), adenocarcinoma (p=0.002), 
no lymph vessel invasion (p=0.002), no vascular invasion (p=0.002) and no 
pleural invasion (p-0.037) are statistically better prognostic factors respec-
tively. Furthermore multivariate analysis revealed that pathological stage I 
(p=0.00001) and no postoperative acute exacerbation (p=0.00005) and female 
are significantly better prognostic factors. Pathological N0 is significantly bet-
ter than pathological N1 or N2 in all over survival, although pN1 prognosis is 
as pessimistic as pN2 prognosis. 
Conclusion: according to our retrospective study it seemed to be operable for 
just pathological stage I lung cancer with IP.
Author Disclosure Block: T. Hirata: None. N. Yoshino: None. T. Ibi: None. 
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MR-Predictive Assay in Preoperative Lung Cancer Therapy
J. C. Grecula1, G. Jia1, W. Yuh1, G. Otterson1, P. Ross1, M. Villalona-Calero1, 
K. Shilo1, S. Lo2, S. Ghosh1, N. Mayr1, 1Ohio State University, Columbus, OH, 
2Case Western University, Cleveland, OH
Purpose/Objective(s): To develop, refine, and test Dynamic Contrast 
Enhancement (DCE) Magnetic Resonance Imaging protocols and analysis 
methodologies for predicting response to preoperative neoadjuvant chemo-
radiation therapy (PNT) and resectability in non-small cell lung cancer. 
Materials/Methods:Patients with stage IIIA (T1-3 N2 or T3N1) nonsmall 
cell lung carcinoma were prospectively studied and received 45 Gy in 25 daily 
fractions of conformal external beam radiotherapy with 2 courses of cisplatin 
(50 mg/m2 IV days 1 & 8; 29 & 36) and etoposide (50 mg/m2 IV days 1-5 
& 29-33). Three MRI studies (pre-contrast and 3 Tesla DCE MRI) before, 
during (2 weeks into treatment) and after PNT (study 1, 2, and 3 respectively) 
were performed for each patient 
Results: Five patients have been enrolled to date. One patient progressed and 
developed pericardial, pulmonary artery branch, and pulmonary vein inva-
sion and did not undergo resection. One patient was found to be unresect-
able at the time of surgery due to invasion of the descending aorta. Both of 
the unresectable patients have expired. Three patients were resectable: 2 of 
3 had complete pathological response with no evidence of residual tumor at 
primary site or nodes; one had residual tumor at both the nodes and primary. 
Among the pharmacokinetic parameters (Amp, k
ep
, and k
el
), k
ep
 of the second 
MR appeared to differentiate unresectable (n= 2; k
ep
= 4.3 min-1) from resect-
able tumors (n= 3; k
ep
= 2.3 min-1); and the case with residual tumor (n = 1; 
k
ep
= 2.6 min-1) from those without residual tumor (n = 2; k
ep
= 2.1 min-1). k
ep
 
represents the exchange rate constant between blood plasma and extravas-
cular extracellular space, which reflects the wash-in slope of the time-signal 
intensity curve. 
Conclusions: This early data shows the feasibility of performing prospec-
tive functional tumor imaging timed with the ongoing radiation course, and 
suggests that therapy responsiveness and resectability may be associated 
with lower k
ep. 
The ability to predict unresectability with the DCE-MRI’s, 
would not only spare patients the morbidity of unsuccessful surgery, but also 
eliminate the detrimental treatment gap in the patient’s therapy, which results 
when patients are found to be unresectable after preoperative therapy and 
require completion of the radiation therapy course. Supported by NCI R21 
CA121582 and NCI P30 CA16058
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Effect of Contour Variability on Dosimetric Tumor Coverage 
in Stereotactic Body Radiation Therapy (SBRT) for Stage I 
Lung Cancer
M. D. Orton1, M. G. Chang2, D. Moghanaki2, K. Neiderer1, E. Weiss1, 1Virginia 
Commonwealth University, Richmond, VA, 2Hunter Holmes McGuire VA 
Medical Center, Richmond, VA
Purpose/Objective(s): To evaluate the effect of contouring variability on 
tumor coverage and lung dose for stage I lung cancers treated with SBRT. 
Materials/Methods: Nine radiation oncologists (3 attendings, 6 residents) 
contoured the lung tumor internal target volumes (ITVs) in 6 patients using 
maximum intensity projection (MIP) images after 4D-CT simulation. 5 mm 
uniform expansion was created on each observer’s ITV to create a volume 
equivalent to the planning treatment volumes (PTV) recommended by cur-
rent SBRT trials. Optimized treatment plans were created for all 54 PTVs. 
Coverage of each observer’s PTV by the following three reference plans was 
analyzed: 1) Dose distribution used in actual patient treatment), 2) dose dis-
tribution for smallest PTV), and 3) dose distribution for largest PTV. The vol-
ume of the PTVs covered by 95% of the prescribed dose (V95) as well as the 
isodose that encompassed 100% of the PTVs volume (D100) was calculated. 
For all three scenarios the percentage of PTV volumes that were underdosed 
by 3% or more compared to the reference plan V95 coverage was determined. 
The variation in volume of total lung minus ITV that received 20 Gy (Lung 
V20) was also measured. 
Results: Average PTV volume (cm3) was 44.1±7.8, 36.4±6.7, 17.4±2.4, 
18.6±3.2, 11.4±1.7 and 18.6±2.0 for patients 1-6 respectively. PTV coverage 
by treated PTV, smallest PTV and largest PTV demonstrated an average V95 
of 97.7%±3.8%, 95.9%±5.1% and 99.1%±1.1% and D100 of 86.7%±14.4%, 
82.4%±15.2 and 79.5%±5.4% respectively. The mean percentage of PTVs 
were V95 underdosed by 3% or more compared to the reference plans were 
23%, 46% and 16% for the three scenarios, respectively and was largest 
in lesions with pleural attachments (50%,63%,13%) and centrally located 
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tumors (38%, 75%,13%). The average lung V20 of all observers for all 
patients was 5.8%±2.7%. 
Conclusions: With tight margins for set up errors and high technical preci-
sion in lung SBRT, contour variability is a potentially larger source of treat-
ment error. This study demonstrates that contour variability introduces >3% 
underdosage on average in 28% of cases. Dosimetrically, variability was 
most relevant for lesions with pleural attachments or those that are cen-
trally located suggesting a need for a standardized approach to contour such 
lesions.
Author Disclosure Block: M.D. Orton: None. M.G. Chang: None. D. 
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1012  
Accelerated Hypofractionated Radiotherapy in Early-
Stage Non-Small Cell Lung Carcinoma with Concurrent 
Chemotherapy
S. K. Bhavsar, J. M. Mann, A. Gajra, J. A. Bogart, SUNY Upstate Medical 
University, Syracuse, NY
Purpose/Objective(s): To review the outcomes of medically inoperable 
patients with early-stage non-small cell lung carcinoma treated with an accel-
erated hypofractionation radiation schedule with and without concurrent sen-
sitizing chemotherapy. 
Materials/Methods: Retrospective chart review of patients treated with 
accelerated hypofractionated radiation therapy with or without concurrent 
chemotherapy for early-stage non-small cell lung carcinoma between 2005 
and 2011. 
Results: 103 patients were identified (median age 72 years). All patients were 
considered high-risk for resection due to pulmonary dysfunction or other 
co-morbidity (32% O2 dependent, 41% GOLD Stage 4, 35% ECOG PS 2). 
Patients analyzed were early stage and were stratified by T-stage (T1a 33%, 
T1b 24%, T2a 35%, T2b 1%, T3 6%, and T4 1%) The median tumor size was 
2.6 cm, and 31% were centrally located, and 93.2% were N0. Radiotherapy 
was given to a median dose of 7000 cGy in 225 cGy to 411 cGy daily frac-
tions (median daily fraction = 250 cGy). Median number of fractions was 26. 
The range of the total dose was 4800-7500 cGy. Weekly concurrent carbopla-
tin (AUC2) /paclitaxel (50 mg/m2) was administered in 29 patients, and was 
more likely to be administered for larger tumors and central lesions. With 
median follow-up time of 39.5 months, median OS for all patients was 40 
months and was not significantly different in patients treated with chemo-
therapy. Treatment was tolerated well without Grade 3 + non-hematologic 
toxicities or ≥ Grade 3 + hematologic toxicity (chemotherapy cohort). No 
significant differences in distant metastases were observed based on central 
location or chemotherapy administration. T2a patients had greatest rate of 
distant failure (56.5%). T2a patients had a significantly higher rate of distant 
failure (56.5%). 
Conclusions: The addition of weekly chemotherapy to accelerated hypofrac-
tionated radiotherapy was well tolerated in a high-risk population. The impact 
of chemotherapy on tumor control or overall survival is difficult to discern 
due to the imbalance in characteristics favoring the RT only cohort. Further 
assessment of concurrent chemoradiotherapy may be justified for high-risk 
patients with stage I NSCLC and large primary tumors.
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Long-term Follow-up and Patterns of Failure for Patients with 
Medically Inoperable Stage I Non-small Cell Lung Cancer 
(NSCLC) treated with Stereotactic Body Radiotherapy 
(SBRT)
J. J. Urbanic, M. Soike, C. J. Hampton, J. Lucas, W. Hinson, W. Kearns, A. W. 
Blackstock, Wake Forest School of Medicine, Winston Salem, NC
Purpose/Objective(s): SBRT program at Wake Forest began in 2002. We 
reviewed all patients with medically inoperable Stage I NSCLC treated with 
SBRT prior to 2009 as these patients would have potential minimum 3 years 
of follow-up. 
Materials/Methods: All patients were treated using the Elekta Bodyframe 
for immobilization and abdominal compression on a conventional LINAC. 
Target localization based on stereotactic coordinates with orthogonal MV 
portal imaging for confirmation. 4D CT used to define ITV beginning January 
2007 (52 patients). PTV expansion of 5 mm used in ITV defined patients 
PTV otherwise 5 mm axial, 10mm cranial caudal. 19 patients prior to 2006 
treated using homogeneous tissue density. Patients scored for local (at the site 
treated), regional (nodal disease in hilum or mediastintum), or distant sites of 
failure. Toxicity graded per NCI CTCAE v4.0. Descriptive statistics used to 
report toxicity. Kaplan Meir estimate of local control, recurrence, survival. 
Results: 85 patients, stage I NSCLC identified who were treated with SBRT 
2003-2008. Median follow-up 31 months (0-83 months). For living patients, 
median follow-up 39 months (1-83 months); 4 living patients with fu <21 
months lost to follow-up. Average patient age 71.3 years (46-87). Average 
smoking pack-years 56.2 (4-150 years). Pre-treatment pulmonary function 
testing 45 patients: FEV1 median 54%, 34 patients: DLCO 55.3% predicted. 
18 patients prior lung surgery, 7 patients treated for bilateral stage I lung. 
76 of 85 patients pathologically diagnosed. Average tumor size 2.3cm (0.7-
3.9). 72 tumors were T1, 13 tumors were T2. The most common dose (45 pts) 
was 5400 cGy in 3 fractions (2250-6000 cGy). 48 deaths occurred. Median 
survival 38 months (95%CI 27-49 months); 5 year overall survival 28.7% 
(95%CI 15-42%). Local failure in 11 patients. Local control at 3 years 84.5% 
(95%CI 74-94%). Regional recurrence 9 patients (7 isolated without local 
failure) 3 year freedom from regional nodal failure 88.2% (95%CI 79-97%); 
6 of 9 regional failures occurred after 2 years. Distant failure predominated 
in 24 of 85 patients at a median of 20.8 months. 3 year freedom from distant 
failure 75.6% (95%CI 65-86%). DF isolated in 15 patients but DF in 8 of 
11 patients with local failure. 9 of 11 patients with LF died with disease. LF 
treated with thermal ablation (2), chemo (4) and no tx (5). Grade 3 or higher 
pulmonary toxicity occurred in 4 patients with one probable grade 5 toxicity 
in a patient with severe underlying COPD. 
Conclusions: Patients treated using SBRT had expected median survival of 3 
years with 29% chance at long term survival. Most patients with local failure 
died of disease suggesting importance of local control. Salvage tx options 
were limited.
Author Disclosure Block: J.J. Urbanic: None. M. Soike: None. C.J. 
Hampton: None. J. Lucas: None. W. Hinson: None. W. Kearns: None. 
A.W. Blackstock: None.
1014 
Clinical Outcomes Following Image-guided Helical 
Stereotactic Body Radiotherapy (SBRT) For Biopsy Proven or 
Radiographically Diagnosed Early-stage Lung Cancer
B. Fischer-Valuck1,2, L. R. Rosen1, S. Katz1, M. Durci1, H. Wu1, J. Syh1, B. 
Patel1, J. Syh1, 1Willis-Knighton Cancer Center, Shreveport, LA, 2Louisiana 
State University School of Medicine, Shreveport, LA
Purpose/Objective(s): Dependent on institution, histological confirmation 
of non-small cell lung cancer (NSCLC) is often required before patients are 
offered stereotactic body radiation therapy (SBRT) as a treatment option. 
Many patients, however, are unsuitable to undergo a biopsy procedure sec-
ondarily to poor pulmonary function or other co-morbidity. Our objective is 
to retrospectively compare the clinical outcomes of patients with biopsy con-
firmed or radiographically diagnosed early-stage NSCLC treated with image-
guided helical SBRT. 
Materials/Methods: The records of 85 patients treated with lung SBRT at a 
single institution were reviewed. Sixty-two patients had biopsy proven (BxPr) 
early-stage (T1-2 N0 M0) NSCLC. Twenty-three patients were radiographi-
cally diagnosed (RadDx) with early-stage NSCLC based on a metabolically 
active FDG-PET chest nodule and CT-findings compatible with NSCLC. 
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Patients were treated with helical image-guided SBRT in 12 Gy fractions to a 
total dose of 48 or 60 Gy. Outcomes of patients with biopsy proven and radio-
graphically diagnosed NSCLC were evaluated in regard to local control and 
overall survival using Kaplan-Meier survival curves and the Cox proportional 
hazard method. 
Results: Median follow-up was 24 months (range, 4 - 82 months). The mean 
age of patients in the BxPr group was 72.1 years compared to 74.3 years 
for patients in the RadDx group (p = 0.91). Patients in the BxPr and RadDx 
groups were also similar with regard to gender, T-stage, tumor location (cen-
tral vs. peripheral), SBRT dose (12 Gy x 4 or 5 fractions), and smoking his-
tory. Patients in the BxPr group had larger median tumor diameters (2.48 cm 
vs. 2.12 cm, p = 0.06). Overall local control rate was 91.9% (95% confidence 
interval [CI], 82.4-96.5%) for the BxPr group compared to 91.3% (95% CI, 
73.2-97.6%) for the RadDx group (p = 0.81). The 2-year overall survival for 
the BxPr and RadDx groups was 76.3% and 78.9% (p = 0.62), respectively. 
In the BxPr group, 3.2% (95% CI, 0.8-11.0%) of patients had locoregional 
failure and 6.5% (95% CI, 2.5-15.5%) of patients developed distant metas-
tasis. Similarly, in the RadDx group, 4.4% (95% CI, 0.8-20.1%) of patients 
had locoregional failure and 8.7% (95% CI, 2.4-26.8%) of patients developed 
distant metastasis. 
Conclusion: SBRT is a practical treatment modality for patients with radio-
logically diagnosed early-stage NSCLC. Clinical outcomes of patients radio-
graphically diagnosed with NSCLC mirror the results of patients treated with 
biopsy proven disease. Our results support the use of image-guided helical 
SBRT in patients without histologically proven NSCLC who have been diag-
nosed by standardized and rigorous radiographic methods including both PET 
and CT imaging.
Author Disclosure Block: B. Fischer-Valuck: None. L.R. Rosen: None. S. 
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Aberrant Stratifin Overexpression Enhances Tumor 
Progression of Early Invasive Lung Adenocarcinoma
A. Shiba, Y. Morishita, M. Noguchi, University of Tsukuba, Ibaraki, Japan
Purpose/Objective(s): Adenocarcinoma in situ (AIS) of the lung has a very 
favorable prognosis, with a 5-year survival rate of 100%. However, early but 
invasive adenocarcinoma (eIA) sometimes has a fatal outcome. We previ-
ously compared the expression profiles of AIS with those of eIA showing 
lymph node metastasis or a fatal outcome, and found that stratifin (SFN, 
14-3-3 sigma) was a differentially expressed gene related to tumor progres-
sion (Aya Shiba-Ishii, IJC. 2011): IHC revealed immunopositivity for SFN 
in more than 95% of eIAs, in comparison with only 13% of AISs. We also 
found that promoter demethylation triggered aberrant SFN overexpression in 
eIAs in a p53-independent manner (Aya Shiba-Ishii, AJP. 2012). Here, we 
performed functional analysis to clarify how SFN affects the progression of 
lung adenocarcinoma. 
Materials/Methods: For in vitro functional analysis, we performed siRNA or 
expression vector transfection and subsequent cell proliferation assays with 
a lung adenocarcinoma cell line (A549). An in vivo animal study was also 
performed. Tumor kinetics were measured by s.c.-injecting 7-week-old nude 
mice with 1 x 106 siSFN-transfected A549 cells in 0.2 ml of DMEM. The 
dimensions of developing tumors were measured using calipers on alternate 
days, and tumors were evaluated by HE staining and IHC after sacrifice. 
Results: Suppression of SFN expression by siSFN significantly reduced cell 
proliferation activity and BrdU uptake. However, transfection of the SFN 
expression vector led to a significant increase in cell proliferation. Also, cell 
cycle analysis revealed that the S-phase subpopulation was decreased after 
siSFN treatment. In vivo, cells that had been treated with siSFN showed 
reduced tumor development in comparison with untreated controls, but there 
was no inter-group difference in the histological features and SFN expression 
levels of the developed tumors. 
Conclusions: Although SFN was originally identified as a negative regulator 
of the cell cycle, especially in response to p53-sensitive DNA damage, sub-
sequent reports indicated that it is a positive mediator of cell proliferation. In 
breast cancer, SFN induces G1/S progression by increasing cyclin D1 expres-
sion. Here, we demonstrated that SFN enhanced the proliferative capacity of 
lung adenocarcinoma cells both in vitro and in vivo. Since the BrdU uptake 
and S-phase subpopulation of the cells also decreased after siSFN transfec-
tion, SFN might regulate DNA replication in S phase. The results of our in 
vivo study suggest that suppression of SFN expression may block lung adeno-
carcinogenesis at a very early stage. In conclusion, aberrant expression of 
SFN in lung adenocarcinoma induces progression of AIS to eIA by facilitat-
ing cell proliferation.
Author Disclosure Block: A. Shiba: None. Y. Morishita: None. M. 
Noguchi: None.
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Prospective Phase I Dose Escalation Trial with 
Hypofractionated Radiotherapy with Stereotactic Boost for 
Stage II and III Non-Small Cell Lung Cancer
P. Lee, E. Garon, S. Tenn, N. Agazaryan, J. Czernin, D. Low, M. Steinberg, P. 
Kupelian, University of California Los Angeles, Los Angeles, CA
Purpose/Objective(s): To investigate the feasibility and tolerance of a hypo-
fractionated 15 day course of radiotherapy with chemotherapy for inoperable 
stage II and III Non-Small Cell Lung Cancer (NSCLC). 
Materials/Methods: This is a single-institution prospective Phase I dose 
escalation study for hypofractionated radiotherapy with weekly carboplatin 
and paclitaxel for medically and technically inoperable stage II-III NSCLC. 
Three cohorts of 7-15 patients per cohort are planned in 3 years. All patients 
receive 40 Gy in 10 fractions with a repeat FDG-PET-CT simulation at the 
8th or 9th fraction for an adaptive boost. Initial cohort is treated with a 25 
Gy in 5 fraction boost. If toxicity is acceptable (without excessive grade 3 
dose-limiting toxicity) in protocol defined number of patients, the boost dose 
is escalated to 30 Gy in 5 fractions, and finally 35 Gy in 5 fractions. Two 
subjects have been treated on this study and cautious follow-up performed. 
Results: Both subjects received radiotherapy to a total dose of 40 Gy in 10 
fractions followed by 25 Gy adapted boost in 5 fractions. Subject 1 has stage 
IIIB left upper lobe NSCLC with involvement of the left paratracheal lymph 
nodes and right supraclavicular fossa with a bulky primary measuring 8 x 6 
x 8.7 cm. Subject 2 has stage IIIB right upper lobe NSCLC with involvement 
of the right paratracheal and subcarinal lymph nodes, and right supraclavicu-
lar fossa. Initial PET-defined internal tumor volume (ITV) for subject 1 and 
2 were 252.2 and 49.5 mL respectively. Volumetric Modulated Arc Therapy 
with daily cone-beam CT guidance was utilized. Adaptive PET-defined ITV 
for the boost were 216.2 and 31.8 mL respectively. Cumulative normal tissue 
doses were (subject 1, subject 2): lung V20: (22.8, 11.3%); mean lung dose: 
(14.4, 7.1 Gy); mean esophageal dose: (22.7, 12.7 Gy); max spinal cord dose: 
(24.0, 30.4 Gy); mean heart dose: (10.9, 1.3 Gy); max skin dose: (47.5, 35.2 
Gy); mean skin dose (4.8, 2.3 Gy); mean proximal bronchus dose: (36.6, 21.4 
Gy); mean tracheal dose: (26.6, 34.0 Gy). There were no treatment interrup-
tions. Follow-up time for subject 1 and 2 are 9 and 8.75 months respectively. 
At one month follow-up, reported toxicities were: subject 1: grade 1 fatigue, 
and grade 2 esophagitis; subject 2: grade 1 skin erythema over the right supra-
clavicular fossa. All acute toxicities resolved by month 3. Both subjects are 
without clinical or radiographic evidence of local or distant progression at the 
date of the last follow-up. 
Conclusions: In this initial experience of an aggressive hypofractionated 
Phase I trial for advanced non-small cell lung cancers, toxicity was cautiously 
observed and was negligible in 2 patients up to 9 months.
Author Disclosure Block: P. Lee: F. Honoraria; BrainLab Medical Systems. 
G. Consultant; Accuray Medical Systems. E. Garon: None. S. Tenn: None. 
N. Agazaryan: F. Honoraria; BrainLab Medical Systems. J. Czernin: None. 
D. Low: None. M. Steinberg: None. P. Kupelian: J. Funding Other; Varian 
Medical Systems.
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Prognostic Value Of Serial FDG-PET/CT Scanning In 
Stage I Non-small Cell Lung Cancer Patients Treated With 
Hypofractionated Radiotherapy
P. Wang1, N. Liu1, C. Qu2, L. Zhu3, B. Wang2, Q. Pang1, Z. Yuan2, L. Zhao1, 
1Department of Radiation Oncology, Tianjin Cancer Institute and Hospital, 
Tianjin, China, 2Cyber Knife Center, Tianjin Cancer Institute and Hospital, 
Tianjin, China, 3PET-CT Center, Tianjin Cancer Institute and Hospital, 
Tianjin, China
Purpose/Objective(s): To evaluate the prognostic value of F-18 fluoro-
deoxyglucose positron emission tomography (FDG-PET) in patients with 
T1-2N0M0 non-small cell lung cancer (NSCLC) treated with hypofraction-
ated radiotherapy. 
Materials/Methods: Thirty-two (20 T1N0M0, 12 T2N0M0) medically inop-
erable patients of Tianjin Cancer Institute & Hospital from November 2006 to 
October 2011 were retrospectively analyzed. All the lung tumors were pathologi-
cally proved and the patients were treated with Cyber knife. Before hypofrac-
tionated radiotherapy, patients were undergoing the first FDG PET/CT scan. All 
patients were followed up with the second FDG PET/CT scan in about a month 
after radiotherapy. A total dose of 45-60 Gy was delivered to the PTV in 3 to 
8 equal fractions in one week or less than two weeks. Median calculated bio-
logical effective dose (BED) was 136.8Gy (range, 76.8 -180 Gy). Standardized 
uptake values (SUVs) at the two times (pre-SUVmax and post-SUVmax) and 
the decreased ratio of these SUVmax (post-SUVmax/pre-SUVmax) were cal-
culated. Cox proportional hazard regression analyses were performed to search 
prognostic factors for local recurrence, distant metastasis, overall survival (OS) 
and disease free survival (DFS) rates. The independent valuables consisted of 
pre-SUVmax, post-SUVmax, decreased SUVmax ratio, age, gender, Karnofsky 
performance status, histology and maximum tumor diameter were analysis. 
Results: The median follow-up time was 33 months (range, 4-62 months). 
At the end of follow-up, twelve patients were still alive with the OS was 
31.8±16.8m and the PFS was 22.4±15.9m. Two-year local control, PFS and 
OS were 95.8%, 56.0% and 82.2%, respectively. The pre-SUVmax and post-
SUVmax did not significantly affect local recurrence, distant metastases or 
OS. On univariate analysis, the only predictor for PFS was pre-SUV (max) 
([95% confidence interval, 22.487-38.622], p=0. 041). Interestingly, HRs of 
post-SUVmax for local recurrence were low (0.662) while early pre-SUVmax 
were relatively high (0.910) though there is no significant correlation. 
Conclusions: The SUVmax of pre-treatment FDG PET/CT scan may be an 
important predict factor for PFS in stage I NSCLC patients treated with hypo-
fractionated radiotherapy.
Author Disclosure Block: P. Wang: None. N. Liu: None. C. Qu: None. L. 
Zhu: None. B. Wang: None. Q. Pang: None. Z. Yuan: None. L. Zhao: None.
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Analysis of Outcomes in Early Stage Non-Small Cell Lung 
Cancer Irradiation: Fractionation Scheme Implications for 
Stage I versus Stage II Disease
X. Qi, D. Low, P. Kupelian, M. Steinberg, P. Lee, Dept. of Radiation Oncology, 
David of Geffen School of Medicine at UCLA, Los Angeles, CA
Purpose/Objective(s): To analyze the available published thoracic irradiation 
studies (including stereotactic body radiation therapy (SBRT) and conventional 
3D Conformal Radiation Therapy (3DCRT) in order to derive plausible radio-
biological parameters for Stage I and II non-small cell lung cancer (NSCLC). 
Materials/Methods: A model based on the generalized linear-quadratic and 
Poisson statistical model was developed to calculate clinical outcomes with 
consideration of clonogen proliferation during the course of radiation therapy 
and exponential behavior of survival rate with follow-up time. A total of six 
independent model parameters, α, α/β, the potential doubling time (T
d
), the 
clonogenic number (k), and tumor cell repopulation at any given follow-up 
time (τ) by an exponential term characterized by two independent parameters 
a and b. Clinical variables specifically evaluated were tumor size (T1 vs. T2) 
and nodal status (stage I vs. II). The SBRT studies were selected based on 
(large) number of patients, relative long follow-up (≥ 3 yrs), and adequate clin-
ical information. The SBRT studies included are Lagerwaard 2008 (206 ps); 
Baumann 2006 (138 pts), Fakiris 2009 (70 pts), etc. The selected conventional 
radiotherapy series are Kaskowitz 1993 (53 pts), Bokyong 2008 (35 pts), etc. 
Clinical staging was done in accordance to AJCC 6th edition staging manual. 
Results: For eight selected SBRT groups, the weighted mean α/β=9.6±0.5 Gy 
(range: 6.8 [Baumann] to 14.7 Gy [Fakiris]), with average clonogenetic cell k 
of 9.7×107 for median tumor sizes of 2.2-3.9 cm. Mean α/β=10.2±4.8 Gy was 
found based on published conventional 3DCRT groups. Better outcomes were 
consistently reported for T1 versus T2 tumors given the same prescription 
dose. Analyzing outcomes based on Lagerwaard (median dose 12 Gy×5), the 
α/β ratios were 10.7±0.4 (T1) and 13.2±0.6 Gy (T2), resulting in biological 
effective doses (BEDs) of 127.3 and 114.5 Gy for T1 and T2 tumors respec-
tively. The predicted disease free survival (DFS) was 90.2, 79.2 and 43.9% for 
T1, and 71.2, 54.6 and 25.6% for T2 at 1, 2 and 5 years. For the entire cohort, 
the predicted DFS were 82.4 and 69.7% compared to the reported DFS of 
83% and 68% at 1 and 2 years respectively. The doubling times for stage I 
and II were found to be 29.7±57.3 and 19.5±34.4 days, respectively, based on 
conventional 3DCRT groups. Delivering 60 Gy in 30 fractions, the calculated 
BEDs were 71.3 and 62.2 Gy for stages I and II, respectively. 
Conclusions: The clinical outcome data analysis suggests that optimal pre-
scription doses for NSCLC are tumor size and nodal status dependent. Given 
potentially shorter doubling times for Stage II versus Stage I lung cancers, 
these disease entities should not be treated with the same dose schedules. 
Also, higher SBRT doses are likely necessary to achieve similar outcomes for 
T2 compared to T1 tumors.
Author Disclosure Block: X. Qi: None. D. Low: None. P. Kupelian: None. 
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Prognositic Factors For Mucinous Adenocarcinoma Of The 
Lung
M. Tsuboi1, K. Nawa2, H. Ito3, T. Woo3, N. Ikeda2, M. Masuda4, K. Yamada3, 
H. Nakayama3, T. Yokose3, 1Yokohama City University Medical Center, 
Yokohama, Japan, 2Tokyo Medical University, Tokyo, Japan, 3Kanagawa 
Cancer Center, Yokohama, Japan, 4Yokohama City University, Yokohama, 
Japan
Purpose/Objective(s): There is no consensus regarding the clinicopathologi-
cal characeristics as for mucinous adenocarcinoma of the lung (MAL). The 
aim of this retrospective study was to clarify the prognostic factors of MAL 
(formerly mucinous bronchioloalveolar carcinoma of the lung). 
Materials/Methods: Fifty-four cases of MAL were selected and analyzed 
from 1,625 lung adenocarcinoma cases which were surgically resected in 
Kanagawa Cancer Center between April 1997 and September 2010. The larg-
est cut surface of the tumor, were prepared and stained using hematoxylin and 
eosin (HE) as well as elastica-van-Gieson (AB-EVG) to detect cytoplasmic 
mucin production and the elastic fiber framework. 
Results: Median follow-up time was 44 months. The 5-year overall survival 
rate of the whole group, group without stromal invasion and group with stro-
mal invasion group was 70.9, 87.2, and 50.0%, respectively (P = .002). A 
multivariate analysis revealed lymphatic permeation, pleural invasion, and 
stromal invasion to be an independent predictive factor (hazard ratio(HR): 
11.85; p = .001, HR: 27.87; p=.001, and HR: 24.12; p=0.030, respectively ). 
Conclusions: The lymphatic permeation, pleural invasion, and stromal inva-
sion are independent poor prognostic factors in patients with mucinous ade-
nocarcinoma of the lung. The patients with these factors may be considered to 
undergo the adjuvant therapy after the complete resection.
Author Disclosure Block: M. Tsuboi: None. K. Nawa: None. H. Ito: None. 
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Treatment Associated Toxicity Following Helical Stereotactic 
Body Radiotherapy For Early-stage Lung Cancer - A 
Retrospective Predictive Analysis Of Patient, Tumor, And 
Treatment Characteristics
B. Fischer-Valuck, L. R. Rosen, M. Durci, S. R. Katz, H. T. Wu, Willis-
Knighton Cancer Center, Shreveport, LA
Purpose/Objective(s): To report on the correlation of patient, tumor, and 
treatment characteristics with toxicity in a large cohort of patients treated with 
helical Stereotactic body radiotherapy (SBRT) for early-stage Non-small-cell 
lung cancer (NSCLC) using image-guided Intensity modulated radiation 
therapy (IMRT). 
Materials/Methods: Records of patients treated between February 2005 and 
July 2011 were retrospectively reviewed. Eighty-five patients with stage 1 
NSCLC were treated with SBRT via a 12 Gy x 4 or 12 Gy x 5 fraction-
ation scheme (48 or 60 Gy). Median follow-up was 26 months (range, 4 - 
82 months). Patient characteristics including age, gender, smoking history, 
smoking status at time of SBRT, body mass index (BMI), and the presence of 
diabetes (DM) or peripheral vascular disease (PVD) were evaluated in regard 
to SBRT-related toxicity. Tumor characteristics and treatment factors were 
also analyzed and included stage, histology, maximal diameter, tumor loca-
tion (central vs peripheral), and radiation dose. Toxicity was scored by the 
Common Terminology Criteria for Adverse Events Version 4. Logistic regres-
sion analysis and the odds ratio were used to associate patient and treatment 
factors to toxicity in univariate models. 
Results: Overall 2-year survival was 76.4% (95% Confidence Interval (CI), 
66.4 - 85.2%). SBRT-related toxicity was reported in 10 patients (11.8%; 95% 
CI, 6.5 - 20.3%) at a median follow-up of 29 months (range, 4 - 60 months). 
Nine patients (10.6%; 95% CI, 5.6 - 18.9%) reported Grade 1/2 chest wall 
pain. One patient (1.2%; 95% CI, 2.1 - 6.4%) suffered from clinical radia-
tion pneumonitis. No correlation between toxicity and gender, smoking sta-
tus at time of SBRT, DM, PVD, and any tumor characteristic was observed. 
Maximal tumor diameter (mean 2.56 cm) did not correlate with increased tox-
icity (Odds Ratio (OR), 1.5%; P = 0.31). Mean age of patients with toxicity 
was 81.2 years versus 71.1 years for those patients without. In our cohort, for 
every 1-year increase in age, the odds of suffering from a SBRT-related toxic-
ity increased by a factor of 1.073 (P = 0.046). Three of the 4 oldest patients 
in our study suffered from toxicity (age 89, 90, and 91 years). Toxicity was 
more common with a total dose of 60 Gy (15.2%) versus 48 Gy total (5.0%), 
however, this difference was not statistically significant (OR, 3.42; P = 0.26). 
A positive smoking history and increasing BMI both had an OR > 1 and 
trended toward an increased incidence of toxicity without reaching statistical 
significance (P = 0.07 and P = 0.08, respectively). 
Conclusion: Toxicity following image-guided SBRT with helical IMRT was 
more common in patients who were older. Other patient, tumor, and treatment 
characteristics were not statistically influential on SBRT-related toxicity.
Author Disclosure Block: B. Fischer-Valuck: None. L.R. Rosen: None. M. 
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Prospective Clinical Study of γ-SBRT for Patients with Stage 
I/II Non-Small Cell Lung Cancer
T. Xia1,2, H. Li1, Y. Wang1, P. Li1, X. Wang1, J. Li1, W. Wu1, 1Air Force 
General Hospital, Beijing, China, 2The General Hospital of Chinese People’s 
Liberation Army, Beijing, China
Purpose/Objective(s): To further evaluate the 2 years local control rate, sur-
vival rate and toxicity of the stereotactic gamma-ray body radiation therapy 
(γ-SBRT) for patients with stage I/II non-small cell lung cancer (NSCLC) 
basing the preliminary studies. 
Materials/Methods: From January, 2007 to July, 2010, 29 eligible patients 
(15 patients refused operation, and 14 patients were not suitable for surgery 
because of old ages or comorbidities such as cardiovascular disease, COPD, 
and diabetes) with pathologically, cytologically or clinical imaging (PET/CT) 
confirmed early stage I (n=26) /II (n=3) NSCLC underwent treatment pro-
spectively using γ-SBRT. There were 22 male patients and 7 female patients. 
The ages ranged from 55-87 years (median 71 years). 8 cases with squamous 
cell carcinoma, 7 cases with adenocarcinoma and 14 cases were diagnosed by 
PET/CT without pathological diagnosis. All the patients received stereotactic 
body frame immobilization and treatment. According to the location of the 
target, the patients were fixed by a vacuum bag. Each patient underwent slow 
CT simulation at 5 s/slide with a CT-slide thickness of 5 mm and CT-slide 
interval of 5 mm to take into consideration tumor motion. Delineated the 
gross target volume (GTV) in the lung window, a minimum margin of 5 mm 
was used to form the clinical target volume (CTV) from the GTV, and a mini-
mum margin of 5 mm was used to form the planning target volume (PTV) 
from the CTV. A total dose of 50 Gy was delivered at 5 Gy/fraction to 50% 
isodose line covering 100% of the PTV, a total dose of 60 Gy was delivered at 
6 Gy/fraction to 60% isodose line covering 90% of the CTV, and a total dose 
of 70 Gy was delivered at 7 Gy/fraction to 70% isodose line covering 80% of 
the GTV, 10 times finished by 2 weeks in 5 fractions per week. The median 
follow-up duration was 24 months (range from 8-42 months). 1 case was lost 
in 8-month making the final follow-up rate to 96.55%. 
Results: The 1-, 3-, 6- month local tumor response rates were 79.31%, 89.65% 
and 93.10% respectively, with CR 17.24%, 44.83%, 86.21%, and PR 62.07%, 
44.82%, 6.90%. The 1-, 2-year local control rates (LCR) were all 93.1%. 
The 1-, 2-year overall survival rates were 96.6% and 89.4%, in those with 
Stage I disease were 100%, 92.0%, Stage II were 66.7%, 66.7%, respectively. 
The 1-, 2-year overall survival rates in pathologically group were 93.3% and 
80.0%, which were all 100% in group without pathology (vs. pathologically 
group, P>0.05). The 1-, 2-year progression-free survival (PFS) were 89.7% 
and 86.1%, respectively. Overall, 2 patients died: 1 died of hemoptysis, and 
another died of multiple organ failure. Only 6.90% (2/29) patients had Grade 
III pneumonitis in 3 months after treatment. 
Conclusion: The evidence showed that γ-SBRT resulted in promising local 
control and survival with minimal toxicity, whose curative effect is the same 
as other SBRT.
Author Disclosure Block: T. Xia: None. H. Li: None. Y. Wang: None. P. Li: 
None. X. Wang: None. J. Li: None. W. Wu: None.
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Implementation Of Linac-based Stereotactic Ablative 
Radiotherapy (SABR) For Early Stage Non-operable Non-
small-cell Lung Cancer (NSCLC) In Community-Based 
Radiotherapy Practice: A Trans-atlantic Hub-and-spoke 
Experience
P. Thirion1, A. Mihai2, C. Lyons1, R. B. Wynn3, J. Armstrong2, L. Rock2, D. 
Heron4, 1St Luke’s Hospital, Dublin, Ireland, 2Beacon Hospital, Dublin, 
Ireland, 3University of Pitssburgh Cancer Institute, Pittsburgh, PA, 4University 
Pittsburgh Cancer Institute, Pittsburgh, PA
Purpose/Objective(s): Numerous academic centers and research groups 
have demonstrated the efficiency of SABR in non-operable stage 1 NSCLC, 
leading to the endorsement of this treatment option by national guidelines. 
However, such complex technology may be felt difficult to deliver in non-
academic community centers. We report the early experience of SABR in two 
community radiotherapy centers. 
Materials/Methods: From 04/09 to 12/11, 82 early stage NSCLC pts with 
significant comorbidity (median Charlson score 4) were treated by SABR. 
90% had histologically-proven disease. Most pts were pet-staged and 
reviewed at tumour board. The M/F was 1.3. The median age was 75 years 
(51-88 ).Tumour stage was T1 (46pts), T2a (22pts), and T3 (8 pt, overall size 
22 mm). 7 pts were treated for synchronous primaries (T1a x 2, T1b x 2, 
T1a&T2a). The median/mean tumour size was 22/25 mm (7 - 56). Using 
centralized protocols developed by University of Pittsburgh Cancer Institute, 
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all pts underwent 4DCT planning. Motion analysis and contouring were per-
formed locally. IMRS planning was outsourced. Varian Trilogy TX with high 
definition MLC was used for treatment delivery, with on-board image guid-
ance (KV, CBCT, fluoroscopy).The used radiation schedules were 60 Gy/3 
(29 pts), 60 Gy/5 (8 pts), 50Gy/5 (10pts),48 Gy/4 (13 pts), , 60 Gy/8 (18 pts) 
and 30 Gy/4 (2 pts, oesophageal MTD), delivered via 2-3 weekly fractions. 
Results: Median follow-up was 9 months (1-25). Acute toxicity was reported 
in 22 pts (8 G1 & 1 G3 pneumonitis, 8 G1 & 1 G2 asthenia, 7 G1 muscu-
loskeletal, 3 G1 skin). No high grade long-term toxicity was reported. Post 
SABR pet scan at 5-6 months was obtained in 41 pts, showing complete meta-
bolic response in 27 pts, with overall metabolic response rate of 90% (37/41). 
Isolated in-field local progression was reported in 2 pts (both treated with 
30Gy/4fr) . Pattern of failure: 7 pts had elsewhere pulmonary progression iso-
lated, 2 with mediastinal nodal progression); 7 pts with extrathoracic distant 
progression (5isolated, 2 with mediastinal progression). At the time of analy-
sis 61 /82 pts were alive; only 4 pts died from confirmed progressive cancer. 
Persistent local control was observed in 85% pts. The 1-year disease-free and 
overall survival were respectively 74% and 77%. 
Conclusions: Our study shows that SABR can be safely delivered in a com-
munity radiotherapy setting via a Hub-and-spoke structure, with a reported 
toxicity and early disease control comparable to published literature, allowing 
to broaden pts eligibility.
Author Disclosure Block: P. Thirion: None. A. Mihai: None. C. Lyons: None. 
R.B. Wynn: None. J. Armstrong: None. L. Rock: None. D. Heron: None.
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Effect Of BMI On The Recurrence And Mortality From Lung 
Cancers Treated Surgically.
B. Dhakal1, S. Sukumaran1, A. Dhakal2, G. Haasler1, D. Eastwood1, N. 
Choong1, 1Medical College of Wisconsin, Milwaukee, WI, 2Northside Medical 
Center, Youngstown, OH
Background: Obesity is considered a risk factor for the incidence and recur-
rence of many cancers like breast and prostate. The correlation of BMI with lung 
cancer risk is variable as shown in different studies. The effect of obesity on the 
recurrence and mortality of lung cancers treated surgically is not well defined. 
Materials/Methods: We performed retrospective study of patients who 
underwent surgical resection for lung cancer at the Medical College of 
Wisconsin from 2006-2010.Data on patient demographics; weight, height, 
pathology findings and hospital course were abstracted after appropriate IRB 
approval. Recurrence is defined as any new lesion of lung cancer occurring 
during the follow up. Mortality is defined as all causes of death occurring 
during the follow up. 
Results: Between 2006 and 2010,320 lung resections were performed for 
lung cancer. Median age was 67 yrs (25-88) and 187(57.6%) were females. 
The body mass index (BMI) distribution was 138 in BMI>= 27 and 182 with 
BMI <27.Tumor histology was: adenocarcinoma 138(42.5%) squamous cell 
cancer 107(31.6%), bronchoalveolar 25(7.1%), large cell 19(5.4%) and mixed 
31(9.68%). All patients who were smokers quit the habit after the surgery. In 
patients with BMI<27,surgical procedures consisted 112(61.8%)lobectomy, 
62(33.9%)wedge resection and 8(4.4%)pneumonectomy. In patients with 
BMI>=27,surgical procedures consisted: 97 (68.6%) lobectomy, 37(27%) 
wedge resection and 6(4.4%) pneumonectomy. Recurrence occurred in 23 
patients (7.2 %) out of which 11(3.44%) had BMI <27 and 12 (3.75%) had 
BMI≥27. 12-month cumulative incidence of recurrence was 3.19% and 7.45% 
in BMI <27 and BMI>=27 groups respectively (p=0.73). Mortality occurred 
in 84 patients during the follow up of which 47(14.69%) had BMI <27 and 37 
(11.56%) had BMI≥27. 12-month cumulative incidence of death was 11.45% 
and 20.94% in BMI<27 and BMI>=27 groups respectively (p=0.30). 
Conclusions: Our study showed no role of higher BMI in the recurrence and 
mortality of patients with lung cancer treated surgically. More large-scale 
studies are needed to understand the effect.
Author Disclosure Block: B. Dhakal: None. S. Sukumaran: None. A. 
Dhakal: None. G. Haasler: None. D. Eastwood: None. N. Choong: None.
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Robotic-Assisted Fluoroscopic Resection of Early Stage Non-
Small Cell Lung Cancer (NSCLC)
S. S. Rehmani1, D. Y. Lee1, F. Y. Bhora1,2, A. J. Evans1,3, A. K. Jain1, W. H. 
Choi1,3, S. S. Belsley1,2, C. P. Connery1,2, 1St. Luke’s Roosevelt Hospital, New 
York, NY, 2Columbia University College of Physicians and Surgeons, New 
York, NY, 3Albert Einstein College of Medicine of Yeshiva University, New 
York, NY
Purpose/Objective(s): Lesions deep in the lung parenchyma are difficult to 
visualize during intraoperative wedge biopsy and therefore may benefit from 
needle localization and use of fluoroscopy. We describe application of fluoro-
scopic localization using the picture in picture (PIP) capabilities of the robotic 
system in order to achieve a precise resection of the tumor. This resection 
guides our intraoperative decision making on whether to continue with robotic 
brachytherapy with lymphadenectomy versus formal robotic lobectomy. 
Materials/Methods: Three patients 70, 65 and 56 years old (patients 1, 2 and 
3 respectively), presented with a NSCLC primary less than 1.5cm. Based on 
their clinical staging and functional status, a consensus was reached through a 
multidisciplinary conference that patients 1 and 2 would be unable to tolerate 
a formal lobectomy but could benefit from limited resection with placement 
of local brachytherapy seeds. Patient 3 could tolerate a lobectomy, but intra-
operative pathology would be used to guide whether a complete lobectomy is 
required. Preoperatively, CT guided localization of the tumor was performed. 
These patients were then brought to the operating room, and the operation 
commenced with single lung ventilation. We applied fluoroscopic guidance 
with PIP technology built into the da-Vinci robotic system (Intuitive surgical, 
Sunnyvale, CA) to direct VATS wedge resection of the lesion. 
Results: On intraoperative pathology, lesions from patients 1 and 2 were 
well localized with adequate margins. Therefore, we sutured Iodine-125 
brachytherapy seeds 1 cm away from the staple line. Patient 3 had predomi-
nantly invasive cancer on intraoperative pathology, therefore we performed a 
completion lobectomy via robotic approach. In patients 1 and 2, we sampled 
lymph nodes from stations 5 and 6. These nodes were found to be negative 
(0/3, 0/8) in each cases. In patient 3 we performed an extended lymphadenec-
tomy with all nodes negative (0/17). Estimated blood loss was less than 100ml 
in all 3 cases and surgery times were 203, 140 333 minutes, respectively. 
Patients had uneventful recovery and chest tubes were out by days 2, 2, and 3. 
Patients were discharged on postoperative days 2, 4 and 4. 
Conclusion: To our knowledge, this is the first series utilizing needle local-
ization to assist in robotic resection of NSCLC lesions deep in the lung 
parenchyma. This novel approach combines radiologic and traditional visu-
alization for accurate localization of the tumor and achieves precise resection 
with minimal trauma using the PIP technology. Although further studies are 
needed, patients with T1 lesions, who are at high risk for operation due to poor 
pulmonary functions, may be spared a lobectomy in favor of a wide lymphad-
enectomy and implantation of brachytherapy seeds.
Author Disclosure Block: S.S. Rehmani: None. D.Y. Lee: None. F.Y. 
Bhora: None. A.J. Evans: None. A.K. Jain: None. W.H. Choi: None. S.S. 
Belsley: None. C.P. Connery: None.
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Clinical Outcomes and Toxicity after Stereotactic 
Body Radiotherapy (SBRT) with or without Adjuvant 
Chemotherapy for Stage I Non-Small Cell Lung Cancer 
(NSCLC)
S. Vance, H. Ye, A. Baschnagel, V. Mangona, D. Yan, I. Grills, Oakland 
University William Beaumont School of Medicine, Royal Oak, MI
Purpose/Objective(s): There are limited data on the safety of combining 
sequential chemotherapy (ChT) with SBRT. We report the toxicity of a small 
cohort of patients who received ChT before or after SBRT. 
Materials/Methods: 15 stage I NSCLC patients who received some form of 
ChT either pre- or post-SBRT were identified from 144 stage I NSCLC patients 
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in our lung cancer data base. ChT was given at the discretion of the medical 
oncologist. 12 pts received ChT as adjuvant treatment for their NSCLC and 3 
for a secondary malignancy. SBRT was volumetrically prescribed as 48 (IA) or 
60 (IB) Gy in 4-5 fractions with daily image guidance. Toxicity was prospec-
tively collected at SBRT follow up visits. Matched pair analysis was performed 
using stage (IA, IB), Charlson Comorbidity Index (CCI) group (0-2, 3-7, >7), 
and histology (squamous vs non-squamous) to further evaluate toxicity. 
Results: Median follow-up for the 15 ChT pts was 1.8y (0.4-5y); median 
age 76y; 67% (n=10) were stage IA and 33% (n=5) were IB. Median tumor 
size was 2.9 cm (1.5-6.2); median V20 8.4%; median mean lung dose 4800 
cGy; median FEV1 was 1.48L (70% predicted), and DLCO was 9.7 (48% 
predicted). 12 pts received adjuvant ChT post-SBRT, including: cisplatin or 
carboplatin/gemcitabine (n=3), carboplatin/paclitaxel (n=2), carboplatin/eto-
poside (n=2), gemcitabine alone (n=2), or erlotinib (n=3). Median time from 
SBRT to ChT was 6.3 wks (2-18wks). In addition, 1 pt completed FOLFOX 
and bevacizumab for S4 colorectal CA 18wks pre-SBRT for lung 1°, 1 pt 
finished cetuximab for a skull base SCC 13 wks pre-SBRT for lung 1°, and 
1 pt completed RCVP (rituximab, cyclophosphamide, and vincristine) for S4 
follicular lymphoma 8wks pre-SBRT for lung 1°. 2 pts had pneumonitis (1 
G2, 1 G3); 1 developed rib fractures (1 G2); 2 had acute lung toxicity (2 G2); 
3 had chronic lung toxicity (1 G2, 2 G3) and 4 had chronic myositis (3 G2, 1 
G3). None developed esophagitis. 3-y overall survival (OS) was 42%, cause 
specific survival (CSS) 100%, local recurrence (LR) 11%, regional recur-
rence (RR) 0%, distant metastasis (DM) 17%, and disease free survival (DFS) 
29%. 10 ChT pts (C) were then identically matched with 20 SBRT pts not 
receiving ChT (NC). There were no differences between groups in regards to 
follow up time, age, stage, tumor size, operability status or CCI scores. No 
statistically significant differences in toxicity were noted for C vs NC for: > 
2 pneumonitis (10% C vs 5% NC, n=1 each), esophagitis, rib fracture, skin 
reactions, or acute/chronic lung toxicity. There were no significant differences 
in OS, CSS, LR, RR, DM or DFS between the matched groups. 
Conclusions: This small study suggests the combination of SBRT and adju-
vant chemotherapy may be safe. Chemotherapy was not associated with 
improvement in any clinical outcome or failure; however, additional larger 
series are needed.
Author Disclosure Block: S. Vance: None. H. Ye: None. A. Baschnagel: 
None. V. Mangona: None. D. Yan: None. I. Grills: None.
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Sublobar Resection and Robotic Interstitial Brachytherapy 
for Early Stage Non Small Cell Lung Cancer
A. J. Evans, C. Connery, F. Bhora, W. Choi, D. Lee, A. Jain, St. Luke’s 
Roosevelt Hospital Center, New York, NY, NY
Introduction: Lobectomy is the standard of care for early stage lung cancer 
and has been shown to have superior outcomes to limited resection alone. 
However, the addition of brachytherapy to sublobar resection has resulted in 
low recurrence rates with minimal morbidity, making this an attractive option 
for patients who cannot have a lobectomy. Robotic surgery is a minimally 
invasive approach for brachytherapy seed placement while maintaining preci-
sion and dexterity of movement and maximal surgical access. We conducted 
a phase I, prospective study of patients with Stage I Non Small Cell Lung 
Cancer treated with sublobar resection and robotic brachytherapy to evaluate 
clinical outcome of this technique. 
Materials/Methods: 19 patients were enrolled. Patients were determined 
by pre-treatment evaluation to have T1 or T2 disease with tumors<5cm, 
technically resectable, and no evidence of nodal or distant metastases. 
Pathologic mediastinal assessment was performed by either Endobronchial 
Utrasound (EBUS) or mediastinoscopy. Patients underwent Video-Assisted 
Thoracoscopic (VATS) wedge resection followed by robotic brachytherapy 
seed implantation. The da Vinci Robotic system was used to suture I-125 
brachytherapy seeds into the operative bed to deliver 144 Gy to 1 cm from the 
staple line. Patients were followed every three months postoperatively with 
history and physical, and imaging studies (Chest X-ray, CT scan, PET scan) 
as clinically indicated. Surgical outcomes, postoperative course, and local, 
regional and distant disease status at follow up was recorded. 
Results: Final pathologic staging showed T1 disease in 16 patients, T2 dis-
ease in 2 patients, and T4 disease in 1 patient. All patients were node negative. 
Median follow up was 13.3 months (range 3.4 to 52.3 mos). At last follow up, 
18/18 patients were locally controlled. 17/18 patients were regionally con-
trolled with one patient experiencing mediastinal nodal recurrence 6 months 
after the procedure. No patients developed distant metastases. Surgery was 
well tolerated, with 3/19 patients experiencing postoperative complications. 
One patient experienced subcutaneous emphysema requiring chest tube 
placement and one patient experienced pneumothorax. One patient died two 
weeks postoperatively due to multisystem organ failure from pneumosepsis, 
and was not included in the follow up analysis. Median surgery time was 169 
minutes (range 80-244 min), and median length of hospital stay was 4 days 
(range 3-33 days). 
Conclusion: Sublobar resection plus robotic brachytherapy offers a high 
rate of local control for early stage lung cancer with minimal hospital stay 
and acceptable postoperative morbidity. This technique is a viable option for 
patients who cannot tolerate a lobectomy. Further clinical follow up and larger 
randomized trials are needed to validate this treatment approach.
Author Disclosure Block: A.J. Evans: None. C. Connery: None. F. Bhora: 
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Stereotactic Radiosurgery for Stage I Non Small Cell Lung 
Cancer: A Multi Institutional Experience
S. D. Karam1, Z. D. Horne2, R. L. Hong3, D. Duhamel3, D. Mcrae3, G. 
Gagnon4, N. Nasr3, 1Georgetown University Hospital, Washington, DC, 
2George Washington University, Washington, DC, 3Virginia Hospital Center, 
Arlington, VA, 4Fredrick Memorial Hospital, Fredrick, MD
Purpose/Objective(s): To assess local control, overall survival, and toxic-
ity of robotic four-dimensional, stereotactic body radiotherapy (SBRT) with 
respiratory motion tracking in patients with Stage I lung cancer. 
Materials/Methods: We retrospectively reviewed patients who underwent 
SBRT for non-small cell lung cancer (NSCLC) between 2008 and 2011 at 
two different institutions. Thirty-six lesions from 35 patients with Stage I lung 
cancer were included. The median age was 74 with 46% females and 54% 
males. Forty-two percent were T1a, 25% T1b, and 33% were T2a. Sixty-nine 
percent were stage Ia while 32% stage Ib. The median SBRT dose was 50 Gy 
(range 25-75 Gy) delivered in 5 fractions (range 3-5Gy) with a median bio-
logically effective dose (BED10) of 105.6 Gy (range 37.5-180Gy) prescribed 
to a mean isodose line of 81% (range 74-94%). 
Results: With a median followup of 13.5 months, the 2-year local control, 
progression-free survival, and overall survival rates were 80%, 43%, and 73% 
respectively. Two-year regional and distant control rates were estimated at 
54% and 77%, respectively. Univariate analysis revealed that a BED10 greater 
than 105 was predictive of local control (p=0.0268) while size, measured as 
gross tumor volume (GTV), was predictive of overall survival (p=0.0021). 
Although the number of events was small, there was a statistically significant 
difference in local control favoring adnocarcinoma (p=0.0396). Subacute side 
effects included cough in 2 patients (5.6%), fatigue in 8 patients (22.2%), 
chest pain in 4 patients (5%), and shortness of breath in 5 patients (13.9%). 
There were no RTOG grade 4 or 5 toxicities reported. 
Conclusions: The SBRT protocol used in this study yielded reasonable local 
control and overall survival rates with acceptable toxicity for patients with 
stage I NSCLC. The effects of total dose, fractionation, and histology on con-
trol rates require further investigation.
Author Disclosure Block: S.D. Karam: None. Z.D. Horne: None. R.L. 
Hong: None. D. Duhamel: None. D. Mcrae: None. G. Gagnon: None. N. 
Nasr: None.
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Stereotactic Body Radiotherapy using the Cyberknife Robotic 
Radiosurgery System for Lung Cancer Primaries and 
Metastases to the Lung
A. Rashtian, Y. R. Zhang, C. Lee, D. S. Oh, B. J. Gitlitz, S. V. Liu, J. A. Hagen, 
University of Southern California, Los Angeles, CA
Purpose/Objective(s): To review treatment outcomes for stereotactic body 
radiotherapy (SBRT) using the Cyberknife Robotic Radiosurgery System for 
patients with primary lung cancer as well as metastatic disease to the lung. 
Materials/Methods: Between 2010-2011, 30 lesions in 21 patients were 
treated with SBRT using Cyberknife at our institution. Seventeen lesions 
were primary or recurrent lung cancer, while 13 lesions were metastatic dis-
ease from other primaries. Diagnostic CT and PET imaging before treatment, 
immediately after treatment, and at last follow up were reviewed, as were radia-
tion prescription and treatment parameters. The median dose was 48 Gy in 4 fx 
(range 25-54 Gy in 4-5 fx). Median SUVmax pretreatment was 6.7 (range 2.1-
19.7). Median size of the irradiated lesions was 2.14 cm (range in 0.9 cm - 5.6 
cm). Median Biologic Equivalent Dose (BED) assuming an alpha/beta ratio of 
10 was 72 Gy (range 32.6-151 Gy). One patient received radiofrequency abla-
tion (RFA) as part of a combined planned SBRT/RFA approach given a lower 
permissible SBRT dose due to close proximity to critical structures. 
Results: At a median follow up of eight months (range 2-24 months), 28 
of the 30 lesions (93%) had decreased in both size and SUVmax. Median 
SUVmax after treatment was 3.2 (range 0-12.2) and at last follow up was 
2.6 (range 0-12.2). Two lesions had a radiologic failure based on PET and 
CT. One lesion was given a dose of 40 Gy in 4 fractions (BED 80 Gy) due 
to close proximity to the central zone. This lesion recurred at nine months 
after showing an initial decrease in size and activity on PET/CT after three 
months and was salvaged with radiofrequency ablation. The other lesion was 
a mediastinal metastasis from breast cancer. It was given a dose of 25 Gy in 
5 fractions (BED 37.5 Gy) given its close proximity to the heart. That patient 
had previously received 50 Gy in 25 fractions with opposed tangent fields to 
the left breast as part of definitive therapy using external beam radiation. This 
lesion recurred one year after treatment and had continued decreased in size 
and activity for the first nine months and was salvaged with cryoablation. The 
one patient that received the planned combined SBRT/RFA had a pretreat-
ment SUVmax of 16.6 that decreased to SUVmax of 2.5 after treatment. 
Conclusions: SBRT with the Cyberknife Robotic Radiosurgery System is an 
effective method in ablating tumors of the lung as well as metastatic disease 
from other primary sites to the lung. Our results compare favorably to reports 
in the literature. In patients where critical structures would not allow a suf-
ficiently high dose of radiation, a planned combined approach of SBRT to 
a lower dose with RFA may be reasonable to achieve a complete response.
Author Disclosure Block: A. Rashtian: None. Y.R. Zhang: None. C. Lee: 
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Preliminary Results of Definite Radiotherapy for Stage II 
Non-small Cell Lung Cancer at Tokyo Medical University
R. Mikami, H. Nakayama, S. Nogi, Y. Tajima, M. Okubo, N. Kanesaka, S. 
Sugahara, K. Tokuuye, Tokyo Medical University, Tokyo, Japan
Purpose/Objective(s): The outcome of patients with stage II non-small cell 
lung cancer (NSCLC) who underwent definite radiotherapy has not been 
published enough. We aimed to retrospectively investigate the outcomes of 
patients with stage II NSCLC who underwent definitive radiotherapy. 
Materials/Methods: Between June 2001 and November 2009, 25 consecu-
tive patients with clinical stage II NSCLC who underwent definite radiother-
apy at the Tokyo Medical University were assessed. The median age was 71 
years, ranging from 50 to 89. According to the 7th edition of American joint 
committee on cancer, the number of patients of clinical stage IIA and IIB 
were respective eight and 17. Twenty-three patients of the 25 were medically 
inoperable and the remaining two patients refused surgery. Of the 23, 12 
patients had pulmonary disease, five cardiovascular disease, five diabetes 
mellitus and one another cancer. All patients were histologically confirmed as 
NSCLC; 13 patients had squamous cell carcinoma, nine adenocarcinoma, two 
non-small cell carcinoma and one large cell neuroendocrine tumor. Median 
radiation dose of 60 Gy (60 - 70) in 30 sessions (30 - 35) were delivered with 
a daily 2 Gy using 3-D conformal radiotherapy. Irradiation to the elective 
lymph node was omitted from 2009. Ten and six patients underwent chemora-
diotherapy concurrently or sequentially, respectively, and nine patients under-
went radiotherapy alone. 
Results: Median follow-up period was 25 months, ranging from nine to 73. 
Clinically complete response was observed in 48% of the patients, partial 
response 36%, stable disease 8% and progressive disease 8%. Two-year local 
progression free survival, progression free survival and overall survival were 
achieved in 86.9% (95% confidence interval [CI]; 72.9 to 100.1%), 79.0% 
(95% CI; 62.5 to 95.4%) and 80.4% (95% CI; 62.9 to 97.9%), respectively. 
Concerning the initial relapse sites, six patients had local recurrence, one 
mediastinum lymph node and one bone metastases. No factors, such as clini-
cal stage, addition of chemotherapy, performance status, omission of elective 
lymph node irradiation and age, were statistically significant for overall sur-
vival. None had Grade 3 toxicities or more. 
Conclusions: Two-year overall survival of radiotherapy for patients with 
stage II NSCLC appears comparable with that of surgery. Further study of 
definitive radiotherapy for stage II NSCLC was warranted.
Author Disclosure Block: R. Mikami: None. H. Nakayama: None. S. 
Nogi: None. Y. Tajima: None. M. Okubo: None. N. Kanesaka: None. S. 
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Dose Escalation With a Simultaneous Integrated Boost 
Strategy Using Image-Guided Adaptive Radiation Therapy 
for Locally-Advanced Non-Small Cell Lung Cancer: a Virtual 
Clinical Trial
G. D. Hugo, N. Dogan, Y. Wu, M. Fatyga, A. Urdaneta, S. Balik, E. Weiss, 
Virginia Commonwealth University, Richmond, VA
Purpose/Objective(s): To evaluate the potential dose escalation afforded by a 
simultaneous volume-adapted integrated boost implemented through image-
guided adaptive radiation therapy. 
Materials/Methods: Ten patients with locally-advanced non-small cell 
lung cancer were enrolled on an IRB-approved study and underwent weekly 
4D fan beam CT (4DFBCT) and daily 4D cone beam CT after providing 
informed consent. Three plans were generated: an initial plan on the simula-
tion 4DFBCT, an adaptive plan on the 4DFBCT acquired after 15 fractions / 
30 Gy, and a second adaptive plan on the 4DFBCT acquired after 25 fractions 
/ 50 Gy. Replanning at 30 Gy and 50 Gy accounted for volume and shape 
changes of the primary tumor (PT) and lymph nodes (LN), while the 50 Gy 
replan also incorporated a simultaneous integrated boost to the PT volume as 
determined on the 50 Gy scan. The planning target volume was designed to 
give a cumulative physical dose of 66 Gy to the PT and LN from the three 
plans. The simultaneous integrated boost dose was increased in defined dose 
levels up to 82 Gy without extending the treatment duration. For the 30 and 
50 Gy scans clinical target volumes (CTV) were deformably mapped from the 
initial 4DFBCT to account for anatomical changes. Cumulative dose to the 
targets and organs at risk was assessed by recalculating each plan on corre-
sponding 4DCT images, correcting physical to biological equivalent dose per 
fraction, and deformably mapping and accumulating the biological equivalent 
dose to the mid-ventilation phase of the simulation 4DFBCT to obtain a real-
istic assessment of the actual delivered dose. 
Results: The prescribed boost dose was achieved for all boost levels for 9/10 
patients without exceeding toxicity constraints. In one patient with a 312 cc 
primary tumor volume, only the 66 Gy dose level was achieved. The biological 
equivalent dose normalized to 2-Gy fractions (NTD) for the CTV of the PT 
and LN were 68.5 ± 1.0 Gy
10
 and 67.4 Gy ± 1.7 Gy
10
, respectively, for the 66 
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Gy level and 74.4 ± 3.3 Gy
10
 and 64.0 ± 2.0 Gy
10
 for the 82 Gy level. NTD
 
to 
95% of the PT was 68.8 ± 1.7 Gy
10
 and 79.5 ± 3.4 Gy
10
 for the 66 Gy and 82 Gy 
dose levels, respectively. The NTD to 95% of the PT was significantly higher 
at all boost dose levels than the 66 Gy level (p=0.004 - 0.008, Wilcoxon signed 
rank test). The 82 Gy plan resulted in a clinically irrelevant increase in normal-
ized mean lung dose relative to the 66 Gy plan of 0.08 ± 0.06 Gy
4
 (p=0.004). 
The NTD to spinal cord, esophagus, heart, aorta, and major airways was not 
significantly different between any boost level and the 66 Gy plan. 
Conclusions: This virtual clinical trial indicates that delivery of a simultane-
ous integrated boost with image-guided adaptive radiation therapy appears 
feasible for most patients.
Author Disclosure Block: G.D. Hugo: None. N. Dogan: None. Y. Wu: 
None. M. Fatyga: None. A. Urdaneta: None. S. Balik: None. E. Weiss: E. 
Research Grant; Varian Medical Systems.
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Treatment-related Esophagitis For Patients With 
Locoregionally Advanced Non-small Cell Lung Cancer 
Treated With Involved-field Radiotherapy And Concurrent 
Chemotherapy
V. Bar Ad, M. Witek, B. Leiby, Y. Xiao, Y. Cui, Y. Dai, J. Cao, R. Axelrod, B. 
Campling, M. Werner-Wasik, Thomas Jefferson University, Philadelphia, PA
Purpose/Objective(s): To explore the incidence and the risk factors for 
treatment-related esophagitis associated with involved-field radiation therapy 
(RT) delivered concurrently with chemotherapy for patients with locoregion-
ally advanced non-small cell lung cancer (NSCLC). 
Materials/Methods: Forty-nine consecutive patients diagnosed with 
locoregionally advanced NSCLC were treated using involved-field RT. 
Radiotherapy target volumes included the primary lung tumor and involved 
mediastinal lymphadenopathy as defined on imaging studies including 
computed tomography (CT) of the chest and [18F] fluorodeoxyglucose-
positron emission tomography (FDG-PET)/CT. The patients were treated 
to a median total dose of 63 Gy (range, 55.8-74 Gy) using daily fractions 
of 1.8 or 2.0 Gy. No elective radiotherapy of mediastinal lymph nodes was 
used. Concurrent platinum-based chemotherapy was delivered to all patients. 
Treatment-related toxicity was evaluated during the course of RT and subse-
quent  follow-up visits. 
Results: Thirty-one (63%) patients were female and 18 (37%) were male. 
Median age at the time of diagnosis was 68 years (range, 36-83 years). 
Thirty-one patients (63%) developed treatment-related acute esophagitis: 24 
patients (49%) grade 2, and 7 (14%) patients grade 3 esophagitis, respec-
tively, with the peak occurring during the seventh week of radiotherapy. No 
grade >/= 4 esophagitis was seen in this cohort. Eighteen patients (37%) 
developed no radiation-induced esophagitis associated with their course of 
chemoradiotherapy. In the univariate analysis, age at the time of diagnosis, 
radiation dose per fraction and total volume of the esophagus were signifi-
cantly associated with the risk of acute esophagitis. Increasing age reduced 
risk of acute esophagitis (OR for 10-year increase = 0.40) as did increasing 
total esophagus volume (OR for 10-unit increase =0.28). Dose per fraction 
of 1.8 Gy was associated with lower risk of acute esophagitis when com-
pared with dose per fraction of 2 Gy (OR = 0.20). Marginal associations were 
observed for all of the Vx variables. Higher Vx values had a non-significant 
association with an increase in risk of acute esophagitis. However, only the 
younger patients’ age at the time of diagnosis (p= 0.0420), and larger dose 
per fraction (2 Gy vs. 1.8 Gy) (p= 0.0053) remained significantly associated 
with higher risk of developing grade >/= 2 acute esophagitis, in the multi-
variate analysis. 
Conclusions: Higher risk of grade >/= 2 treatment-related esophagitis was 
associated with younger age, and higher radiotherapy dose per fraction and 
should be further evaluated in clinical trials.
Author Disclosure Block: V. Bar Ad: None. M. Witek: None. B. Leiby: 
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The Role Of Positron Emission Tomography - Computed 
Tomography (PET/CT) In The Prognosis Of Patients With 
Non Small Cell Lung Cancer (NSCLC)
A. Tesfaye, M. Mozayen, M. Sarangi, S. Nagpal, McLaren Health Care, 
Flint, MI
Introduction:
Purpose/Objective(s): Use of PET/CT scanning in patients with NSCLC is 
a current standard of care for proper staging prior to treatment. 18-fluoro-
2-deoxyglucose (FDG) maximum Standard uptake values (SUVmax) are 
indicators of metabolic activity of the malignant cells. There are conflicting 
data about the prognostic significance of SUVmax in pretreatment PET/CT 
of patients with NSCLC. Our study was undertaken to evaluate the prognostic 
significance of SUVmax in patients with NSCLC. 
Materials/Methods: A retrospective review of 106 patients diagnosed with 
NSCLC between 2004 and 2008 in a community hospital setting was done. 
Patients with additional malignancies; with no pretreatment staging PET/
CT scan; survival less than 3 months and those with no follow up data were 
excluded from the study. Demographics, PET/CT report, pathology report, 
disease stage, and subsequent follow up data were reviewed. Cox proportional 
hazard model was used to predict independent variables affecting survival. 
Life Tables with Wilcoxon statistic and Kaplan Meier method were used to 
estimate overall survival using IBM SPSS 20. 
Results: Of the total of 106 patients reviewed, Females were 53 (50.5%). 
Majority (95.2%) of the patients were Caucasians. The median values were used 
to dichotomize continuous variables. The median age of the study population was 
70 (Range: 38-92). Adenocarcinoma was seen in 61(58.1%) patients and squa-
mous cell carcinoma in 44 (41.9%). The median SUVmax of the primary tumor 
was 8.3 (range: 2.5-27.0). The median tumor size was 3 cm (range: 0.6-13). Nodal 
disease was seen in 40% of patients, while metastatic disease was seen in 19% 
of patients. Stage I was seen in 43 (41%), II in 12 (11.4%), III in 30 (28.6%) & 
IV in 20 (19%) of the study population. The median follow up duration for the 
study population was 21 months (range: 3-45). The 2 year overall survival for 
the study population was 44.8 %. The 2 years overall survival for patients with 
SUVmax8.3 (Wilcoxon stastistic; p=0.0001). The median survival for patients 
with SUVmax8.3. (Wilcoxon statistic; p=0.0001). Upon univariate analyses, 
advanced staging, Nodal positivity, metastatic disease, high SUVmax were asso-
ciated with worse survival. Upon multivariate analysis, independent predictor 
variables associated with worse outcomes were: Male gender (HR=1.923 (95% 
CI: 1.107-3.339), p=0.02); High SUVmax (HR= 2.253 (95% CI: 1.256-4.040), 
p=0.006); Positive lymph nodes (HR=2.347 (95% CI: 1.237-4.457), p= 0.009); 
and presence of metastases (HR=7.189 (95% CI: 3.135-16.484), p=0.0001). 
Conclusion: Our study suggests that high SUVmax of the primary tumor is 
associated with worse survival and could be used as a prognostic factor in 
stratifying patients with NSCLC. Larger prospective studies are needed to 
validate this finding.
Author Disclosure Block: A. Tesfaye: None. M. Mozayen: None. M. 
Sarangi: None. S. Nagpal: None.
1033 
Radiotherapy Dose-Escalation Protocol: Selection Bias in 
Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)
N. O. Roman1, M. Orton1, S. Baker1, T. Chung2, R. A. Good1, K. Paul3, E. 
Weiss1, 1Virginia Commonwealth Univ MCV Affiliated Hosps, Richmond, VA, 
2Medical College of Georgia, Augusta, GA, 3University of Sydney, Sydney, 
Australia
Purpose/Objective(s): Dose-escalation protocols for locally advanced 
NSCLC may have an inherent selection bias due to enrollment of patients 
to dose steps where dosimetric eligibility criteria are met. In order to avoid 
this bias, a phase I dose intensification protocol was written that required all 
potentially eligible patients to meet dosimetric criteria at the highest dose 
level. This analysis presents the planning results of the study. 
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Materials/Methods: Nineteen lung cancer patients were considered for 
enrollment on a phase I dose intensification protocol. The starting dose was 
66 Gy with dose increases in 4 Gy increments to 78 Gy. Radiotherapy was 
gated and given concurrently with chemotherapy. For all patients intensity 
modulated radiation therapy (IMRT) plans were generated and optimized to 
meet defined PTV and normal tissue dose criteria at the 78 Gy dose level, 
regardless of assignment to lower dose levels for therapy. 
Results: A total of 5/19 patients met all dosimetric criteria for eligibility at 
the 78 Gy dose level. Eleven patients were ineligible due to failure to meet ≥2 
planning eligibility criteria at 78 Gy. The mean gross tumor volume (GTV) 
was 133.2 cm3 and 132.5 cm3 for ineligible and eligible patients, respectively. 
The mean lung volume minus planning target volume (PTV) was 3048.5 cm3 
and 3851.4 cm3 for ineligible and eligible patients, respectively. Fourteen 
patients were ineligible secondary to not meeting pulmonary constraints 
of V
5Gy
<50% (mean 67.1%, 14 patients) and V
20Gy
<30% (mean 34.8%, 5 
patients). The maximum allowed spinal cord dose of 45 Gy was exceeded in 
9/19 patients (mean 51.1 Gy). A total of 7 patients were ineligible because of 
esophageal dose criteria of V
55Gy
<30% (mean 36.3%, 7 patients) and mean 
dose <34 Gy (mean 41 Gy, 5 patients). Three patients were ineligible due to 
exceeding brachial plexus maximum dose of 66 Gy (Mean Maximum 77.1 
Gy, 3 Patients). One patient was ineligible secondary to heart V
40Gy
<50% 
(47.8 Gy). 
Conclusions: Verification of dose escalation eligibility prior to protocol 
enrollment resulted in less than 30% of patients being eligible for this dose 
escalation trial. Patients with smaller lung volumes were more likely to be 
ineligible. Radiotherapy dose-escalation protocols for patients with locally 
advanced non-small-cell lung cancer that do not account for potential selec-
tion bias should be interpreted with caution.
Author Disclosure Block: N.O. Roman: None. M. Orton: None. S. Baker: 
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1034 
Correlation Of PET Response To Treatment Outcomes In 
Patients Treated With Trimodality Therapy For Locally 
Advanced Non-small Cell Lung Cancer.
E. Duffy1, F. Zhu2, W. J. Scott2, J. Q. Yu3, A. Turaka2, 1Bryn Mawr College, 
Bryn Mawr, PA, 2Fox Chase Cancer Center, Philadelphia, PA, 3Fox Chase 
Cancer Center, Philadelphia,, PA
Purpose/Objective(s): To determine the impact of the use of FDG-PET/CT 
for treatment response and subsequent surgery outcomes after preoperative 
chemo-radiation therapy (CRT) for locally advanced non-small cell lung can-
cer (NSCLC) patients. 
Materials/Methods: A retrospective review of 22 patient charts treated with 
trimodality therapy was done. Patients (pts) had either operable N2 disease 
or bulky hilar disease (T1-3, select T4, N0-2, stage II and IIIA, resectable 
chest wall disease), potentially resectable after CRT. Trimodality treatment 
consisted of chemotherapy administered weekly Carboplatin (C, AUC of 2) 
and Paclitaxel (P, 50 mg/m2) during RT, 50.4 Gy (1.8 Gy/day, 5 days a week), 
surgical resection and additional adjuvant C (AUC 6) day 1 and P 100 mg/m2/
wk days 1, 8, and 15 every 4 wks x 3. The pre- and post-treatment PET data 
information, standard uptake values (SUV) along with demographic, treat-
ment related variables were used to assess the outcomes. The pathological 
response rates, recurrence free survival (RFS) and overall survival (OS) were 
estimated using Kaplan-Meier curve at the median SUV and a drop in SUV 
of 3 or more. 
Results: Median follow-up was 41.7 months (range: 4.9-75.7). Median age 
was 60 years (48-78), 14 were former smokers, 7 current smokers. Twelve 
patients had squamous histology and 9 were adenocarcinoma. Ten pts had 
clinical T3, one T4 and 16 had clinical N2 disease. The median primary tumor 
size was 4 cm (range: 1.1-8). The median RT dose was 50.4 Gy (range: 40-54). 
Lobectomy was done in 9 pts, pneumonectomy in 8, 3 pts bilobectomy and 2 
wedge resection. Pathologic CR at the primary site was noted in 19 (86%) pts 
and in 11 pts (52%) at nodal sites. The median interval from completion of 
RT to PET evaluation was 19 days. The median pretreatment SUV for the pri-
mary lesion and lymph node (LN) regions was 11 (2.9-31.2) and 0 (0-13.7). 
Post-treatment SUV was 0 (0-9.3) and 0 (0-6.7) for both sites respectively. 
The median drop in SUV for primary site was 7.75 (0.9-31.2, p= 0.01) and 0 
for LN (-1.5-13.7, p= 0.37). Median survival was 49.7 months (43.4 vs. 49.7 
months at SUV of < vs. ≥ 7.75; p= 0.62). There was no difference in survival 
when the drop in SUV at 3 was estimated (49.7 vs. 44.3 months with SUV of 
< vs. ≥ 3, p= 99). Loco-regional failures were noted in 4 pts (18%): 3 local 
& 1 pt with regional failure. The median recurrence free survival was 41.1 
months and no difference in RFS was noted in relation to the SUV values at 
7.75 (p= 0.54) and 3 (p= 0.99). 
Conclusions: In our series with limited number of pts, the drop in SUV at 
primary site correlated with best pathological CR rates after the trimdality 
therapy and improvement in RFS and OS.
Author Disclosure Block: E. Duffy: None. F. Zhu: None. W.J. Scott: None. 
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The Role of Mediastinal Lymph Node Dissection in Patients 
with II-IIIa Study Non-small Cell Lung Cancer
E. Mantsyrev1, A. Vazhenin1, A. Lukin1, M. Mironchenko2, Y. Gnatyuk1, S. 
Timofeev1, 1Chelyabinsk Regional Oncology Clinic, Chelyabinsk, Russian 
Federation, 2Chelyabinsk Regional Oncology Clinic
Purpose/Objective(s): Despite a lot of research carried out by Russian and 
foreign specialists the question of extensive operation in NSCLC is still dis-
cussed. Specialists differ in opinion if mediastinal lymph node dissection 
is a treatment or diagnostic operation and about the extent of lymph node 
dissection. 
Materials/Methods: This research is based on the retrospective analysis of 
combination and surgical treatment of patients with II-III study NSCLC. The 
time period is 10 years since January 1995 till Dec 2004. Patients (n=191) 
were divided into 4 groups according to the treatment received. The 1st group 
includes patients (n=40) with locally advanced NSCLC who were treated 
using only typical operations. The 2nd group includes patients (n=22) who 
were treated using only extensive operations. The 3rd group (n=78) includes 
those who 1st were treated using typical operations and then using postsurgi-
cal gamma-ray therapy. The 4th group (n=51) includes patients who 1st were 
treated using extensive operations and then using adjuvant radiation therapy. 
Results: Based on the results of the research we consider that using of ipsi-
lateral mediastinal lymph node dissection for patients with IIa-IIb study squa-
mous cell lung cancer directly or indirectly influences treatment long-term 
outcome - in case of using extensive operations median survival is 7,5 months 
more, 3 year survival is 16% more, 5 year survival is 14% more. There is no 
big difference between results of surgical treatment using extensive opera-
tions and results of combination therapy with typical operations ( p=0,40820 
Cox’s F-test; p=0,94584 log-rank test). The survival of the 4th group was 
practically the same as the second and third group. Significant clinical/statis-
tical differences were not found. The reason is this group patients combina-
tion therapy effectiveness limit. The surgical treatment is not effective enough 
for IIa-IIb study non squamous cell lung cancer comparing with squamous 
tumors ( p=0,01850 Cox’s F-test; p=0,03941 log-rank test). Adjuvant drug 
therapy should be used for this category patients. Taking into account lymph 
node dissection extent, no reliable significant clinical and statistical differ-
ences in survival in case of combination therapy used for patients with IIIa 
NSCLC were found out ( p=0,48321 Cox’s F-test; p=0,95281 log-rank test). 
Conclusions: Using mediastinal lymph node dissection for patients with IIIa 
study NSCLC is just an operation diagnostic phase that allow to ascertain 
tumor extent and to evaluate more exactly additional risk factors such as root 
of lung 3 or more lymph nodes damage or/and mediastinum. Information 
about total or subtotal lymph node replacement by tumor tissue allow to deter-
mine more exactly prognosis and necessary adjuvant therapy extent.
Author Disclosure Block: E. Mantsyrev: None. A. Vazhenin: None. A. 
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Assessment of Weekly Lung Ventilation Changes During 
Radiotherapy using 4D-CT
B. Teo, M. Grupp, M. Kirk, P. Bloch, R. Munbodh, G. Song, J. Gee, R. R. 
Rengan, University of Pennsylvania, Philadelphia, PA
Purpose/Objective(s): The purpose of this study is to investigate if 
4D-CT can be used to monitor changes in pulmonary function during lung 
radiotherapy. 
Materials/Methods: Ten locally advanced or recurrent non-small cell lung 
cancer patients receiving lung radiotherapy (3D conformal, IMRT or pro-
ton to 50.4Gy to 74 Gy) underwent weekly 4D-CT imaging (6 to 10 times) 
during treatment. In-house deformable image registration software was used 
to deform each exhale to the inhale phase image. 3D volumetric data of 
lung tissue expansion or contraction maps were derived from the Jacobian 
determinant of the deformable registration. Low ventilating lung (LVL) was 
defined as regions which expanded by less than 5% between the exhale and 
inhale phases. The volumes of LVL for ipsilateral and contralateral as well 
as the ratio of ipsilateral to contralateral LVL volumes were computed for 
analysis. 
Results: The average ipsilateral lung volume was 1656±880 cm3 and the LVL 
subvolume was 696 cm3 (42%). The average contralateral lung volume was 
2019±720 cm3 and the LVL subvolume was 696 cm3 (34%). For nine of the 
patients, the ratio of ipsilateral to contralateral LVL remained moderately 
constant (0.74±0.26, 1.33±0.26, 1.04±0.28, 0.58±0.10, 1.00±0.15, 0.86±0.23, 
1.30±0.28, 1.29±0.27, 0.76±0.18) during the course of radiotherapy. For one 
patient, the overall lung ventilation improved in the ipsilateral lung and the 
ratio of ipsilateral to contralateral LVL decreased from 2.0 to 0.7 during the 
course of radiotherapy. 
Conclusions: Our results demonstrate that lung ventilation does not change 
significantly during radiotherapy except for one patient. For this patient, the 
contralateral lung compensated for the poor response of the ipsilateral lung. 
While 4D-CT can give quantitative measurements of lung ventilation, this 
method is sensitive to 4D artifacts owing to irregular breathing. Further analy-
sis is needed to characterize the robustness of using 4-CT to quantify lung 
ventilation.
Author Disclosure Block: B. Teo: None. M. Grupp: None. M. Kirk: None. 
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Influence of 18F-FDG PET on Radiation Treatment Decision 
in patients with Non Small Cell Lung Cancer
D. Scepanovic1, A. Masarykova1, M. Pobijakova1, P. Bires1, P. Povinec2, 
1National Oncology Institute of Slovakia, Bratislava, Bratislava, Slovakia, 
2BIONT PET Center, Bratislava, Slovakia
Purpose/Objective(s): The purpose of our study was to analyze the influ-
ence of preradiotherapy 18F-FDG PET (Positron Emission Tomography with 
[18F] fluoro-2-deoxy-D-glucose) when deciding whether radiotherapy should 
be curative or palliative in patients with non-small cell lung cancer (NSCLC) 
referred for three dimensional conformal radical radiotherapy (3DCRT). 
Materials/Methods: Twenty five patients with inoperable stages I, II, IIIA, 
IIIB or recurrence of NSCLC on computed tomography (CT), referred for 
radical 3DCRT, underwent both 18F-FDG PET and CT simulation proce-
dures on the same day, in radiation treatment position. In deciding the initial 
treatment strategy, the radiation oncologist and medical physicist produced 
a treatment plan based on the contrast-enhanced CT. FDG PET images were 
analyzed by the associated nuclear physicians. If FDG PET showed distant 
metastases the previous radiotherapy was changed from curative to paliative. 
Results: Between February 2011 and February 2012, 25 non-small cell lung 
cancer patients referred for radiotherapy were included in the prospective 
study. Induction chemotherapy had been performed in 20 patients (80%). The 
prechemotherapy workup did not include 18FDG PET. In four patients (16%), 
the recommended dose of at least 60 Gy could not be achieved because of 
distant metastases were diagnosed by 18FDG PET. In these patients 18FDG-
PET information changed management strategy from radically to paliative. 
Also, the information provided by 18FDG-PET would have contributed to a 
substantial reduction of the PTV in 68% patients. 
Conclusion: The additional 18FDG PET data led to a modification of the 
planned radiotherapy strategy or to changes in the detail of planned radio-
therapy in 84% patients. In our experience, the addition of preradiotherapy 
18FDG PET led to better selection of those patients who need radically 
3DCRT.
Author Disclosure Block: D. Scepanovic: None. A. Masarykova: None. M. 
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Combined Lung Resection VS Pneumonactomy in the 
Combined Treatment of Resectable Stage IIb and III Non-
Small-Cell Lung Cancer
M. Mironchenko1, A. Vazhenin2, A. Lukin2, E. Manzhirev2, Y. Gnatyuk2, S. 
Timofeev2, 1Chelyabinsk Regional Oncology Clinic, 2Chelyabinsk Regional 
Oncology Clinic, Chelyabinsk, Russian Federation
Purpose/Objective(s): To evaluate whether combined lung resection and 
adjuvant radiotherapy could improve survival in respectable stage IIb, and 
III NSCLC 
Materials/Methods: Retrospective comparison of parallel groups of patients 
was carried out. It included 135 patiens with IIb, III stage NSCLC. Each 
patient was carrid out the combined lung resection or pneumonectomy. All 
patients were divided into 4 groups. Group A consist of patients being per-
formed only pneumonectomy (n=60), group B consist of patients undergo 
pneumonectomy and adjuvant radiotherapy (n=32). The group C included 
patients with combined lobectomy/combined bilobectomy (n=24), and group 
D included patients who were performed combined lobectomy/combined 
bilobectomy and adjuvant radiotherapy (n=19). The mean age of patients was 
56+7,8 years old, 33,3 % of patients of researched group were at elderly/
senile age. The stage IIb occured more often, composet 48,1 %. The stage 
IIIа occured in 38,5 % of cases. The smallest percentage (13,3) was in stage 
IIIb. The right lung has been affected in 61 patient (45,2 %), while the left 
lung was impaired in 74 patients (54,8 %). The superior portion of the left 
lung was affected in 53 cases (39,3 %), the right main bronchus was involved 
less often, in 1 case (0,7 %). The central cancer was seen at 102 patients (75,6 
%). Peripheral cancer has seen in 24,4 % of cases. Histologic forms of squa-
mous cell seems to prevail among the other forms (102 cases - 75,6 %). There 
were 92 pneumonectomy (68,1 %), 39 combined lobectomy (28,9 %) 4 com-
bined bilobectomy (3 %). Among them 25,2 % expanded operations, 34,1% 
expanded and combined operations, 28,1 % - combined resections and 12,6 
% - typical pneumonectomy. The most often type of the combined operations 
was vasculoatrial - 51 % (53 resections). Parietalodiaphragm resections were 
preformed less often - 13 % (13 resections). There was preformed 36 % of 
tracheobronhoplastycal resections. In general 103 resections of the thoracic 
cavity have been preformed. 
Results: Postoperative Morbidity was 4,4 % (p =0,049). It has occured only in 
group A, surgical treatment, included pneumonectomy. Postoperative compli-
cations was 18,5 %. There was 14,8 %, after the pneumonectomy executing, 
and 3,7 % after the perform of combined lobectomy (p=0,03). Survival rate in 
group A: at 1year: 57,2 %, at 3 years - 24 %, at 5 years - 21,2 %. In group B 
1, 3 and 5-years survival was 62,5 %, 34,4 % and 25 % accordingly. In group 
C, at 1 year survival was 69,7 %, at 3 years - 39,2 %, and at 5 years - 26,1 
%. Results of treatment of patients of group D it is a little bit better, than in 
the previous groups. At 1 year survival was 76 %, at 3 year - 40 %, and at 5 
years - 26,3 % (p> 0,05). 
Conclusions: The postoperative complications rate of combined lobectomy is 
3,7%. There is not postoperative morbidity.
Author Disclosure Block: A. Vazhenin: None. A. Lukin: None. E. 
Manzhirev: None. Y. Gnatyuk: None. S. Timofeev: None.
S298 Copyright © 2012 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 7, Number 9, Supplement 4, September 2012
1039  
Stereotactic Body Radiation Therapy (SBRT) for 
Oligometastases to the Lung: Initial Outcome and Toxicity 
Analysis
U. Goyal, S. A. Vora, J. B. Ashman, E. Clouser, D. E. Jaroszewski, A. C. 
Dueck, H. J. Ross, H. Paripati, L. Wesselius, S. E. Schild, Mayo Clinic 
Arizona, Phoenix, AZ
Purpose/Objective(s): To review early outcome and toxicity data from 
patients with oligometastatic cancer to the lung treated with SBRT. 
Materials/Methods: This retrospective review comprised all Mayo Clinic 
Arizona patients treated with SBRT for oligometastatic lesions to the 
lung between 3/2008-5/2010. Lung metastases were diagnosed based 
on biopsy where possible or by clinical history/radiologic studies where 
risks of biopsy were prohibitive. Radiation dose was prescribed to a 5 
mm PTV based on the ITV constructed from a 4D CT scan. The most 
common dose/fractionation schedules were 48-50 Gy over 4-5 treatments 
delivered twice weekly using 6 MV arcs or multiple non-coplanar fields 
with pretreatment imaging. Follow-up history and physical, CT imaging 
and toxicity evaluation occurred every three months. Toxicity was scored 
based on CTCAEv4. 
Results: Thirty-four patients with thirty-nine lesions had a median follow 
up of 11 months (range 1.7-39.2 mos.). Primary sites included lung (44%), 
head and neck (15%), colorectal (12%), melanoma (9%), sarcoma (3%), 
bladder (3%), and other (15%). For nine patients (26%) the treated site was 
the only site of oligometastatic disease. Seventeen patients (50%) had other 
sites of lung metastasis and eight patients (24%) had extrathoracic meta-
static disease. The median tumor size was 2.6 cm with 31% located centrally 
and 69% located peripherally. Median age was 71 yrs. Of the 39 lesions, 
34 (87%) lesions remained controlled (82% 1-year actuarial local control). 
One-year survival was 62% (95% confidence interval [CI] 42-77%) and was 
not statistically significantly different between patients with and without 
extrathoracic metastatic disease. One-year progression-free survival (PFS) 
was 9.8% (95%CI 1.8-26%). Median PFS was 9.8 mos for patients with the 
treated site as the only site of oligometastatic disease; 5.0 mos for patients 
with other sites of lung metastasis; and 3.0 mos for patients with meta-
static disease outside the chest (p=0.17). Toxicities included Grade 2 fatigue 
(5.9%) and Grade 2 pneumonitis (2.9%), but no grade ≥3 toxicities were 
observed. 
Conclusions: Stereotactic body radiation therapy is a well tolerated treat-
ment option for patients with oligometastatic cancer to the lungs. Treatment 
achieved high local control with very low toxicity. The risk of developing 
progressive disease outside of the treated lesion was significant, particularly 
for patients with other known sites of metastatic disease. Further study is war-
ranted to determine which patients benefit from this therapy.
Author Disclosure Block: U. Goyal: None. S.A. Vora: None. J.B. Ashman: 
None. E. Clouser: None. D.E. Jaroszewski: None. A.C. Dueck: None. H.J. 
Ross: None. H. Paripati: None. L. Wesselius: None. S.E. Schild: None.
1040 
Long Term Outcome After Minimal Invasive Thymectomy For 
The Treatment Of Stage I And Ii Thymoma: A Propensity-
matched Study
y. Chao, Y. Liu, Chang Gung memorial hospital, Taoyuan, Taiwan
Purpose/Objective(s): Video assisted thoracoscopic surgery(VATS) for thy-
moma remains controversial. The objective of the present study was to evalu-
ate the feasibility of VATS thymothymectomy for the treatment of stage 1&2 
thymoma and to compare the outcomes with those after open resection 
Materials/Methods: Using a propensity score based on 4 variables ( 
Myathesia Gravis, Masaoka stage, tumor size on CT scan, patient age), 48 
patient pairs were matched and followed for time-related events. Outcome 
comparisons included hospital complications,length of stay, tumor recurrence 
and survival 
Results: Of the 96 patients, 34 underwent thymectomy for stage I and 62 
for stage II thymoma. 52 patients had myasthesia gravis. There were 48 men 
and 48 women (median age, 50 years; range, 16-82 years). The mean tumor 
size on CT scan was 5.78 and 5.81 cm in VATS and open group,respectively. 
There was no operative mortality in both group and median length of hospital 
stay was shorter in the VATS group (5.8 days) than in the open group (7 days) 
(P=0 .008). The number of patients undergoing adjuvant radiotherapy were 
also comparable in both surgical groups. With the median follow-up was 53 
months, no significant differences were found in overall 5-year survival rates 
(92 % vs. 100 %, P>0.05 ) between the two groups. 
Conclusions: VATS for stage I&II thymoma appears safe and feasible and 
was associated with a shorter hospital stay. The oncologic outcomes were 
comparable in the open and VATS groups during intermediate-term follow-up.
Author Disclosure Block: Y. Chao: None. Y. Liu: None.
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MGMT Methylation Enhances Response to Temozolomide 
Treatment in Esophageal Cancer
R. Hasina, I. Kawada, R. Kanteti, A. N. Husain, V. M. Villaflor, M. K. 
Ferguson, E. E. Vokes, R. Salgia, The University of Chicago, Chicago, IL
Purpose/Objective(s): Esophageal cancer is a growing epidemic with 
approximately 460,000 new diagnoses and 380,000 deaths worldwide 
(Jemal, Cancer statistics 2011; Kamanger F, Patterns of Cancer, JCO 2006). 
In the western world adenocarcinoma has increased in incidence, while in 
east Asia and developing countries squamous cell carcinoma (SCC) remains 
problematic. These distinct histologies are often classified and treated simi-
larly but have different risk factors and clinical courses. Cytotoxic alkylat-
ing agents such as platinum compounds are often used to treat esophageal 
cancer, however, newer alkylating agents have very little data in the treat-
ment of esophageal cancer but are useful in treatment of other malignan-
cies. The efficacy of alkylating agents is is reduced in the presence of the 
DNA repair gene MGMT, which rapidly reverses the formation of adducts 
at the O6 position of guanine, thereby averting the formation of lethal cross-
links. Thus, a significant relationship exists between MGMT activity and 
resistance to alkylating drugs. Epigenetic silencing of the MGMT gene by 
promoter hypermethylation is associated with loss of MGMT expression and 
diminished DNA repair activity, leading to loss of the drug resistance phe-
notype in the tumor. 
Materials/Methods: We utilized archived esophageal cancer patient samples 
and esophageal cancer cell lines to evaluate MGMT hypermethylation status, 
and carried out in vitro studies to determine sensitivity to the alkylating drug 
Temozolomide (TMZ). In vivo studies were also carried out to demonstrate 
that MGMT hypermethylated tumors indeed respond to TMZ. 
Results: 71% (12/17) of adenocarcinoma and 38% (3/8) of SCC patient 
samples were MGMT hypermethylated. Out of 4 adenocarcinoma and 9 SCC 
cell lines tested, one of each histology was methylated. Immunoblot analyses 
confirmed that hypermethylated cell lines did not express the MGMT pro-
tein. In vitro cell viability assays showed the methylated Kyse-140 and FLO 
cells to be sensitive to TMZ at an IC
50
 of 52-420 µM, whereas unmethylated 
cells Kyse-410 and SKGT-4 did not respond. In an in vivo xenograft tumor 
model, four doses of TMZ treatment abrogated growth of Kyse-140 tumors. 
Conclusion: MGMT methylation and targeting by TMZ may be important in 
subsets of esophageal tumors and potentially could be utilized to successfully 
treat many patients.
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Utilization of a Novel Thoracic Oncology Database to Capture 
Imaging in Evaluation of Chemotherapy Response in Patients 
with Malignant Pleural Mesothelioma
G. B. Carey1, S. Kazantsev2, M. Surati3, N. Bahroos4, B. Raumann1, A. 
Starkey1, A. N. Husain1, S. Armato1, H. L. Kindler1, R. Salgia1, 1University of 
Chicago, Chicago, IL, 2Pritzker School of Medicine, Chicago, IL, 3University 
of Michigan, Ann Arbor, MI, 4University of Illinois at Chicago, Chicago, IL
Purpose/Objective(s): Many efforts have been made to develop informatics 
infrastructures that enable the oncology community to better utilize cancer 
imaging. These efforts have produced improved informatics tools, but they 
have yet to address certain deficit areas in cancer imaging. One of these 
areas of need is a database infrastructure that allows researchers to effec-
tively store and use images for the purposes of translational cancer research. 
We have sought to meet this need by implementing a novel tandem database 
infrastructure. 
Materials/Methods: We had previously implemented the relational Thoracic 
Oncology Program Database Project (TOPDP) database using Microsoft 
Access, which acts as a comprehensive data store for our translational 
research data but is impractical for image storage. To remedy this deficit, we 
developed the Thoracic Oncology Research Program (TORP) imaging data-
base to work alongside the TOPDP database using the Research Electronic 
Data Capture (REDCap) platform created by Vanderbilt University. In order 
to show proof of principle, we utilized the above database infrastructure to 
undertake an investigation into tumor response in patients diagnosed with 
malignant pleural mesothelioma (MPM) and treated with one of two simi-
lar chemotherapy regimens (cisplatin with pemetrexed and carboplatin 
with pemetrexed). Radiological images were obtained from our institution’s 
Human Imaging Research Office (HIRO) and assessed using in-house image-
visualization software. 
Results: At the time of the investigation, the TOPDP database contained 129 
consented MPM patients. Of these 129, a cohort of 22 qualifying patients 
was identified. Clinical data stored in the TOPDP database were transferred 
to the TORP database. For each patient, representative images from pre- and 
post-treatment CT scans were selected and successfully stored in the TORP 
database. In addition, up to 35 histological images per patient were stored in 
the TORP database. 
Conclusion: The TOPDP and the TORP databases both possess unique 
strengths and weaknesses. Consequently, it was decided to utilize these data-
bases in conjunction with one another. While it requires additional effort to do 
so, the resulting database infrastructure enables more comprehensive transla-
tional research.
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ERCC1 is a Prognostic Marker in Malignant Pleural 
Mesothelioma
U. Miglio1, R. Mezzapelle1, O. Rena2, R. Buosi3, O. Alabiso3, C. Casadio2, R. 
Boldorini1, 1Division of Pathology, Department of Health Sciences - University 
of Eastern Piedmont, Novara, Italy, 2Thoracic Surgery Unit, Department of 
Health Sciences - University of Eastern Piedmont, Novara, Italy, 3Division 
of Oncology, Department of Translational Medicine - University of Eastern 
Piedmont, Novara, Italy
Purpose/Objective(s): Malignant pleural mesothelioma (MPM) is an aggres-
sive tumour, with a median survival of 12 months. The current standard of 
care includes the use of platinum compounds and antifolate first-line chemo-
therapy, and in some cases surgery and radiotherapy. Despite these efforts the 
prognosis of MPM is still bad. Therefore, the identification of markers that 
could predict the response to platinum compounds and antifolate therapy is 
mandatory in order to maximize therapeutic efficacy. Platinum compounds 
act by forming DNA adducts; their removal by the action of nucleotide exci-
sion repair system, lead to chemoresistance. The main effector of this system 
is the Excision Repair Cross Complementing Group 1 (ERCC1). The antifo-
late drug, Pemetrexed, interacts with DNA synthesis inhibiting Thymidylate 
Synthase (TS), that is also involved in ex novo synthesis of DNA. In this ret-
rospective study, we analyzed ERCC1 and TS protein expression by immuno-
histochemistry (IHC) in a series of MPM in order to evaluate their predictive 
role in the standard treatment of MPM. Moreover, mRNA levels of ERCC1 
were also investigated and compared with the results obtained by IHC in order 
to identify the best method to predict drug response. 
Materials/Methods: Pleural samples were collected from 42 consecu-
tive patients with an histologic diagnosis of MPM between 2009-2010. 
Hematoxylin-Eosin stained slides were revised to select the tumour area. 
Average patients age was 69.8 years (range: 49-91), 29 (69%) were male. 
Histological subtypes were: epithelioid (n#33, 78%), sarcomatous (n#4, 10%) 
and biphasic (n#5, 12%). After 24 months of follow up 22 patients were died 
and 20 alive (average overall survival (OS) 13.7 months; range 1-24). IHC 
was performed with mAb antiERCC1 and mAb antiTS. mRNA was extracted 
from paraffin-embedded blocks and retrotranscripted in cDNA. Gene expres-
sion assay for ERCC1 was performed by Real-Time PCR. The results of IHC 
were scored from 0 to 3 depending on percentage of stained cells and intensity 
of staining for both antibodies as previously reported (H-Score - Olaussen et 
al. 2006). The results were compared with the status of each patient (dead/
alive) by means of Fisher’s exact Test and with OS using Log-rank test. 
Results: Thirty-six patients were treated with platinum-based and Pemetrexed, 
used as single or in combination. Six did not have any therapies. TS protein 
expression and ERCC1 mRNA levels had no correlations with patient sta-
tus and OS, whereas the comparison between ERCC1 protein expression and 
both patient status (P<.05) and OS (P<.05) was statistically significant when 
H-score was < 1.5.
Conclusions: ERCC1 by IHC seems to be a prognostic factor for the OS in 
MPM patients, and might predict who is more likely to benefit from platinum-
based chemotherapy.
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Management Of Malignant Mesothelioma With Tomotherapy 
Hi-art: Image-guided Intensity Modulated Helical Radiation 
Therapy
J. Aguirre, CIMA, Chihuahua, Mexico
Introduction: Malignant mesothelioma is a tumor that typically appears in 
people exposed to asbestos. In the United States, The management of these 
patients is controversial, and surgery is the best choice in the early stages of 
the disease, but a multimodal approach combining chemotherapy and radia-
tion therapy is an excellent choice. Purpose: To present the dosimetric distri-
bution achieved with a tomotherapy machine in the treatment of patients with 
malignant mesothelioma, and the results obtained both in palliation and in 
local disease control. This paper presents planning and treatment results for 
three patients with mesothelioma using the TomoTherapy technique with a 
TomoTherapy Hi Art machine, with which an adequate dose has been used to 
control the tumor while protecting healthy lung and heart tissue. 
Materials/Methods: A simulation was performed on 3 patients using a 
Philips Brilliance 64 CT scanner, with a 3 mm slice thickness and 3 mm 
spacing, covering an area of 53 cm from the base of the skull to below the 
diaphragm; a thoracoabdominal fixation device was used. The resulting CT 
scan images were exported to a contouring and virtual simulation system, 
Focal CMS v. 4.0, where GTV volumes were contoured per pleural tumor 
with positron emission tomography, PET-CT; from these volumes, the PTVs 
were contoured with margins of up to 1.5 cm depending on the area involved. 
S300 Copyright © 2012 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 7, Number 9, Supplement 4, September 2012
Planning was performed in the Hi Art v. 3.1.5.3 system, so as to cover at least 
95% of the PTV with the prescribed dose of 54 Gy in 30 fractions. Patients 
were selected as unresectable or progression with chemotherapy (Platino, 
Pemetrexed, Taxanos) in an average time greater than 9 months. 
Results: Planned coverage was achieved at 95% of the PTV with the pre-
scribed dose of 54 Gy (in 30 fractions) given in two stages: 1 st stage up to 
45 Gy (Fig. 1) and 2 nd stage up to 54 Gy. The maximum dose to the PTV 
was 106% and the minimum dose was 95%. The resulting dose distribution 
(Fig. 2), analyzed in the dose-volume histogram in Fig. 1, easily complies with 
the tolerance tables for organs at risk recently published by QUANTEC. At 6 
months post-treatment, patients have appropriate palliation, no pain and have 
disease control. One of the patients developed a contralateral progression and 
is undergoing chemotherapy. Pulmonary and cardiac toxicity was RTOG grade 
I-II. 
Conclusions: Using tomotherapy, patients diagnosed with malignant meso-
thelioma were treated with excellent results both in local control and symptom 
palliation with no pulmonary or cardiac toxicity impact. The resulting dose 
distribution is highly conformed, with appropriate coverage for the planned 
volume while providing protection to the organs at risk that is superior to that 
of other IMRT radiation therapy machines.
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High and Durable Complete Response to Bleomycin, 
Etoposide and Cisplatin in Primary Mediastinal Seminomas
D. Callacondo1, J. Quesada-Olarte2, J. Rojas-Camayo1, S. Neciosup2, O. 
Rua-Fernandez3, E. Bravo-Rojas1, L. Mass-Lopez2, 1Universidad Peruana 
Cayetano Heredia, Lima, Peru, 2Instituto Nacional de Enfermedades 
Neoplásicas, Lima, Peru, 3Médicos de Vida del Perú, Lima, Peru
Purpose/Objective(s): Current treatment for primary mediastinal seminoma 
(PMS) is based from data on advanced testicular seminomas using standard 
bleomycin, etoposide and cisplatin (PEB). Our objective was to evaluate the 
results in patients with bulky PMS at our referral center. 
Materials/Methods: Clinical data of 37 patients with PMS who received 
first line cisplatin based chemotherapy between 1990 and 2010 were ana-
lyzed. All patients had a histological proven pure seminoma, absence of 
retroperitoneal or testicular tumors, and normal serum AFP levels. The 
response rates were evaluated by imaging and confirmed by pathology when 
applicable. Kaplan-Meier method and the Cox regression model were used 
for survival analysis. 
Results: The mean age was 26.5 years (range 15 - 67). 35 patients (95%) 
had an anterior mediastinal location and 2 had a posterior location. The 
mean tumor size was 12.1 cm (range 6 - 24). 11 patients (30%) had extra-
mediastinal disease: 9 (24%) had supraclavicular and/or cervical lymph 
node (SCLN) involvement, 3 had lung metastases, and another 3 had liver 
or bone metastases. 10 patients (27%) presented with elevated beta-HCG 
levels (mean 24 ng/mL, range 6 - 99.1), and 31 patients (84%) with high 
LDH levels (mean 1093 U/L, range 262-4741). 26 patients (70%) received 
PEB (4 cycles [n=20, mean tumor size 12.9 cm], 3 cycles [n=4, mean 
tumor size 9.5 cm], 1 progressed in cycle 1). 7 patients received cyclo-
phosphamide and cisplatin (CP) because PEB was not available (4 cycles 
[n=5], 3 cycles [n=1], and 1 progressed in cycle 2). 4 remaining patients 
(11%) received 4 cycles of bleomycin, etoposide, cisplatin and ifosfamide 
(PEI-Bleo). 18 patients (49%) underwent post-chemotherapy resections of 
residual masses. Fibrosis/necrosis was found in 17 patients; viable semi-
noma in 1. This patient had a R1 resection, two more cycles of PEB, and 
adjuvant cervico-mediastinal radiation. The mean follow up was 9.5 years 
(range 2 - 20). 33 patients (89%) achieved complete response (CR) to 
chemotherapy alone. The CR rate was 100% for PEI-Bleo, 88% PEB, and 
86% CP. Both patients (PEB=1 and CP=1) who progressed during initial 
therapy died with progressive disease. 4 patients had relapse (PEB=1 and 
CP=3). The 10 year overall survival/progression free survival rates were: 
100%/100% for PEI-Bleo, 96%/96% PEB, and 86%/57% CP. Single-site 
recurrence occurred in 2 patients: one in the mediastinum, one in the lum-
bar spine. 2 patients relapsed in multiple sites: one with mediastinal + 
SCLN, one with mediastinal + SCLN and lung. Age, initial size of medi-
astinal mass, pre-chemotherapy HCG or LDH levels were not predictors 
of relapse. 
Conclusions: Patients with PMS achieved >95% survival with 3 or 4 cycles 
of PEB regimens. Disease progression while on treatment is rare. PEB was 
well tolerated and there were no significant pulmonary toxicity.
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Tumor-stroma Ratio is an Independent Predictor for Survival 
in Esophageal Squamous Cell Carcinoma
Y. Cheng, K. Wang, W. Ma, J. Wang, Oncology Center, Qilu Hospital of 
Shandong University, Jinan, China
Purpose/Objective(s): Tumor-stroma ratio (TSR) has been identified as a 
new and practicable prognostic histological characteristic of solid tumors. 
The aim of this study was to evaluate the prognostic value of TSR in resected 
esophageal squamous cell carcinoma(ESCC). 
Materials/Methods: A total of 95 patients who underwent esophagectomy 
for ESCC were included in this study. TSR was assessed visually on the 
Haematoxylin-Eosin (H&E) stained tissue sections of surgical specimens by 
two independent observers. Patients with more than 50% intra-tumor stroma 
were quantified as stroma-rich group and those with less than 50% as stroma-
poor group. 
Results: No significant differences were observed in patient, tumor and treat-
ment characteristics between stroma-rich and stroma-poor groups. The 3-year 
overall survival rate and disease-free survival rate were 64% and 57% in the 
stroma-poor group, and 23% and 23% in the stroma-rich group, respectively. 
Both 3-year overall and disease-free survival rates in the stroma-poor group 
was significantly better than those in the stroma-rich group(P <0.01). In a 
multivariate analysis, TSR was identified as a highly significant prognostic 
factor for 3-year overall survival (HR 3.450; P = 0.001) and 3-year disease-
free survival (HR 2.995; P = 0.001), independent of pTNM stage and radical-
ity of the primary tumor. 
Conclusions: Stroma-rich tumors were associated with poor prognosis and 
an increased risk of relapse, which may serve as a new prognostic histological 
characteristic in ESCC.TSR is simple and quickly to determine and reproduc-
ible, and could be easily incorporated in routine histological evaluation.
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Tumor Response after Small Dose of Chemoradiotherapy in 
Patients with Esophageal Carcinoma
N. Kobayashi, R. Mikami, H. Nakayama, S. Nogi, Y. Tajima, M. Okubo, N. 
Kanesaka, S. Sugahara, K. Tokuuye, Tokyo Medical University, Shinjyuku, 
Japan
Purpose/Objective(s): The outcomes of surgery for patients with esophageal 
cancer of T3 or more are poor. To improve the outcomes, we have been per-
forming preoperative chemoradiotherapy since 2002. We aimed to retrospec-
tively investigate tumor response at the time of surgery and overall survival 
after chemoradiotherapy followed by surgery in patients with squamous cell 
carcinoma of the esophagus. 
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Materials/Methods: Between May 2002 and June 2011, 37 consecutive 
patients with clinical T3 or T4 esophageal cancer who underwent chemo-
radiotherapy followed by transthoracic esophagectomy at Tokyo Medical 
University were assessed. All patients were histologically confirmed to have 
squamous cell carcinoma before treatment. Radiation dose of 30 Gy in 15 
sessions were delivered concurrently with cisplatin and 5-fluorouracil for all 
patients. Clinical target volume (CTV) was determined as gross tumor vol-
ume and elective node volume. Clinical stage was defined according to 7th edi-
tion of American joint committee on cancer. Tumor response was evaluated by 
a specimen of surgical resection. 
Results: The median age was 64 years ranging from 43 to 77. The patient 
number of clinical stage IIA/IIB/IIIA/IIIB/IIIC were 2/1/23/7/4, respectively. 
Patients tolerated the treatment well. The median duration between completion 
of chemoradiotherapy and surgery was 1.2 months ranging from 0.9 to 2.3. 
After chemoradiotherapy, 26 patients (70%) were observed to have a reduction 
of clinical stage and six patients (16%) observed to have pathological com-
plete response. The number of microscopically complete (R0) / microscopi-
cally positive margin (R1) / macroscopically positive margin (R2) resections 
were respective 33 / 3 / 1. Median follow-up period was 22.5 months ranging 
from 3.0 to 78.9. Two-year progression free survival and overall survival were 
62.1% (95% confidence interval [CI], 45.8 to 78.4) and 85.5% (95% CI, 55.1 
to 88.7), respectively. Overall and progression free survival of patients with 
pathological stage II was significantly better than those of stage III (P = 0.01, 
P = 0.03, respectively). Statistically significant prognostic factors for overall 
survival were age (hazard ratio 6.6; 95% CI, 1.1 to 38; P = 0.04) and pathologi-
cal T factor (hazard ratio 10.2; 95% CI, 1.4 to 77; P = 0.02). No deaths were 
caused related to surgery. Conclusions: Radiotherapy dose of 30 Gy combined 
with the chemotherapy achieved a reduction of stage in 86% of patients while 
it did not increase risk of complication. Tumor response after the chemoradio-
therapy was an important prognostic factor for overall survival.
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Characteristics Of The Lymph Node Metastases And 
Their Affect In Target Region Delineation In Prophylactic 
Postoperative Radiotherapy For Thoracic Esophageal 
Carcinoma
S. Zhu, Y. Li, W. SHEN, J. LI, J. Su, Z. Liu, S. Li, The Fourth Hospital of 
Hebei Medical University, Shijiazhuang, China
Purpose/Objective(s): The aim of this was to explore the distribution of 
lymph node metastases, to analyze the clinical-pathologic influence factors 
of thoracic esophageal carcinoma after curative resection, and to provide 
the criteria of irradiated region delineation in prophylactic postoperative 
radiotherapy. 
Materials/Methods: Between June 2002 to June 2006, 763 patients (male 
526, female 237, median age 59 years) with esophageal carcinoma received 
definitive resection in our Hospital were included in this retrospective study. 
Primary tumors were located in upper- (116), middle- (464), lower-thoracic 
(175) esophageal and once more lesions (8) in esophageal , and 713 cases 
(93.4%) were squamous cell carcinoma. Statistical methods of x2 test or 
Fisher’s were used to evaluate the rate of regularity in lymph node metastases 
and multivariate Logistic Regression Model to analyze clinical-pathological 
factors with SPSS l3.0 software. 
Results: Of the 763 patients, a total of 5846 lymph nodes were dissected with 
an average of 7.7 lymph nodes in each case.Metastatic lymph nodes were 71l, 
the ratio of metastatic lymph node was 12.2%, and 297 patients had positive 
lymph node, the rate of lymph node metastasis was 38.9%. The metastatic 
lymph nodes of upper-thoracic were mainly observed in supraclavicular and 
paratracheal regions(P<0.05), the middle-thoracic were bidirectional, and 
those of the lower-thoracic esophagus mainly metastasized to regions adja-
cent to esophagus,gastric cardia and gastric artery(P<0.05). Both the ratio and 
the rate of metastasis lymph nodes adjacent to gastric artery in lower-thoracic 
esophageal carcinoma were significantly higher than those in middle- and 
upper- thoracic esophageal(P=0.007,P=0.001). The multivariate factors logistic 
regression analysis showed that tumor length,depth of tumor invasion,vascular 
tumor emboli and distant metastasis were major factors for lymphatic metas-
tasis (P<0.01). For the all patients the lymph node metastatic rate was 28.5%in 
upper-thoracic, significantly lower than 38.8%of lower-thoracic (P=0.039) 
and 43.4%in middle-thoracic esophageal carcinoma(P=0.010). However, the 
lymph node metastatic rates were 37.0%, 37.9% and 41.4% in upper-, middle- 
and lower-thoracic esophageal carcinoma of the 592 patients receiving left 
chest notches, with a non-significant difference among them(P=0.715). 
Conclusions: The lesion length, depth of tumor invasion, vascular tumor 
embolus and distant metastasis are the most important factors for lymph 
node metastases. Operative modality have obvious effect on the distribution 
of regional lymph node metastases. Therefore, the irradiated range region 
of postoperative prophylactic radiotherapy may be selected according to the 
regularity of lymph node metastasis.
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Whole Brain Irradiation Induced Decrease of Histone H3 
Acetylation in Hippocampus of Rats
S. Ji, R. Sun, L. Zhang, Y. Tian, The Second Affiliated Hospital of Soochow 
University, SuZhou, China
Purpose/Objective(s): The aim is to investigate the role of epigenetics in 
the irradiation-induced cognitive deficiency by observing the alterations of 
histone acetylation in the hippocampus of rats after irradiation. Materials/
Methods: A signal dose of 2Gy and 30Gy 4MV electron beam were given 
to adult male Sprague-Dawley rats (150-200g, 4-5 weeks), this dose covered 
a dose range of clinical and experimental applications, and the animals were 
divided into 2Gy group, 30Gy group, and control group. After whole brain 
irradiation, the total protein was extracted from irradiated hippocampus and 
whole brain 30µm cryosections were cut by using a cryostat at day 7 and 
day 30. Western blot was performed and the brain sections were immunohis-
tochemical stained. The alterations of histone H3 acetylation was observed 
and analyzed. To evaluate the consequence of whole brain irradiation on hip-
pocampus-dependent memory formation, Morris water maze test, passive-
avoidance test and open field test were performed. 
Results: We show that both 2Gy and 30Gy 4MV electron beam whole brain 
irradiation induced significant decrease in histone H3 acetylation and dif-
ferent alterations of histone deacetylases (HDACs) in the hippocampus. We 
found a 25% reduction in histone H3 acetylation at day 7 (P < 0.01) and 5% 
reduction at day 30 (P < 0.05) after 2Gy irradiation. Compare to control, 30Gy 
induced 5% reduction at day 7 and 13% reduction at day 30. Interestingly, 
we found that irradiation did not impair the expression of HDAC2, which 
has been indicated negatively regulates memory formation and synaptic plas-
ticity. However, HDAC1 was increased. In Morris water maze test, passive-
avoidance test and open field test, we confirmed whole brain irradiation lead 
to notable memory impairment at day 30 after irradiation. 
Conclusion: This study suggests that the alterations of histone H3 acetylation 
and HDACs after whole brain irradiation. Decreased histone H3 acetylation 
suggests altered hippocampal epigenetic signaling after whole brain irradia-
tion. These results indicate epigenetics was involved in irradiation-induced 
memory deficiency, and alterations in chromatin structure may be a new pos-
sible molecular correlation of irradiation-induced cognitive deficiency. This 
study was supported by the National Natural Scientific Foundation of China 
grants 30870740, 81172128 and 81102077.
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Outcomes of Patients with MPM following The Approval of 
Cisplatin/Pemetrexed: Experience of a Comprehensive Cancer 
Center
D. Jagtap, H. Pass2, M. Alvelo-Rivera1, F. Baciewicz1, A. Wozniak1, A. 
Konski1, S. Gadgeel1, 1Karmanos Cancer Center, Detroit, MI, 2NYU Langone 
medical center and School of medicine, New York, NY
Purpose/Objective(s): Mesothelioma is a rare cancer that is estimated to 
occur in about 2,500 people in the United States every year. MPM is the most 
common type of mesothelioma. Until 2003 there was no chemotherapeutic 
regimen approved for the treatment of MPM. The combination of cisplatin/
pemetrexed was approved based on improved survival in a randomized phase 
III study. We analyzed the data of all MPM patients treated at our center, 
since the approval of this combination, to evaluate the outcomes of these 
patients. 
Materials/Methods: This retrospective analysis included all patients with 
MPM evaluated at Karmanos Cancer Institute in Detroit, Michigan between 
2005 to 2010. We analyzed the demographic data, history of asbestosis expo-
sure, histology, clinical stage of diagnosis, treatment received and survival. A 
multiple Cox regression model was built on age, sex, histology, surgery or not 
and stage (I&IIvs.III&IV). 
Results: Fifty-four MPM patients were evaluated between 2005-2010. The 
median age of patients was 65 years, 70% were males, 74% had known his-
tory of asbestos exposure, 76% had epitheloid histology and 63% had stage 
III/IV disease at diagnosis. 78% of patients received pemetrexed based ther-
apy, 50% underwent pleural surgery (EPP-30%, Pleurectomy- 20%) and 37% 
received radiation therapy as part of the initial therapy. 21 patients underwent 
surgery following neo-adjuvant chemotherapy. 39% of patients went on to 
receive second line therapy. The median overall survival was 18 months (95% 
CI 14- 22). COX model analysis showed that patients with epitheloid histol-
ogy had a HR of 0.40, (p= 0.0168) and patients who were stage I/II had a HR 
of 0.42, (p = 0.0282). Surgery resulted in a HR of 0.66, but it was not statisti-
cally significant (p=0.2637). Age and sex were not significantly associated 
with survival. 
Conclusions: The median survival of MPM patients in this series was 18 
months. As expected epitheloid histology and early stage at diagnosis were 
associated with improved survival. Surgery did improve survival but this 
improvement was not statistically significant.
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Carcinoembryonic Antigen as a Predictive Factor for 
Recurrence After Stereotactic Body Radiotherapy in Stage I 
Lung Adenocarcinoma
K. Asai1, Y. Shioyama2, K. Nakamura1, T. Yoshitake2, T. Sasaki1, S. Ohga1, 
T. Nonoshita1, H. Hirata3, H. Honda1, 1Department of Clinical Radiology, 
Graduate School of Medical Sciences,Kyushu University, Fukuoka, Japan, 
2Department of Heavy Particle Therapy and Radiation Oncology, Graduate 
School of Medical Sciences,Kyushu University, Fukuoka, Japan, 3School of 
Health Sciences, Graduate School of Medical Sciences,Kyushu University, 
Fukuoka, Japan
Purpose/Objective(s): To clarify the usefulness of pretreatment measuring 
serum carcinoembryonic antigen (CEA) to predict prognosis among patients 
diagnosed stage I lung adenocarcinoma treated with stereotactic body radio-
therapy (SBRT). 
Materials/Methods: Forty-seven patients treated with SBRT for stage I lung 
adenocarcinoma between April 2005 and February 2011 at Kyushu University 
Hospital were enrolled in this study. In all patients, serum CEA level was 
measured before SBRT. Gender was male in 31 and female in 16 patients. 
Patient’s age was 56 - 92 (median; 78) yeas-old. T-stage was T1a in 11, T1b 
in 23 and T2a in 13 patients. Pretreatment serum CEA level ranged from 
1.1 to 213.4 (median; 3.6) ng/ml. SBRT was given using 7 - 8 non-coplanar 
beams with 48Gy in 4 fractions during 4-8 (median; 6) days. Overall survival, 
progression-free survival and local control rates were calculated according to 
the Kaplan-Meier method. Factors including age, gender, T-category, clinical 
stage, smoking history, and pretreatment serum CEA level were evaluated 
with regard to progression-free survival using the log-rank test and the Cox 
proportional hazards model. 
Results: Five-year overall survival, progression-free survival and local con-
trol rates were 73.8%, 63.6% and 84.2%, respectively, with a median follow-
up of 32 months. Patterns of failure were local failure in 6, regional failure 
in 5, and distant failure in 9 patients. In univariate analysis, female and lower 
pretreatment CEA level were significantly correlated with favorable out-
come in progression-free survival. There was no significant survival differ-
ence between stage IA and IB. Five-year progression-free survival in female 
and in the low-CEA (<4.3 ng/ml) group was 93.3% and 73.1%, respectively, 
whereas this value was 50.0% in male and 47.1% in the high-CEA (≥–4.3 ng/
ml) group. Multivariate analysis also demonstrated that gender and pretreat-
ment CEA level were significantly correlated with progression-free survival. 
The difference of progression-free survival between the low- and high- CEA 
groups was significant in stage IA (76.9% vs. 43.3% at 5 year, p=0.02) rather 
than in stage IB (75.0% vs. 61.0% at 5 year, p=0.98). 
Conclusion: The pretreatment serum CEA levels in addition to the gender 
can be a prognostic factor in patients with stage I lung adenocarcinoma 
treated with SBRT.
Author Disclosure Block: K. Asai: None. Y. Shioyama: None. K. 
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1052 
Early Outcomes and Toxicity in Patients Treated with 
Bimodality or Trimodality Therapy for Esophageal 
Carcinoma with Intensity Modulated Radiation Therapy 
(IMRT)
K. V. Kowalchik, G. Kim, E. Johnson, N. Paryani, S. Ko, Mayo Clinic Florida, 
Jacksonville, FL
Purpose/Objective(s): Patients with locally advanced esophageal carcinoma 
are recommended to undergo treatment with radiation and chemotherapy, 
which may be followed by surgery in appropriate operative candidates. 
Radiation has traditionally been delivered with 3D conformal radiation ther-
apy (3D CRT). This study is evaluating early outcomes and acute and late tox-
icity in patients treated with Intensity Modulated Radiation Therapy (IMRT) 
with concurrent chemotherapy. 
Materials/Methods: This is a retrospective review of 17 patients with esoph-
ageal carcinoma treated with IMRT and chemotherapy at Mayo Clinic Florida 
from 2008 - 2010. Pathology includes squamous cell and adenocarcinomas. 
Tumor sites include middle thoracic, lower thoracic and GE junction. Initial 
clinical stages are TX-T3, N0-3, M0-1. All patients received at least one cycle 
of concurrent 5-fluorouracil with either cisplatin or oxaliplatin. IMRT dose 
was 50.4 Gy in 28 fractions prescribed to a target volume which included the 
tumor and regional lymphatics. All IMRT plans utilized coplaner beams in a 
7-9 beam arrangement. 
Results: Median follow-up is 9 months (range 4-20). Median patient age is 72 
(range 55-87). Sixteen patients received 50.4 Gy via an IMRT plan, and one 
received 25.2 Gy. Trimodality treatment was completed in 11 patients (65%). 
Surgery was either esophagogastrectomy or minimally invasive esophagec-
tomy. Of the 11 patients who proceeded to surgery, 3 (27%) had a pathologic 
complete response, 7 (64%) had a partial response (PR) and 1 patient (9%) had 
stable disease. Of the 6 patients who received chemotherapy and IMRT alone, 
2 patients had a clinical PR, 1 had disease progression and 3 did not have fol-
low-up data available. In the initial 17 patients, there were no local or regional 
recurrences, though 2 patients developed distant metastases. Twelve patients 
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are alive at last follow-up. Of the 5 deaths, 2 were due to esophageal cancer, 1 
from radiation complications, 1 from chemotherapy complications and 1 from 
surgical complications. Acute CTCAE V4.0 grade 3 toxicities from concurrent 
chemotherapy and IMRT developed in the following patients: 2 esophagitis, 1 
fatigue, 1 nausea/vomiting, 4 dehydration, 1 anemia, 1 thrombocytopenia and 
5 neutropenia. Patients with grade 4 toxicities included 1 thrombocytopenia 
and 1 neutropenia. Four patients developed late grade 3 esophageal strictures. 
There was one grade 4 cardiac complication, and one grade 5 pleuro-esopha-
geal fistula. There were no cases of radiation pneumonitis or ulcers. 
Conclusions: IMRT is a feasible treatment modality which may be equally effi-
cacious to 3D CRT for the treatment of esophageal carcinoma, and may offer 
fewer treatment complications, including a lower incidence of pneumonitis.
Author Disclosure Block: K.V. Kowalchik: None. G. Kim: None. E. 
Johnson: None. N. Paryani: None. S. Ko: None.
1053 
Role of Radiation Therapy for Malignant Thymoma: A Single 
Institution Experience
A. Turaka, T. Li, W. J. Scott, H. Borghaei, P. C. Shah, M. K. Buyyounouski, 
Fox Chase Cancer Center, Philadelphia, PA
Purpose/Objective(s): To evaluate the benefit of radiation therapy (RT) fol-
lowing surgery for malignant thymoma and identify risk factors that may 
affect treatment related outcomes. 
Materials and Methods: We conducted a retrospective review of 34 patients 
(pts) with malignant thymoma treated between 1995-2010 at our institution. 
The clinico-pathological factors were reviewed for all pts including gender, 
WHO histology, modified Masaoka stage, presence of myasthenia gravis, size 
of the lesion, type & extent of surgery and margin status. Overall survival 
(OS), local relapse free (LRFS) and distant metastases free (DMFS) survival 
rates were estimated using Kaplan-Meier method. Cox’s proportional hazard 
regression model was used to assess the relationship of OS and LRFS with 
the risk factors. 
Results: Six of thirty-four were Masaoka stage IA-B, 11 stage IIB (32%), 
four stage III and 10 stage IVA. Median age was 58 years (range: 24-79). 
Myasthenia gravis was seen in 5 pts. Seventeen had large tumors (> 8 cm). 
WHO classification: type A five, AB five, B1 & B2 four patients each, B3 in 
11 and five pts had type C. R0 resection was done in 14 pts, R1 in 10 pts, R2 
in 3 and no surgery (biopsy only) in seven pts. Thirteen pts had positive mar-
gins. Adjuvant RT was given to 19 pts, 4 had preoperative RT and one pt was 
treated with definitive concurrent chemoradiation (stage IVA). Neoadjuvant 
chemotherapy was given to 10 pts (5 pts had Cyclophosphamide, Adriamycin, 
Cisplatin [CAP]; 3 pts Cisplatin, Etoposide [EP] and 2 pts Carboplatin, 
Paclitaxel). Four pts received adjuvant chemotherapy (2 CAP, 1 EP and 1 pt 
Carboplatin, Paclitaxel). Median follow up was 56 months (range: 4.1-248). 
The median RT dose was 5040 cGy (range: 4500-6600) with 180-200 cGy 
dose per fraction in 25-35 fractions over 42 days (32-69). The 5-year OS for 
patients with stage I was 66.7%, stage II 90%, stage III 75% and stage IVA 
41.7% (p= 0.02). The 5 yr LRFS was 100% for stage I, 91% stage II, 100% 
stage III and 65.6% stage IVA (p= 0.51). In a subset analysis for stage II pts 
treated with and without RT (N=11), the 5 yr OS, LRFS and DMFS rates 
were 100%, 50% (p= 0.04); 100%, 50% (p= 0.03) and 76%, 100% (p= 0.54) 
respectively. At last visit, 16 pts were disease free (47%), 3 pts had local 
recurrence (9%) and 12 developed distant metastases (35%). On Univariate 
analysis, OS varied with Masaoka stage (p= 0.02), WHO histology (p= 0.005) 
and size of the lesion (8 cm or more, p= 0.08). None of the other factors such 
as gender, myasthenia gravis, type & extent of surgery and margin status had 
an impact on OS, LRFS or DMFS. 
Conclusions: In this analysis, high risk pts based on Masaoka stage, WHO 
classification and bulky tumors (> 8 cm size) benefited from radiation therapy 
and use of RT should be strongly considered based on the risk factors particu-
larly for stage II pts.
Author Disclosure Block: A. Turaka: None. T. Li: None. W.J. Scott: None. 
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Definitive Chemoradiotherapy Using 3-field Extended 
Radiotherapy For T4M1Lym Squamous Cell Carcinoma Of 
The Thoracic Esophagus
M. Myojin1, M. Hosokawa1, N. Nishikawa1, H. Takahashi1, K. Ito1, 
S. Shimizu2, 1Keiyukai Sapporo, Sapporo, Japan, 2Hokkaido University 
School of Medicine, Sapporo, Japan
Purpose/Objective(s): To investigate the efficacy and toxicities of concur-
rent chemoradiotherapy (CRT)using 3-field extended radiotherapy (ERT) for 
locally advanced squamous cell carcinoma of the esophagus (SCCE). 
Materials/Methods: Two hundred- twelve patients (pts.) with thoracic SCCE 
initially assessed as unresectable or inoperable had been treated with defini-
tive CRT using 3-field ERT consecutively since 2006 to 2010 as a cohort. 
One hundred- twenty pts. of them who were defined retrospectively as T4M0 
and/or M1Lym in UICC 7th Staging System were analyzed for survival and 
toxicities in this study. All of the 120 pts. were diagnosed by PET-CT, CT, and 
GTF. EUS and MRI were optional in 85% and 66% of all, respectively. RT 
schedule was initiated with 50.4 Gy/ 28F/ 6 weeks of 3-field ERT involving 
SCF, thoracic, and abdominal lymphatics for all of the 120 pts. and followed 
by 9Gy/ 5F/ week of boost to localized tumors for 101 pts. of all. The concur-
rent chemotherapy regimen was 2 cycles of fractionated CDDP (20mg/m2, 
day 1-5) and protracted 5-FU (700mg/m2, day 1-5) with a 4-5 weeks interval. 
Acute and late toxicities were evaluated by CTCAE v. 4.0. 
Results: There were 100 pts. with T4Nx disease, 20 pts. with T1-3Nx, and 36 
out of 120 pts. with TxM1Lym. N staging distribution was 11 pts., 60 pts., 46 
pts. and 3 pts. for N0, N1, N2 and N3, respectively. Two cycles of concurrent 
chemotherapy was performed in 81% (104 pts.), one cycle in every other 
pts.. The 47 pts. (39%) achieved a complete response. Salvage surgery was 
followed to the loco-regional recurrence in 5 pts. (4%). Two-year and 4-year 
overall survival rates of all 120 pts. were 44% and 26%, respectively. The 
median survival time was 16 months. In the acute blood toxicities, WBC; 
Grade≥–3 was found in 63% of all and platelet; Grade≥–3 in 15%.However 
average protraction of the total treatment time was 7.2 days for protracted 
cases. Radiation pneumonitis Grade≥–3 was experienced in 5 pts. (4%), and 2 
of the 5 died of respiratory disease. Pleural effusion Grade 2 and Grade 3 were 
found in 2 pts. each. Pericardial effusion Grade 2 was found in 15 pts. (13%) 
but Grade 3 was not found. 
Conclusion: Although the role of 3-field ERT is not definite in the multi-
modality therapy for SCCE, we observed high efficacy of definitive CRT for 
unresectable SCCE cases by using 3-field extended field. Late toxicities must 
be observed more in long survivors.
Author Disclosure Block: M. Myojin: None. M. Hosokawa: None. N. 
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Is Use of Radiation Therapy for Stage II Malignant Thymoma 
A Controversy?
A. Turaka, T. Li, W. J. Scott, P. C. Shah, M. K. Buyyounouski, Fox Chase 
Cancer Center, Philadelphia, PA
Purpose/Objective(s): Use of adjuvant radiation therapy for stage II thy-
moma is controversial based on the published data. We evaluated if adjuvant 
radiation therapy (RT) following surgery for Masaoka stage IIB malignant 
thymoma is beneficial or not. 
Materials/Methods: We identified 34 patients (pts) with malignant thymoma 
treated between1995-2010 at our institution. The primary goal was to evaluate 
the necessity of adjuvant radiation therapy for stage II patients and also com-
pare the outcomes including local recurrence free (LRFS), distant metastases 
free (DMFS) and overall survival (OS) for those patients who were treated 
with and without RT after surgical resection. Univariate analysis was done 
to know the impact of risk factors like gender, WHO histology, myasthenia 
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gravis, size of the lesion, type & extent of surgery and margin status on the 
outcomes for Masaoka stage IIB patients treated with and without RT. 
Results: Of 34 pts, 11 belong to stage IIB (32%). Median age was 65 years 
(range: 36-79) and myasthenia gravis seen in 2 pts. R0 resection was done in 
4 pts, R1 in 4, R2 in 2 and no surgery (biopsy only) in one pt. Four pts had 
positive margins. Adjuvant RT was given to 9 pts and 2 pts did not receive 
RT. Median follow up was 75.79 months (range: 27.83-195.04). The median 
RT dose was 50.4 Gy (range: 45-66). Two pts were treated with adjuvant che-
motherapy (one with 3 cycles of Cyclophosphamide, Adriamycin, Cisplatin 
and second pt received 6 cycles of Carboplatin, Paclitaxel). The 5-year overall 
survival was 100% and 50% for pts treated with & without RT, p = 0.04. The 
5-year LRFS and DMFS rates were 100%, 50% (p= 0.03) and 76%, 100% (p= 
0.54) respectively for pts treated with & without RT. At last visit, one pt had 
local recurrence in the group treated without RT. In Univariate analysis, type 
of surgery (R0 vs. R1/2) was predictor of outcome for OS (p= 0.03) and LRFS 
(p= 0.04). WHO classification (p= 0.05) also had an impact on OS. Size of the 
lesion influenced the DMFS (p= 0.004). 
Conclusions: Patients with R1/R2 resection should be treated with adjuvant 
radiation therapy. Radiation therapy provides better local control rates and 
improved survival for Masaoka stage IIB patients.
Author Disclosure Block: A. Turaka: None. T. Li: None. W.J. Scott: None. 
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1056 
Esophageal Cancer Incidence Gender Disparity.
L. Mathieu1, N. Kanarek2, C. Hooker2, C. Rudin1, M. V. Brock1, 1Johns 
Hopkins Hospital, Baltimore, MD, 2Johns Hopkins Bloomberg School of 
Public Health, Baltimore, MD
Purpose/Objective(s): Over the past thirty years, esophageal cancer inci-
dence has been increasing more rapidly than any other solid neoplasm in 
the Western world. Globally, there is a large male predominance in both 
esophageal squamous cell carcinoma (ESCC) and esophageal adenocarci-
noma (EAC). The reasons for this gender difference and the possible role of 
estrogen are unclear. We conducted an analytical epidemiological study to 
determine if estrogen exposure explains the male predominance in observed 
esophageal cancer incidence. 
Materials/Methods: A database assessment of EAC and ESCC incidence 
rates (age-adjusted) from 1975 to 2008 in the National SEER 9 Database and 
the Maryland Cancer Registry was undertaken. The population was grouped 
by gender then further divided into ten years age groups. Incidence rates by 
gender and age were calculated per 100,000 and gender-specific incidence 
rate ratios were compared across age groups. In order to assess the different 
age cohorts over time and minimize biases we evaluated the SEER data trends 
from 1975 to 2008 using SEER Stat to calculate the annual percentage change 
(APC) in each age group. 
Results: The male predominance incidence rate of esophageal carcinoma was 
evident more in the younger population and EAC histology. EAC and ESCC 
incidence rates increases with aging. The rate of increase for EAC incidence 
in the post menopausal female is greater than their counterparts. This increas-
ing incidence rate in the post menopausal female was also observed in the 
ESCC, but to a lesser extent. APC was negative (-1.5) between 1975-2008 
only in the 50-64 age female cohort and it increases in the older female age 
groups (age 65-74 = + 0.3 and age 75 and greater = + 0.7). APC rates for 
the males increased gradually in all their age groups (age 50-64 = +1.2, age 
65-74 = +1.4, age 75+ = +1.9). 
Conclusions: The high rate of increase for EAC incidence in the post meno-
pausal female may explain the male to female EAC incidence ratio decrease 
with aging seen in the nation (SEER) and in Maryland databases. The nega-
tive APC in the 50-64 years age group may be historically explained by the 
increase use of post-menopausal hormonal therapy during this time period 
for this age group. Using age as a proxy for estrogen exposure, our findings 
suggest a hormonal component in the declining male to female esophageal 
cancer incidence rate ratios with increasing age. It also confirms gender 
differences in incidence long observed in esophageal cancer and suggest 
estrogen serves as a protection against esophageal cancer. Estrogen expo-
sure may play a protective role in esophageal cancer and its protective role 
dissipates with time. Our initial analytical epidemiological data warrants 
translation into a molecular epidemiological study and use of sophisticated 
molecular markers to confirm the protective appearing role of estrogen in 
esophageal cancer.
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The Value Of Pretreatment 18F-FDG PET/CT In Evaluating 
Local Control And Its Potential Application In Individualized 
Radiotherapy In Patients With Esophageal Squamous Cell 
Carcinoma
Q. Liu1, X. Fu1, X. Cai1, Z. Zhu1, W. Yu1, Y. Zhang2, 1Department of Radiation 
Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, 
2Department of Nuclear Medicine, Fudan University Shanghai Cancer 
Center, Shanghai, China
Purpose/Objective(s): The objective of this study is to evaluate the prog-
nostic value of pretreatment 18F-FDG PET/CT on local control after radical 
radiotherapy or chemoradiotherapy in patients with esophageal squamous cell 
carcinoma (SCC), and investigate its potential value in establishing optimal 
radiation treatment plans. 
Materials/Methods: Thirty patients with pathologically proven esophageal 
SCC who underwent pretreatment 18F-FDG PET/CT in our cancer center 
from January 2007 to August 2010 were retrospectively reviewed. A threshold 
of SUV 2.5 was used to delineate the target volume of primary tumor sepa-
rately. SUV and metabolic tumor volume (MTV) of every pixel in all primary 
malignant lesions delineated on PET/CT images were measured. Cumulative 
SUV-volume histograms (CSH), describing total tumor volume above thresh-
old of SUV (from 2.5 to SUV
max
), were calculated. Receiver operating charac-
teristics (ROC) curve was used to further evaluate the optimal cutoff of MTV 
above some threshold of SUV for predicting local control. The local control 
was estimated and significance between groups was assessed by Log-Rank 
test. 
Results: Mean follow-up for surviving patients was 20 months. The estimated 
1,2-year local progression-free survival rate for the group was 72%, 56.7%, 
respectively. ROC curve showed MTV=12.85 cm3 when delineated with a 
threshold of SUV=5 was the best cut off values. Local control for patients 
with MTV
SUV≥5 < 12.85 cm
3 on pretreatment 18F-FDG PET/CT scan were 
better than those with higher MTV
SUV≥5> 12.85 cm
3,2-year local progression-
free survival rate was 76.6% and 27.7% for two groups,p= 0.003. 
Conclusions: In this study, MTV above some threshold of SUV assessed 
by pretreatment PET/CT might be an adverse factor predicting local con-
trol in esophageal SCC, which indicated variation of biologically meta-
bolic level within tumors should be consider as well as tumor volume 
promising for selecting risk-adapted therapies. These results will need 
to be validated in larger cohorts with longer follow-up, and evaluated 
prospectively.
Author Disclosure Block: Q. Liu: None. X. Fu: None. X. Cai: None. Z. 
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4DCT-based Target Volume Analysis For Irradiation 
Treatment Of Esophageal Cancer During Free Breathing
W. Wang, J. Li, Y. Zhang, Q. Shao, M. Xu, F. Li, S. Wang, Shandong Cancer 
Hospital, Jinan, China
Purpose/Objective(s): To investigate the target volume variance and dif-
ference of primary esophageal cancer during the irradiation treatment using 
four-dimensional computed tomography. 
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Materials/Methods: Thirty patients to be treated for esophageal tumors have 
received respiration-synchronized 4DCT simulation scans on the state of free 
breathing, 10 proximal, 10 mid-, and 10 distal esophageal tumors. The GTV, 
CTV, and PTV were all segmented in 0%, 20%, and 50% phases and these 
three respiratory phase scan images were registered to align them. The dice 
similarity coefficient(DSC) between different phases were compared. 
Results: For proximal esophageal tumors, DSC between GTV
0%
 and 
GTV
20%
, GTV
0%
 and GTV
50%
, GTV
20%
 and GTV
50%
 were 85.62%, 82.5%, 
88.88%; DSC
CTV
 between 0% and 20%, 0% and 50%, 20% and 50% were 
93%, 91.78%, 93.6%; and for PTV the DSC were 95.75%, 94.7%, and 
95.84% respectively. For mid-esophageal tumors, the mean DSC between 
0% and 20%, 0% and 50%, 20% and 50% were 86.73%/81.75%/90.33%, 
92.47%/90.18%/92.12%, 95.08%/84.3%/95.46% for GTV, CTV, and 
PTV respectively. Distal tumors were found to have significantly smaller 
DSC than proximal and mid-esophageal tumors. The mean DSC between 
0% and 20%, 0% and 50%, 20% and 50% were 80.64%/71.52%/79.33%, 
90.89%/85.23%/89.33%, and 93.96%/86.29%/92.6% for GTV, CTV, and 
PTV, respectively. 
Conclusions: Target volume defined from 20% phase image possible ade-
quate coverage the whole respiratory cycle target motion. And target coverage 
rate decreased due to breathing was greatest in the tumors located in the distal 
esophagus.
Author Disclosure Block: W. Wang: None. J. Li: None. Y. Zhang: None. Q. 
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Primary Pulmonary Carcinoid Tumor
R. Herde1, W. Akerley2, Y. J. Hitchcock2, 1University of Utah School of 
Medicine, Salt Lake City, UT, 2University of Utah, Huntsman Cancer 
Hospital, Salt Lake City, UT
Purpose/Objective(s): Carcinoid tumors of the lung are rare tumors which 
comprise approximately 1 to 2% of all lung malignancies in adults and 
roughly 20 to 30% of all carcinoid tumors. In addition, little is known about 
the etiology of these tumors and unlike most lung cancers, no external envi-
ronmental toxin has been clearly identified as a causative agent. In this retro-
spective study, we report the history of primary pulmonary carcinoid tumor 
and a single institution experience. 
Materials/Methods: We conducted a retrospective study in patients with 
a diagnosis of carcinoid tumor treated at the Huntsman Cancer Hospital, 
University of Utah. We identified 35 patients diagnosed with primary pulmo-
nary carcinoid tumor from 1989 to 2009. We obtained patient data from the 
Huntsman Cancer Institute Tumor Registry and directly from chart abstrac-
tion. Kaplan-Meier curves were drawn and used to calculate disease free sur-
vival and overall survival in our study patients. 
Results: Of 35 patients, there were 22 males and 13 females with an average 
age of 51 years (range 24-77) at diagnosis. Five out of 35 patients (14.3%) had 
atypical carcinoids, and the remaining 30 patients (85.7%) had typical carci-
noids. Only 4 of 35 (11.4%) patients presented with typical carcinoid syndrome 
while 31 (88.6%) had non-carcinoid presentations or incidental findings (n=10). 
Twenty-five (71.4%) patients had a history of tobacco use. The median tumor 
size was 2.0 cm (range 0.9 - 6 cm). Of the 21 patients presenting with non-car-
cinoid symptoms, dyspnea and hemoptysis were each reported in 8 patients and 
persistent cough was seen in 6. Tumors were located at or proximal to the bron-
chus intermedius in 10 patients (28.6%) while 25 (71.4%) had tumors distal 
to this site. All patients received surgical treatment, consistent with lobectomy 
(n=23), wedge/segmental or a less than lobectomy (n=10), and pneumonectomy 
(n=1). In addition to surgery, 3 out of 35 patients received adjuvant chemother-
apy and radiation therapy for atypical carcinoid tumors. Median follow-up time 
was 72.8 months (range 0.2-256.5 months), and only one patient had persistent 
disease while the remaining 34 patients had no recurrent or metastatic disease. 
The Kaplan-Meier 2-, 5-, and 10-year overall survivals and disease-free surviv-
als were 94%, 89% and 86%, and 94%, 87%, and 87%, respectively. 
Conclusions: Most primary pulmonary carcinoid tumors demonstrated non-
classic clinical presentations. Surgical resection was primary and adequate 
therapy for most carcinoid tumors. Overall survival and disease-free survival 
rates were very high in our long term follow-ups. Adjuvant chemotherapy 
or radiotherapy was reserved for patients with atypical carcinoid tumors and 
adverse pathological findings.
Author Disclosure Block: R. Herde: None. W. Akerley: None. Y.J. 
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Clinical Outcomes Of High-dose Hemithoracic Radiotherapy 
In Patients With Unresected Pleural Mesothelioma - 
Impressive Locoregional Control Confirmed By Pet/ct Scan 
Assessments
M. Feigen, S. Lee, A. M. Scott, C. Hamilton, Austin Health, Heidelberg, 
Australia
Purpose/Objective(s): Establishing local control of the primary tumour is 
the first objective in the management of malignant pleural mesothelioma. 
Following radiotherapy, the assessment of residual tumor viability cannot be 
accurately ascertained by radiological methods and we investigated the role of 
18F-FDG PET scans in the long-term followup of patients treated with high-
dose radiotherapy after suboptimal surgical resections. 
Materials/Methods: Patients whose mesothelioma was localized to the ipsi-
lateral hemithorax were given high-dose radiotherapy to doses of 45-60 Gy 
using advanced technologies to a planning target volume (PTV), utilizing 18F-
FDG PET scans to outline tumor volumes. There were no restrictions on prior 
surgery or chemotherapy. Three months following radiotherapy, a second 
PET/CT scan was obtained. Total glycolytic volumes (TGV) within the high 
dose PTV were analyzed on all followup PET scans. 
Results: We treated 28 patients from July 2003 to March 2012 and 88 scans 
were obtained between 3 and 86 months (median 6) after radiotherapy. 82% 
had stage III/IV disease, including 5 patients with non-epithelioid histologies. 
17 underwent pleurectomy/decortication, 7 had a pleurodesis and 3 only a 
pleural biopsy. One post-pneumonectomy patient had a local recurrence that 
preceded radiotherapy. 16 had prior chemotherapy. 10 received 3D-conformal 
radiotherapy and 18 patients had hemithoracic IMRT. Median followup fol-
lowing radiotherapy was 14.3 months (range 4-88) and there were no deaths 
recorded from radiation toxicity. Reductions in TGV measurements of around 
80% were found, and patterns of failure analysis showed that 75% of relapses 
occurred outside the PTV. 
Conclusion: The role of high-dose radiotherapy in the management of meso-
thelioma remains controversial, and many authorities believe it to be inef-
fective and dangerous. It is recommended to optimize locoregional control 
after extrapleural pneumonectomy, where disease burden is minimal, but 
only a minority of mesothelioma patients currently undergo this procedure. 
Pneumonectomy has a high operative morbidity and rates are likely to fall as 
the age of potential patients rises. For those patients suitable for pleurectomy/
decortication or less radical surgery, our findings show that high dose radio-
therapy using advanced technologies offers effective long-term palliation and 
good disease control, particularly in those patients whose mesothelioma does 
not metastasize outside the hemithorax. Inclusion of the whole intact lung 
and adjacent structures should be encompassed within the PTV, gross disease 
should be targetted using PET/CT scans and rigorous radiation dose tolerance 
constraints should be respected.
Author Disclosure Block: M. Feigen: None. S. Lee: None. A.M. Scott: 
None. C. Hamilton: None.
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RT Dose Escalation in Neoadjuvant Chemo-radiotherapy in 
Resectable Squamous Cell Carcinoma of Esophagus
D. Liu1,2, W. Hsu1,2, T. Huang1, B. Chang1,2, T. Wang1,2, S. Chu1,2, R. Wang1, 
Y. Wu1, R. Kao1,2, 1Buddhist Tzu Chi General Hospital, Hualien, Taiwan, 2Tzu 
Chi University, Hualien, Taiwan
Purpose/Objective(s): The efficacy of neoadjuvant chemoradiotherapy 
(CRT) for resectable esophageal cancer has been demonstrated in a number 
of trials. However, postoperative RT is not feasible after neoadjuvant CRT if 
clinically indicated due to normal tissue intolerance. In this study, we tried 
to escalate RT dose to evaluate treatment response of neoadjuvant CRT in 
resectable squamous cell carcinoma of esophagus. 
Materials/Methods: All consecutive esophageal cancer patients received 
standard evaluation and management. Cancer staging workup includes upper 
GI panendoscopy, endoscopic ultrasound (EUS), esophagogram, chest com-
puted tomography (CT), bronchoscopy and FDG PET-CT. All the patients 
were grouped by TNM system of 7th edition of American Joint Committee 
on Cancer (AJCC). Esophageal patients with stage T2-4 or N+ and surgical 
candidate will be arranged to receive neoadjuvant CRT. Neoadjuvant CRT 
consisted of two cycles of chemotherapy with PF regimen (Cisplatin 75 mg/
m2 in D1 & 5-fluoracil 1000 mg/m2 in D1-D4 ) and radiotherapy with IMRT 
or VMAT technique, (total dose 50 Gy, 2 Gy per fraction). Surgical resection 
will be arranged 6-8 weeks after completion of neoadjuvant CRT. 
Results: Twenty-four patients with resectable esophageal cancer were enrolled 
in this study between February, 2009 and June, 2011. All the histology of the 
patients was squamous cell carcinoma. The median age of these patients is 53 
years old (range 41-69). The median follow-up time is twelve months (range 
4-30 months). Seven patients (29.2%) were clinical stage II and seventeen 
patients (70.8%) were clinical stage III. After neoadjuvant CRT, eleven patients 
(45.8%) reached pathologic complete response (pCR). Nineteen patients 
(79.2%) and eighteen patients (75%) got T downstaging and N downstaging, 
respectively. Three patients passed away during follow-up, two with tumor pro-
gression and one with pneumonia-induced respiratory failure. One-year overall 
survival is 81.3%. The patients with pCR all survived at one year. However, all 
patients without N downstaging after neoadjuvant CRT died before one year. 
Conclusions: Neoadjuvant CRT with RT dose escalation followed by surgi-
cal resection could reach higher pCR. Further clinical investigation is worth 
in the future.
Author Disclosure Block: D. Liu: None. W. Hsu: None. T. Huang: None. 
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1062 
Prospective Study Evaluating Image Guided Volumetric 
Modulated Arc Therapy With Concurrent Weekly Cisplatinum 
For Inoperable Thoracic Esophageal Cancer
S. Chilukuri, Y. Pawar, S. S. Subramanyam, M. Singaraju, K. Kumar, 
P. Tike, Y. Nalini, A. Gandhi, S. Thirumalai, M. Kathirvel, Yashoda Hospital, 
Hyderabad, India
Purpose/Objective(s): This prospective study evaluates feasibility, toxicity 
and early clinical outcomes of concurrent image guided volumetric modu-
lated arc therapy (IG-RA) and weekly cisplatinum in the setting of a definitive 
chemoradiotherapy for locally advanced esophageal cancer. 
Materials/Methods: 41 Patients diagnosed with squamous cell carcinoma 
of thoracic esophagus deemed unsuitable for surgery were included in the 
study. Patients with performance status (ECOG) more than 1, involvement 
of cervical esophagus or gastroesophageal junction, visceral metastasis were 
excluded from the study. All the patients were treated in two phases to a total 
dose of 5940cGy. Phase I CTV was generated by expanding the GTV pri-
mary cranio-caudally by 4cm and laterally to include electively, the corre-
sponding level mediastinal nodes. Phase II CTV was generated by expanding 
the GTV by 2cm craniocaudally and 1cm radially. Bilateral supraclavicular 
regions were electively included for supracarinal lesions. ITV was generated 
by expanding the CTV by 0.5cm which was then expanded by 0.5cm to yield 
PTV. IG-RA plans consisted of 2 conformal arcs with a high priority to reduce 
lung V20, mean lung dose and heart dose. The setup was verified by daily 
KV imaging as well as thrice weekly CBCT with oral barium. Chemotherapy 
consisted of 4-6 cycles of weekly cisplatinum 40mg/m2. 
Results: The median age of patients was 53 yrs (43-72). The median length 
of involvement of esophagus was 6cm with 80% of the lesions in the upper 
and middle third. 37/41(90%) patients completed planned chemotherapy 
with atleast 4 cycles of cisplatinum and 40/41 patients completed full dose of 
radiotherapy. 4/41 (10%) patients required tube feeding, 2/41 (5%) patients 
required hospital admission for supportive care but none of the patients had 
grade IV hematological toxicity during treatment. Endoscopy at 8 weeks 
post treatment was performed in 38/41 patients of which 20 (53%) had CR, 
16 (42%) had PR and 2 (5%) had stable disease locally. With a median fol-
low up of 15 (6-20) months, 18/41(44%) patients are alive at last follow-
up of which 13 (32%) are disease free with no dysphagia, the 1 and 2 year 
overall survival are 70% and 42% respectively and median survival of 13.5 
months. 3/18 (16%) alive patients have post radiotherapy stricture requiring 
occasional dilatations. Unfortunately none of the patients underwent salvage 
surgery because of various medical and social reasons. After analysis of KV 
and CBCT images, the ITV and PTV margins of 0.5cm each was found to be 
adequate with current imaging protocol. 
Conclusion: Image guided volumetric modulated arc therapy to a dose of 
60Gy with concurrent weekly cisplatinum is a feasible treatment option for 
squamous cell carcinoma of thoracic esophagus with low acute and late toxic-
ity and with promising early clinical outcomes.
Author Disclosure Block: S. Chilukuri: None. Y. Pawar: None. S.S. 
Subramanyam: None. M. Singaraju: None. K. Kumar: None. P. Tike: 
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1063 
Irish Experience of Neo-adjuvant (NA) Chemoradiotherapy 
(CRT) of Patients With Resectable And Definitive Treatment 
(DT) for Unresectable Esophageal Cancer (EC): Retrospective 
Multicenter Review
A. V. Boychak, F. Jamaluddin, J. Khalid, J. Martin, M. Pomeroy, C. Small, T. 
Dinizulu, F. Sullivan, UCHG, Galway, Ireland
Purpose/Objective(s): as a result of promising phase III study (CROSS) NA 
CRT in patients with EC it became standard of care in some Irish centres. 
Materials/Methods: we retrospectively reviewed databases of patients with 
EC who received NA and DT CRT in 3 Irish centres from 6/3/10 till 1/3/12. 
Patients with resectable (T2-3N0-1M0) EC received NA CRT paclitaxel/
carboplatin (TC) and radiotherapy (RT) (41.4 Gy/23) (n=15) or (50.4Gy/28 
and CDDP/5FU) (n=10). DT CRT group consists of weekly TC and RT 
(50.4Gy/28) (n=10). Parameters analysed included performance status (PS), 
histology, staging, resection margin status, non- and haematological toxicities 
score and others. 
Results: 38 patients were analyzed: males 2/3 and 1/3 females; median age 
63.5 years (range 45-83); median WHO PS 1(range 0-2); histology: adeno/
squamous/other carcinoma 73/19/8 % respectively. Major toxicities (grade ≥ 
3) were haematological toxicities (HT) - 24.3 % in all patients; NA CRT (TC 
and 41.4 Gy/23) group had a HT rate of 15.4 % (mainly-leukopenia/lympho-
penia) and TC/RT (50.4 Gy/28) group had 22.2 %; a group of CDDP/5FU/RT 
(50.4 Gy/28) had HT 40 %. 12 patients had oesophageal stent inserted prior 
commencement of treatment,9 completed DT CRT, 7 had planned for surgery 
with 3 completed NA CRT. Weight loss (grade ≥ 2) was present in 14 patients 
(36.8%), only 2 of these had completed NA CRT and surgery. 80% of patients 
with tumour length >8cm (n=10) had significant weight loss (grade ≥ 2). 24 
patients had planned to have surgery from outset and only 15 had radical 
surgery after NA CRT. In the NA CRT group majority of patients with tumour 
S307Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 7, Number 9, Supplement 4, September 2012 Abstracts
length of 8cm in length. R0 resection rate was 73.3% in the NA CRT groups 
regardless of chemotherapy types. There was no in-hospital mortality during 
treatment. With a median follow-up of 9.3 months, 40 % (n=6) patients had 
died in the NA CRT group versus 45 % DT CRT group. 
Conclusions: In this study we found that CRT with TC has better toxicity 
profile as compared to the standard CDDP/5FU. This however did not reach 
statistical significance due to small numbers of patients in the groups. Patients 
with tumour length beyond 8cm had lesser chance of proceeding towards sur-
gery. This indicated that patients with >8cm tumour should be considered 
instead for DT CRT. Performance status, weight loss and tumour length 
beyond 8cm are factors which can preclude planned surgery. We also noted 
that stent insertion did not have a negative impact on the suitability of the 
patient requiring surgery.
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1064 
Comparison Of The Planning Target Volume Based On 
Three-dimensional CT And Four-dimensional CT Images Of 
Thoracic Esophageal Cancer
W. Wang, J. Li, Y. Zhang, T. Fan, H. Qi, J. Xing, Shandong Cancer Hospital, 
Jinan, China
Purpose/Objective(s): To compare the centroid position, volumetric differ-
ences and dice similarity coefficient (DSC) of planning target volume (PTV) 
based on three-dimensional CT (3DCT) and four-dimensional CT (4DCT) for 
the thoracic primary tumor of esophageal cancer. 
Materials/Methods: Forty-three patients with esophageal cancer underwent 
3DCT and 4DCT simulation scans of the thorax during normal free breathing. 
The motion of primary tumors located in the proximal (group A), mid-(group 
B), and distal (group C) thoracic esophagus were obtained from the 4DCT 
scans. PTV3D was defined on 3DCT using the tumor motion measured by 
4DCT scans; PTV4D was defined as the union of the target volume contoured 
on the 10 phases of 4DCT images. The differences in target centroid position, 
volume, DSC and degree of inclusion (DI) between PTV
3D
 and PTV
4D
 were 
evaluated for tumors in different groups respectively.
Results: The mean centroid shifts between PTV
3D
 and PTV
4D
 in the three 
dimensional directions were less than 0.3 cm, for all the three groups. But 
the target centroid shift was demonstrated significant difference in lateral 
direction for group C (Z=-2.355, P=0.019). The median size ratio of PTV
4D
 
to PTV
3D
 was 0.79±0.07, 0.91±0.25, and 0.70±0.07 for group A, B and C. 
There was no significant correlation between the ratio of PTV
4D
 to PTV
3D
 
and the target motion for the three groups. The DSC between the PTV
4D
 and 
PTV
3D
 were 0.87±0.04, 0.88±0.06, and 0.81±0.03. The median DI of PTV
3D
 
in PTV
4D
 was 0.78, 0.85, 0.69 for group A, B and C, and the median DI of 
PTV
4D
 in PTV
3D
 was 0.98, 0.97, 0.99 for group A, B and C, respectively. 
Conclusions: The 3DCT-based PTV provides a good coverage of the 4DCT-
based PTV, especially for middle esophageal tumors, but for proximal and 
distal esophageal tumors, PTV
3D
 also encompasses relatively large normal 
tissues.
Author Disclosure Block: W. Wang: None. J. Li: None. Y. Zhang: None. T. 
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1065 
Primary Pulmonary Synovial Sarcoma Presenting As 
Recurrent Spontaneous Pneumothorax: Case Report And 
Literature Review
M. Kukar, A. M. Hanna, M. Edelman, R. D. Glick, NSLIJ, Manhasset, NY
Introduction: Primary pulmonary synovial sarcomas (PPSS) are extremely 
rare and usually present with chest pain, cough or lung mass. We report a case 
and literature review of patients with PPSS presenting as recurrent spontane-
ous pneumothorax.
Materials/Methods: A 17 year-old healthy male presented with primary 
spontaneous pneumothorax. He was managed with tube thoracostomy. Chest 
Xray obtained on the follow up visit showed a recurrent pneumothorax. The 
patient underwent video-assisted thoracoscopy where no apical blebs were 
found but a small (5mm) lesion was seen in the right lower lobe and was 
resected. The patient did well postoperatively and was discharged on day 5. 
Pathology review showed a cellular spindle cell tumor with fascicular archi-
tecture. Immunohistochemistry and FISH confirmed the diagnosis of PPSS.
Results: An extensive PUBMED search and review of cited references indi-
cate that 6 previous cases have been reported. The ages ranged from 14-29 
with mean of 21.7 years and only 3 cases occurred in adolescents. Seventy-
one percent of the patients were male. There is no predilection to any particu-
lar lobe but those with pleural involvement indicated a poor outcome (2/2 
patients died). 
Conclusions: PPSS are rare neoplasms and can be an unsuspecting cause of 
recurrent pneumothorax. If no apical blebs are seen on thoracoscopy, close 
inspection of the entire lung should be performed with biopsy of any unusual 
lesions.
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1066 
Biopsy Method And Sample Adequacy For Molecular Testing 
In Advanced Non Small Cell Lung Cancer
S. Subramonia Iyer1, B. Olsen2, B. Hrinczenko1, 1MSU Hematology Oncology 
Fellowship Program, Lansing, MI, 2McLaren Greater Lansing, Lansing, MI
Purpose/Objective(s): Mutated EGFR gene testing transformed the care of 
NSCLC. ASCO now recommends EGFR mutation testing for NSCLC (April 
2011). However, no studies to assess adequacy of biopsy samples for molecu-
lar testing have been done. 
Materials/Methods: A retrospective chart review to identify patients diag-
nosed with NSCLC at a community hospital during 2010. A pathologist 
reviewed the adequacy of archived biopsy samples for EGFR mutation test-
ing based on ASCO criteria. 
Results: In 2010, 64 cases of NSCLC were diagnosed and 18 patients had 
definitive surgery, 46 did not. Demographics: Thirty-six (56%) of the patients 
were male; median age was 69.5 years, 27 were current smokers, 33 were 
ex-smokers, median survival was 4.9 months. Histologic subtypes: squamous 
- 28 (44%), adenocarcinoma - 23 (36%), bronchoalveolar - 3 (5%), adeno 
with mixed bronchoalveolar - 2 (3%), large cell - 3 (5%), and large cell neu-
roendocrine - 2 (3%). Twenty-eight (44%) were considered adenocarcinoma. 
Staging: Stage I, II, III, IV - 18 (28%), 2 (3%), 13 (20%), 23 (36%). Eight 
(13%) had incomplete staging information. Biopsy material: transbronchial 
needle biopsy in 23 (36%), CT-guided needle biopsy in 13 (20%), definitive 
surgery in 18 (28%), other - 10 patients (15%). Imaging: 29 central lesions 
(45%) and 35 (55%) peripheral. Specimen review: 46/64 (72%) were ade-
quate for potential EGFR mutation analysis; 18 cases (28%) were not. Among 
adenocarcinoma, 19/28 (68%) cases had adequate samples, but 9 (32%) did 
not. Among the 46 patients who had advanced or metastatic disease and hence 
did not have definitive surgery, 28 (60%) had sufficient samples, 18 (40%) did 
not. Among advanced adenocarcinoma patients, the proportion without ade-
quate sample was 9/18 (50%). Five patients had multiple samples collected. 
In 4 (80%) of them, one sample was sufficient and the other was not. In one, 
both samples were adequate. Histology and location: There was no statisti-
cally significant difference between sample adequacy among adenocarcinoma 
(19/28) vs. other histology (27/36), nor between central (21/29) vs. peripheral 
(25/35) lesions (p= NS). Route of biopsy: 4/23 transbronchial biopsies (17%), 
8/13 CT guided transthoracic biopsies (62%) and 6/10 from non-thoracic sites 
(60%) were inadequate (p value= 0.01). Only three samples were tested for 
EGFR (pre- ASCO 2011 guideline). 
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Conclusions: In this series, nearly one-third of all NSCLC cases, including 
half of advanced adenocarcinoma, did not yield sufficient specimen from the 
first biopsy for potential EGFR mutation analysis. Transbronchial biopsies 
were at least two times as likely to yield adequate specimens compared to 
CT guided transthoracic biopsies. Lack of satisfactory tumor tissue sampling 
may preclude mutation testing and deny treatment with potential benefit and 
lower toxicity.
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Stereotactic Body Radiotherapy (SBRT) For The Treatment 
Of Primary And Metastatic Lung Nodules In The Elderly
N. N. Paryani, L. Vallow, C. Serago, S. Kim, A. Smith, E. Johnson, M. 
Johnson, M. G. Heckman, D. Serie, S. J. Ko, Mayo Clinic, Jacksonville, FL
Background: While standard therapy for early stage non small cell lung can-
cer (NSCLC) consists of surgical resection, many patients are either unable 
or unwilling to undergo surgery. Historically, standard external beam radio-
therapy had been offered to such patients, with significantly inferior local 
control (LC) rates compared to those of surgery. Recently, several centers 
have explored the use of SBRT as means of dose escalation, in the hopes of 
improving LC rates. Studies have also evaluated the use of SBRT in the man-
agement of metastatic pulmonary nodules as a means of providing durable LC 
with minimal toxicity. 
Materials/Methods: Forty seven lesions in 43 patients were treated from 
September 2008 through August 2011. The median patient age was 79 
(range 53-90). All but one patient was over 60, and 33 patients (70%) were 
over age 70. All patients with non-metastatic lesions underwent pre-treat-
ment PET/CT scan and bronschoscopy with EBUS. Patients were posi-
tioned with their arms down in a vacuum-bag and abdominal compression 
was applied using a pressurized balloon instead of a hard plate, allowing 
for a comfortable, reproducible position for elderly patients. Thirty nine 
lesions (83%) were treated with 48 Gy in 4 fractions. Six (13%) more cen-
tral lesions received 50 Gy in 5 fractions. Two larger, central lesions (4%) 
received 45 Gy in 5 fractions. 38 lesions (80%) were staged as primary 
stage I NSCLC, 1 patient (2%) had stage II NSCLC, and one patient was 
diagnosed with a presumed synchronous head and neck cancer as well as 
a stage I lung cancer, and was treated with curative intent for both. Seven 
metastatic lesions (16%) were treated, the most common of which were 
from breast primaries. 
Results: With a median follow-up of 11 months (range: 3 -28 months), 2 year 
local control, disease-free survival, and overall survival were 100%, 64%, and 
61% respectively. Patients tolerated treatment very well, with only two grade 
3 and three grade 2 toxicities noted, all of which were related to radiation 
pneumonitis. No patients died as a result of treatment. 
Conclusion: Our initial results indicate that our SBRT technique is a safe and 
effective means of treating both early stage lung cancers as well as metastatic 
lesions in elderly patients, and that this type of treatment can achieve excel-
lent LC rates. Further follow-up is required to ensure durability of treatment 
response as well as continued surveillance for long-term toxicity.
Author Disclosure Block: N.N. Paryani: None. L. Vallow: None. C. Serago: 
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1068 
Third-line Therapy And Beyond In Non-small Cell Lung 
Cancer (NSCLC): Clinical Features And Survival In A Real-
world Scenario
C. Ferreira, L. De Lima Araujo, M. Zukin, F. Alencar, R. Helal, J. Salem, N. 
Teich, C. Baldotto, Clínicas Oncológicas Integradas - COI, Rio de Janeiro, 
Brazil
Background: Despite recent advances in NSCLC treatment, there are 
only three approved lines for clinical use. To date, there is limited clini-
cal data suggesting survival benefit for third-line cytotoxic treatment and 
beyond. This retrospective study reports the clinical characteristics and 
outcomes for third-line and greater in a real-world scenario of a develop-
ing country.
Materials/Methods: Medical charts from patients with metastatic NSCLC 
treated in a private oncology center in Brazil between 1999 to 2010 were 
retrospectively reviewed. Patients receiving at least three lines of cytotoxic 
treatment were identified and followed. The aim was to assess the clinical 
features and survival of this subgroup and compare them to the subgroup that 
did not receive cytotoxic therapy beyond second-line.
Results: Two hundred thirty-nine patients presenting with advanced disease 
were included. Thirty-five patients (14.6%) received third-line, 14 patients 
(5.8%) received fourth-line and 5 patients (2.1%) received fifth-line treat-
ment. Most common cytotoxic treatments administered in third to fifth line 
were: pemetrexed (31.4%), docetaxel (25.7%), the carboplatin-paclitaxel 
combination (11.4%), vinorelbine (8.6%), and gemcitabine (5.7%). The 
performance status (PS) was 0-1 in 91.7%, and there was a predominance 
of adenocarcinoma hystologic subtype (65.7%). Only 12.5% were never-
smokers and 57.1% had a history of weight lost. The disease stage at pre-
sentation, according to AJCC 6th edition was: I-IIIB 11.4% and wet IIIB-IV 
88.6%. None of these characteristics was statistically different from the 
subgroup that was not treated beyond second-line. Patients receiving third-
line or greater were significantly younger (median age 58 years vs. 64 years, 
p=0.016) and notably showed a better median overall survival compared 
to BSC only patients, 22.7 (95% CI, 15.8-29.5) vs. 9 (95% CI, 7.6-10.5) 
months, respectively (p=0.002).
Conclusions: This retrospective study identified a subgroup of patients that 
was treated outside of predefined guidelines. The wide array of cytotoxic 
treatment utilized in third-line and beyond betrays a lack of pattern in the 
therapy selection. There was a small group of remarkably long-lived survi-
vors, despite no major clinical differences from patients receiving BSC. The 
association of this survival with chemotherapy requires further evaluation.
Author Disclosure Block: C. Ferreira: None. L. De Lima Araujo: None. 
M. Zukin: None. F. Alencar: None. R. Helal: None. J. Salem: None. N. 
Teich: None. C. Baldotto: None.
1069 
Accelerated Hypofractionated Radiotherapy to Primary 
Tumor May Benefit Select Patients with Stage IV Metastatic 
Non-Small Cell Lung Carcinoma
J. M. Mann, S. K. Bhavsar, A. Gajra, J. A. Bogart, SUNY Upstate Medical 
University, Syracuse, NY
Purpose/Objective(s): To review the outcomes of patients with stage IV non-
small cell lung carcinoma and a good performance status treated aggressively 
with systemic chemotherapy and an accelerated hypofractionation radiation 
schedule to the primary tumor, between 2003 and 2010. 
Materials/Methods: We identified 9 patients (median age 57) who initially 
presented with metastatic disease secondary to a non-small cell lung carci-
noma primary, who had not been treated previously. All primary tumors were 
found on imaging, following discovery of metastatic disease, which had been 
the inciting factor that brought the patient to our attention. The patients ana-
lyzed were stage IV and all had minimal co-morbidities (100% ECOG PS ≤1, 
0% O2 dependent). The median primary tumor size was 4 cm and adenocarci-
noma was the dominant histology. Three patients were staged as M1a and the 
remaining six as M1b. Accelerated hypofractionated radiotherapy was deliv-
ered to primary lung lesions at a median dose of 6000 cGy in 225 cGy to 350 
cGy daily fractions (median daily fraction = 263 cGy). Median fraction num-
ber was 20, with total dose ranging from 5000-7000 cGy. Median treatment 
duration was 30 days, and no patients had any treatment interruptions. Five 
out of nine patients received weekly concurrent radiosensitizing chemother-
apy (median 4 cycles) during the course of radiation treatments. Concurrent 
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chemotherapy consisted of carboplatin/paclitaxel, cisplatin/vinorelbine, or 
docetaxel. Four out of nine patients received additional chemotherapy with 
systemic doses of carboplatin plus paclitaxel or permetrexed following the 
completion of radiation treatments. 
Results: For all patients, median overall survival from time of diagnosis was 
19 months. Overall survival at 1 year and 1.5 years following diagnosis of 
stage IV NSCLC were 89% and 56%, respectively. Four out of nine patients 
experienced local recurrences while six out of nine patients suffered distant 
failures within 5 months. Treatment to the primary lesion was tolerated well 
without any Grade ≥3 non-hematologic toxicities.
Conclusions: Well selected patients with limited disease burden and good 
performance status may derive a survival benefit from local treatment to the 
primary tumor. Advances in staging and systemic therapy stand to increase 
the number of patients who may benefit from this aggressive approach.
Author Disclosure Block: J.M. Mann: None. S.K. Bhavsar: None. A. 
Gajra: None. J.A. Bogart: None.
1070 
Comparisons Of Clinical Target Volumes Defined On 3DCT 
And 4DCT Images For The Mediastinal Metastatic Lymph 
Nodes In Non-small Cell Lung Cancer
S. Wang, J. b. Li, Y. j. Zhang, T. y. Fan, J. Xing, M. Xu, Q. Shao, T. h. Liu, 
Shandong Cancer Hospital, Jinan, China
Purpose/Objective(s): To compare positional and volumetric differences 
of clinincal target volumes(CTVs) defined on axial three dimensional CT 
(3DCT) and four dimensional CT (4DCT) for the mediastinal metastatic 
lymph nodes in non-small cell lung cancer (NSCLC). 
Materials/Methods: Nineteen patients with mediastinal metastatic lymph 
nodes in NSCLC underwent 3DCT and 4DCT simulation scans during normal 
breathing. The mediastinal metastatic lymph nodes motion was measured by 
4DCT. CTVvector was defined on 3DCT using the individual tumor motion 
vector measured by 4DCT accounting for tumor motion; CTV
4D
 was defined 
on all phases of 4DCT images, CTVmip was defined on the MIP images of 
4DCT. In addition, a 5 mm margin for microscopic disease were used for 
above CTVs, respectively, The differences in target position, volume and cov-
erage between CTVvector, CTV
4D
 and CTV
mip
 were evaluated for mediastinal 
metastatic lymph nodes in different regions, respectively. 
Results: The median motion vector for mediastinal metastatic lymph nodes 
located in the left of trachea (group A),in the right of trachea (group B) and 
below of the eminence(group C) was 3.5 mm, 5.3 mm and 5.3mm, respectively. 
There were no statistically significant differences between the displacements in 
the group A, group B and group C (F = 1.414, P =0.264). The volume is similar 
between CTV
4D
 and CTVvector for group A, B and C. The median size ratio of 
CTV
4D
 to CTVvector was 1.0, 0.7 and 2.0 for group A, B and C, respectively. 
The motion vector showed a significant correlation to the ratio of CTV
4D
 to 
CTVvector for group B (P = 0.029). The volume of the CTVmip is smaller than 
CTV
4D
 and CTVvector for group A, B and C. The mean size ratio of CTV
4D
 to 
CTVmip was 2.3, 0.4 and 2.3 for group A, B and C, respectively. The motion 
vector showed a significant correlation to the ratio of CTV
4D
 to CTVvector for 
group B and C (P = 0.002 and 0.020 ).The mean degree of inclusion(DI) of 
CTVvector in CTV
4D
 was 82.26% ,79.49% and 79.59% for group A ,group B 
and group C, respectively. The mean DI of CTV
4D
 in CTVvector was 78.93%, 
92.31% and 88.60% for group A, group B and group C. 
Conclusions: The volume is similar the CTVvector based on the 3DCT and 
CTV
4D
 for the mediastinal metastatic lymph nodes in different regions. The 
3DCT-based CTV using individual margins provides a good coverage of the 
4DCT-based CTV, meanwhile encompasses relatively large normal tissues. 
We should be cautious about the use of the individual CTV derived from 
3DCT in involved-field radiotherapy.
Author Disclosure Block: S. Wang: None. J.B. Li: None. Y.J. Zhang: 
None. T.Y. Fan: None. J. Xing: None. M. Xu: None. Q. Shao: None. T.H. 
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1071 
Bevacizumab (bev) With Pemetrexed (pem) And Carboplatin 
(carbo) For Advanced Lung Adenocarcinoma. Preliminary 
Results With Focus To Cns Response
S. Stamatopoulou, A. Ntokou, K. Florou, E. Pouliou, A. Raptis, V. Stavrinides, 
s. kaltsas, A. Tzovaras, A. Ardavanis, Agios Savvas, Athens, Greece
Purpose/Objective(s): BEV has interesting activity in non-squamous 
NSCLC while PEM/CARBO is an established combination for lung adeno-
carcinoma (LAC). Recently, a combination of BEV/PEM/CARBO has shown 
interesting activity in NSCLC. Preliminary results of this combination with 
focus to activity in CNS metastasis are reported here. Materials/
Methods: Patients with advanced LAC (stage IIIB-IV), ECOG/PS <2 are eli-
gible. Treatment consists of BEV 15mg/Kg, PEM 500mg/m2,CARBO AUC5 
q3w for six cycles. In responding or stabilized pts maintenance BEV/PEM is 
administered until progression or unacceptable toxicity. Pts with bone metas-
tasis receive zoledronate . 
Results: TwTwenty three pts (15 men and 8 women, and 16 and 7 stage IIIB 
and IV respectively), aged 40-60, ECOG/PS 0-1 have been treated so far; seven 
pts had CNS involvement with minimal symptoms or asymptomatic. A total 
of 90 induction and 40 maintenance courses have been administered Toxicity 
was acceptable mainly hematologic (GIII/IV anemia 3%, neutropenia 10%, 
thrombocytopenia 4%). No GIII/IV non-hematologic toxicity was observed 
while epistaxis and manageable hypertension are common; no treatment-
related death occurred. Efficacy: 9 partial remissions and 4 stabilizations in 
18 pts evaluable for response; too early for PFS and OS estimations. It should 
be reported however, that 2 and 3 pts out of 7 with multiple brain metastatic 
foci experienced CR and PR respectively, lasting > 3 months without brain 
irradiation so far 
Conclusions: As previously shown, the BEV/PEM/CARBO combination 
seems to be effective in LAC. Given the dismal prognosis of CNS involve-
ment from LAC as well as and the detrimental effects of brain irradiation, the 
above preliminary results suggesting an interesting activity against in CNS 
metastasis warrant further assessment in more patients and longer follow up.
Author Disclosure Block: S. Stamatopoulou: None. A. Ntokou: None. K. 
Florou: None. E. Pouliou: None. A. Raptis: None. V. Stavrinides: None. S. 
kaltsas: None. A. Tzovaras: None. A. Ardavanis: None.
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Hypoalbuminemia: a prognostic factor in metastatic Non 
Small Cell Lung Cancer.
Z. Benbrahim1, S. Arifi1, L. Amaadour1, N. Abda2, C. Nejjari2, N. Mellas1, 
O. El Mesbahi1, 1Hassan II University Hospital, Morocco, Fez, Morocco, 
2Faculty of Medecine and Pharmacy of Fez, Fez, Morocco
Background: Hypoalbuminemia is a frequent manifestation of advanced non 
small cell lung cancer (NSCLC) which is often related with a poor survival. 
The aim of our study was to establish the correlation between hypoalbumin-
emia and survival (disease-free survival (DFS) and overall survival (OS)) in 
Moroccan patients with metastatic NSCLC. 
Materials/Methods: We reviewed 115 cases of metastatic non small cell lung 
carcinomas diagnosed between January 2007 and June 2011 at the Medical 
Oncology Department of Hassan II University Hospital. Albumin level was 
performed at the time of diagnosis and prior to treatment. Survival curves 
were plotted by the Kaplan-Meier method and compared using the log-rank 
test. 
Results: Median age was 57 ± 10 years. Eighty one per cent of patients were 
treated with platinum based chemotherapy. Forty eight per cent had albu-
minemia ≤35 mg/mL with a mean level of 28 mg/L. Hypoalbuminemia was 
more frequently associated with body mass index <18.5 kg/m2 (p=0,008). 
However, it was not correlated to age, performance status, histologic type, 
number of metastatic sites involved, pleural effusion, liver metastasis, hyper-
calcemia and anemia. The median duration of follow-up was 7.4 months 
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(range: 1-99 months). In the univariate analysis, hypoalbuminemia was sig-
nificantly correlated to lower OS (mean: 15 vs 4 months, p =0,0023) and 
lower DFS (mean :10,8 versus 3,8 months, p=0,033). The response rate was 
shorter (10% vs 43 %) but not significantly different (p = 0,09). In multivari-
ate analysis, hyoalbuminemia was significantly associated with shorter OS 
and DFS. 
Conclusion: This study suggests that hypoalbuminemia could be an indepen-
dent prognostic marker to predict unfavorable OS and PFS in patients with 
metastatic non small lung cancer.
Author Disclosure Block: Z. Benbrahim: None. S. Arifi: None. L. 
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Metastatic Non-Small Cell Lung Cancer (mNSCLC) in 
Elderly Patients: Survival Analysis Based on Platinum 
Retreatment
T. Linsalmeida1,2, R. Fernandes3, A. Faccio3, P. Reis Filho3, H. Oliveira3, F. 
Tavares3, F. Peria3, 1Hospital das Clinicas USP FMRP, Ribeirão Preto São 
Paulo, Brazil, 2Centro Avançado de Oncologia do Hospital São José, São 
Paulo, Brazil, 3Hospital da Clinicas USP FMRP, Ribeirão Preto São Paulo, 
Brazil
Purpose/Objective(s): More than 50% of lung cancer patients (pts) are 60 
or older at diagnosis. Moreover, mNSCLC´s both incidence and prevalence 
in elderly pts is rising, as a result of the world aging population. Spite of this, 
a lack of knowledge remains regarding the efficacy and safety of second-line 
chemotherapy. The aim of this study was to evaluate the feasibility of plati-
num rescue scheme in mNSCLC elderly pts.
Materials/Methods: The database between Jan08 to Jan12 from Oncology 
Division (HCFMRP-USP) was retrospectively analyzed. The inclusion crite-
ria observed were: age ≥60 years old (WHO-UN-Brazil), carcinoma patho-
logical diagnosis (Adeno/Squamous cell), metastatic staging and follow-up 
assessments (AJCC7th/RECIST1.1) and combined regimens of platinum-
based chemotherapy in both first and second-line. The first end point was 
overall survival.
Results: Forty-six pts showed average age of 67 (60-85), and 95% of which 
had an ECOG of 0-1. The treatment agents dose consisted of carboplatin 
(CA AUC=5), paclitaxel (PA175mg/m2), gemcitabine (GE 1000mg/m2), 
cisplatin (CI 60mg/m2), and docetaxel (DO 60mg/m2). In first-line (46), 
the medium time to progression (mTTP) of the pts treated with CA+GE 
(4) was 63 days for those with adenocarcinoma (ADENO) and 84 days 
for SCC. Analyzing CA + PA (39), fourteen pts had stable disease after 
three cycles, and were observed mTTP of 87.5 and 90 days for ADENO 
(18) and SCC (21), respectively. Regarding the second-line (20), the mTTP 
to ADENO and SCC were 100,8/63 and 63/94,5 days based on CA+GE/
DO chemotherapy. The CA+PA treatment (first-line) followed by CA+GE 
(second-line) for ADENO was favorable (p,05), with a trend toward higher 
overall survival rate at 1082 days for 50% of these pts. The WHO grades 3/4 
toxicity observed was rare, and the grades 1/2 most common were anemia 
and dizziness.
Conclusions: We observed that lower doses of platinum chemotherapy could 
reduce toxicity and allow recombine the platinum agent in the second line. It 
was feasible to get a better mTTP and overall survival with platinum in both 
first and second lines. In this analysis, elderly pts with ADENO mNSCLC 
showed a trend toward higher overall survival rate in pts undergoing therapy 
based on CA + PA followed by CA + GE, with acceptable toxicities.
Author Disclosure Block: T. Linsalmeida: None. R. Fernandes: None. A. 
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Carcino Embryonic Antigen (CEA) Elevation As A Predictor 
Of Better Response To First Line Pemetrexed In Advanced 
Lung Adenocarcinoma.
T. Braik, S. Gupta, H. Poola, P. Jain, A. Beiranvand, T. E. Lad, L. Hussein, 
John H Stroger Jr Hospital of Cook County, Chicago, IL
Introduction: Pemetrexed is approved for treatment of locally advanced and 
metastatic non small-cell lung cancers of non-squamous histology. We noted 
a phenomenon where patients with lung adenocarcinoma and elevated CEA 
level had excellent response to pemetrexed. This study was undertaken to ret-
rospectively review all lung adenocarcinoma patients who had a CEA level 
available before chemotherapy and to see if an elevated CEA level in such 
patients can predict a better response rate to pemetrexed. 
Materials/Methods: All patients who received pemetrexed from 
January-2005 to December-2011 were identified from our pharmacy data-
base. All charts were retrospectively reviewed for stage, pathology, CEA level 
and treatment details. All patients stage III or IV who had CEA level done at 
the time of diagnosis or before starting chemotherapy were included in the 
study. Patients who did not have CT scan post treatment, patients not yet com-
pleted treatment and patients with incomplete charts were excluded. 
Results: A total 167 patients were identified out of which 19 patients met the 
inclusion criteria. Of those included 12 had an elevated CEA level (group 
1) and 7 had normal CEA level (Group 2) at the time of diagnosis or prior 
to starting chemotherapy. Seven (58.3%) patients in Group 1 had partial 
response (PR) or stable disease (SD) with average 6 cycles of pemetrexed-
based therapy per RECIST criteria, as compared to 3 (42.8%) patients in 
Group 2. Pemetrexed was given as a single agent in 50% of Group 1 and 43% 
patients in Group 2. All patients who received combination therapy received 
Carboplatin or Cisplatin with pemetrexed. Pemetrexed based chemotherapy 
was first line in 41.7% patients in Group 1 compared to 70% in Group 2. 
When used first line the PR or SD rate increased to 71.1% in patients with 
elevated CEA, however it remained stable at 40% in patients with normal 
CEA levels. 
Conclusions: Elevated CEA level can be used to assess response in patients 
with lung adenocarcinomas. Our study, though small, points towards a poten-
tial phenomenon where an elev1xated CEA may be a predictor of better 
response to Pemetrexed especially when used as first line agent (single or 
combined with platinum) in patients with advanced lung adenocarcinomas. 
Prospective studies are needed to study this relationship further and define its 
potential clinical significance.
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Nanoparticle Albumin-bound Paclitaxel (NabP) As A Single 
Agent For The Treatment Of Recurrent Stage 4 Non-small 
Cell Lung Cancer (NSCLC).
A. Saxena, P. J. Christos, J. M. Cagney, R. J. Scheff, Weill Cornell Medical 
College, New York, NY
Purpose/Objective(s): NabP is a formulation of paclitaxel designed to reduce 
toxicity of therapy and increase drug delivery to tumor cells. An established 
therapy for stage 4 breast cancer, single-agent nabP has also been shown to 
produce responses in frontline therapy of stage 4 NSCLC. However, its role in 
relapsed NSCLC has not been well reported. We reviewed our own experience 
using nabP in this setting. 
Materials/Methods: We analyzed the records of stage 4 NSCLC patients 
(pts) treated with single-agent nabP at our institution. Cases were assessed 
with regard to age, sex, KPS, histology, line of systemic therapy, prior tax-
ane exposure, # of cycles administered, dose attenuation, and progression-
free survival (PFS) estimated by Kaplan-Meier analysis. Standard dosing 
of nabP was considered to be 260 mg/m2 IV Q 21 days. Disease was 
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considered to have progressed on the date of any clinical assessment (typi-
cally CT scan) that led the treating oncologist to conclude that disease had 
progressed. All pts ultimately progressed on nabP therapy except for 2, one 
who was last assessed at 71 days of follow up and one who was last assessed 
at 484 days. 
Results: From Oct 2008 to March 2012, 16 stage 4 NSCLC pts (median age 
68.5, range 48 to 82; 9 F, 7 M; KPS 60-80%; 12 adenocarcinoma, 1 large cell, 
2 squamous cell, 1 unspecified) received a median of 3.5 cycles (range 1-19) 
of single-agent nabP. All pts received at least 1 prior line of systemic therapy 
in the stage 4 setting: 7 received nabP as 2nd line therapy, 4 as 3rd line, and 5 
as 4th line. 6 pts had also received prior chemotherapy for early stage NSCLC. 
9 pts were taxane-naïve; 7 had received prior taxane therapy. 10 pts began 
nabP at standard dose; 6 began on an attenuated dose or schedule. Subsequent 
dose reduction occurred in 4 pts due to toxicity (fatigue, myelosuppression). 
Only 1 patient discontinued treatment due to toxicity (myalgias, arthralgias). 
Median PFS for all pts was 82 days (95% CI 39 to 240 days). Older age 
reduced risk of progression [hazard ratio 0.92 per 1-year age increase (95% 
CI 0.86 to 0.99), P=0.03]. Prior taxane exposure decreased PFS (median 66 
vs. 113 days, P=0.12 by log-rank test). PFS did not vary by KPS, histology, 
or line of therapy. 
Conclusions: Single-agent nabP administered in relapsed Stage 4 NSCLC is 
well tolerated and associated with extension of PFS, particularly in older and 
taxane-naïve pts.
Author Disclosure Block: A. Saxena: None. P.J. Christos: None. J.M. 
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Lung Squamous Cell Carcinoma Metastatic To The 
Gastrointestinal Tract: Report Of Three Cases.
R. S. Mehta1, A. D. Liman2, V. A. Passero1, A. K. Liman2, 1University of 
Pittsburgh Medical Center, Pittsburgh, PA, 2VA Pittsburgh Healthcare System, 
Pittsburgh, PA
Purpose/Objective(s): Common sites for lung metastases include lymph 
nodes, pleura, liver, brain, adrenals, and bones. The gastrointestinal (GI) tract 
is an exceptionally rare site of metastasis 
Materials/Methods: Report of three cases of squamous cell lung carcinoma 
with GI metastasis. 
Results: Case 1: 60 year old man with remote history of pancreatic cancer 
was found to have a right upper lobe mass on a chest x-ray. The lung biopsy 
showed squamous cell carcinoma. Staging PET/CT showed hypermetabolic 
circumferential thickening of the sigmoid colon. Pathology from segmen-
tal colon resection showed squamous cell carcinoma, most likely metastasis 
from lung cancer. He subsequently developed abdominal abscess and pneu-
monia after surgery and died 2 weeks later. Case 2: 62 year old man with 
hepatitis C cirrhosis was found to have a left upper lobe mass and left hilar 
lymphadenopathy. Biopsy showed squamous cell carcinoma. No metastases 
were noted on PET/CT. Restaging PET/CT 6 months after completion of 
chemoradiation therapy showed marked progression of the lung mass and 
a new focal area of metabolic uptake in the transverse colon. Colonoscopy 
showed a 3 cm mass in the transverse colon; pathology was consistent with 
metastatic squamous cell carcinoma. The patient received second line che-
motherapy but his disease continued to progress and he died 6 months after 
colonic biopsy. CASE 3: 79 year old man with multiple medical conditions 
was admitted with acute abdominal pain. CT scan showed free intraperito-
neal air and jejunal perforation. Exploratory laparotomy revealed a proximal 
3 cm jejunal mass. Pathology showed well differentiated squamous cell car-
cinoma. CT scan of the chest showed a large obstructing left hilar and medi-
astinal masses and bilateral pleural effusions. No lung biopsy was performed 
as family decided on hospice care and the patient died within a month after 
laparotomy. 
Conclusions: Metastatic lung carcinoma to the colon or small intestine is 
very rare. Patients with metastases to the GI tract tend to have a worse progno-
sis than other metastatic sites. Theories of metastasis include role of genetics, 
adhesion molecules and proangiogenic chemokines. Compared to other sites, 
GI tract may be a less attractive environment for lung cancer.
Author Disclosure Block: R.S. Mehta: None. A.D. Liman: None. V.A. 
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Pulmonary Blastoma: A Clinical Study Of Three Cases.
D. Hansra1, J. Sandoval-Sus1, M. Ponce1, R. Ochoa1, E. S. Santos2, 1Jackson 
Memorial Hospital, Miami, FL, 2Jackson Memorial Hospital/University of 
Miami, Miami, FL
Background: Pulmonary blastoma (PB) is a rare biphasic neoplasm com-
posed of both immature mesenchymal and epithelial cells representing 
0.2-0.5% of pulmonary malignancies. Initial presentation ranges from 
asymptomatic to classical symptoms of advanced pulmonary tumors. 
Surgical resection is the preferred treatment with no consensus on the role of 
other adjuvant therapies.
Materials/Methods: We report the clinical features of PB in 3 patients 
(pts). Retrospective review of medical records of pts diagnosed with pul-
monary blastoma at Jackson Memorial Hospital, Miami, FL since 2009. 
Staging was done using the 2009 AJCC staging system for NSCLC. All 
cases required to have confirmed pathological diagnosis before inclusion. 
Variables analyzed were demographics, clinical presentation, treatments 
and outcomes.
Results: Mean age at diagnosis was 53 years old; two were male; 2 were 
Hispanic and one African American. Two of them were heavy smokers 
(80 and 45 packs year, respectively). At diagnosis, all cases where symp-
tomatic; one had mild hypercalcemia of 12.9 mg/dL and two where stage 
IV with confirmed metastatic disease (bone and thyroid gland). Two of 
the cases where treated with surgical resection and both achieved com-
plete remission (CR); one pt still remains on CR after 8 months post-
surgery and the other one relapsed after 22 months post-surgery. This pt 
was placed on palliative chemotherapy (3 cycles of cisplatin/docetaxel) 
with no response. Further palliation was radiotherapy (37 Gy) with no 
response. The other case was treated with chemotherapy alone (6 cycles of 
cisplatin/docetaxel) and attained partial remission. All 3 patients remain 
alive.
Conclusions: In our case series, all pts were symptomatic at diagnosis 
and two presented with metastatic disease. Surgery was the most benefi-
cial intervention in regard to CR and disease-free interval as in previous 
reports. Chemotherapy has shown mixed responses, thus, larger studies are 
needed to define the role of chemotherapy in the adjuvant and palliative 
settings.
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Local Control Rates With Stereotactic Body Radiotherapy 
(sbrt) For Primary Lung Tumors: Single Institution 
Experience Of 153 Consecutive Patients
D. P. Singh, M. T. Milano, M. Z. Hare, N. Joyce, T. Smudzin, Y. Chen, Wilmot 
Cancer Center, Rochester, NY
Purpose/Objective(s): To report our institutional experiencing with SBRT 
for treatment of non-small cell lung cancer (NSCLC). 
Materials/Methods: One hundred and fifty-three consecutive patients with 
NSCLC were diagnosed and treated with image guided SBRT between 2008 
and 2011. The median prescription dose was 50 Gy in 5 fractions (range 
40-60 Gy) with most (n=121) receiving 50 Gy in 5 fractions. Dose was pres-
cibed to the isocenter, with the 80% isodose line covering the PTV (defined 
as GTV + 7-10 mm volumetric expansion). The follow-up ranged from 1-46 
months with a median of 13 months. 
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Results: The 1- and 2-year local control (LC) rates for all patients were 92% 
and 85% respectively. For 111 patients with stage I NSCLC, 1- and 2- year LC 
was 95% and 85%, with all local failures (LF) occurring within 2 years. The 
LC at 1- and 2-year were, 87% and 87% for both stage II (19 patients), stage III 
(14) patients) with all LF occurring in <10 months and <9 months respectively. 
The 1- year and 2-year LC for stage IV (9 patients with oligometastases) were 
71% each with all LF occurring in <5 months. The 2-year LC of tumors <1 cm 
was 100% compared to 84% for tumor size > 1 cm. Tumor histology, prescribed 
dose, patient age, prior RT or surgery had no significant impact on LC rates, 
where as prior chemotherapy had significant negative impact on LC with 1 and 
2 year LC of 59% compared to the group with no prior chemotherapy with 1 
and 2 year LC of 93 and 85% respectively (p=0.015). However, this difference 
was not statistically significant with multivariate analysis where NSCLC stage 
was the single most significant factor for LC. Among Stage I NSCLC patients, 
6 of 111 developed LF, 13 developed distant failure (of whom 5 also developed 
LF). Of these 111 patients, 5 died from NSCLC and 2 died from causes other 
than NSCLC; no patient died from treatment related toxicity.
 Conclusions: SBRT plays vital role and offers excellent LC in NSCLC 
patients who are deemed medically inoperable with initial early stage of the 
disease emerging as single most significant factor on multivariate analysis.
Author Disclosure Block: D.P. Singh: None. M.T. Milano: None. M.Z. 
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Jak/Stat Axis as a Target for Tumor Radio and 
Chemosensitization: Potential Application to Lung Cancer?
N. N. Khodarev, S. Song, S. A. Khan, S. Perakis, L. Pulido, Z. Liao, M. C. 
Posner, R. R. Weichselbaum, The University of Chicago, Chicago, IL
Purpose/Objective(s): To identify the role of the Jak/Stat pathway in the 
development of aggressive, radio/chemoresistant epithelial tumors and to 
investigate the role of this pathway in colonization of the lung by tumor clones 
Materials/Methods: To detect genes involved in tumor radioresistance, we 
used repetitive cycles of x-irradiation of xenografts in nude mice derived from 
a radiosensitive squamous cell carcinoma, SCC61, to select a radioresistant 
tumor, nu61. Using expressional profiling 49 unique genes were associated 
with the radioresistant phenotype and 24 were represented by genes in the 
Jak/Stat pathway. We identified these genes as the Interferon-Related DNA 
damage Signature (IRDS). Gene knock-downs were generated using shRNA 
constructs in pLKO.1 vectors. Jak1/Jak2 inhibitor (Ruxolitinib) and Jak2 
inhibitor (TG101209) were obtained from ChemieTek (Indianapolis, IN). 
Results: Analysis of clinical databases revealed that the IRDS is constitutively 
expressed in 37% of head and neck cancers, 48% of lung cancers, 29% of pros-
tate cancers, 46% of breast cancers and 50% of high grade gliomas. The IRDS 
predicts local control failure (LCF) in breast cancer patients in response to 
radiotherapy and distant failures following adjuvant chemotherapy. Suppression 
of Stat1 by shRNAs led to radiosensitization of three different experimental 
tumors and also sensitization to doxorubicin. Additionally, RNAi suppression 
of two Stat1-dependent genes (ISG15 and IFIT1) led to sensitization of nu61 to 
Doxorubicin while overexpression of two other Stat 1 dependent genes, IFITM1 
and IFITM3 led to increased growth and radioprotection. Using a B16F1 mouse 
melanoma model we screened tumor clones that constitutively expressed genes 
in the Stat1 pathway. These expressors (IRDS+ phenotype) colonized lungs 
10-fold more efficiently compared to IRDS- clones. Suppression of Stat1 by 
shRNA led to radio-and chemosensitization of IRDS+ clones and suppres-
sion of their metastatic capacity. Consistent with these data, the Jak2 inhibitor 
TG101209 and Jak1/Jak2 inhibitor Ruxolitinib suppressed growth and viability 
of tumor cell lines of different histological types including lung cancer cell lines 
H460 and A549 in vitro and blocked phosphorylation of both Stat1 and Stat3. 
Conclusions: Our results demonstrate that genes in the IRDS are predictors 
of individual response to radio/chemotherapy in some tumor types. Data also 
show that Stat1 and other members of the Jak/Stat axis can be therapeutic tar-
gets for tumor sensitization to genotoxic stress. These data are consistent with 
the recent findings of activating Jak2 mutations in lung adenocarcinomas and 
emphasize the importance of investigation of Jak/Stat pathway in lung cancer 
and other cancer types
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Comparison The Target Volume Of Esophageal Cancer By 
Different Methods.
Q. Shao, J. b. Li, S. Wang, Shandong Cancer Hospital, Jinan, China
Purpose/Objective(s): To compare the planning target volume(PTV) of 
esophageal cancer target delineation with different methods. 
Materials/Methods: There were fifteen patients with middle chest esophageal 
cancer , involving 12 males and 3 females and aged 45-72 years.The median 
age was 59 years. Positioning in the CT slice thickness of 3mm on the outline 
of esophageal lesions as GTV.The CTV0 was created by manually contouring 
the esophagus for 30mm superiorly and inferior to GTV then adding 5mm cir-
cumferentially to the created volume to account for microscopic spread.For the 
PTV0 ,a 10mm margin in all direction was added to CTV0.The CTV6 was cre-
ated by manually contouring the esophagus for 24mm superiorly and inferior 
to GTV then adding 5mm For circumferentially. The PTV6 ,a 16mm margin in 
superiorly and inferiorall direction and a 10mm margin in other direction was 
added to CTV6.The CTV15 was created by manually contouring the esopha-
gus for 15mm superiorly and inferior to GTV then adding 5mm For circum-
ferentially. The PTV15 ,a 25mm margin in superiorly and inferiorall direction 
and a 10mm margin in other direction was added to CTV15.The CTV30 was 
created by manually contouring the esophagus for 0mm superiorly and inferior 
to GTV then adding 5mm For circumferentially. The PTV30 ,a 40mm margin 
in superiorly and inferiorall direction and a 10mm margin in other direction 
was added to CTV15. Paired t-test using SPSS17.0 to p <0.05 was considered 
significant difference, compared PTV30, PTV15, PTV6, PTV0 volume. 
Results: The volumes of PTV30, PTV15, PTV6 and PTV0 showing with the 
mean ± standard deviation, were 392.51 ± 123.32cm3, 366.07 ± 112.78cm3, 
346.55 ± 103.70cm3 and 342.36 ± 108.65cm3,respectively. The results were 
significant differences(p ≤ 0.001) except PTV6 vs PTV0 .The results were 
shown in Table 1.
Conclusion: Different methods of esophageal cancer target delineation make 
significant effects on the PTVs. Choosing the delineation methods of CTV6 
or CTV0 are better.It may be benifit to patients. Table 1 Comparison of dif-
ferent PTVs
PTVs
PTV30 vs 
PTV15
PTV30 vs 
PTV6
PTV30 vs 
PTV0
PTV15 vs 
PTV6
PTV15 vs 
PTV0
PTV6 vs 
PTV0
t 4.609 4.791 6.267 4.318 5.097 0.895
p 0.000 0.000 0.000 0.001 0.000 0.386
Author Disclosure Block: Q. Shao: None. J.B. Li: None. S. Wang: None.
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Comparison Of Treatment Planning Geometric Parameters 
For Non-small Cell Lung Cancer Before And After 
Implementation Of The Collapsed Cone Dose Algorithm
A. Macdonald, H. McCallum, S. Ramamurthy, F. McDonald, G. Lawrence, 
Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, 
United Kingdom
Purpose/Objective(s): At the Northern Centre for Cancer Care, UK, the 
collapsed cone (CC) algorithm for calculating dose deposition on the treat-
ment planning system Oncentra Masterplan (Elekta) replaced pencil beam 
(PB) around December 2007. The CC algorithm takes into account beam 
scatter from surrounding tissue and is considered to give a more realistic 
and complex map of dose deposition than the PB algorithm, particularly in 
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heterogeneous tissue such as the lungs. It was thought that this may result in 
more complex treatment plans and larger field sizes in order to conform to the 
tumour. The aim of this work was to find out if the change to using the CC 
algorithm altered the geometric parameters used for the treatment. 
Materials/Methods: 51 treatment plans for non-small cell lung cancer 
patients using the collapsed cone algorithm(CC) were compared with 41 
plans using the pencil beam(PB) algorithm. All were prescribed 55Gy in 20 
fractions at 6MeV. The treatment planning geometric parameters compared 
were the number of fields, wedges, gantry angles and field within fields, and 
the volume contained within the field intersection. The volume of the PTV 
was used to compare cohorts. 
Results: See Table (all values +/- standard deviation)
Conclusions: The treatment parameters suggest that the plans done using the 
CC algorithm have not become more complex. In fact, the reduced number of 
fields and reduced number of field within fields imply that the plans are less 
complex. This means that introducing the routine use of the collapsed cone 
algorithm for non-small cell lung cancers has not increased the complexity 
and therefore the time-cost of the treatment plans.
PB plans (n=41) CC plans (n=51)
Number of fields 7.1 +/- 1.5 (range 4-10) 6.4 +/- 1 (range 5-8)
Number of wedges 2.5 +/- 0.9 (range 2-4) 2.6 +/- 0.8 (range 1-4)
Number of gantry 
angles
3.0 +/- 0.3 (range 2-4) 3.0 +/- 0.3 (range 2-4)
Number of field 
within fields
1.7 +/- 1.1 (range 0-3) 0.73 +/- 0.88 (range 0-3)
Volume of field 
intersection
857 +/- 409cc 846 +/- 379cc
Volume of PTV 429 +/- 250cc 429 +/- 220cc
Author Disclosure Block: A. Macdonald: None. H. McCallum: None. S. 
Ramamurthy: None. F. McDonald: None. G. Lawrence: None.
1082 
Variability of Tumor Motion in 4DCT: the Effects of 
Abdominal Compression on Lung Tumor Displacement
S. Rosenberg, S. K. Jabbour, N. J. Yue, A. Rasheed, B. G. Haffty, S. Goyal, 
A. Khan, Department of Radiation Oncology, The Cancer Institute of New 
Jersey, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
Purpose/Objective(s): Lung tumors exhibit motion during the normal 
respiratory cycle, which complicates the delivery of radiation therapy to 
neoplasms. Organ and tumor size, deformation, and motion may have pro-
found impacts on delivering accurate lung RT. Abdominal compression plates 
(ACPs) have been used to limit tumor motion during the respiratory cycle 
to supposedly more safely and effectively deliver radiotherapy. The purpose 
of this study was to determine whether ACPs affect lung tumor motion, as 
demonstrated by 4DCT. 
Materials/Methods: Patients (n=6) simulated for Stereotactic Ablative 
Radiotherapy (SABR), a Free Breathing (FB) CT and 4DCT scans with and 
without ACP were obtained. Twenty-one scans per patient consisting of FB, 
4DCT with ACP including 0%-90% breathing phases (n=10 scans), and 
4DCT without ACP including 0%-90% breathing phases (n=10 scans) for 
a total 126 scans analyzed. Tumor volumes on each CT frame were manu-
ally contoured using Eclipse software (Varian, Palo Alto, CA). For respiratory 
cycle phase, contoured images were analyzed to quantify tumor motion. The 
displacement of tumor from the CT 50% phase (corresponding to end expi-
ration) of the respiratory cycle for each patient with and without ACP was 
determined. Maximum and minimum deviations of the tumor in all directions 
(AP, SI, and lateral) from the CT 50% were calculated for each patient. The 
differences in tumor movement magnitude with and without ACP in 3-dimen-
sions was determined for each case. 
Results: The average range of tumor movement in the lateral, AP, and SI 
direction was 1.62, 2.94, and 5.36 mm with ACP and 2.26, 2.92 and 5.09 mm 
without ACP, respectively (p=NS). The average 3-D tumor displacement was 
5.75 mm with ACP and 6.18 without ACP (p=0.37). Of the 6 cases evaluated, 
2 showed decreased tumor motion with ACP use, 3 showed minimal to no 
change in tumor motion with ACP use compared to no ACP, and 1 showed 
increased tumor displacement with the use of ACP. 
Conclusions: These results suggest the effects of ACP on lung tumor motion 
may be patient specific. Factors, such as severity of COPD, chest wall elastic-
ity, and lung tumor location may contribute to the efficacy of ACP in limiting 
tumor motion. The use of ACP during lung cancer SABR should be evaluated 
on a case by case basis and requires further study.
Author Disclosure Block: S. Rosenberg: None. S.K. Jabbour: None. N.J. 
Yue: None. A. Rasheed: None. B.G. Haffty: None. S. Goyal: None. A. 
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Intrafraction Fiducial Tracking with Real-Time Treatment 
Intervention in Lung SBRT
R. B. Taylor, M. Dobelbower, J. B. Fiveash, S. A. Spencer, D. Minnich, R. A. 
Popple, University of Alabama Medical Center, Birmingham, AL
Purpose/Objective(s): Stereotactic body radiation therapy (SBRT) has 
gained importance for treatment of early lung cancers in non-surgical 
candidates. The high fractional dose and tight margins require accurate 
target localization; however, for respiratory gated delivery there typically 
remains no real-time intrafraction target alignment. We report a pilot study 
using intrafraction 2-D kilovoltage (kV) X-ray imaging during respira-
tory gated SBRT with intrafraction intervention based on real-time target 
localization. 
Materials/Methods: A total of 1527 localization images were analyzed 
from 21 fractions delivered to 7 patients with lung cancer. The patients 
underwent bronchoscopic implantation of fiducial markers in the tumor for 
subsequent target localization. 4D-CT-simulation was performed and volu-
metric modulated arcs were used for treatment delivery. Pre-treatment image 
guidance consisted of orthogonal kV images followed by cone beam CT. 
During treatment, kV images were acquired at the start of beam delivery for 
each respiratory cycle. Each image was displayed in real-time with a super-
imposed 1 cm diameter circle around the expected fiducial position to enable 
visualization of the target misalignment. The operator was able to suspend 
treatment if the fiducials were observed to move beyond an acceptable range 
and restart treatment if real-time imaging demonstrated acceptable position-
ing or reposition the patient. All intrafraction kV images were reviewed and 
real-time fiducial positions were compared to expected positions as deter-
mined on planning CT. 
Results: Fiducial motion was successfully tracked in real-time and real 
time intervention was performed during treatment. While the use of a single 
imager does not allow full 3 dimensional resolution of the target position, 
it does allow resolution in 2 dimensions and always in the most important 
direction, the cranial-caudal (c-c). The mean vector displacement was 2.4 mm 
(median 2.1 mm) and the root-mean-square c-c displacement was 2.1 mm. 
The vector displacement was within 5 mm (PTV expansion) of the expected 
position 94% of the time. However, we identified several large discrete shifts 
of up to 1 cm corresponding to intrafraction patient movement. Real time 
identification of these events allowed a halt to beam delivery, patient reposi-
tioning, and avoidance of a geographic miss. 
Conclusion: Real-time fiducial tracking with intrafraction kV imaging during 
lung SBRT is feasible and demonstrated the target is within the 5 mm PTV the 
majority of the time. However, infrequent but significant translational error in 
target localization due to intrafraction patient movement does occur. Use of 
real-time imaging allows for treatment interruption and target realignment, 
which may improve the quality of the radiation therapy.
Author Disclosure Block: R.B. Taylor: None. M. Dobelbower: None. J.B. 
Fiveash: E. Research Grant; Varian. F. Honoraria; Varian. S.A. Spencer: 
None. D. Minnich: None. R.A. Popple: E. Research Grant; Varian. F. 
Honoraria; Varian.
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Feasibility And Stability Of Trans-thoracic Implanted 
Markers In Peripheral Lung Tumors For Stereotactic Body 
Radiotherapy
G. Persson1, M. Josipovic1, D. E. Nygaard1, M. Aznar1, P. Munck af 
Rosenschöld1, P. von der Recke1, T. Juhler-Nøttrup2, S. S. Korreman3, 
L. Specht1, 1Rigshospitalet, Copenhagen, Denmark, 2Herlev Hospital, 
Copenhagen, Denmark, 3Roskilde University, Roskilde, Denmark
Purpose/Objective(s): Implanted fiducial markers are used as surrogates for 
position of mobile tumors in beam tracking or gating. A stable position of 
the marker within the tumor is therefore important. We evaluated the clinical 
feasibility of trans-thoracic implantation of markers in peripheral lung tumors 
and estimated the stability of the marker position during stereotactic body 
radiotherapy (SBRT).
Materials/Methods: We prospectively included 15 patients referred for 
lung SBRT. A complex fiducial marker was implanted in each tumor com-
puted tomography (CT) guided by trans-thoracic puncture a week before 
planning. Voluntary deep inspiration breathhold CTs (BHCT) (3 mm slice 
thickness) were acquired at planning and on the three treatment days. The 
treatment days’ BHCTs were registered to the planning BHCT. All regis-
trations were performed twice to determine intra-observer uncertainty for 
both tumor and marker registration. Differences between tumor and marker 
based image registrations of the BHCTs were evaluated from four possible 
combinations of tumor and marker based image registrations. Deviation in 
registration differences in the three translational directions quantified the 
marker stability.
Results: All patients were eligible for the feasibility evaluation while 13 were 
eligible for the stability evaluation. Four patients had pneumothorax after the 
marker implantation, three needed a chest tube. One of the patients coughed 
up the marker between implantation and planning. Intra-observer uncertain-
ties in image registration were -0.2 ± 0.9 mm (mean ± SD) in left-right (LR) 
direction, 0.0 ± 0.9 mm in anterior-posterior (AP) direction, and 0.2 ± 1.0 
mm in cranio-caudal (CC) direction for tumor registration and -0.0 ± 0.3 mm 
in LR, 0.5 ± 0.5 mm in AP and 0.1 ± 0.7 mm in CC for marker registration. 
Mean 3D differences for tumor registrations on all days were significantly 
larger than for 3D marker registrations (p=0.007; paired t-test). Mean devia-
tions between tumor and marker position of the four registration combina-
tions ranged -2.9 to 2.6 mm in LR, -0.8 to 1.5 mm in AP and -2.6 to 2.8 mm in 
CC. Four patients had deviations exceeding 2 mm in one or more registrations 
throughout the SBRT course.
Conclusions: Trans-thoracic marker implantation is feasible but with a high 
risk of pneumothorax (27%). Marker deviations were within the magnitude 
of the intra-observer variation of the registration procedure for the majority 
of patients. The intra-observer uncertainty in marker registration was signifi-
cantly smaller than for tumor registration. Markers implanted in lung tumors 
can be used as a surrogate for tumor position during a short course of SBRT 
but the uncertainty of the marker position within the tumor should be included 
in planning target volume definition.
Author Disclosure Block: G. Persson: None. M. Josipovic: None. D.E. 
Nygaard: None. M. Aznar: None. P. Munck af Rosenschöld: None. 
P. von der Recke: None. T. Juhler-Nøttrup: None. S.S. Korreman: None. 
L. Specht: None.
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Phase I Randomized Trial of Dietary Flaxseed in Non-Small 
Cell Lung Cancer Patients Receiving Chemoradiation
A. Milby, R. Mick, J. Turowski, K. Cengel, N. Farnese-McFarlane, C. Mesaros, 
J. Lawson, M. Christofidou-Solomidou, J. Lee, R. Rengan, University of 
Pennsylvania, Philadelphia, PA
Purpose/Objectives: The standard of care in locally advanced non-small cell 
lung cancer (NCSLC) is chemoradiation; however, 5-year survival is poor at 
less than 20%. Maximum benefit from radiation therapy (RT) is impeded by 
radiation-induced lung injury (RILI). Flaxseed (FS) has potent anti-inflam-
matory, anti-fibrotic and antioxidant properties in models of thoracic RILI. 
We evaluated the feasibility of this dietary supplement in a phase I double-
blinded, placebo-controlled study assessing toxicity and tolerability while 
quantifying human serum FS metabolite levels in tandem with validated uri-
nary markers of systemic oxidative stress. 
Materials/Methods: Patients with locally-advanced or oligometastatic NSCLC 
requiring definitive thoracic radiation (RT) without a history of gastrointesti-
nal malabsorption, concurrent antioxidant use, or herbal hypersensitivities were 
randomized to ingest one FS or Durham wheat muffin daily from start of RT to 
2 weeks after RT. RT dose was 60-80 Gray (Gy) in 2 Gy fractions. Blood and 
urine were collected before, during, and after RT to quantify plasma levels of the 
flaxseed metabolites, enterodiole (ED) and enterolactone (EL) as well as urinary 
biomarkers of oxidative stress, 8,12-iso-iPF-2alpha-VI and 8-oxo-7,8-dihydro-
2’deoxyguanosine (8-oxo-dGuo). Tolerability was defined as the ability consume 
> 75% of the intended number of muffins and no grade 3 toxicities. 
Results: Fourteen patients were enrolled in this study and consumed at 
least one control (n=7) or one FS muffin (n=7). The tolerability rates were 
42.9% versus 71.4% (p=0.59) for FS and control groups, respectively. The 
mean percentages of intended number of muffins consumed were 37% (range 
2.8-100%) versus 73% (range 8.5-100%, p=0.12) for FS and control groups, 
respectively. Plasma ED and EL levels were elevated at onset of therapy and 
decreased with discontinuation of FS confirming bioavailability. Systemic 
oxidative stress biomarkers, isoprostane and 8-oxo-dGuo, were detect-
able from radiotherapy. In the flaxseed group, urinary markers of oxidative 
stress decreased at week 1 of RT, increased by the end of RT, and ultimately 
decreased one month after completion of radiotherapy. Rates of pneumonitis 
and esophagitis were lower in the FS patients as compared to control (0% vs. 
42.9% and 57.1% vs. 85.7%, respectively). 
Conclusion: This is the first study to report the bioavailability of flaxseed and 
to quantify urinary markers of systemic oxidative stress in NSCLC patients. 
Further investigations should focus on the optimal method for administration 
of FS in patients with locally advanced NSCLC receiving radiotherapy.
Author Disclosure Block: A. Milby: None. R. Mick: None. J. Turowski: 
None. K. Cengel: None. N. Farnese-McFarlane: None. C. Mesaros: None. 
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The Preliminary Results and Early Response for Centrally 
Located Lung Cancer Treated by Stereotactic Radiotherapy 
in Consecutive Daily Fractions
H. Zhuang1, B. Wang1, Y. Sun1, Y. Song1, F. Li1, Y. Dong1, L. Zhao1, C. Wang2, 
Z. Yuan1, P. Wang1, 1Cyberknife Center&Department of Radiotherapy,Tianjin 
Medical University Cancer Hospital & Institute, Tianjin, China, 2Department 
of Lung Cancer,Tianjin Medical University Cancer Hospital & Institute, 
Tianjin, China
Purpose/Objective(s): To evaluate the early toxicity and efficacy of centrally 
located lung cancer treated by CyberKnife stereotactic radiotherapy in con-
secutive daily fractions. 
Materials/Methods: We retrospectively reviewed 56 patients with centrally 
located lung cancer from November 2006 to February 2011. Of which, 36 
lesions were primary,11 were recurrent, 10 were metastatic; and 40 patients 
were male, 16 were female ; the median age was 71 years (range 37-86 years); 
the median PTV was 35.7ml (range 4.0-169.2 ml), and 31 patients were 
treated with the Synchrony® Respiratory Tracking System which needs 1-2 
gold markers implantation. 25 patients were treated with the X-sight® tech-
nology. A total prescription dose of 30-60Gy(median 54Gy)was delivered in 
3-12 consecutive daily fractions (median 5Fx). Of which, the dose for the pri-
mary lesions was 45-60Gy(median 55Gy),which was delivered in 3-10 frac-
tions (median 5Fx); the dose for the recurrent lesions was 30-60Gy(median 
48Gy),which was delivered in 3-12 fractions (median 6Fx); the BED was 
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45-180Gy(median 100.8Gy), of which, the BED for 27 (48.2%)lesions was 
no more than 100Gy, the other were over 100Gy. 
Results: 21 patients (37.5%) achieved complete response (CR), and 
27(46.4%) achieved partial response (PR), 9 (16.1%) achieved stable disease 
(SD). At a median follow-up of 19 months (3-64 months), the median sur-
vival time was 25.5 months, the local control rate and overall survival at 1, 
2, 3 years were 100%, 90.3%, 90.3% and 80.4%, 52.1%, 38.4% respectively; 
there was no significant difference in local control rate between the groups of 
BED≤100Gy and BED>100Gy. Three patients, who belonged to the group 
of BED ≤100Gy obtained local failure at 16, 19, 19.5months after treatment. 
Eight patients obtained regional recurrence, 8 patients obtained distant metas-
tasis. 28 patients died after the treatment, of which 20 patients (71.4%) died 
of cancer, 8 patients died of comorbid problems. Of the patients, 5 developed 
dyspnea(1 was grade 1, 1 was grade 2, 2 were grade 3(Tab1)) after treat-
ment, 2 developed dysphagia(1 was grade 1,1 was grade 2 ), 3 developed 
cough(grade 1), 1 developed fatigue and 1 developed atelectasis. 
Conclusions: CyberKnife stereotactic radiotherapy, which is a reasonable 
therapeutic modality in consecutive daily fractions for centrally located 
lung cancer, can provide high primary tumor local control rate and minimal 
toxicity.
Table 1 Summary of grade3 dyspnea after treatment
1 2
Prescription dose 50Gy/5FX 50Gy/3FX
Isodose surface (%) 78 81
PTV (mm3) 78697.23 26277.28
Dose of bronchial tree
0.1ml(Gy) 27.91 34.75
1ml(Gy) 17.13 17.68
5ml(Gy) 6.98 13.14
Previous surgery NO Pneumonectomy
Pulmonary heart disease YES YES
Author Disclosure Block: H. Zhuang: None. B. Wang: None. Y. Sun: 
None. Y. Song: None. F. Li: None. Y. Dong: None. L. Zhao: None. C. 
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The Utility of PET/4DCT-Derived Target Volumes for 
Stereotactic Body Radiation Therapy in the Treatment of 
Non-Small Cell Lung Cancer
B. Lynch1,2, A. Bhatt1, A. Zacarias1, N. Dunlap1, 1University of Louisville, 
Louisville, KY, 2University of Florida, Gainesville, FL
Purpose/Objective(s): To evaluate the impact of incorporating PET imag-
ing to aid target delineation for lung stereotactic body radiotherapy (SBRT) 
in addition to four dimensional computer tomography (4DCT) only based 
planning. 
Materials/Methods: Twenty-four patients who received positron emis-
sion tomography (PET) imaging as part of their lung SBRT planning were 
included in this study. PET and 10-phase 4DCT volumes were acquired as 
part of the treatment planning process. The 4DCT was used to calculate a 
maximum intensity projection (MIP) for target delineation and 4D average 
for dose calculation. PET and 4D average CT volumes were co-registered and 
two internal target volumes (ITV)per patient were generated, using the MIP 
and the MIP/PET. ITV contours were expanded 5 mm to create the planning 
target volume (PTV). Volumetric modulated arc therapy treatment plans were 
generated using inverse planning and the Eclipse treatment planning system 
(Varian Medical Systems, Inc., Palo Alto, CA). The end points of the study 
were to compare the 4DCT- and PET/CT-based treatment plans on the basis 
of ITV volume, mean lung dose (MLD), the volume of lung exceeding 20 
Gy (V20), and the ratio of the 50% prescription isodose volume to the PTV 
volume (R
50%
). A nonparametric Wilcoxon matched-pairs signed-ranks test 
was applied to determine the statistical significance of any differences noted 
between the measurement variables. 
Results: Median age was 73 (52-81) and KPS was 80 (60-100). Twenty-
five tumors were treated to a median dose of 49 Gy (40-54) in 3-5 fractions. 
Median biologic effective dose (BED) was 105.6 (72-151.2). The results of 
our study are shown in Table 1. The mean ITV volume for 4DCT/MIP was 
13.89 cm3 vs. 11.51 cm3 for 4DCT/PET (p< 0.05). The difference between 
MLD and V20 for the 4DCT/PET plans vs 4DCT were also statistically sig-
nificant (p< 0.01). The mean R50% for both 4DCT and PET/4DCT was 4.13, 
and the difference was not statistically significant. 
Conclusions: While 4DCT has shown great utility in determining the extent 
of tumor motion during respiration, our study shows that PET imaging aids 
the accurate delineation of early stage lung tumors. ITVs generated when 
PET was included were significantly smaller than those derived from 4DCT 
alone, and this reduction in ITV size is accompanied with a reduction in MLD 
and V20.
Differences between 4DCT and 4DCT/PET
Variable 4DCT 4DCT/PET p value
ITV volume (cm3) 
Mean (standard 
deviation) Median 
(range)
13.89 (13.70)  
9.75 (1.28-59.69)
11.51 (10.37)  
8.38 (0.81-33.72)
<0.05
Mean lung dose (Gy) 
Mean (standard 
deviation) Median 
(range)
4.53 (1.80)  
4.57 (1.70-8.11)
4.14 (1.79)  
4.30 (1.34-7.61)
<0.01
V20 (%) Mean 
(standard deviation) 
Median (range)
4.65 (2.57)  
4.59 (0.76-8.99)
3.95 (2.34)  
4.06 (0.51-8.24)
<0.01
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A Clinical Guide to Evaluate Non-Monte Carlo Treatment 
Plans in Lung SBRT
A. Sethi, I. Rusu, J. Zhung, E. Melian, S. Nagda, Loyola University Medical 
Center, Maywood, IL
Purpose/Objective(s): Monte Carlo (MC) treatment plans provide the most 
accurate estimate of dose in lung SBRT. However, most treatment planning 
systems (TPS) do not permit real time MC dose calculations. This leads to 
significant under dosing of lung targets. We evaluate planned dose distribu-
tion for lung SBRT patients and recommend a method to create realistic treat-
ment plans using non-MC planning systems. 
Materials/Methods: Tissue equivalent spherical targets of different size were 
simulated in central and peripheral lung. Target volumes ranged from 0.47 to 
66.5 cc. First, all treatment plans were calculated with a pencil beam (PB) 
dose algorithm in BrainLAB iPlan4.1, to deliver 50Gy in 5 fractions to the 
periphery of PTV, using 10-12 non-coplanar conformal fields. To determine 
actual dose delivered, MC dose calculations were performed without chang-
ing beam parameters (MLC shape and monitor units). PTV dose distribution 
was evaluated using Dmin, Dmean, Dmax and D90. Furthermore, MC cal-
culated spatial dose distributions within PTV were analyzed as a function of 
target size. To improve target coverage, the effect of increasing PTV to MLC 
margin on dose parameters was investigated. PTV margins were increased 
in steps (1-5mm) and MC calculations performed without changing beam 
parameters. All treatment plans were evaluated using RTOG 0813 dose crite-
ria for D2cm, R50% and conformality index (CI). 
Results: Compared to PB plans, average values of PTV Dmin, Dmean, 
Dmax, and D90 in MC plans were lower by 21±9%, 10±8%, 6±4%, and 
14±6% respectively. Spatial dose distribution within PTV indicated that the 
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greatest dose deficit occurred in the superficial target layers. For the PTV 
core (5mm below surface) all dose parameters were in good agreement with 
delivered dose. Based on MC results, the ratio of delivered to calculated dose 
for Dmean, Dmax and D90 for PTV core was 97±4%, 95±4%, and 98±2% 
respectively. With an increase in PTV to MLC margin, the agreement between 
PB results and actual dose improved significantly. The margin increase was 
specific to target size, location and surrounding medium. For central lesions 
surrounded by lung, a uniform expansion of 5mm was found to be suffi-
cient. Peripheral targets, adjacent to chest-wall or mediastinum, required a 
non-uniform expansion: 5mm within the lung, and 1-2 mm elsewhere. With 
this recipe, PB predictions for Dmean, Dmax and D90 were all within 2% of 
delivered dose. The average values of CI, D2cm and R50% were 8%, 5%, and 
28% larger than PB predictions. However, except for R50%, all met RTOG 
specified guidelines. 
Conclusions: We have presented a novel and simple method of evaluating 
and optimizing non-MC plans so that planned dose distributions agree with 
delivered dose for lung SBRT patients.
Author Disclosure Block: A. Sethi: None. I. Rusu: None. J. Zhung: None. 
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Respiratory Gated Radiotherapy With Hypofractionated 
Doses For Lung Tumors: Four Years’ Experience Of A Single-
institution
M. Y. Almaghrabi, M. Mahé, E. Rio, E. Bardet, F. Thillays, A. Lisbona, S. 
Gaudaire-Josset, Integrated Center of Oncology, Nantes, France
Purpose/Objective(s): To report our institutional experience including local 
control (LC), overall survival (OS) and toxicity after Respiratory Gated 
Radiotherapy (RGRT) with Hypofractionated doses for primary and second-
ary lung tumours. 
Materials/Methods: forty patients with 48 lung tumors (18 primary lesions 
and 30 metastases, 27 peripheral and 21 central) were treated with RGRT 
during deep inspiratory breath hold (DIBH), between November 2007 to 
November 2011. Inclusion criteria were: KPS ≥ 70%, ≤ 3 lesions, ineligibility 
for surgery or radiofrequency or fiducial implantation for stereotactic radio-
therapy (SBRT). Prior anti-cancer treatments, significant chronic obstructive 
pulmonary disease (COPD) and poor pulmonary function test (PFT) were 
not exclusion criteria. The first CT evaluation was from 8 to 12 weeks after 
RGRT. Lesions with at least 3 months of CT follow-up were considered 
assessable for local control. 3-D margins from clinical target volume (CTV) 
to planning target volume (PTV) were 15 mm. PTV was encompassed by 
the 83% to 95% isodose line of the prescribed dose (the median dose was 32 
Gy (range, 25-42)); using 3-D conformal radiation therapy with non-opposed 
coplanar, 10 or 25 MV beams. Treatment was delivered in 5 to 6 fractions /2 
weeks. Acute and late toxicities were graded according to the NCI CTCAE 
v3.0 scale. 
Results: The median CTV was 40 cm3 (range, 1-81). The median PTV was 
89 cm³ (range, 12-907).The median follow-up for assessable lesions was 
17 months (range, 2-36). Kaplan-Meier 2 years LC was 73%. The overall 
response rate was 55%. Of the 48 tumors, 25 (52%) had no treatment fail-
ure and 23 (48%) did, including 5(22%) within the PTV and 18 (78%) out-
side the PTV. CTV volumes (<40 cm3 and ≥ 40 cm³) did not significantly 
impacted local control: 18 months LC was 74% (95%CI, 53-87%) and 64% 
(95%CI, 15-90%), respectively, p= 0.77. Median survival was 18 months and 
the estimated 24 months overall survival rate was 62 %( 95%CI, 43-76%). 
There was no significant two-year survival difference between patients with 
primary (55%) vs. secondary tumors (67%), p= 0. 8. Three patients with cen-
tral lesions had acute grade 2 esophagitis. Two patients with severe COPD 
presented grade 3 acute and late pulmonary toxicity. 
Conclusions: This study adds to the evidence that Hypofractionated RGRT 
with DIBH for lung tumors allows clinical benefit. Favourable safety profile 
and good local control can be achieved by this technique, when treating larger 
or centrally-located lung tumors. Based on this data we suggest this treatment 
modality for patients with lung tumors who are not eligible for other curative 
treatments. Although the impact of this strategy on survival seems to be posi-
tive, participation in clinical trials with more patients is strongly encouraged.
Author Disclosure Block: M.Y. Almaghrabi: None. M. Mahé: None. 
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Novel Applications Of An Injectable Radio-opaque Hydrogel 
Tissue Marker For Management Of Thoracic Malignancies
L. M. de Souza-Lawrence, E. Ford, C. Gilbert, L. Yarmus, A. Meneshian, D. 
Feller-Kopman, R. Hales, The Johns Hopkins University, Baltimore, MD
Purpose/Objective(s): Radio-opaque markers (otherwise known as fiducials) 
are utilized clinically to mark sites of biopsy or resection, which aids with the 
targeting of adjuvant or definitive local therapy, including surgery and/or radia-
tion therapy. We performed a human cadaveric imaging series using a novel 
injectable, radio-opaque absorbable hydrogel marker to demonstrate the poten-
tial for such a material to be used in the management of thoracic malignancies. 
Materials/Methods: Baseline CT images were performed on 3 unfixed cadav-
eric specimens. Hydrogel marker implants were performed in the submucosa 
of the esophagus, the mediastinum and lung parenchyma by an endoscopic 
approach. Real-time endobronchial and esophageal ultrasound were utilized 
to confirm hydrogel placement. Sub-pleural implants in peripheral lung paren-
chyma were also performed via an anterolateral thoracotomy. Post-implant 
simulation CT, T2-MRI and cone-beam CT were performed. Gross dissection 
of the lung parenchyma was used to evaluate localization of the hydrogel. 
Results: Transthoracic and endoscopic marker placements were readily 
achieved. The hydrogel appeared hyperechoic by ultrasound, hyper-enhanc-
ing on T2-MRI imaging, and demonstrated radio-opacity of approximately 
300 HU in simulation CT and cone-beam CT. Gross dissection of the lung 
revealed well-localized blebs of hydrogel marker within lung parenchyma. 
Conclusions: This cadaveric series demonstrates the excellent visibility of 
a radio-opaque injectable hydrogel marker in the human thorax by multiple 
common imaging techniques, and because it forms a well-localized palpable 
bleb within tissue it can potentially be used to triangulate disease during mini-
mally invasive thoracic surgery. Future in-vivo studies are warranted, because 
radiopaque injectable compounds are promising alternatives to metal fiducials.
Author Disclosure Block: L.M. de Souza-Lawrence: None. E. Ford: E. 
Research Grant; Augmenix Inc.(Waltham, MA).. C. Gilbert: None. L. 
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Prospective Evaluation of Cardiac Toxicity After 
Stereotactic Body Radiotherapy for Thoracic Tumors Using 
Echocardiographic Findings
S. K. Yi1, W. J. Bommer2, L. A. Beckett3, M. E. Daly1, A. M. Chen1, 1University 
of California Davis Cancer Center, Sacramento, CA, 2University of California 
Davis Medical Center, Sacramento, CA, 3University of California Davis 
School of Medicine, Sacramento, CA
Purpose/Objective(s): Stereotactic Body Radiation Therapy (SBRT) is 
increasingly utilized for the treatment of thoracic malignancies. Radiation-
induced cardiac toxicity is a well documented side effect of treatment for 
patients irradiated using conventional fractionation for lymphoma, breast 
cancer, and lung cancer. However, little is known about the cardiac effects of 
extreme hypofractionation using thoracic SBRT. We prospectively evaluated 
cardiac function in 10 patients treated with SBRT to the lung. 
Materials/Methods: Ten patients with early-stage primary lung and oligo-
metastatic tumors were enrolled into an Institutional Review Board approved 
study prospectively evaluating echocardiographic findings pre and post SBRT. 
Eight patients had peripheral lesions and were treated to a dose of 54 to 60 Gy 
in 3 fractions over the course of 2 weeks. Two patients with centrally-located 
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lesions were treated to a dose of 50 Gy in 5 fractions over 2 weeks. SBRT was 
delivered with 9-14 static noncoplanar beams using a body fixation system 
with abdominal compression. Echocardiograms were performed by a board-
certified cardiologist prior to the first fraction and between 1 and 6 months 
post treatment (median 3 months). Four key echocardiographic indices were 
evaluated including: presence or absence of pericardial effusion, systolic, dia-
stolic and valvular function. 
Results: Seventy percent of 10 lesions treated were left sided. The planning 
target volume (PTV) volume ranged from 10 to 111cc (median 33.5cc). Forty 
percent of tumors were located in the upper lobes and 60% in the lower lobes. 
Maximum cardiac dose ranged from 1.7 - 26.4 Gy (median 18.8 Gy). Mean 
cardiac dose ranged from 0.3 - 7.7 Gy (median 2.5 Gy). One patient devel-
oped a trivial pericardial effusion at 6 months post SBRT. Two patients had 
pericardial effusions at baseline which were no longer detectable post treat-
ment. Fifty percent of patients had decreased systolic function by ejection 
fraction (mean percent change -6.6%). Three of 10 patients had decreased 
diastolic function by E/A ratio measurement (mean percent change -0.25). 
There were no significant differences noted in valvular function. 
Conclusions: SBRT appears to have minimal impact on echocardiographic 
findings 1-6 months post treatment. Small changes in ejection fraction and 
diastolic function were observed in the acute setting but appeared subclinical 
in nature. Continued follow-up will be needed to further evaluate the contri-
bution of SBRT to late cardiac toxicity.
Author Disclosure Block: S.K. Yi: None. W.J. Bommer: None. L.A. 
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1092 
Rotational Dual-Energy Image-Guided Radiotherapy for 
Lung Tumors
T. S. Bray, J. Luce, M. A. Hoggarth, J. Y. Lin, S. N. Nagda, J. C. Roeske, 
Loyola University Medical Center, Chicago, IL
Purpose/Objective(s): Dual energy (DE) imaging is a technique commonly 
used in diagnostic radiology to enhance visualization of lung tumors. DE 
imaging exploits the differential attenuation of bone versus soft tissue (as a 
function of energy) to produce tissue-selective composite images. The ability 
to eliminate overlying bony anatomy on planar images could allow improved 
tumor definition in the thorax from a variety of oblique angles in patients 
undergoing kV-based image guided radiotherapy (IGRT). Our goal was to 
evaluate the theoretical role of DE imaging in tracking lung tumors through-
out a full (0-360°) range of gantry angles. 
Materials/Methods: Free-breathing planning CT scans of 20 patients with 
stage IA or IB NSCLC were evaluated for this study. Gross tumor volumes 
(GTV) were contoured on axial CT images. Hounsfield units (HU) of the 
CT scans were converted into attenuation coefficients for 60 kV and 120 kV 
x-rays at oblique angles from 0-360° in increments of 20°. Weighted subtrac-
tion of the 60 kV and 120 kV images was performed to create soft-tissue 
selective DE images at each angle. DE images were compared to the 120 kVp 
image using contrast-to-noise ratio (CNR), a quantitative measure of tumor 
visibility. CNR represents the difference between the average tumor signal 
and the background signal, divided by the standard deviation (noise) of these 
regions. A total of 720 images were analyzed. 
Results: DE imaging effectively subtracted the overlying bone at all angles. 
When compared to the single energy x-rays of corresponding angles, DE 
imaging resulted in at least 10% improvement in CNR in 37% of all images, 
and at least 20% improvement in CNR in 20% of all images analyzed. 
Oblique angles providing the greatest improvement in CNR with DE imag-
ing were patient-dependent, likely due to tumor location relative to nearby 
soft tissue structures such as the heart and mediastinum that do not subtract 
out with DE imaging. However there was an overall trend for greatest CNR 
improvement for clusters of angles in the following ranges: 40-60º, 100-120º, 
and 160-300 º. 
Conclusions: Rotational DE subtraction imaging demonstrates a patient-
dependent improvement in lung tumor visibility at oblique angles. This 
technique could improve our ability to localize lung tumors at oblique angles 
for patients treated with thoracic IGRT using an OBI. DE imaging that allows 
improved tumor visibility at oblique angles provides an important image- 
verification advantage and may ultimately allow for real-time rotational tumor 
tracking.
Author Disclosure Block: T.S. Bray: None. J. Luce: None. M.A. Hoggarth: 
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Analysis Of GTV Position And Displacement For Peripheral 
Lung Cancer Based On Four Dimensional CT And Three 
Dimensional CT Assisted With Active Breathing Control
H. Qi, J. B. Li, Y. j. zhang, Shandong Cancer Hospital, Jinan, China
Purpose/Objective(s): To analyze GTV position and displacement for periph-
eral lung cancer based on four dimensional CT (4DCT) and three dimensional 
CT (3DCT) assisted with active breathing control (ABC).
Materials/Methods: After respiratory training sufficiently, 18 patients (upper 
lobe group 13 and middle-lower lobe group 5) with peripheral lung cancer 
underwent 4DCT simulation scan during free breathing and 3DCT simulation 
scans in end inspiration hold (CT
EIH
) and end expiration hold (CT
EEH
) in turn. 
To calculate distances between the centroid position of GTV
0 
and GTV
EIH
, 
GTV
50 
and GTV
EEH 
contoured based on CT
0 
and CT
EIH
 , CT
50
 and CT
EEH
. The 
displacements between the centroid position of GTV
0 
and GTV
50
, GTV
EIH 
and 
GTV
EEH 
were d
1
 and d
2
. The maximum displacement among the centroid posi-
tion of GTVs in 4DCT was d
3
. To compare the differences between d
1
 and d
2
, 
and between d
2
 and d
3
 in three axes. To calculate the matching index (MI) of 
GTV
0 
and GTV
EIH
, GTV
50 
and GTV
EEH
.
Results: The mean distances between the centroid position of GTV
0 
and 
GTV
EIH
, GTV
50 
and GTV
EEH
 were 4.28mm (p=0.000), 3.50mm (p=0.000) 
in upper lobe group and 6.10mm (p=0.031), 5.87mm (p=0.029) in 
middle-lower lobe group and the mean MIs between GTV
0 
and GTV
EIH
, 
GTV
50 
and GTV
EEH 
were 0.53, 0.56 and 0.19, 0.25 respectively. There 
were no significant differences between d
1
 and d
2
 in x, y, and z axes in the 
two groups (t = -1.866, -2.155, -0.821 and 1.280, 0.674, 0.570, p=0.087, 
0.052, 0.428 and 0.270, 0.537, 0.599). There were also no significant dif-
ferences between d
2
 and d
3
 in x, y, and z axes in the two groups (t =-0.606, 
-0.261, -0.606 and 1.926, 2.268, 1.016, p=0.556, 0.798, 0.556 and 0.126, 
0.086, 0.367).
Conclusions: Although the differences of GTVs centroid position were 
obvious between extreme phases in 4DCT and corresponding phases in 
3DCT assisted with ABC, and the MIs were smaller especially in middle-
lower lobe group and in end inspiration, in other words, compared with 
GTVs centroid position in 4DCT scan, the accuracy of breathing control 
in 3DCT scan was not good, though sufficient respiratory training was 
done before simulation, there were no significant differences in tumor 
displacements between 4DCT and 3DCT assisted with ABC. To take 
advantage of this, internal margin may be acquired in the internal target 
volume generation using active breathing control technique, if 4DCT is 
not available.
Author Disclosure Block: H. Qi: None. J.B. Li: None. Y.J. zhang: None.
1094 
Dosimetric Accuracy Of Ray-Tracing Algorithm For 
Treatment Of Thoracic Spine Lesions Using Robotic 
Radiosurgery
R. L. Ebeling, III1, J. Hiatt2, O. Adetokunbo3, M. Goldman3, B. Curran2, T. 
DiPetrillo1, T. Kinsella2, J. T. Hepel2, 1Tufts University Affiliated Hospitals, 
Boston, MA, 2Rhode Island Hospital, Department of Radiation Oncology, 
Providence, RI, 3Rhode Island Hospital, Department of Neursurgery, 
Providence, RI
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Purpose/Objective(s): Frequently, dose adjustments or optimization using 
Monte Carlo are employed to correct for tissue homogeneity inaccuracies of 
the ray-tracing dose calculation algorithm used for Cyberknife (CK) robotic 
radiosurgery treatment planning of lung tumors. CK spine radiosurgery 
patients are required to be treated in the supine position to allow for accurate 
intra-treatment spine tracking, yet posterior oriented beams are not possible 
with this system. As such, in the treatment of thoracic spine lesions the major-
ity of treatment beams traverse the lungs. In addition, high density surgical 
hardware is often present in and around the target lesion. The dosimetric 
impact of inaccuracies in correcting for these marked differences in tissue 
density for the treatment planning of thoracic spine lesions is not known. 
Materials/Methods: Thirty one patients with 43 thoracic vertebral lesions 
treated in our department using CK radiosurgery between 2009 and 2012 
were identified. All patients were planned using the CK Multiplan system 
employing ray-tracing algorithm (RTA) for tissue heterogeneity correction to 
a median dose of 24Gy in 1-5 fractions. For each patient, a comparison plan 
was generated using Monte Carlo dose calculation algorithm (MCA) using 
identical beam arrangement and monitor units. Plans were compared for dif-
ferences in GTV coverage by the prescription isodose line, GTV D
90%
, spinal 
cord maximum dose, and dose to 0.25cc of spinal cord. 
Results: Mean GTV coverage was 26.3% lower for the MCA as compared 
with RTA, 60.3% vs 86.6%, respectively (p<0.0001). Similarly, mean GTV 
D
90%
 was 2.7% lower for MCA (range: -7.34% to 9.26%, p=0.001). Conversely, 
mean doses to the spinal cord were significantly higher using MCA by 6.9% 
(range: -9.8% to 24.1%) for maximum dose and by 1.2% (range: -8.9% to 
10.6%) for 0.25cc; p<0.0001 and p<0.01, respectively. Presence of surgi-
cal hardware (n=8) had only a small effect with mean differences of -5.4% 
for GTV coverage (p=0.6), -2.2% for GTV D
90%
 (p=0.3), 4.3% for cord max 
(p=0.2), and 5.4% for cord 0.25cc (p=0.04). 
Conclusion: Ray-tracing dose calculation algorithm for the thoracic spine 
overestimates GTV coverage and underestimates spinal cord dose. This can 
result in significant impact on both disease control and potential for cord 
injury, especially in the retreatment setting where treatment doses and cord 
constraints are pushed to tolerance levels. Optimization of treatment plans 
using Monte Carlo dose calculation algorithm is, thus, warranted in these 
patients.
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A Phase Ib Study Of Bavituximab Plus Carboplatin And 
Pemetrexed In Chemotherapy Naïve Stage IV Non-Squamous 
Non-Small Cell Lung Cancer
J. Grilley-Olson1, J. Weiss1, T. Stinchcombe1, A. Ivanova1, J. Shan2, L. 
Villaruz3, M. Socinski3, 1The University of North Carolina at Chapel Hill, 
Chapel Hill, NC, 2Peregrine Pharmaceuticals, Inc., Tustin, CA, 3University of 
Pittsburgh Cancer Institute, Pittsburgh, PA
Purpose/Objective(s): Bavituximab (B) is a novel chimeric IgG
1
 anti-phos-
phatidylserine monoclonal antibody. B selective binds to phosphatidylserine 
complexed with β2-glycoprotein I exposed on tumor vasculature resulting in 
enhanced immune response and inhibition of existing as well as novel tumor 
vasculature. Pre-clinical data suggest a synergistic action using anti-phospha-
tidylserine antibodies in combination with chemotherapy. B has previously 
been reported to be safe and well tolerated when given in combination with 
paclitaxel and carboplatin (C) in non-small cell lung cancer (NSCLC) and 
has produced a promising 52% overall response rate (ORR). Here, we report 
on the currently enrolling trial of B in combination with pemetrexed (P) and 
C, in treatment naïve locally advanced or metastatic non-squamous NSCLC. 
Materials/Methods: This is an ongoing open-label, single arm phase Ib study 
(standard 3+3 design) of B (0.3mg/kg, 1mg/kg, and 3mg/kg) with fixed dose 
CP. B is given weekly in combination with C (AUC 6) plus P (500mg/m2), 
given every 3 weeks, maximum of 6 cycles. Patients may elect to continue 
on maintenance B until disease progression. At the MTD, up to 16 additional 
patients will be enrolled to further characterize safety and preliminary evi-
dence of efficacy, using an adaptive design incorporating an early stopping 
rule based on excessive proportion of DLTs observed. The study objectives 
are to determine the safety, tolerability and recommended phase 2 dose of 
B in combination with CP. We will also estimate ORR, progression free and 
overall survival. DCE-MRI at baseline and end of cycle 1 will be explored as 
a potential pharmacodynamics biomarker in up to 10 patients. Due to theo-
retical concern for prothrombotic effects of B, an optional but encouraged 
prothrombotic evaluation will be performed on all consenting patients, con-
sisting of baseline and end of study Doppler ultrasound, and blood collection 
for evaluation of D-Dimer and tissue-factor microparticles. 
Results: As of March 2012, 5 patients have been enrolled into Cohorts 1 
(n=3) and 2 (n=2), with a median age=59 (range 43-65y), female=2 (40%). 
One patient in each cohort has experienced grade 3 thrombocytopenia result-
ing in dosing interruption. No DLTs or SAEs have been reported. Currently 5 
patients are evaluable for response, with 3 (60%) reporting partial responses, 
the other 2 with stable disease. 
Conclusions: To date, the combination of carboplatin, pemetrexed and bavi-
tuximab has been well tolerated, with no unexpected safety events. Response 
rates reported to date are encouraging, although conclusions are limited due 
to the small number. Dose escalation is ongoing and results will be updated.
Author Disclosure Block: J. Grilley-Olson: E. Research Grant; Peregrine 
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Institutional Experience of Local Control and Locoregional/
Distant Recurrences after Stereotactic Body Radiation 
Therapy for Non-Small Cell Lung Cancer
I. Csiki1, M. Savani2, Z. Zhao1, W. Kirby1, B. Lu3, d. gius1, 1Vanderbilt 
University Medical Center, Nashville, TN, 2Vanderbilt University, Nashville, 
TN, 3Thomas Jefferson University Hospital, Philadelphia, PA
Purpose/Objective(s): The treatment of choice for patients with early stage 
non-small cell lung cancer (NSCLC) has been surgical resection, however, 
stereotactic body radiotherapy (SBRT) has emerged as a new treatment 
modality associated with greater than 85% local control (LC) rates at 2 years. 
Here, we report our institutional experience using image-guided SBRT for 
early stage and recurrent/advanced lung cancer, including an analysis into 
potential factors associated with local, regional and distant failures (LF, RF 
and DF). 
Materials/Methods: Forty-nine patients with early-stage primary lung can-
cer and twenty-three patients with recurrent and advanced lung cancer were 
treated with image-guided SBRT between 2005 and 2010. Median prescrip-
tion dose was 48 Gy in 4 fractions. Toxicity was graded according to the NCI 
CTCAE v3.0 scale. The rate of LF, RF and DF was calculated for each cohort 
of patients. Competing risk method was used to determine disease-specific 
survival (DSS), recurrence-free survival (RFS) and to evaluate the associa-
tion of tumor size, histology and SBRT fractionation scheme with recurrence. 
Results: In the early stage primary lung cancer patient cohort LF was detected 
in one patient (2%) with overall LC rate of 98%. During the follow-up period 
for the primary cohort, the cumulative incidence of RF was 4%, and of DF was 
8.2%. In the recurrent/advanced NSCLC patient cohort LF was detected in 3 
patients (13%) with overall LC rate of 87%. During the follow-up period for 
the advanced/recurrent cohort the cumulative incidence of RF was 22%, and 
DF was 4%. No grade 3 toxicity was observed in either cohort. At 48 months 
follow-up DSS was 90% and RFS was 65% for the primary lung cancer cohort. 
There was no statistically significant association found between patients’ age, 
tumor size, tumor histology and SBRT fractionation scheme with recurrence 
although a trend was noted with worsened RFS in early stage NSCLC patients 
with adenocarcinoma histology, >3cm tumors and 20GyX3 fractionation. 
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Conclusions: Image-guided SBRT can produce excellent LC rates with mini-
mal toxicity. Distant failure is the major determinant of DSS and the most 
common pattern of failure, indicating a potential role for systemic therapy 
in early stage lung cancer patients. In addition, SBRT is a feasible treatment 
approach in selected recurrent/advanced NSCLC patients with excellent con-
trol rates.
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Stereotactic Body Radiation Therapy (SBRT) for Early Stage 
Medically Inoperable Non-Small Cell Lung Cancer
C. L. Matthiesen, S. Thompson, E. Syzek, T. De La Fuente Herman, 
S. Ahmad, T. Herman, Stephenson Cancer Center, University of Oklahoma 
Helath Sciences Center, Oklahoma City, OK
Purpose/Objective(s): SBRT delivers a highly conformal, high dose per frac-
tion to a target volume while minimizing dose to surrounding normal tissue. 
The use of SBRT has become increasingly popular for medically inoperable 
patients diagnosed with early stage non-small cell lung cancer (NSCLC). 
We reviewed our clinical outcomes and toxicity profiles regarding our use of 
SBRT for such patients. 
Materials/Methods: A retrospective review was done of 49 consecutive 
patients diagnosed with early stage NSCLC and treated with SBRT from 
2006-2011. Patients had a median age 66 years (range 53-92). Cancers were 
medically inoperable due to tumor location (9) or patient comorbidities (40). 
Thirty-six lesions (73.5%) were T1N0M0 (median maximum diameter 2.0 
cm) and 13 (26.5%) were T2N0M0 (median maximum diameter 4.3 cm). 
Histologies included squamous cell carcinoma (53.1%), adenocarinoma 
(28.6%), NSCLC not otherwise specified (4.0%), and undetermined / not 
biopsied (14.3%). The median SBRT prescription was 60 Gy in 3-5 fractions 
(range 48-72 Gy in 3-6 fractions). PET/CT imaging within one month prior 
to treatment was performed in 38 patients (77.6%). The median SUV was 
10.7 (range 2.0-51), and 90.9% of T2 lesions with pretreatment PET/CT had 
SUV’s greater than 10.0. 
Results: Median follow-up was 16 months, (range 1-59 months). Infield local 
control for all patients was 87.8%. Thirteen patients (26.5%) failed within the 
chest. Six (12.2%) were infield and 7 (14.3%) were nodal. Twenty-eight of the 49 
patients (57.1%) are alive (median follow-up 16 months), of which 26 (92.9%) 
have no local recurrence or systemic progression. Twenty patients (40.8%) have 
died, of whom nine deaths (18.3%) were attributed to local/regional recurrence 
and / or systemic progression of lung cancer. Other causes of death included 
medical comorbidities in eight patients (16.3%) and second primaries in three 
patients (6.1%). Median survival in patients with non-cancer deaths was 14 
months, (range 8-32 months). Factors associated with local / nodal failure 
included squamous cell histology (9 of 13 patients, 69.2%), and tumor SUV 
> 12.0 (8 of 13 patients, 61.5 %,). Median SUV of recurring patients was 12.8, 
(range 1.6-25.7), and included nine T1 and four T2 lesions. Nine patients (18.4%) 
had complications following SBRT including chest wall pain (6) and rib fracture 
(3). High dose per fraction (20 Gy x 3 courses, 44% of complications) and PTV 
involving the rib (56% of complications) were associated with these outcomes. 
Conclusions: SBRT for medically inoperable NSCLC is a reasonable treat-
ment approach for many patients. Squamous cell histology and SUV > 12.0 
are associated with increased risk of local / regional recurrence. High dose 
per fraction courses and PTV involving the rib increases the risk for post-
treatment chest wall complications.
Author Disclosure Block: C.L. Matthiesen: None. S. Thompson: None. 
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The Role of Pretreatment PET/CT Parameters in Predicting 
Response after Lung Cancer Treatment
A. Lavaf, A. Tejwani, P. Daya, M. Atia, H. Ashamalla, New York Methodist 
Hospital, Brooklyn, NY
Purpose/Objective(s): While PET/CT has been validated in lung cancer stag-
ing, its utility in radiation therapy treatment planning and predicting response 
are still investigational. The objective of this study was to evaluate pretreat-
ment PET/CT imaging and treatment parameters for their ability to predict 
response to therapy in patients treated for lung cancer. 
Materials/Methods: 35 consecutive patients with newly diagnosed lung can-
cer underwent a PET/CT at our institution before initiating definitive therapy 
and post-treatment to gauge tumor response. Imaging parameters included 
the Standardized Uptake Value (SUV) and the Anatomical Biological Value 
(ABV), calculated by the product of the SUV and greatest tumor diameter. 
Maximum SUV and ABV values were evaluated for each patient before and 
after treatment. Patients having achieved both a max ABV < 5.4 and max 
SUV < 2.5 on post treatment PET/CT were classified as having a complete 
response (CR). Treatment parameters evaluated included total radiotherapy 
dose, dose per fraction, number of fractions, chemotherapy and time interval 
between initial and follow up imaging studies. 
Results: The median follow up was 15 months (10-28 months). Sixteen of 35 
(45.7%) patients met the criteria for having a CR. The median interval between 
pre and post treatment scans was 6 months (3-13 months) for those with a 
CR and 4 months (2-12 months) for those with a partial response (PR). For 
those patients with a CR there was a significant decrease in all pre versus post 
treatment imaging parameters including median Size (p<0.001), SUVmean 
(p<0.001), SUVmax (p<0.001), ABVmean (p<0.003) and ABVmax (p<0.003). 
For patients with a PR there was no significant difference in all pre versus post 
imaging parameters. When comparing CR versus PR , we found that only pre-
treatment size (p=0.033) was significantly different between the two groups. 
Pretreatment SUVmean (p=0.392), SUVmax (p=0.486), ABVmean (p=0.196), 
and ABVmax (p=0.152) were all not significant. On multivariate analysis of 
imaging (Size, SUV, ABV) and treatment (total radiotherapy dose, dose per 
fraction, number of fractions, chemotherapy and time interval between initial 
and follow up imaging studies) parameters, with post treatment ABV max as 
the dependent variable, only size (p=0.019) was significant. 
Conclusions: The Anatomical Biological Value has the advantage of charac-
terizing both the size and functional activity of the tumor. In our study, only 
the anatomical component of ABV, the pretreatment size was found to cor-
relate on univariate and multivariate analysis with a complete response. With 
a larger cohort, it may be possible to correlate other significant parameters to 
a complete response.
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Stereotactic Body Radiation Therapy (SBRT) is a Safe 
Treatment Modality for Early Stage Non-Small Cell Lung 
Cancer (NSCLC) in Patients with Implantable Cardiac 
Devices (ICD)
L. Puckett, P. D. Aridgides, W. Li, M. Kilpatrick, J. A. Bogart, SUNY Upstate 
Medical University, Syracuse, NY
Purpose/Objective(s): There is little data regarding the potential impact 
of delivering stereotactic body radiation therapy (SBRT) to patients with 
implantable cardiac devices (ICDs). We assessed the impact of extreme hypo-
fractionation for patients with early stage NSCLC and ICDs. 
Materials/Methods: A retrospective assessment of patients treated with 
SBRT for early stage NSCLC who also had cardiac ICDs. Included patients 
had either an automatic implantable cardioverter defibrillator (AICD) or 
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pacemaker. Institutional and AAPM guidelines were utilized in treatment 
planning for all patients with ICDs receiving fractionated radiotherapy. 
Results: Between 2009 and 2011, six patients with early stage NSCLC and 
ICDs were treated with a total of eight courses of SBRT (prescribed dose 54 
Gy / 3 fractions or 48 Gy/ 4 fractions). Treatment was delivered with 3D con-
formal radiotherapy (3DCRT) and non-coplanar beam arrangements (median 
9 beams) in seven cases and IMRT with helical delivery in one case. The 
mean ICD dose (maximum point dose) was 53 cGy (range 15 to 147 cGy) by 
treatment planning software with a maximum ICD dose per fraction of 16cGy 
(range 3 to 69cGy). No patient required device deactivation or removal in 
order to deliver treatment. With a median follow-up of 15.7 months (range 5 
to 33), there were no cases of device malfunction or cardiac incidents during 
or following treatment. The median dose to ICD leads was 1083 cGy (range 
383 to 4398 cGy), confirming a high tolerance of device leads to radiotherapy. 
The mean measured ICD dose (TLD) was 46cGy (range 15 to 147cGy) and 
generally correlated well with the predicted dose from planning software. The 
average difference (predicted - measured) was +7.4cGy (range -9 to +60cGy). 
Predicted dose (planning software) correlated better with the measured dose 
(TLD ) for tumors further away (>8cm) from the ICD (5.3cGy mean differ-
ence from TLD) as compared to closer (< 8cm) tumors (40cGy mean dif-
ference, p <.01). For ipsilateral tumors, regression analysis showed the Y 
distance (superior-inferior) from the ICD to the tumor to be strongly cor-
related with decreasing ICD dose (1/Y2 vs dose by linear regression, r2=.92). 
Conclusion: We did not find evidence of device malfunction after SBRT in 
patients with ICDs when institutions guidelines were followed. TLD dose 
measurement appears to be particularly beneficial in assessing dose to the 
ICD for tumors <8cm from the ICD.
Author Disclosure Block: L. Puckett: None. P.D. Aridgides: None. W. Li: 
None. M. Kilpatrick: None. J.A. Bogart: None.
1100 
A Patient Alignment Solution For Lung SBRTSetups Based 
On A Deformable Registration Technique
B. Lu, K. Mittauer, S. samant, D. Kahler, R. Dagan, P. Okunieff, J. g. Li, C. 
Liu, University of Florida, gainesville, FL
Purpose/Objective(s): In this work, we propose a novel registration strategy 
for translational-only correction scenarios of lung SBRT setups, which can 
not only achieve optimal dose coverage for tumors but can also preserve the 
consistency of registrations with minimum human interference. 
Materials/Methods: The proposed solution (centroid-to-centroid CTC) 
involves using the average 4-dimensional CT (A4DCT) as the reference CT, 
and deforming with cone-beam CT (CBCT) to acquire a new centroid of 
Internal Tumor Volume (ITV) in the CBCT, then simply aligning the cen-
troids of the ITVs between the A4DCT and the CBCT to accomplish the 
registration. Sixteen cases with 13 patients (each case is associated with sepa-
rate isocenters) have been investigated with the CTC method, the grey value 
(G) mode registration method and the bone (B) mode registration method. 
Statistical data of comparison among the three methods have been presented 
and analyzed. Deformable registration results have also been validated. 
Results: The registration results demonstrate the superiority of the CTC method 
compared with the other two methods. The difference between the D99 and D95 
dose coverage of the ITV using the CTC method versus the original plan is small 
(within 5%) for all of the cases except for one for which the tumor presented 
significant growth during the period between the CT scan and the treatment. 
Meanwhile, the dose coverage differences between the original plan and the reg-
istration results using either the B or G method are significant as tumor positions 
varied dramatically from their positions on the original CT, relative to the rib cage. 
The largest difference between the D99 and D95 dose coverage of the ITV using 
the B or G methods versus the original plan are as high as 50%. The D20 differ-
ences between any of the methods versus the original plan are all less than 2%. 
Conclusions: The CTC method can generate optimal dose coverage to tumors 
with much better consistency compared with the G and B methods, and it is 
especially useful as the tumor position varies greatly from its position on the 
original CT, relative to the rib cage.
Author Disclosure Block: B. Lu: None. K. Mittauer: None. S. samant: 
None. D. Kahler: None. R. Dagan: None. P. Okunieff: None. J.G. Li: None. 
C. Liu: None.
1101 
Do Surrogates Reliably Represent Lung Tumor Motion? 
Assessment of Intrafraction Motion Variability of Lung 
Tumors, Implanted Markers and Carina
E. Weiss, N. Roman, G. Hugo, VCU, Richmond, VA
Purpose/Objective(s): Implanted markers and anatomical landmarks such as 
carina are used as surrogates for positioning and tracking of lung tumors. This 
study investigates respiratory motion over a conventional radiotherapy series 
and determines the reliability of surrogates for tumor targeting. 
Materials/Methods: Seven patients with locally advanced lung cancer and 
bronchoscopically implanted gold coils underwent weekly free breathing 4D 
CBCTs with audiovisual biofeedback during radiotherapy. Lung tumors T, 
gold marker M (1-3 per patient) and carina C were manually contoured by 
one physician on 58 4D images (=580 3D images). A vertebra V was con-
toured in the time-averaged phase of each 4D scan only, assuming no respira-
tory motion.For all structures the respiratory range of motion and variations 
thereof during a radiotherapy series were analyzed. Changes in the position 
of these structures relative to each other during respiration were identified. 
Results: The mean range ± SD of respiratory motion for all patients and scans 
for T, M and C were 3 ± 1, 3 ± 2, 2 ± 2 mm in LR, 3 ± 1, 2 ± 1, 2 ± 0 mm in 
AP and 5 ± 1, 5 ± 2, 5 ± 3 mm in CC direction, respectively. First scan vs. last 
scan mean motion for T, M and C were 3 ± 1, 2 ± 1, 1 ± 1 vs. 2 ± 1, 2 ± 1, 1 ± 
1 mm in LR, 3 ± 1, 2 ± 0, 2 ± 1 vs. 2 ± 1, 2 ± 1, 2 ± 1 mm in AP, and 6 ± 2, 5 ± 
2, 6 ± 4 vs. 3 ± 2, 4 ± 3, 6 ± 3 mm in CC direction indicating a decreased range 
of tumor and marker motion mostly in CC direction at the end of treatment, 
while carina motion was stable (p=0.05 for T, p=0.03 for M in LR direction, 
all other p>0.05). Over a 6-7 week period the average 3D variation ± SD in the 
relative position of T relative to M, C and V during respiration was 4 ± 1 mm 
for T-M, 4 ± 2 mm for T-C, and 3 ± 1 mm for T-V. Relative position changes 
during respiration of T-V were smaller than T-M (p=0.05). First scan vs. last 
scan relative 3D position changes were 4 ± 2 vs. 4 ± 2 mm for T-M, 4 ± 2 vs. 
5 ± 2 mm for T-C and 3 ± 1 vs. 3 ± 2 mm for T-V indicating stable respira-
tory motion patterns (p>0.05) between structures during a radiotherapy series. 
Conclusions: While the average motion range of tumor, markers and carina 
were comparable, tumor and marker motion decreased at the end of treatment 
suggesting reassessment of the motion range during free-breathing respira-
tion-managed radiotherapy. The observed magnitude in the relative position 
change of tumor relative to marker, carina and bone during respiration of on 
average 4 mm questions the usefulness of these landmarks to directly guide 
tumor targeting for complex locally advanced lung cancer geometries. Future 
studies need to investigate the stability of the spatial relation between tumor 
and landmarks during respiration in individual patients to determine the 
applicability of motion models for radiotherapy planning.
Author Disclosure Block: E. Weiss: E. Research Grant; Varian Medical 
Systems. N. Roman: None. G. Hugo: None.
1102 
Clinical Experience with Respiratory-Gated Stereotactic 
Body Radiotherapy (SBRT) for Lung Tumors Using Audio 
Coaching
F. Baba1,2, Y. Shibamoto2, T. Matsui1, Y. Nonogaki3, S. Tanaka3, S. Hasegawa3, 
A. Miyakawa2, S. Takemoto4, S. Otsuka2, H. Iwata5, 1Department of 
Radiology, Social Insurance Chukyo Hospital, Nagoya, Japan, 2Department 
of Radiology, Nagoya City University Graduate School of Medical Sciences, 
Nagoya, Japan, 3Department of Radiological Technology, Social Insurance 
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Chukyo Hospital, Nagoya, Japan, 4Nambu Tokushukai Hospital, Okinawa, 
Japan, 5Bureau of Health and Welfare, City of Nagoya, Nagoya, Japan
Purpose/Objective(s): Management of respiratory motion is important in 
SBRT for lung tumors. One approach to the issue is to use respiratory gat-
ing, but controversy exists regarding the technique. One is regarding the 
reproducibility of breathing and another is regarding the correlation between 
the surrogate and tumor motion. Some studies suggested audio instructions 
could partly solve these problems. The purpose of this study was to evaluate 
respiratory-gated SBRT using audio coaching. 
Materials/Methods: CT images for treatment planning were obtained using 
4D-CT under audio instruction. Images were reconstructed into 10 phases 
of the respiratory cycle (0-90%). When the target motion was greater than 
1 cm in the craniocaudal (CC) direction, the respiratory-gating method was 
applied. Clinical target volumes around end-expiration were merged individu-
ally to form the internal target volume (ITV). The planning target volume 
(PTV) margin was 5 mm. Patient set-up was verified using cone-beam CT. 
Tumor motion was checked by fluoroscopy of an on-board imager system 
before every treatment. When a phase shift between the tumor motion and the 
duty cycle occurred, the thresholds for gating were modified. Electronic portal 
images were used to verify the tumor position during SBRT. Between March 
2010 and August 2011, 15 patients with 17 lesions of primary or metastatic 
lung cancer underwent respiratory-gated SBRT using audio coaching. In 10 
of them, we compared the variability of the cycle, amplitude and lowest point 
of respiratory waves between audio coaching and free-breathing conditions. 
Results: The individually selected percentage of the duty cycle was 30% to 
60%. The thresholds for gating were adjusted in 5 patients before treatment. 
Compared to the entire tumor motion, the amplitude of tumor motion during 
irradiation was decreased by 0.8-4.1 cm in the CC direction using respiratory 
gating. The mean ITV and PTV were decreased by 37.6% (range, 16-60%) 
and 33.8% (range, 15-56%), respectively (p<0.0001). The mean reduction in 
the lung V20 and the mean lung dose was 1.7% (range, 0.5-4.5%) and 1.0 
Gy (range, 0.3-2.3 Gy), respectively (p<0.0001). Furthermore, the dose to 
the stomach could be significantly reduced for 4 lesions at the base of the left 
lung. During follow-up of 6 months or longer, grade 2 and 3 radiation pneu-
monitis was observed in 1 patient each with severe emphysema. Compared to 
free-breathing conditions, the respiratory cycle was improved in 6 cases, and 
the amplitude and the lowest point of respiratory waves were improved in 1 
and 2 cases, respectively. 
Conclusions: In SBRT for lung tumors, respiratory gating could reduce the 
dose to the normal tissue. To further control respiration, we are planning to 
investigate the use of additional devices like visual feedback.
Author Disclosure Block: F. Baba: None. Y. Shibamoto: None. T. Matsui: 
None. Y. Nonogaki: None. S. Tanaka: None. S. Hasegawa: None. A. 
Miyakawa: None. S. Takemoto: None. S. Otsuka: None. H. Iwata: None.
1103 
It Should Be Very Cautious In The Radiotherapy Of Long 
Thoracic Esophageal Cancer Applied Rapidarc With Whole 
Arc(s)
G. Gong, Y. Yin, T. Liu, Shandong Cancer Hospital, Jinan, China
Purpose/Objective(s): To investigate the irradiation dose feature of total lung 
in the radiotherapy of esophageal cancer comparing the dosimetric differ-
ences among intensity modulated radiotherapy (IMRT) and volumetric modu-
lated radiotherapy (VMAT) which applied RapidArc. 
Materials/Methods: 9 patients with esophageal cancer were select, and the 
length of all planning target volumes (PTVs) exceeded the four fifths length 
of the oesophagus in thorax. The step and shoot IMRT pans with 7 coplanar 
equispaced fields and RapidArc plans (named Arc
1
, Arc
2
, Arc
3
 and Arc
4
) were 
designed for every PTV. Arc
1
 with one single whole arc (arc=358°), Arc
2
 with 
two whole arcs (arc =716°), Arc
3
 with two whole arcs avoiding the regions 
irradiated vertically in two lung (Arc=600°), and the same to Arc
4 
(arc=540°). 
All plans were optimized applying 6MV and 15MV, the dosimetric differ-
ences were compared. Results: The conformity index (CI), the maximum and 
minmum dose of PTV in IMRT and RapidArc plans were similar (P>0.05), 
while homogeneity index (HI) in IMRT was better than in RapidArc plans 
and differed significantly (P<0.05). Compared to IMRT, RapidArc plans 
increased the V
10
, V
13
 and V
15
 of total lung, and increased the mean dose, V
20
, 
V
30
, V
40 
of heart, while only V
10
 of total lung differed significantly (P<0.05). 
While the V
20
, V
30
 and V
40 
of total lung was similar in IMRT and RapidArc 
plans.(P>0.05) There were no dosimetric benefit were found in sparing total 
lung applying Arc
3
 and Arc
4
.The dosimetric differences in the same plan type 
applying different energy X-ray were similar. The mean monitor units ratio of 
IMRT to RapidArc plans were 2.30. 
Conclusions: The low irradiation dose region of total lung should not be 
neglectful in the radiotherapy for long thoracic EC applying RapidArc with 
whole arc(s); 6MlV X-ray should be applied prudently in the radiotherapy of 
thoracic EC using IMRT or RapidArc.
Author Disclosure Block: G. Gong: None. Y. Yin: None. T. Liu: None.
1104 
Quality Assurance of Nasopharyngeal Carcinoma Intensity 
Modulated Radiotherapy Treatment Plans Using Three 
Dimensional Dosimetry Verification System
C. Ma, Y. Yin, Shandong Cancer Hospital & Institution, Jinan, China
Purpose/Objective(s): We evaluated the performance of the COMPASS sys-
tem to reconstruct three dimensional dose distributions on computed tomog-
raphy (CT) image of the nasopharyngeal carcinoma(NPC) patient anatomy 
based on measured fluences using the MatriXX two-dimensional (2D) array 
(offline). 
Materials/Methods: For benchmarking the COMPASS dose calculation, 
various dose-volume indices of plan target volume and organs at risk were 
compared against 10 NPC patients intensity modulated radiotherapy (IMRT) 
treatment plan dose distributions. Gamma index evaluation and absolute point 
dose measurements were also performed in an inhomogeneous brain phantom 
using extended dose range films and ion chamber for 10 additional treatment 
plans. 
Results: MatriXX-based dose reconstruction showed excellent agreement 
with the ion chamber ( <1.5% ), film (95% pixels passing gamma criteria 
3%/3 mm) and mean dose volume indices ( <5% ). The dose-volume histo-
gram of plan target volume (maximum <3% )and organs at risk (maximum 
<5% ) based dose reconstruction showed good agreement with Treatment 
Planning System CT plans. 
Conclusions: The COMPASS system qualifies for NPC IMRT pretreatment 
verification with the MatriXX detector and has good agreement for verifica-
tion of treatment delivery with the dose-volume histogram of CT plans.
Author Disclosure Block: C. Ma: None. Y. Yin: None.
1105 
Helical Tomotherapy Improves Tumor Coverage and 
Decreases Dose to Normal Critical Structures in a Patient 
with Recurrent Head and Neck Cancer
T. W. Speer, D. Tewatia, R. Tolakanahalli, University of Wisconsin School of 
Medicine, Madison, WI
Purpose/Objective(s): To report a case study of recurrent squamous cell car-
cinoma of the nasopharynx: Dosimetric analysis and outcome. 
Materials/Methods: The patient was diagnosed with a T4 N0 squamous 
cell carcinoma of the Nasopharynx. He was initially diagnosed with a base 
of skull tumor and underwent a sublabial transsphenoidal biopsy. Pathology 
was consistent with a moderately differentiated squamous cell carcinoma. 
He was treated with comprehensive head and neck chemoradiotherapy to a 
total dose of 70 Gy in 33 fractions (Tomotherapy Hi-ART system) delivered 
concurrently with weekly cisplatin and adjuvant chemotherapy. The patient 
was diagnosed with recurrent disease in the premaxilla. This was felt to rep-
resent iatrogenic seeding from the initial biopsy and the patient underwent 
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resection with positive margins. The initial nasopharyngeal carcinoma was 
clinically and radiographically controlled. His salvage regimen consisted of 
concurrent chemotherapy and hyperfractionated radiotherapy (69.60 Gy/58 
fractions, bid). An initial “step and shoot” IMRT plan delivered unacceptably 
high composite doses to the temporal lobes (>80 Gy) and optic nerves and 
chiasm (>70 Gy). The IMRT plan was abandoned and the patient initiated 
therapy using a 3D conformal plan to 16.80 Gy/14 fractions bid. The patient 
received the remaining 52.8/44 fractions bid, on Tomotherapy, due to a sig-
nificant improvement in PTV coverage and comparable normal tissue sparing, 
when compared to the 3D technique. 
Results: The 95% target coverage was significantly improved by Tomotherapy 
when compared to the 3D conformal arrangement (100% vs. 48%). The 
homogeneity index (D
2
-D
98
)/D
50
) was significantly improved by Tomotherapy 
(0.02 vs. 0.577). Dose volume and maximum dose statistics for relevant 
organs at risk (OAR) are shown in Table1. In addition to improved target cov-
erage, Tomotherapy decreased the dose to all normal tissue structures except 
for the brain stem. 
Conclusions: In the setting of re-irradiation, standard IMRT results in good 
target coverage but high normal tissue doses (data not shown). The 3D 
conformal plan resulted in normal tissue sparing but poor target coverage. 
Tomotherapy resulted in both excellent target coverage and normal tissue 
sparing. Further investigation needs to be performed to validate the use of 
Tomotherapy for recurrent head and neck cases.
Table 1
OAR
Initial (old) 
plan
3D 
Plan
Tomotheapy 
Plan
Composite; 
Initial and 
Tomotherapy
Composite; 
Initial and 
3D
Brainstem 69.2 (<2cc), 
50 Gy
1.3 2.0 70 (<2cc), 
52 Gy
70 (<2cc), 
51 Gy
Chiasm 54.6 2.0 1.8 56.5 56.5
R Optic n. 51.8 62.5 56.1 60.0 65.0
L Optic n. 50.5 59.6 26.5 50.1 65.0
L Orbit 8.8 61.6 56.2 55.0 58.0
R Orbit 10.3 61.2 54.4 55.0 58.0
Temporal 
Lobes
60.0 6.0 3.5 63.5 66.0
Lenses 3.0 18.3 7.8 10.9 21.0
Author Disclosure Block: T.W. Speer: None. D. Tewatia: None. R. 
Tolakanahalli: None.
1106 
Comparative Study of Internal Target Volume (ITV) Based 
on PET-CT and 4DCT for Stereotactic Body Radiotherapy of 
Non-Small Cell Lung Cancer
S. Rahman, J. Rahimian, Kaiser Permanente Medical Center, Los Angeles, CA
Purpose/Objective(s): Intrafractional tumor motion with respiration brings 
a unique challenge to the treatment planning of stereotactic body radio-
therapy (SBRT) for non-small cell lung cancers (NSCLC). The current gold-
standard technique involves tumor volume delineation on each phase image 
set of a planning 4DCT scan to generate a combined phase summation. As 
an optional alternative, contours from maximum intensity projections (MIP) 
are often used, but tend to overestimate target volumes for centrally-located 
tumors. In this study, we evaluate the use of PET-CT as another reasonable 
alternative for internal target volume (ITV) delineation. 
Materials/Methods: Six patients with early stage NSCLC, who were 
treated definitively using SBRT were identified. All of these patients had 
a prior PET-CT scan and a 4DCT scan acquired by a General Electric 
Lightspeed 16-slice scanner for treatment planning. Retrospective 4D 
images with 14 phases were reconstructed and fused, along with PET-CT 
using a mutual information technique. Images were exported to a Phillips 
Pinnacle planning system, and tumor volumes were contoured indepen-
dently by each of the two investigators using images from combined 
phases, maximum intensity projections (MIP), PET-CT, and the 50% 
phase. The PET sequences were contoured using 15-40% of the maximum 
tumor activity, depending upon the degree of tumor excursion. Volumes 
generated from MIP images and PET-CT were compared against the gold-
standard technique of combined phase summation for each investigator 
separately and combined. 
Results: Tumor volumes generated using MIP or PET-CT were not sta-
tistically different from combined phase summation volumes (p=0.13 and 
0.09, respectively). However, 50% phase contours were significantly dif-
ferent from combined phase summation volumes (p=0.01), representing 
significant tumor motion. When contoured volumes were analyzed for 
each investigator independently, no differences were found between MIP 
or PET-CT-derived volumes, as compared to combined phase summation 
volumes. 
Conclusion: For early stage non-small cell lung tumors with significant 
motion, the use of MIP image sets or PET-CT both allow for the accurate 
delineation of internal target volumes for SBRT treatment planning. In the 
absence of 4DCT technology, PET-CT may be used for tumor delineation, but 
requires further investigation.
Author Disclosure Block: S. Rahman: None. J. Rahimian: None.
1107 
Dosimetric Evaluation of the Interplay between LINAC 
Movement and Tumor Motion in Respiratory Gated VMAT of 
Lung Cancer
C. Ng, V. H. Lee, T. Leung, Queen Mary Hospital, Hong Kong, Hong Kong
Purpose/Objective(s): Respiratory gated radiotherapy of lung cancer helps 
to minimize the treated volume and hence treatment side effects. VMAT can 
reduce the treatment time while producing a highly conformed dose dis-
tribution. However, in gated VMAT delivery, the interplay effect between 
the LINAC movement (MLC and gantry) and tumor motion may result in 
undesirable hot and cold spots jeopardizing tumor coverage. In this study we 
investigated the possible dosimetric errors caused by the interplay between 
the tumor motion and the LINAC movement for gated VMAT lung cancer 
treatment. 
Materials/Methods: We studied 2 lung cancer cases prescribed to 60 Gy 
given in 30 fractions. GTVs were contoured on each of the 10 phases of 4DCT. 
The end-expiration phase and 3 neighboring phases were chosen for gating 
(40%-70%). The GTV
gating
 consisted of the volume encompassing GTVs of 
the 4 phases. 5 mm margin was added to the GTV
gating
 to create the CTV
gating
 
and 8 mm margin was added to generate the PTV
gating
. A highly modulated 
single arc VMAT plan (RapidArc, Varian Medical Systems) was derived for 
each case based on the 50% phase image. The plans aimed to minimize dose 
to the spinal cord while maintaining PTV coverage. A program was written to 
segment the arc in the original plan with 177 control points into 88 mini arcs 
with 3 control points each. Each mini arc spanned about 0.67 second and was 
assumed to irradiate 1 phase of the gating window during which there should 
be relatively little movement of the anatomy. Every one in four arcs was then 
inserted into a VMAT plan irradiating each of the 4 phases, thus generating 
4 plans each having 22 mini arcs. Dose calculation was done for each plan 
on the CT image for the particular phase. The resulting dose from each plan 
was then mapped to the base phase image (50%) and finally summed with a 
deformable dose accumulation software (MIM Maestro, MIM Software). The 
resulting dose was compared to the original dose distribution. 
Results: See Table. 
Conclusion: The dosimetric effect of the interplay between tumor motion and 
LINAC movement was studied for 2 lung cancer cases. It was found that there 
was no significant difference in tumor coverage when the original plan was 
done assuming a static target. The dose to critical structures also remained 
very close to the original plan. It can be concluded that interplay between 
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LINAC movement and tumor motion will not affect the dosimetric quality of 
gated VMAT plans for lung cancer.
Summary of Dosimetric Results
Plan
PTV Vol 
(cc)
PTV 
D95% 
(Gy)
PTV D1% 
(Gy)
Mean 
Lung 
Dose (Gy)
Spinal 
Cord 
D1% (Gy)
Case 1 VMAT 254.8 60.0 65.7 19.2 41.6
Sum 4 
Phase 
Plan
254.8 59.7 66.0 19.3 41.0
Case 2 VMAT 22.7 60.6 63.9 7.0 7.0
Sum 4 
Phase 
Plan
22.7 60.1 63.9 7.0 7.3
Author Disclosure Block: C. Ng: None. V.H. Lee: None. T. Leung: None.
1108 
4D Cone-Beam CT Ventilation Imaging to Facilitate Adaptive 
Functional Avoidance Lung Cancer Radiotherapy
J. Kipritidis1, E. Eslick1, B. Cooper1, R. O’Brien1, T. Yamamoto2, J. F. 
Williamson3, P. Keall1, 1Radiation Physics Laboratory, Sydney Medical School, 
University of Sydney, Sydney, Australia, 2Department of Radiation Oncology, 
School of Medicine, Stanford University, Stanford, CA, 3Department of 
Radiation Oncology, School of Medicine, Virginia Commonwealth University, 
Richmond, VA
Purpose/Objective(s): 4D-CT ventilation imaging has been proposed as an 
alternative to nuclear medicine (NM) ventilation imaging and may allow func-
tional avoidance of the healthiest lung regions in lung cancer radiotherapy. 
However, the efficacy of functional avoidance will diminish if there are temporal 
changes in the ventilation pattern throughout a course of radiotherapy. To account 
for the temporal changes in ventilation patterns, we investigated 4D cone-beam 
CT (4D-CBCT) imaging to quantify ventilation. Successful validation of this 
method will facilitate adaptive functional avoidance lung cancer radiotherapy. 
Materials/Methods: For this study we analyze 7 pre-treatment 4D-CBCT 
scans for a lung cancer patient undergoing radiotherapy. The 4D-CBCT scans 
were performed using a commercially available on board imaging device in 
conjunction with a real-time position management system. Each scan used a 
slow gantry rotation covering 360 degrees in about 8 minutes, using an audiovi-
sual feedback method for breathing guidance. Reconstructions were obtained 
using about 300 projections for each of 8 respiratory-correlated phases. An 
optical flow method was then used to perform deformable image registration 
(DIR) and calculate the deformation vector field (DVF) between adjacent 
phases. Finally the ventilation was computed from the Jacobian of the DVFs. 
Results: 4D-CBCT ventilation was calculated and can exhibit variation both 
spatially and in the time domain (between phases of the respiratory cycle and 
between scans). For a fixed number of total projections the spatial (temporal) 
resolution is improved by decreasing (increasing) the number of phase bins. 
While CBCT image quality affected the results, ventilation imaging may be 
improved through the choice of reconstruction technique, binning methods 
and DIR algorithms. 
Conclusions: For the first time, serial 4D-CBCT ventilation images were 
created by (1) acquisition of 4D-CBCT scans, (2) application of DIR meth-
ods and (3) analysis of the resulting DVFs. Preliminary results suggest that 
4D-CBCT ventilation imaging may identify changes in lung function using 
readily available image processing software. Validation of this method against 
gold standard NM methods may yield a new tool to facilitate adaptive func-
tional avoidance in lung cancer radiotherapy.
Author Disclosure Block: J. Kipritidis: None. E. Eslick: None. B. Cooper: 
None. R. O’Brien: None. T. Yamamoto: None. J.F. Williamson: None. 
P. Keall: J. Funding Other; Supported by NIH/NCI P01CA116602 and an 
NHMRC Australia Fellowship.
1109 
Interfractional Variation of Respiratory Lung Tumor 
Displacement
D. Nygaard1, G. Persson1, C. Brink2,3, L. Specht1,4, S. Korreman1,5, 1Department 
of Radiation Oncology, Rigshospitalet, Copenhagen University Hospital, 
Copenhagen, Denmark, 2Laboratory of Radiation Physics, Odense University 
Hospital, Odense, Denmark, 3Faculty of Health Sciences, University of 
Southern Denmark, Odense, Denmark, 4Faculty of Health Sciences, University 
of Copenhagen, Copenhagen, Denmark, 5Department of Science, Systems and 
Models, Roskilde University, Roskilde, Denmark
Purpose/Objective(s): Breathing related lung tumor displacement can be 
evaluated by 4DCT and incorporated in radiotherapy planning as motion 
encompassing volumes or included as an uncertainty in the calculation of the 
planning target volume. However, these techniques are based on tumor dis-
placement being reproducible throughout the treatment sessions. This study 
evaluates interfractional variations of respiratory lung tumor displacement. 
Materials/Methods: The study is based on 14 patients with peripheral lung 
tumors referred for stereotactic radiotherapy (45 Gy / three fractions). Prior 
to treatment planning, the patients had a fiducial marker implanted in or close 
to the tumor. The patients had a free breathing 4DCT scan (ten phase bins) 
acquired as a part of treatment planning and at each treatment session. Data 
acquisition was incomplete for two patiens who were not 4DCT scanned at 
their first treatment session. For 12 of the patients, with the marker implanted 
in the tumor, the marker was delineated in Eclipse™ and tumor displacement 
was represented by peak-to-peak displacement of the centre of volume (CoV) 
of the marker. For one patient the implanted marker had disappeared at the 
time of the treatment planning session, and another patient had the marker 
implanted outside the tumor. For these two patients, the gross tumor volume 
(GTV) was delineated and tumor displacement was represented by peak-to-
peak displacement of CoV of GTV. Maximal displacement was defined as the 
maximal value of the displacement in the LR, AP or CC direction. 
Results: Median (range) tumor displacement at the planning session was 2.5 
(0.5 - 3.6) mm, 2.8 (0.7 - 8.7) and 5.5 (0.7 - 24.4) mm in the left-right (LR), 
anterior-posterior (AP) and cranio-caudal (CC) directions. Median (range) 
maximal change in displacement between the planning session and the treat-
ment sessions was 0.9 (0.2 - 2.3) mm, 1.7 (0.2 - 6.5) mm and 3.6 (0.8 - 14.1) 
mm in the LR, AP and CC directions - for five tumors this change was ≥ 5 
mm in at least one direction, for one tumor the change was ≥ 10 mm. Maximal 
tumor displacement at planning session was significantly positively correlated 
with maximal change between displacement at the planning session and the 
treatment sessions (Spearman, probability value p = 0.049, correlation coef-
ficient r = 0.535).
Conclusions: A motion encompassing volume based on tumor displacement 
in the planning session may not be robust throughout the treatment sessions. 
Daily imaging and more robust motion encompassing methods are required, 
especially for tumors with large displacement.
Author Disclosure Block: D. Nygaard: None. G. Persson: None. C. Brink: 
None. L. Specht: None. S. Korreman: None.
1110 
Prospective Evaluation of Dual-Energy Imaging in Patients 
Undergoing Image Guided Radiotherapy for Lung Cancer: 
Initial Clinical Results
T. S. Bray, M. A. Hoggarth, J. Luce, J. Y. Lin, A. Block, S. N. Nagda, J. C. 
Roeske, Loyola University Medical Center, Chicago, IL
Purpose/Objective(s): Dual energy (DE) imaging takes advantage of the 
higher differential attenuation of bone as a function of energy relative to soft 
tissue to produce tissue-selective composite images. In the thorax, planar 
DE imaging can improve tumor visualization by removing obscuring bony 
anatomy. To our knowledge, DE imaging has not been studied clinically in a 
therapeutic radiation setting, but it may have a role in improving localization 
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of lung tumors in patients undergoing kV-based image guided radiotherapy 
(IGRT). A prospective clinical trial was conducted to investigate the utility of 
DE imaging as it compares to conventional x-ray imaging in terms of tumor 
visibility. 
Materials/Methods: A prospective, IRB-approved clinical trial enrolling 
patients with lung cancer undergoing IGRT was initiated at our institution in 
September 2011. Consenting patients underwent RT planning according to 
standard protocol. During daily setup, two sequential respiratory-gated x-ray 
images were obtained using the On-Board Imager (OBI; Varian Medical 
Systems, Palo Alto, CA). Imaging comprised one standard anterior-posterior 
(AP) x-ray at 120kVp (1 mAs) and a second AP x-ray at 60 kVp (4mAs). 
Weighted subtraction of the two images was performed offline to create soft-
tissue selective DE images. Single energy (SE) and DE images were evalu-
ated by measuring tumor contrast-to-noise ratio (CNR). Imaging dose was 
assessed using a phantom with a calibrated ion chamber. 
Results: To date, 7 patients with Stage IA-IIIA lung cancer have been enrolled 
and 28 DE images have been analyzed. Gross tumor volume (GTV) ranged 
from 0.5-243cc. Gated DE image acquisition was easily incorporated into the 
standard treatment time allotted for IGRT patients. Mean skin dose per DE 
image set was 0.55 mGy ± 0.04 vs. 0.61 mGy ± 0.05 using conventional kV 
imaging parameters (75kVp, 5mAs). Qualitatively, DE subtraction resulted in 
complete disappearance of overlying bone, with an average improvement in 
CNR of 1.4 ± 1.2 over SE (60kVp) images. Tumor size affected the degree of 
CNR improvement; for GTVs ≥ 2.5 cm diameter, CNR was improved by an 
average 1.54 ± 1.05, while GTVs < 2.5 cm diameter, CNR was improved by 
and average 1.21 ± 1.45. 
Conclusions: Initial results of this prospective trial suggest that planar DE 
thoracic imaging enhances tumor localization in lung cancer patients receiv-
ing kV-based IGRT, while decreasing the imaging dose. We believe this 
approach has potential to improve tumor localization in many patients treated 
with thoracic IGRT and could possibly be used as part of an adaptive RT 
program.
Author Disclosure Block: T.S. Bray: None. M.A. Hoggarth: E. Research 
Grant; Varian Medical Systems. J. Luce: None. J.Y. Lin: None. A. Block: 
None. S.N. Nagda: None. J.C. Roeske: E. Research Grant; Varian Medical 
Systems.
1111 
Evaluation of the Therapeutic Effects for Non-small Cell 
Lung Cancer after Chemoradiotherapy Using Standardized 
Uptake Value Change by Fluorodeoxyglucose Positron 
Emission Tomography
C. Ma, Y. Yin, Shandong Cancer Hospital & Institution, Jinan, China
Purpose/Objective(s): The purpose of this study was to detect non-small cell 
lung cancer after chemoradiotherapy using standardized uptake value (SUV) 
change by fluorodeoxyglucose positron emission tomography (FDG- PET) 
scanning. 
Materials/Methods: A total of 21 stage III non-small cell lung cancer lesions 
acceptting chemoradiotherapy were examined. The therapeutic effects were 
evaluated by pre-treatment SUV, post-treatment SUV and % change in SUV. 
Results: All patients after therapy were observed the volume of gross targets 
(GTV) became smaller than pre-treatment ( P<0.05). A significant differ-
ence was found at the post-treatment SUV and the % change in SUV. Taking 
the post-treatment SUV of 3 and the % change of 60 as a cut-off value, a 
significant difference was found in all cases. Therefore, it is useful to predict 
the therapeutic effects after chemoradiotherapy by a combined analysis of the 
post-treatment SUV and the % change in SUV( P<0.05). 
Conclusions: The results suggest that it may be possible to predict stage III 
non-small cell lung cancer therapeutic effects using SUV and % change in 
SUV. Therefore, the use of analysis of FDG-PET between the pre-treatment 
and post-treatment findings is considered to be helpful in choosing the opti-
mal therapy.
Author Disclosure Block: C. Ma: None. Y. Yin: None.
1112 
A Non-Uniform Dose Prescription Based on Tumor Position 
Probabilities for Patients with Lung Cancer
T. Zhao, UF Proton Therapy Institute, Jacksonville, FL
Purpose/Objective(s): Respiration may cause significant organ motion in 
thorax. To avoid missing a tumor, ITV is contoured and treated uniformly 
with full dose to achieve a desired tumor control probability (TCP). However, 
this practice will also deliver significant dose to the surrounding normal tis-
sues that move into the treated volume during the treatment. A novel non-
uniform dose prescription based on tumor location probability is proposed to 
achieve a lower normal tissue complication probability (NTCP) while main-
tain the same TCP
Materials/Methods: A spherical target of 1cm radius was contoured on a 
patient’s 4D CT data. A previously verified and published free-breathing lung 
motion model was employed to recover the respiratory trajectories of the 
target over 30 breathing cycles. The position probabilities were obtained by 
tracking the trajectories in a 3D space that was divided into subvolumes of 
2mmx2mmx2mm. Dose to each subvolume was calculated through a logistic 
function that models the binary dose response of a uniformly irradiated tumor 
volume. TCP of the whole target was maintained at 50%. To account for the 
impact of two dose prescriptions, uniform and non-uniform, on NTCP and 
exclude the dependence on treatment modalities and plan qualities, ideal dose 
distributions were assumed and NTCP was defined on all normal tissues that 
passed the treated volume. Parameters used in estimating TCP and NTCP 
were D
50
=72Gy, γ=2, m=0.39 and TD
50
=28.6Gy. 
Results: High dose up to 85.0Gy were observed to concentrate in the center 
of the ITV and gradually taper off toward the edge. The motion magnitude 
of the target was 7.8mm. The NTCP from the uniform dose prescription was 
93.9% and reduced to 44.1% with the non-uniform dose prescription. 
Conclusions: A non-uniform dose prescription based on tumor position prob-
abilities can be optimized to deliver higher dose to regions where a tumor is 
more likely to occupy while maintain the same overall TCP. Normal tissues 
are spared and the NTCP is reduced.
Author Disclosure Block: T. Zhao: None.
1113 
Stereotactic Body Radiotherapy for Superior Vena Cava 
Syndrome
J. T. McKenzie, D. Kunaprayoon, T. B. Skidmore, K. P. Redmond, University 
of Cincinnati, Barrett Cancer Center, Cincinnati, OH
Purpose/Objective(s): To report the successful utilization of stereotactic 
body radiotherapy (SBRT) for a case of superior vena cava syndrome (SVCS). 
Materials/Methods: SVCS is a clinical diagnosis resulting from the imped-
ance of blood flow through the SVC into the right atrium of the heart with 
up to 90% of cases being due to malignancy. The obstruction could be due 
to primary extension of a right upper lobe tumor or more commonlydue to 
enlarging mediastinal adenopathy with the right paratracheal lymph node 
being most frequently involved. Although SVCS was previously considered 
a medical emergency, it may be reasonable to obtain a tissue diagnosis and 
complete staging prior to beginning therapy. This approach may help guide 
the appropriate treatment strategy and the intent of treatment, i.e., definitive 
or palliative. While head elevation, diuretics and steroids are frequently uti-
lized for initial treatment of SVCS, additional treatment with radiotherapy, 
chemotherapy or endovascular stenting is usually indicated. Radiotherapy in 
this setting is frequently given with palliative intent over five to ten fractions 
of 3 - 4 Gy per fraction. While the use of any of the aforementioned therapies 
is well documented in the literature, to our knowledge, there are no reported 
cases utilizing SBRT for SVCS. Our case is an 82 year old former smoker 
who presented with a one week history of new onset varicosities involving the 
anterior chest wall associated with facial edema. He was asymptomatic at the 
time, but the change in his physical appearance was noted by his wife who 
prompted further work-up. Imaging revealed an enlarged right paratracheal 
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lymph node obstructing the SVC. PET/CT scan revealed significant FDG 
avidity within the lymph node with no other abnormalities noted throughout. 
Endoscopic ultrasound guided biopsy of the lymph node revealed adenocar-
cinoma consistent with a lung primary. He was not felt to be a chemotherapy 
candidate and was referred for consideration of radiotherapy. Given that he 
was asymptomatic and had no other evidence of disease he was treated with 
SBRT. The total dose delivered the malignant adenopathy was 50 Gy in five 
fractions over ten days. 
Results: After completing only three fractions of therapy he was noted to 
have a good response with a decrease in the prominence of the anterior chest 
wall varicosities. He then completed therapy without experiencing any acute 
toxicities of treatment. 
Conclusions: SBRT may be a reasonable option for patients presenting with 
non-emergent SVCS.
Author Disclosure Block: J.T. McKenzie: None. D. Kunaprayoon: None. 
T.B. Skidmore: None. K.P. Redmond: None.
1114 
Ventilation Imaging for Lung Radiation Therapy Planning: 
Free Breathing 4DCT vs. Breath-Hold MRI
K. Ding1, K. Cao2, K. Du2, Q. Chen1, D. Ennis3, G. Christensen2, J. Reinhardt2, 
B. Libby1, S. Benedict1, K. Sheng3, 1University of Virginia, Charlottesville, 
VA, 2University of Iowa, Iowa City, IA, 3University of California, Los Angeles, 
Los Angeles, CA
Purpose/Objective(s): Current Radiation Therapy (RT) planning for lung 
stereotactic body radiotherapy (SBRT) is based on dose volume histogram 
such as V20 and mean lung dose to avoid radiation induced lung injury based 
on the assumption that the pulmonary function is the same everywhere inside 
lung. However, the actual lung function is indeed region specific and it can be 
incorporated into RT planning for functional lung avoidance. We have previ-
ously developed ventilation imaging methods coupling either free breathing 
4DCT or breath hold MRI with deformable image registration. In this study, 
we compare the ventilation measurements from two imaging modalities on a 
regional basis. 
Materials/Methods: The max inhale phase and the max exhale phase were 
extracted from the free breathing 4DCT for one lung cancer patient planned 
with SBRT with 55 Gy to PTVs in the right and the left lung respectively. A 
MRI scan pair near the end of inhale and near the end of exhale with breath 
hold were also acquired before RT. B-spline based vesselness preserving image 
registration algorithm was applied to register the breath hold MRI pair and the 
extreme phase pair from 4DCT separately for the calculation of regional ven-
tilation measured as the Jacobian determinant of the displacement field from 
the registration result. The ventilation maps from the both breath hold MRI 
and free breathing 4DCT were then mapped to the planning CT using the same 
algorithm tuned for MRI-CT and CT-CT registrations. The ratio of the ventila-
tion values from two methods were compared in a regional basis. 
Results: The ratio between the ventilation measured from free breathing 
4DCT and the breath hold MRI has the mean value of 1.61. 91.8% of the lung 
voxels have the ratio large than 1 indicating the breath hold may recruit dif-
ferent breathing unit of the lung for breathing between the free breathing and 
the breath hold procedure. A strong heterogeneity was found inside the lung 
from the ratio map which also suggests different breathing pattern between 
the two procedures. 
Conclusion: We compared free breathing 4DCT based and static breath-hold 
MRI based lung imaging to evaluate regional ventilation for RT planning 
which may take the underlying lung function into account. Further investiga-
tion is needed to study which method is more sensitive and robust for regional 
lung ventilation measurement.
Author Disclosure Block: K. Ding: None. K. Cao: None. K. Du: None. Q. 
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1115 
Transpulmonary Chemoembolization (tpce) For Colorectal 
Lung Metastases Using Irinotecan Soaked Drug-eluting-beads 
(deb): A Case Report
A. G. West, D. Sessions, M. Meek, University of Arkansas for Medical 
Sciences, Little Rock, AR
Purpose/Objective(s): To report our experience with a new technique for 
treatment of unresectable colorectal metastases to the lung. We performed 
transpulmonary chemoembolization (TPCE) using irinotecan soaked drug 
eluting beads in one patient with colorectal lung metastases. 
Materials/Methods: We devised the following method for TPCE based on 
our clinical experience with chemoembolization of the liver, pulmonary angi-
ography, and a review of the literature. We treated a 39 year old patient with 
colorectal lung metastases who had exhausted all other treatment options. 
Drug eluting beads loaded with irinotecan were injected into a segmental 
branch of the pulmonary artery. Side effects and complications of treatment 
were recorded. 
Results: The procedure was performed as an outpatient and was well toler-
ated. The patient experienced no significant side effects from the emboliza-
tion including cough, chest pain, or shortness of breath and no significant side 
effects from the chemotherapy such as nausea, vomiting or diarrhea. Now 
thirty days out from the procedure, the patient has developed no complications. 
Conclusions: TPCE is a promising technique for patients with non-surgical 
lung metastases. The procedure was well tolerated in our patient and is less 
invasive than other techniques such as isolated lung perfusion. No therapeutic 
conclusions can be drawn from this one case, but the lack of significant side 
effects suggests that further research is warranted using irinotecan drug elut-
ing beads for TPCE of colorectal lung metastases.
Author Disclosure Block: A.G. West: None. D. Sessions: None. M. Meek: 
None.
1116 
Early Death After Palliative Radiotherapy For Brain 
Metastases In Lung Cancer Patients And Analysis Of 
Predictive Factors
F. L. Ampil, G. Caldito, G. Mills, A. Balandin, J. Ponugupati, Louisiana State 
University Health Sciences Center, Shreveport, LA
Purpose/Objective(s): The literature suggests that a significant proportion of 
people with brain metastases die within a short period of time after palliative 
radiotherapy. To avoid non-beneficial cranial irradiation which might repre-
sent over-treatment of such patients, identification of risk factors predictive of 
short survival would be an important goal. We aimed to determine the differ-
ences in time of death and potential prognostic factors in lung cancer patients 
after palliative radiotherapy for brain metastases. 
Materials/Methods: Retrospective cohort study of 50 people with lung can-
cer and brain metastases who were treated by cranial irradiation for palliation. 
Charts were reviewed for patient age, duration of survival, number of meta-
static lesions in the brain, intrathoracic extent of the lung tumor, performance 
status, tumor histology, the presence or absence of intercurrent illness and 
extracranial metastases. 
Results: Twenty individuals (40%) succumbed (within 2 months) early 
while the other 30 people died later. Among the evaluated prognostic fac-
tors, advanced regional intrathoracic disease was significantly present in the 
patients who had an early demise compared to the individuals who died later 
(63% and 30% respectively, p=.02). The impact of other clinicopathologi-
cal features (elderly age group, p=.30; other coexisting illness, p=.16; mul-
tiple metastases in the brain, p=.63; extracranial systemic spread, p>.99; 
performance score of 3, p=.88; small cell cancer histology, p=.90) was not 
significant. 
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Conclusions: The finding of a single predictive factor in our reviewed expe-
rience is not sensitive/specific enough to reliably select which lung cancer 
patients do not deserve cranial irradiation for palliation of brain metastases.
Author Disclosure Block: F.L. Ampil: None. G. Caldito: None. G. Mills: 
None. A. Balandin: None. J. Ponugupati: None.
1117 
Curriculum Development for Medical Students on 
the Diagnosis and Management of Lung Cancer: A 
Multidisciplinary Approach
M. Kettler, Oregon Health and Science University, Portland, OR
Purpose/Objective(s): Lung cancer is the leading cause of cancer death in the 
United States and most clinicians will care for many patients with this disease 
during their medical careers. Newly diagnosed patients frequently receive 
suboptimal care with suboptimal outcomes due to suboptimal communication 
among multiple care givers Multidisciplinary lung cancer treatment teams 
bridge this communication gap so that all caregivers are knowledgeable about 
the patient’s clinical status and the pertinent imaging and pathologic find-
ings and can therefore develop coordinated treatment plans based on accurate 
information and up-to-date scientific data. Our specific curricular aim was to 
design a 4-week multidisciplinary elective clerkship for senior medical stu-
dents stressing a team-based approach to the diagnosis and management of 
lung cancer and other pulmonary diseases. We utilized the multi-disciplin-
ary lung cancer conferences and clinics at the Oregon Health and Science 
University (OHSU) and the Portland Veterans Administration Hospital (VAH) 
as educational focal points and lung cancer as a central educational theme. 
Materials/Methods: Students attend the weekly multidisciplinary lung cancer 
clinics at OHSU and VAH, preceded by tumor boards during which diagnostic 
data is presented and preliminary treatment plans are developed by the spe-
cialists at the conference. Students accompany newly-diagnosed lung cancer 
patients as they rotate among appointments with thoracic surgery, medical 
oncology, radiation oncology and, when indicated, palliative care. All students 
spend 1 week in a pulmonary medicine practice at a community hospital , 
1 week focused on learning pulmonary radiology stressing use of electronic 
resources, 1-2 weeks in thoracic surgery at OHSU/VAH and ½ day rotations 
in pulmonary pathology and pulmonary radiation oncology Each student 
prepares a detailed case analysis of a newly diagnosed lung cancer patient 
demonstrating their mastery of the complementary roles of surgery, medical 
oncology, radiation oncology and palliative care in the treatment plan and sub-
mit analyses of 2 journal articles relating to lung cancer diagnosis/treatment. 
Conclusions: Based on specific verbal and written feedback from students 
and faculty, this course, provides a unique opportunity to actively participate 
in care of lung cancer/ pulmonary disease patients from the team-based multi-
disciplinary perspective. The student and faculty evaluations are continuously 
analyzed to modify course content and teaching methodology. This course 
shows promise as on offering for both undergraduate and graduate medical 
education.
Author Disclosure Block: M. Kettler: G. Consultant; Seno Medical.
1118 
Effects Of Radiotherapy On Pulse Rate And Blood Pressure 
In Patients With Lung Cancer
T. Biswas, T. K. Podder, Brody School of medicine at East Carolina University, 
Greenville, NC
Purpose/Objective(s): Radiation therapy can impact cancer patients physi-
cally as well as psychologically, which may temporarily or permanently affect 
the physiodynamics of the treated patients. The purpose of this study is to 
investigate the effects of radiation on the pulse rate and blood pressure of the 
treated lung cancer patients. 
Materials/Methods: A total of 51 patients with lung cancer treated 
with external beam radiation (EBRT) in our clinic between 2008 and 
2010 were randomly selected for this study. 94% of the tumors were cen-
trally located (involved mediastinum), in left lung (39.2%), and right lung 
(60.8%). Treatment dose for each of the selected patients was at least 50 Gy 
(mean=60.1 Gy, median=60 Gy, range=50-74 Gy; 1.8-2 Gy/ fraction). Each 
of the patient’s weight, pulse rate, systolic and diastolic pressure readings 
were collected from the electronic medical record (Centricity). IRB approval 
was obtained for this retrospective study. Five sets of data during pre-EBRT, 
intra-EBRT and post-EBRT were gathered for about from 3 months to 1week 
prior to EBRT, 5 consecutive weeks in the middle of EBRT and from 1 week 
up to about 4 months after EBRT. Statistical significance was assessed using 
two-tailed student’s t-test and p-value less than 5% was considered significant. 
Results: The median age of the studied patent population was 66.4 years 
(range = 36.6-75.6 years). As compared to pre-EBRT conditions, a signifi-
cant increase in pulse rate was observed in intra-EBRT (7.73%, p-value < 
0.01) and post-EBRT (12.4%, p-value <0.002) periods. The systolic pres-
sure decreased during both intra-EBRT period (-4.5, p-value = 0.013) and 
post-EBRT period (-3.3%, p-value = 0.023). There was a marginal change in 
diastolic pressure: -0.25% in intra-EBRT and 0.85% in post-EBRT; but they 
were not statistically significant. No significant weight loss was observed: in 
intra-EBRT (-0.8%, p-value = 0.86) and in post-EBRT (-3%, p-value = 0.50). 
Observed large fluctuations in pulse rate and systolic pressure at the begin-
ning of treatment (during the day of simulation and/or first treatment). 
Conclusions: This study revealed that patients undergoing thoracic radiation 
for lung cancer might have significant change in pulse rate and systolic pres-
sure. Fluctuation of these parameters at the beginning of treatment may be 
attributed to psychological. Further study in this regard is warranted.
Author Disclosure Block: T. Biswas: None. T.K. Podder: None.
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A Study Comparing Clinical Outcomes In Non-Small 
Cell Lung Cancer Patients Treated With Radical Thoracic 
Radiotherapy Planned Using Pencil Beam Algorithm And 
Collapsed Cone Algorithm
S. Ramamurthy, F. McDonald, A. Macdonald, H. McCallum, G. Lawrence, 
Northern Centre for Cancer Care, Newcastle- Upon -Tyne, United 
Kingdom
Purpose/Objective(s): The pencil beam (PB) algorithm was previously used by 
the treatment planning system, Oncentra Masterplan (TPS) for dose calculation 
in all patients with lung cancer receiving thoracic radiotherapy (TRT) in our 
institution, Northern Centre for Cancer Care (NCCC). The PB algorithm was 
replaced by Collapsed cone (CC) algorithm in TPS to calculate dose in TRT, in 
2007, following a study conducted in NCCC1. It showed CC plans had improved 
dose coverage of the planning target volume (PTV) but compared with the origi-
nal PB plans, the volume of lung receiving greater than 20 Gy (V20) increased. 
This raised the concern regarding potential increase in long term toxicity. 
Current study compared clinical outcomes and toxicity of radical TRT using PB 
plans with CC plans in patients with non-small cell lung cancer (NSCLC). 
Materials/Methods: Patients who received radical TRT for NSCLC were 
included in the study. A cohort of 40 patients who were treated using PB plans 
was compared to another cohort of 48 patients who were treated using CC 
plans. All patients were followed-up prospectively to date. All patients were 
prescribed 55 Gy in 20 fractions. The PB plans aimed to deliver a minimum of 
95% of prescribed dose to PTV. However, with the CC plans as it is more dif-
ficult to achieve a minimum of 95% of the prescribed dose to the PTV, the aim 
was to deliver 90% of the prescribed dose to the PTV and 95% to clinical tar-
get volume. Information regarding disease recurrence, survival, dyspnoea and 
radiological evidence of pneumonitis post TRT were recorded for all patients 
in both cohorts from patient notes and hospital electronic patient data base. 
Results: The median progression free interval in both cohorts was 12 months 
(Kaplan Meier method- KMM; and log-rank test p= 0.96). The median over-
all survival in PB cohort was 20 months compared to 18 months in CC cohort 
(KMM). However, the difference did not reach significance level (Log- rank 
test p=0.195). Although radiologically PB cohort had higher incidence of 
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pneumonitis, the two groups did not differ significantly in terms of clinical 
dyspnoea (p= 0.004 and 0.14 respectively using Fisher exact probability test). 
Conclusions: Implementation of CC algorithm has not had a negative impact 
on patient outcomes. It is reassuring that concerns regarding CC plans result-
ing in higher V20 have not resulted in increased clinical toxicity.
Author Disclosure Block: S. Ramamurthy: None. F. McDonald: None. A. 
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1120 
Analysis of the Relationship Between Response to 
Chemotherapy and Response to Radiation Therapy in 
Patients With Non-Small-Cell Lung Cancer Receiving 
Sequential Treatment
G. Maquilan1, S. Grover2, E. Xanthopoulos2, T. L. Evans2, C. Aggarwal2, C. J. 
Langer2, R. B. Cohen2, J. P. Stevenson3, C. Simone2, R. Rengan2, 1Perelman 
School of Medicine at the University of Pennsylvania, Philadelphia, PA, 
2Hospital of the University of Pennsylvania, Philadelphia, PA, 3Penn 
Presbyterian Medical Center, Philadelphia, PA
Purpose/Objective(s): Response to induction chemotherapy has been shown 
to predict response to radiotherapy for several solid tumors such as head and 
neck cancers. It is unclear if a similar relationship exists in NSCLC. The 
purpose of this single institution study was to examine whether response to 
induction chemotherapy predicts response to thoracic radiotherapy in locally 
advanced or oligometastatic NSCLC. 
Materials/Methods: Between January 2001 and August 2010, 25 con-
secutive patients (pts) were identified who received systemic dose chemo-
therapy followed by definitive thoracic radiotherapy without concurrent 
chemotherapy and had serial CT images available for response assess-
ment. All pts underwent baseline, post-chemotherapy/pre-radiotherapy, 
and post-radiotherapy CT scans. The selected pts all had measurable dis-
ease after chemotherapy that was evaluable for a response to radiotherapy. 
Response to each modality was scored by RECIST as stable disease (SD), 
progressive disease (PD), partial response (PR), or complete response 
(CR). Response to chemotherapy and radiotherapy were analyzed using 
the Chi-squared test and Pearson correlation. For the Chi-squared test, pts 
were grouped into chemotherapy responders and non-responders as well as 
radiation therapy responders (CR/PR) and non-responders (SD/PD). The 
correlation coefficient was generated from a line of best fit plotting che-
motherapy response against radiation response using the percent change 
of the short axis or sum of the short axes for the selected lesion(s) across 
the three scans. 
Results: All pts had stage III or oligometastatic stage IV NSCLC. 
44% were male; histology was 13 adenocarcinoma, 8 SCC, and 4 
other; 6 pts had stage IIIA, 14 stage IIIB, and 5 stage IV disease. Pts 
received 2 - 6 cycles (median 4 cycles) of platinum-based chemo-
therapy followed by definitive dose radiotherapy with a median dose 
of 66.6 Gy (range 50 – 84 Gy). Median time between the end of che-
motherapy and start of radiotherapy was 1 month (range 3 wks - 12 
mo). 12 pts responded to chemotherapy (PR only—none were CR) 
and 13 pts did not (SD + PD). 15 pts responded to radiotherapy (CR + 
PR) and 10 pts did not (SD +PD). Chi-squared analysis did not find any 
association between chemotherapy and radiotherapy response (p = 0.513). 
Regression analysis also failed to identify any correlation between che-
motherapy and radiotherapy response (r2= 0.008). Conclusions: This 
study suggests that response to chemotherapy does not predict likelihood 
of response to radiation therapy in locally advanced or oligometastatic 
NSCLC. Based on these limited data, a lack of response to chemotherapy 
should not preclude treatment with definitive radiotherapy. These observa-
tions need to be confirmed in a larger series or prospective trial.
Author Disclosure Block: G. Maquilan: None. S. Grover: None. E. 
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1121 
Stereotactic Lung Radiotherapy: Outcomes and Toxicity of 
Various Dose Regimens used at the McGill University Health 
Center
L. Shakibnia, N. Kopek, S. Faria, D. Roberge, B. Abdulkarim, E. Soisson, J. 
Wan, McGill University, Montreal, QC, Canada
Purpose/Objective(s): Stereotactic body radiotherapy (SBRT) offers an 
alternative option for high-risk patients who are not surgical candidates with 
stage I lung cancer or oligometastatic cancer to the lungs. The purpose of this 
study was to assess our rates of local control and toxicity in patients treated at 
the McGill University Health Centre (MUHC). 
Materials/Methods: Treatment records for all patients with primary NSCLC 
or metastatic lesions to the lung treated with SBRT at the MUHC were ret-
rospectively reviewed. Choice of dose and fractionation(#) depended on ana-
tomical location and treating physician (range: 48-60Gy in 3#; 25-34Gy in 
1#, 40-50Gy in 5#). Treatments were delivered using Tomotherapy or 4-10 
noncoplanar nonopposing beams. CT chests were completed 3 months after 
completion of treatment, then every 6 months. PET scans were obtained upon 
suspicion of local recurrence on CT. Local tumour recurrence was defined as 
progressive CT scan soft-tissue abnormalities between successive CT scans 
that corresponded to avid areas on the PET scan. 
Results: Between November 2007 and May 2011, 106 consecutive patients 
with a median age of 73 years and with 130 lesions were treated with SBRT 
at the MUHC. The majority of lesions were peripheral (90%) and represented 
primary lung cancers (75%). Median follow-up time was 9.8 months. Median 
overall survival was 11.1 months. Local control was achieved in 93 patient 
(85%), 5 (5%) had indeterminate scans requiring further follow up or investi-
gation and 11 (10%) had local failure at a median time of 7.0 months post end 
of RT. Toxicity was graded according to RTOG criteria for fibrosis and acute 
radiation pneumonitis was graded according to CTC v.4. Three patients (2%) 
developed symptomatic grade 2 acute pneumonitis. 52% of patients devel-
oped asymptomatic radiographic changes compatible with radiation fibrosis; 
22% developed grade 1 fibrosis, 17% grade 2 fibrosis and 13% grade 3 radia-
tion induced fibrosis at a median time of 7.6 months post RT (range 4.0 - 17.6 
months). Eight patients developed bone toxicity: 5 with rib fracture (grade 4), 
1 with severe pain without fracture (grade 3), and 2 with mild pain (grade 2) 
Conclusions: This review of the MUHC experience with SBRT in patients 
with either metastatic lesions or primary NSCLC demonstrates that treat-
ments can be delivered with acceptable safety. Overall, no acute grade ≥3 
toxicity was observed. 52% of patients developed asymptomatic radiographic 
changes compatible with radiation fibrosis, 3.8% of patients developed rib 
fracture. Although median follow up time of 9.8 months is short, preliminary 
estimate of local control at this time is 85% which is comparable to results 
reported by other series in the literature.
Author Disclosure Block: L. Shakibnia: None. N. Kopek: None. S. Faria: 
None. D. Roberge: None. B. Abdulkarim: None. E. Soisson: None. J. Wan: 
None.
1122 
Factors Influencing Physicians’ Decision To Continue 
Bevacizumab Treatment To Progression: Survey Results From 
The Oncology Portal
A. Ravelo1, A. Hunek2, K. B. Whitlock3, E. Yu1, 1Genentech, South San 
Francisco, CA, 2McKesson Specialty Health, The Woodlands, TX, 3McKesson 
Specialty Health, San Rafael, CA
Introduction/Objective: Bevacizumab (BV) as a continuation maintenance 
therapy is supported in current NCCN guidelines for NSCLC based on Phase 
III pivotal trial (E4599) of bevacizumab. However, BV monotherapy (BvM) 
is not always continued until disease progression (PD) in clinical practice. A 
survey of physicians was conducted to better understand this treatment (tx) 
practice and identify reasons and clinical factors in physicians’ decision to 
treat or not treat with BV maintenance. 
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Materials/Methods: A web-based survey through The Oncology Portal was 
conducted among physicians in the US Oncology/McKesson network from 
Nov 2011 to Jan 2012. 579 physicians were invited to participate if they had 
treated patients with BV for metastatic NSCLC in the first-line (1L) setting 
between June 2007 and Nov 2011. Those who treat vs. not treat with BvM 
until PD were self-reported by physicians. Physicians completed between 9 
and 14 questions about their 1L tx practices, and concerns and experiences 
with BV use in the maintenance setting. 
Results: 92 physicians completed the survey; 19 (21%) reported they have 
never treated patients with BvM until PD (Group 1) and 73 (79%) reported 
that they have (Group 2). The 3 most important factors they consider in 
their decision to continue BV in the maintenance setting were: for Group 
1, patient’s decision to continue/discontinue tx, BV-related toxicities experi-
enced in 1L induction tx, and cost of therapy; for Group 2, BV-related tox-
icities experienced in 1L induction tx, type of response to tx, and patients’ 
performance status (PS). Most physicians in Group 2 (78%) expect to see at 
least stable disease in order to continue BvM until PD; 22% expect a com-
plete/partial response to tx. The toxicities of greatest concern for both groups 
were VTEs, ATEs, hemorrhage, and proteinuria of varying toxicity grades. 
89% in Group 1 and 42% in Group 2 reported they were not aware of data 
supporting the effectiveness of BvM until PD. 
Conclusion: Based on this survey of US physicians in the community setting, 
physicians’ decision to continue BV tx in the maintenance setting may be 
influenced by awareness of BV data, patient choice to continue tx, and clinical 
factors such as toxicities, treatment response, and PS.
Author Disclosure Block: A. Ravelo: A. Employee; Genentech. K. 
Stock; Roche. A. Hunek: A. Employee; McKesson Specialty Health. K.B. 
Whitlock: A. Employee; McKesson Specialty Health. E. Yu: A. Employee; 
Genentech. K. Stock; Roche.
1123 
The Influence of the Inhomogeneity Correction Factor on 
Dose Distributions in Lung Cancer Radiation Therapy 
Treatment Plans: A Retrospective Study
R. Murphy, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, 
Canada
Purpose/Objective(s): The purpose of this retrospective study is to analyse 
the effect of the Convolution/Superposition Inhomogeneity Correction Factor 
(ICF) on the dose distribution when applied to lung cancer radiation therapy 
plans. The objective of this study is to better the delivery of care for patients 
with lung cancer by providing valuable information that can help determine 
what adaptations need to be made when moving from homogeneous planning 
to heterogeneous planning of lung cancer radiation treatments. 
Materials/Methods: The treatment plans of 27 patients prescribed radiation 
treatment for lung cancer planned within the last 3 years at the Thunder Bay 
Regional Health Sciences Center (TBRHSC) using homogeneous calcula-
tions were restored from archives. Included are 18 plans of patients treated 
for radical stage III non-small cell lung cancer (NSCLC), 9 of patients treated 
for radical T1N0 (NSCLC). Each plan was recalculated with the same pre-
scribed dose but applying the ICF so as to analyse the effect of the ICF on 
the dose distribution. Dose distributions of the inhomogeneity plans were 
compared with the original plan by the following criteria: dose to the ICRU 
reference point, percent of the planning target volume (PTV) receiving 95% 
and 100% of the prescribed dose (V95% and V100% respectively), volume 
of lung receiving 20Gy (lung V20), maximum dose to the cord (Dmax Cord) 
and the mean lung dose (MLD). 
Results: The preliminary results showed a strongly correlated decrease (5%) 
in the number of monitor units needed to provide the prescribed dose to the 
ICRU reference point from the original plan to the plan with the ICF applied 
for both the radical stage III group and the T1N0 group. The volume of the 
PTV receiving 100% of the prescribed dose varied dramatically while the 
volume receiving 95% of the prescribed dose consistently showed a decrease 
in coverage (stage III = 7%, T1N0 = 5%). The lungV20 and mean lung dose 
were consistent with one another. Both the lungV20 and the MLD rarely 
decreased from the original plan with ICF applied and some plans showed an 
increase of as much as 21% of the volume of lung receiving 20Gy and 12% 
increase of the MLD. However both showed a small average increase of dose 
to the lung (LungV20 = 0.3%, MLD = 0.3%). 
Conclusions: Inhomogeneity corrections have a great influence on the cal-
culated dose delivered to the PTV. Without the ICF applied there is an over-
dosing to the surrounding tissues as well as decreased coverage of the target 
volume. Further investigations could be done with a larger population in order 
to provide statistically significant results, however even in this small patient 
population, trends can be seen that can help provide direction when begin-
ning to plan using the Convolution/Superposition Inhomogeneity Correction 
Factor.
Author Disclosure Block: R. Murphy: None.
1124 
Stereotactic Hypofractionated Radiation For Non-small Cell 
Lung Cancer (NSCLC): An Analysis Of Clinical Outcome As 
A Function Of Biologically Equivalent Dose
T. Skrepnik1, R. Kumar1, B. Stea2, 1University of Arizona, College of Medicine, 
Tucson, AZ, 2University of Arizona, Department of Radiation Oncology, 
Tucson, AZ
Purpose/Objective(s): Stereotactic body radiation therapy (SBRT) given 
in 1-5 fractions is a popular approach for early stage NSCLC, achieving 
excellent local control (LC). No consensus exists on the recommended frac-
tionation schema for centrally located tumors, and there is concern with long-
term toxicity associated with high dose per fraction regimens. This study is 
a retrospective analysis of stereotactic and variably hypofractionated body 
radiation therapy (SHRT) for all stages of NSCLC to determine the biologi-
cally equivalent dose (BED
10
) corresponding to durable LC. 
Materials/Methods: We retrospectively reviewed 31 patients (16 female, 
15 male, mean age 70.5 years) with NSCLC harboring 43 lesions. Patients 
were treated from 2004 to 2011 with SHRT to the lung and/or mediasti-
num (62.5% central, 37.5% peripheral); none were surgical candidates and 
minimum follow up of 3 months was required. The primary endpoint was 
LC; secondary endpoints were overall survival (OS), toxicity, and patterns 
of recurrence. Stage IA disease was most common (48.4%), while 29.1% 
of the patients had advanced disease. Average GTV was 22.75 cc (0.79 - 
97.5). Adeno (38.7%) and squamous cell carcinoma (25.8%) were the most 
common histologies. Most (64.5%) of patients received chemotherapy 
(19% neoadjuvant, 19% adjuvant, 25% both). Either an internal target vol-
ume expansion (average expansion of 0.7cm) or an active breathing control 
device was used to account for motion. The average prescription isodose line 
was 90%. 
Results: The median dose per fraction was 7Gy (2.5 to 15 Gy) and the aver-
age number of fractions was 10 (3 to 20). The median BED
10
 was 95.2 Gy. 
After a median follow-up of 21 months (3 to 92 mos.), LC and OS at 1 year 
was 97% and 82.3%, respectively, and at 5 years was 84% and 52%, respec-
tively. Three lesions (2 central) had local recurrence occurring 4, 6, and 19 
months after SHRT; median BED
10
 for these lesions was 71.7Gy, whereas 
the median BED
10
 for LC tumors was 89.9 (p=0.15). All 9 advanced stage 
patients showed LC for their treated lesions. The patterns of failure were 51% 
distantly, 15% regionally, and 6.7% locally. Only 4.4% developed new prima-
ries and 22% exhibited no recurrence. NCI-CTAC toxicity scoring showed 5 
patients with grade 3 toxicity (4 dyspnea, 1 pericardial effusion). There were 
no grade 4 or 5 events. 
Conclusions: Though the BED
10
 was not statistically different between LF 
and LC, our data suggests that a minimum BED
10
 of ~90 Gy is necessary to 
achieve LC. For centrally located lesions treated with BED
10
 of 90 Gy, a more 
fractionated approach, SHRT, provides a high rate of LC without significant 
toxicity.
Author Disclosure Block: T. Skrepnik: None. R. Kumar: None. B. Stea: 
None.
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1125 
Multidisciplinary Approach to Screening through Treatment 
of Thoracic Abnormalities in the Community Setting
K. Rohan, M. Quejada, Edward Cancer Center, Naperville, IL
Purpose/Objective(s): To assess the impact of a multidisciplinary approach 
to the care of thoracic oncology patients in the community setting. 
Objectives: 1. 100% of patients offered appointment within 5 business days. 
2. First visit to first treatment within 2 weeks. 3. 90% of patients diagnosed 
at Edward stay for their care. 4. 90% correlation between clinical and patho-
logic staging and 5. 100% patients will have post treatment surveillance scans 
according to guidelines. 6. Initiation of successful lung screening program 
Materials/Methods: Edward Multidisciplinary Thoracic Oncology Clinic 
data, cancer registry data 
Results: 100% patients seen within 5 business days, 90% of patients started 
therapy within 2 weeks of visit, 87% of patients diagnosed at Edward received 
treatment at Edward, 75% correlation between clinical and pathologic staging 
and 100% of patients had surveillance scans according to guidelines. 
Conclusions: A multidisciplinary approach to care of the thoracic oncology 
patient improves patient outcomes and increased physician and patient satis-
faction. The lung screening program’s successful implementation is attributed 
to the multidisciplinary review of all imaging and the patient navigator role.
Author Disclosure Block: K. Rohan: None. M. Quejada: None.
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Referral of Suspected Lung Cancer by Family Physicians and 
Other Primary Care Providers: A Clinical Practice Guideline
Y. C. Ung1, L. Del Giudice2, S. Young3, E. Vella4, M. Ash5, P. Bansal6, A. 
Robinson7, R. Skrastins8, R. Zeldin8, C. Levitt9, 1Odette Cancer Centre, 
Toronto, ON, Canada, 2Sunnybrook Health Sciences Centre, Toronto, ON, 
Canada, 3Lakeridge Health, Oshawa, ON, Canada, 4McMaster University, 
Hamilton, ON, Canada, 5North York General Hospital, Toronto, ON, Canada, 
6Credit Valley Hospital, MIssissauga, ON, Canada, 7Northeast Cancer Centre, 
Sudbury, ON, Canada, 8Toronto East General Hospital, Toronto, ON, Canada, 
9Cancer Care Ontario, Toronto, ON, Canada
Purpose/Objective(s): Clinical practice guidelines (CPGs) help practitio-
ners make optimal use of appropriate resources and give guidance for disease 
specific care pathways. Once lung cancer is suspected, appropriate manage-
ment and timely referrals by the primary care providers (PCPs) may impact 
clinical outcomes. This systematic review and CPG was developed for family 
physicians and other PCPs evaluating four aspects relevant to lung cancer 
suspicion. (1) The clinical features predictive of lung cancer. (2) The diag-
nostic accuracy of investigations for lung cancer. (3) Risk factors predictive 
of lung cancer. (4) Factors associated with delayed referrals attributable to 
both patients and providers. This guideline was intended to coincide with the 
introduction of Lung Cancer Diagnostic Assessment Programs (DAPs) that 
help fast track diagnostic procedures and consultative evaluation by a multi-
disciplinary thoracic oncology team with the assistance of a clinical navigator 
to help coordinate patient care. A unique challenge was to design a practical 
algorithm for PCPs. 
Materials/Methods: A review of the available evidentiary base for primary 
care referral for suspected lung cancer was done based on (1) published guide-
lines from the National Institute for Health and Clinical Excellance (NICE) 
2005 and the New Zealand Guidelines Group (NZGG) 2009, (2) adapatation 
of existing guidelines from the American College of Chest Physicians (ACCP) 
Evidence-based Clinical Practice Guidelines, Australian National Health 
and Medical Research Council and the Scottish Intercollegiate Guidelines 
Network (SIGN) (3) consensus of the Lung Cancer Working Group in Ontario 
and (4) input form external review by practitioners in Ontario. 
Results: The multidisciplinary Lung Cancer Working Group evaluated pub-
lished guidelines and based recommendations on best available evidence. 
Where there was insufficient evidence to make a recommendation, a con-
sensus recommendation was developed taking into consideration the local 
resources and accepted standard of care practice patterns in the province of 
Ontario. A unique feature was the development of a one page algorithm for 
quick and easy reference to guide practitioners to use appropriate diagnostic 
tests and to make early referral to the appropriate specialist for the suspicion 
of lung cancer. 
Conclusions: A useful one page algorithm has been designed for PCPs 
regarding patient management once lung cancer is suspected. The alogorithm 
is the result of reviewing the best available evidence modified by local prac-
tice patterns based on experts in the mangement of lung cancer and relevant 
practitioner feedback. This algorithm is desinged to be used in conjunction 
with available DAPs to coordinate and facilitate patient care.
Author Disclosure Block: Y.C. Ung: None. L. Del Giudice: None. S. 
Young: None. E. Vella: None. M. Ash: None. P. Bansal: None. A. Robinson: 
None. R. Skrastins: None. R. Zeldin: None. C. Levitt: None.
1127 
Limited-Stage Small Cell Lung Cancer in the Contemporary 
Period: Impact of New Technologies on Outcomes
A. Juloori, S. M. Shirvani, P. Allen, R. Komaki, Z. Liao, J. Welsh, D. Gomez, 
J. V. Heymach, J. Y. Chang, MD Anderson Cancer Center, Houston, TX
Purpose/Objective(s): Technological innovations have changed the land-
scape of diagnosis and treatment of limited-stage small cell lung cancer. 
Advances including positron emission tomography (PET) staging, magnetic 
resonance imaging (MRI) of the brain, intensity-modulated radiotherapy, 
and dose escalation using image guided radiotherapy have been intro-
duced into practice without phase III evidence. To determine the impact 
of these technologies on outcomes for limited-stage small cell lung carci-
noma (LS-SCLC) in the contemporary period, we retrospectively reviewed 
patients definitively treated for this disease during the last decade at our 
institution. 
Materials/Methods: Between 2000 and 2009, 224 patients with LS-SCLC 
were treated with definitive radiation at our institution. In the majority of 
cases, concurrent platinum-based chemotherapy was administered. Overall 
survival and progression-free survival were assessed using the Kaplan-
Meier method. Multivariable analysis using Cox regression was utilized to 
determine the influence of patient, tumor, and treatment variables on these 
outcomes. 
Results: The median age of the study patients at diagnosis was 62 (range 39 
– 82). The median follow-up was 33 months (range 2-145). The median over-
all survival, 2-year actuarial overall survival and relapse-free survival rates 
were 25 months, 53% and 42% respectively. Progression was predominantly 
driven by distant metastases, which represented 58% of first progressions. 
Using Cox regression, improved overall survival was associated with the 
absence of contralateral mediastinal involvement, better performance status 
(ECOG stage 0-1), utilization of pretreatment brain MRI, and an interval 
between PET scan to radiation start time of less than 30 days. Improved pro-
gression free survival was associated with absence of contralateral medias-
tinal involvement and the administration of prophylactic cranial irradiation. 
The use of IMRT as opposed to 3D conformal radiation did not influence 
overall survival or progression-free survival in either univariable or multi-
variable analysis. 
Conclusion: To the best of our knowledge, our institutional experience repre-
sents the largest contemporary series of limited-stage small cell lung cancer 
patients treated with definitive chemoradiation. Our findings suggest that the 
introduction of advanced diagnostic modalities including PET scanning and 
brain MRI have improved outcomes in LS-SCLC. Whether this is due to a 
benefit on therapeutic efficacy or stage migration requires additional study. 
The transition to treatment delivery with IMRT did not compromise rates of 
overall and progression-free survival, with distant metastatic disease remain-
ing the most common pattern of failure.
Author Disclosure Block: A. Juloori: None. S.M. Shirvani: None. P. Allen: 
None. R. Komaki: None. Z. Liao: None. J. Welsh: None. D. Gomez: None. 
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CXCR4 As A Prognostic Marker For Small Cell Lung Cancer
R. Hseu1, T. Gangadhar2, C. Rolle1, R. Kanteti1, E. E. Vokes1, A. N. Husain1, 
T. Karrison1, R. Salgia1, 1The University of Chicago, Chicago, IL, 2University 
of Pennsylvania, Philadelphia, PA
Purpose/Objective(s): Lung cancer is the leading cause of cancer death 
worldwide. Small cell lung cancer (SCLC) is characterized by extensive 
metastasis, treatment resistance, and almost certain relapse. CXCR4 is a che-
mokine receptor that is expressed in lung cancer cells. Signaling induced by 
its ligand, CXCL12, is important in tumor cell proliferation, migration, and 
metastasis, making the pathway a possible therapeutic target for lung cancer. 
Materials/Methods: We analyzed tissue microarrays composed of paired 
tumor/normal lung tissue samples from 38 patients with SCLC. Mutational 
analysis of CXCR4 and CXCL12 was performed on 6 SCLC cell lines and on 
84 SCLC tumor DNA samples. Circulating tumor cells (CTC) were evaluated 
for CXCR4 expression. We assessed CXCR4 gene copy number by qPCR. 
CXCR4 protein expression in SCLC cell lines was analyzed by immunob-
lot. The effect of SDF-1(CXCL12) stimulation on proliferation of SCLC cell 
lines was measured with a standard MTT assay. 
Results: We found that tumor tissue expressed significantly higher levels of 
CXCR4 (p<0.0001) and CXCL12 (p<0.0001) compared to normal lung tis-
sue from the same patient using both a 9 point pathology scoring system and 
Integrated Optical Density (IOD) calculated using an Automated Cellular 
Imaging System (ACIS). Increased CXCL12 (p=0.018) and CXCR4 levels 
(p=0.056) were associated with improved survival. CTCs from SCLC patients 
showed expression of CXCR4. Mutational analysis of SCLC tumor DNA 
samples identified a synonymous CXCR4 SNP (rs2228014) in 3 patients. 
No mutations or SNPs were identified in cell lines. Two patients had a more 
than 9-fold increase in CXCR4 gene copy number by qPCR with 3 additional 
patients having a copy number greater than 4. No mutations or SNPs were 
found in CXCL12. SDF-1 stimulation induced proliferation in 4 SCLC cell 
lines. 
Conclusions: We have observed both higher CXCR4 and CXCL12 expres-
sion in tumor versus normal tissue, and higher expression correlated with 
longer survival. Neither genetic mutation nor alteration of gene copy number 
appears to regulate expression. Further clinical testing is needed to evaluate 
CXCR4 and CXCL12 as both prognostic and predictive markers in SCLC and 
to determine the efficacy of CXCR4 inhibition in combination with cytotoxic 
chemotherapy.
Author Disclosure Block: R. Hseu: None. T. Gangadhar: None. C. 
Rolle: None. R. Kanteti: None. E.E. Vokes: None. A.N. Husain: None. T. 
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Vimentin Score Predicts Resistance to Erlotinib and 
Radiotherapy for Patients with Stage III Non-Small Cell Lung 
Cancer on A Prospective Phase II Trial
R. U. Komaki, Y. B. Kim, I. I. Wistuba, X. M. Tang, R. Meyn, P. K. Allen, 
X. Wei, M. S. O’Reilly, G. Blumenschein, W. Hong, MD Anderson Cancer 
Center, Houston, TX
Purpose/Objective(s): We have examined predictive biomarker resistant 
to Erlotinib and radiotherapy following chemoradiotherapy for Stage III 
NSCLC by using Vimentin IHC which is a strong multigene signature indica-
tive of epithelial to mesenchymal transition (EMT).
Materials/Methods: We conducted a prospective phase II study for stage III 
NSCLC patients. Eligibility included good PS, weight loss ≤ 5%, adequate 
lung, hematologic, hepatic, and renal functions. ChT/RT was given every 
Monday then erlotinib/RT on Tuesday-Friday and erlotinib alone over the 
weekend. RT (63Gy/35fx) with weekly paclitaxel (45mg/m²) / carboplatin 
(AUC=2) and erlotinib (150 mg p.o. daily) were given for 7 wks followed 
by x 2 paclitaxel (AUC=6) and carboplatin (200mg/m2). The response was 
measured by RECIST criteria (v3.0) by CT scan after treatment. Fisher’s exact 
and Kaplan-Meier’s estimates were used for the statistical analysis. Primary 
endpoint was 2-year overall survival (OS), progression-free survival (PFS), 
local recurrence-free survival (LRFS) and distant metastasis free survival 
(DMFS). Second endpoint point was to assess correlation between pretreat-
ment biopsy specimens as biomarkers (EGFR IHC staining and Vimentin 
Score) and patient outcome.
Results: 46/48 patients completed therapy between 3/2008 and 6/2010 and 
are evaluable for response. 17 (37%) were female, 23 adenocarcinoma, and 
87% former or current smokers, with median age 63y.o. Responses showed 
14 (30%) CR, 23 (50%) PR and 9 (20%) stable or progressive disease. The 
median OS and PFS were 34.1 months & 14.5 months, respectively. 1-year 
& 2-year OS were 83% & 71 %. There were 22 specimens analyzable for 
Vimentin IHC. The Vimentin Cytoplasm Score (VCS) < 240 vs. ≥ 240 were 
compared regarding OS, PFS, LRFS and DMFS. There were significant dif-
ferences in 2 years between the groups with VCS <240 vs. ≥ 240 regarding 
OS (72% vs., 0%, P= 0.02), PFS (30% vs. 0%, P=0.002) and LRFS (80% vs. 
0%, P<0.0001), but not DMFS (36% vs. 0%,P=0.07), respectively. 
Conclusions: This prospective phase II clinical study demonstrated an excel-
lent 2-year OS 71 % and median OS 34 months. Vimentin Cytoplasmic Score 
might be used as a predictor for patients with stage III NSCLC who are resis-
tant to erlotinib/radiotherapy combined by chemoradiotherapy, although we 
need validation with larger number of patients.
Author Disclosure Block: R.U. Komaki: None. Y.B. Kim: None. I.I. 
Wistuba: None. X.M. Tang: None. R. Meyn: None. P.K. Allen: None. X. 
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1130 
Prophylactic Cranial Irradiation in Patients with Limited 
Stage Small Cell Lung Cancer: A Pilot Study Investigating the 
Effects of Radiation Therapy on Neurocognitive Function
D. Bernad1, A. J. Fiocco2, G. Shenouda1, V. Panet-Raymond1, P. S. Giacomini3, 
R. del Carpio4, L. Souhami1, 1Department of Radiation Oncology, McGill 
University Health Centre, McGill University, Montréal, QC, Canada, 
2Department of Psychology, Ryerson University, Toronto, ON, Canada, 
3Department of Neurology, McGill University Health Centre, McGill 
University, Montréal, QC, Canada, 4Department of Radiology, McGill 
University Health Centre, McGill University, Montréal, QC, Canada
Purpose/Objective(s): Current standard of care for limited stage small cell 
lung cancer (L-SCLC) is combined platinum based chemotherapy (CT) and 
thoracic radiotherapy (RT), followed by prophylactic cranial irradiation 
(PCI). Although evidence supports reduced risk of brain metastases (BM) 
and improved survival post-PCI, the effects of PCI on neurocognitive function 
(NCF) is unclear. Our objective was to prospectively investigate the effects of 
PCI (25 Gy in 10 fractions) on NCF in patients with L-SCLC and to deter-
mine whether potential impairment in NCF correlated with hippocampal 
volumetric changes. 
Materials/Methods: Nineteen patients (median age= 70 years) diagnosed 
with L-SCLC were prospectively enrolled and underwent brain magnetic 
resonance imaging and NCF testing at baseline given before CT/thoracic RT 
and PCI (B), after CT/thoracic RT but before PCI (T1), and after CT/thoracic 
RT and PCI (T2). Change in performance on Hopkins Verbal Learning Test- 
Revised (HVLT-R), Controlled Oral Word Association (COWA), and Trail 
Making Tests were compared to baseline. 
Results: Only seven patients completed NCF testing (median time from base-
line to T1 = 142 days and median time from T1 to PCI = 21 days, median time 
from baseline to T2 = 286 days and median time from PCI to T2 = 111 days). 
Seven patients withdrew or had incomplete testing, three patients developed 
BM prior to PCI, and two patients died. Our results show worse average per-
formance after CT/thoracic RT in comparison to baseline on HVLT-R (11.3 
vs. 12.17), whereas we found improvement in average performance on Trail 
Making Tests (65.06s vs. 73.42s) and COWA (10.2 vs. 9.8). However, when 
performance after PCI (T2) was compared to pre-PCI scores (T1), we found 
greater impairment on HVLT-R (average difference in performance from 
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baseline = -1.83 vs. -0.833), Trail Making Tests (average difference in perfor-
mance from baseline = 10s vs. -8.36s) and COWA (average difference from 
baseline = -0.5 vs. 0.4). Hippocampal volumetric data will be discussed. 
Conclusions: Our results suggest that patients with L-SCLC undergoing 
platinum based CT may be susceptible to hippocampal dependant memory 
impairment which can be exacerbated with PCI. Further investigations in a 
larger cohort are necessary to better characterize the severity, dose thresholds, 
and time course of these effects.
Author Disclosure Block: D. Bernad: None. A.J. Fiocco: None. G. 
Shenouda: None. V. Panet-Raymond: None. P.S. Giacomini: None. R. del 
Carpio: None. L. Souhami: None.
1131 
New Strategy for the Identification of Lung Cancer Antigens 
that Induce Therapeutic Immune responses in Tumor-bearing 
Mice
E. Cohen, University of Illinois Chicago, Chicago, IL
The majority of non-small cell lung cancers are squamous cell carcinoma. 
We report a new vaccination strategy for squamous cell carcinoma (SCC). In 
a mouse model system, the vaccine is prepared by transfer of genomic DNA-
fragments (25 kb) from squamous carcinoma cells (KLN205, DBA/2 origin 
(H-2d)) into LM cells (C3H/He origin, (H-2k), a mouse fibroblast cell line. As 
the transferred DNA integrates spontaneously into the genome of the recipi-
ent cells, and is replicated as the cells divide, sufficient DNA to prepare the 
vaccine could be obtained from as few as 107 squamous carcinoma cells (4 
mm tumor). Since only a small proportion of the transfected cell-population 
was expected to have incorporated DNA-segments that included genes for 
tumor-associated antigens (TAA), we devised a novel approach to enrich the 
vaccine for immunotherapeutic cells. Microarrays of the enriched vaccines 
were used to identify genes that specified “therapeutic” lung cancer antigens. 
(Immunity to “therapeutic” lung cancer antigens results in tumor regression 
and prolongs the survival of tumor-bearing mice.) Aliquots of the transfected 
cell-population were divided into a number of small pools (initial inoculums = 
1 X 103). We reasoned that if the starting inoculums were sufficiently small, 
then the distribution of immunotherapeutic and non-therapeutic cells in each 
pool would not be the same. Cells from individual pools were allowed to 
increase in number. A portion of the expanded cell populations was main-
tained frozen/viable for later recovery. The remaining portion was used to 
immunize naïve DBA/2 mice. Pools containing greater numbers of immuno-
therapeutic cells were identified by two independent in vitro assays. (Frozen 
aliquots of cells from the pools that stimulated immunity to the squamous car-
cinoma cells to the greatest (and least) extent were recovered and subdivided 
for additional rounds of positive or negative immune selection. Enhanced 
immunity to squamous carcinoma mediated by CD8+ T-cells was induced in 
tumor-bearing mice treated solely by immunization with cell pools enriched 
for immunotherapeutic cells. Microarrays of the enriched pools resulted it in 
the identification of 10 newly described lung cancer antigens.
Author Disclosure Block: E. Cohen: K. Stock; Immune Cell Therapy, Inc..
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Xerostomia and the Brain: Prophylactic Cranial/Whole Brain 
Radiation (PCI) Using Opposed Lateral Fields (OLF): Impact 
Of Planning Technique And Dosimetric Considerations On 
Doses To Brain, Eyes And Parotids (PG).
D. D. Howell, M. J. Huberts, P. W. McLaughlin, University of Michigan 
Medical School, Ann Arbor, MI
Purpose/Objective(s): PCI is one component of definitive therapy for 
patients with small cell undifferentiated cancer of the lung. Classically, PCI 
was delivered using simple planning techniques of OLF using the anatomic 
landmarks of the mastoid tip (MT) and superior orbital ridge (SOR), or the 
bottom of the second cervical vertebral body (C2) and the SOR (also known 
as the “German Helmet” (GH) field) as indicators for the caudal border of the 
radiation fields. With the increased use of axial tomography for radiation sim-
ulation and the availability of three-dimensional conformal (3DC) techniques, 
complex or 3DC plans have seen greater utilization. There are anecdotes of 
patients receiving PCI who have developed xerostomia or mouth dryness. 
This study was designed to determine if there was a dosimetric explanation 
for this occurrence, and to look at the impact of various treatment planning 
techniques on radiation dose to the whole brain as well as doses to the critical 
structures of the eyes and PG. 
Materials/Methods: Ten cases of patients simulated for brain radiation were 
reviewed. All were in thermoplastic masks. 1/2 and 1 cm multileaf collimators 
(MLCs) were modeled for blocking. Dosimetry plans were created using two 
OLF rectangular field techniques using MT-SOR and bottom of C2-SOR (GH) 
as caudal borders. Two 3DC plans were created using one-half cm (BGTV+5), 
and 1cm (BGTV+10) margins around the contoured brain (BGTV), using 
the Eclipse© Analytic Anisotropic Algorithm (Varian Medical Systems). The 
eyes, lenses, and PG were also contoured, and doses to these structures were 
calculated in each situation. Dose volume histograms were calculated for the 
95% BGTV, 99% BGTV, as well as total eye, lens and parotid volumes. 
Results: Four dosimetric models-- MT-SOR, C2-SOR (GH), BGTV+5 and 
BGTV+10 were modeled. Mean 99% BGTV dose for the four situations 
respectively was 98.3, 98.3, 97.8, and 98.7% of prescribed dose (PD). Mean 
95% BGTV dose was 99.7, 99.5, 99.8, and 99.9% of PD. Mean total PG dose 
was 16.7, 57.2, 16.9, and 27.5 % of PD. Mean eye dose was 23.3, 12.6, 25.5, 
and 43.1% of PD. There were no significant differences in mean doses to the 
95% and 99% BGTV for the four techniques. The greatest mean doses to the 
PG volume were seen in C2-SOR (GH), with 3/10 subjects’ total parotid dose 
receiving >66% of PD. The greatest mean doses to the eyes with was in the 
BGTV+10 technique, with 4/10 subjects’ total eye dose receiving >50% of PD. 
Conclusions: The four dosimetric models simulated all showed excellent 
mean doses to 95% and 99% of the BGTV. There were wide variations in nor-
mal tissue doses, depending on technique. Normal tissue doses and tolerance 
should always be contemplated when considering brain radiation technique.
Author Disclosure Block: D.D. Howell: None. M.J. Huberts: None. P.W. 
McLaughlin: None.
1133 
Retreatment with Definitive Chemoradiation for Thoracic-
Only Recurrences of Limited Stage SCLC is Well-Tolerated: A 
Case Series of 4 Patients
J. M. Mann, P. A. Aridgides, A. Gajra, J. A. Bogart, SUNY Upstate Medical 
University, Syracuse, NY
Purpose/Objective(s): In the landmark trial establishing twice-daily RT with 
concurrent chemotherapy as the standard of care for limited-stage small cell 
lung cancer (L-SCLC), roughly one-third of patients in the hyperfractionated 
arm experienced local failure. Data is limited for the treatment of localized 
L-SCLC as distant failure is common. Here we report on 4 patients who were 
re-treated with definitive chemoRT for local relapse from L-SCLC. 
Materials/Methods: Medical records of 4 patients with thoracic recurrence 
of L-SCLC were analyzed for patient and treatment characteristics from ini-
tial and re-treatment. 
Results: We identified 4 patients (median age 66) with biopsy and PET con-
firmed thoracic-only recurrence following initial chemoRT for L-SCLC (stage 
I-III). Prior treatment (median time 3.6 years earlier, range 1-14 yrs) consisted 
of concurrent chemotherapy (4 cycles platinum/etoposide) and twice daily RT 
(45Gy) for 3 patients; however 1 patient received sequential chemotherapy fol-
lowed by daily RT (64.8Gy). All patients had a complete response (NED). 
Previous RT in all patients included lung, mediastinum, as well as prophylactic 
cranial RT (30-36Gy). All patients had a complete response (NED) to initial 
treatment before developing thoracic recurrence. Relapsed tumors were in the 
same lobe in 3 of 4 patients, with one patient recurring in the contralateral 
lung. Retreatment consisted of concurrent chemotherapy of either cisplatin/
irinotecan or carboplatin/etoposide with RT. IMRT was used for 3 patients and 
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one patient received 3DCRT, and 4-D planning was used in all cases. Three 
patients received 45Gy (1.5Gy BID) for salvage, while the remaining patient 
received a hypofractionated course to 50Gy in 2.5Gy daily fractions. Two 
patients received further sequential chemotherapy (carboplatin/irinotecan) for 
a median of 3 cycles. There were no significant interruptions or grade ≥ 3+ tox-
icities associated with re-treatment. The median lung V5 and V20 was 32% and 
10%, and median spinal cord maximum was 896 cGy. Cumulative V5, V20, 
V40, V60 (median values) were 57%, 28%, 20%, and 12%.The cumulative 
cord max median value was 3765 cGy. All patients were free of progression 
at 4 months (actuarial local control 100%); however each patient ultimately 
developed distant failure within 16 months of re-treatment. Two patients have 
expired (8.5 and 18 months) and two are alive receiving salvage therapy. The 
median survival from time of local recurrence was 310 days (range 261-534). 
Conclusions: Retreatment with definitive chemoRT for thoracic-relapse 
of L-SCLC was well-tolerated without significant adverse effects. Despite 
aggressive combined twice daily RT with systemic chemotherapy, these 
patients appear to be at a very high risk for developing distant disease.
Author Disclosure Block: J.M. Mann: None. P.A. Aridgides: None. A. 
Gajra: None. J.A. Bogart: None.
1134 
Efficacy and Toxicity of Etoposide/Cisplatin (EP) in Elderly 
Patients With Extensive Neuroendocrine Small Cell Lung 
Cancer (ENSCLC)
T. Almeida1, R. Fernandes2, A. Faccio2, P. Reis Filho2, H. Oliveira2, F. Tavares2, 
F. Peria2, 1Hospital das Clínicas FMRP USP - Centro Avançado de Oncologia 
do Hospital São José, São Paulo - Brazil, Brazil, 2Hospital das Clínicas 
FMRP USP, Ribeirão Preto-SP, Brazil
Purpose/Objective(s): Despite the ENSCLC is a rare and heterogeneous 
disease, it is highly symptomatic and determines poor survival. Moreover, 
treatment of elderly patients with small cell lung cancer (SCLC) is based on 
scanty evidence. The aim of this study is to examine the efficacy and toxicity 
of EP therapy for elderly patients, retrospectively.
Materials/Methods: Twenty-eight elderly patients with ENSCLC were 
selected from Oncology Division Data (HCFMRP-USP, Brazil), treated 
between Nov 2005 until Dec 2010, and were analyzed in order to evaluate: 
response rate (RR), overall survival (OS) and toxicities. Were included: age 
≥60 years old (WHO-UN-Brazil), extensive staging and follow-up assess-
ments (AJCC7th/RECIST1.1).
Results: The sample had a mean age of 67 years old (range, 61-80), gender 
3/1 male/females, and a predominance of ECOG 0-1 (89%). After completed 
four cycles of EP scheduled (E 100 mg/m2 plus P 60-80 mg/m2, q3w), the 
analysis observed: 50% pts had progression disease (12), 33% stable disease 
(8) and 16,6% partial response (4). The mean OS reached 10 months, with 
mortality of 64,3% (18). Only six pts were able to receive second-line therapy 
(carboplatin and paclitaxel), and another 14,2% remained in follow-up with 
best support of care. None could be retreated with EP. None carcinoid or 
paraneoplastic syndrome were detected. Grade 1/2 myelotoxicity and grade 
1/2 nausea were the main managed adverse effect related.
Conclusion: EP scheme to treat ENSCLC showed to be safe and effective 
besides low toxicity for Brazilian elderly pts. These results are in accor-
dance with the literature. Author Disclosure Block: T. Almeida: None. R. 
Fernandes: None. A. Faccio: None. P. Reis Filho: None. H. Oliveira: None. 
F. Tavares: None. F. Peria: None.
1135 
Small Cell Lung Cancer: A 3 Year County Hospital 
Experience
S. V. Liu, A. Rashtian, B. J. Gitlitz, University of Southern California Norris 
Comprehensive Cancer Center, Los Angeles, CA
Background: Lung cancer remains the leading cause of cancer-related death 
in the United States. Small cell lung cancer (SCLC) accounts for 13% of 
newly diagnosed cases of lung cancer and is among its most aggressive and 
lethal subtypes. An impressive response can be achieved in advanced SCLC 
with platinum-based chemotherapy but this response is often transient; despite 
high response rates, the survival for patients with SCLC remains poor. We 
reviewed contemporary outcomes at a County Hospital over the past 3 years. 
Materials/Methods: All patients diagnosed with SCLC at the Los Angeles 
County Hospital between 2009 and 2011 who received at least one cycle of 
chemotherapy were included. Through retrospective review of the treatment 
records, several variables were captured including demographic information, 
treatment regimen, date of diagnosis, date of treatment start, date of treat-
ment completion, best response and date of relapse when available. Staging 
followed the modified Veterans Administration Lung Group staging system. 
Time to progression (TTP) was defined as the duration of time from comple-
tion of initial chemotherapy to clinical or pathologic diagnosis of relapse. 
Follow-up was defined as the duration of time from diagnosis to last clini-
cal evaluation. “Platinum refractory” was used to describe patients who pro-
gressed during initial platinum-based chemotherapy. “Platinum resistant” was 
used to describe patients who progressed within 3 months of completing ini-
tial platinum-based chemotherapy. 
Results: Between January 2009 and December 2011, 17 patients were diag-
nosed with SCLC and received at least one cycle of chemotherapy at the 
Los Angeles County Hospital. Six patients (35%) presented with limited 
stage disease and received cisplatin and etoposide with definitive thoracic 
radiation therapy. All 6 patients achieved at least a partial response (PR) and 
2 patients (33%) achieved a complete response (CR). With a median fol-
lowup of 8.5 months (range 4-39), only one patient has experienced a relapse 
(17%), which occurred 6 months after completing therapy. Eleven patients 
(65%) presented with extensive stage disease. Eight patients (73%) had a 
PR with platinum + etoposide, though none achieved a CR. With a median 
followup of 7.9 months (range 2-16), only 1 patient has not had progression. 
Of the 10 who had progressive disease, 3 were platinum refractory (30%), 4 
were platinum resistant (40%) and had a median time to progression of 1.8 
months, and the remaining 4 patients were platinum sensitive (40%) with 
a median TTP of 6 months (range 5-10). Of the 10 patients with extensive 
stage SCLC who progressed, 4 received second line chemotherapy, most 
commonly topotecan. 
Conclusions: Outcomes in patients with SCLC treated at a County Hospital 
are similar to published results with standard therapy. Novel therapeutic 
approaches remain an unmet need.
Author Disclosure Block: S.V. Liu: None. A. Rashtian: None. B.J. Gitlitz: 
None.
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Specific Modulation of Chemoimmunotherapy(SMCIT) 
Induced by ChemoVac for Latest NSCLC
B. Yu1, Z. Ma2, C. Guan2, F. Gao2, W. Han3, Y. Xu4, G. Liu3, 1Beijing Baofa 
Cancer Hospital, Beijing, China, 2Taimei Baofa Cancer Hospital, Taian, 
China, 3Jinan Baofa Cancer Hospital, Jinan, China, 4JinanBaofa Cancer 
Hospital, Jinan, China
Purpose/Objective(s): Currently latest lung cancer therapy is not satisfied 
with the effectiveness of available treatment. Provenge represents a significant 
milestone for cancer immunotherapy and generates renewed interest in the 
field. Chemoimmunotherapy(CIT) as a attractive way has been studied over 
years but this is not generated a specific powerful clinical immunotherapy 
yet. SMCIT induced by ChemoVac is similarly with Provenge’s function and 
plays an important role in drug-killing tumor masse meanwhile it induces 
patient’s own specific immunological effect against micro-cancers more than 
CIT Introtumoral alone. 
Materials/Methods: ChemoVac is a proprietary therapeutic regimen com-
posed of three components for SMCIT, i.e. an oxidant, a cytotoxic anti-
cancer drug and a hapten. SMCIT performed by Introtumoral injection of 
ChemoVac into the tumor of latest NSCLC (25 cases in the SMCIT to 14 
cases in control of CIT). 
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Results: Immediately SMCIT is performed, coagulation in tumor with drugs 
injected for sustained drug release. While chemotherapeutic drug kills tumor 
cells, a small molecule hapten binds to these antigens or other cell proteins of 
tumor for special modulation by modifying the tumor antigens, then autolo-
gous tumor antigens released from the dead tumor cells and trigger immune 
response as a self-vaccination to further boost systemic cellular immunity 
for suppression and eradication of tumor recurrence and metastasis which 
is approved in our animal research study. Clinical effective is so promising, 
SMCIT resulted in more immunological reactions including inflammation at 
site of tumor than CIT, so that the response rate (CR+PR) for SMCIT 16% 
lower than CTIT 34%; but 6 months survival rate of SMCIT is 64% higher 
than CIT is 28.57% (P<0.01), 12 months survival rate of SMCIT is 36% 
higher than CIT is 12.29%(P<0.05). Therefore, more importantly, SMCIT 
provides a new option for cancer therapy by integrating local chemothera-
peutic effect with systemic anti-tumor immunity; immunogenic cell death 
induced by drugs is a priming event and allows the injected tumor act as its 
own vaccine. 
Conclusions: SMCIT is a safe, aggressive and cost-effective clinical treat-
ment for all of kind of NSCLC and displays the following advantages: clini-
cally effective for lung cancer and minimal side effects and better quality 
of life; simple and cost-effective treatment and strong intellectual property 
position.
Author Disclosure Block: B. Yu: None. Z. Ma: None. C. Guan: None. F. 
Gao: None. W. Han: None. Y. Xu: None. G. Liu: None.
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The Influence of Social and Geographic Isolation on 
Depressive Symptoms in Patients Wtih Lung Cancer 
Receiving Radiotherapy (RT)
I. G. Mohamed, C. F. Docherty, F. Germain, D. Hoegler, D. Petrik, R. Halperin, 
BCCA—Southern Interior, Kelowna, BC, Canada
Purpose/Objective(s): Depression is common among those diagnosed with 
cancer, affecting quality of life (QoL), survival, length of hospital stay and 
therapy compliance. This study investigates the relationship between different 
aspects of isolation and depressive symptoms in lung cancer patients treated 
with radiotherapy. 
Materials/Methods: Patients over 18 with lung cancer receiving RT only 
were eligible to participate in this study. Participants were given a question-
naire package to complete one week following their RT. The questionnaire 
collected responses to demographic queries, the EORTC QLQ-C30 and 
LC13 QoL and symptom scales, the Multidimensional Scale of Perceived 
Social Support (MSPSS), the Loneliness Index (LI) and the Centre for 
Epidemiologic Studies-Depression Scale (CES-D). Each participant was also 
followed up with a phone interview. All data was assessed using multivariate 
and covariate analysis. 
Results: Accrual began May 2010. A total of 73 subjects consented to par-
ticipate and of those 53 returned their questionnaires as of February 2012. 
Initial univariate analysis reveals that nearly all the scales measured show 
substantial correlation against the CES-D, with | r &gt 0.3 |: the EORTC 
QoL scale (r=-0.627, p&lt0.001), EORTC level of function scale (r=-0.692, 
p&lt0.001), EORTC symptom (r=0.588, p&lt0.001) and lung-specific symp-
tom scales (r=0.380, p=0.002), MSPSS (r= -0.416, p=0.001), and LI (r=0.515, 
p&lt0.001). Distance to the regional cancer centre (r=-0.121, p=0.198) or 
nearest hospital (r=-0.095, p=0.253) did not demonstrate any correlation with 
CES-D score. However, incorporating all the variables in a single analysis 
determined that only perceived level of function, a subset of the EORTC-
QLQ, accounted for significant variance in levels of depression beyond that 
of the other variables (t(6,41) = -2.029, p = 0.049). 
Conclusions: Most factors assessed are correlated with the level of 
depressive symptoms in lung cancer patients treated with RT. Only dis-
tance to the cancer centre or nearest regional hospital failed to show any 
correlation. However, from this study perceived level of function is the 
only strong independent predictor of levels of depression in lung cancer 
patients.
Author Disclosure Block: I.G. Mohamed: None. C.F. Docherty: None. F. 
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Survival Prediction in Ambulatory Stage III/ IV Non Small 
Cell Lung Cancer patients using the Palliative Performance 
Scale, ECOG and Lung Cancer Symptom Scale.
R. Mohajer, S. Nathan, K. Wells, N. Kern, M. Batus, M. Fidler, P. Bonomi, S. 
O’Mahony, Rush University Medical Center, CHICAGO, IL
Purpose/Objective(s): Patients with advanced NSCLC have a life expec-
tancy of less than one year, therefore, it is important to maximize their quality 
of life (QOL) and to find a tool that gives the patients and their families more 
accurate means of survival time prediction. 
Materials/Methods: The Palliative Performance Scale (PPS) has been 
designed and used for patients with far advanced disease for predicting 
survival probabilities. The PPS rates the physical performance of palliative 
care patients. It is adapted from the Karnofski performance status measure 
(KPRS) and has five functional dimensions: ambulation, activity level and 
evidence of disease, self-care, oral intake, and level of consciousness. It is 
scored in 11 levels from PPS 0 % to PPS 100% in 10 percent increments- PPS 
0% represents death and PPS 100% represents fully ambulatory and healthy 
status. PPS has been shown to be an effective tool in life expectancy prog-
nostication in patients who are receiving palliative care service or hospice. 
The value of PPS in ambulatory cancer patients has not been examined to 
date. The Lung Cancer Symptom Scale (LCSS) is a tool designed to measure 
the quality of life of lung cancer patients. It evaluates six major symptoms 
associated with lung malignancies and their affect on overall symptomatic 
distress, functional activities and global quality of life. Higher scores indicate 
greater symptom intensity. We evaluated 62 adult patients with stage III or IV 
NSCLC in the thoracic oncology clinic. All of them had ECOG 1 or greater 
at the time of baseline evaluation. Symptoms and performance status were 
evaluated at baseline for 62 patients, of those 54 patients followed- up after 4 
week using LCCS, PPS and ECOG. 
Results and Conclusions: 54 patients completed baseline and follow-up 
measures. The mean age for patients was 63.7 years. 63% were receiving 
active chemotherapy at the time of evaluation. Seventeen patients died. Mean 
(range) baseline measures score were as follows: LCSS 6.18(1-14); PPS 
66.6(40-90) and 1.82(1-4 ) for the ECOG. Censored survival times were cal-
culated from the enrollment of the first subject for 380 days. The last subject 
was recruited 357 days after the first subject. A proportional hazardous model 
was computed for survival status. Hazards ratios for death were 1.25(p= 
0.013) for LCCS, 2.12(p= 0.027) for the ECOG and 1.02 for PPS (p= 0.49). 
The LCCS performed best as a predictor of prognosis in this study. Further 
analysis will include an assessment of association between symptom clusters 
and biomarkers. The PPS only functioned well as a predictor of survival time 
in patients receiving active treatment for advanced cancer.
Author Disclosure Block: R. Mohajer: None. S. Nathan: None. K. Wells: 
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Stereotactic Ablative Image-Guided Helical Tomotherapy for 
Pulmonary Oligometastasis
C. V. Sole1,2, J. Lopez1, R. Matute1, F. Puebla1, J. Jaen1, C. Acevedo1, M. 
Bruna1, C. Beltran1, F. Calvo3, H. Marsiglia1,4, 1Instituto Madrileño de 
Oncologia, Madrid, Spain, 2Instituto de Radiomedicina, Santiago, Chile, 
3Hospital General Universitario Gregorio Marañon, Madrid, Spain, 4Institut 
Gustave Roussy, Paris, France
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Purpose/Objective(s): Several recent studies have shown that patients with 
metastatic cancer in limited organs benefit from metastasis-directed therapy. 
We present a series of patients treated with hypofractionated image-guided 
helical tomotherapy (HT), and assess the efficacy and toxicity of this ablative-
intent approach in the treatment of pulmonary oligometastasis. 
Materials/Methods: From August 2006 through July 2011, twenty-eight 
consecutive patients (8 M, 19 F; median age 63 years, range 51-87) with 1 
to 3 metastatic cancer sites and a life expectancy of >3 months received HT. 
At the beginning of radiotherapy no patient had evidence of primary tumor 
disease. Seventeen patients (61%) had a single metastatic lesion, nine patients 
(32%) 2 lesions, and 2 patients (7%) 3 lesions. Twenty-six patients (93%) 
received at least one line of chemotherapy before HT. A pre-irradiation mega-
voltage computed tomography was performed every day to verify and correct 
the patient set-up. The response was evaluated using the RECIST v.1.1. Acute 
toxicities were scored using the National Cancer Institute’s CTC AE v.3.0. 
Results: A total of forty-one lung lesions (14 central; 27 peripheral loca-
tion) with a median planning tumor volume of 42 cm3 (range,14-374) were 
treated with hypofractionated HT (median total dose 39 Gy [range 36-72.5]; 
median dose per fraction 12 Gy [range, 5-20]). The most common fraction-
ation schemes used were 36 Gy at 12 Gy/fraction (n=14) and 60 Gy at 12 
Gy/fraction (n=10). Mean dose homogeneity and Paddick conformity index 
values were 1.13 and 1.28, respectively. Complete response, partial response, 
stable response, and progression disease was observed in 6 (21%), 9 (32%), 
12 (43%), and 1 (4 %) patients, respectively. With a median follow-up period 
of 13 months (range, 4-58), 1- and 2-year local control (LC) was 90% and 
77%, respectively; 1- and 2-year overall survival (OS) was 84% and 58%, 
respectively; and 1- and 2-year disease-free survival (DFS) was 57% and 
36%, respectively. Regarding treatment-related acute Grade ≥ 2 toxicity, 
there were 3 and 1 patient with pneumonitis Grade 2 and 3, respectively; and 
two patients experienced Grade 2 esophagitis. No patient reported serious 
(Grade ≥ 3) treatment-related chronic toxicity. 
Conclusions: Hypofractionated image-guided HT is well tolerated and offers 
adequate local control with low acute morbidity in patients with pulmonary 
oligometastatic disease. A predominant distant-pattern of treatment failure 
highlights the importance of continued efforts to improve systemic disease 
control.
Author Disclosure Block: C.V. Sole: None. J. Lopez: None. R. Matute: 
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Feasibility Of Hypofractionated Radiotherapy (RT) For End-
of-life Palliation: Preliminary Results From A Prospective 
Randomized Study.
A. Mohamed, N. A. Eldeeb, A. M. Belal, A. Ganady, Faculty of Medicine, 
University of Alexandria, Alexandria, Egypt
Purpose/Objective(s): Extended palliative RT for patients at the end-of-
life may be logistically and economically expensive, with limited/minimal 
expected survival gain. To this end, we investigated the feasibility of a hypo-
fractionated palliative RT regimen in poor performance status (PS) patients 
with inoperable, symptomatic, locally advanced/metastatic NSCLC. 
Materials/Methods: A total of 30 patients with ≤ 6 month-life expectancy, 
PS ≥ 2 and symptomatic stage III or stage IV NSCLC, seen at Alexandria 
University hospital from June 2008 till July 2009, were enrolled. Patients 
were randomly assigned to two groups: A (15 pts) received 30 Gy in 10 frac-
tions and B (15 pts) 17 Gy in 2 fractions separated by one week. The primary 
end point of the study was the control of the intrathoracic symptoms as mea-
sured, by patients’ self reported symptom control using the EORTC lung can-
cer-specific module (LC13) as well as clinicians’ reported assessment using 
the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, 
at base line, 1, 6 and 16 weeks after the end of radiotherapy. Secondary end-
points were: acute toxicity profile, overall Quality of Life QOL using EORTC 
QLQ-C30, tumor control and survival. 
Results: The patients’ major clinical characteristics and incidence/degree of 
initial disease-related symptoms were homogenous between both study groups 
(p > 0.05). Significant improvement in the mean scores of airway symptoms 
(p < 0.05) was achieved equally in both arms as reported by patients using 
LC13. Hemoptysis had the highest improvement rate in 100% of patients in 
both groups followed by chest pain, cough, and dyspnea with improvement 
rates ranging from 60-73.3%. According to clinicians’ symptom assessment, 
improvement of symptoms meant a ≥1 step decrease in Symptom’s grade. 
Hemoptysis again had the highest improvement rate of 100% in both groups 
followed by chest pain, dyspnea, and cough with improvement rates rang-
ing from 60-71.4%. Treatment was well tolerated in both groups. Dysphasia 
was considered the main side effect with RTOG grade 3 toxicity seen in one 
patient (6.7%), and in 2 patients (13.3%) of group A and B, respectively. No 
other RTOG toxicities of grades ≥3 were noted. Quality of life was preserved 
equally in both groups with no significant differences in the mean scores of 
QLQ-30 (all p >0.05) at any time point. No significant difference in the over-
all survival was seen, with median survival of 5 and 6 months in group A and 
B, respectively (KM p= 0.55) 
Conclusions: The explored hypofractionated regimen was feasible, less 
expensive, and more convenient for patients with symptomatic advanced dis-
ease and limited expected survival versus the standard regimen. It also proved 
to be equally effective in terms of palliative effect, treatment tolerance, qual-
ity of life, and overall survival.
Author Disclosure Block: A. Mohamed: None. N.A. Eldeeb: None. A.M. 
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Does a Metallic Tracheobronchial Stent Affect Radiation Dose 
in the Airway and Surrounding Tissues? An in vivo study 
using a Porcine Model and Computed Tomography (CT) 
Radiation Treatment Planning
A. K. Jain, A. Evans, D. Lee, F. Trichter, J. Ostenson, S. Razi, K. Park, G. 
Schwartz, F. Bhora, St. Luke’s-Roosevelt Hospital, New York, NY
Purpose/Objective(s): Malignant airway obstruction is optimally managed 
with a multidisciplinary approach. Tracheobronchial stents provide rapid 
relief of symptoms, and radiation therapy can provide local tumor control. 
However, airway stents are commonly composed of a metallic framework and 
it is not clear if presence of these stents can affect radiation dose received by 
the tumor and surrounding tissues. The existing data in the literature are pre-
dominantly in vitro phantom studies with uncertain clinical applicability. We 
conducted in vivo studies using a porcine model and Computed Tomography 
(CT) radiation treatment planning to assess the effect of metallic stents on 
radiation dose. 
Materials/Methods: Three Yorkshire pigs (25-35kg) were anesthetized and 
AERO tracheobronchial stents were placed bronchoscopically. MOSFET 
OneDose™ point dosimeters (MPD) were implanted in and around the stent, 
and in the subcutaneous tissues. The pigs then underwent CT simulation and 
treatment planning (Varian Eclipse 8.6) for a 300 cGy dose fraction to the 
thorax. The MPD were identified on the CT images and designated as either 
Group 1 (away from the stent, control group) or Group 2 (near the stent, with 
potential for dose perturbation) and the planned dose was recorded from the 
treatment planning system. The treatment fraction was delivered on a linear 
accelerator and animals were subsequently euthanized and all of the MPD 
were removed for measurement, and designated as either Group 1 or Group 
2 based on careful correlation with CT images. The dose received was read 
from each individual dosimeter. Dose perturbation factor (DPF) values were 
calculated by comparing the difference between doses of each MPD group 
calculated by the treatment planning system and received dose from MPD 
readings. An example of a DPF calculation for Group 1 is as follows: DPF 
(Group 1) = Mean Group 1 MPD dose readings/Mean Group 1 planned MPD 
doses 
Results: In each pig the treatment planning system predicted that the doses 
to Group 1 MPD would be slightly higher than the Group 2 MPD and this 
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reached statistical significance only in Pig 1 (336 cGy vs. 324 cGy, p = 
<0.05). For each pig, the DPF was similar between Group 1 and Group 2 and 
the difference did not reach statistical significance for any of the pigs; Group 
1 vs. Group 2 (Pig 1 0.90 vs. 0.93 p=0.145, Pig 2 0.80 vs. 0.76 p=0.143, Pig 
3 0.85 vs. 0.90 p=0.384). 
Conclusions: Our in vivo porcine model shows that external beam radiation 
can be delivered in the presence of a metallic stent without concern for signifi-
cant dose perturbation in the region of the stent. CT-based treatment planning 
should be used and provides accurate radiation dosimetry in the presence of 
a metallic stent
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Psychosocial Distress Among Patients With Lung Cancer: An 
Approach To Assessment And Intervention
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Purpose/Objective(s): The prognosis of lung cancer remains poor and the 
effects on emotional and psychological health suppose a significant reduc-
tion in patients’quality of life (QOL). The aims are: (1) to identify previously 
published factors influencing the QOL among patients with lung cancer; 
(2) to identify instruments to assess psychological distress and intervention 
mechanisms. 
Materials/Methods: A MEDLINE literature review was carried out to iden-
tify studies which assess QOL and distress among patients with lung cancer 
(newly diagnosed, candidates to surgery, in advanced disease or palliative 
care). Particular attention was focused on the emotional and psychological 
effects, as well as limitations in the assessment and intervention. 
Results: Over 35 studies about QOL in lung cancer patients monitoring dis-
tress were identified. Those with more advanced stages, living alone, with func-
tional impairment, depressed mood, significative dyspnoea, and high number of 
comorbid diseases had higher scores in pain, depression and anxiety and lower 
scores in QOL. The most common psychological symptoms were worrying, dif-
ficulty sleeping and feeling nervous and sad. Over 30 instruments were used to 
measure QOL. Of these, the European Organisation for Research and Treatment 
of Cancer Quality of Life Lung Cancer Questionnaire (EORTC QLQ-LC13) in 
conjunction with the Core Cancer Questionnaire (QLQ-C30) and the generic 
health related QOL (HRQoL) questionnaire SF-36 were found to be the most 
widely used. Self-report assessments of QOL, pain and psychological distress, as 
well as personality tests were used in an attempt to assess psychological problems 
related to lung cancer and treatment side-effects. As far as non-invasive interven-
tions is concerned, few trials were found showing great variability among them: 
nurse follow-up programmes, interventions to manage breathlessness, reflexol-
ogy and other psychotherapeutic, psychosocial and educational interventions 
can play some role in improving patients’ QOL, whereas nutritional interven-
tions and exercise programmes showed no significant changes. 
Conclusions: Disclosure of lung cancer diagnosis has an impact on social 
and emotional QOL of patients, who may suffer physical and psychologi-
cal problems related to cancer and treatment side-effects. Few studies have 
been carried out to assess psychosocial distress with great heterogeneity and 
inconsistent results. These findings reinforce: (1) the importance to consider 
the assessment of psychosocial distress as an end point in all major clinical 
trials and (2) find feasible ways to incorporate an appropriate intervention into 
daily clinical practice.
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